PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gregory, JK; Clary, DC; Liu, K; Brown, MG; Saykally, RJ				Gregory, JK; Clary, DC; Liu, K; Brown, MG; Saykally, RJ			The water dipole moment in water clusters	SCIENCE			English	Article							DISTRIBUTED MULTIPOLE ANALYSIS; LIQUID WATER; AB-INITIO; MOLECULAR-INTERACTIONS; SPECTROSCOPY; DYNAMICS; TRIMER; DIMER; (H2O)(N); N=1-6	The average dipole moment of a water molecule in the condensed phase is enhanced by around 40 percent relative to that of an isolated monomer. This enhancement results from the large polarization caused by the electric field induced by surrounding monomers, A quantitative molecular description of this polarization is essential for modeling aqueous solvation phenomena. This combined theoretical and experimental study of dipole moments in small water clusters provides such a description and also gives insights into the structure of liquid water.	UNIV CAMBRIDGE,DEPT CHEM,CAMBRIDGE CB2 1EW,ENGLAND; UNIV LONDON UNIV COLL,DEPT CHEM,LONDON WC1H 0AJ,ENGLAND; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of Cambridge; University of London; University College London; University of California System; University of California Berkeley			Clary, David C/AAC-3903-2019	Clary, David C/0000-0003-4439-741X; SAYKALLY, RICHARD/0000-0001-8942-3656				ADAMS DJ, 1981, NATURE, V293, P447, DOI 10.1038/293447a0; AMOS RD, 1992, CADPAC CAMBRIDGE ANA; BLAKE GA, 1991, REV SCI INSTRUM, V62, P1701, DOI 10.1063/1.1142410; BLAKE GA, 1996, REV SCI INSTRUM, V67, P410; CALDWELL J, 1990, J AM CHEM SOC, V112, P9144, DOI 10.1021/ja00181a017; CORONGIU G, 1993, J CHEM PHYS, V98, P2241, DOI 10.1063/1.464204; COULSON CA, 1966, PROC R SOC LON SER-A, V291, P454, DOI 10.1098/rspa.1966.0106; Cruzan JD, 1996, SCIENCE, V271, P59, DOI 10.1126/science.271.5245.59; DELBENE J, 1970, J CHEM PHYS, V52, P4858, DOI 10.1063/1.1673723; DYKE TR, 1977, J CHEM PHYS, V66, P498, DOI 10.1063/1.433969; Eisenberg D. S., 2005, STRUCTURE PROPERTIES; GREGORY JK, 1995, J CHEM PHYS, V103, P8924, DOI 10.1063/1.470082; GREGORY JK, 1995, J CHEM PHYS, V102, P7817, DOI 10.1063/1.468982; Gregory JK, 1996, J CHEM PHYS, V105, P6626, DOI 10.1063/1.471976; Heggie MI, 1996, CHEM PHYS LETT, V249, P485, DOI 10.1016/0009-2614(95)01427-6; KENDALL RA, 1992, J CHEM PHYS, V96, P6796, DOI 10.1063/1.462569; KIM K, 1994, J AM CHEM SOC, V116, P11568, DOI 10.1021/ja00104a047; KIM K, 1994, J PHYS CHEM-US, V98, P10089, DOI 10.1021/j100091a024; KIM KS, 1986, CHEM PHYS LETT, V131, P451, DOI 10.1016/0009-2614(86)80564-4; LAASONEN K, 1993, J CHEM PHYS, V99, P9080, DOI 10.1063/1.465574; LINNARTZ H, 1993, J CHEM PHYS, V99, P2449, DOI 10.1063/1.465208; Liu K, 1996, MOL PHYS, V89, P1373, DOI 10.1080/00268979609482547; Liu K, 1996, SCIENCE, V271, P62, DOI 10.1126/science.271.5245.62; Liu K, 1996, SCIENCE, V271, P929, DOI 10.1126/science.271.5251.929; Liu K, 1996, NATURE, V381, P501, DOI 10.1038/381501a0; Lovas F. J., 1978, Journal of Physical and Chemical Reference Data, V7, P1445, DOI 10.1063/1.555588; Moller C, 1934, PHYS REV, V46, P0618, DOI 10.1103/PhysRev.46.618; MURPHY WF, 1977, J CHEM PHYS, V67, P5877, DOI 10.1063/1.434794; PETERSON SW, 1957, ACTA CRYSTALLOGR, V10, P70, DOI 10.1107/S0365110X5700016X; PUGLIANO N, 1992, J CHEM PHYS, V96, P1832, DOI 10.1063/1.462084; PUGLIANO N, 1992, SCIENCE, V257, P1937, DOI 10.1126/science.1411509; Rahman A, 1973, J AM CHEM SOC, V95, P7943, DOI 10.1021/ja00805a003; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; SCHUTZ M, 1993, J CHEM PHYS, V99, P5228, DOI 10.1063/1.465991; SPEEDY RJ, 1987, J PHYS CHEM-US, V91, P909, DOI 10.1021/j100288a029; SPRIK M, 1991, J CHEM PHYS, V95, P6762, DOI 10.1063/1.461515; STONE AJ, 1985, MOL PHYS, V56, P1047, DOI 10.1080/00268978500102891; STONE AJ, 1981, CHEM PHYS LETT, V83, P233, DOI 10.1016/0009-2614(81)85452-8; TSAI CJ, 1993, CHEM PHYS LETT, V213, P181, DOI 10.1016/0009-2614(93)85438-T; Tunon I, 1995, J MOL MODEL, V1, P196, DOI 10.1007/s008940050016; VERHOEVEN J, 1970, J CHEM PHYS, V52, P3222, DOI 10.1063/1.1673462; WEI DQ, 1994, CHEM PHYS LETT, V224, P291, DOI 10.1016/0009-2614(94)00540-0; XANTHEAS SS, 1994, J CHEM PHYS, V100, P7523, DOI 10.1063/1.466846; XANTHEAS SS, 1993, J CHEM PHYS, V99, P8774, DOI 10.1063/1.465599; XANTHEAS SS, 1995, J CHEM PHYS, V102, P4505, DOI 10.1063/1.469499; [No title captured]	46	611	626	4	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					814	817		10.1126/science.275.5301.814	http://dx.doi.org/10.1126/science.275.5301.814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012344				2022-12-28	WOS:A1997WG77700055
J	Groves, JT; Ulman, N; Boxer, SG				Groves, JT; Ulman, N; Boxer, SG			Micropatterning fluid lipid bilayers on solid supports	SCIENCE			English	Article							T-CELLS; MEMBRANES; ADHESION	Lithographically patterned grids of photoresist, aluminum oxide, or gold on oxidized silicon substrates were used to partition supported lipid bilayers into micrometer-scale arrays of isolated fluid membrane corrals. Fluorescently labeled lipids were observed to diffuse freely within each membrane corral but were confined by the micropatterned barriers. The concentrations of fluorescent probe molecules in individual corrals were altered by selective photobleaching to create arrays of fluid membrane patches with differing compositions. Application of an electric field parallel to the surface induced steady-state concentration gradients of charged membrane components in the corrals, In addition to producing patches of membrane with continuously varying composition, these gradients provide an intrinsically parallel means of acquiring information about molecular properties such as the diffusion coefficient in individual corrals.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT ELECT ENGN,EDWARD L GINZTON LAB,STANFORD,CA 94305	Stanford University; Stanford University			Zdilla, Michael J/B-4145-2011; Wunder, Stephanie L/B-5066-2012	Boxer, Steven/0000-0001-9167-4286				ABBOTT NL, 1992, SCIENCE, V257, P1380, DOI 10.1126/science.257.5075.1380; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; Groves JT, 1995, BIOPHYS J, V69, P1972, DOI 10.1016/S0006-3495(95)80067-6; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; Koenig BW, 1996, LANGMUIR, V12, P1343, DOI 10.1021/la950580r; KUMR A, 1993, APPL PHYS LETT, V63, P2002; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i; STELZLE M, 1992, BIOPHYS J, V63, P1346, DOI 10.1016/S0006-3495(92)81712-5; TOZEREN A, 1992, J CELL BIOL, V116, P997, DOI 10.1083/jcb.116.4.997; WATTS TH, 1987, ANNU REV IMMUNOL, V5, P461, DOI 10.1146/annurev.immunol.5.1.461; Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347	18	488	519	1	123	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					651	653		10.1126/science.275.5300.651	http://dx.doi.org/10.1126/science.275.5300.651			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005848				2022-12-28	WOS:A1997WF07700035
J	Du, XL; Cruickshank, K; McNamee, R; Saraee, M; Sourbutts, J; Summers, A; Roberts, N; Walton, E; Holmes, S				Du, XL; Cruickshank, K; McNamee, R; Saraee, M; Sourbutts, J; Summers, A; Roberts, N; Walton, E; Holmes, S			Case-control study of stroke and the quality of hypertension control in north west England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; HIGH BLOOD-PRESSURE; GENERAL-PRACTICE; MORTALITY; MANAGEMENT; MORBIDITY; PROJECT; RISKS; TRIAL	Objective: To examine the risk of stroke in relation to quality of hypertension control in routine general practice across an entire health district. Design: Population based matched case-control study. Setting: East Lancashire Health District with a participating population of 388 821 aged less than or equal to 80. Subjects: Cases were patients under 80 with their first stroke identified from a population based stroke register between 1 July 1994 and 30 June 1995. For each case two controls matched with the case for age and sex were selected from the same practice register. Hypertension was defined as systolic blood pressure greater than or equal to 160 mm Hg or diastolic blood pressure greater than or equal to 95 mm Hg, Or both, on at least two occasions within any three month period or any history of treatment with antihypertensive drugs. Main outcome measures: Prevalence of hypertension and quality of control of hypertension (assessed by using the mean blood pressure recorded before stroke) and odds ratios of stroke (derived from conditional logistic regression). Results: Records of 267 cases and 534 controls were examined; 61% and 42% of these subjects respectively were hypertensive. Compared with non-hypertensive subjects hypertensive patients receiving treatment whose average pre-event systolic blood pressure was controlled to <140 mm Hg had an adjusted odds ratio for stroke of 1.3 (95% confidence interval 0.6 to 2.7). Those fairly well controlled (140-149 mm Hg), moderately controlled (150-159 mm Hg), or poorly controlled (greater than or equal to 160 mm Hg) or untreated had progressively raised odds ratios of 1.6, 2.2, 3.2, and 3.5 respectively. Results for diastolic pressure were similar; both were independent of initial pressures before treatment Around 21% of strokes were thus attributable to inadequate control with treatment, or 46 first events yearly per 100 000 population aged 40-79. Conclusions: Risk of stroke was clearly related to quality of control of blood pressure with treatment In routine practice consistent control of blood pressure to below 150/90 mm Hg seems to be required for optimal stroke prevention.	UNIV MANCHESTER, SCH MED, SCH EPIDEMIOL & HLTH SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT COMPUTAT, MANCHESTER M60 1QD, LANCS, ENGLAND; E LANCASHIRE HLTH AUTHOR, DEPT PUBL HLTH, NELSON BB9 5SZ, LANCS, ENGLAND; QUEENS PK HOSP, DEPT MED ELDERLY, BLACKBURN BB2 3HH, LANCS, ENGLAND; THE SURGERY, EARBY BB8 6QT, LANCS, ENGLAND	University of Manchester; University of Manchester								ALROOMI KA, 1990, MED J AUSTRALIA, V153, P595, DOI 10.5694/j.1326-5377.1990.tb126271.x; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; ARROLL B, 1996, EVIDENCE BASED MED, V1, P105; BULPITT CJ, 1994, CIRCULATION, V90, P225, DOI 10.1161/01.CIR.90.1.225; COLHOUN HM, 1996, J HYPERTENS S1, V14, P289; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRUICKSHANK JK, 1994, J HYPERTENS, V12, P1315; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; HART JT, 1993, BRIT MED J, V306, P437, DOI 10.1136/bmj.306.6875.437; HART JT, 1993, HYPERTENSION COMMUNI; HELLER RF, 1977, BRIT MED J, V1, P1442, DOI 10.1136/bmj.1.6074.1442; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; Jackson RT, 1996, BRIT MED J, V313, P64, DOI 10.1136/bmj.313.7049.64; KURJI KH, 1984, BMJ-BRIT MED J, V288, P903, DOI 10.1136/bmj.288.6421.903; LANGER RD, 1995, CLIN EXP HYPERTENS, V17, P1127, DOI 10.3109/10641969509033658; Lindenstrom E, 1995, AM J EPIDEMIOL, V142, P1279, DOI 10.1093/oxfordjournals.aje.a117595; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; PAYNE JN, 1993, BRIT MED J, V307, P1027, DOI 10.1136/bmj.307.6911.1027; Pearce K A, 1995, Arch Fam Med, V4, P943, DOI 10.1001/archfami.4.11.943; Qizilbash N, 1995, LANCET, V346, P1647; RABKIN SW, 1978, ANN INTERN MED, V88, P342, DOI 10.7326/0003-4819-88-3-342; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; *STAT EP RES CORP, 1991, EP GRAPH EST TEST PA; Tuomilehto J, 1996, STROKE, V27, P210, DOI 10.1161/01.STR.27.2.210; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; *WHO EXP COMM, 1978, WHO TECH REP SER, V628	34	85	86	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1997	314	7076					272	276		10.1136/bmj.314.7076.272	http://dx.doi.org/10.1136/bmj.314.7076.272			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022492	Green Published, Green Accepted			2022-12-28	WOS:A1997WE63300027
J	James, JE				James, JE			Is habitual caffeine use a preventable cardiovascular risk factor?	LANCET			English	Editorial Material							CORONARY HEART-DISEASE; AMBULATORY BLOOD-PRESSURE; COFFEE CONSUMPTION; STROKE; MEN; HYPERTENSION; TOLERANCE; WOMEN				James, JE (corresponding author), LA TROBE UNIV,SCH BEHAV HLTH SCI,MELBOURNE,VIC 3083,AUSTRALIA.							BAK AAA, 1990, J HUM HYPERTENS, V4, P259; BAK AAA, 1989, NEW ENGL J MED, V321, P1432, DOI 10.1056/NEJM198911233212103; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; EGGERTSEN R, 1993, J INTERN MED, V4, P351; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; HEYDEN S, 1978, ARCH INTERN MED, V138, P1472, DOI 10.1001/archinte.138.10.1472; James J E, 1994, J Cardiovasc Risk, V1, P159; James J.E., 1997, UNDERSTANDING CAFFEI; JAMES JE, 1994, ADDICTION, V89, P1595, DOI 10.1111/j.1360-0443.1994.tb03760.x; JAMES JE, 1994, NEUROPSYCHOBIOLOGY, V30, P124, DOI 10.1159/000119151; JEONG DU, 1990, AM J HYPERTENS, V3, P749, DOI 10.1093/ajh/3.10.749; KLATSKY AL, 1986, CIRCULATION, V73, P628, DOI 10.1161/01.CIR.73.4.628; LACROIX AZ, 1986, NEW ENGL J MED, V315, P977, DOI 10.1056/NEJM198610163151601; LANE JD, 1989, PSYCHOSOM MED, V51, P373, DOI 10.1097/00006842-198907000-00001; MACDONALD TM, 1991, BRIT MED J, V303, P1235, DOI 10.1136/bmj.303.6812.1235; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MYERS MG, 1991, AM J HYPERTENS, V4, P427, DOI 10.1093/ajh/4.5.427; PERITI M, 1987, CLIN SCI, V72, P443, DOI 10.1042/cs0720443; PICKERING TG, 1991, ARCH MAL COEUR VAISS, V84, P17; ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124; SALVAGGIO A, 1992, EUR J EPIDEMIOL, V8, P776; SALVAGGIO A, 1990, J HYPERTENS, V8, P585, DOI 10.1097/00004872-199006000-00013; SHI J, 1993, CLIN PHARMACOL THER, V53, P6, DOI 10.1038/clpt.1993.3; SMITS P, 1985, AM J CARDIOL, V56, P958, DOI 10.1016/0002-9149(85)90412-6; STENSVOLD I, 1989, J CLIN EPIDEMIOL, V42, P877, DOI 10.1016/0895-4356(89)90101-7; SUPERKO HR, 1994, AM J CARDIOL, V73, P780, DOI 10.1016/0002-9149(94)90881-8; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; Urgert R, 1996, BRIT MED J, V313, P1362, DOI 10.1136/bmj.313.7069.1362; VANDUSSELDORP M, 1989, HYPERTENSION, V14, P563, DOI 10.1161/01.HYP.14.5.563; WEUSTENVANDERWOUW MPME, 1994, J LIPID RES, V35, P721	30	60	64	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					279	281		10.1016/S0140-6736(96)04253-5	http://dx.doi.org/10.1016/S0140-6736(96)04253-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014929				2022-12-28	WOS:A1997WD90600048
J	Mulcahy, D; Husain, S; Zalos, G; Rehman, A; Andrews, NP; Schenke, WH; Geller, NL; Quyyumi, AA				Mulcahy, D; Husain, S; Zalos, G; Rehman, A; Andrews, NP; Schenke, WH; Geller, NL; Quyyumi, AA			Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SILENT-MYOCARDIAL-ISCHEMIA; LEFT-VENTRICULAR FUNCTION; LONG-TERM PROGNOSIS; ST SEGMENT CHANGES; FOLLOW-UP; ANGINA-PECTORIS; MEDICAL THERAPY; BYPASS-SURGERY; HEART-DISEASE; DAILY LIFE	Objective.-To assess long-term prognostic significance of transient ischemia in patients with documented coronary artery disease and stable symptoms and to examine the relation between transient ischemia and the site of angiographic disease progression following acute cardiac events. Design.-Cohort study with a mean+/-SD follow-up of 51.5+/-23.8 months. Setting.--Ambulatory patients with stable coronary artery disease, assigned to medical therapy. Patients.-A total 221 patients (173 men; mean age, 60.8 years) were recruited, Of the 221 patients, 101 (45.7%) had single-vessel, 86 (38.9%) had 2-vessel, and 34 (15.4%) had 3-vessel disease. A total of 135 had a positive exercise test for ischemia, and mean+/-SD resting left ventricular ejection fraction (LVEF) was 49.8%+/-11.4%. Using conventional criteria, patients were prospectively stratified as low risk for continued medical therapy (single-vessel disease, 2-vessel disease with negative exercise test, or LVEF greater than or equal to 40%; n=189 [85.5%]) or high risk for continued medical therapy (multivessel disease with ischemia and/or left ventricular dysfunction; n=32 [14.5%]). Interventions.-Ambulalory ST-segment monitoring, treadmill exercise testing, radionuclide ventriculography, and coronary angiography. Main Outcome Measures.-Demographic, clinical, ambulatory monitoring, treadmill exercise, and left ventricular function variables as independent predictors of acute (cardiac death, myocardial infarction, or unstable angina) or all (including revascularization) cardiac events in the overall and the low-risk population. Results.-None of the clinical or noninvasive measures of ischemia were of prognostic significance in the overall or the low-risk group. The only significant independent predictor of outcome in all patients for all events, including revascularization, was the number of diseased vessels (chi(2)=13.5 [df=1]; P<.001). Exclusion of vessel disease resulted in conventional risk stratification as the most significant predictor of outcome from all events in all patients (chi(2)=10.3 [df=1]; P=.001). In the low-risk group, the number of diseased vessels was the only predictor for all events (chi(2)=4.6; P=.03). For acute cardiac events, none of the variables tested were of prognostic significance. Based on the frequency of events in the low-risk patients, a 2-fold increase in the rate of cardiac events in patients with transient ischemia compared with those without transient ischemia during ambulatory monitoring could be excluded with greater than 85% power and alpha of .05. Of 30 patients suffering acute nonfatal cardiac events during follow-up, angiography was performed in 27, revealing significant progression of coronary disease in 24 (88.8%) and the development of new significant lesions al sites remote from previously significant lesions in 20 (74%) cases. These new lesions were equally likely to occur in those with or without transient ischemia at initial assessment. Conclusions.-Acute cardiac events in predominantly low-risk stable angina patients with confirmed coronary disease are unpredictable, and those more likely to suffer such an event cannot be identified by the detection of ambulatory ischemia. Acute nonfatal cardiac events result predominantly from the development of significant new coronary lesions, not initially severe enough to cause ischemia. Patients categorized as high risk for long-term medical therapy have an increased rate of cardiac events (mainly revascularization) when compared with low-risk patients.	NHLBI, CARDIOL BRANCH, NIH, BETHESDA, MD 20892 USA; NHLBI, OFF BIOSTAT RES, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; AMBROSE JA, 1986, J AM COLL CARDIOL, V7, P472, DOI 10.1016/S0735-1097(86)80455-7; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; BONOW RO, 1984, NEW ENGL J MED, V311, P1339, DOI 10.1056/NEJM198411223112103; BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; CAMPBELL S, 1986, CIRCULATION, V74, P72, DOI 10.1161/01.CIR.74.1.72; Cox D. R., 1984, ANAL SURVIVAL DATA; CREA F, 1987, AM J CARDIOL, V60, P40, DOI 10.1016/0002-9149(87)90981-7; Dargie HJ, 1996, EUR HEART J, V17, P104; DAVIES MJ, 1985, BRIT HEART J, V53, P363; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; EPSTEIN SE, 1989, NEW ENGL J MED, V321, P320, DOI 10.1056/NEJM198908033210511; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GORLIN R, 1986, CIRCULATION, V74, P6, DOI 10.1161/01.CIR.74.1.6; HACKETT D, 1989, AM J CARDIOL, V63, P1517, DOI 10.1016/0002-9149(89)90018-0; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kay R, 1977, APPL STATIST, V26, P227, DOI 10.2307/2346962; KENNEDY HL, 1990, AM J CARDIOL, V65, P14, DOI 10.1016/0002-9149(90)90019-W; KENT KM, 1982, NEW ENGL J MED, V306, P441, DOI 10.1056/NEJM198202253060801; KUNKES SH, 1980, AM HEART J, V100, P813, DOI 10.1016/0002-8703(80)90061-7; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MOISE A, 1988, AM J CARDIOL, V61, P1255, DOI 10.1016/0002-9149(88)91165-4; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; MULCAHY D, 1989, J AM COLL CARDIOL, V14, P1166, DOI 10.1016/0735-1097(89)90411-7; MULCAHY D, 1995, EUR HEART J, V16, P317, DOI 10.1093/oxfordjournals.eurheartj.a060913; MULCAHY D, 1988, BRIT HEART J, V60, P417; MULCAHY D, 1992, AM HEART J, V123, P597, DOI 10.1016/0002-8703(92)90495-H; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V18, P904, DOI 10.1016/0735-1097(91)90745-U; PANDULLA C, 1991, J ITAL CARDIOL, V21, P735; PATEL D, 1993, BRIT HEART J, V70, P337; QUYYUMI AA, 1985, BRIT HEART J, V54, P557; QUYYUMI AA, 1993, J AM COLL CARDIOL, V21, P700, DOI 10.1016/0735-1097(93)90103-8; QUYYUMI AA, 1985, BRIT HEART J, V53, P186; QUYYUMI AA, 1992, J AM COLL CARDIOL, V19, P962, DOI 10.1016/0735-1097(92)90279-V; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROGERS WJ, 1995, J AM COLL CARDIOL, V26, P594, DOI 10.1016/0735-1097(95)00228-V; *SAS I INC, 1984, P229 SASSTST; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; TZIVONI D, 1989, AM J CARDIOL, V63, P273, DOI 10.1016/0002-9149(89)90329-9; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YEUNG AC, 1991, CIRCULATION, V83, P1598, DOI 10.1161/01.CIR.83.5.1598	45	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					318	324		10.1001/jama.277.4.318	http://dx.doi.org/10.1001/jama.277.4.318			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002495				2022-12-28	WOS:A1997WC45800032
J	Markowitz, N; Hansen, NI; Hopewell, PC; Glassroth, J; Kvale, PA; Mangura, BT; Wilcosky, TC; Wallace, JM; Rosen, MJ; Reichman, LB				Markowitz, N; Hansen, NI; Hopewell, PC; Glassroth, J; Kvale, PA; Mangura, BT; Wilcosky, TC; Wallace, JM; Rosen, MJ; Reichman, LB			Incidence of tuberculosis in the United States among HIV-infected persons	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infection; acquired immunodeficiency syndrome; tuberculosis; mumps; CD4 lymphocyte count	HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE TUBERCULOSIS; DRUG-USERS; PROGRESSION; RISK; EPIDEMIOLOGY; ANERGY; OUTBREAK; SURVIVAL; COHORT	Background: The resurgence of tuberculosis in the United States is largely linked to the human immunodeficiency virus (HIV) epidemic. Despite this link, the epidemiology of tuberculosis and preventive strategies in patients infected with HIV are not completely understood. Objectives: To determine the incidence and predictors of tuberculosis in HIV-infected persons. Design: Prospective, multicenter cohort study. Setting: Community-based cohort of persons with and without HIV infection at centers in the eastern, midwestern, and western United States. Participants: 1130 HIV-seropositive patients without AIDS who were followed for a median of 53 months (814 homosexual men, 261 injection drug users, and 55 women who had acquired HIV through heterosexual contact). Measurements: Delayed hypersensitivity response to purified protein derivative (PPD) tuberculin and mumps antigen, CD4 T-lymphocyte counts, and frequency of tuberculosis. Results: 31 HIV-seropositive patients developed tuberculosis (0.7 cases per 100 person-years [95% CI, 0.5 to 1.0]). The most important demographic risk factor was location (adjusted risk ratio for eastern compared with midwestern and western United States, 4.1 [CI, 2.0 to 8.4]). Tuberculosis occurred more frequently in persons with CD4 counts of less than 200 cells/mm(3) (1.2 cases per 100 person-years [CI, 0.7 to 1.9]) than in those with higher counts (0.5 cases per 100 person-years [CI, 0.3 to 0.8]). The rate of tuberculosis was highest among tuberculin converters (5.4 cases per 100 person-years [CI, 1.1 to 15.7]), lower among patients who were PPD positive at first testing (4.5 cases per 100 person-years [CI, 1.6 to 9.7]), and lowest among patients who remained PPD negative (0.4 cases per 100 person-years [CI, 0.2 to 0.7]). Tuberculosis was not reported among persons who had PPD reactions of 1 to 4 mm. Compared with that of patients who tested positive for mumps, the risk for tuberculosis of those who tested negative was increased about sevenfold if they were PPD positive (P < 0.03) and fourfold if they were PPD negative (P < 0.02). Conclusions: Incidence of tuberculosis was higher in the eastern United States, in patients with CD4 counts of less than 200 cells/mm(3), and in PPD-positive patients. Analysis of tuberculin reaction size supports the current interpretive criteria of the Centers for Disease Control and Prevention. Nonreactivity to mumps antigen indicated increased risk for tuberculosis independent of PPD response.	RES TRIANGLE INST, RES TRIANGLE PK, NC 27709 USA; SAN FRANCISCO GEN HOSP, CHEST SERV, SAN FRANCISCO, CA 94110 USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; UNIV MED & DENT NEW JERSEY, UNIV HOSP 1354, NEWARK, NJ 07103 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	Research Triangle Institute; San Francisco General Hospital Medical Center; Northwestern University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California Los Angeles; Icahn School of Medicine at Mount Sinai	Markowitz, N (corresponding author), HENRY FORD HOSP, DIV INFECT DIS, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.			Hansen, Nellie/0000-0003-4794-9646	DIVISION OF LUNG DISEASES [N01HR076033] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL48511-02, N01-HR-76033] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1994, MMWR MORB MORTAL WKL; ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BLATT SP, 1993, ANN INTERN MED, V119, P177, DOI 10.7326/0003-4819-119-3-199308010-00001; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Centers for Disease Control and Prevention, 1987, MMWR-MORBID MORTAL W, V36, p1S; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93, DOI 10.1164/ajrccm/149.3_Pt_2.S93; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; DUPON M, 1995, AIDS, V9, P577, DOI 10.1097/00002030-199506000-00008; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; GRAHAM NM, 1993, INT C AIDS, V9, P328; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HOPEWELL PC, 1993, J CLIN EPIDEMIOL, V46, P497; KAHN HA, 1989, STATISTICAL METHODS, P219; KORNBLUTH RS, 1993, ANN INTERN MED, V119, P241, DOI 10.7326/0003-4819-119-3-199308010-00011; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; ONORATO I, 1993, 33 INT C ANT AG CHEM, P1363; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P155; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; 1991, MMWR-MORBID MORTAL W, V40, P27; 1991, MMWR MORB MORATL WKL, V40, P129; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P703; 1996, MMWR-MORBID MORTAL W, V45, P366	40	179	187	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					123	+		10.7326/0003-4819-126-2-199701150-00005	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005746				2022-12-28	WOS:A1997WD29800007
J	Tin, W; Wariyar, U; Hey, E				Tin, W; Wariyar, U; Hey, E			Changing prognosis for babies of less than 28 weeks' gestation in the north of England between 1983 and 1994	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; DEVELOPMENT NEONATAL NETWORK; EXTREMELY PRETERM INFANTS; SURFACTANT THERAPY; PREMATURE-INFANTS; SURVIVAL; AGE; MORTALITY; BORN; OUTCOMES	Objective: To investigate the changing prognosis for babies of less than 28 weeks' gestation. Design: A prospective, collaborative, population based survey. Setting: The former Northern Regional Health Authority. Subjects: All the births between 1983 and 1994 at 22 to 27 completed weeks' gestation to women normally resident in the region. Main outcome measures: Miscarriage, stillbirth, death in the first year of life, and disability in survivors. Results: There were 419 070 registered births in the study period. No baby of 22 weeks' gestation survived; only eight (4%) of the 197 babies of 23 weeks who were alive at the onset of labour survived for a year-a proportion that did not change during the study period. Survival among other babies of less than 28 weeks improved progressively between 1983-6 and 1991-4, but administration of artificial surfactant to babies requiring ventilation from mid-1990 was associated with further improvement in survival only in those over 25 weeks' gestation. Babies of 24 weeks required three times as much high dependency care per survivor as babies of 27 weeks (76 v 26 days). The rate of severe disability in the one year survivors of less than 26 weeks' gestation (30/123; 24%) was similar to that seen in the sampled survivors of 26 and 27 weeks (29/108; 27%); the proportion disabled did not change significantly during the study period. All the children born in 1983, 1987, and 1991 were later reassessed in greater detail: 10% (13/136) seemed destined for a continuing life of total dependency. Conclusions: Gestation, if accurately assessed, can give a woman facing very preterm delivery a dear indication of the prognosis for her baby and help her judge the appropriateness of accepting obstetric intervention and sustained perinatal support.	ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND	Newcastle University - UK	Tin, W (corresponding author), S CLEVELAND HOSP, MIDDLESBROUGH TS4 3BW, CLEVELAND, ENGLAND.							ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; Battin M., 1996, Early Human Development, V45, P133, DOI 10.1016/0378-3782(96)81314-4; Bohin S, 1996, ARCH DIS CHILD-FETAL, V74, pF110, DOI 10.1136/fn.74.2.F110; CARTLIDGE PHT, IN PRESS ACTA PAEDIA; COOKE RWI, 1994, ARCH DIS CHILD-FETAL, V71, pF28, DOI 10.1136/fn.71.1.F28; DOYLE LW, 1989, MED J AUSTRALIA, V150, P558, DOI 10.5694/j.1326-5377.1989.tb136693.x; EGANDERSEN G, 1989, ACTA PAEDIATR SCAND, P56; FANAROFF AA, 1995, AM J OBSTET GYNECOL, V173, P1423, DOI 10.1016/0002-9378(95)90628-2; FENTON AC, 1990, BRIT MED J, V300, P434, DOI 10.1136/bmj.300.6722.434; FERRARA TB, 1994, J PEDIATR-US, V124, P119, DOI 10.1016/S0022-3476(94)70266-7; HACK M, 1995, AM J OBSTET GYNECOL, V172, P457, DOI 10.1016/0002-9378(95)90557-X; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, IN PRESS PEDIATRICS; HAYWOOD JL, 1994, AM J OBSTET GYNECOL, V171, P432, DOI 10.1016/0002-9378(94)90279-8; HEINONEN K, 1988, LANCET, V2, P204; HERSCHEL M, 1982, OBSTET GYNECOL, V60, P154; HEY EN, 1984, BRIT MED J, V288, P1717; HORBAR JD, 1993, PEDIATRICS, V92, P191; JOHNSON A, 1993, BRIT MED J, V306, P1715, DOI 10.1136/bmj.306.6894.1715; KITCHEN W, 1985, OBSTET GYNECOL, V66, P149; LEE SK, 1991, PEDIATRICS, V88, P110; Lefebvre F, 1996, AM J OBSTET GYNECOL, V174, P833, DOI 10.1016/S0002-9378(96)70309-5; LUBCHENCO LO, 1972, J PEDIATR-US, V81, P814, DOI 10.1016/S0022-3476(72)80114-8; MALLOY MH, 1991, OBSTET GYNECOL, V77, P498; MCLLWAINE GM, 1990, LANCET, V336, P782; MILLIGAN JE, 1984, AM J OBSTET GYNECOL, V148, P499, DOI 10.1016/0002-9378(84)90734-8; MILLS MD, 1990, AM J OBSTET GYNECOL, V163, P1568, DOI 10.1016/0002-9378(90)90629-L; National Perinatal Epidemiology Unit, 1994, DIS CAR MEAS HLTH ST; NWAESEI CG, 1987, AM J OBSTET GYNECOL, V157, P890, DOI 10.1016/S0002-9378(87)80080-7; OH W, 1995, PEDIATRICS, V96, P974; PICKERING J, 1993, ARCH DIS CHILD-FETAL, V68, P539; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; SMYTH J, 1995, J PEDIATR-US, V126, pS81, DOI 10.1016/S0022-3476(95)70012-9; *SOC OBST GYN CAN, 1994, CANADIAN MED ASS J, V151, P547; SOLA A, 1992, LANCET, V340, P1363; STEVENSON D, 1992, J PEDIATR-US, V120, pS3, DOI 10.1016/S0022-3476(05)81226-0; SYNNES AR, 1994, J PEDIATR-US, V125, P952, DOI 10.1016/S0022-3476(05)82015-3; TARNOWMORDI W, 1995, LANCET, V346, P58; TIN W, IN PRESS BR J OBSTET; TURKEL SB, 1986, AM J DIS CHILD, V140, P576, DOI 10.1001/archpedi.1986.02140200086034; VEEN S, 1991, LANCET, V338, P33, DOI 10.1016/0140-6736(91)90015-H; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; WALKER EM, 1987, BRIT J OBSTET GYNAEC, V94, P670, DOI 10.1111/j.1471-0528.1987.tb03172.x; WARIYAR U, 1989, ARCH DIS CHILD, V64, P678, DOI 10.1136/adc.64.5.678; WARIYAR U, IN PRESS EARLY HUM D; Weissman A, 1989, J Perinatol, V9, P372; WHYTE HE, 1993, OBSTET GYNECOL, V82, P1; WOOD B, 1989, OBSTET GYNECOL, V74, P889; YU VYH, 1992, AM J PERINAT, V9, P164, DOI 10.1055/s-2007-999313; YU VYH, 1986, BRIT MED J, V293, P1200, DOI 10.1136/bmj.293.6556.1200	50	140	141	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1997	314	7074					107	111		10.1136/bmj.314.7074.107	http://dx.doi.org/10.1136/bmj.314.7074.107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006468	Green Published			2022-12-28	WOS:A1997WC47900020
J	Cao, H; Glazebrook, J; Clarke, JD; Volko, S; Dong, XN				Cao, H; Glazebrook, J; Clarke, JD; Volko, S; Dong, XN			The Arabidopsis NPR1 gene that controls systemic acquired resistance encodes a novel protein containing ankyrin repeats	CELL			English	Article							PLANT-DISEASE RESISTANCE; TOBACCO MOSAIC-VIRUS; NF-KAPPA-B; SALICYLIC-ACID; HYDROGEN-PEROXIDE; THALIANA; SIGNAL; TRANSDUCTION; INDUCTION; EXPRESSION	The Arabidopsis NPR1 gene controls the onset of systemic acquired resistance (SAR), a plant immunity, to a broad spectrum of pathogens that is normally established after a primary exposure to avirulent pathogens. Mutants with defects in NPR1 fail to respond to various SAP-inducing treatments, displaying little expression of pathogenesis-related (PR) genes and exhibiting increased susceptibility to infections. NPR1 was cloned using a map-based approach and was found to encode a novel protein containing ankyrin repeats. The lesion in one npr1 mutant allele disrupted the ankyrin consensus sequence, suggesting that these repeats are important for NPR1 function. Furthermore, transformation of the cloned wild-type NPR1 gene into npr1 mutants not only complemented the mutations, restoring the responsiveness to SAP induction with respect to PR-gene expression and resistance to infections, but also rendered the transgenic plants more resistant to infection by P. syringae in the absence of SAP induction.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA; UNIV MARYLAND, BIOTECHNOL INST, AGR BIOTECHNOL CTR, COLLEGE PK, MD 20742 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University System of Maryland; University of Maryland College Park	Cao, H (corresponding author), DUKE UNIV, DEPT BOT, DEV CELL & MOL BIOL GRP, DURHAM, NC 27708 USA.			Glazebrook, Jane/0000-0001-5167-736X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048707, R37GM048707] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48707] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1993, CURRENT PROOTOCOLS M; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Glazebrook J, 1996, GENETICS, V143, P973; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; JEFFERSON RA, 1987, EMBO J, V6, P3901; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; PARKER JE, 1993, PLANT J, V4, P821, DOI 10.1046/j.1365-313X.1993.04050821.x; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; ROSS AF, 1961, VIROLOGY, V14, P329, DOI 10.1016/0042-6822(61)90318-X; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; Sokal R. R., 1981, BIOMETRY; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809	40	1076	1209	8	158	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					57	63		10.1016/S0092-8674(00)81858-9	http://dx.doi.org/10.1016/S0092-8674(00)81858-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019406	Bronze			2022-12-28	WOS:A1997WC56900009
J	Levin, HL				Levin, HL			It's prime time for reverse transcriptase	CELL			English	Review							INTRON MOBILITY; MECHANISM; RNA				Levin, HL (corresponding author), NICHHD,LAB EUKARYOT GENE REGULAT,BETHESDA,MD 20892, USA.			Levin, Henry/0000-0003-1728-118X				BONNEVILLE J, 1993, REVERSE TRANSCRIPTAS; CHAPMAN KB, 1992, P NATL ACAD SCI USA, V89, P3236, DOI 10.1073/pnas.89.8.3236; Eickbush Thomas H., 1994, P121; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; GABRIEL A, 1993, REVERSE TRANSCRIPTAS, P275; HU J, 1996, IN PRESS EMBO J; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; INOUYE S, 1993, REVERSE TRANSCRIPTAS, P391; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Leis J, 1993, REVERSE TRANSCRIPTAS, P33; LEVIN HL, 1995, MOL CELL BIOL, V15, P3310; Levin HL, 1996, MOL CELL BIOL, V16, P5645; LIN J, 1996, IN PRESS GENES DEV; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; TRAVIS JE, 1993, P NATL ACAD SCI USA, V90, P4107; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	20	31	70	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					5	8		10.1016/S0092-8674(00)81851-6	http://dx.doi.org/10.1016/S0092-8674(00)81851-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019405	Bronze			2022-12-28	WOS:A1997WC56900002
J	Hancock, BW; Aitken, M; Radstone, C; Hudson, GV				Hancock, BW; Aitken, M; Radstone, C; Hudson, GV			Why don't cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group's collaboration in British National Lymphoma Investigation studies	BRITISH MEDICAL JOURNAL			English	Article									MIDDLESEX HOSP,BRITISH NATL LYMPHOMA INVEST,LONDON W1N BAA,ENGLAND	University of London; University College London	Hancock, BW (corresponding author), WESTON PK HOSP,DEPT CLIN ONCOL,YORKSHIRE CANC RES CAMPAIGN,SHEFFIELD S10 2SJ,S YORKSHIRE,ENGLAND.							SLEVIN M, 1995, BRIT J CANCER, V71, P1270, DOI 10.1038/bjc.1995.245; SMITH R, 1995, BRIT MED J, V310, P1277; SMYTH JF, 1994, BRIT MED J, V309, P457, DOI 10.1136/bmj.309.6952.457; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; TANNOCK IF, 1995, BRIT J CANCER, V71, P1134, DOI 10.1038/bjc.1995.221	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					36	37		10.1136/bmj.314.7073.36	http://dx.doi.org/10.1136/bmj.314.7073.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001479	Green Published			2022-12-28	WOS:A1997WB68400024
J	Ancilotto, F; Chiarotti, GL; Scandolo, S; Tosatti, E				Ancilotto, F; Chiarotti, GL; Scandolo, S; Tosatti, E			Dissociation of methane into hydrocarbons at extreme (planetary) pressure and temperature	SCIENCE			English	Article							NEPTUNE; URANUS; APPROXIMATION; INTERIOR; BEHAVIOR; ENERGY	Constant-pressure, first-principles molecular dynamic simulations were used to investigate the behavior of methane at high pressure and temperature. Contrary to the current interpretation of shock-wave experiments, the simulations suggest that, below 100 gigapascals, methane dissociates into a mixture of hydrocarbons, and it separates into hydrogen and carbon only above 300 gigapascals. The simulation conditions (100 to 300 gigapascals; 4000 to 5000 kelvin) were chosen to follow the isentrope in the middle ice layers of Neptune and Uranus. implications on the physics of these planets are discussed.	SISSA,I-34014 TRIESTE,ITALY; UNIV PADUA,DIPARTIMENTO FIS G GALILEI,I-35131 PADUA,ITALY; IST NAZL FIS MAT,TRIESTE,ITALY	International School for Advanced Studies (SISSA); University of Padua; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua			Scandolo, Sandro/AAC-9081-2019; Chiarotti, Guido/A-9909-2012	Scandolo, Sandro/0000-0003-3826-4813; 				BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; BERNASCONI M, 1996, P JOINT 15 AIRAPT 33, P846; BEZARD B, 1991, J GEOPHYS RES-PLANET, V96, P18961, DOI 10.1029/91JA01930; ECK RV, 1966, SCIENCE, V153, P628, DOI 10.1126/science.153.3736.628; FOCHER P, 1994, EUROPHYS LETT, V26, P345, DOI 10.1209/0295-5075/26/5/005; Focher P., 1995, PROGR COMPUTATIONAL, P1; HOOVER WG, 1991, COMPUTATIONAL STAT M; HUBBARD WB, 1980, J GEOPHYS RES, V85, P225, DOI 10.1029/JB085iB01p00225; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; KOHANOFF J, UNPUB; MOSES JI, 1995, ICARUS, V113, P232, DOI 10.1006/icar.1995.1022; NELLIS WJ, 1981, J CHEM PHYS, V75, P3055, DOI 10.1063/1.442401; NELLIS WJ, 1984, J CHEM PHYS, V80, P2789, DOI 10.1063/1.447027; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; REE FH, 1979, J CHEM PHYS, V70, P974, DOI 10.1063/1.437487; ROSS M, 1981, NATURE, V292, P435, DOI 10.1038/292435a0; Scandolo S, 1996, PHYS REV B, V53, P5051, DOI 10.1103/PhysRevB.53.5051; SCANDOLO S, 1995, PHYS REV LETT, V74, P4015, DOI 10.1103/PhysRevLett.74.4015; Somayazulu MS, 1996, SCIENCE, V271, P1400, DOI 10.1126/science.271.5254.1400	20	117	119	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1288	1290		10.1126/science.275.5304.1288	http://dx.doi.org/10.1126/science.275.5304.1288			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036849				2022-12-28	WOS:A1997WK64400036
J	Marion, DW; Penrod, LE; Kelsey, SF; Obrist, WD; Kochanek, PM; Palmer, AM; Wisniewski, SR; DeKosky, ST				Marion, DW; Penrod, LE; Kelsey, SF; Obrist, WD; Kochanek, PM; Palmer, AM; Wisniewski, SR; DeKosky, ST			Treatment of traumatic brain injury with moderate hypothermia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE HEAD-INJURY; FOREBRAIN ISCHEMIA; MILD HYPOTHERMIA; DAMAGE; RAT; ISOFLURANE; SCALE; MODEL	Background Traumatic brain injury initiates several metabolic processes that can exacerbate the injury. There is evidence that hypothermia may limit some of these deleterious metabolic responses. Methods In a randomized, controlled trial, we compared the effects of moderate hypothermia and normothermia in 82 patients with severe closed head in juries (a score of 3 to 7 on the Glasgow Coma Scale). The patients assigned to hypothermia were cooled to 33 degrees C a mean of 10 hours after injury, kept at 32 to 33 degrees C for 24 hours, and then rewarmed. A specialist in physical medicine and rehabilitation who was unaware of the treatment assignments evaluated the patients 3, 6, and 12 months later with the use of the Glasgow Outcome Scale. Results The demographic characteristics and causes and severity of injury were similar in the hypothermia and normothermia groups. At 12 months, 62 percent of the patients in the hypothermia group and 38 percent of those in the normothermia group had good outcomes (moderate, mild, or no disabilities). The adjusted risk ratio for a bad outcome in the hypothermia group was 0.5 (95 percent confidence interval, 0.2 to 1.2). Hypothermia did not improve the outcomes in the patients with coma scores of 3 or 4 on admission. Among the patients with scores of 5 to 7, hypothermia was associated with significantly improved outcomes at 3 and 6 months (adjusted risk ratio for a bad outcome, 0.2; 95 percent confidence interval, 0.1 to 0.9 at both intervals), although not at 12 months (risk ratio, 0.3; 95 percent confidence interval, 0.1 to 1.0). Conclusions Treatment with moderate hypothermia for 24 hours in patients with severe traumatic brain injury and coma scores of 5 to 7 on admission hastened neurologic recovery and may have improved the outcome. (C) 1997, Massachusetts Medical Society.	UNIV PITTSBURGH,MED CTR,BRAIN TRAUMA RES CTR,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Marion, Donald/AAR-5749-2021; Palmer, Alan/AAP-8650-2020	DeKosky, Steven/0000-0003-3743-2758; Kochanek, Patrick/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHS [NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS030318, P50NS030318] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERING EA, 1961, AM J PHYSIOL, V200, P417, DOI 10.1152/ajplegacy.1961.200.3.417; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BUCHAN A, 1990, J NEUROSCI, V10, P311; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; GELB AW, 1989, ANESTHESIOLOGY, V70, P678, DOI 10.1097/00000542-198904000-00023; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Mouritzen CV, 1966, J THORAC CARDIOVASC, V51, P579; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TEASDALE G, 1974, LANCET, V2, P81; THOMAS PD, 1988, J LAB CLIN MED, V111, P286; WARNER DS, 1986, ANESTHESIOLOGY, V64, P19, DOI 10.1097/00000542-198601000-00004; WORINGER E, 1954, Anesth Anal, V11, P34; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	39	939	984	1	63	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					540	546		10.1056/NEJM199702203360803	http://dx.doi.org/10.1056/NEJM199702203360803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023090				2022-12-28	WOS:A1997WJ24000003
J	Thwaites, G; Taviner, M; Gant, V				Thwaites, G; Taviner, M; Gant, V			The English sweating sickness, 1485 to 1551	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HANTAVIRUS PULMONARY SYNDROME		UNIV ST ANDREWS,ST ANDREWS KY16 9AL,FIFE,SCOTLAND; UNITED MED & DENT SCH,LONDON SE1 7EH,ENGLAND	University of St Andrews; University of London; King's College London	Thwaites, G (corresponding author), GUYS & ST THOMAS NATL HLTH SERV HOSP TRUST,LONDON SE1 7EH,ENGLAND.		Thwaites, Guy E/R-4993-2019	Thwaites, Guy E/0000-0002-2858-2087				CAIUS J, 1552, BOKE COUNSEILL DIS C, P8; CHANTEMESSE M, 1906, B ACAD MED, V56, P293; COHEN MS, 1982, REV INFECT DIS, V4, P992; COX JC, 1910, PARISH REGISTERS ENG, P142; CREIGHTON C, 1965, HIST EPIDEMICS BRITA, P237; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; FORESTIER T, TRACTATUS PESTILENTI; FORESTIER T, TREATISE VENYMS FEVE; GOTTFRIED RS, 1977, J BRIT STUD, V17, P12, DOI 10.1086/385710; GRAFTON R, 1569, CHRONICLE LARGE MECR, P857; HALL E, 1809, HALLS CHRONICLE CONT, P425; HECKER JFC, 1844, EPIDEMICS MIDDLE AGE, P178; HIRSCH A, 1883, HDB GEOGRAPHICAL HIS, V1, P283; HOLINSHED R, 1806, CHRONICLES ENGLAND S, V3, P482; HUNTER PR, 1991, REV INFECT DIS, V13, P303; Khan AS, 1996, J INFECT DIS, V173, P1297, DOI 10.1093/infdis/173.6.1297; LAMB HH, 1977, CLIMATE PAST PRESENT, V2; LEVY H, 1994, AM J RESP CRIT CARE, V149, P1710, DOI 10.1164/ajrccm.149.6.8004332; PAABO S, 1988, NUCLEIC ACIDS RES, V16, P9775, DOI 10.1093/nar/16.20.9775; PATRICK A, 1965, Med Hist, V9, P272; Roberts R S, 1965, Med Hist, V9, P385; SLACK P, 1979, HLTH MED MORTALITY 1, P26; SLACK P, 1985, IMPACT PLAGUE TUDOR, P64; Stubbe H., 1671, LORD BACONS RELATION; WENZEL RP, 1994, NEW ENGL J MED, V330, P1004, DOI 10.1056/NEJM199404073301410; Wigley T., 1981, CLIMATE HIST STUDIES; WILSON T, 1551, VITA OBITUS DUORUM E; WWRIGLEY EA, 1981, POPULATION HIST ENGL, P337; WYLIE JAH, 1981, J HIST MED ALL SCI, V36, P425; WYLIE JAH, 1984, REP T DEV ASS ADV SC, V116, P97	30	19	19	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					580	582		10.1056/NEJM199702203360812	http://dx.doi.org/10.1056/NEJM199702203360812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023099				2022-12-28	WOS:A1997WJ24000012
J	MacMahon, S; Sharpe, N; Doughty, R; Krum, H; Tonkin, A; Trotter, A; Burton, R; Garrett, J; Lane, G; Owensby, D; Ryan, J; Shepherd, J; Singh, B; Jackson, B; Rudge, G; Stephensen, J; Woodhouse, S; Davidson, P; Turner, J; Walsh, W; Bradbury, J; Hamer, A; Cross, D; Hall, C; Kimber, V; Spaulding, C; Thompson, PL; Horowitz, J; Leslie, S; Zhang, Y; Colquhoun, D; Hicks, B; Jeffery, I; Taverner, P; Bond, C; Murphy, J; Ikram, H; Richards, M; Low, C; Scott, D; Brown, G; Lewis, G; Bruning, J; Nairn, L; CLayton, A; Crawford, J; McAlister, H; Bartram, H; McCulloch, A; Milne, A; Prasad, R; Yee, T; Whalley, G; Reid, I				MacMahon, S; Sharpe, N; Doughty, R; Krum, H; Tonkin, A; Trotter, A; Burton, R; Garrett, J; Lane, G; Owensby, D; Ryan, J; Shepherd, J; Singh, B; Jackson, B; Rudge, G; Stephensen, J; Woodhouse, S; Davidson, P; Turner, J; Walsh, W; Bradbury, J; Hamer, A; Cross, D; Hall, C; Kimber, V; Spaulding, C; Thompson, PL; Horowitz, J; Leslie, S; Zhang, Y; Colquhoun, D; Hicks, B; Jeffery, I; Taverner, P; Bond, C; Murphy, J; Ikram, H; Richards, M; Low, C; Scott, D; Brown, G; Lewis, G; Bruning, J; Nairn, L; CLayton, A; Crawford, J; McAlister, H; Bartram, H; McCulloch, A; Milne, A; Prasad, R; Yee, T; Whalley, G; Reid, I			Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease	LANCET			English	Article							DOUBLE-BLIND; DILATED CARDIOMYOPATHY; EXERCISE CAPACITY; TERM	Background In patients with heart failure, beta-blocker therapy improves left-ventricular function after 3-6 months of treatment, but effects of such treatment on symptoms and exercise performance are inconsistent, and the longer-term effects on death and other serious clinical events remain uncertain. We have investigated these issues in a double-blind, placebo-controlled, randomised trial of the beta-adrenergic blocker carvedilol (which also has alpha(1)-blocking properties). Methods 415 patients with chronic stable heart failure were randomly assigned treatment with carvedilol (207) or matching placebo (208), At baseline, 6 months, and 12 months, we measured left-ventricular ejection fraction, left-ventricular dimensions, treadmill exercise duration, 6 min walk distance, New York Heart Association (NYHA) class, and specific activity scale ISAS) score. Double-blind followup continued for an average of 19 months, during which all deaths, hospital admissions, and episodes of worsening heart failure were documented, Findings After 12 months, left-ventricular ejection fraction had increased by 5.3% (2p<0.0001) and end-diastolic and end-systolic dimensions had decreased by 1.7 mm (2p=0.06) and 3.2 mm (2p=0.001), respectively, in the carvedilol group compared with the placebo group. During the same period that were no clear changes in treadmill exercise duration, 6 min walk distance, NYHA class, or SAS score, After 19 months, the frequency of episodes of worsening heart failure was similar in the carvedilol and placebo groups (82 vs 75; relative risk 1.12 [95% CI 0.82-1.53]) but the rate of death or hospital admission was lower in the carvedilol group than in the placebo group (104 vs 131; relative risk 0.74 [0.57-0.95]). Interpretation The beneficial effects of carvedilol on left-ventricular function and size were maintained for at least a year after the start of treatment, but carvedilol had no effect on exercise performance, symptoms, or episodes of worsening heart failure. There was an overall reduction in events resulting in death or hospital admission, and a year of treatment with carvedilol resulted in the avoidance of one such serious event among every 12-13 (SE 5) of these patients with chronic stable heart failure.	AUSTIN HOSP,MELBOURNE,VIC 3084,AUSTRALIA; FREMANTLE HOSP,FREMANTLE,WA,AUSTRALIA; ILLAWARRA REG HOSP,WOLLONGONG,NSW,AUSTRALIA; LAUNCESTON HOSP,LAUNCESTON,TASMANIA,AUSTRALIA; PRESTON & NORTHCOTE COMMUNITY HOSP,MELBOURNE,VIC,AUSTRALIA; PRINCESS ALEXANDRA HOSP,BRISBANE,QLD 4102,AUSTRALIA; PRINCE HENRY HOSP,SYDNEY,NSW,AUSTRALIA; REPATRIAT GEN HOSP,MELBOURNE,VIC,AUSTRALIA; ROYAL BRISBANE HOSP,BRISBANE,QLD 4029,AUSTRALIA; ROYAL HOBART HOSP,HOBART,TAS,AUSTRALIA; SIR CHARLES GAIRDNER HOSP,PERTH,WA,AUSTRALIA; QUEEN ELIZABETH HOSP,ADELAIDE,SA,AUSTRALIA; WESLEY COLL HOSP,BRISBANE,QLD,AUSTRALIA; WODEN VALLEY HOSP,CANBERRA,ACT,AUSTRALIA; AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; CHRISTCHURCH HOSP,CHRISTCHURCH,NEW ZEALAND; DUNEDIN PUBL HOSP,DUNEDIN,NEW ZEALAND; NAPIER HOSP,NAPIER,NEW ZEALAND; TAURANGA HOSP,TAURANGA,NEW ZEALAND; WAIKATO HOSP,HAMILTON,NEW ZEALAND	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Western Australia; Royal Brisbane & Women's Hospital; Royal Hobart Hospital; University of Western Australia; Wesley Hospital; Australian National University; Canberra Hospital; Auckland City Hospital; Christchurch Hospital New Zealand; Dunedin Public Hospital; Waikato Hospital	MacMahon, S (corresponding author), UNIV AUCKLAND,DEPT MED,CLIN TRIALS RES UNIT,ANZ HEART FAILURE TRIALS OFF,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.		Thompson, Peter L/P-1071-2014; Whalley, Gillian/H-7376-2019	Whalley, Gillian/0000-0002-5713-6967				*AUSTR NZ HEART FA, 1995, CIRCULATION, V92, P212; *BT BLOCK POOL PRO, 1988, EUR HEART J, V9, P8; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; *CIBIS INV COMM, 1994, CIRCULATION, V90, P1765; DOUGHTY RN, 1994, J AM COLL CARDIOL, V23, P814, DOI 10.1016/0735-1097(94)90773-0; EICHHORN EJ, 1994, J AM COLL CARDIOL, V24, P1310, DOI 10.1016/0735-1097(94)90114-7; Feuerstein Giora Z., 1995, Drugs of Today, V31, P1; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; KRUM H, 1995, CIRCULATION, V92, P1499, DOI 10.1161/01.CIR.92.6.1499; METRA M, 1994, J AM COLL CARDIOL, V24, P1678, DOI 10.1016/0735-1097(94)90174-0; OLSEN SL, 1995, J AM COLL CARDIOL, V25, P1225, DOI 10.1016/0735-1097(95)00012-S; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; POLLOCK SG, 1990, AM J CARDIOL, V66, P603, DOI 10.1016/0002-9149(90)90488-M; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; *SOLVD INV, 1991, NEW ENGL J MED, V325, P293; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	17	594	608	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					375	380						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033462				2022-12-28	WOS:A1997WH29600008
J	Rohr, S; Kucera, JP; Fast, VG; Kleber, AG				Rohr, S; Kucera, JP; Fast, VG; Kleber, AG			Paradoxical improvement of impulse conduction in cardiac tissue by partial cellular uncoupling	SCIENCE			English	Article							PATTERNED GROWTH; TRANSMEMBRANE VOLTAGE; FATTY-ACIDS; HEART; CULTURES; MUSCLE; CELLS; BLOCK; PROPAGATION; EXCITATION	Generally, impulse propagation in cardiac tissue is assumed to be impaired by a reduction of intercellular electrical coupling or by the presence of structural discontinuities. Contrary to this notion, the spatially uniform reduction of electrical coupling induced successful conduction in discontinuous cardiac tissue structures exhibiting unidirectional conduction block. This seemingly paradoxical finding can be explained by a nonsymmetric effect of uncoupling on the current source and the current sink in the preparations used. It suggests that partial cellular uncoupling might prevent the initiation of cardiac arrhythmias that are dependent on the presence of unidirectional conduction block.			Rohr, S (corresponding author), UNIV BERN,DEPT PHYSIOL,BUHLPL 5,CH-3012 BERN,SWITZERLAND.		Rohr, Stephan/B-9166-2008	Rohr, Stephan/0000-0003-4358-7035; Kucera, Jan/0000-0003-0310-6962				Akima H., 1978, ACM Transactions on Mathematical Software, V4, P148, DOI 10.1145/355780.355786; BURT JM, 1991, AM J PHYSIOL, V260, pC439, DOI 10.1152/ajpcell.1991.260.3.C439; CABO C, 1994, CIRC RES, V75, P1014, DOI 10.1161/01.RES.75.6.1014; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; FAST VG, 1995, CARDIOVASC RES, V29, P697, DOI 10.1016/S0008-6363(96)88643-3; FAST VG, 1995, CARDIOVASC RES, V30, P449, DOI 10.1016/0008-6363(95)00071-2; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; LEGRICE IJ, 1995, AM J PHYSIOL-HEART C, V269, pH571, DOI 10.1152/ajpheart.1995.269.2.H571; MIURA I, 1991, CLIN EXP PHARMACOL P, V18, P259, DOI 10.1111/j.1440-1681.1991.tb01440.x; ROHR S, 1995, J CARDIOVASC ELECTR, V6, P551, DOI 10.1111/j.1540-8167.1995.tb00428.x; ROHR S, 1994, J GEN PHYSIOL, V104, P287, DOI 10.1085/jgp.104.2.287; ROHR S, 1991, CIRC RES, V68, P114, DOI 10.1161/01.RES.68.1.114; SMITH JH, 1991, AM J PATHOL, V139, P801; STREIT J, 1989, J NEUROSCI, V9, P4190; URSELL PC, 1985, CIRC RES, V56, P436, DOI 10.1161/01.RES.56.3.436; VEENSTRA RD, 1984, CIRC RES, V54, P500, DOI 10.1161/01.RES.54.5.500; WINFREE AT, 1987, TIME BREAKS DOWN	17	222	225	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					841	844		10.1126/science.275.5301.841	http://dx.doi.org/10.1126/science.275.5301.841			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012353				2022-12-28	WOS:A1997WG77700064
J	Gooley, AA; Williams, KL				Gooley, AA; Williams, KL			How to find, identify and quantitate the sugars on proteins	NATURE			English	Article							LINKED GLYCOSYLATION MOTIFS; EDMAN DEGRADATION; MASS-SPECTROMETRY; IDENTIFICATION	A new sequenator allows the identification, quantification and characterization of sites of glycosylation on proteins, making it possible to analyse the glycosylation at serine and threonine sites in mucin-like domains.										Bures EJ, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P57; CARR SA, 1991, ANAL CHEM, V63, P2802, DOI 10.1021/ac00024a003; CARR SA, 1993, PROTEIN SCI, V2, P183; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GOOLEY AA, 1995, TECH PROT CHEM, V6, P83, DOI 10.1016/S1080-8914(06)80013-X; GOOLEY AA, 1992, GENETICS, V130, P749; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; Pisano A, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P69; PISANO A, 1996, TECHNIQUES GLYCOBIOL, P299; REDMOND JW, 1994, Patent No. 164; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; WROTNOWSKI C, 1996, GENET ENG NEWS  0515, P7; Zachara NE, 1996, EUR J BIOCHEM, V238, P511, DOI 10.1111/j.1432-1033.1996.0511z.x	17	26	29	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					557	559		10.1038/385557a0	http://dx.doi.org/10.1038/385557a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020365				2022-12-28	WOS:A1997WG23500055
J	Burton, K; Taylor, DL				Burton, K; Taylor, DL			Traction forces of cytokinesis measured with optically modified elastic substrata	NATURE			English	Article							CONTRACTILE RING; CELL-DIVISION; ANIMAL-CELLS; ACTIN-FILAMENTS; CULTURED-CELLS; MYOSIN; MECHANISM; MOVEMENT; ESTABLISHMENT; DICTYOSTELIUM	Animal cells dividing in culture undergo a dramatic sequence of morphological changes, characterized by cytoskeletal disassembly as cells round up, redistribution of actin, myosins and other cytoplasmic and surface molecules into the cleavage furrow(1-11), and respreading(12), before daughter cells finally separate at the mid-body(13). Knowledge of forces governing these movements is critical to understanding their mechanisms, including whether formation of the cleavage furrow results from increased force generation at the equator(14,15) or relaxation at the poles(16), and whether traction force subsequently mediates cytofission of the intercellular bridge(5,13,17,18). We have quantitatively mapped traction forces in dividing cells, by extending the silicone-rubber substratum method(19) to detect forces of nanonewtons to micro-newtons. We used a new silicone polymer to fabricate substrata whose compliance can be adjusted precisely by ultraviolet irradiation. We show that traction force appears locally at the furrow in the absence of relaxation at the poles during cleavage. Force also rises as connected daughter cells respread and attempt to separate, suggesting that tension contributes to the severing of the intercellular bridge when cytokinesis is completed.	CARNEGIE MELLON UNIV, DEPT BIOL, PITTSBURGH, PA 15213 USA	Carnegie Mellon University	Burton, K (corresponding author), CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, 4400 5TH AVE, PITTSBURGH, PA 15213 USA.			Taylor, D. Lansing/0000-0001-6947-1343				BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRECKLER J, 1994, CELL MOTIL CYTOSKEL, V29, P312, DOI 10.1002/cm.970290404; Burton K., 1993, Molecular Biology of the Cell, V4, p114A; CAO LG, 1990, J CELL BIOL, V111, P1905, DOI 10.1083/jcb.111.5.1905; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DeBiasio RL, 1996, MOL BIOL CELL, V7, P1259, DOI 10.1091/mbc.7.8.1259; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Dembo M, 1996, BIOPHYS J, V70, P2008, DOI 10.1016/S0006-3495(96)79767-9; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; FISHKIND DJ, 1993, J CELL BIOL, V123, P837, DOI 10.1083/jcb.123.4.837; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; FUKUI Y, 1993, INT REV CYTOL, V144, P85, DOI 10.1016/S0074-7696(08)61514-4; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; HARRIS AK, 1988, METHOD ENZYMOL, V163, P623; HARRIS AK, 1984, J BIOMECH ENG-T ASME, V106, P19, DOI 10.1115/1.3138449; HARRIS AK, 1994, NATO ADV SCI INST SE, V84, P37; HIRAMOTO Y, 1979, CELL MOTILITY MOL OR, P653; MABUCHI I, 1994, J CELL SCI, V107, P1853; MAUPIN P, 1994, J CELL SCI, V107, P3077; MULLINS JM, 1977, J CELL BIOL, V73, P672, DOI 10.1083/jcb.73.3.672; OLIVER T, 1995, CELL MOTIL CYTOSKEL, V31, P225, DOI 10.1002/cm.970310306; Peterson MA, 1996, BIOPHYS J, V71, P657, DOI 10.1016/S0006-3495(96)79266-4; RAPPAPORT R, 1967, SCIENCE, V156, P1241, DOI 10.1126/science.156.3779.1241; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RAPPAPORT R, 1986, J EXP ZOOL, V240, P55, DOI 10.1002/jez.1402400108; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SANGER JM, 1994, CELL MOTIL CYTOSKEL, V27, P26, DOI 10.1002/cm.970270104; SHU HB, 1995, J CELL SCI, V108, P2955; WANG YL, 1994, J CELL BIOL, V127, P963, DOI 10.1083/jcb.127.4.963; WHITE JG, 1983, J THEOR BIOL, V101, P289, DOI 10.1016/0022-5193(83)90342-9	31	257	264	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					450	454		10.1038/385450a0	http://dx.doi.org/10.1038/385450a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009194				2022-12-28	WOS:A1997WF00700056
J	Wallace, SJ				Wallace, SJ			Nasal benzodiazepines for management of acute childhood seizures?	LANCET			English	Editorial Material							MIDAZOLAM				Wallace, SJ (corresponding author), UNIV WALES HOSP,DEPT PAEDIAT NEUROL,CARDIFF CF4 4XW,S GLAM,WALES.							JAWAD S, 1986, J NEUROL NEUROSUR PS, V49, P1050, DOI 10.1136/jnnp.49.9.1050; Newman M, 1993, J Cardiothorac Vasc Anesth, V7, P615, DOI 10.1016/1053-0770(93)90325-F; ORegan ME, 1996, DEV MED CHILD NEUROL, V38, P1037; REY E, 1991, EUR J CLIN PHARMACOL, V41, P355, DOI 10.1007/BF00314967; SHORVON SD, 1994, STATUS EPILEPTICUS, P213	5	32	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					222	222		10.1016/S0140-6736(05)64856-8	http://dx.doi.org/10.1016/S0140-6736(05)64856-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014904				2022-12-28	WOS:A1997WD90600004
J	Funamori, N; Yagi, T; Miyajima, N; Fujino, K				Funamori, N; Yagi, T; Miyajima, N; Fujino, K			Transformation in garnet from orthorhombic perovskite to LiNbO3 phase on release of pressure	SCIENCE			English	Article							EARTHS LOWER MANTLE; CRYSTAL-CHEMISTRY; MGSIO3; TRANSITION; MNTIO3	High-pressure in situ x-ray diffraction and transmission electron microscopy on quenched samples show that natural garnet transforms to orthorhombic perovskite (and minor coexisting phases) containing increasing amounts of aluminum with increasing pressure. This suggests that the perovskite is the dominant host mineral for aluminum in Earth's lower mantle. Orthorhombic perovskite is quenched from similar to 35 gigapascals but, because of the increased aluminum content, transforms to the LiNbO3 structure upon quenching from similar to 60 gigapascals.	HOKKAIDO UNIV,DEPT EARTH & PLANETARY SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	Funamori, N (corresponding author), UNIV TOKYO,INST SOLID STATE PHYS,MINATO KU,TOKYO 106,JAPAN.		FUNAMORI, NOBUMASA/F-1002-2010	FUNAMORI, NOBUMASA/0000-0002-1363-8463				AHMEDZAID I, 1995, EARTH PLANET SC LETT, V129, P233, DOI 10.1016/0012-821X(94)00245-T; FUNAMORI N, 1994, P 14 AIRAPT C, P791; HEINZ DL, 1987, J GEOPHYS RES-SOLID, V92, P11437, DOI 10.1029/JB092iB11p11437; IRIFUNE T, 1994, NATURE, V370, P131, DOI 10.1038/370131a0; Irifune T, 1996, PHYS EARTH PLANET IN, V96, P147, DOI 10.1016/0031-9201(96)03147-0; Ito E., 1978, Earth and Planetary Science Letters, V38, P443, DOI 10.1016/0012-821X(78)90119-X; Ito E., 1977, HIGH PRESSURE RES, P193; KESSON SE, 1995, EARTH PLANET SC LETT, V134, P187, DOI 10.1016/0012-821X(95)00112-P; KO JD, 1988, PHYS CHEM MINER, V15, P355, DOI 10.1007/BF00311040; LEINENWEBER K, 1994, AM MINERAL, V79, P197; LEINENWEBER K, 1991, PHYS CHEM MINER, V18, P244; LIU LG, 1976, EARTH PLANET SC LETT, V31, P200, DOI 10.1016/0012-821X(76)90212-0; Liu LG, 1974, GEOPHYS RES LETT, V1, P277, DOI 10.1029/GL001i006p00277; MAO HK, 1991, J GEOPHYS RES-SOLID, V96, P8069, DOI 10.1029/91JB00176; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; MIYAHARA J, 1986, NUCL INSTRUM METH A, V246, P572, DOI 10.1016/0168-9002(86)90156-7; ONEILL B, 1994, J GEOPHYS RES-SOL EA, V99, P19901, DOI 10.1029/94JB01752; ONEILL B, 1990, GEOPHYS RES LETT, V17, P1477, DOI 10.1029/GL017i010p01477; ROSS NL, 1989, PHYS CHEM MINER, V16, P621; SHANNON RD, 1969, ACTA CRYSTALL B-STRU, VB 25, P925, DOI 10.1107/S0567740869003220; SOVOLEV NV, 1995, 6 INT KIMB C ALMAZY, P60; Weng K., 1981, CARNEGIE I WASHINGTO, V81, P273; YAGI T, 1978, PHYS CHEM MINER, V3, P97, DOI 10.1007/BF00308114; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553	24	39	39	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					513	515		10.1126/science.275.5299.513	http://dx.doi.org/10.1126/science.275.5299.513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999791				2022-12-28	WOS:A1997WE25700038
J	Sone, M; Hoshino, M; Suzuki, E; Kuroda, S; Kaibuchi, K; Nakagoshi, H; Saigo, K; Nabeshima, Y; Hama, C				Sone, M; Hoshino, M; Suzuki, E; Kuroda, S; Kaibuchi, K; Nakagoshi, H; Saigo, K; Nabeshima, Y; Hama, C			Still life, a protein in synaptic terminals of Drosophila homologous to GDP-GTP exchangers	SCIENCE			English	Article							GENE; RHO; EXPRESSION; GTPASES; RAC; ORGANIZATION; SPECIFICITY; INVASION; ENCODES; FUSION	The morphology of axon terminals changes with differentiation into mature synapses. A molecule that might regulate this process was identified by a screen of Drosophila mutants for abnormal motor activities. The still life (sif) gene encodes a protein homologous to guanine nucleotide exchange factors, which convert Rho-like guanosine triphosphatases (GTPases) from a guanosine diphosphate-bound inactive state to a guanosine triphosphate-bound active state. The SIF proteins are found adjacent to the plasma membrane of synaptic terminals. Expression of a truncated SIF protein resulted in defects in neuronal morphology and induced membrane ruffling with altered actin localization in human KB cells. Thus, SIF proteins may regulate synaptic differentiation through the organization of the actin cytoskeleton by activating Rho-like GTPases.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOL GENET,KODAIRA,TOKYO 187,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT FINE MORPHOL,MINATO KU,TOKYO 108,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,NARA 63001,JAPAN	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo; Nara Institute of Science & Technology			Sone, Masaki/Q-9058-2019; NAKAGOSHI, Hideki/B-2145-2011	NAKAGOSHI, Hideki/0000-0003-0850-1814; Suzuki, Emiko/0000-0002-4005-0542				BRAND AH, 1993, DEVELOPMENT, V118, P401; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HART MJ, 1994, J BIOL CHEM, V269, P62; HOSHINO M, 1993, NEURON, V10, P395, DOI 10.1016/0896-6273(93)90329-P; Hoshino M, 1996, DEVELOPMENT, V122, P589; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHANSEN J, 1989, J NEUROSCI, V9, P710; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MEINERTZHAGEN IA, 1991, J COMP NEUROL, V305, P232, DOI 10.1002/cne.903050206; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; VANBERKUM MFA, 1995, NEURON, V14, P43, DOI 10.1016/0896-6273(95)90239-2; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; YAO KM, 1994, J NEUROCHEM, V63, P41	35	111	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					543	547		10.1126/science.275.5299.543	http://dx.doi.org/10.1126/science.275.5299.543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999801				2022-12-28	WOS:A1997WE25700048
J	Nishina, H; Fischer, KD; Radvanyi, L; Shahinian, A; Hakem, R; Rubie, EA; Bernstein, A; Mak, TW; Woodgett, JR; Penninger, JM				Nishina, H; Fischer, KD; Radvanyi, L; Shahinian, A; Hakem, R; Rubie, EA; Bernstein, A; Mak, TW; Woodgett, JR; Penninger, JM			Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3	NATURE			English	Article							AMINO-TERMINAL KINASES; C-JUN; ACTIVATION; DEFICIENT; CELLS; JNK	Distinct and evolutionarily conserved signal transduction cascades mediate survival or death in response to developmental and environmental cues, The stress-activated protein kinases, or Jun N-terminal kinases (SAPKs/JNKs)(1,2), are activated in response to a variety of cellular stresses such as changes in osmolarity and metabolism, DNA damage, heat shock, ischaemia, or inflammatory cytokines(3-6). Sek1 (JNKK/MKK4) is a direct activator of SAPKs/JNKs in response to environmental stresses or mitogenic factors(7-9). Here we investigate the role of Sek1 in development and apoptosis by deleting sek1 in embryonic stem (ES) cells by homologous recombination, We provide genetic evidence that different stresses utilize distinct signalling pathways for SAPK/JNK activation, sek1(-/-)/rag2(-/-) chimaeric mice have normal numbers of mature T cells but fewer immature CD4(+)CD8(+) thymocytes, The sek1 mutation did not affect the induction of apoptosis in response to environmental stresses in ES and T cells: instead, sek1 protected thymocytes from CD95 (Fas)- and CD3-mediated apoptosis, These data indicate that SEK1 mediates survival signals in T-cell development.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,TORONTO,ON M5G 2C1,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 2C1,CANADA; UNIV WURZBURG,INST RADIAT & CELL RES,D-97078 WURZBURG,GERMANY; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Wurzburg; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Penninger, Josef M/I-6860-2013; Woodgett, Jim/F-1087-2010	Penninger, Josef M/0000-0002-8194-3777; Woodgett, Jim/0000-0003-3731-5797; Hakem, Razqallah/0000-0001-5948-7931				DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Kruisbeek AM, 1996, CURR OPIN IMMUNOL, V8, P233, DOI 10.1016/S0952-7915(96)80062-8; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POMBO CM, 1994, J BIOL CHEM, V269, P26546; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	20	308	323	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					350	353		10.1038/385350a0	http://dx.doi.org/10.1038/385350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002521				2022-12-28	WOS:A1997WD91400053
J	Cragg, DK; McKinley, RK; Roland, MO; Campbell, SM; Van, F; Hastings, AM; French, DP; MankuScott, TK; Roberts, C				Cragg, DK; McKinley, RK; Roland, MO; Campbell, SM; Van, F; Hastings, AM; French, DP; MankuScott, TK; Roberts, C			Comparison of out of hours care provided by patients' own general practitioners and commercial deputising services: A randomised controlled trial .1. The process of care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOURS CALLS	Objective: To compare the process of out of hours care provided by general practitioners from patients' own practices and by commercial deputising services. Design: Randomised controlled trial. Setting: Four urban areas in Manchester, Salford, Stockport, and Leicester. Subjects: 2152 patients who requested out of hours care, and 49 practice doctors and 183 deputising doctors (61% local principals) who responded to those requests. Main outcome measures: Response to call, time to visit, prescribing, and hospital admissions. Results: 1046 calls were dealt with by practice doctors and 1106 by deputising doctors. Practice doctors were more likely to give telephone advice (20.2% v 0.72% of calls) and to visit more quickly than deputising doctors (median delay 35 minutes v 52 minutes). Practice doctors were less likely than deputising doctors to issue a prescription (56.1% v 63.2% of patients) or to prescribe an antibiotic (43.7% v 61.3% of prescriptions issued) and more likely to prescribe generic drugs (58.4% v 32.1% of drugs prescribed), cheaper drugs (mean cost per prescription pound 3.28 v pound 5.04), and drugs in a predefined out of hours formulary (49.8% v 41.1% of drugs prescribed. There was no significant difference in the number of hospital admissions. Conclusions: By contrast with practice doctors, deputising doctors providing out of hours care less readily give telephone advice, take longer to visit at home, and have patterns of prescribing that may be less discriminating.	UNIV LEICESTER, LEICESTER GEN HOSP, DEPT GEN PRACTICE & PRIMARY HLTH CARE, LEICESTER LE5 4PW, LEICS, ENGLAND; UNIV MANCHESTER, NATL PRIMARY CARE RES & DEV, MANCHESTER M13 9PL, LANCS, ENGLAND; UNIV MANCHESTER, DEPT GEN PRACTICE, RUSHOLME HLTH CTR, MANCHESTER M14 5NP, LANCS, ENGLAND	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; University of Manchester; University of Manchester			McKinley, Robert Kee/H-9211-2013; French, David P/K-7283-2012	McKinley, Robert Kee/0000-0002-3684-3435; French, David P/0000-0002-7663-7804; Campbell, Stephen/0000-0002-2328-4136				ACHESON D, 1981, PRIMARY HLTH CARE IN; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; CRAGG D, 1994, BRIT MED J, V309, P1630; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; CROWE MGF, 1976, BRIT MED J, V1, P1582, DOI 10.1136/bmj.1.6025.1582; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; *DEP HLTH SOC SEC, 1984, GEN PRACT DEP SERV; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; *EL REF BALL SERV, 1992, YOUR CHOIC FUT SURV; GOLDSTEIN H, 1995, MULTILEEL STAT MODEL; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; HASTINGS A, 1996, PHARM J, V256, P900; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; McKinley RK, 1997, BMJ-BRIT MED J, V314, P190, DOI 10.1136/bmj.314.7075.190; NAZARETH I, 1993, BRIT MED J, V306, P1103, DOI 10.1136/bmj.306.6885.1103; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; Rasbash J., 1995, MLN COMMAND REFERENC; RIDSDILLSMITH RM, 1983, UPDATE, V26, P274; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; WHITBY M, 1989, PRACTITIONER, V233, P493; WILLIAMS BT, 1973, BRIT J PREV SOC MED, V27, P129	27	34	34	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					187	189		10.1136/bmj.314.7075.187	http://dx.doi.org/10.1136/bmj.314.7075.187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022434	Green Published			2022-12-28	WOS:A1997WD91100029
J	McKinley, RK; MankuScott, T; Hastings, AM; French, DP; Baker, R				McKinley, RK; MankuScott, T; Hastings, AM; French, DP; Baker, R			Reliability and validity of a new measure of patient satisfaction with out of hours primary medical care in the United Kingdom: Development of a patient questionnaire	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; HOURS CALLS; PRACTITIONERS; HEALTH	Objective: To develop a reliable, valid measure of patient satisfaction with out of hours care suitable for large scale service evaluation. Design: Focus group meetings and semistructured interviews with patients to identify issues of importance to patients and possible questionnaire items; interviews and two pilot studies to test and identify new questionnaire items; modification or removal of items to eliminate ambiguity and reduce non-response and skewed responses; questionnaire survey of out of hours care. Setting: Greater Manchester and Leicester. Subjects: 11 general practice patients participated in the focus groups and 28 in the semistructured interviews; 41 in the preliminary interviews; 41 and 378 in the postal pilots; and 1466 in the survey of out of hours care. Results: A 32 item questionnaire was developed. Component analysis indicated seven scales (satisfaction with communication and management, doctor's attitude, continuity of care, delay until visit, access to out of hours care, initial contact person, telephone advice) related to overall satisfaction and containing issues identified as important to patients. Levels of reliability were satisfactory, Cronbach's alpha correlation coefficient exceeding 0.60 for all scales. Conclusion: A reliable, valid measure of patient satisfaction has been developed, suitable for large scale evaluation of out of hours care.			McKinley, RK (corresponding author), UNIV LEICESTER, LEICESTER GEN HOSP, DEPT GEN PRACTICE & PRIMARY HLTH CARE, LEICESTER LE5 4PW, LEICS, ENGLAND.		McKinley, Robert Kee/H-9211-2013; French, David P/K-7283-2012	McKinley, Robert Kee/0000-0002-3684-3435; French, David P/0000-0002-7663-7804				Aiken L. R., 1994, PSYCHOL TESTING ASSE; ALLEN D, 1988, J ROY COLL GEN PRACT, V38, P163; BAKER R, 1991, FAM PRACT, V8, P171, DOI 10.1093/fampra/8.2.171; BAKER R, 1995, BRIT J GEN PRACT, V45, P654; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; CARTWRIGHT A, 1989, USER SURVEYS GEN PRA; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; Cragg DK, 1997, BMJ-BRIT MED J, V314, P187, DOI 10.1136/bmj.314.7075.187; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DONABEDIAN A, 1987, P INT S QUAL ASS HLT; *EL REF BALL SERV, 1992, YOUR CHOIC FUT SURV; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HIGGINS E, 1993, A Z QUALITY; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; Kincey J, 1975, J R Coll Gen Pract, V25, P558; Klein P, 1993, HDB PSYCHOL TESTING; LINDERPELZ S, 1982, SOC SCI MED, V16, P577, DOI 10.1016/0277-9536(82)90311-2; LOCKER D, 1978, SOC SCI MED, V12, P123; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MANLEY BJF, 1983, MULTIVARIATE STAT ME; MAXWELL RBH, 1993, BRIT J GEN PRACT, V43, P226; MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470; McKinley RK, 1997, BMJ-BRIT MED J, V314, P190, DOI 10.1136/bmj.314.7075.190; *NHS EX, 1996, NAT HLTH SERV GEN ME; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PRUDHOE RH, 1984, BRIT MED J, V288, P718, DOI 10.1136/bmj.288.6418.718-a; SALISBURY C, 1993, BRIT MED J, V306, P762, DOI 10.1136/bmj.306.6880.762; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; Stevens A, 1991, Health Trends, V23, P20; Streiner DL., 2001, HLTH MEASUREMENT SCA, V2nd; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; WALKER RD, 1985, J ROY COLL GEN PRACT, V35, P427; Ware J.E., 1978, HLTH MED CARE SERVIC, V1, P1; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; WILKIN D, 1992, MEASURES NEED OUTCOM; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237	42	143	147	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					193	198		10.1136/bmj.314.7075.193	http://dx.doi.org/10.1136/bmj.314.7075.193			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022436	Green Published			2022-12-28	WOS:A1997WD91100031
J	Lyman, SK; Schekman, R				Lyman, SK; Schekman, R			Binding of secretory precursor polypeptides to a translocon subcomplex is regulated by BiP	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PREPRO-ALPHA-FACTOR; CELL-FREE SYSTEM; PROTEIN TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; SIGNAL SEQUENCE; SEC PROTEINS; EUKARYOTIC HOMOLOGS; SEC63P-BIP COMPLEX; ATP HYDROLYSIS	The translocation of a secretory precursor protein across the ER membrane comprises three phases: docking of the precursor at the membrane, insertion into the translocation pore, and exit from the pore into the ER lumen. We demonstrate that Sec62p, Sec71p and Sec72p form a translocon subcomplex that engages secretory precursors at the membrane site of the ER translocation machinery. Binding of a precursor to the subcomplex depends on the presence of an intact signal sequence and occurs only in the absence of ATP. In the presence of ATP, the precursor is released from the subcomplex in a reaction mediated by the lumenal hsp70, BiP. This release reaction, which is specific to BiP and requires interaction between BiP and the DnaJ homolog Sec63p, defines a role for BiP and Sec63p early in the ER translocation process.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026755] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; ALLISON DS, 1989, MOL CELL BIOL, V9, P4977, DOI 10.1128/MCB.9.11.4977; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; LYMAN SK, IN PRESS GUIDEBOOK M; LYMAN SK, 1996, THESIS U CALIFORNIA; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NELSON MK, 1993, GENETICS, V134, P159; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J BIOL CHEM, V263, P6209; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	51	121	125	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					85	96		10.1016/S0092-8674(00)81861-9	http://dx.doi.org/10.1016/S0092-8674(00)81861-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019409	Bronze			2022-12-28	WOS:A1997WC56900012
J	Nyamugunduru, G; Roper, H				Nyamugunduru, G; Roper, H			A difficult case: Childhood onset insulin dependent diabetes presenting with severe hyperlipidaemia	BRITISH MEDICAL JOURNAL			English	Article								Confronted with a child deteriorating during treatment of diabetic ketacidosis, Godfrey Nyamugunduru and Helen Roper describe how the child's management was complicated by gross hyperlipidaemia. At the point where the child's condition was deteriorating despite conventional management we invited two experts-Gilbert R Thompson and J I Mann-to suggest a course of action. The original authors then describe how they did manage the case, and our experts comment again.	BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham								BAGDADE JD, 1967, NEW ENGL J MED, V276, P427, DOI 10.1056/NEJM196702232760802; CHANCE GW, 1969, LANCET, V1, P1126	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					62	62		10.1136/bmj.314.7073.62	http://dx.doi.org/10.1136/bmj.314.7073.62			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001485	Green Published			2022-12-28	WOS:A1997WB68400034
J	Kuhn, C; Franceschi, VR; Schulz, A; Lemoine, R; Frommer, WB				Kuhn, C; Franceschi, VR; Schulz, A; Lemoine, R; Frommer, WB			Macromolecular trafficking indicated by localization and turnover of sucrose transporters in enucleate sieve elements	SCIENCE			English	Article							PLASMA-MEMBRANE; MINOR VEINS; COMPANION CELLS; MESSENGER-RNAS; PHLOEM; PROTEIN; PLASMODESMATA; PLANTS; LEAF	The leaf sucrose transporter SUT1 is essential for phloem loading and long-distance transport of assimilates. Both SUT1 messenger RNA (mRNA) and protein were shown to be diurnally regulated and to have high turnover rates. SUT1 protein was detected by immunolocalization in plasma membranes of enucleate sieve elements (SEs) in tobacco, potato, and tomato. Analysis by in situ hybridization showed that SUT1 mRNA localizes mainly to the SE and is preferentially associated with plasmodesmata. Antisense inhibition of SUT1 expression under control of a companion cell (CC)-specific promoter indicated synthesis of SUT1 mRNA in the CC. These results provide evidence for targeting of plant endogenous mRNA and potentially SUT1 protein through phloem plasmodesmata and for sucrose loading at the plasma membrane of SE.	UNIV TUBINGEN,INST BOT,D-72076 TUBINGEN,GERMANY; CHRISTIAN ALBRECHTS UNIV KIEL,INST BOT,D-24098 KIEL,GERMANY; WASHINGTON STATE UNIV,CTR ELECTRON MICROSCOPY,PULLMAN,WA 99164; UNIV POITIERS,LAB PHYSIOL & BIOCHIM VEGETALES,CNRS,URA 574,POITIERS,FRANCE	Eberhard Karls University of Tubingen; University of Kiel; Washington State University; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers			Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008; Schulz, Alexander/A-3357-2013	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Schulz, Alexander/0000-0001-6796-3598; Kuhn, Christina/0000-0002-8370-9706				Boorer KJ, 1996, J BIOL CHEM, V271, P25139, DOI 10.1074/jbc.271.41.25139; BOSTWICK DE, 1992, PLANT CELL, V4, P1539, DOI 10.1105/tpc.4.12.1539; BOUCHEPILLON S, 1994, PLANT PHYSIOL, V105, P691, DOI 10.1104/pp.105.2.691; BROPHY PJ, 1993, TRENDS NEUROSCI, V16, P515, DOI 10.1016/0166-2236(93)90196-S; BURKLE L, UNPUB; DeWitt ND, 1995, PLANT CELL, V7, P2053, DOI 10.1105/tpc.7.12.2053; EVERT RF, 1990, SIEVE ELEMENTS, P103; FROMMER WB, 1996, MEMBRANES SPECIALIZE, P319; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; GRASSO JA, 1963, P NATL ACAD SCI USA, V50, P134, DOI 10.1073/pnas.50.1.134; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEKE D, 1994, PLANTA, V193, P174, DOI 10.1007/BF00192527; KENNECKE M, 1971, PLANTA, V98, P330, DOI 10.1007/BF00380234; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Kuhn C, 1996, PLANT CELL ENVIRON, V19, P1115, DOI 10.1111/j.1365-3040.1996.tb00426.x; LACKNEY VK, 1991, PLANT CELL ENVIRON, V14, P213, DOI 10.1111/j.1365-3040.1991.tb01338.x; LEHMANN A, 1981, PFLANZENPHYSIOL, V102, P415; LEMOINE C, 1996, PLANT CELL ENVIRON, V19, P1124; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; MARKS PA, 1962, P NATL ACAD SCI USA, V48, P2163, DOI 10.1073/pnas.48.12.2163; MAYNARD JW, 1982, PLANT PHYSIOL, V70, P1436, DOI 10.1104/pp.70.5.1436; MCCAULEY MM, 1989, BOT GAZ, V150, P351, DOI 10.1086/337781; NAKAMURA S, 1993, PLANT CELL PHYSIOL, V34, P927; NEUMANN S, 1964, Z NATURFORSCH PT B, VB 19, P1066, DOI 10.1515/znb-1964-1116; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; NUSKE J, 1976, PLANTA, V132, P109, DOI 10.1007/BF00388891; PARTHASARATHY MV, 1980, BER DEUT BOT GES, V93, P57; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; RLESMEIER JW, 1994, EMBO J, V13, P1; ROECKL B, 1949, PLANTA, V36, P530, DOI 10.1007/BF01909361; SCHOBERT C, 1995, PLANTA, V196, P205, DOI 10.1007/BF00201375; SJOLUND RD, 1983, J ULTRA MOL STRUCT R, V82, P189, DOI 10.1016/S0022-5320(83)90052-7; STADLER R, 1995, PLANT CELL, V7, P1545, DOI 10.1105/tpc.7.10.1545; Stadler R, 1996, BOT ACTA, V109, P299, DOI 10.1111/j.1438-8677.1996.tb00577.x; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; THORSCH J, 1981, J ULTRA MOL STRUCT R, V74, P183, DOI 10.1016/S0022-5320(81)80076-7; VANBEL AJE, 1993, ANNU REV PLANT PHYS, V44, P253, DOI 10.1146/annurev.pp.44.060193.001345; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018	38	358	398	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1298	1300		10.1126/science.275.5304.1298	http://dx.doi.org/10.1126/science.275.5304.1298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036853				2022-12-28	WOS:A1997WK64400040
J	Meng, J; Wyss, AR				Meng, J; Wyss, AR			Multituberculate and other mammal hair recovered from Palaeogene excreta	NATURE			English	Article							ACCUMULATIONS	Evidence of hair from several extinct mammals has been recovered from a rich accumulation of fossil excrement from the Late Palaeocene beds of Inner Mongolia, China, This highly unusual and previously undocumented depositional occurrence consists of hundreds of mammalian carnivore coprolites (fossil faeces) and a lesser number of probably raptorial bird regurgitalites(1) (fossil pellets). The fossil hair occurs as impressions and natural casts in the extremely fine-grained, calcareous matrix that cements the skeletal remains within these faecal structures and preserves even the cuticular scale pattern on individual hair, Hair from at least four mammalian taxa, most notably the multituberculate Lambdopsalis bulla(2), has been identified. This record constitutes the first tangible evidence that, along with monotremes and therian mammals, multituberculates were hirsuite, and lends support for the presence of this mammalian feature in the most recent common ancestor of these three groups.	UNIV MASSACHUSETTS,GRAD PROGRAM ORGANISM & EVOLUTIONARY BIOL,AMHERST,MA 01003; UNIV CALIF SANTA BARBARA,DEPT GEOL,SANTA BARBARA,CA 93106	University of Massachusetts System; University of Massachusetts Amherst; University of California System; University of California Santa Barbara	Meng, J (corresponding author), UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003, USA.							ANDREWS P, 1983, PALEOBIOLOGY, V9, P289, DOI 10.1017/S0094837300007703; [Anonymous], NEW MEXICO BUREAU MI; Brunner H., 1974, IDENTIFICATION MAMMA, DOI [10.1017/S0030605300014253, DOI 10.1017/S0030605300014253]; CHOW M, 1978, VERTEBRAT PALASIATIC, V16, P77; CIFELLI R L, 1989, Bulletin of the Museum of Comparative Zoology, V152, P1; DEBROT S, 1982, ATALS POILS MAMMIFER; EDWARDS P, 1974, Contributions to Geology University of Wyoming, V13, P67; FISHER D C, 1981, Contributions from the Museum of Paleontology University of Michigan, V25, P259; Hahn G., 1987, B SOC BELGE GEOLOGIE, V96, P39; Hopson James A., 1994, Short Courses in Paleontology, V7, P190; Hunt Adrian P., 1994, P221; JENKINS FA, 1983, SCIENCE, V220, P712, DOI 10.1126/science.220.4598.712; Kemp T.S, 1982, MAMMAL LIKE REPTILES; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; Krause D. W., 1986, CONTRIBUTIONS GEOLOG, V3, P95; LANDRY SO, 1967, SYST ZOOL, V16, P172, DOI 10.2307/2411412; Matthew W.D., 1925, AM MUSEUM NATURAL HI, V189, P1; MELLETT JS, 1974, SCIENCE, V185, P349, DOI 10.1126/science.185.4148.349; MENG J, 1994, NATURE, V370, P134, DOI 10.1038/370134a0; MENG J, IN PRESS B CARNEGIE; Meng Jin, 1994, Journal of Mammalian Evolution, V2, P185, DOI 10.1007/BF01473528; Miao D-S., 1988, CONTRIB GEOL U WYOMI, V4, P1; OSTRANDER G, 1984, NEBRASKA ACAD SCI T, V12, P71; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; RUSSELL D E, 1987, Memoires du Museum National d'Histoire Naturelle Serie C Sciences de la Terre, V52, P1; SCHAAL S, 1992, MESSEL ART INSIGHT H; Vaughan TA, 1986, MAMMALOGY	27	53	56	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					712	714		10.1038/385712a0	http://dx.doi.org/10.1038/385712a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034186				2022-12-28	WOS:A1997WJ42300043
J	Pollack, R				Pollack, R			A crisis in scientific morale	NATURE			English	Editorial Material											Pollack, R (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.							POLLACK R, 1994, SIGNS LIFE	1	2	2	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					673	674		10.1038/385673a0	http://dx.doi.org/10.1038/385673a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034180				2022-12-28	WOS:A1997WJ42300018
J	Averof, M; Cohen, SM				Averof, M; Cohen, SM			Evolutionary origin of insect wings from ancestral gills	NATURE			English	Article							PATTERN-FORMATION; DROSOPHILA; EXPRESSION; PROTEIN; ENCODES; GENES; DISC	Two hypotheses have been proposed for the origin of insect wings. One holds that wings evolved by modification of limb branches that were already present in multibranched ancestral appendages and probably functioned as gills(1-5). The second proposes that wings arose as novel outgrowths of the body wall, not directly related to any pre-existing limbs(6). If wings derive from dorsal structures of multibranched appendages, we expect that some of their distinctive features will have been built on genetic functions that were already present in the structural progenitors of insect wings, and in homologous structures of other arthropod Limbs. We have isolated crustacean homologues of two genes that have wing-specific functions in insects, pdm (nubbin) and apterous. Their expression patterns support the hypothesis that insect wings evolved from gill-like appendages that were already present in the aquatic ancestors of both crustaceans and insects.			Averof, M (corresponding author), EUROPEAN MOL BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163; Averof, Michalis/0000-0002-6803-7251				AVEROF M, 1995, PHILOS T R SOC B, V347, P293, DOI 10.1098/rstb.1995.0028; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BHAT KM, 1995, MOL CELL BIOL, V15, P4052; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHEN SM, 1983, DROSOPHILA DEV, P747; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRIEDRICH M, 1995, NATURE, V376, P165, DOI 10.1038/376165a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kukalova-Peck J., 1991, P141; KUKALOVAPECK J, 1992, CAN J ZOOL, V70, P236, DOI 10.1139/z92-037; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LLOYD A, 1991, MECH DEVELOP, V36, P87, DOI 10.1016/0925-4773(91)90075-H; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; NG M, 1995, DEVELOPMENT, V121, P589; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PATEL NH, 1989, DEVELOPMENT, V107, P201; Snodgrass RE, 1935, PRINCIPLES INSECT MO; WIGGLESW.VB, 1973, NATURE, V246, P127, DOI 10.1038/246127a0; WIGGLESWORTH VB, 1976, INSECT FLIGHT, P255; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; Yeo Su Ling, 1995, Genes and Development, V9, P1223, DOI 10.1101/gad.9.10.1223	27	174	183	11	124	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					627	630		10.1038/385627a0	http://dx.doi.org/10.1038/385627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024659				2022-12-28	WOS:A1997WH29400048
J	Moarefi, I; LaFevreBernt, M; Sicheri, F; Huse, M; Lee, CH; Kuriyan, J; Miller, WT				Moarefi, I; LaFevreBernt, M; Sicheri, F; Huse, M; Lee, CH; Kuriyan, J; Miller, WT			Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement	NATURE			English	Article							INTERMOLECULAR AUTOPHOSPHORYLATION; GENE HCK; BINDING; PP60C-SRC; PROTEIN; DEPHOSPHORYLATION; PHOSPHORYLATION; SPECIFICITY; TERMINUS; PEPTIDES	The protein Hck is a member of the Src family of non-receptor tyrosine kinases which is preferentially expressed in haematopoietic cells of the myeloid and B-lymphoid lineages(1,2). Src kinases are inhibited by tyrosine-phosphorylation at a carboxy-terminal site(3-9). The SH2 domains of these enzymes play an essential role in this regulation by binding to the tyrosine-phosphorylated tail(8-11). The crystal structure of the downregulated form of Hck has been determined(12) and reveals that the SH2 domain regulates enzymatic activity indirectly; intramolecular interactions between the SH3 and catalytic domains appear to stabilize an inactive form of the kinase, Here we compare the roles of the SH2 and SH3 domains in modulating the activity of Hck in an investigation of the C-terminally phosphorylated form of the enzyme, We show that addition of the HIV-1 Nef protein, which is a high-affinity ligand for the Hck SH3 domain, to either the downregulated or activated form of Hck causes a large increase in Hck catalytic activity, The intact SH3-binding motif in Nef is crucial for Hck activation. Our results indicate that binding of the Hck SH3 domain by Nef causes a more marked activation of the enzyme than does binding of the SH2 domain, suggesting a new mechanism for regulation of the activity of tyrosine kinases.	SUNY STONY BROOK, SCH MED, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; ROCKEFELLER UNIV, MOL BIOPHYS LAB, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Sicheri, Frank/F-8856-2013; Lee, Chi-Hon/G-9190-2012	Lee, Chi-Hon/0000-0002-6138-711X				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIU XQ, 1993, ONCOGENE, V8, P1119; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TILL JH, 1994, J BIOL CHEM, V269, P7423; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	24	526	530	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					650	653		10.1038/385650a0	http://dx.doi.org/10.1038/385650a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024665				2022-12-28	WOS:A1997WH29400054
J	Plaut, AG				Plaut, AG			Trefoil peptides in the defense of the gastrointestinal tract	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Plaut, AG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.				NIDDK NIH HHS [DK34928] Funding Source: Medline; PHS HHS [NIDR 06977] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6	4	34	34	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					506	507		10.1056/NEJM199702133360712	http://dx.doi.org/10.1056/NEJM199702133360712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017947				2022-12-28	WOS:A1997WG77600011
J	Andrews, LB; Stocking, C; Krizek, T; Gottlieb, L; Krizek, C; Vargish, T; Siegler, M				Andrews, LB; Stocking, C; Krizek, T; Gottlieb, L; Krizek, C; Vargish, T; Siegler, M			An alternative strategy for studying adverse events in medical care	LANCET			English	Article							HOSPITALIZED-PATIENTS; MALPRACTICE	Background Data about the frequency of adverse events related to inappropriate care in hospitals come from studies of medical records as if they represented a true record of adverse events. In a prospective, observational design we analysed discussion of adverse events during the care of all patients admitted to three units of a large, urban teaching hospital affiliated to a university medical school. Discussion took place during routine clinical meetings. We undertook the study to enhance understanding of the incidence and scope of adverse events as a basis for preventing them. Methods Ethnographers trained in qualitative observational research attended day-shift, weekday, regularly scheduled attending rounds, residents' work rounds, nursing shift changes, case conferences, and other scheduled meetings in three study units as well as various departmental and section meetings. They recorded all adverse events during patient care discussed at these meetings and developed a classification scheme to code the data. Data were collected about health-care providers' own assessments about the appropriateness of the care that patients received to assess the nature and impact of adverse events and how health-care providers and patients responded to the adverse events. Findings Of the 1047 patients in the study, 185 (17.7%) were said to have had at least one serious adverse event; having an initial event was linked to the seriousness of the patient's underlying illness. Patients with long slays in hospital had more adverse events than those with short stays. The likelihood of experiencing an adverse event increased about 6% for each day of hospital stay. 37.8% of adverse events were caused by an individual, 15.6% had interactive causes, and 9.8% were due to administrative decisions. Although 17.7% of patients experienced serious events that led to longer hospital stays and increased costs to the patients, only 1.2% (13) of the 1047 patients made claims for compensation. Interpretation This study shows that there is a wide range of potential causes of adverse events that should be considered, and that careful attention must be paid to errors with interactive or administrative causes. Healthcare providers' own discussions of adverse events can be a good source of data for proactive error prevention.	AMER BAR FDN,CHICAGO,IL 60611; UNIV CHICAGO,DEPT MED,MACLEAN CTR CLIN MED ETH,CHICAGO,IL 60637; UNIV CHICAGO,DEPT SURG,CHICAGO,IL 60637; UNIV S FLORIDA,DEPT SURG,TAMPA,FL 33620	University of Chicago; University of Chicago; State University System of Florida; University of South Florida	Andrews, LB (corresponding author), CHICAGO KENT COLL LAW,565 W ADAMS ST,CHICAGO,IL 60661, USA.							BOSK CL, 1989, FORGIVE REMEMBER; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BROOK RH, 1973, ANN INTERN MED, V78, P333, DOI 10.7326/0003-4819-78-3-333; *CAL MED ASS CAL H, 1977, MED INS FEAS STUD; CASSEL J, 1996, EXPECTED MIRACLES SU; Cox D. R., 1984, ANAL SURVIVAL DATA; *HARV MED PRACT ST, 1990, PAT DOCT LAW MED INJ; HIATT HH, 1989, NEW ENGL J MED, V321, P480, DOI 10.1056/NEJM198908173210725; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MEYERS AR, 1987, AM J PUBLIC HEALTH, V77, P1544, DOI 10.2105/AJPH.77.12.1544; MILLS DH, 1978, WESTERN J MED, V128, P360; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SOWKA MP, 1981, CONN MED, V45, P91; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; Tuma N.B., 1984, SOCIAL DYNAMICS MODE, P578	16	337	348	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					309	313		10.1016/S0140-6736(96)08268-2	http://dx.doi.org/10.1016/S0140-6736(96)08268-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024373				2022-12-28	WOS:A1997WF79400009
J	Jones, AH				Jones, AH			Literature and medicine: Physician-poets	LANCET			English	Editorial Material											Jones, AH (corresponding author), UNIV TEXAS, MED BRANCH, INST MED HUMANITIES, ASHBEL SMITH BLDG SUITE 2210, 301 UNIV BLVD, GALVESTON, TX 77555 USA.							ABSE D, 1983, ONE LEGGED ICE; ABSE D, 1994, INTERMITTENT J, P11; ABSE D, 1978, MY MED SCH, P111; ABSE D, 1977, COLLECTED POEMS 1948; BRYANT DC, 1994, LIT MED, V13, P284, DOI 10.1353/lm.2010.0003; BUSH D, 1950, SCI ENGLISH POETRY; Campo Rafael, 1996, WHAT BODY TOLD; CHARACH R, 1990, NAKED PHYSICIAN POEM; CLAIRE W, 1984, LIT MED PHYSICIANS W, V3, P1; COHEN J, 1983, POETRY D ABSE CRITIC, P7; COLES R, 1981, JAMA-J AM MED ASSOC, V245, P41, DOI 10.1001/jama.245.1.41; COULEHAN J, 1991, KNITTED GLOVE; Dana Charles Loomis, 1916, POETRY DOCTORS CATAL; EVANS L, 1969, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5661.7; GITTINGS R, 1973, JAMA-J AM MED ASSOC, V224, P51, DOI 10.1001/jama.224.1.51; GOELLNICHT DC, 1984, POET PHYSICIAN KEATS; Graham Theodora R., 1983, LIT MED, V2, P9; Horowitz HW, 1996, LANCET, V347, P447, DOI 10.1016/S0140-6736(96)90015-X; HUNTER KM, 1991, 2 OPINION, V16, P64; JONES A, 1992, KNOT; Jones AH, 1996, LANCET, V348, P1360, DOI 10.1016/S0140-6736(96)09219-7; JONES AH, 1990, ST COMPAR L, V22, P11; KOHN M, 1984, LIT MED, V3, P102; KOHN M, 1986, POETRY COLLECTION PO; LOWBURY E, 1990, APOLLO ANTHOLOGY POE; MCDONOUGH ML, 1945, POET PHYSICIANS ANTH; MOORE M, 1945, POET PHYSICIANS ANTH, P197; MUKAND J, 1994, ARTICULATIONS BODY I; OSLER W, 1896, J HOPKINS HOSP B, V7, P11; RAINS AJH, 1994, J ROY SOC MED, V87, P742; RATZAN RM, 1982, ANN INTERN MED, V97, P933, DOI 10.7326/0003-4819-97-6-933; ROUSSEAU GS, 1981, ISIS, V72, P406, DOI 10.1086/352790; SHELLEY PB, COMPLETE POETICAL WO, P650; SMITH H, 1984, REV INFECT DIS, V6, P390; SMITH HM, 1984, MD, V28, P113; SMITH HM, 1984, MD, V28, P108; STONE J, 1983, JAMA-J AM MED ASSOC, V250, P1421, DOI 10.1001/jama.250.11.1421; STONE J, 1978, MY MED SCH, P179; STONE J, 1985, RENAMING STREETS; Stone J, 1985, RENAMING STREETS, P21; STONE J, 1980, ALL THIS RAIN; STONE J, 1988, SMELL MATCHES; Wagner Linda, 1968, JAMA-J AM MED ASSOC, V204, P113; WILLIAMS EE, 1983, TECHNOVATION, V2, P3, DOI 10.1016/0166-4972(83)90003-2; WILLIAMS WC, 1962, PICTURES BRUEGHEL OT, P161; 1969, BRIT MED J, V3, P1	46	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					275	278		10.1016/S0140-6736(96)12240-6	http://dx.doi.org/10.1016/S0140-6736(96)12240-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014928				2022-12-28	WOS:A1997WD90600047
J	Offermanns, S; Mancino, V; Revel, JP; Simon, MI				Offermanns, S; Mancino, V; Revel, JP; Simon, MI			Vascular system defects and impaired cell chemokinesis as a result of G alpha(13) deficiency	SCIENCE			English	Article							G-PROTEINS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ENDOTHELIUM; PATHWAY; MICE; ACTIVATION; RECEPTORS; KINASE; RHO	Heterotrimeric GTP-binding proteins (G proteins) participate in cellular signaling and regulate a variety of physiological processes. Disruption of the gene encoding the G protein subunit alpha(13) (G alpha(13)) in mice impaired the ability of endothelial cells to develop into an organized Vascular system, resulting in intrauterine death. In addition, G alpha(13) (-/-) embryonic fibroblasts showed greatly impaired migratory responses to thrombin. These results demonstrate that G alpha(13) participates in the regulation of cell movement in response to specific-ligands, as well as in developmental angiogenesis.			Offermanns, S (corresponding author), CALTECH,DIV BIOL 14775,PASADENA,CA 91125, USA.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012288] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12288] Funding Source: Medline; NIGMS NIH HHS [GM 34236] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BIMBAUMER L, 1992, CELL, V71, P1068; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DAVIS CA, 1993, METHOD ENZYMOL, V225, P502; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGGINS T, 1994, CELL BIOL LAB HDB, P294; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OFFERMANNS S, UNPUB; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SA G, 1994, J BIOL CHEM, V269, P3219; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; YANG JT, 1993, DEVELOPMENT, V119, P1093; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; [No title captured]	41	283	289	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					533	536		10.1126/science.275.5299.533	http://dx.doi.org/10.1126/science.275.5299.533			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999798				2022-12-28	WOS:A1997WE25700045
J	Toubro, S; Astrup, A				Toubro, S; Astrup, A			Randomised comparison of diets for maintaining obese subjects' weight after major weight loss: Ad lib, low fat, high carbohydrate diet v fixed energy intake	BRITISH MEDICAL JOURNAL			English	Article							LOW CALORIE DIET; COVERT MANIPULATION; FOOD-INTAKE; WOMEN; LIBITUM; RATIO; TRIAL; MEN; REDUCTION; DENSITY	Objectives: To compare importance of rate of initial weight loss for long term outcome in obese patients and to compare efficacy of two different weight maintenance programmes. Design: Subjects were randomised to either rapid or slow initial weight loss. Completing patients were re-randomised to one year weight maintenance programme of ad lib diet or fixed energy intake diet Patients were followed up one year later. Setting: University research department in Copenhagen, Denmark. Subjects: 43 (41 women) obese adults (body mass index 27-40) who were otherwise healthy living in or around Copenhagen. Interventions: 8 weeks of low energy diet (2 MJ/day) or 17 weeks of conventional diet (5 MJ/day), both supported by an anorectic compound (ephedrine 20 mg and caffeine 200 mg thrice daily); one year weight maintenance programme of ad lib, low fat, high carbohydrate diet or fixed energy intake diet (less than or equal to 7.8 MJ/day), both with reinforcement sessions 2-3 times monthly. Main outcome measures: Mean initial weight loss and proportion of patients maintaining a weight loss of > 5 kg at follow up. Results: Mean initial weight loss was 12.6 kg (95% confidence interval 10.9 to 14.3 kg) in rapid weight loss group and 12.6 (9.9 to 15.3) kg in conventional diet group. Rate of initial weight loss had no effect on weight maintenance after 6 or 12 months of weight maintenance or at follow up. After weight maintenance programme, the ad lib group had maintained 13.2 (8.1 to 18.3) kg of the initial weight loss of 13.5 (11.4 to 15.5) kg, and the fixed energy intake group had maintained 9.7 (6.1 to 13.3) kg of the initial 13.8 (11.8 to 1.7) kg weight loss (group difference 3.5 (-2.4 to 9.3) kg). Regained weight at follow up was greater in fixed energy intake group than in ad lib group (11.3 (7.1 to 15.5) kg v 5.4 (2.3 to 8.6) kg, group difference 5.9 (0.7 to 11.1) kg, P < 0.03), At follow up, 65% of ad lib group and 40% of fixed energy intake group had maintained a weight loss of > 5 kg (P < 0.07). Conclusion: Ad lib, low fat, high carbohydrate diet was superior to fixed energy intake for maintaining weight after a major weight loss. The rate of the initial weight loss did not influence long term outcome.			Toubro, S (corresponding author), ROYAL VET & AGR UNIV,RES DEPT HUMAN NUTR,ROLIGHEDSVEJ 30,DK-1958 FREDERIKSBERG,COPENHAGEN,DENMARK.		Astrup, Arne/B-1407-2015	Astrup, Arne/0000-0001-8968-8996				ASTRUP A, 1992, INT J OBESITY, V16, P269; ASTRUP A, 1994, AM J CLIN NUTR, V59, P350, DOI 10.1093/ajcn/59.2.350; ASTRUP A, 1995, INT J OBESITY, V19, pS27; Blundell John E., 1993, American Journal of Clinical Nutrition, V57, p772S, DOI 10.1093/ajcn/57.5.772S; CHEN YDI, 1995, DIABETES CARE, V18, P10, DOI 10.2337/diacare.18.1.10; COLDITZ GA, 1992, AM J CLIN NUTR, V55, P503; DREON DM, 1988, AM J CLIN NUTR, V47, P995, DOI 10.1093/ajcn/47.6.995; GARROW J, 1991, BRIT MED J, V303, P704, DOI 10.1136/bmj.303.6804.704; GARROW JS, 1989, LANCET, V1, P1429; HEITMANN BL, 1995, AM J CLIN NUTR, V61, P1213, DOI 10.1093/ajcn/61.6.1213; HEITMANN BL, 1995, BRIT MED J, V311, P986; HEITMANN BL, 1990, INT J OBESITY, V14, P789; HEY H, 1987, CLIN NUTR, V6, P195, DOI 10.1016/0261-5614(87)90057-4; HILL JO, 1995, AM J CLIN NUTR, V62, p264S, DOI 10.1093/ajcn/62.1.264S; HOIE LH, 1993, INT J OBESITY, V17, P17; JEFFERY RW, 1995, INT J OBESITY, V19, P132; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LYON XH, 1995, INT J OBESITY, V19, P260; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; SCHLUNDT DG, 1993, INT J OBESITY, V17, P623; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P330, DOI 10.1093/ajcn/62.2.330; STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316; STUNKARD AJ, 1993, OBESITY THEORY THERA, P197; TREMBLAY A, 1994, AM J CLIN NUTR, V59, P975, DOI 10.1093/ajcn/59.5.975; TREMBLAY A, 1995, INT J OBESITY, V19, pS10; TUCKER LA, 1992, AM J CLIN NUTR, V56, P616, DOI 10.1093/ajcn/56.4.616; WADDEN TA, 1989, INT J OBESITY, V13, P39; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386	29	148	150	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					29	34		10.1136/bmj.314.7073.29	http://dx.doi.org/10.1136/bmj.314.7073.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001476	Green Published			2022-12-28	WOS:A1997WB68400021
J	Worrall, A; Rea, JN; BenShlomo, Y				Worrall, A; Rea, JN; BenShlomo, Y			Counting the cost of social disadvantage in primary care: Retrospective analysis of patient data	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; CONSULTATION; DEPRIVATION; MORBIDITY; WORKLOAD; HEALTH; EQUITY; AREAS; RATES	Objective: To cost the relation between socioeconomic status and various measures of primary care workload and assess the adequacy of current ''deprivation'' payments in relation to actual costings for patients living in qualifying areas. Design: Retrospective data on primary care were collected over a 4.5 year period from both computerised and manually filed records. Standardised data on socioeconomic status were obtained by postal questionnaire. Setting: Inner city group with a socioeconomically diverse population. Subjects: 382 male and female subjects of all ages, with a total of 1296 person years of observation. Main outcome measures: Primary care costs resulting from consultations with a general practitioner or a practise nurse and both new and repeat prescriptions. Results: Morbidity, workload, and costs of drug treatment increased with decreasing socioeconomic status. The difference in cost for patients in social classes IV and V combined compared with those in I and II combined was about pound 150 per person year at risk (pound 47 for workload and pound 103 for drugs). Deprivation payments met only half the extra workload cost for patients from qualifying wards. Conclusions: The greater workload caused by social disadvantage has been previously underestimated by simple consultation rates. The absolute difference in costs for socially disadvantaged patients increases as more detailed measures of workload and drug treatment are included. Current deprivation payments only partially offsets the increased expenditure on workload. This shortfall will have to be addressed to attract general practitioners to, or retain them in, deprived areas.	UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND; KENTISH TOWN HLTH CTR,LONDON NW5 2AJ,ENGLAND	University of Bristol			Ben-Shlomo, Yoav/ABD-2004-2021	Ben-Shlomo, Yoav/0000-0001-6648-3007				ALLAN K, 1994, MIQUEST PROJECT REPO; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUNIT, V16, P532; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; BLAXTER M, 1984, BRIT MED J, V288, P1963, DOI 10.1136/bmj.288.6435.1963; *BRIT MED ASS ROYA, 1994, BRIT NAT FORM; BUCHAN IC, 1973, SCOTTISH HLTH STUDIE, V27; CARRHILL R, 1995, BRIT J GEN PRACT, V45, P505; CarrHill RA, 1996, BRIT MED J, V312, P1008; CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; CHATURVEDI N, 1995, BRIT J GEN PRACT, V45, P127; COLLINS E, 1980, BRIT MED J, V281, P1111, DOI 10.1136/bmj.281.6248.1111; FOX J, 1990, LONGITUDINAL STUDY M, P99; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P164; HILL RAC, 1991, BRIT MED J, V302, P393; Hills, 1993, STAT MODELS EPIDEMIO; HOBBS R, 1993, BRIT MED J, V306, P534, DOI 10.1136/bmj.306.6877.534; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JARMAN B, 1990, PAPERS SCI TECHNOLOG, V22; JEFFERYS M, 1983, RETHINKING GEN PRACT, P91; JEFFREYS LA, 1995, BRIT J GEN PRACT, V45, P415; JOYCE CRB, 1969, Q J MED, V38, P183; LEESE B, 1995, BRIT MED J, V311, P546, DOI 10.1136/bmj.311.7004.546; LUCAS J, 1995, BRIT J GEN PRACT, V45, P692; MARMOT M, 1996, HLTH SOCIAL ORG, P42; MARSH GN, 1986, BRIT MED J, V292, P1173, DOI 10.1136/bmj.292.6529.1173; MARSH GN, 1991, EFFICIENT CARE GEN P, P40; MCCORMICK A, 1995, MORBIDITY STAT GEN P; NETTEN A, 1995, UNIT COSTS COMMUNITY; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; REA JN, 1962, MED WORLD, V37, P291; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; WALSH K, 1994, BRIT J GEN PRACT, V44, P118	32	42	42	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					38	42		10.1136/bmj.314.7073.38	http://dx.doi.org/10.1136/bmj.314.7073.38			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001480	Green Published			2022-12-28	WOS:A1997WB68400026
J	Iyengar, R				Iyengar, R			Signal transduction - There are GAPS and there are GAPS	SCIENCE			English	Editorial Material							SACCHAROMYCES-CEREVISIAE; MECHANISM; GTPASE; ACTIVATION; HYDROLYSIS; MUTANTS; SUBUNIT				Iyengar, R (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,NEW YORK,NY 10029, USA.							Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HUNT TW, 1996, NATURE, V383, P178; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KURJAN J, 1993, ANNU REV GENET, V27, P147; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LINDER ME, 1987, J BIOL CHEM, V265, P8283; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1994, J BIOL CHEM, V269, P6039; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WANG J, IN PRESS J BIOL CHEM; WATSON N, 1996, NATURE, V383, P175	25	27	27	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					42	43		10.1126/science.275.5296.42	http://dx.doi.org/10.1126/science.275.5296.42			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8999536				2022-12-28	WOS:A1997WA90300039
J	Kluck, RM; BossyWetzel, E; Green, DR; Newmeyer, DD				Kluck, RM; BossyWetzel, E; Green, DR; Newmeyer, DD			The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION; NUCLEAR-ENVELOPE; OUTER-MEMBRANE; CA2+ FLUXES; PROTEIN; ONCOPROTEIN; INHIBITION; REDUCTION	In a cell-free apoptosis system, mitochondria spontaneously released cytochrome c, which activated DEVD-specific caspases, leading to fodrin cleavage and apoptotic nuclear morphology. Bcl-2 acted in situ on mitochondria to prevent the release of cytochrome c and thus caspase activation. During apoptosis in intact cells, cytochrome c translocation was similarly blocked by Bcl-2 but not by a caspase inhibitor, zVAb-fmk. In vitro, exogenous cytochrome c bypassed the inhibitory effect of Bcl-2. Cytochrome c release was unaccompanied by changes in mitochondrial membrane potential. Thus, Bcl-2 acts to inhibit cytochrome c translocation, thereby blocking caspase activation and the apoptotic process.	LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,SAN DIEGO,CA 92121	La Jolla Institute for Immunology			Kluck, Ruth M/C-8413-2013; Green, Douglas R/N-8083-2018	Kluck, Ruth M/0000-0002-7101-1925; Green, Douglas R/0000-0002-7332-1417	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NCI NIH HHS [CA69381] Funding Source: Medline; NIGMS NIH HHS [GM50284, GM52735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAO Y, 1994, CANCER RES, V54, P2468; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BABA ML, 1981, J MOL EVOL, V17, P197, DOI 10.1007/BF01732758; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; DEJONG D, 1994, CANCER RES, V54, P256; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FARSCHON DM, UNPUB; KLUCK R, UNPUB; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Vance BA, 1996, J BIOL CHEM, V271, P30811, DOI 10.1074/jbc.271.48.30811; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORNIG M, 1995, ONCOGENE, V11, P2165	50	4150	4296	3	353	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1132	1136		10.1126/science.275.5303.1132	http://dx.doi.org/10.1126/science.275.5303.1132			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027315				2022-12-28	WOS:A1997WJ50300046
J	Moss, ML; Jin, SLC; Milla, ME; Burkhart, W; Carter, HL; Chen, WJ; Clay, WC; Didsbury, JR; Hassler, D; Hoffman, CR; Kost, TA; Lambert, MH; Leesnitzer, MA; McCauley, P; McGeehan, G; Mitchell, J; Moyer, M; Pahel, G; Rocque, W; Overton, LK; Schoenen, F; Seaton, T; Su, JL; Warner, J; Willard, D; Becherer, JD				Moss, ML; Jin, SLC; Milla, ME; Burkhart, W; Carter, HL; Chen, WJ; Clay, WC; Didsbury, JR; Hassler, D; Hoffman, CR; Kost, TA; Lambert, MH; Leesnitzer, MA; McCauley, P; McGeehan, G; Mitchell, J; Moyer, M; Pahel, G; Rocque, W; Overton, LK; Schoenen, F; Seaton, T; Su, JL; Warner, J; Willard, D; Becherer, JD			Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha	NATURE			English	Article							CYSTEINE SWITCH; TNF RECEPTOR; CELL-LINE; INHIBITOR; MECHANISM; FAMILY	Tumour-necrosis factor-alpha (TNF-alpha) is a cytokine that contributes to a variety of inflammatory disease states(1). The protein exists as a membrane-bound precursor(2,3) of relative molecular mass 26K which can be processed by a TNF-alpha-converting enzyme (TACE), to generate secreted 17K mature TNF-alpha. We have purified TACE and cloned its complementary DNA. TACE is a membrane-bound disintegrin metalloproteinase. Structural comparisons with other disintegrin-containing enzymes indicate that TACE is unique, with noteable sequence identity to MADM(4), an enzyme implicated in myelin degradation, and to KUZ(5), a Drosophila homologue of MADM important for neuronal development. The expression of recombinant TACE (rTACE) results in the production of functional enzyme that correctly processes precursor TNF-alpha to the mature form. The rTACE provides a readily available source of enzyme to help in the search for new anti-inflammatory agents that target the final processing stage of TNF-alpha production.	GLAXO WELLCOME RES & DEV LTD,DEPT DIVERS SCI,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT MOL SCI,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT ANALYT CHEM,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT STRUCT CHEM,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME RES & DEV LTD,DEPT MOL PHARMACOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Moss, ML (corresponding author), GLAXO WELLCOME RES & DEV LTD,DEPT MOL BIOCHEM,5 MOORE DR RES,RES TRIANGLE PK,NC 27709, USA.			Schoenen, Frank/0000-0003-2711-1117				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DECKER T, 1987, J IMMUNOL, V138, P957; GEARING A, 1994, NATURE, V370, P558; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; GRANADOS RR, 1994, J INVERTEBR PATHOL, V64, P260, DOI 10.1016/S0022-2011(94)90400-6; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MORRIS SA, 1995, CANCER RES, V55, P3629; MOYER MB, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P195; MULLBERG J, 1995, J IMMUNOL, V155, P5198; O'Byrne E. M., 1995, Inflammation Research, V44, pS117, DOI 10.1007/BF01778290; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Zhou Q, 1996, BIOCHEM BIOPH RES CO, V219, P720, DOI 10.1006/bbrc.1996.0301; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	25	1413	1475	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					733	736		10.1038/385733a0	http://dx.doi.org/10.1038/385733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034191				2022-12-28	WOS:A1997WJ42300049
J	Radler, JO; Koltover, I; Salditt, T; Safinya, CR				Radler, JO; Koltover, I; Salditt, T; Safinya, CR			Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes	SCIENCE			English	Article							SYNCHROTRON X-RAY; GENE-THERAPY; PHASE; TRANSFECTION; EXPRESSION; HUMANS	Cationic liposomes complexed with DNA (CL-DNA) are promising synthetically based nonviral carriers of DNA vectors for gene therapy. The solution structure of CL-DNA complexes was probed on length scales from subnanometer to micrometer by synchrotron x-ray diffraction and optical microscopy. The addition of either linear lambda-phage or plasmid DNA to CLs resulted in an unexpected topological transition from liposomes to optically birefringent liquid-crystalline condensed globules. X-ray diffraction of the globules revealed a novel multilamellar structure with alternating lipid bilayer and DNA monolayers. The lambda-DNA chains form a one-dimensional lattice with distinct interhelical packing regimes. Remarkably, in the isoelectric point regime, the lambda-DNA interaxial spacing expands between 24.5 and 57.1 angstroms upon lipid dilution and is indicative of a long-range electrostatic-induced repulsion that is possibly enhanced by chain undulations.	UNIV CALIF SANTA BARBARA, DEPT MAT, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, DEPT PHYS, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, BIOCHEM & MOL BIOL PROGRAM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara			Rädler, Joachim/AAD-8747-2019	Rädler, Joachim/0000-0002-5846-1489				BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BOLTENHAGEN P, 1992, PHYS REV A, V46, pR1743, DOI 10.1103/PhysRevA.46.R1743; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DAN N, IN PRESS BIOPHYS J; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P7132, DOI 10.1073/pnas.83.19.7132; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; Kamien RD, 1996, PHYS REV E, V53, P650, DOI 10.1103/PhysRevE.53.650; KEMWORTHY AK, 1995, BIOPHYS J, V68, P1921; KOLOVER I, UNPUB; LASIC D, IN PRESS ADV DRUG DE; LIGOURE C, 1993, PHYS REV LETT, V71, P3600, DOI 10.1103/PhysRevLett.71.3600; LIN AL, UNPUB; LIVOLANT F, 1989, NATURE, V339, P724, DOI 10.1038/339724a0; MANNING GS, 1969, J CHEM PHYS, V51, P924, DOI 10.1063/1.1672157; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; MARSHALL E, 1995, SCIENCE, V270, P1751, DOI 10.1126/science.270.5243.1751; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048; RADLER JO, UNPUB; REICH Z, 1994, SCIENCE, V264, P1460, DOI 10.1126/science.8197460; ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SAFINYA CR, 1989, NATO ADV SCI I B-PHY, V211, P249; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SELINGER JV, 1991, PHYS REV A, V43, P2922, DOI 10.1103/PhysRevA.43.2922; SINGHAL A, 1994, GENE THERAPEUTICS ME; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	38	1244	1293	4	277	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					810	814		10.1126/science.275.5301.810	http://dx.doi.org/10.1126/science.275.5301.810			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012343				2022-12-28	WOS:A1997WG77700054
J	Rees, G; Frackowiak, R; Frith, C				Rees, G; Frackowiak, R; Frith, C			Two modulatory effects of attention that mediate object categorization in human cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; INFERIOR TEMPORAL CORTEX; SHORT-TERM-MEMORY; RHESUS-MONKEY; PREFRONTAL CORTEX; VISUAL-ATTENTION; NEURONAL MECHANISMS; ASSOCIATION CORTEX; PARIETAL CORTEX; FRONTAL-CORTEX	Attentional modulation of cortical activity was examined by varying the rate of visual stimuli in object categorization tasks according to single and conjoined features. Activation of dorsolateral frontal cortex was independent of the stimulus presentation rate and elicited by the participant's attention to conjoined compared with single features. Several cortical regions showed attentionally modulated activity. In inferior temporal cortex, modulation was due to an additional bias signal underlying normal rate-correlated activity, In two other regions (premotor cortex and cerebellum), attention modified the correlation of activity and the stimulus presentation rate, Attentional effects in the human cortex are expressed by at least two physiologically distinct mechanisms acting on spatially distributed areas.			Rees, G (corresponding author), INST NEUROL,WELCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Frackowiak, Richard S/I-1809-2013; Rees, Geraint/C-1493-2008; Frith, Chris D/A-2171-2009; Frackowiak, Richard/H-4383-2011	Rees, Geraint/0000-0002-9623-7007; Frith, Chris D/0000-0002-8665-0690; Frackowiak, Richard/0000-0002-3151-822X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allport DA, 1987, PERSPECTIVES PERCEPT, P395; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BARBAS H, 1981, J COMP NEUROL, V200, P407, DOI 10.1002/cne.902000309; Broadbent D.E., 1958, PERCEPTION COMMUNICA; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CHAVIS DA, 1976, BRAIN RES, V117, P369, DOI 10.1016/0006-8993(76)90089-5; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; DUNCAN J, 1993, PERCEPTION, V22, P1261, DOI 10.1068/p221261; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; EGLIN M, 1991, CEREB CORTEX, V1, P263; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1985, NEUROPHYSIOLOGY, V64, P349; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; Harter M. R., 1984, VARIETIES ATTENTION, P293; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; JACOBSON S, 1977, BRAIN RES, V132, P209, DOI 10.1016/0006-8993(77)90417-6; JAMES W, 1976, PRINCIPLES PSYCHOL; JONES E G, 1970, Brain Behavior and Evolution, V93, P793, DOI 10.1093/brain/93.4.793; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1994, SCIENCE, V263, P520, DOI 10.1126/science.8290960; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; Neisser U., 1967, COGNITIVE PSYCHOL; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; PANDYA DN, 1969, BRAIN RES, V13, P13, DOI 10.1016/0006-8993(69)90141-3; PANDYA DN, 1971, BRAIN RES, V31, P35, DOI 10.1016/0006-8993(71)90632-9; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; PETRIDES M, 1978, NEUROPSYCHOLOGIA, V16, P527, DOI 10.1016/0028-3932(78)90080-5; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; PRAGAY EB, 1987, EXP NEUROL, V96, P481, DOI 10.1016/0014-4886(87)90213-5; PRICE C, 1992, NEUROSCI LETT, V146, P179, DOI 10.1016/0304-3940(92)90072-F; Price CJ, 1996, NEUROIMAGE, V3, P40, DOI 10.1006/nimg.1996.0005; RICHMOND BJ, 1987, J NEUROPHYSIOL, V58, P1292, DOI 10.1152/jn.1987.58.6.1292; RICHMOND BJ, 1982, SOC NEUR ABSTR, V8, P812; SAHGAL A, 1975, NATURE, V257, P672, DOI 10.1038/257672a0; SAKAGAMI M, 1994, EXP BRAIN RES, V97, P423; SELTZER B, 1989, J COMP NEUROL, V281, P97, DOI 10.1002/cne.902810108; Talairach J., 1988, COPLANAR STEREOTAXIC; TANAKA K, 1993, SCIENCE, V262, P685, DOI 10.1126/science.8235589; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; Vandenberghe R, 1995, NEUROIMAGE, V2, P306, DOI 10.1006/nimg.1995.1038; VECERA SP, 1994, J EXP PSYCHOL GEN, V123, P146, DOI 10.1037/0096-3445.123.2.146; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	51	139	142	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					835	838		10.1126/science.275.5301.835	http://dx.doi.org/10.1126/science.275.5301.835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012351				2022-12-28	WOS:A1997WG77700062
J	Velez, I; Agudelo, S; Hendrickx, E; Puerta, J; Grogl, M; Modabber, F; Berman, J				Velez, I; Agudelo, S; Hendrickx, E; Puerta, J; Grogl, M; Modabber, F; Berman, J			Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Hundreds of thousands of cases of cutaneous leishmaniasis occur each year worldwide. Available therapies are parenteral, moderately toxic, and costly. Objective: To determine the efficacy of and tolerance for oral allopurinol as monotherapy for cutaneous leishmaniasis. Design: Randomized, controlled trial. Setting: Outpatient clinics in 11 regions of Colombia in which cutaneous leishmaniasis is endemic. Patients: 187 otherwise healthy adults with cutaneous leishmaniasis. Eighty-four percent of patients were infected with or were from regions with Leishmania panamensis; 16% were infected or were from regions with L. braziliensis. Intervention: Patients were randomly assigned to one of three treatment groups. The first group received allopurinol, three 100-mg tablets four times daily (20 mg/kg of body weight per day) for 28 days. The second group received three placebo tablets four times daily for 28 days. The third group received Glucantime, 20 mg of intramuscular antimony/kg per day for 20 days. Measurement: Complete cure was defined as complete clinical reepithelialization of all lesions at 3 months and no relapse during 12 months of follow-up. Results: Of 182 patients whose data could be analyzed, 157 (86%) were evaluated. in the allopurinol group, 18 of 55 (33% [95% CI, 21% to 47%]) patients were cured; in the placebo group, 17 of 46 patients (37% [CI, 23% to 52%]) were cured (difference, 4% [CI, -14% to 22%]; P = 0.68); and in the Glucantime group, 52 of 56 patients (93% [CI, 83% to 98%]) were cured (P < 0.001 compared with the allopurinol and placebo groups combined). In most cases. therapy was considered to have failed because the lesion did not reepithelialize by 1.5 months after the end of therapy. Three cases of relapse (two in the allopurinol group and one in the placebo group) at the nasal mucosa (mucosal leishmaniasis) had occurred by the end of 12 months of follow-up. Conclusions: Allopurinol monotherapy has no effect on Colombian cutaneous disease primarily caused by L. panamensis and therefore is unlikely to be effective against cutaneous leishmaniasis in other endemic regions.			Velez, I (corresponding author), UNIV ANTIOQUIA, PECET, APARTADO AEREO 1226, MEDELLIN, COLOMBIA.							CHUNGE CN, 1985, T ROY SOC TROP MED H, V79, P715, DOI 10.1016/0035-9203(85)90200-7; GASSER RA, 1994, CLIN INFECT DIS, V18, P83, DOI 10.1093/clinids/18.1.83; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; HERWALDT BL, 1992, NEW ENGL J MED, V327, P498, DOI 10.1056/NEJM199208133270715; LAFON SW, 1985, J BIOL CHEM, V260, P9660; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; MOMENI AZ, 1995, INT J DERMATOL, V34, P129, DOI 10.1111/j.1365-4362.1995.tb03598.x; PRATT DM, 1981, NATURE, V291, P581, DOI 10.1038/291581a0; SOTOMANCIPE J, 1993, CLIN INFECT DIS, V16, P417, DOI 10.1093/clind/16.3.417	9	78	87	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					232	236		10.7326/0003-4819-126-3-199702010-00010	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027276				2022-12-28	WOS:A1997WF16800010
J	Nicklas, RB				Nicklas, RB			How cells get the right chromosomes	SCIENCE			English	Article							NEWT LUNG-CELLS; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; MICROTUBULE DEPOLYMERIZATION; KINETOCHORE FUNCTION; DYNAMIC INSTABILITY; CHECKPOINT; MITOSIS; ATTACHMENT; ANAPHASE	When cells divide, the chromosomes must be delivered flawlessly to the daughter cells. Missing or extra chromosomes can result in birth defects and cancer. Chance events are the starting point for chromosome delivery, which makes the process prone to error, Errors are avoided by diverse uses of mechanical tension from mitotic forces. Tension stabilizes the proper chromosome configuration, controls a cell cycle checkpoint, and changes chromosome chemistry.			Nicklas, RB (corresponding author), DUKE UNIV, DEPT ZOOL, BOX 91000, LSRC BLDG, DURHAM, NC 27708 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM013745, R01GM013745] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-13745] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; AULT JG, 1992, CELL MOTIL CYTOSKEL, V22, P155, DOI 10.1002/cm.970220302; BARGMANN CI, 1994, CELL, V78, P729; BAUER H, 1961, CHROMOSOMA, V12, P116, DOI 10.1007/BF00328918; Boveri T, 1929, ORIGIN MALIGNANT TUM; CALLAN H. G., 1957, JOUR GENETICS, V55, P200, DOI 10.1007/BF02981625; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CLEVELAND DW, 1995, TRENDS CELL BIOL, V5, P60, DOI 10.1016/S0962-8924(00)88947-3; CONLEY RW, 1985, ANEUPLOIDY ETIOLOGY, P35; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESAI A, 1995, J CELL BIOL, V128, P1, DOI 10.1083/jcb.128.1.1; DIETZ R, 1958, CHROMOSOMA, V9, P359; GLOTZER M, 1995, CURR BIOL, V5, P970, DOI 10.1016/S0960-9822(95)00190-4; GOLDSTEIN LSB, 1981, CELL, V25, P591, DOI 10.1016/0092-8674(81)90167-7; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; Hughes-Schrader S, 1943, BIOL BULL-US, V85, P265, DOI 10.2307/1538227; HYMAN AA, 1995, CURR BIOL, V5, P483, DOI 10.1016/S0960-9822(95)00097-2; INGBER DE, 1994, INT REV CYTOL, V150, P173; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; John B., 1990, MEIOSIS; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI X, IN PRESS J CELL SCI; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LYALL F, 1994, SOC EXPT BIOL SEMINA, V54; MANCHESTER KL, 1995, TRENDS CELL BIOL, V5, P384, DOI 10.1016/S0962-8924(00)89080-7; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MERDES A, 1990, EUR J CELL BIOL, V53, P313; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NEFF MW, 1992, MOL CELL BIOL, V12, P3857, DOI 10.1128/MCB.12.9.3857; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; NICKLAS RB, 1988, J CELL SCI, V89, P283; NICKLAS RB, 1967, CHROMOSOMA, V21, P17, DOI 10.1007/BF00330545; NOWELL PC, 1993, ADV CANCER RES, V62, P1, DOI 10.1016/S0065-230X(08)60313-9; OSTERGREN G, 1951, HEREDITAS, V37, P85; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; Schrader P., 1939, Chromosoma Berlin, V1, P230, DOI 10.1007/BF01271632; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; TIPPIT DH, 1980, J CELL BIOL, V86, P402, DOI 10.1083/jcb.86.2.402; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; WANG YC, 1995, MOL CELL BIOL, V15, P6838; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	67	499	508	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 31	1997	275	5300					632	637		10.1126/science.275.5300.632	http://dx.doi.org/10.1126/science.275.5300.632			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005842				2022-12-28	WOS:A1997WF07700029
J	Hoofnagle, JH; DiBisceglie, AM				Hoofnagle, JH; DiBisceglie, AM			The treatment of chronic viral hepatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; NON-B-HEPATITIS; PLACEBO-CONTROLLED TRIAL; HUMAN ALPHA-INTERFERON; C VIRUS-INFECTION; CHRONIC NON-A; LONG-TERM; POSTTRANSFUSION HEPATITIS; LIVER-DISEASE; RECOMBINANT INTERFERON-ALPHA-2B		ST LOUIS UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO USA	Saint Louis University	Hoofnagle, JH (corresponding author), NIDDKD, LIVER DIS SECT,DIGEST DIS BRANCH,NIH,BLDG 31, RM 9A23, BETHESDA, MD 20892 USA.							ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALBERTI A, 1993, J HEPATOL, V17, pS123, DOI 10.1016/S0168-8278(05)80436-2; ALBERTI A, 1994, VIRAL HEPATITIS LIVE, P604; ALEXANDER GJM, 1987, LANCET, V2, P66; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; Bacon B. R., 1995, Hepatology, V22, p152A; Belle S H, 1994, Clin Transpl, P19; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BODENHEIMER HC, 1994, HEPATOLOGY, V20, pA207; BOKER KHW, 1994, TRANSPLANTATION, V57, P1706; BOYER N, 1992, J INFECT DIS, V165, P723, DOI 10.1093/infdis/165.4.723; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; Chemello L., 1994, Journal of Hepatology, V21, pS12; CONJEEVARAM HS, 1995, GASTROENTEROLOGY, V109, P540, DOI 10.1016/0016-5085(95)90343-7; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; CRAXI A, 1992, Journal of Hepatology, V16, pS8; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; DIBISCEGLIE AM, 1995, ANN INTERN MED, V123, P897, DOI 10.7326/0003-4819-123-12-199512150-00001; DIBISCEGLIE AM, 1993, AM J GASTROENTEROL, V88, P1887; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1992, HEPATOLOGY, V16, P649, DOI 10.1002/hep.1840160307; Dienstag J. L., 1996, Hepatology, V24, p188A; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARCI P, 1994, NEW ENGL J MED, V330, P88, DOI 10.1056/NEJM199401133300202; FATTOVICH G, 1992, HEPATOLOGY, V15, P584, DOI 10.1002/hep.1840150405; FERAY C, 1995, HEPATOLOGY, V22, P1084, DOI 10.1002/hep.1840220411; FONG TL, 1994, GASTROENTEROLOGY, V107, P196, DOI 10.1016/0016-5085(94)90077-9; Habersetzer F., 1995, Hepatology, V22, p119A; HADZIYANNIS SJ, 1995, VIRAL HEPATITIS REV, V1, P7; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P3552; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1994, ADV INTERNAL MED, V39, P241; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; HOOFNAGLE JH, 1991, SEMIN LIVER DIS, V11, P73, DOI 10.1055/s-2008-1040426; HOOFNAGLE JH, 1993, GASTROENTEROLOGY, V104, P1116, DOI 10.1016/0016-5085(93)90281-G; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; HOUGHTON M, 1994, VIRAL HEPATITIS LIVE, P33; HWANG SJ, 1994, J HEPATOL, V21, P831, DOI 10.1016/S0168-8278(94)80246-7; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; KANAZAWA Y, 1994, HEPATOLOGY, V20, P1121, DOI 10.1002/hep.1840200504; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KUHNS MC, 1990, J HEPATOL, V11, pS90, DOI 10.1016/0168-8278(90)90171-M; LAI CL, 1987, LANCET, V2, P877; LAI MY, 1993, HEPATOLOGY, V18, pA93, DOI 10.1016/0270-9139(93)91900-D; LAMPERTICO P, 1994, HEPATOLOGY, V19, P19, DOI 10.1016/0270-9139(94)90047-7; Lau D., 1995, Hepatology, V22, p325A; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; LAU JYN, 1993, LANCET, V342, P1335; LIN R, 1995, J HEPATOL, V23, P487, DOI 10.1016/0168-8278(95)80052-2; Lindsay KL, 1996, HEPATOLOGY, V24, P1034; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; MAHANEY K, 1994, HEPATOLOGY, V20, P1405, DOI 10.1002/hep.1840200605; MARCELLIN P, 1994, LANCET, V344, P690, DOI 10.1016/S0140-6736(94)92129-6; MARCELLIN P, 1995, GASTROENTEROLOGY, V109, P156, DOI 10.1016/0016-5085(95)90281-3; MARCELLIN P, 1991, HEPATOLOGY, V13, P393, DOI 10.1002/hep.1840130302; MARCELLIN P, 1994, LIVER, V14, P302; MARCELLIN P, 1993, GUT, V34, pS106, DOI 10.1136/gut.34.2_Suppl.S106; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MISIANI R, 1994, NEW ENGL J MED, V330, P751, DOI 10.1056/NEJM199403173301104; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; MUTCHNICK MG, 1995, GASTROENTEROLOGY, V108, pA1127; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; NOLTE FS, 1995, J CLIN MICROBIOL, V33, P1775, DOI 10.1128/JCM.33.7.1775-1778.1995; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OMATA M, 1991, LANCET, V338, P914, DOI 10.1016/0140-6736(91)91774-O; PAPO T, 1992, ANN INTERN MED, V116, P51, DOI 10.7326/0003-4819-116-1-51; PERRILLO R, 1995, GASTROENTEROLOGY, V109, P908, DOI 10.1016/0016-5085(95)90401-8; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Poynard T, 1996, HEPATOLOGY, V24, P778; REICHARD O, 1994, HEPATOLOGY, V19, P280; Reichard O, 1996, HEPATOLOGY, V24, P917; ROSINA F, 1991, HEPATOLOGY, V13, P1052; RUIZMORENO M, 1991, HEPATOLOGY, V13, P1035, DOI 10.1002/hep.1840130605; RUIZMORENO M, 1992, HEPATOLOGY, V16, P882, DOI 10.1002/hep.1840160405; RYFF JC, 1995, J HEPATOL, V22, P101; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Serfaty L, 1996, GASTROENTEROLOGY, V110, P291, DOI 10.1053/gast.1996.v110.pm8536870; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; SHINDO M, 1992, HEPATOLOGY, V15, P1013, DOI 10.1002/hep.1840150607; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SHOUVAL D, 1995, J HEPATOL, V23, P98, DOI 10.1016/0168-8278(95)80317-3; Simon D. M., 1995, Hepatology, V22, p151A; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TONG MJ, 1995, GASTROENTEROLOGY, V108, pA1188; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; URDEA MS, 1993, CLIN CHEM, V39, P725; VANTHIEL DH, 1994, J HEPATOL, V20, P410, DOI 10.1016/S0168-8278(94)80017-0; VILADOMIU L, 1992, HEPATOLOGY, V15, P767, DOI 10.1002/hep.1840150504; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662; VONWEIZSACKER F, 1992, BIOCHEM BIOPH RES CO, V189, P743, DOI 10.1016/0006-291X(92)92264-X; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WRIGHT HI, 1992, TRANSPLANTATION, V53, P121, DOI 10.1097/00007890-199201000-00023; WU GY, 1992, J BIOL CHEM, V267, P12436; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502	107	835	882	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					347	356		10.1056/NEJM199701303360507	http://dx.doi.org/10.1056/NEJM199701303360507			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011789				2022-12-28	WOS:A1997WG23300007
J	Robson, J				Robson, J			Information needed to decide about cardiovascular treatment in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; COST-EFFECTIVENESS; RISK-DISK; MEDICAL LITERATURE; GENERAL-PRACTICE; BLOOD-PRESSURE; USERS GUIDES; HELP ME; PREVENTION; HEALTH	There is growing consensus that treatment of cardiovascular risks should be based on multiple rather than single factors and on absolute rather than relative risks. Thresholds for treatment should reflect the level of absolute risk at which the benefits and hazards of treating outweigh the benefits and hazards of not treating. Once a decision has been made to initiate a treatment programme, clinicians need to know the patient's absolute risk. At this level of risk, do the benefits of treatment outweigh the hazards? Given this information, which treatment option does the patient prefer? Using cardiovascular disease as an example, I review some measures that assist decision making in primary care. Practice guidelines should routinely include accessible presentation of treatment outcomes on benefit, hazard, and costs for a range of absolute risks. These measures enable patients and their doctors to weigh the pros and cons of treatment in their particular circumstances.	UNIV LONDON QUEEN MARY & WESTFIELD COLL, LONDON HOSP, SCH MED, LONDON E1 4NS, ENGLAND	University of London; Queen Mary University London	Robson, J (corresponding author), ST BARTHOLOMEWS HOSP, ACAD DEPT GEN PRACTICE, LONDON E1 4NS, ENGLAND.		Robson, John/H-3904-2014	Robson, John/0000-0001-6889-0415				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BEARD K, 1992, BRIT MED J, V304, P142; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; COPPOLA WGT, 1995, BRIT J GEN PRACT, V45, P185; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; DRUMMOND MF, 1993, MED DECIS MAKING, V13, P184, DOI 10.1177/0272989X9301300303; FIELD K, 1995, BRIT MED J, V310, P1109, DOI 10.1136/bmj.310.6987.1109; FLETCHER A, 1991, J HYPERTENS, V9, P193, DOI 10.1097/00004872-199103000-00001; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JACKSON R, 1995, LANCET, V346, P1440, DOI 10.1016/S0140-6736(95)92466-3; Kannel W B, 1995, Hypertens Res, V18, P181, DOI 10.1291/hypres.18.181; KANNEL WB, 1991, J HYPERTENS, V9, pS13, DOI 10.1097/00004872-199112007-00005; KAWACHI I, 1991, J HYPERTENS, V9, P199, DOI 10.1097/00004872-199103000-00002; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; Lindholm L, 1996, J EPIDEMIOL COMMUN H, V50, P190, DOI 10.1136/jech.50.2.190; LOGAN AG, 1994, CANADIAN GUIDE CLIN; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; PEDERSEN TR, 1994, LANCET, V344, P1383; Pettiti DB, 1994, META ANAL DECISION A; PYORALA K, 1994, EUR HEART J, V15, P1300; Ramsay LE, 1996, LANCET, V348, P1251, DOI 10.1016/S0140-6736(05)65536-5; RANDALL T, 1992, BRIT MED J, V305, P227, DOI 10.1136/bmj.305.6847.227; RAYNER MJ, 1991, BMJ-BRIT MED J, V303, P748; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; ROBERTSON JAL, 1995, RISK ANAL, V15, P289, DOI 10.1111/j.1539-6924.1995.tb00322.x; RUSSELL LB, 1993, NEW ENGL J MED, V329, P352, DOI 10.1056/NEJM199307293290511; RUSSELL LB, 1989, HYPERTENSION S1, V13, P141; RUSSELL LB, 1986, IS PREVENTION REALLY; Shaper A G, 1987, Health Trends, V19, P37; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SUTHERLAND HJ, 1995, MED DECIS MAKING, V15, P286; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; TUNSTALLPEDOE H, 1992, BRIT MED J, V305, P231, DOI 10.1136/bmj.305.6847.231; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807; Warren K, 1993, DOING MORE GOOD HARM; WENNBERG JE, 1993, ANN NY ACAD SCI, V703, P52, DOI 10.1111/j.1749-6632.1993.tb26335.x; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Yusuf S, 1996, CIRCULATION, V93, P1774, DOI 10.1161/01.CIR.93.10.1774	47	13	13	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1997	314	7076					277	280		10.1136/bmj.314.7076.277	http://dx.doi.org/10.1136/bmj.314.7076.277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022493	Green Published			2022-12-28	WOS:A1997WE63300029
J	Mittrucker, HW; Matsuyama, T; Grossman, A; Kundig, TM; Potter, J; Shahinian, A; Wakeham, A; Patterson, B; Ohashi, PS; Mak, TW				Mittrucker, HW; Matsuyama, T; Grossman, A; Kundig, TM; Potter, J; Shahinian, A; Wakeham, A; Patterson, B; Ohashi, PS; Mak, TW			Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function	SCIENCE			English	Article							IMMUNOGLOBULIN-KAPPA GENE; FACTOR IRF-1; MICE; COMPARTMENT; APOPTOSIS; MEMBER; FAMILY; REGION	Lymphocyte-specific interferon regulatory factor (LSIRF) (now called IRF4) is a transcription factor expressed only in lymphocytes. Mice deficient in IRF4 showed normal distribution of B and T lymphocyes at 4 to 5 weeks of age but developed progressive generalized lymphadenopathy. IRF-4-deficient mice exhibited a profound reduction in serum immunoglobulin concentrations and did not mount detectable antibody responses. T lymphocyte function was also impaired in vivo; these mice could not generate cytotoxic or antitumor responses. Thus, IRF4 is essential for the function and homeostasis of both mature B and mature T lymphocytes.	UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5G 2C1,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2C1,CANADA; AMGEN INST,TORONTO,ON M5G 2C1,CANADA; NAGASAKI UNIV,FAC MED,DEPT ONCOL,NAGASAKI 852,JAPAN; ONTARIO CANC INST,DEPT ONCOL PATHOL,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University of Toronto; Nagasaki University; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Ohashi, Pamela S./0000-0003-2915-9317				Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Grossman A, 1996, GENOMICS, V37, P229, DOI 10.1006/geno.1996.0547; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KNEITZ B, 1995, EUR J IMMUNOL, V25, P2572, DOI 10.1002/eji.1830250925; LAMPHIER M, 1994, IMMUNOLOGIST, V2, P167; LEIST TP, 1987, J IMMUNOL, V138, P2278; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; Mittrucker HW, 1996, J EXP MED, V183, P2481, DOI 10.1084/jem.183.6.2481; MITTRUCKER HW, UNPUB; MOMBAERTS P, 1994, INT IMMUNOL, V6, P1061, DOI 10.1093/intimm/6.7.1061; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; Schmits R, 1996, J EXP MED, V183, P1415, DOI 10.1084/jem.183.4.1415; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Yamagata T, 1996, MOL CELL BIOL, V16, P1283	25	456	460	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					540	543		10.1126/science.275.5299.540	http://dx.doi.org/10.1126/science.275.5299.540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999800				2022-12-28	WOS:A1997WE25700047
J	Minn, AJ; Velez, P; Schendel, SL; Liang, H; Muchmore, SW; Fesik, SW; Fill, M; Thompson, CB				Minn, AJ; Velez, P; Schendel, SL; Liang, H; Muchmore, SW; Fesik, SW; Fill, M; Thompson, CB			Bcl-x(L) forms an ion channel in synthetic lipid membranes	NATURE			English	Article							ENDOPLASMIC-RETICULUM; MITOCHONDRIAL-MEMBRANE; NUCLEAR-ENVELOPE; DIPHTHERIA-TOXIN; BCL-2; BILAYERS; TRANSLOCATION; COLICIN-E1; MECHANISM; APOPTOSIS	Bcl-2-related proteins are critical regulators of cell survival that are localized to the outer mitochondrial, outer nuclear and endoplasmic reticulum membranes(1-4). Despite their physiological importance, the biochemical function of Bcl-2-related proteins has remained elusive. The three-dimensional structure of Bcl-x(L), an inhibitor of apoptosis, was recently shown to be similar to the structures of the pore-forming domains of bacterial toxins(5). A key feature of these pore-forming domains is the ability to form ion channels in biological membranes(6,7). Here we demonstrate that Bcl-x(L) shares this functional feature. Like the bacterial toxins, Bcl-X(L) can insert into either synthetic lipid vesicles or planar Lipid bilayers and form an ion-conducting channel. This channel is pH-sensitive and becomes cation-selective at physiological pH. The ion-conducting channel(s) formed by Bcl-x(L) display multiple conductance states that have identical ion selectivity. Together, these data suggest that Bcl-x(L) may maintain cell survival by regulating the permeability of the intracellular membranes to which it is distributed.	LOYOLA UNIV, STRITCH SCH MED, CARDIOVASC INST, DEPT PHYSIOL, MAYWOOD, IL 60153 USA; UNIV CHICAGO, COMM IMMUNOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA; PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; ABBOTT LABS, DIV PHARMACEUT DISCOVERY, PROT CRYSTALLOG, ABBOTT PK, IL 60064 USA; ABBOTT LABS, NMR RES, ABBOTT PK, IL 60064 USA; UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, CHICAGO, IL 60637 USA	Loyola University Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Abbott Laboratories; Abbott Laboratories; University of Chicago				Schendel, Sharon/0000-0002-5062-7261; Minn, Andy/0000-0003-1418-0906				CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Cramer W.A., 1990, ENERGY TRANSDUCTION; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DAVIDSON VL, 1984, J MEMBRANE BIOL, V79, P105, DOI 10.1007/BF01872115; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; PETERSON AA, 1987, J MEMBRANE BIOL, V99, P197, DOI 10.1007/BF01995700; RAYMOND L, 1985, J MEMBRANE BIOL, V84, P173, DOI 10.1007/BF01872215; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; Tomarev SI, 1996, EUR J BIOCHEM, V235, P449, DOI 10.1111/j.1432-1033.1996.00449.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zakharov SD, 1996, BIOPHYS J, V70, P2774, DOI 10.1016/S0006-3495(96)79847-8; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	29	717	736	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1997	385	6614					353	357		10.1038/385353a0	http://dx.doi.org/10.1038/385353a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002522				2022-12-28	WOS:A1997WD91400054
J	Haley, RW; Kurt, TL; Hom, J				Haley, RW; Kurt, TL; Hom, J			Is there a gulf war syndrome? Searching for syndromes by factor analysis of symptoms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Research Conference on the Gulf War Illness	OCT 26, 1995	CTR DIS CONTROL & PREVENT, ATLANTA, GA		CTR DIS CONTROL & PREVENT		VALIDITY; RELIABILITY; VALIDATION; MODEL; MMPI	Objective.-To search for syndromes in Persian Gulf War veterans. Participants.-Two hundred forty-nine (41%) of the 606 Gulf War veterans of the Twenty-fourth Reserve Naval Mobile Construction Battalion living in 5 south-eastern states participated; 145 (58%) had retired from service, and the rest were still serving in the battalion. Design.-Participants completed a standardized survey booklet measuring the anatomical distributions or characteristics of each symptom, a booklet measuring wartime exposures, and a standard psychological personality assessment inventory. Two-stage factor analysis was used to disentangle ambiguous symptoms and identify syndromes. Main Outcome Measures.-Factor analysis-derived syndromes, Results.-Of 249 participants, 175 (70%) reported having had serious health problems that most attributed to the war, and 74 (30%) reported no serious health problems. Principal factor analysis yielded 6 syndrome factors, explaining 71% of the variance. Dichotomized syndrome indicators identified the syndromes in 63 veterans (25%). Syndromes 1 (''impaired cognition,'' characterized by problems with attention, memory, and reasoning, as well as insomnia, depression, daytime sleepiness, and headaches), 2 (''confusion-ataxia,'' characterized by problems with thinking, disorientation, balance disturbances, vertigo, and impotence), and 3 (''arthro-myo-neuropathy,'' characterized by joint and muscle pains, muscle fatigue, difficulty lifting, and extremity paresthesias) represented strongly clustered symptoms; whereas, syndromes 4 (''phobia-apraxia''), 5 (''fever-adenopathy''), and 6 (''weakness-incontinence'') involved weaker clustering and mostly overlapped syndromes 2 and 3. Veterans with syndrome 2 were 12.5 times (95% confidence interval, 3.5-44.8) more likely to be unemployed than those with no health problems. A psychological profile, found in 48.4% of those with the syndromes, differed from posttraumatic stress disorder, depression, somatoform disorder, and malingering. Conclusion.-These findings support the hypothesis that clusters of symptoms of many Gulf War, veterans represent discrete factor analysis-derived syndromes that appear to reflect a spectrum of neurologic injury involving the central, peripheral, and autonomic nervous systems.	UNIV TEXAS, SW MED CTR, DEPT NEUROL, DALLAS, TX 75235 USA; NEUROPSYCHOL CTR, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Haley, RW (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DIV EPIDEMIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Haley, Robert/P-9026-2014	Haley, Robert/0000-0001-8849-9579				Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Anastasi A., 1988, PSYCHOL TESTING; [Anonymous], 1994, JAMA, V272, P391; [Anonymous], 1995, Arch Intern Med, V155, P262; [Anonymous], 1990, SAS STAT US GUID VER; BLACK FW, 1974, J CLIN PSYCHOL, V30, P571, DOI 10.1002/1097-4679(197410)30:4<571::AID-JCLP2270300432>3.0.CO;2-W; Cattell R.B., 1978, SCI USE FACTOR ANAL, DOI [DOI 10.1007/978-1-4684-2262-7_5, 10.1007/978-1-4684-2262-7_5]; Cattell RB., 1966, HDB MULTIVARIATE EXP, P174; CERNY BA, 1977, MULTIVAR BEHAV RES, V12, P43, DOI 10.1207/s15327906mbr1201_3; COMREY AL, 1978, J CONSULT CLIN PSYCH, V46, P648, DOI 10.1037/0022-006X.46.4.648; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; ELLENBERG JH, 1994, STAT MED, V13, P557, DOI 10.1002/sim.4780130518; FINK LA, 1995, AM J PSYCHIAT, V152, P1329, DOI 10.1176/ajp.152.9.1329; Gorsuch R., 1983, FACTOR ANAL; Gould S. J., 1981, MISMEASURE OF MAN; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P223, DOI 10.1001/jama.277.3.223; HOSMER DW, 1989, APPL LOGISTIC REGRES; *I MED MED FOLL AG, 1995, HLTH CONS SERV PERS; Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105; KAMARCK TW, 1994, HEALTH PSYCHOL, V13, P471, DOI 10.1037/0278-6133.13.6.471; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kleinbaum D, 1982, EPIDEMIOLOGIC RES PR, P194; LEVY A, 1992, Brain Injury, V6, P401, DOI 10.3109/02699059209008136; LINDENMAYER JP, 1995, PSYCHOPATHOLOGY, V28, P22, DOI 10.1159/000284896; MENDELSON G, 1991, THEOR MED, V12, P227, DOI 10.1007/BF00489608; MEYERINK LH, 1988, J CLIN PSYCHOL, V44, P764, DOI 10.1002/1097-4679(198809)44:5<764::AID-JCLP2270440517>3.0.CO;2-Y; Morey, 1996, INTERPRETATIVE GUIDE; Morey L.C., 1991, PERSONALITY ASSESSME; Morey L. C., 1993, 101 ANN M AM PSYCH A; *PERS GULF VET COO, 1994, SUMM ISS IMP HLTH PE; STREINER DL, 1994, CAN J PSYCHIAT, V39, P135, DOI 10.1177/070674379403900303; Taub E, 1995, DIGEST DIS SCI, V40, P2647, DOI 10.1007/BF02220455; *US DEP DEF, 1996, COMPREHENSIVE CLIN E	37	286	292	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					215	222		10.1001/jama.277.3.215	http://dx.doi.org/10.1001/jama.277.3.215			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WB446	9005271				2022-12-28	WOS:A1997WB44600023
J	Mellor, DJ; Bhandari, S; Kerr, K; Bodenham, AR				Mellor, DJ; Bhandari, S; Kerr, K; Bodenham, AR			Lesson of the week: Man's best friend: Life threatening sepsis after minor dog bite	BRITISH MEDICAL JOURNAL			English	Article							CAPNOCYTOPHAGA-CANIMORSUS SEPTICEMIA; INFECTIONS; PATIENT		LEEDS GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds	Mellor, DJ (corresponding author), BRADFORD ROYAL INFIRM,BRADFORD BD9 6RJ,W YORKSHIRE,ENGLAND.		Bhandari, Sunil/ABD-5159-2021	bhandari, sunil/0000-0002-0996-9622				CALLAHAM M, 1994, ANN EMERG MED, V23, P577, DOI 10.1016/S0196-0644(94)80284-X; Dire D J, 1994, Acad Emerg Med, V1, P258; HANTSON P, 1991, ANN EMERG MED, V20, P93, DOI 10.1016/S0196-0644(05)81130-8; KROLVANSTRAATEN MJ, 1990, NETH J MED, V36, P304; NDON JA, 1992, J CLIN MICROBIOL, V30, P211, DOI 10.1128/JCM.30.1.211-213.1992; ROBLOT P, 1993, EUR J CLIN MICROBIOL, V12, P302, DOI 10.1007/BF01967265; WESTWELL AJ, 1987, AM J MED, V83, P1170, DOI 10.1016/0002-9343(87)90966-1; WIGGINS ME, 1994, ORTHOPEDICS, V17, P617	8	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					129	130		10.1136/bmj.314.7074.129	http://dx.doi.org/10.1136/bmj.314.7074.129			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006476	Green Published			2022-12-28	WOS:A1997WC47900030
J	Pobel, D; Viel, JF				Pobel, D; Viel, JF			Case-control study of leukaemia among young people near La Hague nuclear reprocessing plant: The environmental hypothesis revisited	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD LEUKEMIA INCIDENCE; NON-HODGKINS-LYMPHOMA; WEST CUMBRIA; RADIATION; CHILDREN; CANCER; INSTALLATION; WINDSCALE; CAITHNESS; RESIDENT	Objective: To investigate the association between childhood leukaemia and established risk factors or other factors related to La Hague nuclear waste reprocessing plant. Design: Case-control study. Setting: Area within a 35 km radius of La Hague, Normandy, France. Subjects: Twenty seven cases of leukaemia diagnosed during the period 1978-93 in people aged under 25 years and 192 controls matched for sex, age, place of birth, and residence at time of diagnosis. Main outcome measures: Antenatal and postnatal exposure to x rays and viral infections, occupational exposure of parents (particularly ionising radiation), living conditions, lifestyle of parents and children. Results: Increased trends were found for use of local beaches by mothers and children (P less than or equal to 0.01); relative risks 2.87 (95% confidence intervals 1.05 to 8.72) and 4.49 (1.52 to 15.23) when categories were aggregated in two levels (more or less than once a month). Consumption of local fish and shellfish also showed an increased trend (P 0.01); relative risk 2.66 (0.91 to 9.51) when categories were grouped in two levels (more or less than once a week). A relative risk of 1.18 a year (1.03 to 1.42) was observed for length of residence in a granite-built house or in a granitic area. No association was shown with occupational radiation exposure in parents. Conclusions: There is some convincing evidence in childhood leukaemia of a causal role for environmental radiation exposure from recreational activities on beaches. New methods for identifying the environmental pathways, focusing on marine ecosystems, are warranted.	FAC MED,DEPT PUBL HLTH,BIOSTAT & EPIDEMIOL UNIT,F-25030 BESANCON,FRANCE	Universite de Franche-Comte; CHU Besancon			Viel, Jean-Francois/K-2224-2015	Viel, Jean-Francois/0000-0002-6716-7468				ALEXANDER FE, 1990, LANCET, V335, P1336; BLACK RJ, 1994, J EPIDEMIOL COMMUN H, V48, P232, DOI 10.1136/jech.48.3.232; *COMM MED ASP RAD, 1988, 2 REP INV POSS INCR; *CYT SOFTW, 1995, STATX 3 WIND; *CYT SOFTW, 1993, LOGX; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; HATCH M, 1990, INT J EPIDEMIOL, V19, P546, DOI 10.1093/ije/19.3.546; HEASMAN MA, 1986, LANCET, V266, P385; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; *IND ADV GROUP, 1984, INV POSS INCR INC CA; KNOX E G, 1988, Journal of Radiological Protection, V8, P9, DOI 10.1088/0952-4746/8/1/302; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; MULDER YM, 1994, J EPIDEMIOL COMMUN H, V48, P161, DOI 10.1136/jech.48.2.161; *NAT RES COUNC COM, RAD DOS REC EP US; RICHARDSON S, 1995, STAT MED, V14, P2487, DOI 10.1002/sim.4780142116; URQUHART J, 1984, LANCET, V1, P217; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; VIEL JF, 1995, STAT MED, V14, P2459, DOI 10.1002/sim.4780142114; VIEL JF, 1993, CANCER CAUSE CONTROL, V4, P341, DOI 10.1007/BF00051336; VIEL JF, 1990, BRIT MED J, V300, P580, DOI 10.1136/bmj.300.6724.580	24	69	71	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					101	106		10.1136/bmj.314.7074.101	http://dx.doi.org/10.1136/bmj.314.7074.101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006467	Green Published			2022-12-28	WOS:A1997WC47900019
J	Huszar, D; Lynch, CA; FairchildHuntress, V; Dunmore, JH; Fang, Q; Berkemeier, LR; Gu, W; Kesterson, RA; Boston, BA; Cone, RD; Smith, FJ; Campfield, LA; Burn, P; Lee, F				Huszar, D; Lynch, CA; FairchildHuntress, V; Dunmore, JH; Fang, Q; Berkemeier, LR; Gu, W; Kesterson, RA; Boston, BA; Cone, RD; Smith, FJ; Campfield, LA; Burn, P; Lee, F			Targeted disruption of the melanocortin-4 receptor results in obesity in mice	CELL			English	Article							MELANOCYTE-STIMULATING-HORMONE; YELLOW A(VY)/ MICE; MOLECULAR-CLONING; AGOUTI GENE; BODY-WEIGHT; ECTOPIC EXPRESSION; COAT COLOR; MOUSE; PROTEIN; MSH	The melanocortin-4 receptor (MC4-R) is a G protein-coupled, seven-transmembrane receptor expressed in the brain. Inactivation of this receptor by gene targeting results in mice that develop a maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, and hyperglycemia. This syndrome recapitulates several of the characteristic features of the agouti obesity syndrome, which results from ectopic expression of agouti protein, a pigmentation factor normally expressed in the skin. Our data identify a novel signaling pathway in the mouse for body weight regulation and support a model in which the primary mechanism by which agouti induces obesity is chronic antagonism of the MC4-R.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT PEDIAT, PORTLAND, OR 97201 USA; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA	Oregon Health & Science University; Oregon Health & Science University; Roche Holding	Huszar, D (corresponding author), MILLENNIUM PHARMACEUT INC, 640 MEM DR, CAMBRIDGE, MA 02139 USA.							ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRAY GA, 1984, INT J OBESITY, V8, P119; BRAY GA, 1987, NUTR REV, V45, P33; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CARPENTER KJ, 1958, AM J PHYSIOL, V193, P499, DOI 10.1152/ajplegacy.1958.193.3.499; Castle WE, 1941, GENETICS, V26, P177; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1977, DIABETOLOGIA, V13, P25, DOI 10.1007/BF00996323; DEWIED D, 1982, PHYSIOL REV, V62, P976, DOI 10.1152/physrev.1982.62.3.976; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; DICKIE MM, 1946, J HERED, V37, P365, DOI 10.1093/oxfordjournals.jhered.a105562; DUBUC PU, 1975, HORM METAB RES, V7, P102, DOI 10.1055/s-0028-1095645; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; FAN W, 1997, IN PRESS NATURE; FENG JD, 1987, BRAIN RES BULL, V18, P473, DOI 10.1016/0361-9230(87)90111-0; FERRY WL, 1995, GENETICS, V140, P267; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FRIGERI LG, 1983, ENDOCRINOLOGY, V113, P2097, DOI 10.1210/endo-113-6-2097; FRIGERI LG, 1988, INT J OBESITY, V12, P305; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HESTON WE, 1962, J NATL CANCER I, V29, P197; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; JOHNSON PR, 1972, J LIPID RES, V13, P2; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KLEIN MC, 1985, LIFE SCI, V36, P769, DOI 10.1016/0024-3205(85)90197-3; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LIN SY, 1987, HYPERTENSION, V10, P619, DOI 10.1161/01.HYP.10.6.619; LIPTON JM, 1980, PEPTIDES, V1, P15, DOI 10.1016/0196-9781(80)90029-7; Low M.J., 1994, CURR OPIN ENDOCRINOL, V1, P79; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; MICHAUD EJ, 1993, GENE DEV, V7, P1203, DOI 10.1101/gad.7.7a.1203; MICHAUD EJ, 1994, P NATL ACAD SCI USA, V91, P2562, DOI 10.1073/pnas.91.7.2562; MICHAUD EJ, 1994, GENE DEV, V8, P1483; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Mizuno TM, 1996, P NATL ACAD SCI USA, V93, P3434, DOI 10.1073/pnas.93.8.3434; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; MURPHY JV, 1955, J COMP PHYSIOL PSYCH, V48, P47, DOI 10.1037/h0043004; MURPHY MT, 1983, SCIENCE, V221, P192, DOI 10.1126/science.6602381; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SEARLE AG, 1968, J HERED, V59, P341, DOI 10.1093/oxfordjournals.jhered.a107739; SHIMIZU H, 1989, LIFE SCI, V45, P543, DOI 10.1016/0024-3205(89)90105-7; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SOLOMON J, 1973, ENDOCRINOLOGY, V93, P510, DOI 10.1210/endo-93-2-510; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARBRITTON A, 1994, P SOC EXP BIOL MED, V206, P145, DOI 10.3181/00379727-206-43733; WATSON SJ, 1978, NATURE, V275, P226, DOI 10.1038/275226a0; WOLFF GL, 1971, NATURE-NEW BIOL, V232, P181, DOI 10.1038/newbio232181a0; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; WOLFF GL, 1987, AM J CLIN NUTR, V45, P168, DOI 10.1093/ajcn/45.1.168; WOLFF GL, 1978, J HERED, V69, P295, DOI 10.1093/oxfordjournals.jhered.a108953; WOLFF GL, 1963, GENETICS, V48, P1041; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; YEN TT, 1976, BIOCHIM BIOPHYS ACTA, V441, P213, DOI 10.1016/0005-2760(76)90164-8; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; YEN TT, 1976, HORM METAB RES, V8, P159, DOI 10.1055/s-0028-1093672; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	86	2394	2538	3	102	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					131	141		10.1016/S0092-8674(00)81865-6	http://dx.doi.org/10.1016/S0092-8674(00)81865-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019399	Bronze			2022-12-28	WOS:A1997WC56900016
J	Mogami, H; Nakano, K; Tepikin, AV; Petersen, OH				Mogami, H; Nakano, K; Tepikin, AV; Petersen, OH			Ca2+ flow via tunnels in polarized cells: Recharging of apical Ca2+ stores by focal Ca2+ entry through basal membrane patch	CELL			English	Article							PANCREATIC ACINAR-CELLS; CAPACITATIVE CALCIUM-ENTRY; INOSITOL TRISPHOSPHATE; EXOCRINE PANCREAS; ACTIVATION; CHANNELS; SIGNALS; OSCILLATIONS; HEPATOCYTES; MICROSCOPY	Intracellular Ca2+ store depletion induces Ca2+ entry across the plasma membrane, allowing the store to recharge. In our experiments, Ca2+ stores in pancreatic acinar cells were depleted by acetylcholine (ACh) stimulation in Ca2+-free solution. Thereafter, Ca2+ entry was only allowed through a CaCl2-containing pipette attached to the basal membrane. Recharging intracellular Ca2+ stores via a patch pipette occurred without a rise in the cytosolic Ca2+ concentration and depended on the operation of a thapsigargin-sensitive Ca2+ pump. After a period of focal Ca2+ entry, ACh could again evoke a rise in the cytosolic Ca2+ concentration, and this rise always started in the apical secretory pole. Recharging the apical Ca2+ store therefore depends on Ca2+ flow through a tunnel from the basal to the secretory pole, and the endoplasmic reticulum Ca2+ pump is essential for this process.	UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513				BAUM BJ, 1988, BIOCHEM J, V254, P649, DOI 10.1042/bj2540649; BENNETT DL, 1995, CURR BIOL, V5, P1225, DOI 10.1016/S0960-9822(95)00243-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; Gorelick Frederick S., 1994, P1353; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORBER JKH, 1995, BIOPHYS J, V68, P1687, DOI 10.1016/S0006-3495(95)80346-2; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kern Horst F., 1993, P9; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PETERSEN OH, 1983, SINGLE CHANNEL RECOR, P425; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; RUKNUDIN A, 1991, J CELL BIOL, V112, P125, DOI 10.1083/jcb.112.1.125; Sasaki S, 1996, PFLUG ARCH EUR J PHY, V432, P538, DOI 10.1007/s004240050167; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS AP, 1995, CIBA F SYMP, V188, P18; Thorn P, 1996, EMBO J, V15, P999, DOI 10.1002/j.1460-2075.1996.tb00436.x; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1992, J BIOL CHEM, V267, P23467; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	39	238	240	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					49	55		10.1016/S0092-8674(00)81857-7	http://dx.doi.org/10.1016/S0092-8674(00)81857-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019404	Bronze			2022-12-28	WOS:A1997WC56900008
J	Haslam, F				Haslam, F			Rowlandson's Death in the Nursery	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1605	1605		10.1136/bmj.313.7072.1605	http://dx.doi.org/10.1136/bmj.313.7072.1605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011290	Green Published			2022-12-28	WOS:A1996VZ81100030
J	Cooper, JP; Nimmo, ER; Allshire, RC; Cech, TR				Cooper, JP; Nimmo, ER; Allshire, RC; Cech, TR			Regulation of telomere length and function by a Myb-domain protein in fission yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAP1; CELLS; END; ELONGATION; COMPONENT; STABILITY; POMBE	Telomeres, the specialized nucleoprotein structures that comprise the ends of eukaryotic chromosomes(1,2), are essential for complete replication(3-5), and regulation of their length has been a focus of research on tumorigenesis(6-8). In the budding yeast Saccharomyces cerevisiae, the protein Rap1p binds to telomeric DNA and functions in the regulation of telomere length(9-12). A human telomere protein, hTRF (human TTAGGG repeat factor) binds the telomere sequence in vitro(13) and localizes to telomeres cytologically(14), but its functions are not yet known. Here we use a genetic screen to identify a telomere protein in fission yeast, Taz1p (telomere-associated in Schizosaccharomycesrces pombe), that shares homology to the Myb proto-oncogene DNA-binding domain with hTRF. Disruption or deletion of the taz1(+) gene causes a massive increase in telomere length. Taz1p is required for the repression of telomere-adjacent gene expression and for normal meiosis or sporulation. It may be a negative regulator of the telomere-replicating enzyme, telomerase(1,3), or may protect against activation of telomerase-independent pathways of telomere elongation(8).	UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Edinburgh				cooper, julia promisel/0000-0003-2171-2587; Allshire, Robin/0000-0002-8005-3625				ALLSHIRE RC, 1995, SEMIN CELL BIOL, V6, P55, DOI 10.1016/1043-4682(95)90001-2; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Blackburn EH, 1995, TELOMERES; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LIU ZP, 1991, GENE DEV, V5, P49, DOI 10.1101/gad.5.1.49; LOUIS EJ, 1994, GENETICS, V136, P789; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sugawara NF, 1989, THESIS HARVARD U; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	30	441	443	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1997	385	6618					744	747		10.1038/385744a0	http://dx.doi.org/10.1038/385744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034194				2022-12-28	WOS:A1997WJ42300052
J	Belonoshko, AB				Belonoshko, AB			Atomistic simulation of shock wave-induced melting in argon	SCIENCE			English	Article							SHOCK-WAVES	A three-dimensional molecular dynamics simulation of shock wave loading was undertaken to investigate the Hugoniot equation of state at the transition of argon from solid to liquid. The simulated data agree with shock wave and static high-pressure experimental data. The melting transition in this simulation occurs without overshooting the argon melting temperature. There are two discontinuities that may bracket a mixed-phase region of solid and liquid along the simulated argon Hugoniot. This is an intrinsic feature of the Hugoniot crossing the argon melting curve and does not require the addition of any solid-solid phase transition.			Belonoshko, AB (corresponding author), UPPSALA UNIV,INST EARTH SCI,THEORET GEOCHEM PROGRAM,S-75236 UPPSALA,SWEDEN.		Belonoshko, Anatoly/AAC-4815-2021	Belonoshko, Anatoly/0000-0001-7531-3210				Belonoshko A.B., 1992, HIGH PRESS RES, V10, P583, DOI [10.1080/08957959208202841, DOI 10.1080/08957959208202841]; BOEHLER R, 1996, STRUCT EARTH DEEP IN; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; DICK RD, 1970, J CHEM PHYS, V53, P1648, DOI 10.1063/1.1674238; DUBROVINSKY LS, 1996, AM MINERAL, V81, P303; HOLIAN BL, 1995, SHOCK WAVES, V5, P149, DOI 10.1007/BF01435522; Jephcoat AP, 1996, PHILOS T R SOC A, V354, P1333, DOI 10.1098/rsta.1996.0051; Klimenko V. Y., 1978, DETONATION CRITICAL, P79; ROBERTSON DH, 1991, PHYS REV LETT, V67, P3132, DOI 10.1103/PhysRevLett.67.3132; ROSS M, 1986, J CHEM PHYS, V85, P1028, DOI 10.1063/1.451346; ROSS M, 1973, PHYS REV A, V8, P1466, DOI 10.1103/PhysRevA.8.1466; STISHOV SM, 1970, JETP LETT-USSR, V11, P13	12	71	71	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					955	957		10.1126/science.275.5302.955	http://dx.doi.org/10.1126/science.275.5302.955			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020073				2022-12-28	WOS:A1997WH38800038
J	Janda, KD; Lo, LC; Lo, CHL; Sim, MM; Wang, R; Wong, CH; Lerner, RA				Janda, KD; Lo, LC; Lo, CHL; Sim, MM; Wang, R; Wong, CH; Lerner, RA			Chemical selection for catalysis in combinatorial antibody libraries	SCIENCE			English	Article							GLYCOSIDASE INHIBITORS; GENERATION; GLUCOPYRANOSYL; INTERMEDIATE; MECHANISM; SYSTEM	For the past decade the immune system has been exploited as a rich source of de novo catalysts. Catalytic antibodies have been shown to have chemoselectivity, enantioselectivity, large rate accelerations, and even an ability to reroute chemical reactions. In many instances catalysts have been made for reactions for which these are no known natural or man-made enzymes. Yet, the full power of this combinatorial system can only be exploited if there was a system that allows for the direct selection of a particular function. A method that allows for the direct chemical selection for catalysis from antibody libraries was so devised, whereby the positive aspects of hybridoma technology were preserved and re-formatted in the filamentous phage system to allow direct selection of catalysis. This methodology is based on a purely chemical selection process, making it more general than biologically based selection systems because of its not limited to reaction products that perturb cellular machinery.	SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Janda, KD (corresponding author), Scripps Res Inst, DEPT CHEM, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Lo, Lee-Chiang Lo/G-9165-2015	Lo, Lee-Chiang Lo/0000-0002-5821-1690	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044154, R01GM043858, R29GM043858, R37GM044154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44154, GM-43858] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen H. J., 1992, GLYCOCONJUGATES COMP; AMYES TL, 1989, J AM CHEM SOC, V111, P78; Barbas Carlos F. Iii, 1995, Methods (Orlando), V8, P94, DOI 10.1006/meth.1995.9997; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; COLLET TA, 1992, P NATL ACAD SCI USA, V89, P10026, DOI 10.1073/pnas.89.21.10026; FENNIRI H, 1995, P NATL ACAD SCI USA, V92, P2278, DOI 10.1073/pnas.92.6.2278; GONG B, 1992, J AM CHEM SOC, V114, P1486, DOI 10.1021/ja00030a056; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; HORTON HR, 1969, BIOCHIM BIOPHYS ACTA, V194, P272; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; ICHIKAWA Y, 1995, TETRAHEDRON LETT, V36, P4585, DOI 10.1016/0040-4039(95)00870-I; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P10779, DOI 10.1073/pnas.91.23.10779; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JANDA KD, 1994, PHARM MONOCLONAL ANT; JANDA KD, 1996, COMPREHENSIVE SUPRAM, V4, P43; Jeong JH, 1996, J AM CHEM SOC, V118, P4227, DOI 10.1021/ja951602z; Kirby AJ, 1996, NAT STRUCT BIOL, V3, P107, DOI 10.1038/nsb0296-107; Kirby AJ, 1994, ADV PHYS ORG CHEM, V29, P87, DOI 10.1016/S0065-3160(08)60076-3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUAPP S, 1994, J AM CHEM SOC, V116, P7461; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; LAMPEN JO, 1946, J BIOL CHEM, V164, P789; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; LIU KKC, 1991, J ORG CHEM, V56, P6280, DOI 10.1021/jo00022a013; LO CHL, 1996, OSR J CHEM, V36, P195; LOOK GC, 1993, ACCOUNTS CHEM RES, V26, P182, DOI 10.1021/ar00028a008; MACBEATH G, 1994, J AM CHEM SOC, V116, P6101, DOI 10.1021/ja00093a006; Matsumura I, 1996, BIOCHEMISTRY-US, V35, P1890, DOI 10.1021/bi951672i; MOLE JE, 1973, BIOCHEMISTRY-US, V12, P5278, DOI 10.1021/bi00750a009; PAPANDREOU G, 1993, J AM CHEM SOC, V115, P11682, DOI 10.1021/ja00078a004; PAUL WE, 1992, FUNDAMENTAL IMMUNOLO; PEARSON B, 1961, P SOC EXP BIOL MED, V108, P619; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; Roepke RR, 1944, J BACTERIOL, V48, P401, DOI 10.1128/JB.48.4.401-412.1944; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Seiler N, 1978, ENZYME ACTIVATED IRR; SILVERMAN RB, 1988, MECH BASED ENZYME IN, V1; SILVERMAN RB, 1988, MECH BASED ENZYME IN, V2; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SUGA H, 1994, J AM CHEM SOC, V116, P11197, DOI 10.1021/ja00103a061; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; TRAUT RR, 1973, BIOCHEMISTRY-US, V12, P3266, DOI 10.1021/bi00741a019; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; YU JH, 1994, ANGEW CHEM INT EDIT, V33, P339, DOI 10.1002/anie.199403391; ZHANG YL, 1994, J AM CHEM SOC, V116, P7557, DOI 10.1021/ja00096a012	52	170	213	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					945	948		10.1126/science.275.5302.945	http://dx.doi.org/10.1126/science.275.5302.945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	WH388	9020070				2022-12-28	WOS:A1997WH38800035
J	Britton, TC				Britton, TC			Increased writing activity in neurological disease	LANCET			English	Editorial Material							HYPERGRAPHIA; HEMISPHERE; EPILEPSY				Britton, TC (corresponding author), UNIV LONDON KINGS COLL HOSP,NEUROSCI UNIT,DENMARK HILL,LONDON SE5 9RS,ENGLAND.							FRISONI GB, 1993, J NEUROL NEUROSUR PS, V56, P576, DOI 10.1136/jnnp.56.5.576-b; IMAMURA T, 1992, J NEUROL NEUROSUR PS, V55, P25, DOI 10.1136/jnnp.55.1.25; OKAMURA T, 1993, J NEUROL NEUROSUR PS, V56, P556, DOI 10.1136/jnnp.56.5.556; TRIMBLE MR, 1986, ASPECTS EPILEPSY PSY, P75; vanVugt P, 1996, J NEUROL NEUROSUR PS, V61, P510, DOI 10.1136/jnnp.61.5.510; WAXMAN SG, 1974, NEUROLOGY, V24, P629, DOI 10.1212/WNL.24.7.629; YAMADORI A, 1986, J NEUROL NEUROSUR PS, V49, P1160, DOI 10.1136/jnnp.49.10.1160	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					372	373		10.1016/S0140-6736(97)80004-9	http://dx.doi.org/10.1016/S0140-6736(97)80004-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033459				2022-12-28	WOS:A1997WH29600004
J	Newman, EA; Zahs, KR				Newman, EA; Zahs, KR			Calcium waves in retinal glial cells	SCIENCE			English	Article							ASTROCYTES IN-SITU; FREE AMINO-ACIDS; GAP-JUNCTIONS; GLUTAMATE; THAPSIGARGIN; ACTIVATION; RECEPTORS; NETWORKS; NEURONS; RELEASE	Calcium signals were recorded from glial cells in acutely isolated rat retina to determine whether Ca2+ waves occur in glial cells of intact central nervous system tissue. Chemical (adenosine triphosphate), electrical, and mechanical stimulation of astrocytes initiated increases in the intracellular concentration of Ca2+ that propagated at similar to 23 micrometers per second through astrocytes and Muller cells as intercellular waves. The Ca2+ waves persisted in the absence of extracellular Ca2+ but were largely abolished by thapsigargin and intracellular heparin, indicating that Ca2+ was released from intracellular stores. The waves did not evoke changes in cell membrane potential but traveled synchronously in astrocytes and Muller cells, suggesting a functional linkage between these two types of glial cells. Such glial Ca2+ waves may constitute an extraneuronal signaling pathway in the central nervous system.			Newman, EA (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NEI NIH HHS [R01 EY004077, EY10383, R01 EY004077-19, EY04077] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010383, R01EY004077] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUFFY S, 1995, J NEUROSCI, V15, P5535; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FINKBEINER SM, 1993, GLIA, V9, P83, DOI 10.1002/glia.440090202; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUNNARSON G, 1987, EXP EYE RES, V44, P235, DOI 10.1016/S0014-4835(87)80008-8; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; HEINAMAKI AA, 1986, NEUROCHEM RES, V11, P535, DOI 10.1007/BF00965323; Kettenmann H., 1995, NEUROGLIA; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PARPURA V, 1995, J NEUROSCI, V15, P5831; PORTER JT, 1995, J NEUROCHEM, V65, P1515, DOI 10.1046/j.1471-4159.1995.65041515.x; PORTER JT, 1995, GLIA, V13, P101, DOI 10.1002/glia.440130204; ROBINSON SR, 1993, SCIENCE, V262, P1072; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466	26	352	359	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					844	847		10.1126/science.275.5301.844	http://dx.doi.org/10.1126/science.275.5301.844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012354	Green Accepted			2022-12-28	WOS:A1997WG77700065
J	Palecek, SP; Loftus, JC; Ginsberg, MH; Lauffenburger, DA; Horwitz, AF				Palecek, SP; Loftus, JC; Ginsberg, MH; Lauffenburger, DA; Horwitz, AF			Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness	NATURE			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRONECTIN RECEPTOR; ADHESION; MOTILITY; LOCOMOTION; VITRONECTIN; FIBROBLASTS; ATTACHMENT; ANTIBODIES; DYNAMICS	Migration of cells in higher organisms is mediated by adhesion receptors, such as integrins, that link the cell to extracellular-matrix ligands, transmitting forces and signals necessary for locomotion(1-4). Whether cells will migrate or not on a given substratum, and also their speed, depends on several variables related to integrin-ligand interactions, including ligand levels(5,6), integrin levels(7-9), and integrin-ligand binding affinities(10-12). These and other(13) factors affect the way molecular systems integrate to effect and regulate cell migration. Here we show that changes in cell migration speed resulting from three separate variables-substratum ligand level, cell integrin expression level, and integrin-ligand binding affinity-are all quantitatively predictable through the changes they cause in a single unifying parameter: short-term cell-substratum adhesion strength. This finding is consistent with predictions of a mathematical model for cell migration(14). The ligand concentration promoting maximum migration speed decreases reciprocally as integrin expression increases. Increases in integrin-ligand affinity similarly result in maximal migration at reciprocally lower ligand concentrations. The maximum speed attainable, however, remains unchanged as ligand concentration, integrin expression, or integrin-ligand affinity vary, suggesting that integrin coupling with intracellular motors remains unaltered.	MIT, CTR BIOMED ENGN, CAMBRIDGE, MA 02139 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	Massachusetts Institute of Technology (MIT); Scripps Research Institute; University of Illinois System; University of Illinois Urbana-Champaign	Palecek, SP (corresponding author), MIT, DEPT CHEM ENGN, CAMBRIDGE, MA 02139 USA.							ABERCROMBIE M, 1970, EXP CELL RES, V59, P393, DOI 10.1016/0014-4827(70)90646-4; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Cary LA, 1996, J CELL SCI, V109, P1787; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DUBAND JL, 1991, J CELL SCI, V98, P517; Dunn G A, 1983, Agents Actions Suppl, V12, P14; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAY PY, 1995, J CELL SCI, V108, P387; KEELY PJ, 1995, J CELL SCI, V108, P595; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; Palecek SP, 1996, J CELL SCI, V109, P941; POWERS MJ, IN PRESS BIOTECHNOL; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WESSELS D, 1994, CELL MOTIL CYTOSKEL, V27, P1, DOI 10.1002/cm.970270102	30	1107	1138	2	131	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					537	540		10.1038/385537a0	http://dx.doi.org/10.1038/385537a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020360				2022-12-28	WOS:A1997WG23500048
J	vanderWouw, PA; Bax, M				vanderWouw, PA; Bax, M			Massive pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											vanderWouw, PA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,MEIBERGDREEF 9,NL-1105 AZ AMSTERDAM,NETHERLANDS.								0	8	8	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					416	416		10.1056/NEJM199702063360605	http://dx.doi.org/10.1056/NEJM199702063360605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010148	Green Published			2022-12-28	WOS:A1997WF85900005
J	Nightingale, SL				Nightingale, SL			FDA proposes to withdraw terfenadine approval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1997, FED REGISTER, V62, P1889	1	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					370	370						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010159				2022-12-28	WOS:A1997WE77100008
J	Mattingley, JB; Davis, G; Driver, J				Mattingley, JB; Davis, G; Driver, J			Preattentive filling-in of visual surfaces in parietal extinction	SCIENCE			English	Article							FEATURE-INTEGRATION; NEGLECT; ATTENTION; PERCEPTION; PATIENT; LESIONS; HUMANS; FIELD; LOBE	Unilateral brain damage frequently produces ''extinction,'' in which patients can detect brief single visual stimuli on either side but are unaware of a contralesional stimulus if presented concurrently with an ipsilesional stimulus. Explanations for extinction have invoked deficits in initial processes that operate before the focusing of visual attention or in later attentive stages of vision, Preattentive vision was preserved in a parietally damaged patient, whose extinction was less severe when bilateral stimuli formed a common surface, even if this required visual filling-in to yield illusory Kanizsa figures or completion of partially occluded figures. These results show that parietal extinction arises only after substantial processing has generated visual surfaces, supporting recent claims that visual attention is surface-based.	UNIV LONDON BIRKBECK COLL,DEPT PSYCHOL,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	Mattingley, JB (corresponding author), UNIV CAMBRIDGE,DEPT EXPT PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EB,ENGLAND.		Davis, Gregory/G-9954-2012; Driver, Jon/A-4779-2010; Mattingley, Jason/J-1537-2014	Mattingley, Jason/0000-0003-0929-9216	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLIS GC, 1993, J COGNITIVE NEUROSCI, V5, P453, DOI 10.1162/jocn.1993.5.4.453; Bender M.B., 1952, DISORDERS PERCEPTION; BERTI A, 1992, J COGNITIVE NEUROSCI, V4, P345, DOI 10.1162/jocn.1992.4.4.345; COHEN A, 1991, PSYCHOL SCI, V2, P106, DOI 10.1111/j.1467-9280.1991.tb00109.x; Critchley M, 1966, PARIETAL LOBES; DAVIS G, 1994, NATURE, V371, P79; DIPELLEGRINO G, 1995, NEUROPSYCHOLOGIA, V33, P153, DOI 10.1016/0028-3932(94)00111-2; DRIVER J, 1992, NATURE, V360, P73, DOI 10.1038/360073a0; Duncan J., 1996, ATTENTION PERFORM, P549; ENNS JT, 1992, VSCOPE SOFTWARE MANU; ENNS JT, 1994, VISUAL SEARCH, V3; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; HE ZJ, 1992, NATURE, V359, P231, DOI 10.1038/359231a0; HE ZJ, 1995, P NATL ACAD SCI USA, V92, P11155, DOI 10.1073/pnas.92.24.11155; HUMPHREYS GW, 1994, NATURE, V372, P357, DOI 10.1038/372357a0; Jackendoff R, 1987, CONSCIOUSNESS COMPUT; KANIZSA, 1979, ORG VISION; Kanizsa G., 1955, RIV PSICOL, V49, P7; KARNATH HO, 1988, NEUROPSYCHOLOGIA, V26, P27, DOI 10.1016/0028-3932(88)90028-0; Kinsbourne M., 1993, UNILATERAL NEGLECT C, DOI DOI 10.4324/9780203765258; LADAVAS E, 1993, NEUROPSYCHOLOGIA, V31, P1307, DOI 10.1016/0028-3932(93)90100-E; MARSHALL JC, 1988, NATURE, V336, P766, DOI 10.1038/336766a0; MICHOTTE A, 1964, STUDIA PSYCHOL LOUVA; NAKAYAMA K, 1995, INVITATION COGNITIVE, V2, P1; Ramachandran V. S., 1987, PERCEPTION ILLUSORY, P93, DOI 10.1007/978-1-4612-4760-9_10; RAPCSAK SZ, 1987, J NEUROL NEUROSUR PS, V50, P1117, DOI 10.1136/jnnp.50.9.1117; SHIPLEY TF, 1992, J EXP PSYCHOL HUMAN, V18, P106, DOI 10.1037/0096-1523.18.1.106; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VALLAR G, 1994, J NEUROL NEUROSUR PS, V57, P464, DOI 10.1136/jnnp.57.4.464; VOLPE BT, 1979, NATURE, V282, P722, DOI 10.1038/282722a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; Ward R, 1996, PSYCHOL SCI, V7, P177, DOI 10.1111/j.1467-9280.1996.tb00353.x; Ward R., 1994, VIS COGN, V1, P101, DOI DOI 10.1080/13506289408402295	34	192	194	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					671	674		10.1126/science.275.5300.671	http://dx.doi.org/10.1126/science.275.5300.671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WF077	9005854				2022-12-28	WOS:A1997WF07700041
J	Selkoe, DJ				Selkoe, DJ			Neuroscience - Alzheimer's disease: Genotypes, phenotype, and treatments	SCIENCE			English	Editorial Material							AMYLOID-BETA-PROTEIN; APOLIPOPROTEIN-E GENOTYPE; PRECURSOR PROTEIN; DOWN-SYNDROME; DEPOSITION; GENE; MUTATIONS; LOCUS; CELLS				Selkoe, DJ (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CTR NEUROL DIS,BOSTON,MA 02115, USA.							CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAMES D, 1995, SOC NEUR ABSTR, V21, P258; Gearing M, 1996, ANN NEUROL, V39, P395, DOI 10.1002/ana.410390320; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KHOURY JE, 1996, NATURE, V382, P716; KISSILEVSKI R, 1993, AMYLOID AMYLOIDOSIS; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; Masliah E, 1996, J NEUROSCI, V16, P5795; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; REBECK GW, 1993, NEURON, V11, P575; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3	33	785	859	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					630	631		10.1126/science.275.5300.630	http://dx.doi.org/10.1126/science.275.5300.630			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9019820				2022-12-28	WOS:A1997WF07700028
J	Stone, EM; Fingert, JH; Alward, WLM; Nguyen, TD; Polansky, JR; Sunden, SLF; Nishimura, D; Clark, AF; Nystuen, A; Nichols, BE; Mackey, DA; Ritch, R; Kalenak, JW; Craven, ER; Sheffield, VC				Stone, EM; Fingert, JH; Alward, WLM; Nguyen, TD; Polansky, JR; Sunden, SLF; Nishimura, D; Clark, AF; Nystuen, A; Nichols, BE; Mackey, DA; Ritch, R; Kalenak, JW; Craven, ER; Sheffield, VC			Identification of a gene that causes primary open angle glaucoma	SCIENCE			English	Article							DOMINANT JUVENILE GLAUCOMA; RECEPTOR; PROTEINS; LINKAGE; BLINDNESS; FAMILY	Glaucoma is a major cause of blindness and is characterized by progressive degeneration of the optic nerve and is usually associated with elevated intraocular pressure. Analyses of sequence tagged site (STS) content and haplotype sharing between families affected with chromosome 1q-linked open angle glaucoma (GLC1A) were used to prioritize candidate genes for mutation screening. A gene encoding a trabecular mesh-work protein (TIGR) mapped to the narrowest disease interval by STS content and radiation hybrid mapping. Thirteen glaucoma patients were found to have one of three mutations in this gene (3.9 percent of the population studied). One of these mutations was also found in a control individual (0.2 percent). Identification of these mutations will aid in early diagnosis, which is essential for optimal application of existing therapies.	UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OPHTHALMOL,IOWA CITY,IA 52242; UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143; ALCON LABS INC,FT WORTH,TX 76134; UNIV MELBOURNE,DEPT OPHTHALMOL,MELBOURNE,VIC 3002,AUSTRALIA; UNIV TASMANIA,MENZIES CTR,HOBART,TAS,AUSTRALIA; NEW YORK EYE & EAR INFIRM,DEPT OPHTHALMOL,NEW YORK,NY 10003; MED COLL WISCONSIN,DEPT OPHTHALMOL,MILWAUKEE,WI 53226; UNIV COLORADO,SCH MED,DEPT OPHTHALMOL,DENVER,CO 80262	University of Iowa; University of Iowa; University of California System; University of California San Francisco; Novartis; Alcon; University of Melbourne; University of Tasmania; New York Eye & Ear Infirmary of Mount Sinai; Medical College of Wisconsin; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Mackey, David A/H-5340-2014; Fingert, John/F-8787-2012; Alward, Wallace/AAY-4149-2020; Fingert, John/AAX-4750-2021	Mackey, David A/0000-0001-7914-4709; Fingert, John/0000-0002-0377-0479; Fingert, John/0000-0002-0377-0479; Sheffield, Val/0000-0002-6282-0835; Alward, Wallace/0000-0001-6368-9018; Stone, Edwin M./0000-0003-3343-4414; Craven, Earl/0000-0002-2077-659X	NATIONAL EYE INSTITUTE [R01EY010564, R01EY008905, R01EY002477] Funding Source: NIH RePORTER; NEI NIH HHS [EY08905, EY10564, EY02477] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; HILLER R, 1975, AM J OPHTHALMOL, V80, P62, DOI 10.1016/0002-9394(75)90870-3; JOHNSON AT, 1993, OPHTHALMOLOGY, V100, P524; KAHN HA, 1973, US PHS PUBL NIH, P120; LANGE K, 1995, GENOME RES, V5, P136, DOI 10.1101/gr.5.2.136; LOWE DG, 1990, GENOMICS, V8, P304, DOI 10.1016/0888-7543(90)90286-4; MAO LK, 1991, AM J OPHTHALMOL, V111, P51, DOI 10.1016/S0002-9394(14)76896-5; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MORISSETTE J, 1995, AM J HUM GENET, V56, P1431; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NGUYEN TD, 1996, Patent No. 14024; NGUYEN TV, UNPUB; Polansky J R, 1989, Prog Clin Biol Res, V312, P113; Polansky JR, 1993, BASIC ASPECTS GLAUCO, P307; QUIGLEY HA, 1979, AM J OPHTHALMOL, V87, P519, DOI 10.1016/0002-9394(79)90241-1; RICHARDS JE, 1994, AM J HUM GENET, V54, P62; SHEFFIELD VC, 1993, NAT GENET, V4, P47, DOI 10.1038/ng0593-47; SHEFFIELD VC, UNPUB; Sunden SLF, 1996, GENOME RES, V6, P862, DOI 10.1101/gr.6.9.862; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIELSCH JM, 1993, T N ORL ACA, P61; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WATKINS HC, 1993, HUM MOL GENET, V2, P1084, DOI 10.1093/hmg/2.7.1084-a; WIGGS JL, 1994, GENOMICS, V21, P299, DOI 10.1006/geno.1994.1269	27	1110	1203	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					668	670		10.1126/science.275.5300.668	http://dx.doi.org/10.1126/science.275.5300.668			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005853				2022-12-28	WOS:A1997WF07700040
J	Trach, DD; Clemens, JD; Ke, NT; Thuy, HT; Son, ND; Canh, DG; Hang, PVD; Rao, MR				Trach, DD; Clemens, JD; Ke, NT; Thuy, HT; Son, ND; Canh, DG; Hang, PVD; Rao, MR			Field trial of a locally produced, killed, oral cholera vaccine in Vietnam	LANCET			English	Article							VIBRIO-CHOLERAE; WHOLE-CELL; FOLLOW-UP; B-SUBUNIT; BANGLADESH; MODEL	Background Several studies have shown that orally administered killed cholera vaccines are safe and protective in populations at risk of cholera in developing countries. However, these vaccines have not been adopted for use in developing countries because of their expense and limited efficacy in young children. We have tested an inexpensive, killed whole-cell cholera vaccine developed and produced in Vietnam. Methods The efficacy of the vaccine was assessed in a large-scale, open field trial in people at least 1 year old residing in 22 653 households in the central coastal city of Hue. Alternate households were assigned vaccine (67 395 people; two doses per person) or no vaccine (67 058 people). Surveillance for cholera was conducted in all Ministry of Health facilities serving this population. Analysis was by intention to treat. Findings During an outbreak of El Tor cholera 8-10 months after vaccination, 37 cases of cholera requiring inpatient care occurred among age-eligible people allocated to the vaccine group, and 92 cases among age-eligible people allocated to the no-vaccine group (protective impact 60% [95% CI 40-73]). Among the 51 975 people who received the complete two-dose vaccine regimen, the protective efficacy was 66% (46-79); in this subset, the protective efficacy was similar for children aged 1-5 years (68%) and for older people (66%). Interpretation These findings suggest that oral killed whole-cell vaccines can confer substantial protection against El Tor cholera in young children, who are at highest risk of cholera in endemic settings. An inexpensive, locally produced, and effective oral cholera vaccine may be within reach of the limited healthcare budgets of poor countries with endemic cholera, if our findings can be replicated in a randomised double-blind trial.	NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,BETHESDA,MD 20892; NATL INST HYG & EPIDEMIOL,HANOI,VIETNAM; CTR PREVENT MED,HUE,VIETNAM; INST VACCINES,NHA TRANG,VIETNAM	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Hygiene & Epidemiology (NIHE)								BATTACHARYA M, 1993, LANCET, V341, P1346; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; CLEMENS JD, 1986, J INFECT DIS, V154, P175, DOI 10.1093/infdis/154.1.175; CLEMENS JD, 1988, LANCET, V1, P1375; CLEMENS JD, 1989, VACCINE, V7, P111; Diggle PJ, 1994, ANAL LONGITUDINAL DA; HOLMGREN J, 1990, NEW GENERATION VACCI, P289; *INT CTR DIARRH DI, 1993, LANCET, V342, P387; Kay Bradford A., 1994, P3; OSEK J, 1994, INFECT IMMUN, V62, P2901, DOI 10.1128/IAI.62.7.2901-2907.1994; SHARMA DP, 1989, VACCINE, V7, P451, DOI 10.1016/0264-410X(89)90161-8; SUN D, 1990, J INFECT DIS, V161, P1231, DOI 10.1093/infdis/161.6.1231; TRACH DD, 1990, PROSPECTS PUBLIC HLT, P217; *WHO, 1992, WHOCDDSER804	17	137	142	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					231	235		10.1016/S0140-6736(96)06107-7	http://dx.doi.org/10.1016/S0140-6736(96)06107-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014909				2022-12-28	WOS:A1997WD90600009
J	VanEssen, DC				VanEssen, DC			A tension-based theory of morphogenesis and compact wiring in the central nervous system	NATURE			English	Article							RETINAL GANGLION-CELLS; RHESUS-MONKEY; CEREBRAL-CORTEX; STRIATE CORTEX; MIGRATING NEURONS; TISSUE-CULTURE; CORTICAL AREAS; CALLOSAL AXONS; MACAQUE MONKEY; ORGANIZATION	Many structural features of the mammalian central nervous system can be explained by a morphogenetic mechanism that involves mechanical tension along axons, dendrites and glial processes. In the cerebral cortex, for example, tension along axons in the white matter can explain how and why the cortex folds in a characteristic species-specific pattern. in the cerebellum, tension along parallel fibres can explain why the cortex is highly elongated but folded like an accordion. By keeping the aggregate length of axonal and dendritic wiring low, tension should contribute to the compactness of neural circuitry throughout the adult brain.			VanEssen, DC (corresponding author), WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ALLMAN JM, 1974, BRAIN RES, V76, P247, DOI 10.1016/0006-8993(74)90458-2; AULADELL C, 1995, NEUROSCIENCE, V64, P1091, DOI 10.1016/0306-4522(94)00393-J; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BARBAS H, 1988, J COMP NEUROL, V276, P353; BARLOW HB, 1986, VISION RES, V26, P81, DOI 10.1016/0042-6989(86)90072-6; BARRON DH, 1950, J EXP ZOOL, V113, P553, DOI 10.1002/jez.1401130304; Bok S. T., 1959, HISTONOMY CEREBRAL C; BRAY D, 1979, J CELL SCI, V37, P391; Burke R.E., 1981, HDB PHYSL SECTION 1, VII, P345, DOI 10.1002/cphy.cp010210; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; CHERNIAK C, 1995, TRENDS NEUROSCI, V18, P522, DOI 10.1016/0166-2236(95)98373-7; CHERNIAK C, 1992, BIOL CYBERN, V66, P503, DOI 10.1007/BF00204115; Coogan TA, 1996, J COMP NEUROL, V372, P327, DOI 10.1002/(SICI)1096-9861(19960826)372:3<327::AID-CNE1>3.0.CO;2-4; COULOMBRE AJ, 1956, J EXP ZOOL, V133, P211, DOI 10.1002/jez.1401330202; COWEY A, 1979, Q J EXP PSYCHOL, V31, P1, DOI 10.1080/14640747908400703; DECARLOS JA, 1992, J NEUROSCI, V12, P1194; Dehay C, 1996, J COMP NEUROL, V367, P70, DOI 10.1002/(SICI)1096-9861(19960325)367:1<70::AID-CNE6>3.0.CO;2-G; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; DESMOND ME, 1977, DEV BIOL, V57, P188, DOI 10.1016/0012-1606(77)90364-5; Drury HA, 1996, J COGNITIVE NEUROSCI, V8, P1, DOI 10.1162/jocn.1996.8.1.1; DRURY HA, UNPUB J NEUROSCI; Enlow D. H., 1990, FACIAL GROWTH; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; FRIEDMAN DP, 1980, J COMP NEUROL, V192, P21, DOI 10.1002/cne.901920103; Fuller R. B., 1979, SYNERGETICS; GALABURDA AM, 1983, J COMP NEUROL, V221, P169, DOI 10.1002/cne.902210206; Goldman-Rakic PS, 1980, PROG BRAIN RES, V53, P3; Harrison RG, 1935, PROC R SOC SER B-BIO, V118, P155, DOI 10.1098/rspb.1935.0053; HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603; HOFMAN MA, 1989, PROG NEUROBIOL, V32, P137, DOI 10.1016/0301-0082(89)90013-0; HOPFIELD JJ, 1985, BIOL CYBERN, V52, P141; Ingber D. E, 1989, CELL SHAPE DETERMINA, P3; JONES EG, 1978, J COMP NEUROL, V181, P291, DOI 10.1002/cne.901810206; Jouandet M L, 1989, J Cogn Neurosci, V1, P88, DOI 10.1162/jocn.1989.1.1.88; KIRBY MA, 1992, VISUAL NEUROSCI, V9, P603, DOI 10.1017/S095252380000184X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAMOUREUX P, 1992, J CELL BIOL, V118, P655, DOI 10.1083/jcb.118.3.655; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; LEGROSCLARK WE, 1945, ESSAYS GROWTH FORM, P1; Mead C., 1978, INTRO VLSI SYSTEMS; MILLER J D, 1987, Neurological Research, V9, P193; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; MOREST DK, 1969, Z ANAT ENTWICKLUNGS, V128, P290, DOI 10.1007/BF00522529; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; Ono M, 1990, ATLAS CEREBRAL SULCI; Polyak S, 1957, VERTEBRATE SYSTEM; PONS TP, 1986, J COMP NEUROL, V248, P313, DOI 10.1002/cne.902480303; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Ramon y Cajal S, 1960, STUDIES VERTEBRATE N; RICHMAN DP, 1975, SCIENCE, V189, P18, DOI 10.1126/science.1135626; Sauer FC, 1935, J COMP NEUROL, V62, P377, DOI 10.1002/cne.900620207; SCANNELL JW, 1995, J NEUROSCI, V15, P1463; SCHWARTZ ML, 1991, P NATL ACAD SCI USA, V88, P1354, DOI 10.1073/pnas.88.4.1354; SELTZER B, 1980, BRAIN RES, V192, P339, DOI 10.1016/0006-8993(80)90888-4; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SOUSA APB, 1991, J COMP NEUROL, V308, P665, DOI 10.1002/cne.903080411; STEINEKE TC, 1993, DEV BRAIN RES, V74, P151, DOI 10.1016/0165-3806(93)90001-Q; STEWART RM, 1975, ACTA NEUROPATHOL, V31, P1, DOI 10.1007/BF00696881; STOPAK D, 1982, DEV BIOL, V90, P383, DOI 10.1016/0012-1606(82)90388-8; Sultan Fahad, 1993, Journal fuer Hirnforschung, V34, P79; TAKADA K, 1988, CLIN NEUROPATHOL, V7, P111; Thompson D.W, 1917, GROWTH FORM; TOGA AW, 1996, DEV NEUROIMAGING MAP, P15; TUSA RJ, 1979, J COMP NEUROL, V185, P657, DOI 10.1002/cne.901850405; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; VANESSEN DC, 1986, J COMP NEUROL, V244, P451, DOI 10.1002/cne.902440405; Wainwright SA., 1988, AXIS CIRCUMFERENCE C; Welker W, 1990, CEREB CORTEX, P3, DOI DOI 10.1007/978-1-4615-3824-0; WELKER WI, 1990, ARCH ITAL BIOL, V128, P87; Whittaker V.P., 1984, HDB NEUROCHEMISTRY, V7, P1; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0	77	1215	1221	3	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					313	318		10.1038/385313a0	http://dx.doi.org/10.1038/385313a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002514				2022-12-28	WOS:A1997WD91400042
J	Bates, DW; Spell, N; Cullen, DJ; Burdick, E; Laird, N; Petersen, LA; Small, SD; Sweitzer, BJ; Leape, LL				Bates, DW; Spell, N; Cullen, DJ; Burdick, E; Laird, N; Petersen, LA; Small, SD; Sweitzer, BJ; Leape, LL			The costs of adverse drug events in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADMISSIONS; MORBIDITY	Objective.-To assess the additional resource utilization associated with an adverse drug event (ADE). Design.-Nested case-control study within a prospective cohort study, Participants.-The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay. Main Outcome Measures.-Postevent length of stay and total costs. Methods.-Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges. Results.-During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was $3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and $5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were $2595 for all ADEs and $4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are $5.6 million and $2.8 million, respectively. Conclusions.-The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.	BRIGHAM & WOMENS HOSP, DIV GEN MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT ANESTHESIA, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, HLTH SERV RES & DEV, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University					AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM HOSP ASS, 1993, HOSP STAT; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CULLEN DJ, 1989, PROBL CRIT CARE, V3, P545; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KORIN J, 1993, HOSP FORMUL, V28, P59; KOSKA MT, 1989, HOSPITALS, V63, P24; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MCKENNEY JM, 1976, AM J HOSP PHARM, V33, P792, DOI 10.1093/ajhp/33.8.792; *NAT ASS INS COMM, 1980, MED MALPR CLOS CLAIM; Rogowski J R, 1990, Health Care Financ Rev, V12, P87; SANDRICK K, 1995, HOSP HEALTH NETWORK, V69, P46; SANDRICK K, 1995, HOSP HEALTH NETWORK, V69, P36; *SAS, 1988, SAS PROC GUID REL 6; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; 1996, US NEWS WORLD R 0812, P67	24	1191	1230	2	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					307	311		10.1001/jama.277.4.307	http://dx.doi.org/10.1001/jama.277.4.307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC458	9002493				2022-12-28	WOS:A1997WC45800030
J	Salisbury, C				Salisbury, C			Observational study of a general practice out of hours cooperative: Measures of activity	BRITISH MEDICAL JOURNAL			English	Article							NORMAL WORKING HOURS; PRIMARY-CARE; DEPUTIZING SERVICES; TELEPHONE ADVICE; HOURS WORKLOAD; HOURS CALLS; ORGANIZATION; EMERGENCY; ACCIDENT; RATES	Objective: Tb evaluate an out of hours cooperative of Department of general practitioners compared with a deputising Primary Health service. Design: Observational study of two services in overlapping geographical areas. Setting: A general practice cooperative in Kensington, Chelsea, and Westminster and a deputising service operating in that area and the neighbouring area of Brent and Harrow. Subjects: All patients contacting a doctor at either service in an eight week period beginning 1 September 1995. Main outcome measures: Patients' age and sex; rates of home visiting, telephone advice, and attendance at a primary centre; hospital admission rates prescribing rates; times of patient calls; and response times. Results: Data were collected on 5812 patient contacts. Doctors from the cooperative visited 32.0% (1253/3920) of patients, offered telephone advice to 57.8% (2267), and saw 7.1% (278) of patients at the primary care centre. By contrast, the deputising service visited 76.3% (1444/1892) of patients and gave telephone advice to 19.3% (365). Doctors from the cooperative prescribed drugs to fewer patients (37.6%; 1473/3915) than did the deputising service (51.7%; 941/1821) (odds ratio 0.56 (95% confidence interval 0.50 to 0.63) adjusted for age and sex) and admitted 8.5% (339/3888) of patients to hospital compared with 6.8% (128/1889) from the deputising service (odds ratio 1.30 (1.05 to 1.61) adjusted for age and sex). Response times for the deputising service were faster (median time to visit 65 minutes) than for the cooperative (median time to visit 75 minutes) but the time to first contact with a doctor was shorter for the cooperative because most people initially received telephone advice. Conclusions: The cooperative in this study dealt with patient contacts very differently from the way the deputising service dealt with contacts, fewer patients being visited and fewer receiving prescriptions. The data presented enable other out of hours services to compare their own performance using a standard data collection and analysis program.			Salisbury, C (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,PRAED ST,LONDON W2 1PG,ENGLAND.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				ANDALO D, 1996, GEN PRACTITIONE 0614, P89; BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BARDSLEY M, 1995, 1 E LOND CIT HLTH AU; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; DALE J, 1992, BRIT J GEN PRACT, V42, P90; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; *DEP HLTH, 1984, HCFP842; *DEP HLTH, 1995, AM STAT FEES ALL OUT; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; *NAT HLTH SERV EX, 1996, 1994 5 HLTH SERV IND; *OFF POP CENS SURV, 1996, MID POP EST 1994 GOV; *OFF POP CENS SURV, 1993, 1994 CENS COUNT REP; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; REYNOLDS M, 1995, PULSE           0311, P48; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474	22	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					182	186		10.1136/bmj.314.7075.182	http://dx.doi.org/10.1136/bmj.314.7075.182			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022433	Green Published			2022-12-28	WOS:A1997WD91100028
J	Antz, C; Geyer, M; Fakler, B; Schott, MK; Guy, HR; Frank, R; Ruppersberg, JP; Kalbitzer, HR				Antz, C; Geyer, M; Fakler, B; Schott, MK; Guy, HR; Frank, R; Ruppersberg, JP; Kalbitzer, HR			NMR structure of inactivation gates from mammalian voltage-dependent potassium channels	NATURE			English	Article							SHAKER K-CHANNELS; IK(A) CHANNELS; BALL PEPTIDE; SPECTROSCOPY; PROTEINS; SPECTRA; BRAIN	The electrical signalling properties of neurons originate largely from the gating properties of their ion channels, N-type inactivation of voltage-gated potassium (K-v) channels is the best-understood gating transition in ion channels, and occurs by a 'ball-and-chain' type mechanism. In this mechanism an N-terminal domain (inactivation gate), which is tethered to the cytoplasmic side of the channel protein by a protease-cleavable chain, binds to its receptor at the inner vestibule of the channel, thereby physically blocking the pore(1,2). Even when synthesized as a peptide, ball domains restore inactivation in K-v channels whose inactivation domains have been deleted(2,3), Using high-resolution nuclear magnetic resonance (NMR) spectroscopy, we analysed the three-dimensional structure of the ball peptides from two rapidly inactivating mammalian K-v channels (Raw3 (K(v)3.4) and RCK4 (K(v)1.4)). The inactivation peptide of Raw3 (Raw3-IP) has a compact structure that exposes two phosphorylation sites and allows the formation of an intramolecular disulphide bridge between two spatially close cysteine residues. Raw3-IP exhibits a characteristic surface charge pattern with a positively charged, a hydrophobic, and a negatively charged region, The RCK4 inactivation peptide (RCK4-IP) shows a similar spatial distribution of charged and uncharged regions, but is more flexible and less ordered in its amino-terminal part.	MAX PLANCK INST MED RES,DEPT BIOPHYS,D-69120 HEIDELBERG,GERMANY; NIH,MATH BIOL LAB,BETHESDA,MD 20892; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY	Max Planck Society; National Institutes of Health (NIH) - USA; Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen				Geyer, Matthias/0000-0002-7718-5002; Kalbitzer, Hans Robert/0000-0002-6514-2355				AUER WP, 1976, J CHEM PHYS, V64, P2229; BRUNGER AT, 1992, X PLOR VERSION 3 1; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; FERNANDEZBALLESTER G, 1995, BIOPHYS J, V68, P858, DOI 10.1016/S0006-3495(95)80262-6; FRANK R, 1988, MODERN METHODS PROTE; GUY HR, 1992, BIOPHYS J, V62, P238; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEE CWB, 1993, BIOPHYS J, V61, pA379; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; OTTING G, 1993, BIOCHEMISTRY-US, V32, P3571, DOI 10.1021/bi00065a008; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	97	101	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					272	275		10.1038/385272a0	http://dx.doi.org/10.1038/385272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000078				2022-12-28	WOS:A1997WC71100053
J	Clarke, R; Frost, C; Collins, R; Appleby, P; Peto, R				Clarke, R; Frost, C; Collins, R; Appleby, P; Peto, R			Dietary lipids and blood cholesterol: Quantitative meta-analysis of metabolic ward studies	BRITISH MEDICAL JOURNAL			English	Article							MONOUNSATURATED FATTY-ACIDS; CORONARY HEART-DISEASE; SERUM-LIPIDS; LIPOPROTEINS; WOMEN; MEN	Objective: To determine the quantitative importance of dietary fatty acids and dietary cholesterol to blood concentrations of total, low density lipoprotein, and high density lipoprotein cholesterol. Design: Meta-analysis of metabolic ward studies of solid food diets in healthy volunteers. Subjects: 395 dietary experiments (median duration 1 month) among 129 groups of individuals. Results: Isocaloric replacement of saturated fats by complex carbohydrates for 10% of dietary calories resulted in blood total cholesterol falling by 0.52 (SE 0.03) mmol/l and low density lipoprotein cholesterol falling by 0.36 (0.05) mmol/l. Isocaloric replacement of complex carbohydrates by polyunsaturated fats for 5% of dietary calories resulted in total cholesterol falling by a further 0.13 (0.02) mmol/l and low density lipoprotein cholesterol falling by 0.11 (0.02) mmol/l. Similar replacement of carbohydrates by monounsaturated fats produced no significant effect on total or low density lipoprotein cholesterol. Avoiding 200 mg/day dietary cholesterol further decreased blood total cholesterol by 0.13 (0.02) mmol/l and low density lipoprotein cholesterol by 0.10 (0.02) mmol/l. Conclusions:ln typical British diets replacing 60% of saturated fats by other fats and avoiding 60% of dietary cholesterol would reduce blood total cholesterol by about 0.8 mmol/l (that is, by 10-15%), with four fifths of this reduction being in low density lipoprotein cholesterol.	RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,EPIDEMIOL STUDIES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT STAT,LONDON WC1E 7HT,ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Clarke, R (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,CLIN TRIAL SERV UNIT,OXFORD OX2 6HE,ENGLAND.							BINGHAM S, 1991, BRIT MED J, V303, P353, DOI 10.1136/bmj.303.6798.353; BLOEMBERG B, 1993, THESIS U LEIDEN LEID; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; Gregory J., 1990, DIETARY NUTR SURVEY; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HEGSTED DM, 1990, J VASC MED BIOL, V2, P68; JACOBS DR, 1979, AM J EPIDEMIOL, V110, P77, DOI 10.1093/oxfordjournals.aje.a112791; KEYS A, 1957, LANCET, V2, P959; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LIU K, 1978, J CHRON DIS, V31, P339; MARGARETTS BM, 1991, DESIGN CONCEPTS NUTR; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MENSINK RP, 1989, METABOLISM, V38, P172, DOI 10.1016/0026-0495(89)90258-8; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; YU SM, 1995, AM J CLIN NUTR, V61, P1129, DOI 10.1093/ajcn/61.5.1129; ZOCK PL, 1994, ARTERIOSCLER THROMB, V14, P567, DOI 10.1161/01.ATV.14.4.567	23	437	449	1	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					112	117		10.1136/bmj.314.7074.112	http://dx.doi.org/10.1136/bmj.314.7074.112			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006469	Green Published			2022-12-28	WOS:A1997WC47900022
J	Weissmann, G				Weissmann, G			Puerperal priority	LANCET			English	Article											Weissmann, G (corresponding author), NYU,DEPT MED,DIV RHEUMATOL,550 1ST AVE,NEW YORK,NY 10016, USA.		Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552				BARKER F, 1857, NEW YORK J MED COLLA, V3, P348; BARKER F, 1857, NEW YORK J MED COLLA, V3, P105; CARTER KC, 1994, CHILDBED FEVER SCI B, P51; CLARKE A, 1857, NEW YORK J MED COLLA, V3, P105; CROSSETTE B, 1996, NY TIMES        0821, pA1; Cullingworth C J, 1905, Br Med J, V2, P1161; Gordon AA., 1795, TREATISE EPIDEMIC PU; HARRIS E, 1855, NEW YORK J MED COLLA, V15, P258; HOLMES OW, 1855, PUERPERAL FEVER PRIV, P103; HOLMES OW, 1894, B JOHNS HOPKINS HOSP, V42, P86; HOLMES OW, 1842, N ENGL Q J MED SURG, V1, P503; HOLMES OW, 1892, COLLECTED POEMS, V2, P270; LEA A, 1987, BRIT MED J, V295, P485; Lister J., 1870, LANCET, V1, P4; LISTER J, 1870, LANCET, V1, P40; Lister J., 1867, LANCET, V90, P668, DOI [10.1016/S0140-6736(02)58116-2, DOI 10.1016/S0140-6736(02)58116-2]; Lister J, 1867, LANCET, V90, P353, DOI [10.1016/S0140-6736(02)51827-4, DOI 10.1016/S0140-6736(02)51827-4]; LOUIS PC, 1835, RECH EFFETS SAIGNEE; MORTON LT, 1983, MED BIBLIO, P844; OSLER W, 1894, B JOHNS HOPKINS HOSP, V42, P86; PASTEUR L, 1879, B ACAD MED PARIS, V8, P505; SEMMELWEIS I, 1847, Z GESELLSCHAFT AERZT, V4, P242; SEMMELWEIS IF, 1861, AETIOLOGIE BEGRIFF D, P350; SEMMELWEISS IP, 1849, ZDK K GESELLSCH AERZ, V5, P64; VALLERYRADOT RT, 1926, LIFE PASTEUR, P289; WEISSMANN G, 1996, DEMOCRACY DNA, P179; ZOLTAN I, 1995, ENCY BRITANNICA	27	2	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					122	125		10.1016/S0140-6736(96)06481-1	http://dx.doi.org/10.1016/S0140-6736(96)06481-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996434				2022-12-28	WOS:A1997WB80000045
J	Sejnowski, T				Sejnowski, T			The year of the dendrite	SCIENCE			English	Editorial Material											Sejnowski, T (corresponding author), UNIV CALIF SAN DIEGO,SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,SAN DIEGO,CA 92186, USA.		Sejnowski, Terrence/AAV-5558-2021					Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; Gaudreau H., 1996, Society for Neuroscience Abstracts, V22, P790; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; JESTER JM, 1995, J PHYSIOL-LONDON, V484, P689, DOI 10.1113/jphysiol.1995.sp020696; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MAGEE J, 1997, SCIENCE, V275, P213; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; NADEL L, COMMUNICATION; Rieke F., 1997, SPIKES EXPLORING NEU; Shepherd G.M., 1995, THEORETICAL FDN DEND; Svoboda K., 1996, Society for Neuroscience Abstracts, V22, P1058; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	17	23	23	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					178	179		10.1126/science.275.5297.178	http://dx.doi.org/10.1126/science.275.5297.178			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8999546				2022-12-28	WOS:A1997WC02200026
J	Isaac, A; Sargent, MG; Cooke, J				Isaac, A; Sargent, MG; Cooke, J			Control of vertebrate left-right asymmetry by a snail-related zinc finger gene	SCIENCE			English	Article							CHICK HEART; HANDEDNESS; EXPRESSION; EMBRYO	A gene encoding a zinc finger protein of the Snail family, cSnR, is expressed in the right-hand lateral mesoderm during normal chick development. Antisense disruption of cSnR function during the hours immediately preceding heart formation randomized the normally reliable direction of heart looping and subsequent embryo torsion. Implanted ectopic sources of intercellular signal proteins that are involved in establishing normal left-right information randomized the handedness of heart development and also altered the asymmetry of cSnR expression. cSnR thus appears to act downstream of these signals, or perhaps in parallel with the latest expressed of them, the Nodal protein, in controlling the anatomical asymmetry.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research								BROWN NA, 1990, DEVELOPMENT, V110, P949; BROWN NA, 1990, DEVELOPMENT, V109, P1; CAMPBELL M, 1966, BRIT HEART J, V28, P472; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; COOKE J, MOL EMBRYOLOGY METHO; ESSEX LJ, 1993, DEV DYNAM, V198, P108, DOI 10.1002/aja.1001980205; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOYLE C, 1992, DEVELOPMENT, V115, P1071; ITASAKI N, 1991, ANAT EMBRYOL, V183, P29; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; NIETO MA, 1992, DEVELOPMENT, V116, P227; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; SARGENT M, UNPUB; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL, P317; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STALSBER.H, 1969, DEV BIOL, V19, P109, DOI 10.1016/0012-1606(69)90051-7; STALSBER.H, 1970, AM J CARDIOL, V25, P265, DOI 10.1016/S0002-9149(70)80002-9; STALSBERG H, 1969, DEV BIOL, V19, P128, DOI 10.1016/0012-1606(69)90052-9; TORGERSEN J, 1949, ARCH PATHOL, V47, P566; Tsuda T, 1996, DEV BIOL, V173, P39, DOI 10.1006/dbio.1996.0005; WETZEL R, 1924, VERH PHYS MED GES WU, V49, P227; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178	31	165	166	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1997	275	5304					1301	1304		10.1126/science.275.5304.1301	http://dx.doi.org/10.1126/science.275.5304.1301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036854				2022-12-28	WOS:A1997WK64400041
J	Brody, H; Campbell, ML; FaberLangendoen, K; Ogle, KS				Brody, H; Campbell, ML; FaberLangendoen, K; Ogle, KS			Withdrawing intensive life-sustaining treatment - Recommendations for compassionate clinical management	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CRITICALLY ILL PATIENTS; TERMINALLY ILL; PALLIATIVE CARE; DEHYDRATION; DIALYSIS; DEATH; SUPPORT; DISCONTINUATION; PHYSICIANS; VECURONIUM		DETROIT RECEIVING HOSP & UNIV HLTH CTR, DETROIT, MI 48201 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	Detroit Receiving Hospital & University Health Center; University of Minnesota System; University of Minnesota Twin Cities	Brody, H (corresponding author), MICHIGAN STATE UNIV, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022	Campbell, Margaret/0000-0003-4517-690X				ANDREWS M, 1993, POSTGRAD MED, V93, P201; Asch DA, 1996, MED CARE, V34, P103, DOI 10.1097/00005650-199602000-00002; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN; Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; Campbell M L, 1992, Am J Crit Care, V1, P52; Campbell M L, 1996, Dimens Crit Care Nurs, V15, P4, DOI 10.1097/00003465-199601000-00002; Campbell M L, 1991, ANNA J, V18, P202; Campbell M L, 1993, Am J Crit Care, V2, P354; Campbell M L, 1996, Am J Crit Care, V5, P339; Carlson RW, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852-b; CARLSON RW, 1995, ARCH INTERN MED, V155, P13; CHERNOW B, 1994, PHARM APPROACH CRITI; CITRON ML, 1984, AM J MED, V77, P199, DOI 10.1016/0002-9343(84)90691-0; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; Daly B J, 1996, Am J Crit Care, V5, P331; Doyle D., 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; ELLERSHAW JE, 1995, J PAIN SYMPTOM MANAG, V10, P192, DOI 10.1016/0885-3924(94)00123-3; ENCK RE, 1994, MED CARE TERMINALLY; FaberLangendoen K, 1996, ARCH INTERN MED, V156, P2130, DOI 10.1001/archinte.156.18.2130; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FABERLANGENDOEN K, 1996, AM J RESP CRIT CARE, V153, pA365; GIANAKOS D, 1995, CHEST, V108, P1405, DOI 10.1378/chest.108.5.1405; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; GRENVIK A, 1983, CRIT CARE MED, V11, P394, DOI 10.1097/00003246-198305000-00019; *HAST CTR, 1987, GUID TERM LIF SUST T; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; LO B, 1989, ARCH INTERN MED, V149, P1925, DOI 10.1001/archinte.149.9.1925; LUCE JM, 1991, RESP CARE, V109, P417; MAILLOUX LU, 1993, J AM SOC NEPHROL, V3, P1631; MALONE N, 1994, NURSING STANDAR 0720, P29; *MAN CANC PAIN GUI, 1994, AHCPR PUBL; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; *MULT TASK FORC PV, 1995, NEW ENGL J MED, V33, P130; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PARTRIDGE BL, 1990, CRIT CARE MED, V18, P1177, DOI 10.1097/00003246-199010000-00025; Payne K, 1996, ANN INTERN MED, V125, P104, DOI 10.7326/0003-4819-125-2-199607150-00004; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; ROUSSEAU PC, 1992, PATIENT CARE, V26, P71; Rushton C H, 1995, Am J Crit Care, V4, P112; SAUNDERS C, 1993, MANAGEMENT TERMINAL; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Shekleton M E, 1994, AACN Clin Issues Crit Care Nurs, V5, P523; Siegel MD, 1996, CHEST, V109, P852, DOI 10.1378/chest.109.3.852; SLOMKA J, 1995, ARCH INTERN MED, V155, P1258, DOI 10.1001/archinte.155.12.1258; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; TRUOG RD, 1994, J CLIN ETHIC, V5, P39; VACHON MLS, 1995, PALLIATIVE MED, V9, P91, DOI 10.1177/026921639500900202; Vachon MLS., 1987, OCCUPATIONAL STRESS; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weatherill G G, 1995, AACN Clin Issues, V6, P344, DOI 10.1097/00044067-199505000-00018; WEIR RF, 1990, JAMA-J AM MED ASSOC, V264, P1846, DOI 10.1001/jama.264.14.1846; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	63	174	175	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					652	657		10.1056/NEJM199702273360910	http://dx.doi.org/10.1056/NEJM199702273360910			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WK028	9032053				2022-12-28	WOS:A1997WK02800010
J	Duggan, DJ; Gorospe, JR; Fanin, M; Hoffman, EP; Angelini, C; Pegoraro, E; Noguchi, S; Ozawa, E; Pendlebury, W; Waclawik, AJ; Duenas, DA; HausmanowaPetrusewicz, I; Fidzianska, A; Bean, SC; Haller, JS; Bodensteiner, J; Greco, CM; Pestronk, A; Berardinelli, A; Gelinas, DF; Abram, H; Kunel, RW				Duggan, DJ; Gorospe, JR; Fanin, M; Hoffman, EP; Angelini, C; Pegoraro, E; Noguchi, S; Ozawa, E; Pendlebury, W; Waclawik, AJ; Duenas, DA; HausmanowaPetrusewicz, I; Fidzianska, A; Bean, SC; Haller, JS; Bodensteiner, J; Greco, CM; Pestronk, A; Berardinelli, A; Gelinas, DF; Abram, H; Kunel, RW			Mutations in the sarcoglycan genes in patients with myopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECESSIVE MUSCULAR-DYSTROPHY; ADHALIN GENE; BETA-SARCOGLYCAN; 50DAG A2; COMPLEX; PROTEINS; DEFICIENCY; GLYCOPROTEINS; EXPRESSION; MUSCLES	Background Some patients with autosomal recessive limb-girdle muscular dystrophy have mutations in the genes coding for the sarcoglycan proteins (alpha-, beta-, gamma-, and delta-sarcoglycan). To determine the frequency of sarcoglycan-gene mutations and the relation between the clinical features and genotype, we studied several hundred patients with myopathy. Methods Antibody against alpha-sarcoglycan was used to stain muscle-biopsy specimens from 556 patients with myopathy and normal dystrophin genes (the gene frequently deleted in X-linked muscular dystrophy). Patients whose biopsy specimens showed a deficiency of alpha-sarcoglycan on immunostaining were studied for mutations of the alpha-, beta-, and gamma-sarcoglycan genes with reverse transcription of muscle RNA, analysis involving single-strand conformation polymerphisms, and sequencing, Results Levels of alpha-sarcoglycan were found to be decreased on immunostaining of muscle-biopsy specimens from 54 of the 556 patients (10 percent); in 25 of these patients no alpha-sarcoglycan was detected. Screening for sarcoglycan-gene mutations in 50 of the 54 patients revealed mutations in 29 patients (58 percent): 17 (34 percent) had mutations in the alpha-sarcoglycan gene, 8 (16 percent) in the beta-sarcoglycan gene, and 4 (8 percent) in the gamma-sarcoglycan gene. No mutations were found in 21 patients (42 percent). The prevalence of sarcoglycan-gene mutations was highest among patients with severe (Duchenne-like) muscular dystrophy that began in childhood (18 of 83 patients, or 22 percent); the prevalence among patients with proximal (limb-girdle) muscular dystrophy with a later onset was 6 percent (11 of 180 patients). Conclusions Defects in the genes coding for the sarcoglycan proteins are limited to patients with Duchenne-like and limb-girdle muscular dystrophy with normal dystrophin and occur in 11 percent of such patients. (C) 1997, Massachusetts Medical Society.	UNIV PITTSBURGH, SCH MED, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT HUMAN GENET, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT NEUROL, PITTSBURGH, PA 15260 USA; UNIV PADUA, DEPT NEUROL, REG NEUROMUSCULAR CTR, PADUA, ITALY; NATL CTR NEUROL & PSYCHIAT, TOKYO, JAPAN; UNIV VERMONT, BURLINGTON, VT USA; UNIV WISCONSIN, SCH MED, MADISON, WI USA; MIAMI CHILDRENS HOSP, MIAMI, FL USA; POLISH ACAD SCI, WARSAW, POLAND; MED CTR DELAWARE, NEWARK, DE USA; ALBANY MED CTR, ALBANY, NY USA; ROBERT C BYRD HLTH SCI CTR, MORGANTOWN, WV USA; CALIF PACIFIC MED CTR, SAN FRANCISCO, CA 94115 USA; WASHINGTON UNIV, ST LOUIS, MO USA; UNIV PAVIA, NEUROL INST C MONDINO, I-27100 PAVIA, ITALY; NEMOURS CHILDRENS CLIN, JACKSONVILLE, AL USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Padua; National Center for Neurology & Psychiatry - Japan; University of Vermont; University of Wisconsin System; University of Wisconsin Madison; Polish Academy of Sciences; Albany Medical College; California Pacific Medical Center; Washington University (WUSTL); IRCCS Fondazione Casimiro Mondino; University of Pavia; Johns Hopkins University			Berardinelli, angela/AAA-9496-2019; Angelini, Corrado I/J-3655-2019	Angelini, Corrado I/0000-0002-9554-8794; berardinelli, angela/0000-0002-4645-8055; Hoffman, Eric/0000-0001-6470-5139	NINDS NIH HHS [NS-28403] Funding Source: Medline; Telethon [552, 695] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon)		Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Bonnemann CG, 1996, HUM MOL GENET, V5, P1953, DOI 10.1093/hmg/5.12.1953; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BUENO MRP, 1995, HUM MOL GENET, V4, P1163, DOI 10.1093/hmg/4.7.1163; Duggan DJ, 1996, J NEUROL SCI, V140, P30, DOI 10.1016/0022-510X(96)00028-7; FANIN M, 1996, BASIC APPL MYOL, V6, P95; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HOFFMAN EP, 1992, NEUROLOGY, V42, P967, DOI 10.1212/WNL.42.5.967; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KAWAI H, 1995, J CLIN INVEST, V96, P1202, DOI 10.1172/JCI118152; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LITTLE S, 1994, CURRENT PROTOCOLS HU; LJUNGGREN A, 1995, ANN NEUROL, V38, P367, DOI 10.1002/ana.410380305; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; McNally EM, 1996, HUM MOL GENET, V5, P1841, DOI 10.1093/hmg/5.11.1841; McNally EM, 1996, AM J HUM GENET, V59, P1040; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIZUNO Y, 1993, J BIOCHEM-TOKYO, V114, P936, DOI 10.1093/oxfordjournals.jbchem.a124281; MIZUNO Y, 1994, MUSCLE NERVE, V17, P206, DOI 10.1002/mus.880170212; MIZUNO Y, 1994, BIOCHEM BIOPH RES CO, V203, P979, DOI 10.1006/bbrc.1994.2278; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PEGORARO E, 1995, NEUROLOGY, V45, P677, DOI 10.1212/WNL.45.4.677; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	32	174	181	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					618	624		10.1056/NEJM199702273360904	http://dx.doi.org/10.1056/NEJM199702273360904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032047				2022-12-28	WOS:A1997WK02800004
J	Panush, RS; Sergent, JS				Panush, RS; Sergent, JS			A rude awakening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					515	516		10.1001/jama.277.7.515	http://dx.doi.org/10.1001/jama.277.7.515			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032141				2022-12-28	WOS:A1997WH29700001
J	Cronin, JR; Pizzarello, S				Cronin, JR; Pizzarello, S			Enantiomeric excesses in meteoritic amino acids	SCIENCE			English	Article							REPORTED OPTICAL-ACTIVITY; MURCHISON METEORITE; ALKANOIC ACIDS; BIOMOLECULAR CHIRALITY	Gas chromatographic-mnas spectral analyses of the four stereoisomers of 2-amino-2,3-dimethylpentanoic acid (DL-alpha-methylisoleucine and DL-alpha-methylalloisoleucine) obtained from the Murchison meteorite show that the L enantiomer occurs in excess (7.0 and 9.1%, respectively) in both of the enantiomeric pairs. Similar results were obtained for two other alpha-methyl amino acids, isovaline and alpha-methylnorvaline, although the a hydrogen analogs of these amino acids, alpha-amino-n-butyric acid and norvaline, were found to be racemates. With the exception of alpha-amino-n-butyric acid, these amino acids are either unknown or of limited occurrence in the biosphere. Because carbonaceous chondrites formed 4.5 billion years ago, the results are indicative of an asymmetric influence on organic chemical evolution before the origin of life.			Cronin, JR (corresponding author), ARIZONA STATE UNIV, DEPT CHEM & BIOCHEM, TEMPE, AZ 85287 USA.							BADA JL, 1991, PHILOS T R SOC B, V333, P349, DOI 10.1098/rstb.1991.0084; BADA JL, 1986, NATURE, V319, P314, DOI 10.1038/319314a0; BADA JL, 1983, NATURE, V301, P494, DOI 10.1038/301494a0; BAKER CG, 1952, J AM CHEM SOC, V74, P4701, DOI 10.1021/ja01138a502; BAYER E, 1983, Z NATURFORSCH B, V38, P1281, DOI 10.1515/znb-1983-1019; BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; BONNER WA, 1987, BIOSYSTEMS, V20, P99, DOI 10.1016/0303-2647(87)90025-6; BRUCE DW, 1991, J MATER CHEM, V1, P251, DOI 10.1039/jm9910100251; CAHN RS, 1966, ANGEW CHEM INT EDIT, V5, P385, DOI 10.1002/anie.196603851; CHRISTIE BD, 1987, ANAL CHIM ACTA, V200, P347, DOI 10.1016/S0003-2670(00)83782-4; COOMBES F, 1995, ASTRON ASTROPHYS, V308, P618; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Cronin J R, 1995, Adv Space Res, V15, P91, DOI 10.1016/S0273-1177(99)80068-4; CRONIN JR, 1993, GEOCHIM COSMOCHIM AC, V57, P4745, DOI 10.1016/0016-7037(93)90197-5; CRONIN JR, 1981, J MOL EVOL, V17, P265, DOI 10.1007/BF01795748; CRONIN JR, 1986, GEOCHIM COSMOCHIM AC, V50, P2419, DOI 10.1016/0016-7037(86)90024-4; CRONIN JR, 1985, GEOCHIM COSMOCHIM AC, V49, P2259, DOI 10.1016/0016-7037(85)90226-1; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; CRONIN JR, 1982, ANAL BIOCHEM, V124, P139, DOI 10.1016/0003-2697(82)90231-7; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; ENGEL MH, 1990, NATURE, V348, P47, DOI 10.1038/348047a0; ENGEL MH, 1983, NATURE, V301, P496, DOI 10.1038/301496a0; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; FLORES JJ, 1977, J AM CHEM SOC, V99, P3622, DOI 10.1021/ja00453a018; GELPI E, 1969, J CHROMATOGR SCI, V7, P604, DOI 10.1093/chromsci/7.10.604; Greenberg JM, 1996, AIP CONF PROC, P185; IPSEN J, 1970, BARCROFTS INTRO BIOS; KISUMI M, 1976, J BIOCHEM-TOKYO, V80, P333, DOI 10.1093/oxfordjournals.jbchem.a131281; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; LAWLESS JG, 1971, ANAL BIOCHEM, V44, P473, DOI 10.1016/0003-2697(71)90235-1; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; MacDermott AJ, 1996, CHEMICAL EVOLUTION: PHYSICS OF THE ORIGIN AND EVOLUTION OF LIFE, P373; MEINSCHEIN WG, 1966, SCIENCE, V154, P377, DOI 10.1126/science.154.3747.377; Miao Y., 1994, B AM ASTRON SOC, V26, P906; NAGY BARTHOLOMEW, 1964, NATURE, V202, P228, DOI 10.1038/202228a0; NANDI P, 1953, NATURE, V171, P871; ORO J, 1971, NATURE, V230, P107, DOI 10.1038/230107a0; PELTZER ET, 1978, NATURE, V272, P443, DOI 10.1038/272443a0; POLLOCK GE, 1975, GEOCHIM COSMOCHIM AC, V39, P1571, DOI 10.1016/0016-7037(75)90159-3; RUBENSTEIN E, 1983, NATURE, V306, P118, DOI 10.1038/306118a0; SCHOLLKOPF U, 1987, LIEBIGS ANN CHEM, P399; WALD G, 1957, ANN NY ACAD SCI, V69, P353; Zolensky M., 1988, METEORITES EARLY SOL, P114	44	703	717	1	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					951	955		10.1126/science.275.5302.951	http://dx.doi.org/10.1126/science.275.5302.951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020072				2022-12-28	WOS:A1997WH38800037
J	He, JL; Chen, YZ; Farzan, M; Choe, HY; Ohagen, A; Gartner, S; Busciglio, J; Yang, XY; Hofmann, W; Newman, W; Mackay, CR; Sodroski, J; Gabuzda, D				He, JL; Chen, YZ; Farzan, M; Choe, HY; Ohagen, A; Gartner, S; Busciglio, J; Yang, XY; Hofmann, W; Newman, W; Mackay, CR; Sodroski, J; Gabuzda, D			CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BRAIN; CELLS; TROPISM; IDENTIFICATION; SEQUENCES; AIDS	Several members of the chemokine receptor family are used together with CD4 for HIV-1 entry into target cells(1-6). T cell line-tropic (T-tropic) HIV-1 viruses use the chemokine receptor CXCR4 as a co-receptor(1), whereas macrophage-tropic (M-tropic) primary viruses use CCR5 (refs 2-6). Individuals with defective CCR5 alleles exhibit resistance to HIV-1 infection(7,8), suggesting that CCR5 has an important role in vivo in HIV-1 replication. A subset of primary viruses can use CCR3 as well as CCR5 as a co-receptor(5,6), but the in vivo contribution of CCR3 to HIV-1 infection and pathogenesis is unknown. HIV-1 infects the central nervous system (CNS) and causes the dementia associated with AIDS(9). Here we report that the major target cells for HIV-1 infection in the CNS, the microglia(9-11), express both CCR3 and CCR5. The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1 beta, which is a CCR5 ligand. Our results suggest that both CCR3 and CCR5 promote efficient infection of the CNS by HIV-1.	LEUKOSITE INC,CAMBRIDGE,MA 02142; DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; CHILDRENS HOSP,MED CTR,DEPT NEUROL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University; Harvard University; Boston Children's Hospital			Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340; Farzan, Michael/0000-0002-2990-5319				ALKAHATIB G, 1996, SCIENCE, V272, P1955; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GARTNER S, 1990, AIDS RES HUM RETROV, V6, P1017, DOI 10.1089/aid.1990.6.1017; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HE JL, 1995, J VIROL, V69, P4587, DOI 10.1128/JVI.69.7.4587-4592.1995; HEATH H, IN PRESS J CLIN INVE; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; OBERLIN E, 1996, NATURE, V382, P883; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER C, 1994, J VIROL, V68, P4643, DOI 10.1128/JVI.68.7.4643-4649.1994; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmidtmayerova H, 1996, P NATL ACAD SCI USA, V93, P700, DOI 10.1073/pnas.93.2.700; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Strizki JM, 1996, J VIROL, V70, P7654, DOI 10.1128/JVI.70.11.7654-7662.1996; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	30	776	815	1	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					645	649		10.1038/385645a0	http://dx.doi.org/10.1038/385645a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024664				2022-12-28	WOS:A1997WH29400053
J	Cai, DG; Kleine, M; Kifle, S; Harloff, HJ; Sandal, NN; Marcker, KA; KleinLankhorst, RM; Salentijn, EMJ; Lange, W; Stiekema, WJ; Wyss, U; Grundler, FMW; Jung, C				Cai, DG; Kleine, M; Kifle, S; Harloff, HJ; Sandal, NN; Marcker, KA; KleinLankhorst, RM; Salentijn, EMJ; Lange, W; Stiekema, WJ; Wyss, U; Grundler, FMW; Jung, C			Positional cloning of a gene for nematode resistance in sugar beet	SCIENCE			English	Article							HETERODERA-SCHACHTII RESISTANCE; PLANT-PARASITIC NEMATODES; LEUCINE-RICH REPEAT; BETA-VULGARIS; DISEASE RESISTANCE; PROCUMBENS; SEQUENCE; SECTION; PROTEIN	Hs1(pro-1) locus confers resistance to the beet cyst nematode (Heterodera schachtii Schmidt), a major pest in the cultivation of sugar beet (Beta vulgaris L.). The Hs1(pro-1) gene was cloned with the use of genome-specific satellite markers and chromosomal breakpoint analysis, Expression of the corresponding complementary DNA in a susceptible sugar beet conferred resistance to infection with the beet cyst nematode. The native HS1(pro-1) gene, expressed in roots, encodes a 282-amino acid protein with imperfect leucine-rich repeats and a putative membrane-spanning segment, features similar to those of disease resistance genes previously cloned from higher plants.	CHRISTIAN ALBRECHTS UNIV KIEL,INST CROP SCI & PLANT BREEDING,D-24118 KIEL,GERMANY; AARHUS UNIV,DEPT MOL & STRUCT BIOL,DK-8000 AARHUS,DENMARK; DLO,CTR PLANT BREEDING & REPROD RES,NL-6700 AA WAGENINGEN,NETHERLANDS; CHRISTIAN ALBRECHTS UNIV KIEL,INST PHYTOPATHOL,D-24118 KIEL,GERMANY	University of Kiel; Aarhus University; University of Kiel			Grundler, Florian MW/I-6508-2012; Klein Lankhorst, René/HGD-0360-2022	Grundler, Florian M.W./0000-0001-8101-0558				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BRANDES A, 1987, PLANT BREEDING, V99, P56, DOI 10.1111/j.1439-0523.1987.tb01150.x; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GRUNDLER EMW, IN PRESS PHYSL MOL P; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIJBROEK W, 1988, EUPHYTICA, V38, P121, DOI 10.1007/BF00040182; Heller R, 1996, THEOR APPL GENET, V92, P991, DOI 10.1007/BF00224039; HOLTMANN B, UNPUB; HUSSEY RS, 1989, ANNU REV PHYTOPATHOL, V27, P123, DOI 10.1146/annurev.py.27.090189.001011; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Jones JDG, 1996, CURR OPIN BIOTECH, V7, P155, DOI 10.1016/S0958-1669(96)80006-1; JUNG C, 1987, PLANT BREEDING, V98, P205, DOI 10.1111/j.1439-0523.1987.tb01118.x; JUNG C, 1992, MOL GEN GENET, V232, P271, DOI 10.1007/BF00280006; KIFLE S, UNPUB; KLEINE M, 1995, THEOR APPL GENET, V90, P399, DOI 10.1007/BF00221982; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PAUL H, 1990, EUPHYTICA, V48, P153, DOI 10.1007/BF00037194; SALENTIJN EMJ, 1995, THEOR APPL GENET, V90, P885, DOI 10.1007/BF00222027; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SAVITSKY H, 1978, CAN J GENET CYTOL, V20, P177, DOI 10.1139/g78-019; SPIEGEL Y, 1995, J NEMATOL, V27, P127; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; TOXOPEUS JH, 1979, P EUCARPIA CRUCIFERA, P151; TRAUT TW, 1994, EUR J BIOCHEM, V229, P9; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YU MH, 1984, EUPHYTICA, V33, P633, DOI 10.1007/BF00021891	35	320	410	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					832	834		10.1126/science.275.5301.832	http://dx.doi.org/10.1126/science.275.5301.832			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012350				2022-12-28	WOS:A1997WG77700061
J	Frey, U; Morris, RGM				Frey, U; Morris, RGM			Synaptic tagging and long-term potentiation	NATURE			English	Article							PROTEIN-SYNTHESIS; DENTATE GYRUS; HIPPOCAMPAL-NEURONS; CA1 REGION; LATE-PHASE; RAT; TETANIZATION; MAINTENANCE; ANISOMYCIN; INDUCTION	Repeated stimulation of hippocampal neurons can induce an immediate and prolonged increase in synaptic strength that is called long-term potentiation (LTP)-the primary cellular model of memory in the mammalian brain(1). An early phase of LTP (lasting less than three hours) can be dissociated from late-phase LTP by using inhibitors of transcription and translation(2-8) Because protein synthesis occurs mainly in the cell body(9-12), whereas LTP is input-specific, the question arises of how the synapse specificity of late LTP is achieved without elaborate intracellular protein trafficking. We propose that LTP initiates the creation of a short-lasting protein-synthesis-independent 'synaptic tag' at the potentiated synapse which sequesters the relevant protein(s) to establish late LTP. In support of this idea, we now show that weak tetanic stimulation, which ordinarily leads only to early LTP, or repeated tetanization in the presence of protein-synthesis inhibitors, each results in protein-synthesis-dependent late LTP, provided repeated tetanization has already been applied at another input to the same population of neurons. The synaptic tag decays in less than three hours. These findings indicate that the persistence of LTP depends not only on local events during its induction, but also on the prior activity of the neuron.	UNIV EDINBURGH,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Frey, U (corresponding author), FED INST NEUROBIOL GENE REGULAT & PLAST,POB 1860,BRENNECKESTR 6,D-39008 MAGDEBURG,GERMANY.		Morris, Richard G M/C-9982-2013					Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN R, 1977, COGNITION, V5, P73, DOI 10.1016/0010-0277(77)90018-X; DAVIS L, 1987, NATURE, V330, P477, DOI 10.1038/330477a0; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; FAZELI MS, 1988, BRAIN RES, V473, P51, DOI 10.1016/0006-8993(88)90314-9; FAZELI MS, 1993, J NEUROSCI, V13, P1346; FREY U, 1995, NEUROSCIENCE, V67, P799, DOI 10.1016/0306-4522(95)00117-2; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; Frey U, 1996, J PHYSIOL-LONDON, V490, P703, DOI 10.1113/jphysiol.1996.sp021179; HEBB DO, 1949, ORG BEHAVIOR; Huang Y Y, 1994, Learn Mem, V1, P74; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; LOVINGER DM, 1988, J PHYSIOL-LONDON, V400, P321, DOI 10.1113/jphysiol.1988.sp017122; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; RAWLINS JNP, 1985, BEHAV BRAIN SCI, V8, P479, DOI 10.1017/S0140525X00001291; SQUIRE LR, 1981, ANNU REV PHARMACOL, V21, P323, DOI 10.1146/annurev.pa.21.040181.001543; STANTON PK, 1984, J NEUROSCI, V4, P3080; Staubli U, 1996, J NEUROSCI, V16, P853; STEWARD O, 1986, J NEUROSCI, V6, P412	26	1185	1205	2	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					533	536		10.1038/385533a0	http://dx.doi.org/10.1038/385533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020359				2022-12-28	WOS:A1997WG23500047
J	Nightingale, SL				Nightingale, SL			Ruminant-to-ruminant feeding ban proposed to reduce risk of transmissible spongiform encephalopathies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1997, FED REGISTER, V62, P551	1	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					370	370						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010159				2022-12-28	WOS:A1997WE77100006
J	Swamidoss, CP				Swamidoss, CP			The road to Morrakonnam	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					362	362						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010154				2022-12-28	WOS:A1997WE77100001
J	Roberts, AG; Whatley, SD; Morgan, RR; Worwood, M; Elder, GH				Roberts, AG; Whatley, SD; Morgan, RR; Worwood, M; Elder, GH			Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda	LANCET			English	Article							HLA-LINKED HEMOCHROMATOSIS; UROPORPHYRINOGEN DECARBOXYLASE	Background Sporadic porphyria cutanea tarda is a skin disease associated with hepatic siderosis. Depletion of iron stores by phlebotomy is curative. The role of haemochromatosis genes in determining susceptibility to this disorder is controversial, We have examined the frequency in sporadic porphyria cutanea tarda of mutations (Cys282Tyr, His63Asp) in a novel MHC class-I-like gene, one of which (Cys282Tyr) is believed to cause haemochromatosis. Methods 41 patients with sporadic porphyria cutanea tarda, in whom the frequency of microsatellite alleles that define the ancestral haemochromatosis haplotype had previously been determined, and 101 healthy blood donors were studied for the presence of the Cys282Tyr and His63Asp mutations. We used restriction-enzyme digestion of PCR-amplified genomic DNA. Findings The Cys282Tyr mutation occurred in 18 (44%) of patients compared with 11 (11%) of controls (relative risk 6.2, 95% CI 2.6-14.5, p=0.00003). Seven (17%) patients, aged 48-79 years, were homozygotes. In 12 patients, the Cys282Tyr mutation was associated with markers of the HLA-A3-containing ancestral haemochromatosis haplotype. Ages at presentation were the same for those with or without the Cys282Tyr mutation. There was no difference in the frequency of the His63Asp mutation. Interpretation Inheritance of one or more haemochromatosis genes is an important susceptibility factor for sporadic porphyria cutanea tarda. Some homozygotes for the Cys282Tyr mutation present late in life with porphyria cutanea tarda, indicating that not all homozygotes present clinically with haemochromatosis. The relation between this genotype and disease needs further investigation.	UNIV WALES COLL MED,DEPT BIOCHEM MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT HAEMATOL,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								ADAMS PC, 1987, GASTROENTEROLOGY, V92, P2033, DOI 10.1016/0016-5085(87)90643-3; BEAUMONT C, 1987, GASTROENTEROLOGY, V92, P1833, DOI 10.1016/0016-5085(87)90612-3; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BOTTOMLEY SS, 1986, B I DERMATOLOGICO S, V8, P237; EDWARDS CQ, 1989, GASTROENTEROLOGY, V97, P972, DOI 10.1016/0016-5085(89)91506-0; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; ELDER GH, 1985, LANCET, V2, P229; ELDER GH, 1995, J BIOENERG BIOMEMBR, V27, P207, DOI 10.1007/BF02110035; Fargion S, 1996, J HEPATOL, V24, P564, DOI 10.1016/S0168-8278(96)80141-3; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GAREY JR, 1993, GASTROENTEROLOGY, V105, P165, DOI 10.1016/0016-5085(93)90022-5; Kappas A, 1995, METABOLIC MOL BASES, P2103; KOSTLER VE, 1984, DTSCH Z VERDAU STOFF, V44, P95; KUNTZ BME, 1984, TISSUE ANTIGENS, V24, P67; LLORENTE L, 1980, ARCH DERMATOL RES, V269, P209, DOI 10.1007/BF00406542; LUNDVALL O, 1970, ACTA MED SCAND, V188, P37; LUNDVALL O, 1971, ACTA MED SCAND, V189, P33; MERRYWEATHERCLA.AT, IN PRESS J MED GENET; RAHACHOWDHURY, 1996, HUM MOL GENET, V4, P1869; Roberts AG, 1997, HEPATOLOGY, V25, P159, DOI 10.1002/hep.510250129; SANTOIANNI P, 1980, DERMATOLOGICA, V160, P371, DOI 10.1159/000250524; SMITH AG, 1993, BIOCHEM J, V291, P29, DOI 10.1042/bj2910029; TIWAWRI JL, 1985, HLA DIS ASS; WORWOOD M, 1993, TRANSFUSION MED, V3, P21, DOI 10.1111/j.1365-3148.1993.tb00100.x; WORWOOD M, 1996, BRIT J HAEMATOL, V93, P833	25	269	278	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					321	323		10.1016/S0140-6736(96)09436-6	http://dx.doi.org/10.1016/S0140-6736(96)09436-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024376				2022-12-28	WOS:A1997WF79400012
J	Yu, ZQ; Fu, WB; Hua, HM; Feng, CT				Yu, ZQ; Fu, WB; Hua, HM; Feng, CT			Viper's blood and bile	LANCET			English	Article							PENTASTOMIASIS		ZHEJIANG MED UNIV,DEPT PARASITOL,HANGZHOU,PEOPLES R CHINA; ZHEJIANG MED UNIV,DEPT BIOL,HANGZHOU,PEOPLES R CHINA	Zhejiang University; Zhejiang University	Yu, ZQ (corresponding author), SIR RUN RUN SHAW HOSP,GASTROINTESTINAL DEPT,HANGZHOU 310016,PEOPLES R CHINA.							DRABICK JJ, 1987, REV INFECT DIS, V9, P1087; GUARDIA SN, 1991, ARCH PATHOL LAB MED, V115, P515; HUANG M, 1983, AGKISTRODON ACUTUS, P64; SELF IT, 1966, T AM MICROSC SOC, V85, P258	4	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					250	250		10.1016/S0140-6736(96)11088-6	http://dx.doi.org/10.1016/S0140-6736(96)11088-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014913				2022-12-28	WOS:A1997WD90600013
J	Russell, NH				Russell, NH			Biology of acute leukaemia	LANCET			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; COLONY-STIMULATING FACTOR; PROGNOSTIC IMPLICATIONS; P53 MUTATIONS; EXPRESSION; GRANULOCYTE; CHEMOTHERAPY; MACROPHAGE	The leukaemias vary in their response to therapy. In acute myeloid leukaemia, for instance, response to therapy is poorer in order than in younger patients. One explanation for this is that in older patients the acute myeloid leukaemia is more likely to have arisen from a pluripotent stem cell than from a lineage-restricted progenitor cell; the former has a high self-renewal capacity, an active drug-efflux pump, and high content of anti-apoptotic proteins, all of which contribute to chemoresistance. Unravelling the biology of the leukaemias should help in the development of novel therapies.	UNIV NOTTINGHAM,DEPT CLIN LAB SCI,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham								BEDI A, 1994, BLOOD, V83, P2038; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BOEKHORST PAWT, 1995, LEUKEMIA, V9, P1025; Bonnet D., 1996, British Journal of Haematology, V93, P144; BRADBURY D, 1994, LEUKEMIA, V8, P786; CAMPOS L, 1993, BLOOD, V81, P3091; Campos L, 1996, LEUKEMIA, V10, P434; DELPOETA B, 1996, BLOOD, V87, P1992; DICCIANNI MB, 1994, BLOOD, V84, P3105; DONG F, 1994, P NATL ACAD SCI USA, V91, P4480, DOI 10.1073/pnas.91.10.4480; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GOASGUEN JE, 1993, BLOOD, V81, P2394; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; HAASE D, 1995, BLOOD, V86, P2906; HUNTER AE, 1993, BLOOD, V82, P899; JANOSSY G, 1989, LEUKEMIA, V3, P170; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; MANABE A, 1992, BLOOD, V79, P2370; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; MCCULLOCH EA, 1982, BLOOD, V59, P601; PORWITTMCDONALD, 1996, BLOOD, V87, P1162; SECKERWALKER LM, 1993, LEUKEMIA, V7, P147; SWANSBURY GJ, 1994, CANCER GENET CYTOGEN, V73, P1, DOI 10.1016/0165-4608(94)90174-0; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; vanLom K, 1996, BRIT J HAEMATOL, V93, P594, DOI 10.1046/j.1365-2141.1996.d01-1692.x; WATARI K, 1994, BLOOD, V84, P36; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLMAN CL, 1996, LEUKEMIA S, V10, P533	30	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					118	122		10.1016/S0140-6736(96)07185-1	http://dx.doi.org/10.1016/S0140-6736(96)07185-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996433				2022-12-28	WOS:A1997WB80000044
J	Waters, MR; Forman, SL; Pierson, JM				Waters, MR; Forman, SL; Pierson, JM			Diring Yuriakh: A lower paleolithic site in central Siberia	SCIENCE			English	Article							LATE PLEISTOCENE; LOESS; LUMINESCENCE; CHINA; ASIA	Lower Paleolithic artifacts have been recovered from a single occupation surface within stratified deposits at Diring Yuriakh, an archaeological site in central Siberia. Thermoluminescence age estimates from eolian sediments indicate that the cultural horizon is greater than 260,000 years old. Diring Yuriakh is an order of magnitude older than documented Paleolithic sites in Siberia and is important for understanding the timing of human expansion into the far north, early adaptations to cold climates, and the peopling of the Americas.	TEXAS A&M UNIV, DEPT GEOG, COLLEGE STN, TX 77843 USA; UNIV ILLINOIS, DEPT GEOL SCI, CHICAGO, IL 60607 USA	Texas A&M University System; Texas A&M University College Station; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Waters, MR (corresponding author), TEXAS A&M UNIV, DEPT ANTHROPOL, COLLEGE STN, TX 77843 USA.		Waters, Michael/ABI-2377-2020; Forman, Steven/ABD-7720-2021; Waters, Michael R/A-9430-2009; Pierson, Jean-Marc/V-2290-2019; Klein, Richard G/B-5910-2009	Waters, Michael/0000-0003-2660-3355; Forman, Steven/0000-0002-2080-7915				ACKERMAN RE, 1991, CURRENT RES PLEISTOC, V8, P1; AITKEN MJ, 1975, ARCHAEOMETRY, V17, P132, DOI 10.1111/j.1475-4754.1975.tb00127.x; ALEKSEEV MN, 1990, UNPUB PROBLEMS GEOLO; DUMOND, 1994, SCI NEWS, V145, P243; FORMAN SL, 1991, QUATERNARY RES, V36, P19, DOI 10.1016/0033-5894(91)90014-V; FRECHEN M, 1992, QUATERNARY SCI REV, V11, P93, DOI 10.1016/0277-3791(92)90048-D; HUNTLEY DJ, 1981, CAN J EARTH SCI, V18, P419, DOI 10.1139/e81-036; HUNTLEY DJ, 1987, NUCL TRACKS RAD MEAS, V105, P279; Krinsley D. H., 2011, ATLAS QUARTZ SAND SU; Kuzmin Y.V., 1994, GEOARCHAEOLOGY, V9, P287; LARICHEV V, 1987, J WORLD PREHIST, V1, P415, DOI 10.1007/BF00974881; LU YC, 1987, QUATERNARY RES, V28, P356, DOI 10.1016/0033-5894(87)90003-2; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; MICHAEL HN, 1984, ARCTIC ANTHROPOL, V21, P1; MOCHANOV YA, 1993, ARCTIC ANTHROPOL, V30, P22; MOCHANOV YA, 1996, AM BEGINNINGS PREHIS, P157; MOCHANOV YA, 1992, ANCIENT PALEOLITHIC; MOCHANOV YA, 1978, EARLY MAN AM CIRCUMP, P54; PACKMAN SC, 1992, QUATERNARY SCI REV, V11, P103, DOI 10.1016/0277-3791(92)90049-E; PAVLOV AG, 1992, ARCHAEOLOGICAL RES Y, P20; Pewe T. L., 1983, 1262 US GEOL SURV; POWERS WR, 1973, ARCTIC ANTHROPOL, V10, P1; PRESCOTT JR, 1994, RADIAT MEAS, V23, P497, DOI 10.1016/1350-4487(94)90086-8; Pye K., 1990, AEOLIAN SAND SAND DU; Ranov V.A., 1991, BIOULLETEN KOMISSII, V60, P79; SINGHVI AK, 1982, NATURE, V295, P313, DOI 10.1038/295313a0; West F.H., 1996, AM BEGINNINGS PREHIS; WINTLE AG, 1990, QUATERNARY SCI REV, V9, P385, DOI 10.1016/0277-3791(90)90029-A; YI SB, 1985, CURR ANTHROPOL, V26, P1, DOI 10.1086/203221	29	34	35	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1281	1284		10.1126/science.275.5304.1281	http://dx.doi.org/10.1126/science.275.5304.1281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WK644	9036846				2022-12-28	WOS:A1997WK64400033
J	Nie, SM; Emery, SR				Nie, SM; Emery, SR			Probing single molecules and single nanoparticles by surface-enhanced Raman scattering	SCIENCE			English	Article							FLUORESCENCE MICROSCOPY; OPTICAL MICROSCOPY; SPECTROSCOPY; SILVER; NANOSTRUCTURES; MONOLAYERS; SOLIDS; SCALE; FILMS	Optical detection and spectroscopy of single molecules and single nanoparticles have been achieved at room temperature with the use of surface-enhanced Raman scattering. Individual silver colloidal nanoparticles were screened from a large heterogeneous population for special size-dependent properties and were then used to amplify the spectroscopic signatures of adsorbed molecules. For single rhodamine 6G molecules adsorbed on the selected nanoparticles, the intrinsic Raman enhancement factors were on the order of 10(14) to 10(15), much larger than the ensemble-averaged values derived from conventional measurements. This enormous enhancement leads to vibrational Raman signals that are more intense and more stable than single-molecule fluorescence.			Nie, SM (corresponding author), INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405, USA.		Im, Hwon/B-5659-2012; Nie, Shuming/E-4843-2011					Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506; Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; AMBROSE WP, 1994, PHYS REV LETT, V72, P160, DOI 10.1103/PhysRevLett.72.160; AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARNES MD, 1993, ANAL CHEM, V65, P2360, DOI 10.1021/ac00065a032; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; CASTRO A, 1993, ANAL CHEM, V65, P849, DOI 10.1021/ac00055a004; CHUMANOV G, 1995, J PHYS CHEM-US, V99, P9466, DOI 10.1021/j100023a025; COLLINSON MM, 1995, SCIENCE, V268, P1883, DOI 10.1126/science.268.5219.1883; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; EMORY SR, 1996, INT C RAM SPECTR, P1176; FAN FRF, 1995, SCIENCE, V267, P871, DOI 10.1126/science.267.5199.871; FLEURY L, 1995, CHEM PHYS LETT, V236, P87, DOI 10.1016/0009-2614(95)00185-7; FREEMAN RG, 1995, SCIENCE, V267, P1629, DOI 10.1126/science.267.5204.1629; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GOLAB JT, 1988, J CHEM PHYS, V88, P7942, DOI 10.1063/1.454251; GUTTLER F, 1994, CHEM PHYS LETT, V217, P393, DOI 10.1016/0009-2614(94)87003-9; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HAAB BB, 1995, ANAL CHEM, V67, P3253, DOI 10.1021/ac00114a023; HILDEBRANDT P, 1984, J PHYS CHEM-US, V88, P5935, DOI 10.1021/j150668a038; JAKOBI H, 1962, BER BUNSEN PHYS CHEM, V66, P46; Keller RA, 1996, APPL SPECTROSC, V50, pA12, DOI 10.1366/0003702963905600; Kneipp K, 1996, PHYS REV LETT, V76, P2444, DOI 10.1103/PhysRevLett.76.2444; KNELPP K, 1996, 23 ANN C FED AN CHEM; LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025; LI WJ, 1992, J PHYS CHEM-US, V96, P6529, DOI 10.1021/j100195a005; LI WJ, 1994, J PHYS CHEM-US, V98, P11751, DOI 10.1021/j100096a020; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MARTIN CR, 1995, ACCOUNTS CHEM RES, V28, P61, DOI 10.1021/ar00050a002; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; MEYERS AB, 1994, J PHYS CHEM-US, V98, P10377; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783; NIE S, IN PRESS ANN REV BIO; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; ORRIT M, 1993, J PHYS CHEM-US, V97, P10256, DOI 10.1021/j100142a003; OTTO A, 1992, J PHYS-CONDENS MAT, V4, P1143, DOI 10.1088/0953-8984/4/5/001; SCHATZ GC, 1984, ACCOUNTS CHEM RES, V17, P370, DOI 10.1021/ar00106a005; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; SHERA EB, 1990, CHEM PHYS LETT, V174, P553, DOI 10.1016/0009-2614(90)85485-U; Skinner JL, 1996, J PHYS CHEM-US, V100, P13251, DOI 10.1021/jp9601328; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; VANDUYNE RP, 1993, J CHEM PHYS, V99, P2101, DOI 10.1063/1.465276; WEBSTER S, 1996, INT C RAM SPECTR, P1146; XIAO T, IN PRESS J PHYS CHEM; XIE XS, 1994, SCIENCE, V265, P361, DOI 10.1126/science.265.5170.361; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	48	8852	9180	101	3427	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1102	1106		10.1126/science.275.5303.1102	http://dx.doi.org/10.1126/science.275.5303.1102			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027306				2022-12-28	WOS:A1997WJ50300037
J	Delmas, PD; Meunier, PJ				Delmas, PD; Meunier, PJ			The management of Paget's disease of bone	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SALMON-CALCITONIN; DICHLOROMETHYLENE DIPHOSPHONATE; CLINICAL RESISTANCE; BISPHOSPHONATE APD; AHPRBP APD; THERAPY; ETIDRONATE; PAMIDRONATE; DISODIUM; ALENDRONATE		HOP EDOUARD HERRIOT, DEPT RHEUMATOL & BONE DIS, F-69437 LYON 03, FRANCE	CHU Lyon	Delmas, PD (corresponding author), HOP EDOUARD HERRIOT, INSERM, U403, PAVILLON F, PL ARSONVAL, F-69437 LYON 03, FRANCE.							ADAMI S, 1994, BONE, V15, P415, DOI 10.1016/8756-3282(94)90818-4; ADAMSON BB, 1993, LANCET, V342, P1459, DOI 10.1016/0140-6736(93)92935-M; ALEXANDRE CM, 1983, CLIN ORTHOP RELAT R, V174, P193; ALTMAN R D, 1983, Arthritis and Rheumatism, V26, pS9; ALTMAN RD, 1985, AM J MED, V79, P583, DOI 10.1016/0002-9343(85)90055-5; ALTMAN RD, 1973, NEW ENGL J MED, V289, P1379, DOI 10.1056/NEJM197312272892601; ALTMAN RD, 1992, DISORDERS BONE MINER, P127; ALVAREZ L, 1995, J BONE MINER RES, V10, P458; ARKINS RM, 1987, J BONEMINER RES, V2, P273; BIJVOET OLM, 1980, ARTHRITIS RHEUM, V23, P1193, DOI 10.1002/art.1780231018; BONE HG, 1992, J CLIN ENDOCR METAB, V75, P1179, DOI 10.1210/jc.75.5.1179; CANTRILL JA, 1986, ANN RHEUM DIS, V45, P1012, DOI 10.1136/ard.45.12.1012; CHARHON S, 1982, LANCET, V1, P391; CHINES A, 1996, J BONE MINER RES  S1, V11, pS371; DELMAS P D, 1989, Calcified Tissue International, V44, pS104; DELMAS PD, 1982, J CLIN ENDOCR METAB, V54, P837, DOI 10.1210/jcem-54-4-837; DELMAS PD, 1987, AM J MED, V83, P276, DOI 10.1016/0002-9343(87)90699-1; DELMAS PD, 1986, CALCIFIED TISSUE INT, V38, P60, DOI 10.1007/BF02556596; DIETRICH FM, 1979, ACTA ENDOCRINOL-COP, V92, P468, DOI 10.1530/acta.0.0920468; DOUGLAS DL, 1980, ARTHRITIS RHEUM, V23, P1185, DOI 10.1002/art.1780231017; ELSAMMAA M, 1986, AM J OTOL, V7, P241; FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262; FLEISCH H, 1993, HDB EXPT PHARM, V107, P377; FLEISCH H, 1995, BISPHOSPHONATE BONE; FRIJLINK WB, 1979, LANCET, V1, P799; GONZALEZ D, 1987, CALCIFIED TISSUE INT, V41, P313, DOI 10.1007/BF02556668; GRAY RES, 1987, Q J MED, V64, P755; HADDAD JG, 1972, J CLIN INVEST, V51, P3133, DOI 10.1172/JCI107140; HARINCK HIJ, 1987, CLIN ORTHOP RELAT R, P79; HEYNEN G, 1982, EUR J CLIN INVEST, V12, P29, DOI 10.1111/j.1365-2362.1982.tb00936.x; JOHNSTON CC, 1983, CLIN ORTHOP RELAT R, V172, P186; Kanis, 1994, BONE MINERAL RES, P265; Kanis J.A., 1991, PATHOPHYSIOLOGY TREA; KANIS JA, 1987, CLIN ORTHOP RELAT R, P99; KNAUS J, 1995, BONE, V17, P614; LIENS D, 1994, LANCET, V343, P953, DOI 10.1016/S0140-6736(94)90069-8; LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190; MATKOVIC V, 1990, LANCET, V335, P72, DOI 10.1016/0140-6736(90)90540-L; MAUTALEN CA, 1985, BONE, V6, P429, DOI 10.1016/8756-3282(85)90219-4; MCCLUNG MR, 1995, BONE, V17, pS493, DOI 10.1016/8756-3282(95)00282-1; MELICK RA, 1976, BRIT MED J, V1, P627, DOI 10.1136/bmj.1.6010.627-a; Meunier P, 1991, PAGETS DIS BONE CLIN, P86; MEUNIER PJ, 1987, CLIN ORTHOP RELAT R, P37; MEUNIER PJ, 1995, BONE, V17, pS489, DOI 10.1016/8756-3282(95)00260-2; MEUNIER PJ, 1980, ARTHRITIS RHEUM-US, V23, P1095, DOI 10.1002/art.1780231005; MEUNIER PJ, 1979, LANCET, V2, P489; MILLS BG, 1994, BONE, V15, P443, DOI 10.1016/8756-3282(94)90823-0; PATEL S, 1993, J BONE MINER RES, V8, P1467; REBEL A, 1974, NOUV PRESSE MED, V3, P1299; ROUX C, 1995, ARTHRITIS RHEUM, V38, P851, DOI 10.1002/art.1780380620; RYAN WG, 1980, ARTHRITIS RHEUM, V23, P1155, DOI 10.1002/art.1780231013; SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422; SCHWEITZER DH, 1993, J BONE MINER RES, V8, P175; SINGER FR, 1972, J CLIN INVEST, V51, P2331, DOI 10.1172/JCI107044; SINGER FR, 1980, ARTHRITIS RHEUM, V23, P1148, DOI 10.1002/art.1780231012; SIRIS ES, 1981, METAB BONE DIS RELAT, V3, P301, DOI 10.1016/0221-8747(81)90046-1; Siris Ethel S., 1993, P375; SOLOMON LR, 1977, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.6085.485; TERREAUX F, 1994, J BONE MINER RES  S1, V9, pS291; THIEBAUD D, 1988, AM J MED, V85, P207; THIEBAUD D, 1987, J BONE MINER RES, V2, P45; UEBELHART D, 1990, BONE MINER, V8, P87, DOI 10.1016/0169-6009(91)90143-N; VEGA E, 1987, J BONE MINER RES, V2, P267; VELLENGA CJLR, 1984, RADIOLOGY, V153, P799, DOI 10.1148/radiology.153.3.6494476; WALTON RJ, 1977, EUR J CLIN INVEST, V7, P37, DOI 10.1111/j.1365-2362.1977.tb01567.x; WOODHOUSE NJY, 1977, BRIT J RADIOL, V50, P699, DOI 10.1259/0007-1285-50-598-699; YATES AJP, 1985, LANCET, V1, P1474; ZELENAKAS K, 1995, BONE, V17, P618; ZIEGLER R, 1978, ENDOCRINOLOGY CALCIU, P406; ZIMOLO Z, 1995, J CLIN INVEST, V96, P2277, DOI 10.1172/JCI118283	70	163	181	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					558	566		10.1056/NEJM199702203360807	http://dx.doi.org/10.1056/NEJM199702203360807			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023094				2022-12-28	WOS:A1997WJ24000007
J	Salmeron, J; Manson, JE; Stampfer, MJ; Colditz, GA; Wing, AL; Willett, WC				Salmeron, J; Manson, JE; Stampfer, MJ; Colditz, GA; Wing, AL; Willett, WC			Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PHYSICAL-ACTIVITY; INDEX DIET; CARBOHYDRATE FOODS; CIGARETTE-SMOKING; FAT DISTRIBUTION; NIDDM SUBJECTS; GLUCOSE; MAGNESIUM; MEN	Objective.-To examine prospectively the relationship between glycemic diets, low fiber intake, and risk of noninsulin-dependent diabetes mellitus. Design.-Cohort study. Setting.-in 1986, a total of 65173 US women 40 to 65 years of age and free from diagnosed cardiovascular disease, cancer, and diabetes completed a detailed dietary questionnaire from which we calculated usual intake of total and specific sources of dietary fiber, dietary glycemic index, and glycemic load. Main Outcome Measure.-Non-insulin-dependent diabetes mellitus. Results.-During 6 years of follow-up, 915 incident cases of diabetes were documented. The dietary glycemic index was positively associated with risk of diabetes after adjustment for age, body mass index, smoking, physical activity, family history of diabetes, alcohol and cereal fiber intake, and total energy intake. Comparing the highest with the lowest quintite, the relative risk (RR) of diabetes was 1.37 (95% confidence interval [CI], 1.09-1.71, Ptrend=.005). The glycemic load (an indicator of a global dietary insulin demand) was also positively associated with diabetes (RR=-1.47; 95% CI, 1.16-1.86, Ptrend=.003). Cereal fiber intake was inversely associated with risk of diabetes when comparing the extreme quintiles (RR=0.72, 95% CI, 0.58-0.90, Ptrend=.001). The combination of a high glycemic load and a low cereal fiber intake further increased the risk of diabetes (RR=2.50, 95% CI,1.14-5.51) when compared with a low glycemic load and high cereal fiber intake. Conclusions.-Our results support the hypothesis that diets with a high glycemic load and a low cereal fiber content increase risk of diabetes in women. Further, they suggest that grains should be consumed in a minimally refined form to reduce the incidence of diabetes.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; INST MEXICANO SEGURO SOCIAL, UNIDAD INVEST EPIDEMIOL, MEXICO CITY, DF, MEXICO; INST MEXICANO SEGURO SOCIAL, SERV SALUD, MEXICO CITY, DF, MEXICO	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Salmeron, Jorge/0000-0002-5113-299X	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS CF, 1975, HDB US DEP AGR, V456; ANDERSON JW, 1987, J AM DIET ASSOC, V87, P1189; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; BENNETT PH, 1984, DIET DIABETES ATHERO, P109; BRAND JC, 1991, DIABETES CARE, V14, P95, DOI 10.2337/diacare.14.2.95; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; CLANDININ MT, 1993, ANN NY ACAD SCI, V683, P151; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1992, AM J CLIN NUTR, V55, P1018, DOI 10.1093/ajcn/55.5.1018; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; CREMEL G, 1993, ANN NY ACAD SCI, V683, P164; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; FONTVIEILLE AM, 1992, DIABETIC MED, V9, P444, DOI 10.1111/j.1464-5491.1992.tb01815.x; FRYER LG, 1993, ANN NY ACAD SCI, V683, P91; GROOP LC, 1992, ANN MED, V24, P483, DOI 10.3109/07853899209167000; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HARRIS M, 1979, DIABETES, V28, P1039; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; JENKINS DJA, 1978, BRIT MED J, V2, P1744, DOI 10.1136/bmj.2.6154.1744; JENKINS DJA, 1984, LANCET, V2, P388; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P968, DOI 10.1093/ajcn/46.6.968; JENKINS DJA, 1988, AM J CLIN NUTR, V48, P248, DOI 10.1093/ajcn/48.2.248; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLIMES I, 1993, ANN NY ACAD SCI, V683, P69; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LECLERE CJ, 1994, AM J CLIN NUTR, V59, P914, DOI 10.1093/ajcn/59.4.914; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LUNDGREN H, 1989, AM J CLIN NUTR, V49, P708, DOI 10.1093/ajcn/49.4.708; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Marshall J A, 1993, Ann Epidemiol, V3, P18, DOI 10.1016/1047-2797(93)90005-O; MARSHALL JA, 1991, AM J EPIDEMIOL, V134, P590, DOI 10.1093/oxfordjournals.aje.a116132; MARSHALL JA, 1994, OBESITY DIABETES INS; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MEDALIE JH, 1974, ISRAEL J MED SCI, V10, P681; MILLER JCB, 1994, AM J CLIN NUTR, V59, p747S, DOI 10.1093/ajcn/59.3.747S; Morris R D, 1992, Ann Epidemiol, V2, P657, DOI 10.1016/1047-2797(92)90010-N; PAOLISSO G, 1989, DIABETES CARE, V12, P265, DOI 10.2337/diacare.12.4.265; PAOLISSO G, 1990, DIABETOLOGIA, V33, P511, DOI 10.1007/BF00404136; PAOLISSO G, 1992, AM J CLIN NUTR, V55, P1161, DOI 10.1093/ajcn/55.6.1161; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; REAVEN GM, 1993, DIABETES METAB REV, V9, pS5, DOI 10.1002/dmr.5610090503; RESNICK LM, 1993, AM J HYPERTENS, V6, pS123, DOI 10.1093/ajh/6.4S.123S; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; RIVELLESE A, 1980, LANCET, V2, P447; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; SALMERON J, 1994, OBESITYY DIABETES IN; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SIMPSON HCR, 1981, LANCET, V1, P1; SJOGREN A, 1988, MAGNESIUM, V7, P117; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; STORLIEN LH, 1993, ANN NY ACAD SCI, V683, P82; SWINBURN BA, 1993, ANN NY ACAD SCI, V683, P102; Trowell H., 1985, DIETARY FIBER FIBER; TROWELL HC, 1975, DIABETES, V24, P762, DOI 10.2337/diab.24.8.762; TURNER R, 1992, ANN MED, V24, P511, DOI 10.3109/07853899209167004; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wolever T M, 1990, World Rev Nutr Diet, V62, P120; Wolever Thomas M. S., 1993, International Journal of Food Sciences and Nutrition, V43, P205, DOI 10.3109/09637489309027544; WOLEVER TMS, 1994, NUTR RES, V14, P651, DOI 10.1016/S0271-5317(05)80201-5; WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265; WOLEVER TMS, 1986, AM J CLIN NUTR, V43, P167, DOI 10.1093/ajcn/43.1.167; WOLEVER TMS, 1992, DIABETIC MED, V9, P451, DOI 10.1111/j.1464-5491.1992.tb01816.x; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846; WOLEVER TMS, 1992, DIABETES CARE, V15, P562, DOI 10.2337/diacare.15.4.562; WOLEVER TMS, 1991, MEDITERRANEAN DIETS, P160; World Health Organization, 1985, WHO TECHN REP SER, V727	82	1310	1360	1	134	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					472	477		10.1001/jama.277.6.472	http://dx.doi.org/10.1001/jama.277.6.472			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020271				2022-12-28	WOS:A1997WG05400034
J	Scully, R; Chen, JJ; Plug, A; Xiao, YH; Weaver, D; Feunteun, J; Ashley, T; Livingston, DM				Scully, R; Chen, JJ; Plug, A; Xiao, YH; Weaver, D; Feunteun, J; Ashley, T; Livingston, DM			Association of BRCA1 with Rad51 in mitotic and meiotic cells	CELL			English	Article							CANCER SUSCEPTIBILITY GENE; DNA STRAND EXCHANGE; OVARIAN-CANCER; BREAST-CANCER; FAMILIAL BREAST; SCHIZOSACCHAROMYCES-POMBE; SYNAPTONEMAL COMPLEXES; CHROMOSOME SYNAPSIS; PROTEIN; MUTATIONS	BRCA1 immunostaining reveals discrete, nuclear foci during S phase of the cell cycle. Human Rad51, a homolog of bacterial RecA, behaves similarly. The two proteins were found to colocalize in vivo and to coimmunoprecipitate. BRCA1 residues 758-1064 alone formed Rad51-containing complexes in vitro. Rad51 is also specifically associated with developing synaptonemal complexes in meiotic cells, and BRCA1 and Rad51 were both detected on asynapsed (axial) elements of human synaptonemal complexes. These findings suggest a functional interaction between BRCA1 and RadB1 in the meiotic and mitotic cell cycles, which, in turn, suggests a role for BRCA1 in the control of recombination and of genome integrity.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA; INST GUSTAVE ROUSSY, CNRS, F-94805 VILLEJUIF, FRANCE	Yale University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Scully, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, 44 BINNEY ST, BOSTON, MA 02115 USA.		Feunteun, Jean/AAZ-1267-2020; Scully, Ralph/F-5008-2013	Feunteun, Jean/0000-0003-1212-9189				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENTLEY NJ, 1996, IN PRESS EMBO J; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOENS PB, 1987, J CELL BIOL, V105, P93, DOI 10.1083/jcb.105.1.93; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rao VN, 1996, ONCOGENE, V12, P523; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Tashiro S, 1996, ONCOGENE, V12, P2165; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILSON CA, 1996, IN PRESS ONCOGENE; Zabludoff SD, 1996, ONCOGENE, V13, P649	76	1273	1301	0	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					265	275		10.1016/S0092-8674(00)81847-4	http://dx.doi.org/10.1016/S0092-8674(00)81847-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008167	hybrid			2022-12-28	WOS:A1997WE97000015
J	Mangano, DT				Mangano, DT			Effects of acadesine on myocardial infarction, stroke, and death following surgery - A meta-analysis of the 5 international randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY BYPASS; PERIOPERATIVE CARDIAC MORBIDITY; ADENOSINE REGULATING AGENT; INDIVIDUAL PATIENT DATA; BLOOD CARDIOPLEGIA; AICA-RIBOSIDE; CLINICAL-TRIALS; PROTECTION; ISCHEMIA; INJURY	Objective.-To determine the effects of a purine nucleoside, acadesine, on the incidence of fatal and nonfatal cardiovascular and cerebrovascular complications following coronary artery bypass graft (CABG) surgery. Data Sources.-Individual patient data from 5 randomized, placebo-controlled, double-blind clinical trials, including 81 international medical centers of the United States, Canada, and Europe. Study Selection.-All patients from all clinical trials were included: a total of 4043 patients undergoing CABG surgery, evaluable for efficacy, and randomized to receive either placebo (n=2031) or acadesine (0.1 mg . kg(-1). min(-1); n=2012) by intravenous infusion for 7 continuous hours and via the cardioplegia solution. Data Extraction.-Individual patient data were collected prospectively using standardized forms and methods and double-data entry. A general parametric approach and analysis-by-patient meta-analysis were used, including both fixed effects and random effects models. Inclusion and exclusion criteria, general methodology, and outcome assessment techniques were similar for all trials. Data Synthesis.-Acadesine decreased the incidence of the primary outcome, perioperative myocardial infarction (MI) by 27% (odds ratio [OR], 0.69; 95% confidence interval [CI], 0.51-0.95; P=.02), decreased the incidence of cardiac death through postoperative day 4 by 50% (OR, 0.52; 95% CI, 0.27-0.98; P=.04), and decreased the incidence of combined outcome (MI, stroke, or cardiac death) by 26% (OR, 0.73; 95% CI, 0.57-0.93; P=.01). The random effects models for these outcomes also yielded significant results. The incidence of cerebrovascular accident was not significantly reduced by acadesine (OR, 0.69; 95% CI, 0.44-1.08; P=.10). A secondary analysis of cardiac death following MI through postoperative day 4 demonstrated that acadesine decreased by 89% the number of deaths from 13.3% (13 deaths/98 MIs) in the placebo group to 1.4% (1 death/71 MIs) in acadesine-treated patients (P=.003). Acadesine also reduced the use of ventricular-assistance devices for severe postoperative heart failure by approximately one third (P=.05). Finally, regarding safety, the incidence of adverse events was similar in the acadesine vs placebo groups, with the exception of a transient increase in serum uric acid in the acadesine group. Conclusions.-The results of this meta-analysis indicate that in patients undergoing CABG surgery, treatment with acadesine before and during surgery can reduce early cardiac death, MI, and combined adverse cardiovascular outcomes.	MULTICTR STUDY PERIOPERAT ISCHEMIA,RES GRP,DEPT MED,SAN FRANCISCO,CA 94143; MULTICTR STUDY PERIOPERAT ISCHEMIA,RES GRP,DEPT SURG,SAN FRANCISCO,CA 94143; MULTICTR STUDY PERIOPERAT ISCHEMIA,RES GRP,DEPT CARDIOL,SAN FRANCISCO,CA 94143; MULTICTR STUDY PERIOPERAT ISCHEMIA,RES GRP,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143		Mangano, DT (corresponding author), MULTICTR STUDY PERIOPERAT ISCHEMIA,RES GRP,DEPT ANESTHESIOL,250 EXECUT PK BLVD,SUITE 3400,SAN FRANCISCO,CA 94143, USA.							AGGARWAL A, 1994, ANESTHESIOLOGY, V81, pA1291; AMBROSIO G, 1989, AM J PHYSIOL, V256, pH560, DOI 10.1152/ajpheart.1989.256.2.H560; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; *CASS PRINC INV TH, 1984, NEW ENGL J MED, V310, P750; Clark RE, 1996, ANN THORAC SURG, V62, pS2, DOI 10.1016/0003-4975(96)00818-1; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; DEMEYERE RH, 1994, CIRCULATION, V90, P370; *DEP APPL STAT, 1980, PEST 3 0 PLANN EV SE; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; GALINANES M, 1992, CIRCULATION, V86, P598, DOI 10.1161/01.CIR.86.2.598; GALINANES M, 1992, CIRCULATION, V86, P589, DOI 10.1161/01.CIR.86.2.589; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GRUBER HE, 1989, CIRCULATION, V80, P1400, DOI 10.1161/01.CIR.80.5.1400; HARAPHONGSE M, 1994, CAN J CARDIOL, V10, P71; HENRY C, 1991, CIRCULATION S, V84, P247; JAIN U, 1994, ANESTHESIOLOGY, V81, pA157; JENG GT, 1995, JAMA-J AM MED ASSOC, V274, P830, DOI 10.1001/jama.274.10.830; JONES EL, 1991, J THORAC CARDIOV SUR, V101, P108; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOUCHOUKOS NT, 1988, ANN THORAC SURG, V45, P348, DOI 10.1016/S0003-4975(10)62482-4; LACHIN J, 1977, BIOMETRICS, V331, P315; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEUNG JM, 1994, ANESTH ANALG, V78, P420; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1994, WESTERN J MED, V161, P87; Mangano DT, 1996, ANESTH ANALG, V82, pSCA42; MANGANO DT, 1993, J CARDIAC SURG, V8, P204; MARTIN TD, 1994, ANN THORAC SURG, V57, P298, DOI 10.1016/0003-4975(94)90987-3; Mazur C, 1991, J MOL CELL CARDIO S3, V23, pS45, DOI [10.1016/0022-2828(91)91458-4, DOI 10.1016/0022-2828(91)91458-4]; MENASCHE P, 1995, J THORAC CARDIOV SUR, V110, P1096, DOI 10.1016/S0022-5223(05)80179-5; MENTZER RM, 1988, J THORAC CARDIOV SUR, V95, P286; MOLINAVIAMONTE V, 1990, CIRCULATION, V82, P645; Mora CT, 1995, CENTRAL NERVOUS SYST, P114, DOI [10.1007/978-1-4612-2484-6_6, DOI 10.1007/978-1-4612-2484-6_6]; MULLANE K, 1993, CARDIOVASC RES, V27, P43, DOI 10.1093/cvr/27.1.43; MULLANE K, 1993, DRUG DEVELOP RES, V28, P336, DOI 10.1002/ddr.430280327; *MULT STUD PER ISC, 1995, ANESTHESIOLOGY, V83, P658; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; OXMAN AD, 1995, JAMA-J AM MED ASSOC, V274, P845, DOI 10.1001/jama.274.10.845; RASHID A, 1994, EUR J CARDIO-THORAC, V8, P265, DOI 10.1016/1010-7940(94)90158-9; SCHAFF HV, 1984, J THORAC CARDIOV SUR, V88, P972; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; *US PUBL HLTH SERV, 1985, VIT HLTH STAT, V2, P10; VAL P G, 1983, Journal of Thoracic and Cardiovascular Surgery, V86, P878; VARNAUSKAS E, 1985, Z KARDIOL, V6, P73; VINTENJOHANSEN J, 1993, CIRCULATION, V88, P350; *WARM HEART INV, 1994, LANCET, V343, P559; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YOUNG M, 1993, EUR HEART J, V31, P14; YOUNG MA, 1991, AM J PHYSIOL, V261, pH1570, DOI 10.1152/ajpheart.1991.261.5.H1570; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1995, BRIT MED J, V310, P751, DOI 10.1136/bmj.310.6982.751	54	123	126	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					325	332		10.1001/jama.277.4.325	http://dx.doi.org/10.1001/jama.277.4.325			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002496				2022-12-28	WOS:A1997WC45800033
J	Ober, KP				Ober, KP			The pre-Flexnerian reports: Mark Twain's criticism of medicine in the United States	ANNALS OF INTERNAL MEDICINE			English	Article								By the time Mark Twain was born, in 1835, the political forces of Jacksonian democracy had created an era of unregulated medical practice in the United States. Licensure laws were almost nonexistent, and any citizen could practice medicine. Regular (''allopathic'') medicine was competing with at least two dozen other sects, including homeopathic, botanical, and hydropathic medicine. Although allopathy presented itself as the ''scientific'' branch of medicine and proclaimed the practices of the other sects to be ''quackery,'' its therapies were aggressive and toxic and had no proven advantage over the treatments used by competitors. Through the efforts of the American Medical Association (AMA), allopathic medicine eliminated its competition by promoting the reestablishment of licensure laws in the late 1800s. In a continuation of the same endeavor, the AMA sought to identify weak and inadequate medical schools and commissioned Abraham Flexner to write the famous Flexner report of 1910 (the year of Mark Twain's death). Twain, an insightful political observer and social critic who was familiar with the competing medical systems and the medical politics of the 19th century, questioned the wisdom of limiting patients' medical options. He doubted the competence and intentions of physicians as a group lit even as he maintained confidence in the abilities of his own physicians. He was critical of the empirical medical practices used during his youth, but he saw hope in the new scientific orientation of medicine in the early 20th century. Twain's commentaries provide a unique perspective on pre-Flexnerian medicine in the United States.			Ober, KP (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT INTERNAL MED, SECT ENDOCRINOL & METAB, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.							Berliner H S, 1977, Bull Hist Med, V51, P603; BERLINER HS, 1975, INT J HEALTH SERV, V5, P573, DOI 10.2190/F31Q-592N-056K-VETL; BRASHEAR MM, 1973, J AM OSTEOPATH ASSOC, V68, P113; Budd Louis J, 1992, M TWAIN COLLECTED TA, P1025; EBERT RH, 1992, ACAD MED, V67, P737, DOI 10.1097/00001888-199211000-00005; Felts J H, 1995, N C Med J, V56, P534; FRIEDLANDER WJ, 1972, ANN INTERN MED, V77, P1007, DOI 10.7326/0003-4819-77-6-1007; Hudson R P, 1972, Bull Hist Med, V46, P545; KING LS, 1984, JAMA-J AM MED ASSOC, V251, P1079, DOI 10.1001/jama.251.8.1079; KING LS, 1982, JAMA-J AM MED ASSOC, V248, P1221, DOI 10.1001/jama.248.10.1221; KREISBERG R, 1995, NEW ENGL J MED, V332, P945, DOI 10.1056/NEJM199504063321409; LEGAN M S, 1971, Bulletin of the History of Medicine, V45, P267; MELTZER M, 1993, M TWAIN HIMSELF, P288; Meyer C T, 1993, J Am Osteopath Assoc, V93, P473; Osler William, 1892, PRINCIPLES PRACTICE, P530; RASMUSSEN RK, 1995, ESSENTIAL REFERENCE, P269; RASMUSSEN RK, 1995, M TWAIN A Z ESSENTIA, P299; RAVIN JG, 1989, ANN INTERN MED, V85, P858; SALMON JW, 1980, J HEALTH POLIT POLIC, V5, P535; TWAIN M, 1976, M TWAIN SPEAKING, P631; TWAIN M, 1976, M TWAIN SPEAKING, P429; TWAIN M, 1975, AUTOBIOGRAPHY M TWAI, P200; TWAIN M, 1979, NOTEBOOKS J, V3, P415; TWAIN M, 1976, M TWAIN SPEAKING, P384; TWAIN M, 1992, M TWAIN COLLECTED TA, P371; TWAIN M, 1975, AUTOBIOGRAPHY M TWAI, P11; TWAIN M, 1979, UNABRIDGED M TWAIN, P135; TWAIN M, 1992, M TWAIN COLLECTED TA, P228; TWAIN M, 1961, COMPLETE HUMOROUS SK, P532; TWAIN M, 1995, LETTERS, V4, P333; Twain Mark, 1992, M TWAIN COLLECTED TA, P648; WEISS HB, 1967, GREAT AM WATER CURE, P18	32	8	8	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					157	163		10.7326/0003-4819-126-2-199701150-00012	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005751				2022-12-28	WOS:A1997WD29800012
J	Savill, J				Savill, J			Science, medicine, and the future: Molecular genetic approaches to understanding disease .2.	BRITISH MEDICAL JOURNAL			English	Review								Molecular genetics has greatly increased the understanding of diseases in which there is a single gene defect such as cystic fibrosis. Discovering the gene responsible and its function not only helps determine the pathogenesis of the disease but also offers a possible treatment-gene therapy. Polygenic disorders such as diabetes may soon yield their secrets to the same approach. Animal models of genetic diseases are proving useful research tools, and transgenesis has made xenografting possible. Furthermore, antisense technology allows specific inhibition of undesirably overexpressed genes such: as those driving unwanted vascular cell proliferation and restenosis after angioplasty. The completion of the human genome project should make the search for ''disease'' genes much quicker and will increase still further the importance of these gene based approaches toward diseases.			Savill, J (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.								0	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					126	129		10.1136/bmj.314.7074.126	http://dx.doi.org/10.1136/bmj.314.7074.126			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006475	Green Submitted, Green Published			2022-12-28	WOS:A1997WC47900029
J	Summerfield, D				Summerfield, D			The Mayas of Guatemala: Surviving terror	LANCET			English	Editorial Material											Summerfield, D (corresponding author), MED FDN CARE VICTIMS TORTURE,96-98 GRAFTON RD,LONDON NW5 3EJ,ENGLAND.							LYKES MB, 1994, SOC SCI MED, V38, P543, DOI 10.1016/0277-9536(94)90250-X; ROHTER L, 1996, NY TIMES        0812; Zur J., 1994, ANTHR TODAY, V10, P12, DOI [10.2307/2783479, DOI 10.2307/2783479]	3	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					130	130		10.1016/S0140-6736(05)63260-6	http://dx.doi.org/10.1016/S0140-6736(05)63260-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB800	8996438				2022-12-28	WOS:A1997WB80000049
J	Yuan, JM; Ross, RK; Gao, YT; Henderson, BE; Yu, MC				Yuan, JM; Ross, RK; Gao, YT; Henderson, BE; Yu, MC			Follow up study of moderate alcohol intake and mortality among middle aged men in Shanghai, China	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; U-SHAPED CURVE; CONSUMPTION; RISK; WOMEN; WINE	Objective: To assess the risk of death associated with various patterns of alcohol intake. Design: Prospective study of mortality in relation to alcohol consumption at recruitment with active annual follow up. Setting: Four small, geographically defined communities in Shanghai, China. Subjects: 18 244 men aged 45-64 years enrolled in a prospective study of diet and cancer during January 1986 to September 1989, Main outcome measure: All cause mortality. Results: By 28 February 1995, 1198 deaths (including 498 from cancer, 269 from stroke, and 104 from ischaemic heart disease) had been identified, Compared with lifelong non-drinkers, chose who consumed 1-14 drinks a week had a 19% reduction in overall mortality (relative risk 0.81; 95% confidence interval 0.70 to 0.94) after age, level of education, and cigarette smoking were adjusted for. This protective effect was not restricted to any specific type of alcoholic drink. Although light to moderate drinking (28 or fewer drinks per week) was associated with a 36% reduction in death from ischaemic heart disease (0.64; 0.41 to 0.998), it had no effect on death from stroke, which is the leading cause of death in this population, As expected, heavy drinking (29 of more drinks per seek) nas significantly associated with increased risks of death from cancer of the upper aerodigestive tract, hepatic cirrhosis, and stroke. Conclusions: Regular consumption of small amounts aic alcohol is associated with lower overall mortality including death from ischaemic heart disease in middle aged Chinese men. The type of alcoholic drink does not affect this association.			Yuan, JM (corresponding author), UNIV SO CALIF,CTR CANC,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT PREVENT MED,LOS ANGELES,CA 90033, USA.		Gao, Yu/HGE-1937-2022	Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [R01 CA43092, R01 CA043092-20, R01 CA043092, R35 CA53890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053890, R01CA043092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS CF, 1975, AGR HDB USDA, V456, P31; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BRESLOW NE, 1987, IARC SCI PUBL, V82, P120; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN KJ, 1993, AM J EPIDEMIOL, V137, P242, DOI 10.1093/oxfordjournals.aje.a116665; DELABRY LO, 1992, J STUD ALCOHOL, V53, P25, DOI 10.15288/jsa.1992.53.25; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; GRONBAEK M, 1994, BRIT MED J, V308, P302, DOI 10.1136/bmj.308.6924.302; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; REHM J, 1995, ADDICTION, V90, P471, DOI 10.1046/j.1360-0443.1995.9044712.x; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SERDULA MK, 1995, J STUD ALCOHOL, V56, P233, DOI 10.15288/jsa.1995.56.233; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646	25	138	145	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					18	23		10.1136/bmj.314.7073.18	http://dx.doi.org/10.1136/bmj.314.7073.18			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB684	9001474	Green Published			2022-12-28	WOS:A1997WB68400018
J	Stork, E; Gorjanc, E; Verter, J; Younes, N; Stenzel, BA; Powers, T; Sokol, G; Wright, LL; Yaffe, SJ; Catz, C; VanMeurs, K; Rhine, W; Ball, B; Brilli, R; Moles, L; Crowley, M; Backstrom, C; Crouse, D; Hudson, T; Konduri, G; Bara, R; Kleinman, M; Hensman, A; Rothstein, RW; Ehrenkranz, RA; Solimano, A; Germain, F; Walker, R; Ramirez, AM; Singhal, N; Bourcier, L; Fajardo, C; Cook, V; Kirpalani, H; Monkman, S; Johnston, A; Mullahoo, K; Finer, NN; Peliowski, A; Etches, P; Kamstra, B; Sankarhan, K; Riehl, A; Blanchard, P; Gouin, R; Wearden, M; Gomez, M; Moon, Y; Bauer, CR; Donovan, EF; Fanaroff, AA; Korones, SB; Lemons, JA; Oh, W; Papile, LA; Shankaran, S; Stoll, BJ; Tyson, JE; Avery, G; DAlton, M; Bracken, MB; Gleason, CA; Maguire, M; Redmond, C; Silverman, W; Sinclair, J				Stork, E; Gorjanc, E; Verter, J; Younes, N; Stenzel, BA; Powers, T; Sokol, G; Wright, LL; Yaffe, SJ; Catz, C; VanMeurs, K; Rhine, W; Ball, B; Brilli, R; Moles, L; Crowley, M; Backstrom, C; Crouse, D; Hudson, T; Konduri, G; Bara, R; Kleinman, M; Hensman, A; Rothstein, RW; Ehrenkranz, RA; Solimano, A; Germain, F; Walker, R; Ramirez, AM; Singhal, N; Bourcier, L; Fajardo, C; Cook, V; Kirpalani, H; Monkman, S; Johnston, A; Mullahoo, K; Finer, NN; Peliowski, A; Etches, P; Kamstra, B; Sankarhan, K; Riehl, A; Blanchard, P; Gouin, R; Wearden, M; Gomez, M; Moon, Y; Bauer, CR; Donovan, EF; Fanaroff, AA; Korones, SB; Lemons, JA; Oh, W; Papile, LA; Shankaran, S; Stoll, BJ; Tyson, JE; Avery, G; DAlton, M; Bracken, MB; Gleason, CA; Maguire, M; Redmond, C; Silverman, W; Sinclair, J			Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERSISTENT PULMONARY-HYPERTENSION; EXTRACORPOREAL MEMBRANE-OXYGENATION; RELAXING FACTOR; BLEEDING-TIME; NEWBORN; VASOCONSTRICTION; HYPERVENTILATION; VASODILATOR; PEROXYNITRITE; MANAGEMENT	Background Neonates with pulmonary hypertension have been treated with inhaled nitric oxide because of studies suggesting that it is a selective pulmonary vasodilator. We conducted a randomized, multicenter, controlled trial to determine whether inhaled nitric oxide would reduce mortality or the initiation of extracorporeal membrane oxygenation in infants with hypoxic respiratory failure, Methods Infants born after a gestation of greater than or equal to 34 weeks who were 14 days old or less, had no structural heart disease, and required assisted ventilation and whose oxygenation index was 25 or higher on two measurements were eligible for the study. The infants were randomly assigned to receive nitric oxide at a concentration of 20 ppm or 100 percent oxygen (as a control). Infants whose partial pressure of arterial oxygen (PaO2) increased by 20 mm Hg or less after 30 minutes were studied for a response to 80-ppm nitric oxide or control gas, Results The 121 infants in the control group and the 114 in the nitric oxide group had similar base-line clinical characteristics. Sixty-four percent of the control group and 46 percent of the nitric oxide group died within 120 days or were treated with extracorporeal membrane oxygenation (P=0.006). Seventeen percent of the control group and 14 percent of the nitric oxide group died (P not significant), but significantly fewer in the nitric oxide group received extracorporeal membrane oxygenation (39 percent vs. 54 percent, P=0.014). The nitric oxide group had significantly greater improvement in PaO2 (mean [+/-SD] increase, 58.2+/-85.2 mm Hg, vs. 9.7+/-51.7 mm Hg in the controls; P<0.001) and in the oxygenation index (a decrease of 14.1+/-21.1, vs, an increase of 0.8+/-21.1 in the controls; P<0,001). The study gas was not discontinued in any infant because of toxicity. Conclusions Nitric oxide therapy reduced the use of extracorporeal membrane oxygenation, but had no apparent effect on mortality, in critically ill infants with hypoxic respiratory failure. (C) 1997, Massachusetts Medical Society.	YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06520; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; GEORGE WASHINGTON UNIV,CTR BIOSTAT,ROCKVILLE,MD; INDIANA UNIV,INDIANAPOLIS,IN 46204; NICHHD,BETHESDA,MD; STANFORD UNIV,PALO ALTO,CA 94304; UNIV CINCINNATI,CINCINNATI,OH; UNIV NEW MEXICO,ALBUQUERQUE,NM 87131; UNIV TENNESSEE,MEMPHIS,TN; WAYNE STATE UNIV,DETROIT,MI; BROWN UNIV,WOMEN & INFANTS HOSP,PROVIDENCE,RI; BRITISH COLUMBIA CHILDRENS HOSP,VANCOUVER,BC V6H 3V4,CANADA; CHILDRENS HOSP EASTERN ONTARIO,OTTAWA,ON K1H 8L1,CANADA; FOOTHILLS PROV GEN HOSP,CALGARY,AB T2N 2T9,CANADA; CTR HLTH SCI,WINNIPEG,MB,CANADA; MCMASTER UNIV,HAMILTON,ON,CANADA; MONTREAL CHILDRENS HOSP,MONTREAL,PQ H3H 1P3,CANADA; ROYAL ALEXANDRA HOSP,EDMONTON,AB,CANADA; ROYAL UNIV HOSP,SASKATOON,SK S7N 0W8,CANADA; UNIV SHERBROOKE,SHERBROOKE,PQ J1K 2R1,CANADA; TEXAS CHILDRENS HOSP,HOUSTON,TX 77030; UNIV MIAMI,MIAMI,FL 33152; EMORY UNIV,ATLANTA,GA 30322; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; CHILDRENS HOSP,NATL MED CTR,WASHINGTON,DC 20010; TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21287; UNIV PENN,PHILADELPHIA,PA 19104; UNIV PITTSBURGH,PITTSBURGH,PA	Yale University; Case Western Reserve University; George Washington University; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Stanford University; University System of Ohio; University of Cincinnati; University of New Mexico; University of Tennessee System; University of Tennessee Health Science Center; Wayne State University; Brown University; Women & Infants Hospital Rhode Island; BC Childrens Hospital; University of British Columbia; University of Ottawa; Children's Hospital of Eastern Ontario; University of Calgary; McMaster University; McGill University; Royal Alexandra Hospital; University of Saskatchewan; University of Sherbrooke; Baylor College of Medicine; University of Miami; Emory University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Children's National Health System; Tufts Medical Center; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NICHD NIH HHS [U10 HD21385, U10 HD21415, U10 HD21364] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021364, U10HD021385] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021415] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCHER SL, 1990, J APPL PHYSIOL, V68, P735, DOI 10.1152/jappl.1990.68.2.735; BARTLETT RH, 1987, ANN SURG, V205, pA11; BARTLETT RH, 1986, ANN SURG, V204, P236, DOI 10.1097/00000658-198609000-00003; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; DRUMMOND WH, 1981, J PEDIATR-US, V98, P603, DOI 10.1016/S0022-3476(81)80775-5; FINER NN, 1994, J PEDIATR-US, V124, P302, DOI 10.1016/S0022-3476(94)70324-8; FOX WW, 1983, J PEDIATR-US, V103, P505, DOI 10.1016/S0022-3476(83)80573-3; FRATACCI MD, 1991, ANESTHESIOLOGY, V75, P990, DOI 10.1097/00000542-199112000-00011; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL C, 1991, CIRCULATION, V84, P2212; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GART JJ, 1985, BIOMETRIKA, V72, P673, DOI 10.1093/biomet/72.3.673; GERSONY WM, 1984, CLIN PERINATOL, V11, P517, DOI 10.1016/S0095-5108(18)30899-6; GRAVES ED, 1988, CHEST, V93, P638, DOI 10.1378/chest.93.3.638; HOGMAN M, 1993, LANCET, V341, P1664, DOI 10.1016/0140-6736(93)90802-N; HOGMAN M, 1994, ACTA PHYSIOL SCAND, V151, P125, DOI 10.1111/j.1748-1716.1994.tb09728.x; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; KULIK TJ, 1984, CLIN PERINATOL, V11, P693, DOI 10.1016/S0095-5108(18)30911-4; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PISON U, 1993, J APPL PHYSIOL, V74, P1287, DOI 10.1152/jappl.1993.74.3.1287; RADOMSKI MW, 1993, THROMB HAEMOSTASIS, V70, P36; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; ROBERTS JD, 1993, CIRC RES, V72, P246, DOI 10.1161/01.RES.72.2.246; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WALSHSUKYS MC, 1994, PEDIATRICS, V94, P303; WUNG JT, 1985, PEDIATRICS, V76, P488	32	603	618	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					597	604						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9036320				2022-12-28	WOS:A1997WK02800001
J	Bau, R; Drabnis, MH; Garlaschelli, L; Klooster, WT; Xie, ZW; Koetzle, TF; Martinengo, S				Bau, R; Drabnis, MH; Garlaschelli, L; Klooster, WT; Xie, ZW; Koetzle, TF; Martinengo, S			Five-coordinate hydrogen: Neutron diffraction analysis of the hydrido cluster complex [H2Rh13(CO)(24)](3-)	SCIENCE			English	Article							CARBONYL CLUSTERS; X-RAY; DIRECT LOCATION; METAL-SURFACES; HE-DIFFRACTION; RHODIUM; ADSORPTION; (1X1)-2H; CRYSTAL; RH(110)	Pentacoordinate hydrogen atoms were identified by single-crystal neutron diffraction analysis of [N(CH3)(4)](3)[H2Rh13(CO)(24)]. The hydrogen atoms are located in square pyramidal cavities of the Rh-13 cluster, in positions almost coplanar with the Rh-4 faces on the surface of the cluster. They are slightly displaced inward, toward the central rhodium atom of the cluster, with average H-Rh(central) and H-Rh(surface) distances of 1.84(2) and 1.97(2) angstroms, respectively. This result shows that hydrogen, which normally forms only one bond, can be attached to five other atoms simultaneously in a large metal cluster.	UNIV MILAN,DIPARTIMENTO CHIM INORGAN MET ORGAN & ANALYT,I-20133 MILAN,ITALY; BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973	University of Milan; United States Department of Energy (DOE); Brookhaven National Laboratory	Bau, R (corresponding author), UNIV SO CALIF,DEPT CHEM,LOS ANGELES,CA 90089, USA.		Xie, Zuowei/A-5669-2010	xie Xie, zuo wei Zuowei/0000-0001-6206-004X				ALBANO VG, 1975, J CHEM SOC CHEM COMM, P859, DOI 10.1039/c39750000859; ALBANO VG, 1979, J CHEM SOC DALTON, P978, DOI 10.1039/dt9790000978; ALLEVI C, 1986, J CHEM SOC DALTON, P1375, DOI 10.1039/dt9860001375; BASHALL A, 1991, ANGEW CHEM INT EDIT, V30, P1164, DOI 10.1002/anie.199111641; Broach R. W., 1979, ADV CHEM SER, V167, P93; BROWN RK, 1980, INORG CHEM, V19, P370, DOI 10.1021/ic50204a018; *CHEM SOC, 1965, SPEC PUBL CHEM SOC, V18; CHRISTMANN K, 1986, CHEM PHYS LETT, V131, P192, DOI 10.1016/0009-2614(86)80543-7; CHRISTMANN K, 1989, MOL PHYS, V66, P1, DOI 10.1080/00268978900100011; CHRISTMANN K, 1995, PROG SURF SCI, V48, P15, DOI 10.1016/0079-6816(95)93412-Z; CIANI G, 1981, J CHEM SOC DALTON, P519, DOI 10.1039/dt9810000519; DEMEULENAER J, 1965, ACTA CRYSTALLOGR, V19, P1014, DOI 10.1107/S0365110X65004802; Eguchi T, 1996, J CHEM SOC DALTON, P625, DOI 10.1039/dt9960000625; FEIBELMAN PJ, 1991, PHYS REV B, V43, P9452, DOI 10.1103/PhysRevB.43.9452; FEIBELMAN PJ, 1990, SURF SCI, V234, P377, DOI 10.1016/0039-6028(90)90570-X; FERNANDEZ MJ, 1984, J AM CHEM SOC, V106, P5458, DOI 10.1021/ja00331a013; HAMANN DR, 1987, PHYS REV B, V37, P3847; HANKE D, 1993, INORG CHEM, V32, P4300, DOI 10.1021/ic00072a024; HART DW, 1981, J AM CHEM SOC, V103, P1458, DOI 10.1021/ja00396a028; HART DW, 1979, ANGEW CHEM INT EDIT, V18, P80, DOI 10.1002/anie.197900801; HEATON BT, 1982, J CHEM SOC DALTON, P1499, DOI 10.1039/dt9820001499; HENNIG D, 1993, SURF SCI, V287, P89, DOI 10.1016/0039-6028(93)90748-9; JACKSON PF, 1980, J CHEM SOC CHEM COMM, P295, DOI 10.1039/c39800000295; KIRSTEN E, 1991, CHEM PHYS LETT, V181, P544, DOI 10.1016/0009-2614(91)80310-T; LEHNBERGER K, 1988, SURF SCI, V217, P511; Lutz F, 1996, INORG CHEM, V35, P2698, DOI 10.1021/ic951297i; MARTINENGO S, 1977, J CHEM SOC CHEM COMM, P39, DOI 10.1039/c39770000039; MCMULLAN RK, 1979, ACTA CRYSTALLOGR B, V35, P688, DOI 10.1107/S0567740879004441; OED W, 1988, J PHYS C SOLID STATE, V21, P237, DOI 10.1088/0022-3719/21/2/007; PARSCHAU G, 1991, PHYS REV B, V43, P12216, DOI 10.1103/PhysRevB.43.12216; RICCI JS, 1984, INORG CHEM, V23, P1828, DOI 10.1021/ic00181a010; RICHTER LJ, 1987, J VAC SCI TECHNOL A, V5, P453, DOI 10.1116/1.574752; TEMPLETON LK, 1965, AM CRYST ASS M STORR, P143; Volkl J., 1978, Hydrogen in metals I, P321; WEBERG RT, 1990, J AM CHEM SOC, V112, P1105, DOI 10.1021/ja00159a033; WILKE S, 1994, PHYS REV B, V50, P2548, DOI 10.1103/PhysRevB.50.2548	36	48	49	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1099	1102		10.1126/science.275.5303.1099	http://dx.doi.org/10.1126/science.275.5303.1099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027305				2022-12-28	WOS:A1997WJ50300036
J	Chinnaiyan, AM; ORourke, K; Lane, BR; Dixit, VM				Chinnaiyan, AM; ORourke, K; Lane, BR; Dixit, VM			Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death	SCIENCE			English	Article							C-ELEGANS; CAENORHABDITIS-ELEGANS; GENE CED-3; PROTEIN; APOPTOSIS; ENCODES; HOMOLOG; ENZYME; BCL-2	Previous genetic studies of the nematode Caenorhabditis elegans identified three important components of the cell death machinery. CED-3 and CED-4 function to kill cells, whereas CED-9 protects cells from death. Here CED-9 and its mammalian homolog Bcl-x(L) (a member of the Bcl-2 family of cell death regulators) were both found to interact with and inhibit the function of CED-4. In addition, analysis revealed that CED-4 can simultaneously interact with CED-3 and its mammalian counterparts interleukin-1 beta-converting enzyme (ICE) and FLICE. Thus, CED-4 plays a central role in the cell death pathway, biochemically linking CED-9 and the Bcl-2 family to CED3 and the ICE family of pro-apoptotic cysteine proteases.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	PHS HHS [7863] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHINNALYAN AM, UNPUB; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; OLTAVI ZN, 1993, CELL, V74, P609; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1993, CURR BIOL, V3, P877, DOI 10.1016/0960-9822(93)90223-B; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	30	535	572	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1122	1126		10.1126/science.275.5303.1122	http://dx.doi.org/10.1126/science.275.5303.1122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027312				2022-12-28	WOS:A1997WJ50300043
J	Kessler, RC; Frank, RG; Edlund, M; Katz, SJ; Lin, E; Leaf, P				Kessler, RC; Frank, RG; Edlund, M; Katz, SJ; Lin, E; Leaf, P			Differences in the use of psychiatric outpatient services between the United States and Ontario	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENTAL-HEALTH SERVICES; DISORDERS; CANADA; SYSTEM; CARE	Background The relation between health insurance and the use of mental health services is unclear. We compared the use of outpatient services for psychiatric problems in the United States and Ontario, Canada, among young and middle-aged adults according to self-reports of disorders listed in the Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) and to other indicators of need. Methods We analyzed two general-population surveys carried out separately in the United States and Ontario in 1990 that used identical assessments of need for services and questions about their use by persons 15 to 54 years of age. Results Respondents in the United States were significantly more likely than those in Ontario to report having had psychiatric disorders, poor mental health, or workdays lost or cut short because of psychiatric problems in the previous year. A significantly higher proportion of respondents in the United States (13.3 percent) than in Ontario (8.0 percent) had obtained outpatient treatment in the previous 12 months for psychiatric problems. However, an analysis of subgroups found that the higher probability of the use of services in the United States was confined to people with less severe mental illness. The average number of visits did not differ significantly between the two countries among patients who had similar numbers of psychiatric disorders over the same time periods. There was a stronger match in Ontario than in the United States between the use of services and the measures of perceived need we considered. Conclusions Although the mental health care system tem in the United States provides treatment to a larger proportion of the population than that in Ontario, the match between some measures of need and treatment is not as strong in the United States. Any plans to expand coverage for psychiatric disorders in the United States must address this problem. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI; UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON,CANADA; CLARKE INST PSYCHIAT,HLTH SYST RES UNIT,TORONTO,ON M5T 1R8,CANADA; JOHNS HOPKINS UNIV,DEPT MENTAL HLTH,BALTIMORE,MD	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Johns Hopkins University	Kessler, RC (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FL,BOSTON,MA 02115, USA.		KATZ, STEVEN/ABH-8886-2020		NIMH NIH HHS [MH52861, MH49098, MH46379] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052861, R01MH049098] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*ALC DRUG RES FDN, 1994, INT PROF 1994 ALC OT; BARER ML, 1992, HEALTH AFFAIR, V11, P44, DOI 10.1377/hlthaff.11.1.44; BIGELOW DA, 1989, HOSP COMMUNITY PSYCH, V40, P805; Cannell C.F., 1981, SOCIOL METHODOL, V12, P389, DOI DOI 10.2307/270748; CANNELL CF, 1977, VITAL HLTH STATIST 2, V2; *CLARK I CONS GRP, 1994, EST UT INP BEDS REF; EVANS RG, 1992, J HEALTH POLIT POLIC, V17, P739, DOI 10.1215/03616878-17-4-739; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; FRANK RG, 1986, HEALTH SERV RES, V21, P241; FRANK RG, 1994, DHHS PUBLICATION, P8; FREEMAN SJJ, 1994, MENTAL HLTH CARE CAN, P11; FUCHS VR, 1992, JAMA-J AM MED ASSOC, V268, P916, DOI 10.1001/jama.268.7.916; GEORGE LK, 1985, HLTH SERVICES VALIDA; *HLTH WELF CAN, 1990, HLTH PERS CAN 1990; HOLLINGSWORTH EJ, 1992, J HEALTH POLIT POLIC, V17, P899, DOI 10.1215/03616878-17-4-899; JAHIEL RI, 1992, HOMELESSNESS PREVENT, P337; KATZ A, 1989, TALE 2 SYSTEMS COMP; KESSLER RC, 1995, EPIDEMIOL REV, V17, P192, DOI 10.1093/oxfordjournals.epirev.a036176; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KISH L, 1970, J AM STAT ASSOC, V65, P1071, DOI 10.2307/2284276; MACNAUGHTON E, 1991, COMMUNITY INVESTMENT, V2; Offord DR, 1994, MENTAL HLTH ONTARIO; Ontario Ministry of Health, 1993, PUTT PEOPL 1 REF MEN; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; ROBACK G, 1992, PHYSICIAN CHARACTERI; ROBINS LN, 1991, PSYCHIATRIC DISORDER; ROCHEFORT DA, 1992, HOSP COMMUNITY PSYCH, V43, P1083; ROOS LL, 1992, HEALTH AFFAIR, V11, P56, DOI 10.1377/hlthaff.11.2.56; *STAT CAN, 1994, SUIC RAT FIG 1950 19; *SUPPL SERV CAN, 1989, STAT CAN CAN YB 1990; *U MI I SOC RES, 1981, OSIRIS 7; US Census Bureau, 1994, STAT ABSTR US; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1; WOODRUFF RS, 1976, J AM STAT ASSOC, V71, P315, DOI 10.2307/2285303; World Health Organization, 1990, COMP INT DIAGN INT C; 1990, MENTAL HLTH SUBSTANC	36	158	159	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					551	557		10.1056/NEJM199702203360806	http://dx.doi.org/10.1056/NEJM199702203360806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WJ240	9023093	Bronze			2022-12-28	WOS:A1997WJ24000006
J	Waiter, J; Newport, JW				Waiter, J; Newport, JW			Regulation of replicon size in Xenopus egg extracts	SCIENCE			English	Article							DNA-REPLICATION; INITIATION; CHROMOSOMES; EMBRYOS; INVITRO; ORIGINS; NUCLEI; SYSTEM; UNITS	Once a specific number of cells have been produced in the early Xenopus laevis embryo, replicon size during the S phase of the cell cycle increases. Here, it is reported that similar increase in replicon size occurred when the concentration of nuclei in replication-competent Xenopus egg extracts exceeded a critical threshold. In this system, the origin recognition complex (ORC) did not become stoichiometrically limiting for initiation, and similar amounts of this complex bound to chromatin regardless of replicon size. These data suggest that in early development, an unidentified factor controls how many preformed ORC-DNA complexes initiate DNA replication.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Walter, Johannes/0000-0002-4186-7570	PHS HHS [1F32FM17980-01, R01FM44656] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BLUMENTH.AB, 1973, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/SQB.1974.038.01.024; CALLAN HG, 1972, PROC R SOC SER B-BIO, V181, P19, DOI 10.1098/rspb.1972.0039; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2	21	145	147	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					993	995		10.1126/science.275.5302.993	http://dx.doi.org/10.1126/science.275.5302.993			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020085				2022-12-28	WOS:A1997WH38800050
J	Hancock, REW				Hancock, REW			Peptide antibiotics	LANCET			English	Review							PSEUDOMONAS-AERUGINOSA; CYSTIC-FIBROSIS; BACTERIA	The era of the ''classical antibiotic'' may be over. The emergence of resistance has seen to that. Yet no truly novel class of antibacterial agent has come on the market in the past 30 years. Currently there is great interest in peptide antibiotics, especially the cationic peptides. Thousands of such molecules have been synthesised and just a few are entering clinical trials. Because they kill bacteria quickly by the physical disruption of cell membranes, peptide antibiotics may not face the rapid emergence of resistance.			Hancock, REW (corresponding author), UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA.		Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J; BODANSZKY M, 1967, J AM CHEM SOC, V89, P6753, DOI 10.1021/ja01001a063; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN MG, 1994, ANTIMICROBIAL PEPTID; CORRIGAN JJ, 1971, INFECT IMMUN, V4, P563, DOI 10.1128/IAI.4.5.563-566.1971; DARVEAU RP, 1991, ANTIMICROB AGENTS CH, V35, P1153, DOI 10.1128/AAC.35.6.1153; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; HANCOCK REW, 1993, ANTIMICROB AGENTS CH, V37, P453, DOI 10.1128/AAC.37.3.453; JENSEN T, 1987, J ANTIMICROB CHEMOTH, V19, P831, DOI 10.1093/jac/19.6.831; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460; KUN P, 1984, AUST PAEDIATR J, V20, P43; KUNG AHC, 1996, 36 INT C ANT AG CHEM; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PIERS KL, 1994, ANTIMICROB AGENTS CH, V38, P2311, DOI 10.1128/AAC.38.10.2311; PIERS KL, 1993, GENE, V134, P7, DOI 10.1016/0378-1119(93)90168-3; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; VAARA M, 1983, ANTIMICROB AGENTS CH, V24, P107, DOI 10.1128/AAC.24.1.107; WRIGHT WW, 1960, ANTIBIOT ANNU, P61; Zopf D, 1996, LANCET, V347, P1017, DOI 10.1016/S0140-6736(96)90150-6	23	934	986	2	128	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					418	422		10.1016/S0140-6736(97)80051-7	http://dx.doi.org/10.1016/S0140-6736(97)80051-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033483				2022-12-28	WOS:A1997WH29600048
J	Prochaska, F				Prochaska, F			The King's Fund: A century of hospital charity	LANCET			English	Article											Prochaska, F (corresponding author), UNIV LONDON,INST HIST RES,SENATE HOUSE,MALET ST,LONDON WC1E 7HU,ENGLAND.							IVES AGL, 1948, BRIT HOSP, P46; IVES AGL, 1939, COMMUNICATION   1214; JONES FA, 1974, BR J HOSP MED    MAR, P393; *KINGS FUND, 1923, 26 ANN REP, P44; *KINGS FUND, 1920, STAT REP YEAR 1920, P9; *KINGS FUND, 1976, CENT ANN REP MAY; LONG F, 1942, KING EDWARDS HOSP FU, P4; PROCHASKA F, 1992, PHILANTHROPY HOSP LO, P47; PROCHASKA FK, 1992, PHILANTHROPY HOSP LO, P39; PROCHASKA FK, 1992, PHILANTHROPY HOSP LO, P19; PROCHASKA FK, 1992, PHILANTHROPY HOSP LO, P136; PROCHASKA FK, 1992, PHILANTHROPY HOSP LO, P162; Prochaska Frank, 1995, ROYAL BOUNTY MAKING; 1902, BURDETTS HOSP CHARIT, P62; 1897, HOSPITAL        0213, P335	15	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					423	425		10.1016/S0140-6736(97)80052-9	http://dx.doi.org/10.1016/S0140-6736(97)80052-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033484				2022-12-28	WOS:A1997WH29600049
J	Studer, A; Hadida, S; Ferritto, R; Kim, SY; Jeger, P; Wipf, P; Curran, DP				Studer, A; Hadida, S; Ferritto, R; Kim, SY; Jeger, P; Wipf, P; Curran, DP			Fluorous synthesis: A fluorous-phase strategy for improving separation efficiency in organic synthesis	SCIENCE			English	Article							BIGINELLI DIHYDROPYRIMIDINE SYNTHESIS; COMBINATORIAL CHEMISTRY; DRUG DISCOVERY; LIBRARIES	Recovery and purification difficulties can limit the yield and utility of otherwise successful organic synthesis strategies. A ''fluorous synthesis'' approach is outlined in which organic molecules are rendered soluble in fluorocarbon solvents by attachment of a suitable fluorocarbon group. Fluorocarbon solvents are usually immiscible in organic solutions, and fluorous molecules partition out of an organic phase and into a fluorous phase in a standard liquid-liquid extraction. Simple yet substantive separations of organic reaction mixtures are achieved without resorting to chromatography. Because fluorous synthesis combines in many respects the favorable purification features of solid-phase synthesis with the favorable reaction, identification, and analysis features of traditional organic synthesis,it should prove valuable in the automated synthesis of libraries of individual pure organic compounds.	UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Wipf, Peter/AAG-1771-2021	Wipf, Peter/0000-0001-7693-5863				Armstrong RW, 1996, ACCOUNTS CHEM RES, V29, P123, DOI 10.1021/ar9502083; Biginelli P., 1893, GAZZ CHIM ITAL, V23, P360; BIRR C, 1978, ASPECTS MERRIFIELD P; Boger DL, 1996, J AM CHEM SOC, V118, P2109, DOI 10.1021/ja9539711; Booth R A, UNPUB; BOUTEVIN B, 1993, J FLUORINE CHEM, V60, P211, DOI 10.1016/S0022-1139(00)80035-4; BROWN D, 1996, J AM CHEM SOC, V118, P6331; Caramella P, 1984, 13 DIPOLAR CYCLOADDI, V1, P291; CARELL T, 1995, CHEM BIOL, V2, P171, DOI 10.1016/1074-5521(95)90072-1; Cheng S, 1996, J AM CHEM SOC, V118, P2567, DOI 10.1021/ja9530681; Curran DP, 1996, J AM CHEM SOC, V118, P2531, DOI 10.1021/ja953287m; Curran DP, 1996, J ORG CHEM, V61, P6480, DOI 10.1021/jo961309x; CURRAN DP, 1996, CHEMTRACTS ORG CHEM, V9, P75; Dressman BA, 1996, TETRAHEDRON LETT, V37, P937, DOI 10.1016/0040-4039(95)02395-X; Ellman JA, 1996, ACCOUNTS CHEM RES, V29, P132, DOI 10.1021/ar950190w; Fruchtel JS, 1996, ANGEW CHEM INT EDIT, V35, P17, DOI 10.1002/anie.199600171; Gait M. J, 1984, OLIGONUCLEOTIDE SYNT; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GALLOP MA, 1994, J MED CHEM, V37, P1386; Gordeev MF, 1996, J ORG CHEM, V61, P924, DOI 10.1021/jo951706s; Gordeev MF, 1996, TETRAHEDRON LETT, V37, P4643, DOI 10.1016/0040-4039(96)00923-9; Gordon EM, 1996, ACCOUNTS CHEM RES, V29, P144, DOI 10.1021/ar950170u; GREENE TW, 1991, PROTECTIVE GROUPS OR; Hamper BC, 1996, TETRAHEDRON LETT, V37, P3671, DOI 10.1016/0040-4039(96)00659-4; HAN HS, 1995, P NATL ACAD SCI USA, V92, P6419, DOI 10.1073/pnas.92.14.6419; Hermkens PHH, 1996, TETRAHEDRON, V52, P4527, DOI 10.1016/0040-4020(96)00216-5; HILDEBRAND JH, 1949, J AM CHEM SOC, V71, P22, DOI 10.1021/ja01169a008; HORVATH IT, 1994, SCIENCE, V266, P72, DOI 10.1126/science.266.5182.72; HOUK KN, 1984, J AM CHEM SOC, V106, P3880, DOI 10.1021/ja00325a040; Hudlicky M., 1992, CHEM ORGANIC FLUORIN; HUTCHINS SM, 1995, TETRAHEDRON LETT, V36, P2583, DOI 10.1016/0040-4039(95)00345-D; Kaldor SW, 1996, TETRAHEDRON LETT, V37, P7193, DOI 10.1016/0040-4039(96)01636-X; KAPPE CO, 1993, TETRAHEDRON, V49, P6937; MITSCHER LA, 1995, CHEMTRACTS ORG CHEM, V8, P19; Mjalli AMM, 1996, TETRAHEDRON LETT, V37, P2943, DOI 10.1016/0040-4039(96)00365-6; Rinnova M, 1996, COLLECT CZECH CHEM C, V61, P171, DOI 10.1135/cccc19960171; SCOTT RL, 1948, J AM CHEM SOC, V70, P4090, DOI 10.1021/ja01192a036; SISIDO K, 1971, J ORGANOMET CHEM, V33, P337, DOI 10.1016/S0022-328X(00)87417-3; Tempest PA, 1996, ANGEW CHEM INT EDIT, V35, P640, DOI 10.1002/anie.199606401; TERRETT NK, 1995, TETRAHEDRON, V51, P8135, DOI 10.1016/0040-4020(95)00467-M; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; UGI I, 1982, ANGEW CHEM INT EDIT, V21, P810, DOI 10.1002/anie.198208101; WIPF P, 1995, TETRAHEDRON LETT, V36, P7819, DOI 10.1016/0040-4039(95)01660-A; ZHU DW, 1993, SYNTHESIS-STUTTGART, P953	44	492	537	15	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					823	826		10.1126/science.275.5301.823	http://dx.doi.org/10.1126/science.275.5301.823			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012347	Green Submitted			2022-12-28	WOS:A1997WG77700058
J	Naatanen, R; Lehtokoski, A; Lennes, M; Cheour, M; Huotilainen, M; Iivonen, A; Vainio, M; Alku, P; Ilmoniemi, RJ; Luuk, A; Allik, J; Sinkkonen, J; Alho, K				Naatanen, R; Lehtokoski, A; Lennes, M; Cheour, M; Huotilainen, M; Iivonen, A; Vainio, M; Alku, P; Ilmoniemi, RJ; Luuk, A; Allik, J; Sinkkonen, J; Alho, K			Language-specific phoneme representations revealed by electric and magnetic brain responses	NATURE			English	Article							LINGUISTIC EXPERIENCE; SENSORY MEMORY; PERCEPTION; INFANTS	There is considerable debate about whether the early processing of sounds depends on whether they form part of speech. Proponents of such speech specificity postulate the existence of language-dependent memory traces, which are activated in the processing of speech(1-3) but not when equally complex, acoustic non-speech stimuli are processed. Here we report the existence of these traces in the human brain, We presented to Finnish subjects the Finnish phoneme prototype /e/ as the frequent stimulus, and other Finnish phoneme prototypes or a non-prototype (the Estonian prototype /(o) over tilde/) as the infrequent stimulus. We found that the brain's automatic change-detection response, reflected electrically as the mismatch negativity (MMN)(4-10), was enhanced when the infrequent, deviant stimulus was a prototype (the Finnish /o/) relative to when it was a non-prototype (the Estonian /(o) over tilde/). These phonemic traces, revealed by MMN, are language-specific, as /(o) over tilde/ caused enhancement of MMN in Estonians. Whole-head magnetic recordings(11,12) located the source of this native-language, phoneme-related response enhancement, and thus the language-specific memory traces, in the auditory cortex of the left hemisphere.	UNIV HELSINKI, DEPT PHONET, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, MED ENGN CTR, BIOMAG LAB, FIN-00014 HELSINKI, FINLAND; UNIV TURKU, DEPT APPL PHYS ELECT & INFORMAT TECHNOL, SF-20500 TURKU, FINLAND; HELSINKI UNIV TECHNOL, ACOUST LAB, FIN-02150 ESPOO, FINLAND; TARTU STATE UNIV, DEPT PSYCHOL, EE-202400 TARTU, ESTONIA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; Aalto University; University of Tartu	Naatanen, R (corresponding author), UNIV HELSINKI, DEPT PSYCHOL, COGNIT BRAIN RES UNIT, FIN-00014 HELSINKI, FINLAND.		Ilmoniemi, Risto/E-9704-2012; Alku, Paavo/E-2400-2012; Lennes, Mietta/M-2197-2016; Allik, Jüri/D-5609-2009; Allik, Jüri/N-3038-2019; Alho, Kimmo/G-2997-2013	Ilmoniemi, Risto/0000-0002-3340-2618; Lennes, Mietta/0000-0003-4735-3017; Allik, Jüri/0000-0002-8358-4747; Allik, Jüri/0000-0002-8358-4747; Alho, Kimmo/0000-0001-8563-2792; Vainio, Martti/0000-0003-2570-0196; Huotilainen, Minna/0000-0002-7251-6984; Alku, Paavo/0000-0002-8173-9418				AALTONEN O, IN PRESS J ACOUST SO; Alho K, 1996, PSYCHOPHYSIOLOGY, V33, P369, DOI 10.1111/j.1469-8986.1996.tb01061.x; ALKU P, 1992, SPEECH COMMUN, V11, P109, DOI 10.1016/0167-6393(92)90005-R; ANLANKO R, 1993, NEUROREPORT, V2, P1356; Fant G., 1960, ACOUSTIC THEORY SPEE; GIARD MH, 1995, J COGNITIVE NEUROSCI, V7, P133, DOI 10.1162/jocn.1995.7.2.133; HAMALAINEN M, 1993, REV MOD PHYS, V65, P413, DOI 10.1103/RevModPhys.65.413; Hari R., 1990, ADV AUDIOL, V6, P222; IIVONEN A, 1995, PHONETICA, V52, P221, DOI 10.1159/000262174; KNUUTILA JET, 1993, IEEE T MAGN, V29, P3315, DOI 10.1109/20.281163; Kraus N, 1996, SCIENCE, V273, P971, DOI 10.1126/science.273.5277.971; KUHL PK, 1993, J PHONETICS, V21, P125; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; LIBERMAN AM, 1957, J EXP PSYCHOL, V54, P358, DOI 10.1037/h0044417; LIIV G, 1970, SOV FINNO UGRIC STUD, V6, P7; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; NAATANEN R, 1994, TRENDS NEUROSCI, V17, P389, DOI 10.1016/0166-2236(94)90048-5; NAATANEN R, 1995, EAR HEARING, V16, P6; Naatanen R, 1995, EEG CL N SU, P179; Naatanen R., 2018, ATTENTION BRAIN FUNC; TIITINEN H, 1994, NATURE, V372, P90, DOI 10.1038/372090a0; WIIK K, 1965, ANN U TURKU, V94, P1	24	897	913	12	189	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					432	434		10.1038/385432a0	http://dx.doi.org/10.1038/385432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WF007	9009189				2022-12-28	WOS:A1997WF00700051
J	Lebwohl, M				Lebwohl, M			New treatments for alopecia areata	LANCET			English	Editorial Material											Lebwohl, M (corresponding author), CUNY MT SINAI SCH MED,DEPT DERMATOL,NEW YORK,NY 10029, USA.							Schuttelaar ML, 1996, BRIT J DERMATOL, V135, P581, DOI 10.1111/j.1365-2133.1996.tb03835.x; Taylor CR, 1995, BRIT J DERMATOL, V133, P914, DOI 10.1111/j.1365-2133.1995.tb06925.x; Vandenbark A A, 1995, J Invest Dermatol, V104, p10S; Weise K, 1996, DERMATOLOGY, V192, P129, DOI 10.1159/000246337	4	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					222	223		10.1016/S0140-6736(05)64857-X	http://dx.doi.org/10.1016/S0140-6736(05)64857-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014905				2022-12-28	WOS:A1997WD90600005
J	Huang, XM; Molema, G; King, S; Watkins, L; Edgington, TS; Thorpe, PE				Huang, XM; Molema, G; King, S; Watkins, L; Edgington, TS; Thorpe, PE			Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SOLID TUMORS; EXPRESSION; SURFACE; PROCOAGULANT; RECEPTORS; ANTIGEN; CANCER; CELLS	Selective occlusion of tumor vasculature was tested as a therapy for solid tumors in a mouse model. The formation of blood clots (thrombosis) within the tumor Vessels was initiated by targeting the cell surface domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker on tumor vascular endothelial cells. This truncated form of tissue factor (tTF) had limited ability to initiate thrombosis when free in the circulation, but became an effective and selective thrombogen when targeted to tumor endothelial cells. Intravenous administration of the antibody-tTF complex to mice with large neuroblastomas resulted incomplete tumor regressions in 38 percent of the mice.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HAMON CTR THERAPEUT ONCOL RES, DALLAS, TX 75235 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute; Scripps Research Institute				Molema, Grietje/0000-0002-4147-6676	NCI NIH HHS [R01-CA59569, R01-CA54168] Funding Source: Medline; NHLBI NIH HHS [P01-HL16411] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054168, R01CA059569] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; BROWN LF, 1993, CANCER RES, V53, P4727; BRULAND OS, 1988, CANCER RES, V48, P5302; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; BURROWS FJ, 1992, CANCER RES, V52, P595; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Folkman J, 1992, Semin Cancer Biol, V3, P65; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; KING SF, UNPUB; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MURRAY JC, 1991, INT J RADIAT BIOL, V60, P273, DOI 10.1080/09553009114551991; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; PLATE KH, 1993, CANCER RES, V53, P5822; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; RUF W, 1991, J BIOL CHEM, V266, P2158; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; TRUCCO M, 1981, IMMUNOLOGICAL METHOD, V2, P1; WANG JM, 1993, INT J CANCER, V54, P363, DOI 10.1002/ijc.2910540303; ZACHARSKI LR, 1993, JNCI-J NATL CANCER I, V85, P1225, DOI 10.1093/jnci/85.15.1225	28	403	492	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					547	550		10.1126/science.275.5299.547	http://dx.doi.org/10.1126/science.275.5299.547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999802				2022-12-28	WOS:A1997WE25700049
J	Kunkel, TA; Resnick, MA; Gordenin, DA				Kunkel, TA; Resnick, MA; Gordenin, DA			Mutator specificity and disease: Looking over the FENce	CELL			English	Review							DNA-SYNTHESIS; REPEATS; REPLICATION				Kunkel, TA (corresponding author), NIEHS,MOL GENET LAB,RES TRIANGLE PK,NC 27709, USA.		Kunkel, Thomas A./D-5088-2019; resnick, Michael/F-1668-2019; Dmitry, Gordenin/C-3907-2018	Kunkel, Thomas A./0000-0002-9900-1788; resnick, Michael/0000-0002-8473-7506; Dmitry, Gordenin/0000-0002-8399-1836				Benzer S., 1957, Proceedings of the International Genetics Symposia, 1956. Tokyo & Kyoto, September 1956, pp; COOPER DN, 1994, HUMAN GENE MUTATION; JEFFREYS AJ, 1995, ELECTROPHORESIS, V16, P1577, DOI 10.1002/elps.11501601261; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LOEB LA, 1991, CANCER RES, V51, P3075; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; MOORE GP, 1984, J THEOR BIOL, V108, P111, DOI 10.1016/S0022-5193(84)80172-1; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SIA EA, 1997, MUTAT RES, V381, P61; STRATHERN JN, 1995, GENETICS, V140, P965; TISHKOFF DX, 1997, CELL, V88; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; TRAN TH, 1996, GENETICS, V143, P1579; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; TRINH TQ, 1993, GENETICS, V134, P409; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875	20	42	42	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					155	158		10.1016/S0092-8674(00)81832-2	http://dx.doi.org/10.1016/S0092-8674(00)81832-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008154	Bronze			2022-12-28	WOS:A1997WE97000001
J	Lee, FS; Hagler, J; Chen, ZJJ; Maniatis, T				Lee, FS; Hagler, J; Chen, ZJJ; Maniatis, T			Activation of the I kappa B alpha kinase complex by MEKK1, a kinase of the JNK pathway	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; C-JUN; ESCHERICHIA-COLI; VIRUS INDUCTION; MAMMALIAN-CELLS; BETA GENE; PHOSPHORYLATION; DOMAIN; PROTEOLYSIS	Both NF-kappa B and c-Jun are activated by cytokines such as TNF-alpha and by stresses such as UV irradiation. A key step in the activation of NF-kappa B is the phosphorylation of its inhibitor, I kappa B alpha, by a ubiquitination-inducible multiprotein kinase complex (I kappa B alpha kinase). A central kinase in the c-Jun activation pathway is mitogen-activated protein kinase/ERK kinase kinase-1 (MEKK1). Here, we show that MEKK1 induces the site-specific phosphorylation of I kappa B alpha in vivo and, most strikingly, can directly activate the I kappa B alpha kinase complex in vitro. Thus, MEKK1 is a critical component of both the c-Jun and NF-kappa B stress response pathways. Since the I kappa B alpha kinase complex can be independently activated by ubiquitination or MEKK1-dependent phosphorylation, it may be an integrator of multiple signal transduction pathways leading to the activation of NF-kappa B.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; PROSCRIPT INC,CAMBRIDGE,MA 02139	Harvard University				Lee, Frank/0000-0003-2511-1834	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, K08AI001241, R37AI020642] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20642, K08 AI01241] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1988, MOL REPROD DEV; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THEVENIN C, 1990, New Biologist, V2, P793; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	47	654	671	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					213	222		10.1016/S0092-8674(00)81842-5	http://dx.doi.org/10.1016/S0092-8674(00)81842-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008162	Bronze			2022-12-28	WOS:A1997WE97000010
J	Cole, TJ				Cole, TJ			3-in-1 weight-monitoring chart	LANCET			English	Article							GAIN				Cole, TJ (corresponding author), MRC,DUNN NUTR CTR,CAMBRIDGE CB4 1XJ,ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				COLE TJ, 1995, ARCH DIS CHILD, V73, P8, DOI 10.1136/adc.73.1.8; COLE TJ, 1994, STAT MED, V13, P2477, DOI 10.1002/sim.4780132311; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; WHITEHEAD R G, 1989, Journal of Human Nutrition and Dietetics, V2, P73, DOI 10.1111/j.1365-277X.1989.tb00012.x; WRIGHT CM, 1994, ACTA PAEDIATR, V83, P351, DOI 10.1111/j.1651-2227.1994.tb18118.x	5	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					102	103		10.1016/S0140-6736(05)60886-0	http://dx.doi.org/10.1016/S0140-6736(05)60886-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996428				2022-12-28	WOS:A1997WB80000019
J	ElHadi, AA				ElHadi, AA			A step forward for opponents of female genital mutilation in Egypt	LANCET			English	Editorial Material											ElHadi, AA (corresponding author), EGYPT TASK FORCE FEMALE GENITAL MUTILAT,26 ST 82,MAADI,CAIRO,EGYPT.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					129	130		10.1016/S0140-6736(05)60910-5	http://dx.doi.org/10.1016/S0140-6736(05)60910-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996437				2022-12-28	WOS:A1997WB80000047
J	Hidalgo, E; Ding, HG; Demple, B				Hidalgo, E; Ding, HG; Demple, B			Redox signal transduction: Mutations shifting [2Fe-2S] centers of the SoxR sensor-regulator to the oxidized form	CELL			English	Article							SUPEROXIDE RESPONSE REGULON; ESCHERICHIA-COLI; OXIDATIVE-STRESS; POSITIVE CONTROL; TRANSCRIPTIONAL ACTIVATION; NITRIC-OXIDE; PROTEIN; GENES; PURIFICATION; MACROPHAGES	SoxR is a [2Fe-2S] transcription factor triggered by oxidative stress and activated in vitro by one-electron oxidation or assembly of the iron-sulfur centers. To distinguish which mechanism operates in cells, we studied constitutively active SoxR (SoxR(c)) proteins. Three SoxR(c) proteins contained [2Fe-2S] centers required for in vitro transcription and, like wild-type SoxR, were inactivated by chemical reduction. However, in vivo spectroscopy showed that even without oxidative stress, the three SoxR(c) proteins failed to accumulate with reduced [2Fe-2S] (less than or equal to 4% compared to greater than or equal to 40% for wild type). One SoxR(c) protein had a redox potential 65 mV lower than wild type, consistent with its accumulation in the oxidized (activated) form in vivo. These results link in vitro and in vivo approaches showing novel redox regulation that couples an iron-sulfur oxidation state to promoter activation.			Hidalgo, E (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Ding, Huangen/AAJ-8550-2020; Hidalgo, Elena/K-2919-2014	Ding, Huangen/0000-0002-4815-7336; Hidalgo, Elena/0000-0002-3768-6785	NCI NIH HHS [CA37831] Funding Source: Medline; NIEHS NIH HHS [F32 ES05726] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Demple B., 1996, REGULATION GENE EXPR, P433; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Dutton P L, 1978, Methods Enzymol, V54, P411; Fraenkel D., 1996, ESCHERICHIA COLI SAL, P189; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GREEN J, 1993, MOL MICROBIOL, V8, P61, DOI 10.1111/j.1365-2958.1993.tb01203.x; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUSLADEN A, 1996, OXYR CELL, V86, P719; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1997, IN PRESS EMBO J; JAIR KW, 1995, J BACTERIOL, V177, P7100, DOI 10.1128/jb.177.24.7100-7104.1995; LI ZY, 1994, J BIOL CHEM, V269, P18371; Lin ECC, 1996, ESCHERICHIA COLI SAL, P1526; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; NAKAJIMA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1323, DOI 10.1271/bbb.59.1323; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; NUNOSHIBA T, 1994, NUCLEIC ACIDS RES, V22, P2958, DOI 10.1093/nar/22.15.2958; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; PRIVALLE CT, 1993, P NATL ACAD SCI USA, V90, P2310, DOI 10.1073/pnas.90.6.2310; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WELSS B, 1997, DNA DAMAGE REPAIR; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991	43	121	124	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					121	129		10.1016/S0092-8674(00)81864-4	http://dx.doi.org/10.1016/S0092-8674(00)81864-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019397	Bronze, Green Published			2022-12-28	WOS:A1997WC56900015
J	Boyington, JC; Gladyshev, VN; Khangulov, SV; Stadtman, TC; Sun, PD				Boyington, JC; Gladyshev, VN; Khangulov, SV; Stadtman, TC; Sun, PD			Crystal structure of formate dehydrogenase H: Catalysis involving Mo, molybdopterin, selenocysteine, and an Fe4S4 cluster	SCIENCE			English	Article							ESCHERICHIA-COLI; SELENIUM; OXIDOREDUCTASE; PROGRAM	Formate dehydrogenase H from Escherichia coli contains selenocysteine (SeCys), molybdenum, two molybdopterin guanine dinucleotide (MGD) cofactors, and an Fe4S4 cluster at the active site and catalyzes the two-electron oxidation of formate to carbon dioxide. The crystal structures of the oxidized [Mo(VI), Fe4S4(ox)] form of formate dehydrogenase H (with and without bound inhibitor) and the reduced [Mo(IV), Fe4S4(red)] form have been determined, revealing a four-domain alpha beta structure with the molybdenum directly coordinated to selenium and both MGD cofactors. These structures suggest a reaction mechanism that directly involves SeCys(140) and His(141) in proton abstraction and the molybdenum, molybdopterin, Lys(44), and the Fe4S4 cluster in electron transfer.	NIAID,STRUCT BIOL SECT,MOL STRUCT LAB,NIH,ROCKVILLE,MD 20852; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; PRINCETON UNIV,HOYT LAB,DEPT CHEM,PRINCETON,NJ 08544	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Princeton University			Gladyshev, Vadim N/J-6187-2013; Albers, Pieter/I-2563-2017	Gladyshev, Vadim/0000-0002-0372-7016				AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; AXLEY MJ, 1991, J BIOL CHEM, V266, P13731; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2019, DOI 10.1093/nar/20.suppl.2019; BARBER MJ, 1986, BIOCHEMISTRY-US, V25, P8150, DOI 10.1021/bi00373a004; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; *DAR LAB, 1979, CCP4 SUIT PROGR PROT; Das SK, 1996, J AM CHEM SOC, V118, P1387, DOI 10.1021/ja9511580; Dong J.-K., UNPUB; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Gladyshev VN, 1996, J BIOL CHEM, V271, P8095, DOI 10.1074/jbc.271.14.8095; HOUSE KL, 1993, BIOCHEMISTRY-US, V32, P3468, DOI 10.1021/bi00064a034; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHANGULOV SV, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PILATO RS, 1993, BIOINORGANIC CATALYS, pCH6; *RIG CORP, 1994, RAX DAT PROC SOFTW V; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SIDMAN KE, 1988, NUCLEIC ACIDS RES, V16, P1869, DOI 10.1093/nar/16.5.1869; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503	31	467	477	4	114	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1305	1308		10.1126/science.275.5304.1305	http://dx.doi.org/10.1126/science.275.5304.1305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036855	Green Submitted			2022-12-28	WOS:A1997WK64400042
J	Iglehart, JK				Iglehart, JK			Health issues, the President, and the 105th Congress	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Anders G., 1996, HLTH WEALTH HMOS BRE; AUERBACH S, 1996, WASH POST HLTH  0625, P12; BAKER P, 1996, WASHINGTON POST 1227, pA4; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; BURROS M, 1997, NY TIMES        0125, P1; BUTLER PA, 1996, PUBLIC OVERSIGHT MAN; Calmes Jackie, 1996, WALL ST J, pR2; CHANDLER C, 1996, WASHINGTON POST 1229, pA8; CHANDLER C, 1997, WASHINGTON POST 0110, pA12; COHEN R, 1996, NATL J, V28, P2681; DUNCAN PD, 1996, POLITICS AM; EDMUNDS M, 1996, MANAGING MANAGED CAR; *FAM US FDN, 1996, HMO CONS RISK STAT R; *GEN ACC OFF, 1996, GAOHEHS9616; *GEN ACC OFF, 1996, HLTH INS CHILDR PRIV; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; HEGNER RE, 1996, MEDICARE COVERAGE HO; HOLAHAN J, IN PRESS HLTH AFF MI; HYMOWITZ C, 1996, WALL STREET J   1024, pR19; Iglehart J K, 1996, N Engl J Med, V334, P203, DOI 10.1056/NEJM199601183340324; Iglehart JK, 1996, NEW ENGL J MED, V334, P1071, DOI 10.1056/NEJM199604183341621; Jensen GA, 1997, HEALTH AFFAIR, V16, P125, DOI 10.1377/hlthaff.16.1.125; Johannes L, 1996, WSJ             0520, pB1; JOHANNES L, 1996, WALL STREET J   0827, pB8; JONES SB, 1996, IMPROVING MEDICARE M; Krieger L M, 1996, Bull Am Coll Surg, V81, P18; Kuttner R, 1996, NEW ENGL J MED, V335, P362, DOI 10.1056/NEJM199608013350524; Kuttner R, 1996, NEW ENGL J MED, V335, P446, DOI 10.1056/NEJM199608083350620; LANGLEY M, 1996, WALL STREET J   1018, P1; *MED GEN ACC OFF, 1996, GAOHEHS9423; MEYR JA, 1996, 9614 AM ASS RET PERS; *PHYS PAYM REV COM, 1996, SEL EXT RES SER, V7; REISCHAUER RD, 1997, SETTING NATL PRIORIT; SCHWARTZ J, 1996, WASHINGTON POST 0822, pA1; Serafini M W, 1996, Natl J (Wash), V28, P2280; VARMUS H, 1995, NEW ENGL J MED, V333, P811, DOI 10.1056/NEJM199509213331224; Welch HG, 1996, NEW ENGL J MED, V335, P324, DOI 10.1056/NEJM199608013350506; 1996, MED EC          0415, P64; 1996, AM MED NEWS     1021, P4	39	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					671	675		10.1056/NEJM199702273360923	http://dx.doi.org/10.1056/NEJM199702273360923			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9036336				2022-12-28	WOS:A1997WK02800035
J	Redelmeier, DA; Tibshirani, RJ				Redelmeier, DA; Tibshirani, RJ			Association between cellular-telephone calls and motor vehicle collisions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEAT-BELT USE; CASE-CROSSOVER; ATTENTION	Background Because of a belief that the use of cellular telephones while driving may cause collisions, several countries have restricted their use in motor vehicles, and others are considering such regulations. We used an epidemiologic method, the case-crossover design, to study whether using a cellular telephone while driving increases the risk of a motor vehicle collision. Methods We studied 699 drivers who had cellular telephones and who were involved in motor vehicle collisions resulting in substantial property damage but no personal injury. Each person's cellular-telephone calls on the day of the collision and during the previous week were analyzed through the use of detailed billing records. Results A total of 26,798 cellular-telephone calls were made during the 14-month study period. The risk of a collision when using a cellular telephone was four times higher than the risk when a cellular telephone was not being used (relative risk, 4.3; 95 percent confidence interval, 3.0 to 6.5). The relative risk was similar for drivers who differed in personal characteristics such as age and driving experience; calls close to the time of the collision were particularly hazardous (relative risk, 4.8 for calls placed within 5 minutes of the collision, as compared with 1.3 for calls placed more than 15 minutes before the collision; P<0.001); and units that allowed the hands to be free (relative risk, 5.9) offered no safety advantage over hand-held units (relative risk, 3.9; P not significant). Thirty-nine percent of the drivers called emergency services after the collision, suggesting that having a cellular telephone may have had advantages in the aftermath of an event. Conclusions The use of cellular telephones in motor vehicles is associated with a quadrupling of the risk of a collision during the brief period of a call. Decisions about regulation of such telephones, however, need to take into account the benefits of the technology and the role of individual responsibility. (C)1997, Massachusetts Medical Society.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT STAT,TORONTO,ON,CANADA; UNIV TORONTO,PROGRAM CLIN EPIDEMIOL & HLTH CARE RES,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Redelmeier, DA (corresponding author), SUNNYBROOK HLTH SCI CTR,DIV CLIN EPIDEMIOL,G-151,2075 BAYVIEW AVE,N YORK,ON M4N 3M5,CANADA.							ALM H, 1995, ACCIDENT ANAL PREV, V27, P707, DOI 10.1016/0001-4575(95)00026-V; BAKER FB, 1971, J CHEM THERMODYN, V3, P77, DOI 10.1016/S0021-9614(71)80068-X; *BCE MOB COMM, 1996, 1995 ANN REP; *BELL MOB, 1996, STAYING TOUCH, P1; BRESLOW NE, 1980, IARC SCI PUBL, V32, P162; BROOKHUIS KA, 1991, ACCIDENT ANAL PREV, V23, P309, DOI 10.1016/0001-4575(91)90008-S; BROWN ID, 1969, J APPL PSYCHOL, V53, P419, DOI 10.1037/h0028103; *BUR CENS, 1995, STAT ABSTR US 1995, P92; *BUR CENS, 1995, STAT ABSTR US 1995, P849; *CAN TASK FORC PER, 1994, CAN GUID CLIN PREV H, P514; CANETE DW, 1985, AT T CELLULAR PHONE, P1; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; EFRON B, 1985, BIOMETRIKA, V72, P45, DOI 10.1093/biomet/72.1.45; Efron B, 1993, INTRO BOOTSTRAP, P178; *I NAC EST GEOGR I, 1994, AN EST EST UN MEX 19, P568; KAHNEMAN D, 1973, J APPL PSYCHOL, V58, P113, DOI 10.1037/h0035426; KELLY RB, 1987, J FAM PRACTICE, V24, P630; MACKNIN ML, 1987, AM J DIS CHILD, V141, P1305, DOI 10.1001/archpedi.1987.04460120067037; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MARSHALL RJ, 1993, STAT MED, V12, P2333, DOI 10.1002/sim.4780122409; MCFARLAND RA, 1957, NEW ENGL J MED, V256, P792, DOI 10.1056/NEJM195704252561706; MCKNIGHT AJ, 1993, ACCIDENT ANAL PREV, V25, P259, DOI 10.1016/0001-4575(93)90020-W; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; *PREV SERV TASK FO, 1996, GUID CLIN PREV SERV, P643; REDELMEIER DA, 1993, J GEN INTERN MED, V8, P199, DOI 10.1007/BF02599267; REISINGER KS, 1981, PEDIATRICS, V67, P201; RICE DP, 1989, COST INJURY US REPOR, P208; *ROG CANT MOB COMM, 1996, ANN REP 1995, P32; Rothman KJ, 1996, EPIDEMIOLOGY, V7, P303, DOI 10.1097/00001648-199605000-00015; *SAF RES OFF MIN T, 1996, ONT ROAD SAF ANN REP, P2; *SCI ADV GROUP CEL, 1994, ASS REAL WORLD CELL, V2, P3; SIMPSON H, 1985, ALC DRUGS DRIV ABSTR, V1, P17; SMITH HW, 1951, CAN MED ASSOC J, V65, P325; Smith V. J., 1978, Twenty-Eighth IEEE Vehicular Technology Conference, P190, DOI 10.1109/VTC.1978.1622532; *STAT CAN, 1993, CAN YB 1994, P149; STEIN AC, 1987, P 31 ANN C AM ASS AU, P181; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; Violanti JM, 1996, ACCIDENT ANAL PREV, V28, P265, DOI 10.1016/0001-4575(95)00070-4	38	682	696	1	55	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					453	458		10.1056/NEJM199702133360701	http://dx.doi.org/10.1056/NEJM199702133360701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WG776	9017937	Bronze			2022-12-28	WOS:A1997WG77600001
J	Silvestry, FE; Kim, B; Pollack, BJ; Haimowitz, JE; Murray, RK; Furth, EE; Nisenbaum, HL; Kochman, ML; Freedman, N; Pine, R; Herrmann, HC				Silvestry, FE; Kim, B; Pollack, BJ; Haimowitz, JE; Murray, RK; Furth, EE; Nisenbaum, HL; Kochman, ML; Freedman, N; Pine, R; Herrmann, HC			Cardiac Whipple disease: Identification of whipple Bacillus by electron microscopy in the myocardium of a patient before death	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV PENN, MED CTR, DIV CARDIOVASC, PHILADELPHIA, PA 19104 USA; MED CTR, PRINCETON, NJ 08540 USA	University of Pennsylvania								DETAKATS PG, 1995, POSTGRAD MED J, V71, P236, DOI 10.1136/pgmj.71.834.236; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; JAMES TN, 1983, AM HEART J, V105, P481, DOI 10.1016/0002-8703(83)90367-8; LIE JT, 1976, AM J CLIN PATHOL, V66, P22, DOI 10.1093/ajcp/66.1.22; MAIZEL H, 1970, MEDICINE, V49, P175, DOI 10.1097/00005792-197005000-00001; MCALLISTER HA, 1975, CIRCULATION, V52, P152, DOI 10.1161/01.CIR.52.1.152; PELECH T, 1991, LANCET, V337, P553, DOI 10.1016/0140-6736(91)91339-V; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; SOSSAI P, 1989, INT J CARDIOL, V23, P275, DOI 10.1016/0167-5273(89)90263-5; UPTON AC, 1952, AM J CLIN PATHOL, V22, P755; WENDLER D, 1995, EUR HEART J, V16, P424, DOI 10.1093/oxfordjournals.eurheartj.a060928; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382	12	10	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					214	216		10.7326/0003-4819-126-3-199702010-00006	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027272				2022-12-28	WOS:A1997WF16800006
J	Suissa, S; Dennis, R; Ernst, P; Sheehy, O; WoodDauphinee, S				Suissa, S; Dennis, R; Ernst, P; Sheehy, O; WoodDauphinee, S			Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						zafirlukast; asthma; receptors, leukotriene; adrenergic beta-agonists; outcome assessment (health care)	ECONOMIC-EVALUATION; THERAPY	Background: The increasing costs of managing asthma are due in part to the introduction of new medications, such as leukotriene receptor antagonists. These antagonists interfere with the action of leukotrienes, which are implicated in bronchoconstriction and the formation of airway edema in patients with asthma. Leukotriene receptor antagonists must be shown to be clinically and economically effective for their clinical use to be justified. Objective: To assess the clinical and economic effectiveness of zafirlukast, a leukotriene receptor antagonist, in patients with mild-to-moderate asthma who might benefit from regular anti-inflammatory therapy. Design: Randomized, double-blind, multicenter, placebo-controlled trial. Setting: 28 outpatient clinics. Patients: 146 patients with mild-to-moderate asthma who were 12 years of age or older, had not smoked cigarettes in the previous 6 months, had a smoking history of less than 10 pack-years, had an FEV(1) at least 55% of the predicted value with no upper limit, had demonstrated bronchial hyperresponsiveness, and were symptomatic during the 7-day run-in period. All patients were seen every 2 to 3 weeks for 13 weeks. Intervention: 103 patients received zafirlukast (20 mg twice daily), and 43 patients received placebo (twice daily). All patients received inhaled beta-agonists as needed. Measurements: Data were obtained from medical examinations, patient questionnaires, and daily diaries. The clinical effectiveness outcomes were days per month without asthma symptoms, limitation of activity, use of beta-agonists, sleep disturbance, and episodes of asthma (the latter was a composite measure made up of the first four outcomes plus the occurrence of adverse events). The economic effectiveness outcomes were frequency and type of unscheduled health care contacts, use of beta-agonist inhalers, consumption of nonasthma medications, and days of absence from work or school. Results: The zafirlukast group had 89% more days without symptoms (adjusted rates, 7.0 compared with 3.7 days per month; P = 0.03), 89% more days without use of beta-agonists (adjusted rates, 11.3 compared with 6.0 days per month; P = 0.001), and 98% more days without episodes of asthma (adjusted rates, 10.1 compared with 5.1 days per month; P = 0.003). They also had 55% (95% CI, 19% to 74%) fewer health care contacts (18.5 compared with 40.7 per 100 per month; P = 0.007) and 55% (CI, 3% to 79%) fewer days of absence from work or school (15.6 compared with 35.0 per 100 per month; P = 0.04). They used 17% fewer canisters of inhaled beta-agonists (P = 0.17) and 19% less nonasthma medication (P > 0.2). Conclusions: A dairy regimen of zafirlukast added to as-needed inhaled beta-agonists is more effective than beta-agonists alone in treating mild-to-moderate asthma. The clinical and economic effectiveness of zafirlukast, a potential alternative to inhaled corticosteroids, provides further impetus to use regular ''preventive'' therapy in patients with mild-to-moderate asthma.	MONTREAL GEN HOSP, MONTREAL, PQ H3G 1A4, CANADA; MCGILL UNIV, RESP EPIDEMIOL UNIT, MONTREAL, PQ H3A 1A3, CANADA; UNIV JAVERIANA, SANTA FE DE BOGOTA, COLOMBIA	McGill University; McGill University; Pontificia Universidad Javeriana	Suissa, S (corresponding author), ROYAL VICTORIA HOSP, DIV CLIN EPIDEMIOL, 687 PINE AVE W, ROSS 429, MONTREAL, PQ H3A 1A1, CANADA.			Dennis, Rodolfo J/0000-0003-3215-9721				Armitage P., 1987, STAT METHODS MED RES; CHUNG KF, 1995, EUR RESPIR J, V8, P1203, DOI 10.1183/09031936.95.08071203; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; Henry D, 1992, Pharmacoeconomics, V1, P54, DOI 10.2165/00019053-199201010-00010; *ICI PHARM, 1992, MULT DOUBL BLIND PLA; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; National Institutes of Health, 1992, NIH PUBL; RUTTENVANMOLKEN MPMH, 1992, SOC SCI MED, V35, P161; RUTTENVANMOLKEN MPMH, 1993, PHARMACOECONOMICS, V4, P257, DOI 10.2165/00019053-199304040-00004; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; SCULPHER MJ, 1993, PHARMACOECONOMICS, V4, P345, DOI 10.2165/00019053-199304050-00005; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; *US DEP HHS, 1991, GUID DIAGN MAN ASTHM; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	17	156	163	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					177	+		10.7326/0003-4819-126-3-199702010-00001	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027267				2022-12-28	WOS:A1997WF16800001
J	Tan, GH; Gharib, H				Tan, GH; Gharib, H			Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	5th Annual Convention of the American-Association-of-Clinical-Endocrinologists / American-College-of-Endocrinology	MAY 01-05, 1996	SEATTLE, WA	Amer Assoc Clin Endocrinologists, Amer Coll Endocrinol			FOLLOW-UP; GLAND; AUTOPSY; ULTRASONOGRAPHY; ULTRASOUND; CARCINOMA; DISEASE; IRRADIATION; PREVALENCE; HYPERPARATHYROIDISM	Background: The introduction of highly sensitive imaging techniques has made it possible to detect many nonpalpable nodules, or ''incidentalomas,'' in the thyroid. Discovery of these lesions raises concerns about their malignancy, but the optimal strategy for managing these lesions has not been clearly established. Purpose: To review evidence about incidentalomas, including prevalence and risk for malignancy, and to provide recommendations for their evaluation and treatment. Data Sources: Literature searches for relevant articles published in the past 15 years in major English-language medical journals, review of selected articles published before this period, and reviews of bibliographies in textbooks. Study Selection: Three studies on autopsy findings, 11 studies on ultrasonographic findings, and other reports on nonpalpable thyroid nodules were included. Data Extraction: Data on the prevalence of nodules on autopsy and in ultrasonographic series, palpation compared with ultrasonography, the risk for malignancy in nodules found in irradiated glands, the natural history of thyroid nodules, and the prevalence of occult cancer were collated and reviewed. Data Synthesis: Prevalence of thyroid incidentalomas estimated from autopsy studies ranges from 30% to 60%. Studies comparing clinical palpation with thyroid imaging show a prevalence of 13% to 50%. Prospective studies of randomly selected patients have reported a prevalence of 19% to 67%. The risk for malignancy in asymptomatic nodules found in nonirradiated glands is 0.45% to 13% (mean +/- SD, 3.9% +/- 4.1%). Conclusions: High-resolution ultrasonography is sensitive and capable of detecting many small, nonpalpable thyroid nodules. Most of these lesions are benign. For most patients with nonpalpable nodules that are incidentally detected by thyroid imaging, simple follow-up neck palpation is sufficient.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic								ARNOLD J, 1975, RADIOLOGY, V115, P653, DOI 10.1148/15.3.653; BONDESON L, 1981, CANCER-AM CANCER SOC, V47, P319, DOI 10.1002/1097-0142(19810115)47:2<319::AID-CNCR2820470218>3.0.CO;2-A; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BRANDER A, 1991, RADIOLOGY, V181, P683, DOI 10.1148/radiology.181.3.1947082; CARROLL BA, 1982, AM J ROENTGENOL, V138, P499, DOI 10.2214/ajr.138.3.499; CHRISTENSEN SB, 1985, ANN CHIR GYNAECOL FE, V74, P151; COOK DM, 1994, ADV ENDOCRINOL METAB, V5, P137; DANIELS GH, 1991, THYROID FUNDAMENTAL, P572; DEACONSON TF, 1986, SURGERY, V100, P1116; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; FUKUNAGA FH, 1975, CANCER-AM CANCER SOC, V36, P1095, DOI 10.1002/1097-0142(197509)36:3<1095::AID-CNCR2820360338>3.0.CO;2-9; FUKUNAGA FH, 1971, ARCH PATHOL, V92, P6; FURMANCHUK AW, 1993, HISTOPATHOLOGY, V23, P319, DOI 10.1111/j.1365-2559.1993.tb01214.x; GIUFFRIDA D, 1995, AM J MED, V99, P642, DOI 10.1016/S0002-9343(99)80252-6; GORMAN B, 1987, RADIOLOGY, V162, P147, DOI 10.1148/radiology.162.1.3538147; GREENSPAN FS, 1991, BASIC CLIN ENDOCRINO, P213; HANSON GA, 1983, SURGERY, V94, P984; HERMANSON L, 1952, J CLIN ENDOCR METAB, V12, P112, DOI 10.1210/jcem-12-1-112; HORLOCKER TT, 1986, FRONTIERS THYROIDOLO, V2, P1309; JARLOV AE, 1991, J INTERN MED, V229, P159, DOI 10.1111/j.1365-2796.1991.tb00324.x; KATZ JF, 1984, RADIOLOGY, V151, P741, DOI 10.1148/radiology.151.3.6718735; KOMOROWSKI RA, 1988, HUM PATHOL, V19, P689, DOI 10.1016/S0046-8177(88)80175-8; KUMA K, 1994, WORLD J SURG, V18, P495, DOI 10.1007/BF00353745; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MAZZAFERRI EL, 1988, MED CLIN N AM, V72, P1177, DOI 10.1016/S0025-7125(16)30736-2; MOLITCH ME, 1990, ANN INTERN MED, V112, P925, DOI 10.7326/0003-4819-112-12-925; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; NISHIYAMA RH, 1977, RAD ASS THYROID CARC, P123; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; SAMPSON RJ, 1974, CANCER-AM CANCER SOC, V34, P2072, DOI 10.1002/1097-0142(197412)34:6<2072::AID-CNCR2820340629>3.0.CO;2-#; SAMPSON RJ, 1969, J AMER MED ASSOC, V209, P65; SCHEIBLE W, 1979, RADIOLOGY, V133, P413, DOI 10.1148/133.2.413; SIMINOSKI K, 1995, JAMA-J AM MED ASSOC, V273, P813, DOI 10.1001/jama.273.10.813; SOBRINHOSIMOES MA, 1979, CANCER-AM CANCER SOC, V43, P1702, DOI 10.1002/1097-0142(197905)43:5<1702::AID-CNCR2820430521>3.0.CO;2-S; SOLBIATI L, 1985, RADIOLOGY, V155, P187, DOI 10.1148/radiology.155.1.3883413; SOLBIATI L, 1990, RADIOLOGY S, V177, P140; STARK DD, 1984, SURGERY, V96, P1083; STARK DD, 1983, SURGERY, V94, P863; STOCKWELL RM, 1984, J CLIN ENDOCR METAB, V58, P804, DOI 10.1210/jcem-58-5-804; TAN GH, 1995, ARCH INTERN MED, V155, P2418, DOI 10.1001/archinte.155.22.2418; TOMIMORI E, 1995, THYROID, V5, P273, DOI 10.1089/thy.1995.5.273; VEITH FJ, 1964, NEW ENGL J MED, V270, P431, DOI 10.1056/NEJM196402272700901; WAGNER DH, 1978, SURG GYNECOL OBSTET, V147, P903; WALKER J, 1985, BRIT J RADIOL, V58, P617, DOI 10.1259/0007-1285-58-691-617; WOESTYN J, 1985, BRIT J RADIOL, V58, P1179, DOI 10.1259/0007-1285-58-696-1179	45	664	715	3	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					226	231		10.7326/0003-4819-126-3-199702010-00009	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WF168	9027275				2022-12-28	WOS:A1997WF16800009
J	Cohen, RE; Mazin, II; Isaak, DG				Cohen, RE; Mazin, II; Isaak, DG			Magnetic collapse in transition metal oxides at high pressure: Implications for the Earth	SCIENCE			English	Article							GENERALIZED-GRADIENT-APPROXIMATION; GROUND-STATE PROPERTIES; LOWER MANTLE; INDUCED METALLIZATION; SIDEROPHILE ELEMENTS; ELECTRONIC-STRUCTURE; BAND THEORY; CORE; PHASE; PEROVSKITE	Magnetic collapse in transition metal ions is predicted from first-principles computations at pressures reached in the Earth's lower mantle and core. Magnetic collapse would lead to marked changes in geophysically important properties, such as elasticity and conductivity, and also to different geochemical behavior, such as element partitioning, than estimated by extrapolating low-pressure data, and thus change the understanding of Earth's structure and evolution, Magnetic collapse results from band widening rather than from changes in crystal field splitting under pressure. Seismic anomalies in the outer core and the lowermost mantle may be due to magnetic collapse of ferrous iron, dissolved in iron liquid in the outer core, and in solution in magnesiowustite in the lowermost mantle.	CARNEGIE INST WASHINGTON,CTR HIGH PRESSURE RES,WASHINGTON,DC 20015; UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095; AZUSA PACIFIC UNIV,DEPT MATH & PHYS,AZUSA,CA 91702	Carnegie Institution for Science; University of California System; University of California Los Angeles	Cohen, RE (corresponding author), CARNEGIE INST WASHINGTON,GEOPHYS LAB,5251 BROAD BRANCH RD NW,WASHINGTON,DC 20015, USA.		Mazin, Igor/L-4294-2019; Cohen, Ronald/B-3784-2010; Cohen, Ronald/AAY-2570-2020; Mazin, Igor I/B-6576-2008; Isaak, Donald/D-4921-2018	Mazin, Igor/0000-0001-9456-7099; Cohen, Ronald/0000-0001-5871-2359; Isaak, Donald/0000-0001-9563-7693				ANDERSEN OK, 1977, PHYSICA B & C, V86, P249, DOI 10.1016/0378-4363(77)90303-5; ANISIMOV VI, 1991, PHYS REV B, V44, P943, DOI 10.1103/PhysRevB.44.943; ARYASETIAWAN F, 1995, PHYS REV LETT, V74, P3221, DOI 10.1103/PhysRevLett.74.3221; BARGERON CB, 1971, INORG CHEM, V10, P1338, DOI 10.1021/ic50101a003; Drickamer H. G., 1973, ELECT TRANSITIONS HI, P126, DOI [10.1007/978-94-011-6896-0_8, DOI 10.1007/978-94-011-6896-0_8]; DUFEK P, 1994, PHYS REV B, V49, P10170, DOI 10.1103/PhysRevB.49.10170; DUFEK P, 1995, PHYS REV B, V51, P4122, DOI 10.1103/PhysRevB.51.4122; FEI YW, 1994, SCIENCE, V266, P1678, DOI 10.1126/science.266.5191.1678; GUNNARSSON O, 1996, PHYS REV B, V54; Holzheid A, 1996, GEOCHIM COSMOCHIM AC, V60, P1181, DOI 10.1016/0016-7037(96)00023-3; Huang E., 1994, J GEOPHYS SOC CHINA, V37, P7; ISAAK DG, 1993, PHYS REV B, V47, P7720, DOI 10.1103/PhysRevB.47.7720; JACKSON WE, 1987, GEOPHYS RES LETT, V14, P224, DOI 10.1029/GL014i003p00224; JEANLOZ R, 1987, J GEOPHYS RES-SOLID, V92, P11433, DOI 10.1029/JB092iB11p11433; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; KRASKO GL, 1987, PHYS REV B, V36, P8565, DOI 10.1103/PhysRevB.36.8565; LAY T, 1990, GEOPHYS RES LETT, V17, P2001, DOI 10.1029/GL017i011p02001; LI XY, 1994, GEOPHYS RES LETT, V21, P2183, DOI 10.1029/94GL01934; LOPER DE, 1995, J GEOPHYS RES-SOL EA, V100, P6397, DOI 10.1029/94JB02048; MURTHY VR, 1991, SCIENCE, V253, P303, DOI 10.1126/science.253.5017.303; NEWSOM HE, 1991, SCIENCE, V252, P926, DOI 10.1126/science.252.5008.926; OHNISHI S, 1979, PHYS EARTH PLANT INT, V17, P130; PASTERNAK MP, 1990, PHYS REV LETT, V65, P790, DOI 10.1103/PhysRevLett.65.790; PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244; SARMA DD, 1995, PHYS REV LETT, V75, P1126, DOI 10.1103/PhysRevLett.75.1126; SHERMAN DM, 1995, GEOPHYS RES LETT, V22, P1001, DOI 10.1029/94GL03010; STIXRUDE L, 1994, PHYS REV B, V50, P6442, DOI 10.1103/PhysRevB.50.6442; Stoner EC, 1939, PROC R SOC LON SER-A, V169, P339, DOI 10.1098/rspa.1939.0003; UCHIDA N, 1972, J ACOUST SOC AM, V51, P1602, DOI 10.1121/1.1913005; WALKER D, 1993, SCIENCE, V262, P1858, DOI 10.1126/science.262.5141.1858	30	271	279	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					654	657		10.1126/science.275.5300.654	http://dx.doi.org/10.1126/science.275.5300.654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005849				2022-12-28	WOS:A1997WF07700036
J	Shepherd, G; Beadsmoore, A; Moore, C; Hardy, P; Muijen, M				Shepherd, G; Beadsmoore, A; Moore, C; Hardy, P; Muijen, M			Relation between bed use, social deprivation, and overall bed availability in acute adult psychiatric units, and alternative residential options: A cross sectional survey, one day census data, and staff interviews	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To examine the relation between bed use, social deprivation, and overall bed availability in acute adult psychiatric units and to explore the range of alternative residential options. Design: Cross sectional survey, combined with one day census data; ratings by and interviews with staff; examination of routine data sources. Settings: Nationally representative sample of acute psychiatric units. Subjects: 2236 patients who were inpatients on census day. Main outcome measures: Bed occupancy levels, judged need for continuing inpatient care, reasons preventing discharge, scores on the Health of the Nation outcome scales. Results: Bed occupancy was related to social deprivation and total availability of acute beds (r=0.66, 95% confidence interval 0.19 to 0.88, F=8.72, df=2, 23; P = 0.002). However, 27% (603/2215) of current inpatients (61% (90/148) of those with stays of >6 months) were judged not to need continuing admission. The major reasons preventing discharge were lack of suitable accommodation (31% (176/482) of patients in hospital <6 months v 36% (31/86) of those in hospital >6 months); inadequate domiciliary based community support (23% (113) v 9% (8)); and lack of long term rehabilitation places (21% (100) v 47% (40)). Scores on the Health of the Nation outcome scale were generally consistent with these staff judgments. Conclusions: The shortage of beds in acute psychiatric units is related to both social deprivation and the overall availability of acute beds. Patients currently inappropriately placed on acute admission wards should be relocated into more suitable accommodation, either in hospital or in the community. A range of provisions is required; simply providing more acute beds is not the answer.			Shepherd, G (corresponding author), SAINSBURY CTR MENTAL HLTH,RES SECT,LONDON SE1 1LB,ENGLAND.							Audit Commission, 1994, FIND PLAC REV MENT H; BURNS BJ, 1995, PSYCHIAT SERV, V46, P669; *CLIN STAND ADV GR, 1995, REP STAND CAR PEOPL; CURTIS R, 1995, MEASUREMENT MENTAL H; *DEP HLTH, 1994, HLTH NAT KEY AR HDB; FORD R, 1996, J MENT HLTH, V5, P361; FULOP N, 1992, J MENTAL HLTH, V1, P335; HOLLANDER D, 1994, PSYCHIAT B, V18, P532; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; LEFF J, 1993, BRIT J PSYCHIAT S19, V162, P1; Lelliot P., 1995, PSYCHIAT B, V19, P273; LELLIOTT P, 1994, BRIT J PSYCHIAT, V165, P160, DOI 10.1192/bjp.165.2.160; *MILMIS PROJ GROUP, 1995, PSYCHIAT B, V19, P276; Muijen M, 1993, DIMENSIONS COMMUNITY; *NAT SCHIZ FELL, 1994, WHATS GONE WRONG; *NHS EX, 1996, 24 HOUR NURS CAR PEO; Shepherd G, 1996, BRIT J PSYCHIAT, V168, P448, DOI 10.1192/bjp.168.4.448; WATSON JP, 1994, PSYCHIAT B, V18, P531	18	55	56	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					262	266		10.1136/bmj.314.7076.262	http://dx.doi.org/10.1136/bmj.314.7076.262			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE633	9022489	Green Published			2022-12-28	WOS:A1997WE63300024
J	Gu, Y; Kuida, K; Tsutsui, H; Ku, G; Hsiao, K; Fleming, MA; Hayashi, N; Higashino, K; Okamura, H; Nakanishi, K; Kurimoto, M; Tanimoto, T; Flavell, RA; Sato, V; Harding, MW; Livingston, DJ; Su, MSS				Gu, Y; Kuida, K; Tsutsui, H; Ku, G; Hsiao, K; Fleming, MA; Hayashi, N; Higashino, K; Okamura, H; Nakanishi, K; Kurimoto, M; Tanimoto, T; Flavell, RA; Sato, V; Harding, MW; Livingston, DJ; Su, MSS			Activation of interferon-gamma inducing factor mediated by interleukin-1 beta converting enzyme	SCIENCE			English	Article							ENDOTOXIC-SHOCK; POLY(ADP-RIBOSE) POLYMERASE; IMMUNE-RESPONSE; MICE DEFICIENT; GRANZYME-B; PROTEASE; APOPTOSIS; INDUCTION; CYTOKINE; CELLS	The interleukin-1 beta (IL-1 beta) converting enzyme (ICE) processes the inactive IL-IP precursor to the proinflammatory cytokine. ICE was also shown to cleave the precursor of interferon-gamma inducing factor (IGIF) at the authentic processing site with high efficiency, thereby activating IGIF and facilitating its export. Lipopolysaccharide-activated ICE-deficient (ICE(-/-)) Kupffer cells synthesized the IGIF precursor but failed to process it into the active form. Interferon-gamma and IGIF were diminished in the sera of ICE(-/-) mice exposed to Propionibacterium acnes and lipopolysaccharide. The lack of multiple proinflammatory cytokines in ICE(-/-) mice may account for their protection from septic shock.	TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN; HYOGO MED UNIV,NISHINOMIYA,HYOGO,JAPAN; HAYASHIBARA CO INC,HAYASHIBARA BIOCHEM LABS,OKAYAMA,JAPAN; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Tokyo Metropolitan Institute of Medical Science; Hyogo College of Medicine; University of Hyogo; Hayashibara Biochemical Laboratories, Inc.; Howard Hughes Medical Institute; Yale University	Gu, Y (corresponding author), VERTEX PHARMACEUT INC,130 WAVERLY ST,CAMBRIDGE,MA 02139, USA.			Tsutsui, Hiroko/0000-0001-7928-4875				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KU G, UNPUB; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARGOLIS N, UNPUB; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OKAMURA H, 1995, INFECT IMMUN, V63, P3966, DOI 10.1128/IAI.63.10.3966-3972.1995; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; QUILL H, 1987, J IMMUNOL, V138, P3704; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Tsuji  N., UNPUB; TSUTSUI H, 1992, HEPATO-GASTROENTEROL, V39, P553; Ushio S, 1996, J IMMUNOL, V156, P4274; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X	33	986	1072	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 10	1997	275	5297					206	209		10.1126/science.275.5297.206	http://dx.doi.org/10.1126/science.275.5297.206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8999548				2022-12-28	WOS:A1997WC02200036
J	Dixon, J; Harrison, A; New, B				Dixon, J; Harrison, A; New, B			Funding the NHS: Is the NHS underfunded?	BRITISH MEDICAL JOURNAL			English	Article							NATIONAL-HEALTH-SERVICE; ALTERNATIVES	Since 1948 there has been constant debate over whether the NHS is underfunded. The debate heats up when crises in the NHS hit the headlines as occurred last year. Various groups, of all shades of the political spectrum, have argued that the NHS is unsustainable with current funding increase because of demands from demographic change, new technology; and increasing expectations. The government is almost a lung voice in arguing that the NHS is sustainable but may not be doing enough to ensure that it remains so in future. This article examines seven broad approaches used to support the case that the NHS is underfunded and concludes that all have flaws. There is no satisfactory answer to the question of whether the NHS is underfunded because the answer requires value judgements that will inevitably give rise to disagreements.			Dixon, J (corresponding author), KINGS FUND,INST POLICY,LONDON W1M 0AN,ENGLAND.							Appleby J, 1992, FINANCING HLTH CARE; APPLEBY J, 1996, MEASURE EFFECTIVENES; BAILEY SJ, 1994, J SOC POLICY, V23, P489, DOI 10.1017/S0047279400023321; Blendon RJ, 1995, HEALTH AFFAIR, V14, P220, DOI 10.1377/hlthaff.14.4.220; BOSANQUET N, 1995, HLTH CARE UK 1994 95; BRINDLE D, 1996, GUARDIAN        0507, P1; *CLIN STAND ADV GR, 1993, COR ART BYP GRAFT CO; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; GLENNERSTER H, 1996, EUROHEALTH, V2, P21; HALL C, 1996, DAILY TELEGRAPH 0625, P9; Ham C, 1988, HLTH CARE VARIATIONS; HARRISON A, 1986, HLTH CARE UK 1986; *HEALTHC 2000, 1995, UK HLTH HEALTHC SERV; Hills J., 1993, FUTURE WELFARE GUIDE; *HLTH POL EC RES U, 1996, 5 BMA HLTH POL EC RE; HOFFMEYER UK, 1994, FINANCING HLTH CARE; HOWELL JBL, 1992, BRIT MED J, V304, P297, DOI 10.1136/bmj.304.6822.297; HUNTER D, 1995, HLTH SERVICE J  1012, P19; *I HLTH SERV MAN R, 1993, LOOK GLASS OP NHS FU; JONES A, 1995, HYPOTHECATED HLTH TA; JUDGE K, 1996, HLTH CAR UK 1995 6, P103; *KINGS FUND I, 1988, 4 KINGS FUND I; MAYNARD A, 1995, HLTH SERVICE J  1005, P2; McGuire A, 1993, Health Econ, V2, P113, DOI 10.1002/hec.4730020205; MCGUIRE A, 1996, 48 CIT U DEP EC APPL; MIHILL C, 1996, GUARDIAN        0517, P1; *NAT ASS HLTH AUTH, 1990, HEALTHC EC REV 1990; *NAT ASS HLTH AUTH, 1996, 21 NAHAT; New B, 1996, BRIT MED J, V312, P1593, DOI 10.1136/bmj.312.7046.1593; *NHS EX, 1995, 1996 7 PURCH EFF IND; OHIGGINS M, 1987, HLTH SPENDING WAY SU; Pope C J, 1991, Health Serv Manage Res, V4, P112; PRITCHARD C, 1992, SOC POLICY ADMIN, V26, P40, DOI 10.1111/j.1467-9515.1992.tb00527.x; ROBINSON R, 1987, PUBLIC EXPENDITURE N; Royal College of Physicians of London, 1995, SETT PRIOR NHS FRAM; SACKETT DL, 1995, HEALTH ECON, V4, P249, DOI 10.1002/hec.4730040401; Smith R, 1996, BRIT MED J, V312, P1553, DOI 10.1136/bmj.312.7046.1553	37	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					58	61		10.1136/bmj.314.7073.58	http://dx.doi.org/10.1136/bmj.314.7073.58			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB684	9001484	Green Published			2022-12-28	WOS:A1997WB68400033
J	Law, RC; Fouque, CA; Waddell, A; Cusick, E				Law, RC; Fouque, CA; Waddell, A; Cusick, E			Lesson of the week - Penetrating intra-oral trauma in children	BRITISH MEDICAL JOURNAL			English	Review							OROPHARYNX; INJURIES; PALATE		BRISTOL CHILDRENS HOSP,DEPT PAEDIAT SURG,BRISTOL BS2 8EG,AVON,ENGLAND; ST MICHAELS HOSP,DEPT PAEDIAT,BRISTOL BS2 8EG,AVON,ENGLAND; ST MICHAELS HOSP,DEPT EAR NOSE & THROAT,BRISTOL BS2 8EG,AVON,ENGLAND; BRISTOL CHILDRENS HOSP,DEPT ANAESTHESIA,BRISTOL BS2 8EG,AVON,ENGLAND	Bristol Royal Hospital For Children; Bristol Royal Hospital For Children								BICKERSTAFF ER, 1964, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5401.82; DOLGIN SR, 1992, ANN OTO RHINOL LARYN, V101, P209, DOI 10.1177/000348949210100303; HELLMANN JR, 1993, INT J PEDIATR OTORHI, V26, P157, DOI 10.1016/0165-5876(93)90021-T; HIGGINS GL, 1991, J FAM PRACTICE, V32, P316; HOLLINSHEAD WH, 1968, ANATOMY SURG; KOSAKI H, 1992, J LARYNGOL OTOL, V106, P813, DOI 10.1017/S002221510012095X; RADKOWSKI D, 1993, LARYNGOSCOPE, V103, P991; SINGER J I, 1989, Pediatric Emergency Care, V5, P250, DOI 10.1097/00006565-198912000-00015	8	26	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					50	51		10.1136/bmj.314.7073.50	http://dx.doi.org/10.1136/bmj.314.7073.50			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001483	Green Published			2022-12-28	WOS:A1997WB68400031
J	Jordan, J; Dietz, R				Jordan, J; Dietz, R			Traumatic ventricular aneurysm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Jordan, J (corresponding author), FRANZ VOLHARD CLIN,D-13122 BERLIN,GERMANY.								0	4	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					625	625		10.1056/NEJM199702273360905	http://dx.doi.org/10.1056/NEJM199702273360905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032048				2022-12-28	WOS:A1997WK02800005
J	Nyce, JW; Metzger, WJ				Nyce, JW; Metzger, WJ			DNA antisense therapy for asthma in an animal model	NATURE			English	Article							ADENOSINE-INDUCED BRONCHOCONSTRICTION; ALLERGIC RABBIT MODEL; RECEPTOR; THEOPHYLLINE; ANTAGONISM; CONTRACTION; SURFACTANT; AIRWAYS; HOE-140; TISSUE	Asthma is an inflammatory disease characterized by bronchial hyper-responsiveness that can proceed to life-threatening airway obstruction. It is one of the most common diseases in industrialized countries, and in the United States accounts for about 1% of all healthcare costs(1). Asthma prevalence and mortality have increased dramatically over the past decade(2), and occupational asthma is predicted to be the pre-eminent occupational lung disease in the next decade(3). Increasing evidence suggests that adenosine, an endogenous purine that is involved in normal physiological processes, may be an important mediator of bronchial asthma(4-15). In contrast to normal individuals, asthmatic individuals respond to adenosine challenge with marked airway obstruction(6,7), and concentrations of adenosine are elevated in the bronchoalveolar lavage fluid of asthma patients(9). We performed a randomized crossover study using the dust mite-conditioned allergic rabbit model of human asthma. Administration of an aerosolized phosphorothioate antisense oligodeoxynucleotide targeting the adenosine A(1) receptor desensitized the animals to subsequent challenge with either adenosine or dust-mite allergen.	EPIGENESIS PHARMACEUT, DEPT MOL PHARMACOL & THERAPEUT, GREENVILLE, NC 27834 USA; E CAROLINA UNIV, SCH MED, DEPT PHARMACOL, GREENVILLE, NC 27858 USA; E CAROLINA UNIV, SCH MED, DEPT MED, SECT ALLERGY ASTHMA & IMMUNOL, GREENVILLE, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University								ALI S, 1992, AGENTS ACTIONS, V37, P165, DOI 10.1007/BF02028098; ALI S, 1994, AM J PHYSIOL, V266, pL271, DOI 10.1152/ajplung.1994.266.3.L271; ALI S, 1994, J PHARMACOL EXP THER, V268, P1328; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CHURCH MK, 1986, TRENDS PHARMACOL SCI, V7, P49, DOI 10.1016/0165-6147(86)90248-8; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; FELETOU M, 1995, EUR J PHARMACOL, V274, P57, DOI 10.1016/0014-2999(94)00709-G; HOLGATE ST, 1991, ANN NY ACAD SCI, V629, P227; HULSMANN AR, 1994, AM J RESP CRIT CARE, V150, P1012, DOI 10.1164/ajrccm.150.4.7921430; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; MANN JS, 1985, BRIT J CLIN PHARMACO, V19, P685, DOI 10.1111/j.1365-2125.1985.tb02696.x; METZGER WJ, 1990, LATE PHASE ALLERGIC, P347; Pauwels R, 1991, Clin Exp Allergy, V21 Suppl 1, P48, DOI 10.1111/j.1365-2222.1991.tb01706.x; PAUWELS RA, 1995, ARCH INT PHARMACOD T, V329, P151; PISON U, 1994, EUR J CLIN INVEST, V24, P586, DOI 10.1111/j.1365-2362.1994.tb01110.x; ROSS GF, 1995, HUM GENE THER, V6, P31, DOI 10.1089/hum.1995.6.1-31; SAIJO Y, 1994, ONCOL RES, V6, P243; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; TRIFILIEFF A, 1992, J PHARMACOL EXP THER, V263, P1377; TSUKAGOSHI H, 1995, J PHARMACOL EXP THER, V273, P1257; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1992, MMWR-MORBID MORTAL W, V41, P733	28	215	275	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 20	1997	385	6618					721	725		10.1038/385721a0	http://dx.doi.org/10.1038/385721a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034188				2022-12-28	WOS:A1997WJ42300046
J	Pryor, JL; KentFirst, M; Muallem, A; VanBergen, AH; Nolten, WE; Meisner, L; Roberts, KP				Pryor, JL; KentFirst, M; Muallem, A; VanBergen, AH; Nolten, WE; Meisner, L; Roberts, KP			Microdeletions in the Y chromosome of infertile men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN SPERMATOGENESIS; DELETION MAP; LONG ARM; GENE; AZF; AZOOSPERMIA; YQ11	Background Some infertile men with azoospermia or severe oligospermia have small deletions in regions of the Y chromosome. However, the frequency of such microdeletions among men with infertility in general is unknown. We sought to determine the prevalence of Y-chromosome microdeletions among infertile men and to correlate the clinical presentation of the men with specific deletions. Methods We studied 200 consecutive infertile men. Each man was evaluated comprehensively for known causes of infertility, and Y-chromosome microdeletions were studied with use of the polymerase chain reaction to amplify specific regions of the chromosome. The Y chromosomes of 200 normal men were also analyzed. Results Fourteen infertile men (7 percent) and four normal men (2 percent) had microdeletions of the Y chromosome. Nine of the infertile men had azoospermia or severe oligospermia (sperm concentration, <5 million per milliliter), four had oligospermia (sperm concentration, 5 million to <20 million per milliliter), and one had normospermia (sperm concentration, greater than or equal to 20 million per milliliter). The size and location of the deletions varied and did not correlate with the severity of spermatogenic failure. The fathers of six infertile men with microdeletions were studied; two had the same deletions as their sons, and four had no deletions. Conclusions A small proportion of men with infertility have Y-chromosome microdeletions, but the size and position of the deletions correlate poorly with the severity of spermatogenic failure, and a deletion does not preclude the presence of viable sperm and possible conception. (C) 1997, Massachusetts Medical Society.	UNIV MINNESOTA,SCH MED,DEPT UROL SURG,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT OBSTET & GYNECOL,MINNEAPOLIS,MN 55455; PROMEGA CORP,MADISON,WI; UNIV WISCONSIN,DEPT MEAT & ANIM SCI,MADISON,WI 53706; UNIV WISCONSIN,DEPT PREVENT MED,MADISON,WI 53706	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Promega Corporation; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Roberts, Ken/D-5701-2012					AFFARA N, 1996, CYTOGENET CELL GENET, V73, P34; ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BARDONI B, 1991, GENOMICS, V11, P443, DOI 10.1016/0888-7543(91)90153-6; CHANDLEY AC, 1989, J MED GENET, V26, P145, DOI 10.1136/jmg.26.3.145; DUBIN L, 1971, FERTIL STERIL, V22, P469; GREENBERG SH, 1978, J UROLOGY, V119, P507, DOI 10.1016/S0022-5347(17)57531-X; HENDRY W F, 1973, British Journal of Urology, V45, P684, DOI 10.1111/j.1464-410X.1973.tb12240.x; HENEGARIU O, 1994, ANDROLOGIA, V26, P97; KOBAYASHI K, 1995, HUM MOL GENET, V4, P974, DOI 10.1093/hmg/4.5.974-a; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; KRUGER TF, 1988, FERTIL STERIL, V49, P112; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MOSHER WD, 1985, DEMOGRAPHY, V22, P415, DOI 10.2307/2061069; NAGAFUCHI S, 1993, J UROLOGY, V150, P1155, DOI 10.1016/S0022-5347(17)35712-9; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Sambrook J., 2002, MOL CLONING LAB MANU; Stuppia L, 1996, CYTOGENET CELL GENET, V72, P155, DOI 10.1159/000134174; Sylora J A, 1994, Curr Ther Endocrinol Metab, V5, P309; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; TORRONI A, 1990, ANN HUM GENET, V54, P287; VERGNAUD G, 1986, AM J HUM GENET, V38, P109; Verma RS, 1995, HUMAN CHROMOSOMES PR, P11; VOGT P, 1992, HUM GENET, V89, P491; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769	27	395	418	2	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					534	539		10.1056/NEJM199702203360802	http://dx.doi.org/10.1056/NEJM199702203360802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023089				2022-12-28	WOS:A1997WJ24000002
J	Sexton, DJ; Rollin, PE; Breitschwerdt, EB; Corey, GR; Myers, SA; Dumais, MR; Bowen, MD; Goldsmith, CS; Zaki, SR; Nichol, ST; Peters, CJ; Ksiazek, TG				Sexton, DJ; Rollin, PE; Breitschwerdt, EB; Corey, GR; Myers, SA; Dumais, MR; Bowen, MD; Goldsmith, CS; Zaki, SR; Nichol, ST; Peters, CJ; Ksiazek, TG			Life-threatening Cache Valley virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; BUNYAMWERA SEROGROUP VIRUSES; MALFORMATIONS		CTR DIS CONTROL & PREVENT,SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333; DUKE UNIV,DEPT MED,DIV INFECT DIS,DURHAM,NC; N CAROLINA STATE UNIV,COLL VET MED,INTRACELLULAR PATHOGENS LAB,RALEIGH,NC; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Duke University; University of North Carolina; North Carolina State University; Centers for Disease Control & Prevention - USA				Breitschwerdt, Edward/0000-0002-3506-0279; Rollin, Pierre/0000-0002-4608-2641; Sexton, Daniel J/0000-0001-9604-5948				CALISHER CH, 1986, AM J TROP MED HYG, V35, P429, DOI 10.4269/ajtmh.1986.35.429; CALISHER CH, 1995, EMERG INFECT DIS, V1, P147, DOI 10.3201/eid0104.950409; CHUNG SI, 1990, AM J VET RES, V51, P1645; DUNN EF, 1994, J GEN VIROL, V75, P597, DOI 10.1099/0022-1317-75-3-597; EDWARDS JF, 1989, VET PATHOL, V26, P33, DOI 10.1177/030098588902600106; GONZALEZSCARANO F, 1996, FIELDS VIROLOGY, V1, P1473; GRIFFIN DE, 1995, SPRINGER SEMIN IMMUN, V17, P121; HOLDEN P, 1959, SCIENCE, V130, P1187, DOI 10.1126/science.130.3383.1187; KSIAZEK TG, 1995, AM J TROP MED HYG, V52, P117, DOI 10.4269/ajtmh.1995.52.117; MANGIAFICO JA, 1988, AM J TROP MED HYG, V39, P593, DOI 10.4269/ajtmh.1988.39.593	10	78	79	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					547	549		10.1056/NEJM199702203360804	http://dx.doi.org/10.1056/NEJM199702203360804			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023091				2022-12-28	WOS:A1997WJ24000004
J	Blum, U; Krumme, B; Flugel, P; Gabelmann, A; Lehnert, T; BuitragoTellez, C; Schollmeyer, P; Langer, M				Blum, U; Krumme, B; Flugel, P; Gabelmann, A; Lehnert, T; BuitragoTellez, C; Schollmeyer, P; Langer, M			Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-LUMINAL ANGIOPLASTY; RENOVASCULAR HYPERTENSION; STENT PLACEMENT; WALLSTENT ENDOPROSTHESIS; ISCHEMIC NEPHROPATHY; NATURAL-HISTORY; FOLLOW-UP; DISEASE; INSUFFICIENCY; MANAGEMENT	Background Percutaneous transluminal renal angioplasty is a safe and effective treatment for nonostial stenoses of the renal arteries, but it has proved to be disappointing for ostial stenoses. Therefore, we prospectively studied the use of intravascular stents for the treatment of critical ostial stenoses after unsuccessful balloon angioplasty. Methods Stainless-steel endoprostheses were placed across 74 renal-artery stenoses located within 5 mm of the aortic lumen in 68 patients with hypertension. Twenty patients had mild or severe renal dysfunction. The indications for stent placement were elastic recoil (63 arteries) or dissection (1 artery) of the vessel after angioplasty, or restenosis after initially successful balloon angioplasty (10 arteries). Patients were followed for a mean of 27 months with measurements of blood pressure and serum creatinine, duplex sonography, and intraarterial angiography. Results Initial technical success was achieved in all patients. Minor complications (local hematomas) occurred in only three patients; there were no major complications. Eighty-four percent of the patients were free of primary occlusion 60 months after the procedure. Restenosis of more than 50 percent of the vessel diameter occurred in 8 of 74 arteries (11 percent). Reintervention resulted in a secondary patency rate of 92 percent. Long-term normalization of blood pressure was achieved in 11 patients (16 percent). Serum creatinine levels did not change significantly after successful stent implantation in patients with previously impaired renal function. Conclusions Accurate placement of renal-artery stents is technically feasible without major complications. The favorable early and long-term results suggest that primary stent placement is Bn effective treatment for renal-artery stenosis involving the ostium. (C)1997, Massachusetts Medical Society.	UNIV HOSP FREIBURG, DEPT INTERNAL MED 4 NEPHROL, D-79106 FREIBURG, GERMANY	University of Freiburg	Blum, U (corresponding author), UNIV HOSP FREIBURG, DEPT DIAGNOST RADIOL, HUGSTETTER STR 55, D-79106 FREIBURG, GERMANY.							CANZANELLO VJ, 1989, HYPERTENSION, V13, P163, DOI 10.1161/01.HYP.13.2.163; CICUTO KP, 1981, AM J ROENTGENOL, V137, P599, DOI 10.2214/ajr.137.3.599; DEAN RH, 1991, ANN SURG, V213, P446, DOI 10.1097/00000658-199105000-00010; DEAN RH, 1987, J VASC SURG, V6, P301, DOI 10.1067/mva.1987.avs0060301; DERKX FHM, 1994, LANCET, V344, P237, DOI 10.1016/S0140-6736(94)93002-3; DORROS G, 1995, AM J CARDIOL, V75, P1051, DOI 10.1016/S0002-9149(99)80723-1; ELDRUPJORGENSEN J, 1995, J VASC SURG, V21, P909, DOI 10.1016/S0741-5214(95)70218-0; HALLETT JW, 1987, J VASC SURG, V5, P622, DOI 10.1067/mva.1987.avs0050622; HANSEN KJ, 1994, AM J KIDNEY DIS, V24, P615, DOI 10.1016/S0272-6386(12)80222-8; HANSEN KJ, 1992, J VASC SURG, V16, P319, DOI 10.1016/0741-5214(92)90364-E; HENNEQUIN LM, 1994, RADIOLOGY, V191, P713, DOI 10.1148/radiology.191.3.8184051; Henry M, 1996, J VASC INTERV RADIOL, V7, P343, DOI 10.1016/S1051-0443(96)72864-6; HOVINGA TKK, 1986, NEPHRON, V44, P64, DOI 10.1159/000184050; JENSEN G, 1995, KIDNEY INT, V48, P1936, DOI 10.1038/ki.1995.494; Kaatee R, 1996, RADIOLOGY, V199, P637, DOI 10.1148/radiology.199.3.8637979; Krumme B, 1996, KIDNEY INT, V50, P1288, DOI 10.1038/ki.1996.440; KUHN FP, 1991, RADIOLOGY, V180, P367, DOI 10.1148/radiology.180.2.1829842; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MacLeod M, 1995, J HYPERTENS, V13, P1791; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; Martin L G, 1992, J Vasc Interv Radiol, V3, P619, DOI 10.1016/S1051-0443(92)72907-8; MARTIN LG, 1986, RADIOLOGY, V159, P631, DOI 10.1148/radiology.159.3.2939491; MILLAN VG, 1985, HYPERTENSION, V7, P668, DOI 10.1161/01.HYP.7.5.668; NOVICK AC, 1987, JAMA-J AM MED ASSOC, V257, P498, DOI 10.1001/jama.257.4.498; OLIN JW, 1995, ANN INTERN MED, V122, P833, DOI 10.7326/0003-4819-122-11-199506010-00004; PALMAZ JC, 1993, AM J ROENTGENOL, V160, P613, DOI 10.2214/ajr.160.3.8430566; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; REES CR, 1991, RADIOLOGY, V181, P507, DOI 10.1148/radiology.181.2.1924796; SCHREIBER MJ, 1984, UROL CLIN N AM, V11, P383; SCHWERK WB, 1994, RADIOLOGY, V190, P785, DOI 10.1148/radiology.190.3.8115628; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; STRANDNESS DE, 1994, AM J KIDNEY DIS, V24, P630, DOI 10.1016/S0272-6386(12)80224-1; TEGTMEYER CJ, 1984, RADIOLOGY, V153, P77, DOI 10.1148/radiology.153.1.6236477; TEGTMEYER CJ, 1986, RADIOLOGY, V161, P577, DOI 10.1148/radiology.161.3.2947260; TEGTMEYER CJ, 1991, CIRCULATION, V83, P155; VANDEVEN PJG, 1995, LANCET, V346, P672, DOI 10.1016/S0140-6736(95)92283-0; WEIBULL H, 1993, J VASC SURG, V18, P841, DOI 10.1016/0741-5214(93)90340-R; WILMS GE, 1991, RADIOLOGY, V179, P457, DOI 10.1148/radiology.179.2.2014292	39	427	461	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					459	465		10.1056/NEJM199702133360702	http://dx.doi.org/10.1056/NEJM199702133360702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017938				2022-12-28	WOS:A1997WG77600002
J	Okubo, Y; Suhara, T; Suzuki, K; Kobayashi, K; Inoue, O; Terasaki, O; Someya, Y; Sassa, T; Sudo, Y; Matsushima, E; Iyo, M; Tateno, Y; Toru, M				Okubo, Y; Suhara, T; Suzuki, K; Kobayashi, K; Inoue, O; Terasaki, O; Someya, Y; Sassa, T; Sudo, Y; Matsushima, E; Iyo, M; Tateno, Y; Toru, M			Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; PREFRONTAL CORTEX; COGNITIVE ACTIVATION; WORKING-MEMORY; HUMAN-BRAIN; DYSFUNCTION; MODULATION; BINDING; INVIVO	Schizophrenia is believed to involve altered activation of dopamine receptors, and support for this hypothesis comes from the antipsychotic effect of antagonists of the dopamine D2 receptor (D2R)(1). D2R is expressed most highly in the striatum, but most of the recent positron emission tomography (PET) studies have failed to show any change in D2R densities in the striatum of schizophrenics(2-5), raising the possibility that other receptors may also be involved. In particular, the dopamine D1 receptor (D1R), which is highly expressed in the prefrontal cortex(6), has been implicated in the control of working memory(7,8), and working memory dysfunction is a prominent feature of schizophrenia(9). We have therefore used PET to examine the distribution of D1R and D2R in brains of drug-naive or drug-free schizophrenic patients. Although no differences were observed in the striatum relative to control subjects, binding of radioligand to D1R was reduced in the prefrontal cortex of schizophrenics. This reduction was related to the severity of the negative symptoms (for instance, emotional withdrawal) and to poor performance in the Wisconsin Card Sorting Test(10). We propose that dysfunction of D1R signalling in the prefrontal cortex may contribute to the negative symptoms and cognitive deficits seen in schizophrenia.	NATL INST RADIOL SCI,DIV ADV TECHNOL MED IMAGING,INAGE KU,CHIBA 263,JAPAN	National Institutes for Quantum Science & Technology	Okubo, Y (corresponding author), TOKYO MED & DENT UNIV,SCH MED,DEPT NEUROPSYCHIAT,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							ANDERSEN PH, 1986, LIFE SCI, V38, P1507, DOI 10.1016/0024-3205(86)90564-3; ASAHINA M, 1995, ACTA NEUROL SCAND, V91, P437; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DAVIDSON M, 1988, ARCH GEN PSYCHIAT, V45, P561; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; FARDE L, 1987, PSYCHOPHARMACOLOGY, V92, P278, DOI 10.1007/BF00210831; FARDE L, 1990, ARCH GEN PSYCHIAT, V47, P213; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; HALL H, 1994, NEUROPSYCHOPHARMACOL, V11, P245, DOI 10.1038/sj.npp.1380111; HESS EJ, 1987, LIFE SCI, V40, P1487, DOI 10.1016/0024-3205(87)90381-X; HIETALA J, 1994, ARCH GEN PSYCHIAT, V51, P116; KASHIMA H, 1991, JPN J PSYCHOPHARMACO, V11, P83; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P44; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; NORDSTROM AL, 1995, PSYCHIAT RES-NEUROIM, V61, P67, DOI 10.1016/0925-4927(95)02732-D; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SEDVALL G, 1995, LANCET, V346, P743, DOI 10.1016/S0140-6736(95)91508-7; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SUHARA T, 1991, PSYCHOPHARMACOLOGY, V103, P41, DOI 10.1007/BF02244071; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; WONG DF, 1984, SCIENCE, V226, P1393, DOI 10.1126/science.6334363	24	550	573	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					634	636		10.1038/385634a0	http://dx.doi.org/10.1038/385634a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WH294	9024661				2022-12-28	WOS:A1997WH29400050
J	Tanner, MA; Cech, TR				Tanner, MA; Cech, TR			Joining the two domains of a group I ribozyme to form the catalytic core	SCIENCE			English	Article							COMPARATIVE SEQUENCE-ANALYSIS; GUANOSINE-BINDING-SITE; TERTIARY STRUCTURE; TETRAHYMENA RIBOZYME; RIBONUCLEASE-P; BASE-TRIPLES; TRANSFER-RNA; INTRON; ARCHITECTURE; CLEAVAGE	Self-splicing group I introns, like other large catalytic RNAs, contain structural domains. Although the crystal structure of one of these domains has been determined by x-ray analysis, its connection to the other major domain that contains the guanosine-binding site has not been known. Site-directed mutagenesis and kinetic analysis of RNA splicing were used to identify a base triple in the conserved core of both a cyanobacterial (Anabaena) and a eukaryotic (Tetrahymena) group I intron. This long-range interaction connects a sequence adjacent to the guanosine-binding site with the domain implicated in coordinating the 5' splice site helix, and it thereby contributes to formation of the active site. The resulting five-strand junction, in which a short helix forms base triples with three separate strands in the Tetrahymena intron, reveals exceptionally dense packing of RNA.	UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM028039] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28039] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; DOUDNA JA, 1995, RNA, V1, P36; EHRENMAN K, 1986, P NATL ACAD SCI USA, V83, P5875, DOI 10.1073/pnas.83.16.5875; GAUTHERET D, 1995, J MOL BIOL, V248, P27, DOI 10.1006/jmbi.1995.0200; Golden BL, 1996, BIOCHEMISTRY-US, V35, P3754, DOI 10.1021/bi952599z; GREEN R, 1994, J MOL BIOL, V235, P140, DOI 10.1016/S0022-2836(05)80022-1; GUTELL RR, 1996, RIBOSOMAL RNA STRUCT, P111; GUTELL RR, UNPUB; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; LACKS S, 1966, GENETICS, V53, P207; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Meervelt L. V., 1995, NATURE, V374, P742; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PRICE JV, 1985, SCIENCE, V228, P719, DOI 10.1126/science.2986286; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; TABAK HF, 1987, CELL, V48, P101, DOI 10.1016/0092-8674(87)90360-6; Tanner MA, 1996, RNA, V2, P74; TANNER MA, UNPUB; Vlieghe D, 1996, SCIENCE, V273, P1702, DOI 10.1126/science.273.5282.1702; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; Zarrinkar PP, 1996, NUCLEIC ACIDS RES, V24, P854, DOI 10.1093/nar/24.5.854; ZAUG AJ, 1993, BIOCHEMISTRY-US, V32, P7946, DOI 10.1021/bi00082a016; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZAUG AJ, 1994, BIOCHEMISTRY-US, V33, P14935, DOI 10.1021/bi00253a033; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	39	38	39	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 7	1997	275	5301					847	849		10.1126/science.275.5301.847	http://dx.doi.org/10.1126/science.275.5301.847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012355				2022-12-28	WOS:A1997WG77700066
J	Neugebauer, R; Kline, J; Shrout, P; Skodol, A; OConnor, P; Geller, PA; Stein, Z; Susser, M				Neugebauer, R; Kline, J; Shrout, P; Skodol, A; OConnor, P; Geller, PA; Stein, Z; Susser, M			Major depressive disorder in the 6 months after miscarriage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPONTANEOUS-ABORTION; PERINATAL DEATH; GRIEF; KARYOTYPE; SYMPTOMS	Objective.-To test a priori hypotheses that miscarrying women are at increased risk for a first or recurrent episode of major depressive disorder in the 6 months following loss and that this increased risk is greater for childless women, women with prior reproductive loss, and women aged 35 years or older; and to evaluate whether risk varies by time of gestation or by attitude toward the pregnancy. Design.-Cohort study. Setting.-The miscarriage cohort consisted of women attending a medical center for a spontaneous abortion (n=229); the comparison group was a population-based cohort of women drawn from the community (n=230). Participants.-Miscarriage was defined as the involuntary termination of a nonviable intrauterine pregnancy before 28 completed weeks of gestation. Half of all participants were between 25 and 34 years of age; 40% were white and 35% Hispanic; 55% had more than a high school education. Participants constituted 60% of miscarrying women and 72% of community women who completed the first phase of this cohort study. Main Outcome Measure.-Major depressive disorder was measured using the Diagnostic Interview Schedule. Results.-Risk for an episode of major depressive disorder among miscarrying women in the 6 months following loss was compared with the 6-month risk among community women who had not been pregnant in the preceding year. Among miscarrying women, 10.9% experienced an episode of major depressive disorder, compared with 4.3% of community women. The overall relative risk (RR) for an episode of major depressive disorder for miscarrying women was 2.5 (95% confidence interval [Cl], 1.2-5.1) and was substantially higher for childless women (RR, 5.0; 95% Cl, 1.7-14.4) than for women with children (RR, 1.3; 95% Cl, 0.5-3.5) (P<.06). Among miscarrying women, 72% of cases of major depressive disorder began within the first month after loss; only 20% of community cases started during the comparable period. Among miscarrying women with a history of major depressive disorder, 54% experienced a recurrence. However, RR did not vary significantly by history of prior reproductive loss or by maternal age, nor did risk vary by time of gestation or attitude toward the pregnancy. Conclusions.-Physicians should monitor miscarrying women in the first weeks after reproductive loss, particularly women who are childless or who have a history of major depressive disorder. Where appropriate, supportive counseling or psychopharmacologic treatment should be considered.	COLUMBIA UNIV,FAC MED,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY; NYU,DEPT PSYCHOL,NEW YORK,NY 10003; COLUMBIA UNIV,FAC MED,DEPT PSYCHIAT,NEW YORK,NY; COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY; RUSSELL SAGE COLL,DEPT PSYCHOL,TROY,NY	Columbia University; New York University; Columbia University; Columbia University	Neugebauer, R (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP,DEPT EPIDEMIOL DEV BRAIN DISORDERS,BOX 53,722 W 168TH ST,NEW YORK,NY 10032, USA.		Skodol, Andrew/AAK-9646-2021		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039581] Funding Source: NIH RePORTER; NICHD NIH HHS [HD12207, HD15509] Funding Source: Medline; NIMH NIH HHS [MH39581] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANESHENSEL CS, 1982, PUBLIC OPIN QUART, V46, P110, DOI 10.1086/268703; [Anonymous], 1978, MAIL TELEPHONE SURVE; CLARKE M, 1979, LANCET, V2, P916; *COMM STUD HLTH CO, 1984, BER REACT CONS CAR; EATON WW, 1990, ACTA PSYCHIAT SCAND, V26, P163; FORREST CG, 1982, BRIT MED J, V285, P1475; FRIEDMAN T, 1989, BRIT J PSYCHIAT, V155, P810, DOI 10.1192/bjp.155.6.810; GAREL M, 1992, CONTRACEPT FERTIL S, V20, P75; GRAHAM MA, 1987, AM J OBSTET GYNECOL, V157, P254, DOI 10.1016/S0002-9378(87)80145-X; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOCHSTIM JR, 1967, J AM STAT ASSOC, V62, P976, DOI 10.2307/2283686; KLINE J, 1995, AM J EPIDEMIOL, V141, P417, DOI 10.1093/oxfordjournals.aje.a117444; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; Kline J, 1989, CONCEPTION BIRTH EPI, P43; LAROCHE C, 1984, CAN J PSYCHIAT, V29, P14, DOI 10.1177/070674378402900104; LEINBACH RM, 1982, GERONTOLOGIST, V22, P78, DOI 10.1093/geront/22.1.78; LEPPERT PC, 1984, OBSTET GYNECOL, V64, P119; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; *NAT CTR HLTH STAT, 1995, 1992 VIT STAT US, V1; NEUGEBAUER R, 1992, AM J OBSTET GYNECOL, V166, P104, DOI 10.1016/0002-9378(92)91839-3; NEUGEBAUER R, 1992, AM J PUBLIC HEALTH, V82, P1332, DOI 10.2105/AJPH.82.10.1332; NICOL MT, 1986, MED J AUSTRALIA, V144, P287, DOI 10.5694/j.1326-5377.1986.tb128375.x; PEPPERS LG, 1980, PSYCHIATRY, V43, P155, DOI 10.1080/00332747.1980.11024061; Prettyman RJ, 1994, J REPROD INFANT PSYC, V12, P37, DOI DOI 10.1080/02646839408408866; RABKIN JG, 1982, HDB STRESS THEORETIC, P566; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINS LN, 1991, PSYCHIAT DISORDERS A; ROBINSON GE, 1994, J REPROD INFANT PSYC, V12, P31, DOI DOI 10.1080/02646839408408865; SEIBEL M, 1980, J REPROD MED, V25, P161; THARPAR AK, 1992, BRIT J GEN PRACT, V42, P94; TOEDTER LJ, 1988, AM J ORTHOPSYCHIAT, V58, P435, DOI 10.1111/j.1939-0025.1988.tb01604.x; TUNALEY JR, 1993, PSYCHOL HEALTH, V8, P369, DOI 10.1080/08870449308401929; VIEDERMAN M, 1995, AM J PSYCHIAT, V152, P1	35	126	128	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					383	388		10.1001/jama.277.5.383	http://dx.doi.org/10.1001/jama.277.5.383			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE771	9010170				2022-12-28	WOS:A1997WE77100028
J	Andrews, MR; Townsend, CG; Miesner, HJ; Durfee, DS; Kurn, DM; Ketterle, W				Andrews, MR; Townsend, CG; Miesner, HJ; Durfee, DS; Kurn, DM; Ketterle, W			Observation of interference between two Bose condensates	SCIENCE			English	Article							EINSTEIN CONDENSATION; ATOMS; GAS	Interference between two freely expanding Bose-Einstein condensates has been observed. Two condensates separated by similar to 40 micrometers were created by evaporatively cooling sodium atoms in a double-well potential formed by magnetic and optical forces. High-contrast matter-wave interference fringes with a period of similar to 15 micrometers were observed after switching off the potential and letting the condensates expand for 40 milliseconds and overlap. This demonstrates that Bose condensed atoms are ''laser-like''; that is, they are coherent and show long-range correlations. These results have direct implications for the atom laser and the Josephson effect for atoms.	MIT,ELECT RES LAB,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	Andrews, MR (corresponding author), MIT,DEPT PHYS,CAMBRIDGE,MA 02139, USA.		Stamper-Kurn, Dan/B-5442-2015	Stamper-Kurn, Dan/0000-0002-4845-5835				ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Anderson P. W., 1986, Lesson of Quantum Theory. Niels Bohr Centenary Symposium, P23; ANDERSON PW, 1966, REV MOD PHYS, V38, P298, DOI 10.1103/RevModPhys.38.298; Andrews MR, 1996, SCIENCE, V273, P84, DOI 10.1126/science.273.5271.84; BORDE CJ, 1995, PHYS LETT A, V204, P217, DOI 10.1016/0375-9601(95)00466-G; BRADLEY CA, UNPUB; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; BURNETT K, 1996, PHYSICS WORLD    OCT, P18; Castin Y, 1996, PHYS REV LETT, V77, P5315, DOI 10.1103/PhysRevLett.77.5315; Castin Y., UNPUB; Cirac JI, 1996, PHYS REV A, V54, pR3714, DOI 10.1103/PhysRevA.54.R3714; Cornell E, 1996, J RES NATL INST STAN, V101, P419, DOI 10.6028/jres.101.045; Dalfovo F, 1996, PHYS REV A, V54, P4213, DOI 10.1103/PhysRevA.54.4213; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Edwards M, 1996, PHYS REV LETT, V77, P1671, DOI 10.1103/PhysRevLett.77.1671; GRIFFIN A, UNPUB; Holland M, 1996, PHYS REV A, V53, pR1954, DOI 10.1103/PhysRevA.53.R1954; Holland M, 1996, PHYS REV A, V54, pR1757, DOI 10.1103/PhysRevA.54.R1757; Hoston W, 1996, PHYS REV A, V53, P4254, DOI 10.1103/PhysRevA.53.4254; HUANG K, 1987, STATISTICAL MECHANIC; Jack MW, 1996, PHYS REV A, V54, pR4625, DOI 10.1103/PhysRevA.54.R4625; Javanainen J, 1996, PHYS REV LETT, V76, P161, DOI 10.1103/PhysRevLett.76.161; JAVANAINEN J, 1986, PHYS REV LETT, V57, P3164, DOI 10.1103/PhysRevLett.57.3164; Jin DS, 1996, PHYS REV LETT, V77, P420, DOI 10.1103/PhysRevLett.77.420; Kagan Y, 1996, PHYS REV A, V54, pR1753, DOI 10.1103/PhysRevA.54.R1753; Kagan Y., 1995, BOSE EINSTEIN CONDEN, P202; Ketterle W, 1996, ADV ATOM MOL OPT PHY, V37, P181; LEGGETT AJ, 1991, FOUND PHYS, V21, P353, DOI 10.1007/BF01883640; Mewes MO, 1997, PHYS REV LETT, V78, P582, DOI 10.1103/PhysRevLett.78.582; Mewes MO, 1996, PHYS REV LETT, V77, P416, DOI 10.1103/PhysRevLett.77.416; Mewes MO, 1996, PHYS REV LETT, V77, P988, DOI 10.1103/PhysRevLett.77.988; Naraschewski M, 1996, PHYS REV A, V54, P2185, DOI 10.1103/PhysRevA.54.2185; NOZERES P, 1990, THEORY QUANTUM LIQUI, V2; OLSHANII M, 1996, LASER SPECTROSCOPY, V12, P7; PFLEEGOR RL, 1967, PHYS REV, V159, P1084, DOI 10.1103/PhysRev.159.1084; SPREEUW RJC, 1995, EUROPHYS LETT, V32, P469, DOI 10.1209/0295-5075/32/6/002; STOOF HTC, 1995, BOSE EINSTEIN CONDEN, P226; STRINGARI S, 1996, PHYS REV LETT, V77, P2350; WALLIS H, IN PRESS PHYS REV A; Wong T, 1996, PHYS REV A, V54, pR3718, DOI 10.1103/PhysRevA.54.R3718; Wright EM, 1996, PHYS REV LETT, V77, P2158, DOI 10.1103/PhysRevLett.77.2158; WRIGHT EM, UNPUB	43	1273	1298	3	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					637	641		10.1126/science.275.5300.637	http://dx.doi.org/10.1126/science.275.5300.637			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005843				2022-12-28	WOS:A1997WF07700030
J	Musashi, M; Abe, S; Yamada, T; Tanaka, J; Gotohda, Y; Maeda, S; Sato, Y; Morioka, M; Sakurada, K; Minagawa, T; Asaka, M; Miyazaki, T				Musashi, M; Abe, S; Yamada, T; Tanaka, J; Gotohda, Y; Maeda, S; Sato, Y; Morioka, M; Sakurada, K; Minagawa, T; Asaka, M; Miyazaki, T			Spontaneous remission in a patient with chronic myelogenous leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; INTERFERON-ALPHA; BONE-MARROW; REGION; BCR		HOKKAIDO UNIV,SCH MED,DEPT MICROBIOL,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,CHROMOSOME RES UNIT,FAC SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University	Musashi, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT INTERNAL MED 3,KITA KU,KITA 15,NISHI 7,SAPPORO,HOKKAIDO 060,JAPAN.		Asaka, Masahiro/A-5948-2012; Tanaka, Junji/A-4098-2012; Musashi, Manabu/D-9935-2012					CANELLOS GP, 1972, LANCET, V2, P1227; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM I, 1979, BLOOD, V53, P375; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; MILLS KI, 1991, BLOOD, V78, P1155; Mitelman F, 1995, INT SYSTEM HUMAN CYT; OPALKA B, 1991, BLOOD, V78, P2188, DOI 10.1182/blood.V78.9.2188.bloodjournal7892188; PROVAN AB, 1991, BRIT J HAEMATOL, V78, P578, DOI 10.1111/j.1365-2141.1991.tb04497.x; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SANDBERG AA, 1980, CLIN HAEMATOL, V9, P19; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; SMADJA N, 1986, BRIT J HAEMATOL, V63, P257; SMALLEY RV, 1977, BLOOD, V50, P107; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TALPAZ M, 1991, BRIT J HAEMATOL, V79, P38, DOI 10.1111/j.1365-2141.1991.tb08117.x; TALPAZ M, 1983, BLOOD, V62, P689; Wiernik P H, 1976, Natl Cancer Inst Monogr, V44, P35	18	19	19	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					337	339		10.1056/NEJM199701303360504	http://dx.doi.org/10.1056/NEJM199701303360504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011786	Bronze			2022-12-28	WOS:A1997WG23300004
J	Hughes, RAC; Swan, AV; Cornblath, DR; Hartung, HP; Bril, V; Feasby, T; Hahn, A; Ropper, A; Steck, A; Toyka, KV; Vallat, JM; NewsomDavis, J; Button, S; Hohlfeld, R; Voltz, R; Lecky, BRF; Winer, JB; Rees, J; Donaghy, M; Dehaene, I; Marchau, M; VanZandijcke, M; Hooghe, MD; Hacke, W; Newman, PK; Shakir, R; Tilley, P; Khatri, B; Kumar, J; Sundrani, S; Willison, H; Katifi, H; Wiles, CM; Hamann, G; Merkelbach, S; Stewart, J; Luis, MLS; Alves, M; Conceicao, I; Pye, IF; Robberecht, W; Peeters, E; Aasly, J; Fuhr, P; Tichelli, A; Sindic, C; VandenBurgh, P; Franck, F; Dive, D; Cavaletti, G; Santoro, P; Feasby, TE; Miller, DH; Howard, RS; ORiordan, J; Chalk, C; BenHur, T; Goldstein, JM; VanOrshoven, M; Caekebeke, J; Schmedding, E; Ferguson, IT; Stoll, G; Will, RG; Pollard, J				Hughes, RAC; Swan, AV; Cornblath, DR; Hartung, HP; Bril, V; Feasby, T; Hahn, A; Ropper, A; Steck, A; Toyka, KV; Vallat, JM; NewsomDavis, J; Button, S; Hohlfeld, R; Voltz, R; Lecky, BRF; Winer, JB; Rees, J; Donaghy, M; Dehaene, I; Marchau, M; VanZandijcke, M; Hooghe, MD; Hacke, W; Newman, PK; Shakir, R; Tilley, P; Khatri, B; Kumar, J; Sundrani, S; Willison, H; Katifi, H; Wiles, CM; Hamann, G; Merkelbach, S; Stewart, J; Luis, MLS; Alves, M; Conceicao, I; Pye, IF; Robberecht, W; Peeters, E; Aasly, J; Fuhr, P; Tichelli, A; Sindic, C; VandenBurgh, P; Franck, F; Dive, D; Cavaletti, G; Santoro, P; Feasby, TE; Miller, DH; Howard, RS; ORiordan, J; Chalk, C; BenHur, T; Goldstein, JM; VanOrshoven, M; Caekebeke, J; Schmedding, E; Ferguson, IT; Stoll, G; Will, RG; Pollard, J			Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome	LANCET			English	Article							HUMAN IMMUNE GLOBULIN; PROGNOSTIC VALUE; IMMUNOPATHOGENESIS	Background The relative efficacy of plasma exchange (PE) and intravenous immunoglobulin (IVIg) for the treatment of Guillain-Barre syndrome has not been established. We compared PE with IVIg, and with a combined regimen of PE followed by IVIg, in an international, multicentre, randomised trial of 383 adult patients with Guillain-Barre syndrome. Methods The patients were randomly assigned PE (five 50 mL/kg exchanges over 8-13 days), IVIg (Sandoglobulin, 0.4 g/kg daily for 5 days), or the PE course immediately followed by the IVIg course. The inclusion criteria were severe disease (aid needed for walking) and onset of neuropathic symptoms within the previous 14 days. Patients were followed up for 48 weeks. Findings Four patients were excluded because they did not meet the randomisation criteria. All the remaining 379 patients were assessed for the major outcome criterion-change on a seven-point disability grade scale-by an observer unaware of treatment assignment, 4 weeks after randomisation. At that time, the mean improvement was 0.9 (SD 1.3) in the 121 PE-group patients, 0.8 (1.3) in the 130 IVIg-group patients, and 1.1 (1.4) in the 128 patients who received both treatments (intention-to-treat analysis). None of the differences between the groups for this major outcome criterion was significant. The difference between PE alone and IVIg alone was so small that a 0.5 grade difference was excluded at the 95% level of confidence. There was no significant difference between any of the treatment groups in the secondary outcome measures: time to recovery of unaided walking, time to discontinuation of ventilation, and trend describing the recovery from disability up to 48 weeks. There was a non-significant trend towards a more favourable outcome on some outcome measures with combined treatment. Interpretation In treatment of severe Guillain-Barre syndrome during the first 2 weeks after onset of neuropathic symptoms, PE and IVIg had equivalent efficacy. The combination of PE with IVIg did not confer a significant advantage.			Hughes, RAC (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DEPT NEUROL, MED SCH BLDG, LONDON SE1 9RT, ENGLAND.		Hacke, Werner/ABE-8661-2020; de Carvalho, Mamede/I-6295-2019; BRIL, vera/ABA-6509-2020; willison, hugh/HCI-7819-2022; Rees, Jeremy/AAH-4382-2019; Cavaletti, Guido/AAA-7063-2022	de Carvalho, Mamede/0000-0001-7556-0158; Cavaletti, Guido/0000-0003-4128-2406				Bril V, 1996, NEUROLOGY, V46, P100, DOI 10.1212/WNL.46.1.100; CASTRO LHM, 1993, NEUROLOGY, V43, P1034, DOI 10.1212/WNL.43.5.1034; CORNBLATH DR, 1988, ANN NEUROL, V23, P354, DOI 10.1002/ana.410230407; HARTUNG HP, 1995, MUSCLE NERVE, V18, P137, DOI 10.1002/mus.880180202; HARTUNG HP, 1995, MUSCLE NERVE, V18, P154, DOI 10.1002/mus.880180203; HUGHES RAC, 1993, LANCET, V341, P586; IRANI DN, 1993, NEUROLOGY, V43, P872, DOI 10.1212/WNL.43.5.872; MCKHANN, 1985, NEUROLOGY, V35, P1096; MCKHANN GM, 1988, ANN NEUROL, V23, P347, DOI 10.1002/ana.410230406; Oomes PG, 1996, NEUROLOGY, V46, P96, DOI 10.1212/WNL.46.1.96; Palace J A, 1994, Eur J Neurol, V1, P21, DOI 10.1111/j.1468-1331.1994.tb00046.x; PETRO R, 1977, BRIT J CANCER, V35, P1; RAPHAEL JC, 1987, ANN NEUROL, V22, P753; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Voltz R, 1996, CURR OPIN NEUROL, V9, P360, DOI 10.1097/00019052-199610000-00008; VRIESENDORP FJ, 1991, ARCH NEUROL-CHICAGO, V48, P858, DOI 10.1001/archneur.1991.00530200100027; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P605, DOI 10.1136/jnnp.51.5.605	18	592	605	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					225	230						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014908				2022-12-28	WOS:A1997WD90600008
J	Elliott, G; OHare, P				Elliott, G; OHare, P			Intercellular trafficking and protein delivery by a herpesvirus structural protein	CELL			English	Article							SIMPLEX VIRUS TYPE-1; FIBROBLAST GROWTH-FACTOR; GLYCOPROTEIN-H; TAT PROTEIN; TEGUMENT PROTEIN; BREFELDIN-A; CELLS; TRANSLOCATION; TRANSPORT; SEQUENCE	We show that the HSV-1 structural protein VP22 has the remarkable property of intercellular transport, which is so efficient that following expression in a subpopulation the protein spreads to every cell in a monolayer, where it concentrates in the nucleus and binds chromatin. VP22 movement was observed both after delivery of DNA by transfection or microinjection and during virus infection. Moreover, we demonstrate that VP22 trafficking occurs via a nonclassical Golgi-independent mechanism. Sensitivity to cytochalasin D treatment suggests that VP22 utilizes a novel trafficking pathway that involves the actin cytoskeleton. In addition, we demonstrate intercellular transport of a VP22 fusion protein after endogenous synthesis or exogenous application, indicating that VP22 may have potential in the field of protein delivery.			Elliott, G (corresponding author), MARIE CURIE RES INST,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.			O'Hare, Peter/0000-0003-4508-5602				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BLAHO JA, 1994, J BIOL CHEM, V269, P17401; CAO Y, 1993, J CELL SCI, V104, P77; Cao YH, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037497; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DARGAN D, 1986, VIRAL STRUCTURE, P359; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; ELLIOTT G, 1995, J VIROL, V69, P7932, DOI 10.1128/JVI.69.12.7932-7941.1995; ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FORRESTER A, 1992, J VIROL, V66, P341, DOI 10.1128/JVI.66.1.341-348.1992; FULLER AO, 1989, J VIROL, V63, P3435, DOI 10.1128/JVI.63.8.3435-3443.1989; GOMPELS U, 1986, VIROLOGY, V153, P230, DOI 10.1016/0042-6822(86)90026-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HUTCHINSON L, 1992, J VIROL, V66, P2240, DOI 10.1128/JVI.66.4.2240-2250.1992; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; KRASNEY PA, 1992, CYTOKINE, V4, P134, DOI 10.1016/1043-4666(92)90048-V; Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5; Leslie J, 1996, VIROLOGY, V220, P60, DOI 10.1006/viro.1996.0286; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MENGAUD J, 1996, CELL, V84, P823; PASTAN IH, 1981, SCIENCE, V214, P504, DOI 10.1126/science.6170111; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; RUBARTELLI A, 1995, TRENDS CELL BIOL, V5, P409, DOI 10.1016/S0962-8924(00)89093-5; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025	35	858	1161	0	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					223	233		10.1016/S0092-8674(00)81843-7	http://dx.doi.org/10.1016/S0092-8674(00)81843-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008163	Bronze			2022-12-28	WOS:A1997WE97000011
J	Tishkoff, DX; Filosi, N; Gaida, GM; Kolodner, RD				Tishkoff, DX; Filosi, N; Gaida, GM; Kolodner, RD			A novel mutation avoidance mechanism dependent on S-cerevisiae RAD27 is distinct from DNA mismatch repair	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; SIMPLE REPETITIVE DNA; POLYPOSIS-COLI GENE; SACCHAROMYCES-CEREVISIAE; ADENOMATOUS POLYPOSIS; MICROSATELLITE INSTABILITY; COLORECTAL TUMORS; ESCHERICHIA-COLI; P53 GENE; REPLICATION	Mutations in the S. cerevisiae RAD27 (also called RTH1 or YKL510) gene result in a strong mutator phenotype. In this study we show that the majority of the resulting mutations have a structure in which sequences ranging from 5-108 bp flanked by direct repeats of 3-12 bp are duplicated. Such mutations have not been previously detected at high frequency in the mutation spectra of mutator strains. Epistasis analysis indicates that RAD27 does not play a major role in MSH2-dependent mismatch repair. Mutations in RAD27 cause increased rates of mitotic crossing over and are lethal in combination with mutations in RAD51 and RAD52. These observations suggest that the majority of replication errors that accumulate in rad27 strains are processed by double-strand break repair, while a smaller percentage are processed by a mutagenic repair pathway. The duplication mutations seen in rad27 mutants occur both in human tumors and as germline mutations in inherited human diseases.	DANA FARBER CANC INST,CHARLES A DANA DIV HUMAN CANC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA06516] Funding Source: Medline; NIAID NIH HHS [AI28691] Funding Source: Medline; NIGMS NIH HHS [GM50006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1994, GENETICS, V137, P19; BAYES M, 1995, HUM MUTAT, V5, P228, DOI 10.1002/humu.1380050307; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESPOSITO MS, 1990, CURR GENET, V17, P7, DOI 10.1007/BF00313242; FANG WH, 1993, J BIOL CHEM, V268, P11838; GEITZ RD, 1991, YEAST, V7, P253; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Greenblatt MS, 1996, CANCER RES, V56, P2130; HAMELIN R, 1994, GASTROENTEROLOGY, V107, P1012, DOI 10.1016/0016-5085(94)90225-9; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; Ivanov EL, 1996, GENETICS, V142, P693; JEGO N, 1993, ONCOGENE, V8, P209; JINKSROBERTSON S, 1993, MOL CELL BIOL, V13, P3937, DOI 10.1128/MCB.13.7.3937; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KATABUCHI H, 1995, CANCER RES, V55, P5556; KENNY MK, 1988, J BIOL CHEM, V263, P9801; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUZMINOV A, 1995, BIOESSAYS, V17, P733, DOI 10.1002/bies.950170810; Lea D, 1948, J GENET, V49, P264; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MCGRATH JA, 1995, PRENATAL DIAG, V15, P647, DOI 10.1002/pd.1970150710; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; REENAN RAG, 1992, GENETICS, V132, P975; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STEELE DF, 1992, GENETICS, V132, P9; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TISHKOFF DX, 1995, GENETICS, V139, P495; Tran HT, 1996, GENETICS, V143, P1579; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WILLIAMSON MS, 1985, GENETICS, V110, P609; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	64	393	399	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					253	263		10.1016/S0092-8674(00)81846-2	http://dx.doi.org/10.1016/S0092-8674(00)81846-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008166	Bronze			2022-12-28	WOS:A1997WE97000014
J	Cousens, SN; Vynnycky, E; Zeidler, M; Will, RG; Smith, PG				Cousens, SN; Vynnycky, E; Zeidler, M; Will, RG; Smith, PG			Predicting the CJD epidemic in humans	NATURE			English	Editorial Material									WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Cousens, SN (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Brookmeyer R, 1996, BIOMETRICS, V52, P781, DOI 10.2307/2533042; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *HOUS COMM, 1996, STAT UK SPONG ENC AD; KLITZMAN R L, 1984, Neuroepidemiology, V3, P3, DOI 10.1159/000110837; MARION SA, 1993, STAT MED, V12, P617, DOI 10.1002/sim.4780120702; SARTWELL PE, 1950, AM J HYG, V51, P310, DOI 10.1093/oxfordjournals.aje.a119397; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	10	176	181	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					197	198		10.1038/385197a0	http://dx.doi.org/10.1038/385197a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000063				2022-12-28	WOS:A1997WC71100018
J	Jenuwein, T; Forrester, WC; FernandezHerrero, LA; Laible, G; Dull, M; Grosschedl, R				Jenuwein, T; Forrester, WC; FernandezHerrero, LA; Laible, G; Dull, M; Grosschedl, R			Extension of chromatin accessibility by nuclear matrix attachment regions	NATURE			English	Article							CHROMOSOMAL LOOP ANCHORAGE; IMMUNOGLOBULIN-MU GENE; LOCUS-CONTROL REGION; TRANSGENIC MICE; ENHANCER; TRANSCRIPTION; SEQUENCES; ELEMENTS; DOMAINS	Transcription of the variable region of the rearranged immunoglobulin mu gene is dependent on an enhancer sequence situated within one of the introns of the gene, Experiments with transgenic mice have shown that activation of the promoter controlling this transcription also requires the matrix-attachment regions (MARs) that flank the intronic enhancer(1), As this mu gene enhancer can establish local areas of accessible chromatin(2), we investigated whether the MARs can extend accessibility to more distal positions, We eliminated interactions between enhancer- and promoter-bound factors by linking mu enhancer/MAR fragments to the binding sites for bacteriophage RNA polymerases that were either dose to or one kilobase distal to the enhancer. The mu enhancer alone mediated chromatin accessibility at the proximal site but required a flanking MAR to confer accessibility upon the distal promoter, This long-range accessibilty correlates with extended demethylation of the gene construct but not with whether it is being actively transcribed, MARs thus collaborate with the mu enhancer to generate an extended domain of accessible chromatin.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Fernández-Herrero, Luis Ángel/AAA-2583-2021; Fernández, Luis Ángel/D-2713-2009	Fernández-Herrero, Luis Ángel/0000-0001-5920-0638; Fernández, Luis Ángel/0000-0001-5920-0638; Laible, Goetz/0000-0003-1048-2819				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; CULLEN BR, 1992, AIDS RES HUM RETROV, V8, P387, DOI 10.1089/aid.1992.8.387; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DILLON N, 1994, CURR OPIN GENET DEV, V4, P260, DOI 10.1016/S0959-437X(05)80053-X; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FERSTENSTEIN R, 1996, SCIENCE, V271, P1123; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; YISRAELI J, 1984, DNA METHYLATION BIOC, P353; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	30	219	226	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					269	272		10.1038/385269a0	http://dx.doi.org/10.1038/385269a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000077				2022-12-28	WOS:A1997WC71100052
J	Welch, MD; Iwamatsu, A; Mitchison, TJ				Welch, MD; Iwamatsu, A; Mitchison, TJ			Actin polymerization is induced by Arp2/3 protein complex at the surface of Listeria monocytogenes	NATURE			English	Article							PROLINE-RICH REGION; END-BOUND INSERTIN; MAMMALIAN-CELLS; BARBED ENDS; FILAMENTS; MOTILITY; PURIFICATION; ACANTHAMOEBA; MOVEMENT; PROFILIN	The pathogenic bacterium Listeria monocytogenes is capable of directed movement within the cytoplasm of infected host cells. Propulsion is thought to be driven by actin polymerization at the bacterial ceil surface(1,2), and moving bacteria leave in their wake a tail of actin filaments(3). Determining the mechanism by which L. monocytogenes polymerizes actin may aid the understanding of how actin polymerization is controlled in the cell. Actin assembly by L. monocytogenes requires the bacterial surface protein ActA(4,5) and protein components present in host cell cytoplasm. We have purified an eight-polypeptide complex that possesses the properties of the host-cell actin polymerization factor. The pure complex is sufficient to initiate ActA-dependent actin polymerization at the surface oft. monocytogenes, and is required to mediate actin tail formation and motility. Two subunits of this protein complex are actin-related proteins (ARPs) belonging to the Arp2 and Arp3 subfamilies. The Arp3 subunit localizes to the surface of stationary bacteria and the tails of motile bacteria in tissue culture cells infected with L. monocytogenes; this is consistent with a role for the complex in promoting actin assembly in vivo. The activity and subunit composition of the Arp2/3 complex suggests that it forms a template that nucleates actin polymerization.	KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA,JAPAN	Kirin Brewery Company Limited	Welch, MD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Frankel S, 1996, CURR OPIN CELL BIOL, V8, P30, DOI 10.1016/S0955-0674(96)80045-7; GAERTNER A, 1991, J MUSCLE RES CELL M, V12, P27, DOI 10.1007/BF01781171; HIRANO H, 1990, ELECTROPHORESIS, V11, P573, DOI 10.1002/elps.1150110708; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KELLOGG DR, 1988, DEVELOPMENT, V103, P675; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; LEIMEISTERWACHTER M, 1989, INFECT IMMUN, V57, P2350; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; MICHAILLE JJ, 1995, GENE, V154, P205, DOI 10.1016/0378-1119(94)00865-P; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; RUHNAU K, 1989, J MOL BIOL, V210, P141, DOI 10.1016/0022-2836(89)90296-9; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SAWIN KE, 1992, J CELL SCI, V101, P303; SCHAIER SR, 1992, METHOD ENZYMOL, V215, P58; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; TANAKA T, 1992, BIOCHEM BIOPH RES CO, V187, P1022, DOI 10.1016/0006-291X(92)91299-6; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	31	480	489	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					265	269		10.1038/385265a0	http://dx.doi.org/10.1038/385265a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000076				2022-12-28	WOS:A1997WC71100051
J	Curran, J; Pollard, B				Curran, J; Pollard, B			Beards, academia, and anaesthesia: A controlled study	BRITISH MEDICAL JOURNAL			English	Article									MANCHESTER ROYAL INFIRM,MANCHESTER M13 9WL,LANCS,ENGLAND	University of Manchester	Curran, J (corresponding author), CITY HOSP NOTTINGHAM,NOTTINGHAM NG5 1PB,ENGLAND.							Addis William E., 1954, CATHOLIC DICT; [Anonymous], 2 SAMUEL, V5, P25; BRAUNFALCO O, 1991, DERMATOLOGY, P757; BROWNING DC, 1987, DICT QUOTATIONS PROV; Carcopino J ., 1956, DAILY LIFE ANCIENT R	5	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1643	1644		10.1136/bmj.313.7072.1643a	http://dx.doi.org/10.1136/bmj.313.7072.1643a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011292	Green Published			2022-12-28	WOS:A1996VZ81100053
J	Rief, M; Oesterhelt, F; Heymann, B; Gaub, HE				Rief, M; Oesterhelt, F; Heymann, B; Gaub, HE			Single molecule force spectroscopy on polysaccharides by atomic force microscopy	SCIENCE			English	Article								Recent developments in piconewton instrumentation allow the manipulation of single molecules and measurements of intermolecular as well as intramolecular forces. Dextran filaments linked to a gold surface were, probed with the atomic force microscope tip by vertical stretching. At low forces the deformation of dextran was found to be dominated by entropic forces and can be described by the Langevin function with a 6 angstrom Kuhn length. At elevated forces the strand elongation was governed by a twist of bond angles. At higher forces the dextran filaments underwent a distinct conformational change. The polymer stiffened and the segment elasticity was dominated by the bending of bond angles. The conformational change was found to be reversible and was corroborated by molecular dynamics calculations.	UNIV MUNICH,INST MED OPT,D-80333 MUNICH,GERMANY	University of Munich	Rief, M (corresponding author), UNIV MUNICH,LEHRSTUHL ANGEW PHYS,D-80799 MUNICH,GERMANY.							BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Dammer U, 1996, BIOPHYS J, V70, P2437, DOI 10.1016/S0006-3495(96)79814-4; EICHINGER M, 1995, USER MANUAL EGO 8 RE; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997; KAS J, 1994, NATURE, V368, P226, DOI 10.1038/368226a0; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LEE GU, 1994, SCIENCE, V266, P771, DOI 10.1126/science.7973628; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0	18	924	956	3	282	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1295	1297		10.1126/science.275.5304.1295	http://dx.doi.org/10.1126/science.275.5304.1295			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036852				2022-12-28	WOS:A1997WK64400039
J	Wanke, MC; Lehmann, O; Muller, K; Wen, QZ; Stuke, M				Wanke, MC; Lehmann, O; Muller, K; Wen, QZ; Stuke, M			Laser rapid prototyping of photonic band-gap microstructures	SCIENCE			English	Article								Three-dimensional periodic microstructures of aluminum oxide, which are important for creating photonic band-gap structures (PBGs), were fabricated by laser rapid prototyping by means of laser-induced direct-write deposition from the gas phase, The structures consisted of layers of parallel rods forming a face-centered tetragonal lattice with lattice constants of 66 and 133 micrometers. These structures showed transmission minima centered around 4 terahertz (75 micrometers) and 2 terahertz (150 micrometers), respectively. PBGs will allow precise control of the optical properties of materials, including lasers without threshold.	MAX PLANCK INST BIOPHYS CHEM,D-37018 GOTTINGEN,GERMANY	Max Planck Society								BOGOMOLOV VN, 1996, APPL PHYS A, V63, P617; BOMAN M, 1992, P 5 INT WORKSH MICR; Gruning U, 1996, APPL PHYS LETT, V68, P747, DOI 10.1063/1.116729; Hirayama H, 1996, APPL PHYS LETT, V69, P791, DOI 10.1063/1.117893; LEHMANN O, 1995, SCIENCE, V270, P1644, DOI 10.1126/science.270.5242.1644; LEHMANN O, 1994, MATER LETT, V21, P131, DOI 10.1016/0167-577X(94)90206-2; OZBAY E, 1994, OPT LETT, V19, P1155, DOI 10.1364/OL.19.001155; Ozbay E, 1996, APPL PHYS LETT, V69, P743; Rosenberg A, 1996, OPT LETT, V21, P830, DOI 10.1364/OL.21.000830; SOUKOULIS CM, 1996, PHOTONIC BAND GAP MA; WALLENBERGER FT, 1995, SCIENCE, V267, P1274, DOI 10.1126/science.267.5202.1274; YABLONOVITCH E, 1991, PHYS REV LETT, V67, P3380, DOI 10.1103/PhysRevLett.67.3380; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; 1993, J OPT SOC AM B, V10; 1994, J MOD OPTIC, V41, P171	15	222	232	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1284	1286		10.1126/science.275.5304.1284	http://dx.doi.org/10.1126/science.275.5304.1284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036847				2022-12-28	WOS:A1997WK64400034
J	LeRoith, D; King, G; Flier, JS				LeRoith, D; King, G; Flier, JS			Insulin-like growth factors	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FACTOR-I THERAPY; DEPENDENT DIABETES-MELLITUS; MESSENGER RIBONUCLEIC-ACID; NONISLET CELL TUMORS; BINDING-PROTEINS; HYPOGLYCEMIA; RESISTANCE; SERUM; MECHANISMS; RECEPTORS				LeRoith, D (corresponding author), NIH,DIABET BRANCH,RM 85235A,BLDG 10,BETHESDA,MD 20892, USA.		Flier, jeffrey/AAG-6223-2019					AUGUST GP, 1990, PRINCIPLES PRACTICE, P72; BACH MA, 1994, J CLIN ENDOCR METAB, V79, P1040, DOI 10.1210/jc.79.4.1040; Backeljauw PF, 1996, J CLIN ENDOCR METAB, V81, P3312, DOI 10.1210/jc.81.9.3312; BAXTER RC, 1991, J CLIN ENDOCR METAB, V73, P696, DOI 10.1210/jcem-73-4-696; BONDY CA, 1994, ANN INTERN MED, V120, P593, DOI 10.7326/0003-4819-120-7-199404010-00011; CLEMMONS DR, 1994, J CLIN ENDOCR METAB, V79, P4, DOI 10.1210/jc.79.1.4; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DUNGER DB, 1995, METABOLISM, V44, P119, DOI 10.1016/0026-0495(95)90232-5; EASTMAN RC, 1992, J CLIN INVEST, V89, P1958, DOI 10.1172/JCI115803; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; HALL K, 1989, J INTERN MED, V225, P273, DOI 10.1111/j.1365-2796.1989.tb00078.x; ISLEY WL, 1983, J CLIN INVEST, V71, P175, DOI 10.1172/JCI110757; JABRI N, 1994, DIABETES, V43, P369, DOI 10.2337/diabetes.43.3.369; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAHN CR, 1985, ANNU REV MED, V36, P429; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; KOLACZYNSKI JW, 1994, ANN INTERN MED, V120, P47, DOI 10.7326/0003-4819-120-1-199401010-00009; KUZUYA H, 1993, DIABETES, V42, P696, DOI 10.2337/diabetes.42.5.696; LARON Z, 1992, LANCET, V339, P1258, DOI 10.1016/0140-6736(92)91594-X; Laron Zvi, 1993, Current Opinion in Pediatrics, V5, P474; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LEROITH D, 1992, ANN INTERN MED, V116, P854, DOI 10.7326/0003-4819-116-10-854; LEROITH D, 1995, ENDOCR REV, V16, P143; LOWE WL, 1989, J CLIN ENDOCR METAB, V69, P1153, DOI 10.1210/jcem-69-6-1153; MALOZOWSKI S, 1994, ANN INTERN MED, V121, P549, DOI 10.7326/0003-4819-121-7-199410010-00017; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; Moses AC, 1996, DIABETES, V45, P91, DOI 10.2337/diabetes.45.1.91; MOSES AC, 1995, DIABETES RES CLIN PR, V28, pS185, DOI 10.1016/0168-8227(95)01084-Q; QUIN JD, 1990, NEW ENGL J MED, V323, P1425; *RHIGF I NIDDM STU, 1996, DIABETES S2, V45, pA27; Ruderman Neil, 1994, P969; SCHOENLE EJ, 1991, DIABETOLOGIA, V34, P675, DOI 10.1007/BF00400998; Shalet SM, 1996, TRENDS ENDOCRIN MET, V7, P287, DOI 10.1016/S1043-2760(96)00130-0; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; USALA AL, 1994, J CLIN ENDOCR METAB, V79, P435, DOI 10.1210/jc.79.2.435; Wilton P, 1992, Acta Paediatr Suppl, V383, P137; ZAPF J, 1993, J INTERN MED, V234, P543, DOI 10.1111/j.1365-2796.1993.tb01012.x; ZENOBI PD, 1992, J CLIN INVEST, V90, P2234, DOI 10.1172/JCI116109	41	485	497	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					633	640		10.1056/NEJM199702273360907	http://dx.doi.org/10.1056/NEJM199702273360907			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032050				2022-12-28	WOS:A1997WK02800007
J	Wu, DY; Wallen, HD; Nunez, G				Wu, DY; Wallen, HD; Nunez, G			Interaction and regulation of subcellular localization of CED-4 by CED-9	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; C-ELEGANS; GENE CED-3; BCL-X; PROTEIN; APOPTOSIS; MEMBRANE; ENCODES; SURVIVAL	The Caenorhabditis elegans survival gene ced-9 regulates ced-4 activity and inhibits is cell death, but the mechanism by which this occurs is unknown. Through a genetic screen for CED-4-binding proteins, CED-9 was identified as an interacting partner of CED-4. CED-9, but not loss-of-function mutants, associated specifically with CED-4 in yeast or mammalian cells. The CED-9 protein localized primarily to intracellular membranes and the perinuclear region, whereas CED-4 Was distributed in the cytosol. Expression of CED-9, but not a mutant lacking the carboxy-terminal hydrophobic domain, targeted CED-4 from the cytosol to intracellular membranes in mammalian cells. Thus, the actions of CED-4 and CED-9 are directly linked, which could provide the basis for the regulation of programmed cell death in C. elegans.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline; PHS HHS [T32A107413-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; TANAKA S, 1993, J BIOL CHEM, V268, P10920; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wu D., UNPUB; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	26	294	306	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1126	1129		10.1126/science.275.5303.1126	http://dx.doi.org/10.1126/science.275.5303.1126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027313				2022-12-28	WOS:A1997WJ50300044
J	Drake, DF				Drake, DF			Managed care - A product of market dynamics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPETITION; CALIFORNIA; COST	The development of managed care is described as an unexpected product of competition between public and private purchasers of health care. Managed care is a series of purchasing techniques that employers have applied to reduce the cost of their employees' health benefits. Its most significant use has been as a device for bargaining with individual health care providers by encouraging or requiring employees to purchase health care services from a select set of providers. Selective contracting has broken a 40-year-old barrier to price competition among health care providers, who have responded to this negotiating tactic by forming or joining larger organizational units to strengthen their bargaining power. Although the so-called managed care revolution has reduced the rate of increase in health care costs by creating a more competitive price environment, it is simply a start toward a more effective health care market. It is very much a work in progress that will affect and be affected by both political and market changes occurring over the remainder of this century.	AMER HOSP ASSOC,CHICAGO,IL									*AM HOSP ASS, NAT HOSP PAN SURV; BURKINS G, 1996, WALL ST J       0205, pA16; Cowan C A, 1993, Health Care Financ Rev, V14, P227; Drake David F., 1994, REFORMING HLTH CARE; Feldman R, 1996, INQUIRY-J HEALTH CAR, V33, P118; HELLINGER FJ, 1995, INQUIRY-J HEALTH CAR, V32, P135; Levit K R, 1985, Health Care Financ Rev, V7, P1; Levit KR, 1996, HEALTH CARE FINANC R, V17, P205; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; McMillan A, 1993, Health Care Financ Rev, V15, P135; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MELNICK GA, 1995, AM J PUBLIC HEALTH, V85, P1391, DOI 10.2105/AJPH.85.10.1391; MELNICK GA, 1992, J HEALTH ECON, V11, P217, DOI 10.1016/0167-6296(92)90001-H; MELNICK GA, 1989, HEALTH AFFAIR, V8, P129, DOI 10.1377/hlthaff.8.2.129; Pallarito K, 1995, Mod Healthc, V25, P56; ROBINSON JC, 1987, JAMA-J AM MED ASSOC, V257, P3241, DOI 10.1001/jama.257.23.3241; *US DEP HHS, 1995, HLTH CAR FIN REV MED; ZWANZIGER J, 1994, HEALTH AFFAIR, V13, P118, DOI 10.1377/hlthaff.13.4.118	18	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					560	563		10.1001/jama.277.7.560	http://dx.doi.org/10.1001/jama.277.7.560			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH297	9032163				2022-12-28	WOS:A1997WH29700032
J	McMillan, R				McMillan, R			Therapy for adults with refractory chronic immune thrombocytopenic purpura	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PROTEIN-A-IMMUNOADSORPTION; FETAL PLATELET COUNTS; AUTOIMMUNE THROMBOCYTOPENIA; DANAZOL THERAPY; SLOW INFUSION; INTRAVENOUS IMMUNOGLOBULIN; CYCLOPHOSPHAMIDE THERAPY; ACCESSORY SPLENECTOMY; AMINOCAPROIC ACID; GAMMA-GLOBULIN	Adult chronic immune thrombocytopenic purpura (ITP) is a common hematologic disorder; about 14 000 to 16 000 new cases occur each year in the United States. Initial treatment with corticosteroids and splenectomy results in normal or ''safe'' platelet counts in more than 70% of patients. Treatment of patients refractory to these two treatments is difficult. This paper describes a structured approach to therapy that is based on a literature review and personal experience, including experience with treatment of chronic ITP in special situations (such as emergent bleeding, pregnancy, and central nervous system bleeding). Treatment of most patients with chronic ITP is fairly straightforward, but management of patients refractory to corticosteroids and splenectomy can be difficult. Large, randomized studies are clearly needed to better evaluate the many types of treatment that are recommended for refractory patients.			McMillan, R (corresponding author), SCRIPPS CLIN, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [RR00833] Funding Source: Medline; NHLBI NIH HHS [HL37945] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037945] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DM, 1994, AM J PERINAT, V11, P42, DOI 10.1055/s-2007-994534; AHN YS, 1984, ANN INTERN MED, V100, P192, DOI 10.7326/0003-4819-100-2-192; AHN YS, 1974, NEW ENGL J MED, V291, P376, DOI 10.1056/NEJM197408222910802; AHN YS, 1989, ANN INTERN MED, V111, P723, DOI 10.7326/0003-4819-111-9-723; AHN YS, 1983, NEW ENGL J MED, V308, P1396, DOI 10.1056/NEJM198306093082306; AKWARI OE, 1987, ANN SURG, V206, P529, DOI 10.1097/00000658-198710000-00014; ALMAGRO D, 1985, ACTA HAEMATOL-BASEL, V74, P120, DOI 10.1159/000206184; AMBRIZ P, 1985, RADIOLOGY, V155, P793, DOI 10.1148/radiology.155.3.4039827; AMREIN PC, 1983, NEW ENGL J MED, V308, P1081; ANDERSEN JC, 1994, NEW ENGL J MED, V330, P1560, DOI 10.1056/NEJM199406023302203; ARROWSMITH JB, 1986, NEW ENGL J MED, V315, P585; BARTHOLOMEW JR, 1989, ARCH INTERN MED, V149, P1959, DOI 10.1001/archinte.149.9.1959; BAUMANN MA, 1986, ANN INTERN MED, V104, P808, DOI 10.7326/0003-4819-104-6-808; BELLUCCI S, 1989, BRIT J HAEMATOL, V73, P578, DOI 10.1111/j.1365-2141.1989.tb00308.x; BELLUCCI S, 1988, BLOOD, V71, P1165; BERCHTOLD P, 1989, BLOOD, V74, P2309; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; BOTTIGER LE, 1972, ACTA MED SCAND, V191, P535; BOURONCL.BA, 1969, J AMER MED ASSOC, V207, P2049, DOI 10.1001/jama.207.11.2049; BOURONCLE BA, 1966, NEW ENGL J MED, V275, P630, DOI 10.1056/NEJM196609222751202; BUELLI M, 1985, ACTA HAEMATOL-BASEL, V74, P97, DOI 10.1159/000206176; Burrows R F, 1993, Obstet Gynecol Surv, V48, P781, DOI 10.1097/00006254-199312000-00003; BURROWS RF, 1990, AM J OBSTET GYNECOL, V163, P1147, DOI 10.1016/0002-9378(90)90675-W; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; BURROWS RF, 1993, CURRENT OBSTETRICAL, P83; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; BUSSEL JB, 1990, HEMATOL ONCOL CLIN N, V4, P179, DOI 10.1016/S0889-8588(18)30512-4; BUSSEL JB, 1986, TRANSFUSION, V26, P399, DOI 10.1046/j.1537-2995.1986.26486262755.x; CALVERLEY DC, 1992, ANN INTERN MED, V116, P977, DOI 10.7326/0003-4819-116-12-977; Caulier MT, 1995, BLOOD, V86, P3380; CERVANTES F, 1980, POSTGRAD MED J, V56, P711, DOI 10.1136/pgmj.56.660.711; CORLEY CC, 1966, AM J MED, V41, P404, DOI 10.1016/0002-9343(66)90086-6; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; DUBBELD P, 1994, EUR J HAEMATOL, V52, P233; DURAND JM, 1991, BRIT J HAEMATOL, V78, P460, DOI 10.1111/j.1365-2141.1991.tb04467.x; FACON T, 1994, BRIT J HAEMATOL, V86, P678, DOI 10.1111/j.1365-2141.1994.tb04810.x; FACON T, 1992, AM J HEMATOL, V41, P184, DOI 10.1002/ajh.2830410308; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; FINCH SC, 1974, AM J MED, V56, P4, DOI 10.1016/0002-9343(74)90745-1; FLORES A, 1990, EUR J HAEMATOL, V45, P109; GARDNER FH, 1980, JAMA-J AM MED ASSOC, V243, P35, DOI 10.1001/jama.243.1.35; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1995, WILLIAMS HEMATOLOGY, P1315; GODEAU B, 1993, AM J HEMATOL, V44, P70, DOI 10.1002/ajh.2830440117; GOEBEL KM, 1973, CHEMOTHERAPY, V18, P112, DOI 10.1159/000221252; HERNANDEZ F, 1995, BRIT J HAEMATOL, V90, P473, DOI 10.1111/j.1365-2141.1995.tb05179.x; HOHLFELD P, 1994, BLOOD, V84, P1851, DOI 10.1182/blood.V84.6.1851.bloodjournal8461851; HURTADO R, 1990, BLOOD, V75, P1744; JACOBS P, 1986, Q J MED, V58, P153; JIJI RM, 1973, ARCH INTERN MED, V132, P380, DOI 10.1001/archinte.132.3.380; KABISCH A, 1994, LANCET, V343, P116, DOI 10.1016/S0140-6736(94)90843-5; KAPLAN C, 1990, LANCET, V336, P979, DOI 10.1016/0140-6736(90)92430-P; KARPATKIN S, 1980, BLOOD, V56, P329; KELSEY PR, 1985, BRIT J HAEMATOL, V60, P197, DOI 10.1111/j.1365-2141.1985.tb07400.x; KELTON JG, 1982, SEMIN THROMB HEMOST, V8, P83, DOI 10.1055/s-2007-1005045; KELTON JG, 1983, ANN INTERN MED, V99, P796, DOI 10.7326/0003-4819-99-6-796; KIEFEL V, 1991, BRIT J HAEMATOL, V79, P256, DOI 10.1111/j.1365-2141.1991.tb04530.x; Kyle RA, 1992, CHEMOTHERAPY SOURCE, P689; LAROS RK, 1971, J AMER MED ASSOC, V215, P445; LEFOR AT, 1993, SURGERY, V114, P613; MANOHARAN A, 1986, AM J HEMATOL, V21, P135, DOI 10.1002/ajh.2830210203; MARMONT AM, 1971, ACTA HAEMATOL-BASEL, V46, P74, DOI 10.1159/000208563; MATSUMURA O, 1988, TRANSPL P, V20, P317; MATTHEY F, 1990, LANCET, V335, P471, DOI 10.1016/0140-6736(90)90701-6; MAZZUCCONI MG, 1987, ACTA HAEMATOL-BASEL, V77, P45, DOI 10.1159/000205948; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135, DOI 10.1056/NEJM198105073041904; MCMILLAN R, 1987, BLOOD, V70, P1040; MCMILLAN R, 1994, THROMBOSIS HEMORRHAG, P575; MCVERRY BA, 1985, BRIT J HAEMATOL, V61, P145, DOI 10.1111/j.1365-2141.1985.tb04070.x; MELO J, 1983, BLOOD, V58, P200; *MMWR, 1993, MMWR-MORBID MORTAL W, V42, P1; MOISE KJ, 1988, OBSTET GYNECOL, V72, P346; MOLICA S, 1991, AM J HEMATOL, V36, P297, DOI 10.1002/ajh.2830360417; MUELLERECKHARDT C, 1977, SEMIN THROMB HEMOST, V3, P125; NALLI G, 1988, HAEMATOLOGICA, V73, P55; PIZZUTO J, 1984, BLOOD, V64, P1179; PROCTOR SJ, 1991, EUR J CANCER, V27, pS63, DOI 10.1016/0277-5379(91)90577-Z; PROCTOR SJ, 1989, BLOOD, V74, P1894; QUIQUANDON I, 1990, BRIT J HAEMATOL, V74, P223, DOI 10.1111/j.1365-2141.1990.tb02569.x; REINER A, 1995, BLOOD, V85, P351; RIES CA, 1976, NEW ENGL J MED, V295, P1136; SCHREIBER AD, 1987, NEW ENGL J MED, V316, P503, DOI 10.1056/NEJM198702263160903; SHARON R, 1994, AM J HEMATOL, V46, P87, DOI 10.1002/ajh.2830460206; SIMON M, 1987, EUR J HAEMATOL, V39, P193; SNYDER HW, 1992, BLOOD, V79, P2237; SRICHAIKUL T, 1980, ARCH INTERN MED, V140, P636, DOI 10.1001/archinte.140.5.636; STROTHER SV, 1984, ARCH INTERN MED, V144, P2198, DOI 10.1001/archinte.144.11.2198; SUSSMAN LN, 1967, J AMER MED ASSOC, V202, P259, DOI 10.1001/jama.202.4.259; THOMPSON RL, 1972, ARCH INTERN MED, V130, P730, DOI 10.1001/archinte.130.5.730; VANLEEUWEN EF, 1982, BLOOD, V59, P23; VELU TJ, 1987, EUR J HAEMATOL, V38, P95; VERHEYDEN CN, 1978, MAYO CLIN PROC, V53, P442; VERLIN M, 1976, AM J HEMATOL, V1, P97, DOI 10.1002/ajh.2830010111; WALLACE D, 1982, SURGERY, V91, P134; WEINERMAN B, 1974, CAN MED ASSOC J, V111, P1100; WOODRUFF RK, 1986, LANCET, V2, P217; Young RR, 1995, BLOOD, V86, P252	98	150	157	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					307	314		10.7326/0003-4819-126-4-199702150-00007	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036803				2022-12-28	WOS:A1997WH06800009
J	Ridker, PM; Hennekens, CH; Schmitz, C; Stampfer, MJ; Lindpaintner, K				Ridker, PM; Hennekens, CH; Schmitz, C; Stampfer, MJ; Lindpaintner, K			Pl(A1/A2) polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis	LANCET			English	Article							CORONARY INTERVENTION; IIB/IIIA INTEGRIN; RANDOMIZED TRIAL; RECEPTORS; BLOCKADE; GENE	Background The gene encoding the platelet glycoprotein I[la receptor (GPIIIa), shows polymorphism (P-A1/A2. In a previous study, men with acute coronary ischaemia were more likely than controls to carry the P/(A2) allele. This receptor has an important role in acute thrombus formation; these findings therefore raise the possibility of inherited platelet risk factors for both arterial and venous thrombosis. We investigated whether the P/(A2) allele is associated with myocardial infarction, stroke, and Venous thrombosis in a large prospective cohort of men in the USA. Methods 14916 initially healthy men participating in the Physicians' Health Study provided baseline blood specimens for DNA analysis and were followed prospectively for a mean of 8.6 years. 374 men had a first myocardial infarction, 209 stroke, and 121 venous thrombosis during follow-up (704 cases). Distribution of the P/(A1/A2) polymorphism was investigated by a PCR based on restriction-fragment length polymorphism in these men and in a sample of 704 matched study participants who remained free of thrombosis during follow-up (controls). Findings The frequency of the P/(A2) allele was similar to the control frequency (14.8%) among men who had myocardial infarction (13.5%, p=0.4), stroke (13.4%, p=0.5), or Venous thrombosis (14.5%, p=0.9). The relative risk of any Vascular event among men homozygous or heterozygous for P/(A2) compared with men homozygous for P/(A1) was 0.96 (95% CI 0.8-1.2). We found no evidence of association between the P/(A2) allele and myocardia[ infarction (relative risk 0.93 [95 0.7-1.2]), stroke (0.93 [0.7-1.3]), or venous thrombosis (1.07 [0.7-1.6]). There was no evidence of association in subgroup analyses by age, smoking status, and presence of family history of premature coronary disease, hypercholesterolaemia, hypertension, or diabetes. Aspirin use had no effect on these findings. Interpretation In a large cohort of apparently healthy men, carriage of the GPIIIa P/(A2) allele was not associated with any increase in subsequent risk of myocardial infarction, stroke, or Venous thrombosis.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH MED, CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOL SCI, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Ridker, PM (corresponding author), BRIGHAM & WOMENS HOSP, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02115 USA.							BORNE AEGV, 1990, TRANSFUSION, V30, P477, DOI 10.1046/j.1537-2995.1990.30590296385.x; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; JIN Y, 1993, BLOOD, V82, P2281; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; OHMAN EM, 1994, CIRCULATION, V90, P564; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SCHULMAN SP, 1993, CIRCULATION, V88, P608; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; SIMSEK S, 1993, BLOOD, V81, P835; TCHENG JE, 1995, CIRCULATION, V91, P2151, DOI 10.1161/01.CIR.91.8.2151; THEROUX P, 1994, CIRCULATION, V90, P1; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	17	317	326	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					385	388		10.1016/S0140-6736(97)80010-4	http://dx.doi.org/10.1016/S0140-6736(97)80010-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033464				2022-12-28	WOS:A1997WH29600010
J	Yaryura, R; Vardhan, R; Springer, AJ; Cooley, DA				Yaryura, R; Vardhan, R; Springer, AJ; Cooley, DA			A 66-year-old man with severe angina and previous coronary artery bypass	LANCET			English	Article							SURGERY		ST LUKES EPISCOPAL HOSP,TEXAS HEART INST,DEPT ADULT CARDIOL,HOUSTON,TX 77225; ST LUKES EPISCOPAL HOSP,TEXAS HEART INST,DEPT CARDIOVASC SURG,HOUSTON,TX 77225	Saint Lukes Episcopal Hospital; Texas Heart Institute; Saint Lukes Episcopal Hospital; Texas Heart Institute								Angelini GD, 1996, LANCET, V347, P757, DOI 10.1016/S0140-6736(96)90107-5; BENETTI FJ, 1995, J CARDIAC SURG, V10, P620, DOI 10.1111/j.1540-8191.1995.tb00651.x; Cooley DA, 1996, TEX HEART I J, V23, P81; STANBRIDGE RD, 1995, LANCET, V346, P837, DOI 10.1016/S0140-6736(95)91650-4; UPPAL R, 1994, ANN THORAC SURG, V57, P125	5	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					396	396		10.1016/S0140-6736(97)80013-X	http://dx.doi.org/10.1016/S0140-6736(97)80013-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033467				2022-12-28	WOS:A1997WH29600013
J	Kay, RF; Ross, C; Williams, BA				Kay, RF; Ross, C; Williams, BA			Anthropoid origins	SCIENCE			English	Review							CRANIAL MORPHOLOGY; ANTERIOR TEETH; LATE EOCENE; PRIMATES; ADAPTATIONS; OMOMYIDAE; AFRICA; AEGYPTOPITHECUS; POSTCRANIUM; DENTITION	Recent fossil discoveries have greatly increased our knowledge of the morphology and diversity of early Anthropoidea, the suborder to which humans belong. Phylogenetic analysis of Recent and fossil taxa supports the hypotheses that a haplorhine-strepsir-rhine dichotomy existed at least at the time of the earliest record of fossil primates (earliest Eocene) and that eosimiids (middle Eocene, China) are primitive anthropoids. Functional analysis suggests that stem haplorhines were small, nocturnal, arboreal, visually oriented insectivore-frugivores with a scurrying-leaping locomotion. A change from nocturnality to diurnality was the fundamental adaptive shift that occurred at the base of the tarsier-eosimiid-anthropoid clade. Stem anthropoids remained small diurnal arborealists but adopted locomotor patterns with more arboreal quadrupedalism and less leaping. A shift to a more herbivorous diet occurred in several anthropoid lineages.	SUNY STONY BROOK, DEPT ANAT SCI, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kay, RF (corresponding author), DUKE UNIV, MED CTR, DEPT BIOL ANTHROPOL & ANAT, BOX 3170, DURHAM, NC 27710 USA.			Ross, Callum/0000-0001-7764-761X				Allman J., 1977, PROGR PSYCHOBIOLOGY, V7, P1; [Anonymous], VERTEBRATE EYE ITS A, DOI 10.1097/00005053-194409000-00057; AX P, 1985, Cladistics, V1, P279, DOI 10.1111/j.1096-0031.1985.tb00428.x; Beard K. Christopher, 1994, P55; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1988, NATURE, V331, P712, DOI 10.1038/331712a0; BEARD KC, 1991, NATURE, V349, P64, DOI 10.1038/349064a0; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; CACHEL SM, 1979, AM J PHYS ANTHROPOL, V50, P1, DOI 10.1002/ajpa.1330500102; Cartmill M., 1980, P243; Cartmill M., 1972, FUNCTIONAL EVOLUTION, P97, DOI DOI 10.4324/9781315132129; Cartmill M., 1978, RECENT ADV PRIMATOL, P205; Cartmill Matt, 1994, P549; Cartmill Matt, 1992, Evolutionary Anthropology, V1, P105, DOI 10.1002/evan.1360010308; Ciochon Russell L., 1994, P143; COLBERT EH, 1937, AM MUS NOVIT, P1; Covert Herbert H., 1994, P29; COVERT HH, 1993, J HUM EVOL, V25, P351, DOI 10.1006/jhev.1993.1054; COVERT HH, 1988, J HUM EVOL, V17, P57, DOI 10.1016/0047-2484(88)90049-8; COVERT HH, 1991, J HUM EVOL, V21, P463, DOI 10.1016/0047-2484(91)90096-E; COVERT HH, 1986, COMP PRIMATE BIOL, V1, P335; Dagosto M, 1996, J HUM EVOL, V30, P29, DOI 10.1006/jhev.1996.0003; DAGOSTO M, 1985, INT J PRIMATOL, V6, P45, DOI 10.1007/BF02693696; DAGOSTO M, 1983, FOLIA PRIMATOL, V41, P49, DOI 10.1159/000156119; DAGOSTO M, 1990, J HUM EVOL, V19, P121, DOI 10.1016/0047-2484(90)90014-3; Dagosto M, 1995, J VERTEBR PALEONTOL, V15, p25A; DAGOSTO M, 1996, AM J PHYS ANTHROPOL, V99, P92; Dagosto Marian, 1993, P199; Dagosto Marian, 1994, P567; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; FLEAGLE JG, 1982, AM J PHYS ANTHROPOL, V59, P175, DOI 10.1002/ajpa.1330590207; FLEAGLE JG, 1980, NATURE, V287, P328, DOI 10.1038/287328a0; FLEAGLE JG, 1995, AM J PHYS ANTHROPOL, V97, P235, DOI 10.1002/ajpa.1330970303; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; FLYNN JJ, 1995, NATURE, V373, P603, DOI 10.1038/373603a0; Fogden M.P.L., 1974, P151; FORD S M, 1980, Primates, V21, P31, DOI 10.1007/BF02383822; Franzen Jens Lorenz, 1994, P99; GARBER PA, 1992, AM J PHYS ANTHROPOL, V88, P469, DOI 10.1002/ajpa.1330880404; GEBO D, COMMUNICATION; Gebo Daniel L., 1994, P203; GEBO DL, 1996, AM J PHYS ANTHROPOL, V99, P111; Gheerbrant Emmanuel, 1993, Palaeovertebrata (Montpellier), V22, P141; Gidley J. W., 1923, Proceedings of the United States National Museum, V63, P1; Gingerich P.D., 1980, P123; GINGERICH PD, 1977, FOLIA PRIMATOL, V28, P144, DOI 10.1159/000155804; Gingerich Philip D., 1994, P163; GINSBURG L, 1987, CR ACAD SCI II, V304, P1213; GODINOT M, 1983, J PALEONTOL, V57, P1321; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; GREAVES WS, 1985, J ZOOL, V207, P125; Hartenberger J.-L., 1992, Human Evolution, V7, P9, DOI 10.1007/BF02437474; HOFSTETTER R, 1980, EVOLUTIONARY BIOL NE, P103; Jenkins P., 1987, CATALOGUE PRIMATES 4; Kay R.F., 1984, P467; Kay R.F., 1980, P159; Kay R.F., 1994, EVOL ANTHROPOL, V3, P32; KAY RF, 1977, J HUM EVOL, V6, P19, DOI 10.1016/S0047-2484(77)80040-7; Kay Richard F., 1994, P361; Luckett WP., 1975, PHYLOGENY PRIMATES, P157, DOI [10.1007/978-1-4684-2166-8, DOI 10.1007/978-1-4684-2166-8]; MacPhee R. D. E., 1986, COMP PRIM B, V1, P219; MacPhee RDE, 1995, J HUM EVOL, V29, P501, DOI 10.1006/jhev.1995.1073; MARTIN RD, 1992, J HUM EVOL, V22, P367, DOI 10.1016/0047-2484(92)90066-I; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; PLAVCAN JM, 1995, J HUM EVOL, V28, P245, DOI 10.1006/jhev.1995.1019; POCOCK RI, 1918, P ZOOL SOC LOND, P9; PORTER CA, 1995, J MOL EVOL, V40, P30, DOI 10.1007/BF00166594; RASMUSSEN DT, 1995, J HUM EVOL, V29, P301, DOI 10.1006/jhev.1995.1061; RASMUSSEN DT, 1992, INT J PRIMATOL, V13, P1; RASMUSSEN DT, 1990, INT J PRIMATOL, V11, P437; ROSE KD, 1996, AM J PHYS ANTHR S, V22, P202; Rose Kenneth D., 1994, P1; Rosenberger A.L., 1986, P66; Rosenberger A.L., 1980, P139; ROSENBERGER AL, 1985, FOLIA PRIMATOL, V45, P179, DOI 10.1159/000156227; ROSS C, 1995, AM J PHYS ANTHROPOL, V98, P275, DOI 10.1002/ajpa.1330980304; Ross C, 1996, AM J PRIMATOL, V40, P205, DOI 10.1002/(SICI)1098-2345(1996)40:3<205::AID-AJP1>3.0.CO;2-1; Ross Callum, 1994, P469; Ross CF, 1996, AM J PHYS ANTHROPOL, V101, P183, DOI 10.1002/(SICI)1096-8644(199610)101:2<183::AID-AJPA6>3.0.CO;2-3; ROSS CF, 1995, J HUM EVOL, V29, P210; Sige B, 1990, PALEONTOGRAPHICA, V212, P1; Simons E, 1995, YEARB PHYS ANTHROPOL, V38, P199; SIMONS E. L., 1960, BREVIORA MUS COMP ZOOL [HARVARD], V127, P1; Simons EL, 1996, AM J PHYS ANTHROPOL, V100, P261, DOI 10.1002/(SICI)1096-8644(199606)100:2<261::AID-AJPA7>3.0.CO;2-#; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; Simons EL, 1995, J HUM EVOL, V29, P577, DOI 10.1006/jhev.1995.1076; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1989, AM J PHYS ANTHROPOL, V79, P1, DOI 10.1002/ajpa.1330790103; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; Simons Elwyn L., 1994, Evolutionary Anthropology, V3, P128, DOI 10.1002/evan.1360030407; Smith A.G., 1994, ATLAS MESOZOIC CENOZ; SZALAY F S, 1976, Bulletin of the American Museum of Natural History, V156, P157; Szalay F.S., 1979, EVOLUTIONARY HIST PR; Szalay F.S., 1975, PHYLOGENY PRIMATES M, P91; SZALAY FS, 1972, NATURE, V236, P179, DOI 10.1038/236179a0; Terborgh J, 1983, 5 NEW WORLD PRIMATES; Williams B.A., 1995, EVOL ANTHROPOL, V3, P188; WILLIAMS BA, 1994, AM J PHYS ANTHROPOL, V93, P323, DOI 10.1002/ajpa.1330930305; WILLIAMS BA, 1994, THESIS U COLORADO BO; Wortman J. L., 1903, AM J SCI, V15, P161	102	187	197	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					797	804		10.1126/science.275.5301.797	http://dx.doi.org/10.1126/science.275.5301.797			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	WG777	9012340				2022-12-28	WOS:A1997WG77700051
J	Holleman, WL; Holleman, MC; Moy, JG				Holleman, WL; Holleman, MC; Moy, JG			Are ethics and managed care strange bedfellows or a marriage made in heaven?	LANCET			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT FAMILY PRACTICE & COMMUNITY MED,HOUSTON,TX; BAYLOR COLL MED,DEPT FAMILY MED,HOUSTON,TX 77030; BAYLOR COLL MED,CTR MED ETH & HLTH POLICY,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine				Graves, Julie/0000-0001-6056-5159				BRODY H, 1995, FAM PRACT NEWS  0101, P8; CLANCY CM, 1995, NEW ENGL J MED, V332, P604; *COUNC ETH JUD AFF, 1995, JAMA-J AM MED ASSOC, V273, P330; DEBAKEY ME, 1995, HOUSTON CHRONIC 0618, pC1; *DIV STAT LEG AM M, 1995, SPEC REP UPD STAT PP; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P817, DOI 10.1001/jama.272.10.817; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; FREUDENHEIM M, 1995, NY TIMES        0411, pD4; FREUDENHEIM MA, 1995, NY TIMES        0427, pC1; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; La Puma J, 1994, Arch Fam Med, V3, P665, DOI 10.1001/archfami.3.8.665; LIGHT DW, 1994, LANCET, V344, P1197, DOI 10.1016/S0140-6736(94)90512-6; RODWIN MA, 1995, NEW ENGL J MED, V332, P604, DOI 10.1056/NEJM199503023320913; ROULIDIS ZC, 1994, J FAM PRACTICE, V39, P446	16	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					350	351		10.1016/S0140-6736(96)04025-1	http://dx.doi.org/10.1016/S0140-6736(96)04025-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024391				2022-12-28	WOS:A1997WF79400044
J	Zamponi, GW; Bourinet, E; Nelson, D; Nargeot, J; Snutch, TP				Zamponi, GW; Bourinet, E; Nelson, D; Nargeot, J; Snutch, TP			Crosstalk between G proteins and protein kinase C mediated by the calcium channel alpha(1) subunit	NATURE			English	Article							CA2+ CHANNELS; SYNAPTIC TRANSMISSION; N-TYPE; SUBCELLULAR-DISTRIBUTION; RECEPTOR INHIBITION; SYMPATHETIC NEURONS; BETA-SUBUNIT; K+ CHANNEL; MODULATION; RAT	The modulation of voltage-dependent Ca2+ channels at presynaptic nerve terminals is an important factor in the control of neurotranmitter release and synaptic efficacy, Some terminals contain multiple Ca2+-channel subtypes (N and P/Q)(1-3), which are differentially regulated by G-protein activation(4-8) and by protein kinase C (PKC)-dependent phosphorylation(9-11). Regulation of channel activity by crosstalk between second messenger pathways has been reported(12,13), although the molecular mechanisms underlying crosstalk have not been described. Here we show that crosstalk occurs at the level of the presynaptic Ca2+-channel complex. The alpha(1) subunit domain I-II linker, which connects the first and second transmembrane domains, contributes to the PKC-dependent upregulation of channel activity, while G-protein-dependent inhibition occurs through binding of G beta gamma to two sites in the I-II linker, Crosstalk results from the PKC-dependent phosphorylation of one of the G beta gamma binding sites which antagonizes G beta gamma-induced inhibition. The results provide a mechanism for the highly regulated and dynamic control of neurotransmitter release that depends on bite integration of multiple presynaptic signals.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA; CNRS, CRBM, F-34033 MONTPELLIER, FRANCE	University of British Columbia; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; bourinet, emmanuel/0000-0001-8021-0419; Nargeot, Joel/0000-0003-2893-5636; Zamponi, Gerald W./0000-0002-0644-9066				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; DEWAARD M, NATURE; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RHIM H, 1994, J NEUROSCI, V14, P7608; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; ZHU Y, 1994, J NEUROPHYSIOL, V72, P1549, DOI 10.1152/jn.1994.72.4.1549	27	392	402	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					442	446		10.1038/385442a0	http://dx.doi.org/10.1038/385442a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009192				2022-12-28	WOS:A1997WF00700054
J	Mulcahy, HE; Farthing, MJG; ODonoghue, DP				Mulcahy, HE; Farthing, MJG; ODonoghue, DP			Fortnightly review - Screening for asymptomatic colorectal cancer	BRITISH MEDICAL JOURNAL			English	Review							FECAL OCCULT BLOOD; COLON-CANCER; FAMILY HISTORY; BREAST-CANCER; MORTALITY; SIGMOIDOSCOPY; COLONOSCOPY; RELATIVES; NEOPLASIA; TESTS		ST VINCENTS HOSP,GASTROENTEROL & LIVER UNIT,DUBLIN 4,IRELAND; UNIV COLL DUBLIN,DUBLIN 4,IRELAND	University College Dublin; University College Dublin	Mulcahy, HE (corresponding author), ST BARTHOLOMEWS AND ROYAL LONDON SCH MED & DENT,DIGEST DIS RES CTR,LONDON E1,ENGLAND.			mulcahy, hugh/0000-0002-7087-6177				AITKEN WS, 1996, GUT, V38, pA9; AITKEN WS, 1992, NEW ENGL J MED, V326, P658; AITKEN WS, 1993, LANCET, V341, P736; Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; *AM CANC SOC, 1986, 2077LE AM CANC SOC; Bejes C, 1992, Fam Pract Res J, V12, P83; BHATTACHARYA I, 1996, LANCET, V347, P1774; BRALOW SP, 1979, J FLA MED ASSOC, V66, P915; BROWN ML, 1993, NEW ENGL J MED, V329, P1352; BURT RW, 1992, CANCER, V70, P1296, DOI 10.1002/1097-0142(19920901)70:3+<1296::AID-CNCR2820701516>3.0.CO;2-3; *CAN TASK FORC PER, 1994, CAN GUID CLIN PREV H, P797; CARPENTER S, 1995, GUT, V36, P90, DOI 10.1136/gut.36.1.90; DAVIS NC, 1983, AUST NZ J SURG, V53, P211, DOI 10.1111/j.1445-2197.1983.tb02430.x; DEBINSKI HS, 1995, EUR J CANCER, V31A, P1149, DOI 10.1016/0959-8049(95)00171-E; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; Eguchi S, 1996, CANCER, V77, P1707, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1707::AID-CNCR43>3.3.CO;2-U; FOLEY DP, 1987, GUT, V28, pA1367; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; GNAUCK R, 1995, TUMORI, V81, P30; GNAUCK R, 1986, SECONDARY PREVENTION, P143; GREEN SE, 1995, BRIT J SURG, V82, P1338, DOI 10.1002/bjs.1800821013; HARDCASTLE JD, 1989, LANCET, V1, P1160; HART AR, 1995, GUT, V36, P590, DOI 10.1136/gut.36.4.590; HOULSTON RS, 1990, BRIT MED J, V301, P366, DOI 10.1136/bmj.301.6748.366; HUNTER W, 1991, FAM PRACT, V8, P367, DOI 10.1093/fampra/8.4.367; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KEWENTER J, 1994, SCAND J GASTROENTERO, V29, P468, DOI 10.3109/00365529409096840; *KINGS FUND FOR, 1990, BRIT J SURG, V77, P1063; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANCE P, 1993, GASTROENTEROLOGY, V104, P1852, DOI 10.1016/0016-5085(93)90669-4; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; Launoy G, 1993, Eur J Cancer Prev, V2, P229, DOI 10.1097/00008469-199305000-00006; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; LUCHTEFELD MA, 1991, DIS COLON RECTUM, V34, P763, DOI 10.1007/BF02051067; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MACRAE FA, 1984, PREV MED, V13, P115, DOI 10.1016/0091-7435(84)90044-6; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MARKS G, 1979, DIS COLON RECTUM, V22, P162, DOI 10.1007/BF02586809; MAULE WF, 1994, NEW ENGL J MED, V330, P183, DOI 10.1056/NEJM199401203300307; MUELLER CB, 1994, AM J CLIN ONCOL-CANC, V17, P86; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; RAFFLE AE, 1995, LANCET, V345, P1469, DOI 10.1016/S0140-6736(95)91036-0; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RAVEN JS, 1995, GUT, V36, P81; REX DK, 1994, GASTROENTEROLOGY, V106, P593, DOI 10.1016/0016-5085(94)90690-4; Robinson M H, 1994, Eur J Surg Oncol, V20, P545; ROBINSON MHE, 1995, BRIT J SURG, V82, P318, DOI 10.1002/bjs.1800820310; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SHAPIRO S, 1992, J NATL CANCER I, V84, P1546, DOI 10.1093/jnci/84.20.1546; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; SKRABANEK P, 1985, LANCET, V2, P316; SPIGELMAN AD, 1989, LANCET, V2, P783, DOI 10.1016/s0140-6736(89)90840-4; STJOHN DJB, 1993, GASTROENTEROLOGY, V104, P1661, DOI 10.1016/0016-5085(93)90643-Q; VASEN HF, 1993, DIS COLON RECTUM, V36, P1, DOI 10.1007/BF02050292; Vasen HFA, 1996, LANCET, V348, P433, DOI 10.1016/S0140-6736(96)01340-2; VASEN HFA, 1995, LANCET, V345, P1183, DOI 10.1016/S0140-6736(95)91016-6; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WEBER J, 1996, LANCET, V348, P465; Whynes D K, 1992, Health Econ, V1, P53, DOI 10.1002/hec.4730010108; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909; WRIGHT CJ, 1995, LANCET, V346, P29, DOI 10.1016/S0140-6736(95)92655-0; 1995, AGA NEWS, V29, P12	66	25	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					285	291		10.1136/bmj.314.7076.285	http://dx.doi.org/10.1136/bmj.314.7076.285			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022495	Green Published			2022-12-28	WOS:A1997WE63300032
J	Hentze, MW				Hentze, MW			Translation - elF4G: A multipurpose ribosome adapter?	SCIENCE			English	Editorial Material							CLEAVAGE SITE; INITIATION; BINDING; PROTEASES				Hentze, MW (corresponding author), EUROPEAN MOL BIOL LAB,GENE EXPRESS PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876				CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; IMATAKA H, IN PRESS EMBO J; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LEVYSTRUMPF N, IN PRESS MOL CELL BI; MADER S, 1995, MOL CELL BIOL, V15, P4990; Merrick WC., 1996, TRANSLATION CONTROL, P31; OH SK, 1993, CURR OPIN GENET DEV, V3, P295, DOI 10.1016/0959-437X(93)90037-P; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; TARUN SZ, UNPUB; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2	23	194	199	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					500	501		10.1126/science.275.5299.500	http://dx.doi.org/10.1126/science.275.5299.500			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	9019810				2022-12-28	WOS:A1997WE25700035
J	Gallo, D; George, JR; Fitchen, JH; Goldstein, AS; Hindahl, MS				Gallo, D; George, JR; Fitchen, JH; Goldstein, AS; Hindahl, MS			Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIVIRAL ANTIBODIES; SALIVA; TYPE-1; SURVEILLANCE; ASSAYS; SERUM; ELISA; BLOOD; FLUID	Objective.-To determine accuracy of a human immunodeficiency virus type 1 (HIV-1) antibody testing system using a device to collect and stabilize oral mucosal transudate (OMT), a fluid with increased levels of IgG; an enzyme immunoassay (EIA) screening test optimized for OMT; and a Western blot confirmatory test designed for use with OMT, Design.-The OMT specimens were tested by EIA and, if indicated, confirmatory Western blot according to a standard testing algorithm. The OMT results were compared with true HIV status as determined by serum testing and/or clinical diagnosis. Patients.-Specimens from 3570 subjects (2382 at low risk, 698 at high risk, 242 with acquired immunodeficiency syndrome [AIDS], and 248 ''nonspecificity'' [persons with diseases associated with an increased frequency of false-positive results in HIV testing]) were collected at If geographically diverse sites (including blood banks, public health clinics, general medical clinics, HIV clinics, sexually transmitted disease clinics, and a hemophilia center) in the United States. Main Outcome Measures.-Overall accuracy of testing OMT for HIV-1 antibodies compared with true HIV-1 antibody status; sensitivity and specificity of OMT EIA and Western blot, Results-Sensitivity of OMT EIA testing in 673 true-positive subjects was 99.9% (672/673). The OMT Western blot results in the 673 true-positive subjects were positive in 665 and indeterminate in 8. The EIA followed by Western blot (a EIA was repeatedly reactive) yielded a negative result in 99.9% (2893/2897) of OMT samples from true negatives and an indeterminate result in 4. The OMT testing system provided the correct result or would trigger appropriate follow-up testing in 3569 (>99.9%) of 3570 cases, Conclusion.-HIV-1 antibody testing of OMT samples is a highly accurate alternative to serum testing.	EPITOPE INC,BEAVERTON,OR 97008; CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA	California Department of Health Care Services								ARCHIBALD DW, 1986, BLOOD, V67, P831; BAGG J, 1991, ARCH ORAL BIOL, V36, P221, DOI 10.1016/0003-9969(91)90089-D; BEHETS FM, 1991, J ACQ IMMUN DEF SYND, V4, P183; Brandtzaeg P, 1989, HUMAN SALIVA CLIN CH, VII, P1; COATES R, 1991, CAN J PUBLIC HEALTH, V82, P397; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CORDEIRO ML, 1993, ANN NY ACAD SCI, V694, P330, DOI 10.1111/j.1749-6632.1993.tb18380.x; CROFTS N, 1991, AIDS, V5, P561, DOI 10.1097/00002030-199105000-00013; *CTR DIS CONTR, 1987, MMWR-MORBID MORTAL W, V36, P509; *CTR DIS CONTR, 1992, MMWR-MORBID MORTAL W, V41, P613; *CTR DIS CONTR PRE, 1995, MOD PERF EV PROGR HI; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Doll Lynda S., 1994, P302; EMMONS WW, 1995, J INFECT DIS, V171, P1406, DOI 10.1093/infdis/171.6.1406; *EP INC, 1994, ORASURE HIV 1 OR SPE; FEINBERG J, 1995, P 35 INT C ANT AG CH, P247; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; GAUDETTE D, 1994, J CLIN IMMUNOASSAY, V17, P171; GERBERDING J, 1993, ANN INTERN MED, V118, P979, DOI 10.7326/0003-4819-118-12-199306150-00012; HOLMSTROM P, 1990, J MED VIROL, V30, P245, DOI 10.1002/jmv.1890300403; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; KING A, 1995, J ACQ IMMUN DEF SYND, V9, P172; MAJOR CJ, 1991, J INFECT DIS, V163, P699, DOI 10.1093/infdis/163.4.699; MALAMUD D, 1993, CRIT REV ORAL BIOL M, V4, P461, DOI 10.1177/10454411930040032901; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; Mathez D., 1996, P106; Mortimer P P, 1994, Clin Diagn Virol, V2, P231, DOI 10.1016/0928-0197(94)90048-5; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; SOTORAMIREZ LE, 1992, J CLIN MICROBIOL, V30, P2780; VANDENAKKER R, 1992, AIDS, V6, P953, DOI 10.1097/00002030-199209000-00007; VECCHIO TJ, 1966, NEW ENGL J MED, V274, P1171, DOI 10.1056/NEJM196605262742104; YEUNG SCH, 1993, J INFECT DIS, V167, P803, DOI 10.1093/infdis/167.4.803; [No title captured]	33	134	138	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					254	258		10.1001/jama.277.3.254	http://dx.doi.org/10.1001/jama.277.3.254			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB446	9005276				2022-12-28	WOS:A1997WB44600028
J	Richter, J; Burbach, G; Hellgren, U; Dengler, A; Bienzle, U				Richter, J; Burbach, G; Hellgren, U; Dengler, A; Bienzle, U			Aberrant atrioventricular conduction triggered by antimalarial prophylaxis with mefloquine	LANCET			English	Article									FACHKLIN INNERE KRANKHEITEN SCHWABENLAND,ISNY,GERMANY; KAROLINSKA INST,DEPT CLIN PHARMACOL,HUDDINGE,SWEDEN	Karolinska Institutet	Richter, J (corresponding author), INST TROPENMED,ENGELDAMM 62,D-10179 BERLIN,GERMANY.							BERGQVIST Y, 1988, J CHROMATOGR-BIOMED, V432, P253, DOI 10.1016/S0378-4347(00)80650-7; Davis TME, 1996, BRIT J CLIN PHARMACO, V42, P415, DOI 10.1111/j.1365-2125.1996.tb00003.x; FRIEDMAN HH, 1986, DIAGNOSTIC ELECTROCA; White N. J., 1996, Manson's tropical diseases., P1087; *WHO, 1996, INT TRAV HLTH VACC R	5	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					101	102		10.1016/S0140-6736(05)60885-9	http://dx.doi.org/10.1016/S0140-6736(05)60885-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996427				2022-12-28	WOS:A1997WB80000017
J	Luzzatto, L; Bessler, M; Rotoli, B				Luzzatto, L; Bessler, M; Rotoli, B			Somatic mutations in paroxysmal nocturnal hemoglobinuria: A blessing in disguise?	CELL			English	Review							VARIANT SURFACE GLYCOPROTEIN; PIG-A GENE; PHOSPHATIDYLINOSITOL; MEMBRANE; ANCHOR; BIOSYNTHESIS; PROTEIN		UNIV NAPLES FEDERICO II,SCH MED,DIV HEMATOL,I-80100 NAPLES,ITALY	University of Naples Federico II	Luzzatto, L (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,1275 YORK AVE,NEW YORK,NY 10021, USA.							BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; CARDOSODEALMEID.ML, 1994, J MED BIOL RES, V27, P115; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DACIE JV, 1967, HAEMOLYTIC ANAEMIA, V4, P1128; DAMESHEK W, 1967, BLOOD-J HEMATOL, V30, P251; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1995, ADV IMMUNOL, V60, P57, DOI 10.1016/S0065-2776(08)60584-2; Lee G. Richard, 1993, P1232; Luzzatto L, 1996, Curr Opin Hematol, V3, P101; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSENFELD SJ, 1991, BLOOD REV, V5, P71, DOI 10.1016/0268-960X(91)90037-D; ROSSE WF, 1966, J CLIN INVEST, V45, P736, DOI 10.1172/JCI105388; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T	20	167	169	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					1	4		10.1016/S0092-8674(00)81850-4	http://dx.doi.org/10.1016/S0092-8674(00)81850-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019395	Bronze			2022-12-28	WOS:A1997WC56900001
J	Jenkins, FA; Gatesy, SM; Shubin, NH; Amaral, WW				Jenkins, FA; Gatesy, SM; Shubin, NH; Amaral, WW			Haramiyids and Triassic mammalian evolution	NATURE			English	Article								Isolated teeth referred to the family Haramiyidae are among the earliest known fossil evidence of mammals. First discovered in European Late Triassic deposits a century and a half ago(1), haramiyids have been interpreted as related to multituberculates(2-7), a diverse and widespread lineage that occupied a rodent-like niche from the Late Jurassic to the Early Tertiary. Nonetheless, haramiyid relationships have remained enigmatic(8,9) because the orientation and position of the teeth in the upper or lower jaw could not be determined with certainty; even their mammalian status has been questioned(10). The discovery of haramiyid dentaries, a maxilla and other skeletal remains in the Upper Triassic of East Greenland reveals haramiyids as highly specialized mammals with a novel pattern of puncture-crushing occlusion that differs dramatically from the grinding or shearing mechanisms of other Early Mesozoic mammals.	HARVARD UNIV,MUSEUM COMPARAT ZOOL,CAMBRIDGE,MA 02138; BROWN UNIV,DEPT ECOL & EVOLUTIONARY BIOL,PROVIDENCE,RI 02912; UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	Harvard University; Brown University; University of Pennsylvania	Jenkins, FA (corresponding author), HARVARD UNIV,DEPT ORGANISM & EVOLUTIONARY BIOL,CAMBRIDGE,MA 02138, USA.							BUTLER PM, 1994, PHILOS T ROY SOC B, V345, P433, DOI 10.1098/rstb.1994.0119; Clemens W.A., 1979, P99; Clemens W.A., 1980, Zitteliana, V5, P51; CROMPTON A W, 1974, Bulletin of the British Museum (Natural History) Geology, V24, P397; CROMPTON AW, 1995, FUNCTIONAL MORPHOLOGY IN VERTEBRATE PALEONTOLOGY, P55; Gregory W. K., 1910, B AM MUS NAT HIST, V27, P1, DOI DOI 10.1007/S13364-013-0165-6; Hahn G., 1989, Geologica et Palaeontologica, V23, P205; Hahn G, 1969, PALAEONTOGR ABT A, V133, P1; Hahn G., 1978, GEOLOGICA PALAEONTOL, V12, P177; HAHN G, 1973, PALAEONTOGR ABT A, V142, P1; HENNIG EN, 1922, JB MIN GEOL PALAONT, V46, P181; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; Jenkins Farish A. Jr, 1994, Meddelelser om Gronland Geoscience, V32, P1; Kermack DM, 1968, ZOOL J LINN SOC-LOND, V47, P407; KRAUSE DW, 1990, J PALEONTOL, V64, P1051, DOI 10.1017/S0022336000019922; KRAUSE DW, 1982, PALEOBIOLOGY, V8, P265, DOI 10.1017/S0094837300006989; MARSH OC, 1887, AM J SCI, V33, P327; Mills JRE, 1971, EARLY MAMMALS, V50, P29; Osborn H. F., 1888, J ACAD NAT SCI PHILA, V9, P186; PARRINGTON FR, 1947, P ZOOL SOC LOND, V116, P707; SIGOGNEAU-RUSSELL D, 1989, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V206, P137; SIGOGNEAURUSSELL D, 1994, IN THE SHADOW OF THE DINOSAURS, P197; SIMMONS NB, 1993, MAMMAL PHYLOGENY, P146; Simpson G. G., 1947, Journal of Paleontology Menasha, V21, P497; SIMPSON G. G., 1928, CATALOGUE MESOZOIC M; VONPLIENINGER WHT, 1847, JH VER VATERL NATURK, P164	26	82	86	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					715	718		10.1038/385715a0	http://dx.doi.org/10.1038/385715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034187				2022-12-28	WOS:A1997WJ42300044
J	Valent, S; Kelly, P				Valent, S; Kelly, P			Digoxin-induced bidirectional ventricular tachycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Valent, S (corresponding author), UNIV COLORADO,HLTH SCI CTR,4200 E 9TH AVE,DENVER,CO 80262, USA.								0	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					550	550		10.1056/NEJM199702203360805	http://dx.doi.org/10.1056/NEJM199702203360805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9023092				2022-12-28	WOS:A1997WJ24000005
J	Barbey, JT; Donahue, SR				Barbey, JT; Donahue, SR			Loading dose of digoxin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Barbey, JT (corresponding author), GEORGETOWN UNIV,MED CTR,DIV CLIN PHARMACOL,WASHINGTON,DC 20007, USA.							Hardman J. G., 1996, GOODMAN GILMANS PHAR; Kelly R A, 1992, Heart Dis Stroke, V1, P117; KELLY RA, 1992, AM J CARDIOL, V69, pG108, DOI 10.1016/0002-9149(92)91259-7; MCEVOY GK, 1995, AHFS DRUG INFORMATIO, P1026; OPIE LH, 1995, DRUGS HEART, P148; SMIT AJ, 1990, EUR J CLIN PHARMACOL, V38, P335, DOI 10.1007/BF00315571	6	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					518	518		10.1001/jama.277.7.518	http://dx.doi.org/10.1001/jama.277.7.518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032144				2022-12-28	WOS:A1997WH29700004
J	Weinberg, RB				Weinberg, RB			First love	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Weinberg, RB (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					327	329		10.7326/0003-4819-126-4-199702150-00012	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036807				2022-12-28	WOS:A1997WH06800013
J	Giordano, C; Stassi, G; DeMaria, R; Todaro, M; Richiusa, P; Papoff, G; Ruberti, G; Bagnasco, M; Testi, R; Galluzzo, A				Giordano, C; Stassi, G; DeMaria, R; Todaro, M; Richiusa, P; Papoff, G; Ruberti, G; Bagnasco, M; Testi, R; Galluzzo, A			Potential involvement of fas and its ligand in the pathogenesis of Hashimoto's thyroiditis	SCIENCE			English	Article							INDUCED APOPTOSIS; RECEPTOR; DISEASE; CELLS; EXPRESSION; APO-1; DOG	The mechanisms responsible for thyrocyte destruction in Hashimoto's thyroiditis (HT) are poorly understood. Thyrocytes from HT glands, but not from nonautoimmune thyroids, expressed Fas. Interleukin-1 beta (IL-1 beta), abundantly produced in HT glands, induced Fas expression in normal thyrocytes, and cross-linking of Fas resulted in massive thyrocyte apoptosis. The ligand for Fas (FasL) was shown to be constitutively expressed both in normal and HT thyrocytes and was able to kill Fas-sensitive targets. Exposure to IL-1 beta induced thyrocyte apoptosis, which was prevented by antibodies that block Fas, suggesting that IL-1 beta-induced Fas expression serves as a limiting factor for thyrocyte destruction. Thus, Fas-FasL interactions among HT thyrocytes may contribute to clinical hypothyroidism.	UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,ROME,ITALY; UNIV PALERMO,IMMUNOL LAB,ENDOCRINOL SECT,INST CLIN MED,PALERMO,ITALY; CNR,INST CELL BIOL,DEPT IMMUNOBIOL,ROME,ITALY; UNIV GENOA,GENOA,ITALY	University of Rome Tor Vergata; University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Genoa			De Maria, Ruggero/S-6385-2019; PAPOFF, GIULIANA/AAX-9520-2020; GIORDANO, Carla/R-4296-2017	De Maria, Ruggero/0000-0003-2255-0583; PAPOFF, GIULIANA/0000-0003-2251-8794; GIORDANO, Carla/0000-0003-1731-9395; RUBERTI, Giovina/0000-0003-2367-9709	Telethon [A.066] Funding Source: Medline	Telethon(Fondazione Telethon)		BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cascino I, 1996, J IMMUNOL, V156, P13; CHAMPION BR, 1992, CURR OPIN IMMUNOL, V4, P770, DOI 10.1016/0952-7915(92)90060-R; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; DAVIES TF, 1992, J CLIN INVEST, V89, P157, DOI 10.1172/JCI115556; DEMARIA R, 1996, J CLIN INVEST, V97, P1; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GRUBECKLOEBENSTEIN B, 1989, CLIN EXP IMMUNOL, V77, P324; KOTANI T, 1995, AUTOIMMUNITY, V20, P231, DOI 10.3109/08916939508995700; KRAMMER PH, 1994, IMMUNOL REV, V14, P2175; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WU Z, 1994, CLIN EXP IMMUNOL, V98, P470	23	492	522	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					960	963		10.1126/science.275.5302.960	http://dx.doi.org/10.1126/science.275.5302.960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020075				2022-12-28	WOS:A1997WH38800040
J	Spector, MS; Desnoyers, S; Hoeppner, DJ; Hengartner, MO				Spector, MS; Desnoyers, S; Hoeppner, DJ; Hengartner, MO			Interaction between the C-elegans cell-death regulators CED-9 and CED-4	NATURE			English	Article							CAENORHABDITIS-ELEGANS; MEMBRANE PROTEIN; BCL-2; APOPTOSIS; ENCODES	Programmed cell death (apoptosis) is an evolutionarily conserved process used by multicellular organisms to eliminate cells that are not needed or are potentially detrimental to the organism(1,2). Members of the Bcl-2 family of mammalian proteins are intimately involved in the regulation of apoptosis, but, their precise mechanism of action remains unresolved(3-5). In Caenorhabditis elegans, the Bcl-2 homologue CED-9 prevents cell death by antagonizing the death-promoting activities of CED-3, a member of the Caspase family of death proteases, and of CED-4, a protein with no known mammalian homologue(6-9). Here we show that CED-9 interacts physically with CED-4. Mutations that reduce or eliminate CED-9 activity also disrupt its ability to bind CED-4, suggesting that this interaction is important for CED-9 function. Thus, CED-9 might control C. elegans cell death by binding to and regulating CED-4 activity. We propose that mammalian Bcl-2 family members might control apoptosis in a similar way through interaction and regulation of CED-4 homologues or analogues.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,DEPT MOL MICROBIOL,GRAD PROGRAM GENET,STONY BROOK,NY 11794	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Miller J. H, 1972, EXPT MOL GENETICS; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VANAELST L, IN PRESS METHODS MOL; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	258	270	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					653	656		10.1038/385653a0	http://dx.doi.org/10.1038/385653a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024666				2022-12-28	WOS:A1997WH29400055
J	Lassen, LH; Ashina, M; Christiansen, I; Ulrich, V; Olesen, J				Lassen, LH; Ashina, M; Christiansen, I; Ulrich, V; Olesen, J			Nitric oxide synthase inhibition in migraine	LANCET			English	Article							HYPOTHESIS				Lassen, LH (corresponding author), UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT NEUROL,DK-2600 GLOSTRUP,DENMARK.			Ashina, Messoud/0000-0003-0951-5804; Olesen, Jes/0000-0002-6712-2702				Headache Classification Committee of the International Headache Society, 1998, CEPHALALGIA S7, V8, P19; LASSEN LH, 1995, NEUROREPORT, V6, P1475, DOI 10.1097/00001756-199507310-00003; OLESEN J, 1995, CEPHALALGIA, V15, P94, DOI 10.1046/j.1468-2982.1995.015002094.x; Thomsen L L, 1994, Eur J Neurol, V1, P73, DOI 10.1111/j.1468-1331.1994.tb00053.x; THOMSEN LL, 1995, CEPHALALGIA, V15, P211, DOI 10.1046/j.1468-2982.1995.015003211.x	5	183	193	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					401	402		10.1016/S0140-6736(97)80021-9	http://dx.doi.org/10.1016/S0140-6736(97)80021-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033475				2022-12-28	WOS:A1997WH29600021
J	Yiannakou, JY; Newland, P; Calder, F; Kingsnorth, AN; Rhodes, JM				Yiannakou, JY; Newland, P; Calder, F; Kingsnorth, AN; Rhodes, JM			Prospective study of CAM 17 center dot 1/WGA mucin assay for serological diagnosis of pancreatic cancer	LANCET			English	Article							SERUM; COMBINATION; ANTIGEN; DUPAN-2; DISEASE; CA19-9	Background Serological tests for pancreatic cancer are little used, partly because such assays have proved insufficiently specific for screening. However, retrospective studies have reported results that compare well with commonly used scanning techniques. In this prospective study we assessed a new type of combined lectin/antibody enzyme-linked mucin assay, CAM 17.1, in a routine clinical setting. Methods Clinicians at a 1200-bed teaching hospital were encouraged to request the CAM 17.1 assay for any patient whose differential diagnosis included pancreatic cancer. Serum samples from 250 patients were tested during an 18-month period. Patients were followed up for at least 8 months. 75 patients who did not have symptoms of pancreatic cancer and had alternative diagnoses were also studied as a control group. Findings Of the 250 patients, 36 had pancreatic cancer, as defined by histological and imaging criteria, and eight of these patients had a resectable tumour. The sensitivity and specificity of the CAM 17.1 assay were 86% and 91%, respectively, in all patients, 85% and 81% in those who presented with jaundice, and 89% and 94% in patients who did not have jaundice. The sensitivity of the assay compared well with that of ultrasound scanning (59%) and computed tomography (83%) in these patients. Use of the CAM 17.1 assay in combination with ultrasonography allowed identification of 94% of patients with pancreatic tumours and ail of those with resectable tumours. CAM 17.1 binding activity did not correlate with tumour size. Interpretation Our study confirms the usefulness of the CAM 17.1 tumour-marker assay for the diagnosis of pancreatic cancer. Serological mucin assays should be used more widely in combination with ultrasonography in the investigation of non-jaundiced patients with unexplained abdominal pain or weight loss.	UNIV LIVERPOOL, DEPT MED, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, DEPT SURG, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND; UNIV LIVERPOOL, DEPT CLIN CHEM, LIVERPOOL L69 3GA, MERSEYSIDE, ENGLAND	University of Liverpool; University of Liverpool; University of Liverpool			Rhodes, Jonathan M/C-2496-2009					BOVO P, 1993, ITAL J GASTROENTEROL, V25, P477; COOPER EH, 1990, BRIT J CANCER, V62, P1004, DOI 10.1038/bjc.1990.426; HAGLUND C, 1986, BRIT J CANCER, V53, P197, DOI 10.1038/bjc.1986.35; KAWA S, 1991, BRIT J CANCER, V64, P899, DOI 10.1038/bjc.1991.422; Malesci A, 1987, GASTROENTEROLOGY, V92, P60, DOI 10.1016/0016-5085(87)90840-7; MOLINA L M, 1990, International Journal of Biological Markers, V5, P127; MOOSSA AR, 1986, EXOCRINE PANCREAS BI, P713; PARKER N, 1992, CANCER, V70, P1062, DOI 10.1002/1097-0142(19920901)70:5<1062::AID-CNCR2820700509>3.0.CO;2-P; RAOUF A, 1991, GUT, V32, P1139, DOI 10.1136/gut.32.10.1139; RHODES JM, 1990, CANC PANCREAS, P833; RICHTER JM, 1989, ARCH INTERN MED, V149, P2292, DOI 10.1001/archinte.149.10.2292; STEINBERG WM, 1986, GASTROENTEROLOGY, V90, P343, DOI 10.1016/0016-5085(86)90930-3; THOMPSON JN, 1990, BRIT MED J, V301, P775, DOI 10.1136/bmj.301.6755.775; UMEYAMA K, 1988, J JPN PANC SOC, V3, P528	14	25	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					389	392		10.1016/S0140-6736(97)80011-6	http://dx.doi.org/10.1016/S0140-6736(97)80011-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033465				2022-12-28	WOS:A1997WH29600011
J	Spector, MS; Schnur, JM				Spector, MS; Schnur, JM			DNA ordering on a lipid membrane	SCIENCE			English	Editorial Material							TRANSFECTION				Spector, MS (corresponding author), USN,RES LAB,CTR BIOMOL SCI & ENGN,WASHINGTON,DC 20375, USA.							[Anonymous], 1988, LIPOSOMES DRUG CARRI; Dan N, 1996, BIOPHYS J, V71, P1267, DOI 10.1016/S0006-3495(96)79326-8; FANG Y, IN PRESS J PHYS CHEM; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; Lasic D. D., 1996, HDB NONMEDICAL APPL; Lasic DD, 1996, ADV DRUG DELIVER REV, V20, P221, DOI 10.1016/0169-409X(96)00002-6; *NAT RES COUNC, 1996, BIOM SELF ASS MAT; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; RICH A, 1993, GENE, V135, P99, DOI 10.1016/0378-1119(93)90054-7	11	39	41	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					791	792		10.1126/science.275.5301.791	http://dx.doi.org/10.1126/science.275.5301.791			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9036545				2022-12-28	WOS:A1997WG77700046
J	Tacke, M; Kiyosawa, K; Stark, K; Schlueter, V; OfenlochHaehnle, B; Hess, G; Engel, AM				Tacke, M; Kiyosawa, K; Stark, K; Schlueter, V; OfenlochHaehnle, B; Hess, G; Engel, AM			Detection of antibodies to a putative hepatitis G virus envelope protein	LANCET			English	Article								Background A flavivirus designated hepatitis G virus (HGV) has been isolated from the serum of patients with non-A-E hepatitis. Hitherto, the presence of HGV RNA in serum has been detected with the reverse transcription-polymerase chain reaction (RT-PCR) amplification method. We have now developed an immunoassay for antibodies against an HGV protein. Methods Recombinant HGV envelope protein E2 was used as antigen in an ELISA. 80 blood donors, 99 intravenous-drug users, and 11 patients with acute post-transfusion hepatitis were tested for antibodies to E2. The HGV-RNA status was assessed by RT-PCR. Findings Anti-E2 seroprevalence was 9% among the blood donors and 41% among the drug users; HGV-RNA prevalence was 2.5% and 38%, respectively. Whereas anti-E2 prevalence increased with the duration of drug use, HGV-RNA prevalence declined in parallel. In each group, the presence of anti-E2 and HGV RNA was almost mutually exclusive: none of the blood donors and only 4% of the drug users were positive for both markers at the same time. Of the 11 post-transfusion patients-who were all HGV-RNA positive and anti-E2 negative at the onset of disease-four developed antibodies to E2 during the following year, and two of the four subsequently became HGV-RNA negative. Interpretation We conclude that a humoral immune response to E2 is associated with loss of detectable HGV viraemia. Thus, E2-specific antibodies might serve as useful marker for diagnosing recovery from HGV infections The immunoassay we describe should facilitate investigation of suspected infections and may be helpful in the elucidation of the clinical significance of HGV.	SHINSHU UNIV,SCH MED,DEPT INTERNAL MED 2,MATSUMOTO,NAGANO 390,JAPAN; INST TROP MED,BERLIN,GERMANY	Shinshu University	Tacke, M (corresponding author), BOEHRINGER MANNHEIM GMBH,NONNENWALD 2,D-82377 PENZBERG,GERMANY.							ALTER HJ, 1994, VOX SANG, V67, P19, DOI 10.1111/j.1423-0410.1994.tb04539.x; Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LESNIEWSKI R, 1995, J MED VIROL, V45, P415, DOI 10.1002/jmv.1890450411; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Schlueter V, 1996, J CLIN MICROBIOL, V34, P2660, DOI 10.1128/JCM.34.11.2660-2664.1996; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Stark K, 1996, J INFECT DIS, V174, P1320, DOI 10.1093/infdis/174.6.1320	8	321	323	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					318	320		10.1016/S0140-6736(96)06461-6	http://dx.doi.org/10.1016/S0140-6736(96)06461-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024375				2022-12-28	WOS:A1997WF79400011
J	Hemmings, BA				Hemmings, BA			Signal transduction - Akt signaling: Linking membrane events to life and death decisions	SCIENCE			English	Editorial Material							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; DOMAIN; HOMOLOGY				Hemmings, BA (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ANDJELKOVIC M, UNPUB; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRECH M, IN PRESS J BIOL CHEM; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; SUIDAN H, UNPUB; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	26	429	472	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					628	630		10.1126/science.275.5300.628	http://dx.doi.org/10.1126/science.275.5300.628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9019819				2022-12-28	WOS:A1997WF07700027
J	Johannesson, M; Jonsson, B; Kjekshus, J; Olsson, AG; Pedersen, TR; Wedel, H				Johannesson, M; Jonsson, B; Kjekshus, J; Olsson, AG; Pedersen, TR; Wedel, H			Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; HEALTH-CARE; HYPERTENSION; PREVENTION; THERAPY	Background The Scandinavian Simvastatin Survival Study (4S) showed that lowering cholesterol levels with simvastatin reduces mortality and morbidity in patients with angina pectoris or previous acute myocardial infarction. Before the widespread use of cholesterol-lowering drugs in such patients is recommended, its cost effectiveness should be demonstrated. We estimated the cost effectiveness of simvastatin treatment to lower cholesterol levels in relation to the age, sex, and cholesterol level before treatment of patients with coronary heart disease. Methods We estimated the cost per year of life gained with simvastatin therapy. To model the increased life expectancy, hazard functions from 4S were used. The costs studied included those of the intervention and the direct and indirect costs associated with morbidity from coronary causes. We prepared separate estimates for men and women at various ages (from 35 to 70 years) and total cholesterol levels before treatment (213 to 309 mg per deciliter). Results In the analysis limited to direct costs, the cost of each year of life gained ranged from $3,800 for 70-year-old men with 309 mg of cholesterol per deciliter to $27,400 for 35-year-old women with 213 mg of cholesterol per deciliter, When we included indirect costs, the results ranged from a savings in the youngest patients to a cost of $13,300 per year of life gained in 70-year-old women with 213 mg of cholesterol per deciliter. Conclusions In patients with coronary heart disease, simvastatin therapy is cost effective among both men and women at the ages and cholesterol levels studied. (C) 1997, Massachusetts Medical Society.	UNIV OSLO, RIKSHOSP, CARDIOL SECT, N-0027 OSLO, NORWAY; FAC HLTH SCI, DEPT INTERNAL MED, LINKOPING, SWEDEN; AKER HOSP, DEPT MED, CARDIOL SECT, OSLO, NORWAY; NORD SCH PUBL HLTH, GOTHENBURG, SWEDEN	University of Oslo; National Hospital Norway; University of Oslo	Johannesson, M (corresponding author), STOCKHOLM SCH ECON, CTR HLTH ECON, BOX 6501, S-11383 STOCKHOLM, SWEDEN.		Johannesson, Magnus/E-9680-2011	Johannesson, Magnus/0000-0001-8759-6393				Breslow NE., 1987, IARC SCI PUBL, VII, P131; *DRG, 1995, 395 DRG; *FASS, 1995, LAK SVER; GERDTHAM UG, 1993, HEALTH POLICY, V24, P1, DOI 10.1016/0168-8510(93)90083-2; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; HAY JW, 1991, AM J CARDIOL, V67, P789, DOI 10.1016/0002-9149(91)90609-O; Johannesson M, 1996, J INTERN MED, V240, P23, DOI 10.1046/j.1365-2796.1996.491830000.x; JOHANNESSON M, 1991, MED INFORM, V16, P355, DOI 10.3109/14639239109067657; JOHANNESSON M, 1993, SCAND J CLIN LAB INV, V53, P725, DOI 10.3109/00365519309092577; JOHANNESSON M, 1991, HEALTH POLICY, V19, P55, DOI 10.1016/0168-8510(91)90074-8; Jonsson B, 1996, EUR HEART J, V17, P1001; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; PEDERSEN TR, 1995, LANCET, V345, P1274; Pedersen TR, 1996, CIRCULATION, V93, P1796, DOI 10.1161/01.CIR.93.10.1796; PEDERSEN TR, 1994, LANCET, V344, P1383; RUSSELL LB, 1986, PREVENTION BETTER CU; *STAT CENTR, 1995, STAT ARSB 96; TOSTESON ANA, 1990, ANN INTERN MED, V113, P594, DOI 10.7326/0003-4819-113-8-594; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; Weinstein M C, 1990, Int J Technol Assess Health Care, V6, P93; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; 1992, LANCET, V340, P148; 1995, NEW ENGL J MED, V333, P267	25	320	322	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					332	336		10.1056/NEJM199701303360503	http://dx.doi.org/10.1056/NEJM199701303360503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011785				2022-12-28	WOS:A1997WG23300003
J	Freymann, DM; Keenan, RJ; Stroud, RM; Walter, P				Freymann, DM; Keenan, RJ; Stroud, RM; Walter, P			Structure of the conserved GTPase domain of the signal recognition particle	NATURE			English	Article							CRYSTAL-STRUCTURE; PROTEIN TRANSLOCATION; BINDING DOMAIN; HYDROLYSIS; MECHANISM; SUBUNIT; CONFORMATION; RECEPTOR; SEQUENCE; ERRORS	The signal-recognition particle (SRP) and its receptor (SR) function in the co-translational targeting of nascent protein-ribosome complexes to the membrane translocation apparatus(1). The SRP protein subunit (termed Ffh in bacteria) that recognizes the signal sequence of nascent polypeptides is a GTPase, as is the SR-alpha subunit (termed FtsY)(2,3). Ffh. and FtsY interact directly, each stimulating the GTP hydrolysis activity of the other(4). The sequence of Ffh suggests three domains: an amino-terminal N domain of unknown function, a central GTPase G domain, and a methionine-rich M domain that binds both SRP RNA and signal peptides(5,6). Sequence conservation suggests that structurally similar N and G domains are present in FtsY(7,8). Here we report the structure of the nucleotide-free form of the NG fragment of Ffh. Consistent with a role for apo Ffh in protein targeting, the side chains of the empty active-site pocket form a tight network of interactions which map stabilize the nucleotide-free protein. The structural relationship between the two domains suggests that the N domain senses or controls the nucleotide occupancy of the GTPase domain. A structural subdomain unique to these evolutionarily conserved GTPases constitutes them as a distinct subfamily in the GTPase superfamily(9).			Freymann, DM (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		Stroud, Rhonda M./C-5503-2008; Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda M./0000-0001-5242-8015; Stroud, Rhonda/0000-0001-5242-8015; Freymann, Douglas/0000-0002-5231-8841; Keenan, Robert/0000-0003-1466-0889				Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Evarsson A., 1994, EMBO J, V13, P3669; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113	30	201	204	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					361	364		10.1038/385361a0	http://dx.doi.org/10.1038/385361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002524				2022-12-28	WOS:A1997WD91400056
J	Hirschfield, RMA; Keller, MB; Panico, S; Arons, BS; Barlow, D; Davidoff, F; Endicott, J; Froom, J; Goldstein, M; Horman, JM; Guthrie, D; Marek, RG; Maurer, TA; Meyer, R; Phillips, K; Ross, J; Schwenk, TL; Sharfstein, SS; Thase, ME; Wyatt, RJ				Hirschfield, RMA; Keller, MB; Panico, S; Arons, BS; Barlow, D; Davidoff, F; Endicott, J; Froom, J; Goldstein, M; Horman, JM; Guthrie, D; Marek, RG; Maurer, TA; Meyer, R; Phillips, K; Ross, J; Schwenk, TL; Sharfstein, SS; Thase, ME; Wyatt, RJ			The national depressive and manic-depressive association consensus statement on the undertreatment of depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; TREATING DEPRESSION; ECONOMIC BURDEN; DISORDERS; COST; PSYCHOTHERAPY; COMORBIDITY; IMIPRAMINE; PREVALENCE; PREDICTORS	Objective.-A consensus conference on the reasons for the undertreatment of depression was organized by the National Depressive and Manic Depressive Association (NDMDA) on January 17-18, 1996, The target audience included health policymakers, clinicians, patients and their families, and the public at large, Six key questions were addressed: (1) Is depression undertreated in the community and in the clinic? (2) What is the economic cost to society of depression? (3) What have been the efforts in the past to redress undertreatment and how successful have they been? (4) What are the reasons for the gap between our knowledge of the diagnosis and treatment of depression and actual treatment received in this country? (5) What can we do to narrow this gap? (6) What can we do immediately to narrow this gap? Participants.-Consensus panel members were drawn from psychiatry, psychology, family practice, internal medicine, managed care and public health, consumers, and the general public. The panelists listened to a set of presentations with background papers from experts on diagnosis, epidemiology, treatment, and cost of treatment. Evidence.-Experts summarized relevant data from the world scientific literature on the 6 questions posed for the conference. Consensus Process.-Panel members discussed openly all material presented to them in executive session. Selected panelists prepared first drafts of the consensus statements for each question. All of these drafts were read by all panelists and were edited and reedited until consensus was achieved. Conclusions.-There is overwhelming evidence that individuals with depression are being seriously undertreated. Safe, effective, and economical treatments are available. The cost to individuals and society of this undertreatment is substantial. Long suffering, suicide, occupational impairment, and impairment in interpersonal and family relationships exist. Efforts to redress this gap have included provider educational programs and public educational programs. Reasons for the continuing gap include patient, provider, and health care system factors. Patient-based reasons include failure to recognize the symptoms, underestimating the severity, limited access, reluctance to see a mental health care specialist due to stigma, noncompliance with treatment, and lack of health insurance. Provider factors include poor professional school education about depression, limited training in interpersonal skills, stigma, inadequate time to evaluate and treat depression, failure to consider psychotherapeutic approaches, and prescription of inadequate doses of antidepressant medication for inadequate durations. Mental health care systems create barriers to receiving optimal treatment. Strategies to narrow the gap include enhancing the role of patients and families as participants in care and advocates; developing performance standards for behavioral health care systems, including incentives for positive identification, assessment, and treatment of depression; enhancing educational programs for providers and the public; enhancing collaboration among provider subtypes (eg, primary care providers and mental health professionals); and conducting research on development and testing of new treatments for depression.	NATL DEPRESS & MANIC DEPRESS ASSOC,CHICAGO,IL; SUBST ABUSE & MENTAL HLTH SERV ADM,ROCKVILLE,MD; BOSTON UNIV,BOSTON,MA 02215; AMER COLL PHYSICIANS,PHILADELPHIA,PA; NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY; SUNY STONY BROOK,STONY BROOK,NY 11794; BROWN UNIV,PROVIDENCE,RI 02912; COLUMBIA UNIV,NEW YORK,NY; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; LOVELACE HLTH SYST INC,ALBUQUERQUE,NM; COMMON HLTH USA,LITTLE FALLS,NY; ASSOC ACAD HLTH CTR,WASHINGTON,DC; ANXIETY DISORDERS ASSOC AMER,ROCKVILLE,MD; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI; SHEPPARD PRATT HLTH SYST,BALTIMORE,MD; WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA; NIMH,BETHESDA,MD 20892	Boston University; American College of Physicians; New York State Psychiatry Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Brown University; Columbia University; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Fahimifar, Sepideh/M-5303-2019; anand, amit/A-7222-2009		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH025478] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH025478] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1992, JAMA, V268, P3098; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; CONTI DJ, 1994, J OCCUP ENVIRON MED, V36, P983; COYNE JC, 1994, GEN HOSP PSYCHIAT, V16, P267, DOI 10.1016/0163-8343(94)90006-X; ENDICOTT J, 1995, ANN SCI M NEW YORK S; FINKELSTEIN SN, 1996, NAT DEPR MAN DEPR AS; GOETHE JW, 1988, J NERV MENT DIS, V176, P464; Greenberg P.E., 1996, SELECTIVE SEROTONIN; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; HALL RCW, 1995, PSYCHOSOMATICS, V36, pS11, DOI 10.1016/S0033-3182(95)71699-1; JARRETT RB, 1994, PSYCHIATRY, V57, P115, DOI 10.1080/00332747.1994.11024675; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLER MB, 1982, JAMA-J AM MED ASSOC, V248, P1848, DOI 10.1001/jama.248.15.1848; KELLER MB, 1986, ARCH GEN PSYCHIAT, V43, P458; KELLER MB, 1995, PSYCHOPHARMACOL BULL, V31, P205; KELLER MB, 1984, JAMA-J AM MED ASSOC, V252, P788, DOI 10.1001/jama.252.6.788; KELLER MB, 1988, PSYCHOPHARMACOL BULL, V24, P75; KELLER MB, 1986, AM J PSYCHIAT, V143, P24; KELLER MB, 1983, JAMA-J AM MED ASSOC, V250, P3299, DOI 10.1001/jama.250.24.3299; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KLERMAN GL, 1989, JAMA-J AM MED ASSOC, V261, P2229, DOI 10.1001/jama.261.15.2229; KOCSIS JH, 1988, ARCH GEN PSYCHIAT, V45, P253; KOCSIS JH, IN PRESS ARCH GEN PS; MCFARLAND BH, 1994, AM J MED, V97, pS47, DOI 10.1016/0002-9343(94)90363-8; MINTZ J, 1992, ARCH GEN PSYCHIAT, V49, P761; *NAT MENT HLTH ASS, 1993, ADV NED NAT LOC APR; National Committee for Quality Assurance, 1996, HLTH PLAN EMPL DAT I; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P84; ROBINS LN, 1991, PSYCHIAT DISORDERS A; RUPP A, 1995, BRIT J PSYCHIAT, V166, P29, DOI 10.1192/S0007125000293379; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SHELTON RC, IN PRESS J CLIN PSYC; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; STOUDEMIRE A, 1986, GEN HOSP PSYCHIAT, V8, P387, DOI 10.1016/0163-8343(86)90018-6; STURM R, 1995, JAMA-J AM MED ASSOC, V273, P51; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	38	683	690	0	92	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					333	340		10.1001/jama.277.4.333	http://dx.doi.org/10.1001/jama.277.4.333			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC458	9002497				2022-12-28	WOS:A1997WC45800034
J	Frank, E				Frank, E			Synapse elimination: For nerves it's all or nothing	SCIENCE			English	Editorial Material							NEUROMUSCULAR-JUNCTIONS; MUSCLE JUNCTIONS; SKELETAL-MUSCLE; INNERVATION; MOUSE				Frank, E (corresponding author), UNIV PITTSBURGH,DEPT NEUROBIOL,PITTSBURGH,PA 15261, USA.							BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; LEVAY S, 1980, J COMP NEUROL, V19, P1; SLATER CR, 1982, DEV BIOL, V94, P11, DOI 10.1016/0012-1606(82)90063-X; SLATER CR, 1982, DEV BIOL, V94, P23, DOI 10.1016/0012-1606(82)90064-1; STEINBACH JH, 1981, DEV BIOL, V84, P267, DOI 10.1016/0012-1606(81)90394-8; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; THOMPSON W, 1979, NEUROSCIENCE, V4, P271, DOI 10.1016/0306-4522(79)90088-5	11	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 17	1997	275	5298					324	325		10.1126/science.275.5298.324	http://dx.doi.org/10.1126/science.275.5298.324			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC873	9005555				2022-12-28	WOS:A1997WC87300032
J	Thomson, AM				Thomson, AM			More than just frequency detectors?	SCIENCE			English	Editorial Material							EXCITATORY POSTSYNAPTIC POTENTIALS; SPINY INTERNEURONS; PAIRED-PULSE; FACILITATION; DEPRESSION; NEOCORTEX; SLICES; CORTEX				Thomson, AM (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PHYSIOL, LONDON NW3 2PF, ENGLAND.							Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; BETZ WJ, 1970, J PHYSIOL-LONDON, V206, P629, DOI 10.1113/jphysiol.1970.sp009034; DELCASTILLO J, 1956, PROG BIOPHYS MOL BIO, V6, P122, DOI 10.1016/S0096-4174(18)30106-9; DEUCHARS J, 1995, NEUROSCIENCE, V69, P739, DOI 10.1016/0306-4522(95)00288-T; Deuchars J, 1996, NEUROSCIENCE, V74, P1009, DOI 10.1016/S0306-4522(96)00251-5; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Konig P, 1996, TRENDS NEUROSCI, V19, P130, DOI 10.1016/S0166-2236(96)80019-1; Lubke J, 1996, J NEUROSCI, V16, P3209; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; THOMSON AM, 1993, NEUROSCIENCE, V54, P347, DOI 10.1016/0306-4522(93)90257-G; THOMSON AM, 1995, NEUROSCIENCE, V69, P727, DOI 10.1016/0306-4522(95)00287-S; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; THOMSON AM, 1993, J NEUROPHYSIOL, V70, P2354, DOI 10.1152/jn.1993.70.6.2354; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; TSODYKS MV, 1996, ARTIFICIAL NETWORKS	17	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 10	1997	275	5297					179	180		10.1126/science.275.5297.179	http://dx.doi.org/10.1126/science.275.5297.179			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC022	8999547				2022-12-28	WOS:A1997WC02200027
J	Hall, IP				Hall, IP			The future of asthma	BRITISH MEDICAL JOURNAL			English	Review								Reports in the media describing the discovery of ''the asthma gene'' or ''a new vaccine for asthma'' maybe inaccurate and often raise patients' hopes unjustifiably. This article is a personal view of key areas in current asthma research, and it examines how they may impinge on the care of asthmatic patients in the next decade. I have tried to explain the thinking behind some of the approaches under study I discuss the potential contributions of genetic studies, immunological approaches, and new therapeutic approaches.			Hall, IP (corresponding author), UNIV NOTTINGHAM HOSP, DEPT THERAPEUT, NOTTINGHAM NG7 2UH, ENGLAND.			Hall, Ian/0000-0001-9933-3216				BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BARNES PJ, 1993, PHARM RESP TRACT LUN, V67, P1; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Hall IP, 1996, THORAX, V51, P351, DOI 10.1136/thx.51.4.351; HOWARTH PH, 1994, AM J RESP CRIT CARE, V150, pS18, DOI 10.1164/ajrccm/150.5_Pt_2.S18; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031	6	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					45	49		10.1136/bmj.314.7073.45	http://dx.doi.org/10.1136/bmj.314.7073.45			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001482	Green Published			2022-12-28	WOS:A1997WB68400029
J	Pajarinen, J; Laippala, P; Penttila, A; Karhunen, PJ				Pajarinen, J; Laippala, P; Penttila, A; Karhunen, PJ			Incidence of disorders of spermatogenesis in middle aged Finnish men, 1981-91: Two necropsy series	BRITISH MEDICAL JOURNAL			English	Article							SEMEN QUALITY; SPERM COUNTS; CIGARETTE-SMOKING; TESTICULAR CANCER; ALCOHOL; DECLINE	Objective: To investigate if the incidence of disorders of spermatogenesis and testicular tissue morphology have changed in middle aged Finnish men over 10 years. Design: Two necropsy series completed in 1981 and in 1991. Setting: Department of Forensic Medicine, University of Helsinki, Finland. Subjects: 528 men, aged 35 to 69 years, subjected to medicolegal necropsy. Main outcome measures: Scoring of spermatogenesis and morphometric analysis of testicular tissue components. Individual risk factors for testicular disorders obtained by postmortem blind interviews with acquaintances. Results: Normal spermatogenesis was found in 41.7% of the men (mean age 53.1 years). Between 1981 and 1991, the ratio of normal spermatogenesis decreased significantly (odds ratio 3.5; 95% confidence interval 2.5 to 5.1) from 56.4% to 26.9%, with a parallel increase in the incidence of partial and complete spermatogenic arrest (2.1; 1.4 to 2.9 and 2.9; 1.7 to 5.0, respectively). During this period, the size of seminiferous tubules decreased, the amount of fibrotic tissue increased, and the weight of testicles decreased significantly Alterations in testicular characteristics over time could not be explained by changes in body mass index smoking, alcohol drinking, or exposure to drugs. Conclusions: The incidence of normal spermatogenesis decreased among middle aged Finnish men from 1981 to 1991, and the incidence of disorders of spermatogenesis and pathological alterations in testicles increased. Deteriorating spermatogenesis may thus be one important factor in the explanation of declining sperm counts observed worldwide.	UNIV TAMPERE,DEPT BIOMETR,FIN-33101 TAMPERE,FINLAND; UNIV TAMPERE,SCH MED,TAMPERE,FINLAND	Tampere University; Tampere University	Pajarinen, J (corresponding author), UNIV HELSINKI,DEPT FORENS MED,POB 40,FIN-00014 HELSINKI,FINLAND.							ADLERCREUTZ H, 1990, ANN NY ACAD SCI, V595, P281, DOI 10.1111/j.1749-6632.1990.tb34302.x; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BOIESEN PT, 1979, ACTA PATH MICRO IM A, V87, P139; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; Bujan L, 1996, BRIT MED J, V312, P471, DOI 10.1136/bmj.312.7029.471; CARLSEN E, 1995, ENVIRON HEALTH PERSP, V103, P137, DOI 10.2307/3432523; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; CHIA SE, 1994, ARCH ANDROLOGY, V33, P163, DOI 10.3109/01485019408987820; Comhaire F, 1995, INT J ANDROL, V18, P1; DIKSHIT RK, 1987, FERTIL STERIL, V48, P334; DRIFE JO, 1987, DRUGS, V33, P610, DOI 10.2165/00003495-198733060-00004; FIELD B, 1990, SEMIN REPROD ENDOCR, V8, P44, DOI 10.1055/s-2007-1021422; *FINN STAT ALC CO, 1993, ALC STAT YB; Fisch H, 1996, FERTIL STERIL, V65, P1009, DOI 10.1016/S0015-0282(16)58278-8; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Irvine S, 1996, BMJ-BRIT MED J, V312, P467, DOI 10.1136/bmj.312.7029.467; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JEGOU B, 1992, CELL BIOL TOXICOL, V8, P49, DOI 10.1007/BF00130510; Joffe M, 1996, LANCET, V347, P1519, DOI 10.1016/S0140-6736(96)90673-X; KARHUNEN PJ, 1990, ALCOHOL ALCOHOLISM, V25, P25; KULLER LH, 1978, AM J EPIDEMIOL, V108, P192, DOI 10.1093/oxfordjournals.aje.a112611; MEINHARD E, 1973, BRIT MED J, V3, P577, DOI 10.1136/bmj.3.5880.577; OLSEN GW, 1995, FERTIL STERIL, V63, P887, DOI 10.1016/S0015-0282(16)57498-6; OSTERLIND A, 1986, BRIT J CANCER, V53, P501, DOI 10.1038/bjc.1986.79; Pajarinen J, 1996, ALCOHOL CLIN EXP RES, V20, P332, DOI 10.1111/j.1530-0277.1996.tb01648.x; Pajarinen J, 1996, INT J ANDROL, V19, P155, DOI 10.1111/j.1365-2605.1996.tb00456.x; PAJARINEN JT, 1994, INT J ANDROL, V17, P292, DOI 10.1111/j.1365-2605.1994.tb01259.x; Paulsen CA, 1996, FERTIL STERIL, V65, P1015; ROSENBLUM E, 1985, ENDOCRINOLOGY, V115, P311; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SUOMINEN J, 1993, BRIT MED J, V306, P1579, DOI 10.1136/bmj.306.6892.1579; VERMA AK, 1993, DIAGN CYTOPATHOL, V9, P37, DOI 10.1002/dc.2840090108; Vierula M, 1996, INT J ANDROL, V19, P11, DOI 10.1111/j.1365-2605.1996.tb00427.x; Wanderas EH, 1995, EUR J CANCER, V31A, P2044, DOI 10.1016/0959-8049(95)00321-5; WIDENIUS TV, 1987, J STEROID BIOCHEM, V28, P185, DOI 10.1016/0022-4731(87)90375-X; YAMADA K, 1993, BIOL PHARM BULL, V16, P425	41	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					13	18		10.1136/bmj.314.7073.13	http://dx.doi.org/10.1136/bmj.314.7073.13			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001473	Green Published			2022-12-28	WOS:A1997WB68400017
J	Ofman, JJ; Etchason, J; Fullerton, S; Kahn, KL; Soll, AH				Ofman, JJ; Etchason, J; Fullerton, S; Kahn, KL; Soll, AH			Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: Clinical and economic consequences	ANNALS OF INTERNAL MEDICINE			English	Article						Helicobacter pylori; Helicobacter infections; dyspepsia; cost-benefit analysis; endoscopy	PEPTIC-ULCER DISEASE; OPEN ACCESS ENDOSCOPY; NONULCER DYSPEPSIA; DUODENAL-ULCER; GASTROINTESTINAL ENDOSCOPY; GENERAL-PRACTICE; TRIPLE THERAPY; INFECTION; ERADICATION; PREVALENCE	Background: Noninvasive testing for Helicobacter pylori is widely available and has been considered as an initial management strategy for uninvestigated dyspepsia. However, data to guide clinicians in the management of patients with dyspepsia who are seropositive for H. pylori are lacking. Objective: To examine the economic, clinical, and policy implications of alternative initial management strategies for patients with uninvestigated dyspepsia who are seropositive for H. pylori. Design: Decision analysis comparing the costs and outcomes of initial anti-H. pylori therapy and initial endoscopy. Patients: Helicobacter pylori-seropositive patients with dyspepsia. Measurements: Cost estimates were obtained from the Medicare reimbursement schedule and a health maintenance organization pharmacy. Probability estimates were derived from the medical literature. Results: Initial endoscopy costs an average of $1276 per patient, whereas initial anti-H. pylori therapy costs 8820 per patient; the average saving is $456 per patient treated. The financial effect of a 252% increase in the use of antibiotics for initial H. pylori therapy is more than offset by reducing the endoscopy workload by 53%. Endoscopy-related costs must be reduced by 96% before the two strategies become equally cost-effective. In patients with nonulcer dyspepsia, the financial benefits of initial anti-H. pylori therapy are not substantially affected by varying the rates of H. pylori eradication, the complications of antibiotics, or the response of symptoms to cure of H. pylori infection. Conclusions: In H. pylori-seropositive patients with dyspepsia, initial anti-H. pylori therapy is the most cost-effective management strategy. Randomized studies of these strategies that evaluate outcomes and patient preferences are needed to optimize management decisions. In the meantime, unless physicians are concerned about resistance to antimicrobial agents or the lack of proven benefit of anti-H. pylori therapy in nonulcer dyspepsia, the strategy outlined in this analysis can be used as a basis for management and policy decisions about H. pylori-seropositive patients with dyspepsia.	VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA; EMORY UNIV, CTR CLIN EVALUAT SCI, ATLANTA, GA 30322 USA; RAND CORP, SANTA MONICA, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; RAND Corporation	Ofman, JJ (corresponding author), UNIV CALIF LOS ANGELES, GASTROENTER BIOL CTR, CURE, W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA.		Kahn, Katherine/AAE-2857-2020	Kahn, Katherine/0000-0002-6605-1455				ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BOAER WAD, 1995, SCAND J GASTROENTERO, V30, P401; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; CONWELL CF, 1995, J FAM PRACTICE, V41, P245; CUTLER AF, 1995, GASTROENTEROLOGY, V109, P136, DOI 10.1016/0016-5085(95)90278-3; DAVENPORT PM, 1985, BRIT MED J, V290, P217, DOI 10.1136/bmj.290.6463.217; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; FENDRICK AM, 1995, ANN INTERN MED, V123, P260, DOI 10.7326/0003-4819-123-4-199508150-00003; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; GAD A, 1989, SCAND J GASTROENTERO, V24, P44, DOI 10.3109/00365528909091310; GOODSON JD, 1989, J GEN INTERN MED, V4, P367, DOI 10.1007/BF02599683; GOULSTON KJ, 1991, MED J AUSTRALIA, V155, P20, DOI 10.5694/j.1326-5377.1991.tb116372.x; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GREENBERG RE, 1990, ARCH INTERN MED, V150, P2053, DOI 10.1001/archinte.150.10.2053; HANSEN JM, 1991, DAN MED BULL, V38, P288; HEIKKINEN M, 1995, SCAND J GASTROENTERO, V30, P519, DOI 10.3109/00365529509089783; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; HIRSCHHORN LR, 1994, J INFECT DIS, V169, P127, DOI 10.1093/infdis/169.1.127; HUNGIN APS, 1994, BRIT J GEN PRACT, V44, P519; IBER FL, 1992, J CLIN GASTROENTEROL, V14, P109, DOI 10.1097/00004836-199203000-00007; IMPERIALE TF, 1995, ANN INTERN MED, V123, P665, DOI 10.7326/0003-4819-123-9-199511010-00004; JAUP BH, 1995, AM J GASTROENTEROL, V90, P943; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; JONES R, 1989, BRIT MED J, V298, P30, DOI 10.1136/bmj.298.6665.30; JONES R, 1992, BRIT J CLIN PRACT, V46, P95; JONES R, 1988, PRACTITIONER, V232, P75; KAGEVI I, 1989, SCAND J GASTROENTERO, V24, P145, DOI 10.3109/00365528909093029; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; Kochman M L, 1993, Gastroenterology, V105, P1583; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; LABENZ J, 1995, EUR J GASTROEN HEPAT, V7, P9; LABENZ J, 1994, AM J GASTROENTEROL, V89, P1785; LAMBERT JR, 1993, GASTROENTEROL CLIN N, V22, P141; LOFFELD RJLF, 1990, DIGESTION, V47, P29, DOI 10.1159/000200473; MALFERTHEINER P, 1993, SCAND J GASTROENTERO, V28, P34, DOI 10.3109/00365529309098341; MANSI C, 1993, J CLIN GASTROENTEROL, V16, P149, DOI 10.1097/00004836-199303000-00015; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; MARSHALL BJ, 1988, LANCET, V2, P1437; Marsland D W, 1976, J Fam Pract, V3, P37; MCCARTHY C, 1995, DIGEST DIS SCI, V40, P114, DOI 10.1007/BF02063953; MENDALL MA, 1995, GUT, V36, P330, DOI 10.1136/gut.36.3.330; MORRIS C, 1992, J PSYCHOSOM RES, V36, P751, DOI 10.1016/0022-3999(92)90133-M; NOACH LA, 1994, SCAND J INFECT DIS, V26, P321, DOI 10.3109/00365549409011802; NYREN O, 1991, SCAND J GASTROENTERO, V26, P61, DOI 10.3109/00365529109109538; OCONNOR HJ, 1994, IRISH J MED SCI, V163, P369, DOI 10.1007/BF02942830; ORIORDAN TG, 1991, AGE AGEING, V20, P189, DOI 10.1093/ageing/20.3.189; PACE F, 1995, SCAND J GASTROENTERO, V30, P101, DOI 10.3109/00365529509093245; PATEL P, 1994, LANCET, V344, P511, DOI 10.1016/S0140-6736(94)91899-6; PATEL P, 1995, LANCET, V346, P1315, DOI 10.1016/S0140-6736(95)92340-3; QUINE MA, 1995, BRIT J SURG, V82, P530, DOI 10.1002/bjs.1800820430; REIERTSEN O, 1987, ENDOSCOPY, V19, P1, DOI 10.1055/s-2007-1013011; Silverstein MD, 1996, GASTROENTEROLOGY, V110, P72, DOI 10.1053/gast.1996.v110.pm8536890; SIPPONEN P, 1993, SCAND J GASTROENTERO, V28, P3, DOI 10.3109/00365529309098333; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; Soll AH, 1996, JAMA-J AM MED ASSOC, V275, P622; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; TALLEY NJ, 1993, GASTROENTEROL CLIN N, V22, P153; TEARE JP, 1995, EUR J GASTROEN HEPAT, V7, P275; THAM TCK, 1994, POSTGRAD MED J, V70, P809, DOI 10.1136/pgmj.70.829.809; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; *TREE AG SOFTW, 1994, DAT VERS 2 5 US MAN; VANZANTEN SJOV, 1994, CAN MED ASSOC J, V150, P189; VANZANTEN SJOV, 1993, SCAND J GASTROENTERO, V28, P40, DOI 10.3109/00365529309098356; WALSH JH, 1995, NEW ENGL J MED, V333, P984, DOI 10.1056/NEJM199510123331508; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	69	153	154	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					280	+		10.7326/0003-4819-126-4-199702150-00004	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036800				2022-12-28	WOS:A1997WH06800006
J	Sattler, M; Liang, H; Nettesheim, D; Meadows, RP; Harlan, JE; Eberstadt, M; Yoon, HS; Shuker, SB; Chang, BS; Minn, AJ; Thompson, CB; Fesik, SW				Sattler, M; Liang, H; Nettesheim, D; Meadows, RP; Harlan, JE; Eberstadt, M; Yoon, HS; Shuker, SB; Chang, BS; Minn, AJ; Thompson, CB; Fesik, SW			Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CELL-DEATH; BCL-2; PROTEINS; HETERODIMERIZATION; DISTINCT; DOMAINS; C-13; BH1; BAX	Heterodimerization between members of the Bcl-2 family of proteins is a key event in the regulation of programmed cell death. The molecular basis for heterodimer formation was investigated by determination of the solution structure of a complex between the survival protein Bcl-x(L) and the death-promoting region of the Bcl-2-related protein Bak. The structure and binding affinities of mutant Bak peptides indicate that the Bak peptide adopts an amphipathic or helix that interacts with Bcl-x(L) through hydrophobic and electrostatic interactions. Mutations in full-length Bak that disrupt either type of interaction inhibit the ability of Bak to heterodimerize with Bcl-x(L).	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOL GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Abbott Laboratories; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago			Sattler, Michael/C-1169-2010; Yoon, Ho Sup/A-2193-2011; Sattler, Michael/A-2407-2012	Yoon, Ho Sup/0000-0002-8243-3904; Sattler, Michael/0000-0002-1594-0527; Minn, Andy/0000-0003-1418-0906	NCI NIH HHS [R37 CA48023] Funding Source: Medline; PHS HHS [P01 A135294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA048023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1995, ONCOGENE, V11, P1921; BRUNGER AT, 1992, X PLOR VERSION 3 1; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHANG BC, UNPUB; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; EBERSTADT M, UNPUB; GRZESIEK S, 1994, J BIOMOL NMR, V4, P871; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	23	1239	1362	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					983	986		10.1126/science.275.5302.983	http://dx.doi.org/10.1126/science.275.5302.983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020082				2022-12-28	WOS:A1997WH38800047
J	Fein, AM; Bernard, GR; Criner, GJ; Fletcher, EC; Good, JT; Knaus, WA; Levy, H; Matuschak, GM; Shanies, HM; Taylor, RW; Rodell, TC				Fein, AM; Bernard, GR; Criner, GJ; Fletcher, EC; Good, JT; Knaus, WA; Levy, H; Matuschak, GM; Shanies, HM; Taylor, RW; Rodell, TC			Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127) - Results of a randomized, double-blind, placebo-controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN MONOCLONAL-ANTIBODY; KALLIKREIN-KININ SYSTEM; TUMOR-NECROSIS-FACTOR; SEPTIC SHOCK; ENDOTOXIN; DYSFUNCTION; ACTIVATION; HA-1A	Objective.-To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis. Design.-Multicenter, randomized, placebo-controlled, double-blind, parallel, dose-ranging trial. Follow-up for 28 days or until death. Setting.-A total of 47 US referral hospitals. Patients.-A total of 504 patients with SIRS and documented evidence of infection plus either hypotension or dysfunction of 2 organ systems. Interventions.-Three-day continuous intravenous infusion of either placebo or 1 of 3 doses (0.3, 1.0, or 3.0 mu g . kg(-1). min(-1)) of deltibant, Concurrent therapy at the discretion of the treating physician. Main Outcome Measure.-Risk-adjusted, 28-day, log-normal intent-to-treat survival analysis. Risk adjustment was performed using a study-specific risk model derived from the APACHE III database. Results.-Deltibant had no significant effect on risk-adjusted 28-day survival. In a posthoc analysis, risk-adjusted 7-day survival showed a nonsignificant trend toward improvement (P=.09). The 28-day risk-adjusted survival in the prospectively defined subset of patients with gram-negative infections showed a statistically significant improvement (P=.005). Conclusions.-Deltibant may have some effect on survival in patients with SIRS and gram-negative sepsis; however, additional studies would be required to prove this.	VANDERBILT UNIV, NASHVILLE, TN USA; TEMPLE UNIV HOSP & MED SCH, PHILADELPHIA, PA 19140 USA; VET AFFAIRS MED CTR, HOUSTON, TX 77030 USA; VET AFFAIRS MED CTR, LOUISVILLE, KY USA; UNIV LOUISVILLE HOSP, LOUISVILLE, KY USA; PORTER HOSP, DENVER, CO USA; SWEDISH MED CTR, DENVER, CO USA; GEORGE WASHINGTON UNIV, WASHINGTON, DC USA; UNIV NEW MEXICO, ALBUQUERQUE, NM 87131 USA; ST LOUIS UNIV, MED CTR, ST LOUIS, MO USA; ELMHURST MED CTR, ELMHURST, NY USA; ST JOHNS MERCY MED CTR, ST LOUIS, MO USA	Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Louisville; George Washington University; University of New Mexico; Saint Louis University; Saint Johns Mercy Medical Center	Fein, AM (corresponding author), WINTHROP UNIV HOSP, 222 STN PLAZA N, MINEOLA, NY 11501 USA.		Knaus, William/AAX-2138-2020					AASEN AO, 1983, ARCH SURG-CHICAGO, V118, P343; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CARVALHO AC, 1988, J LAB CLIN MED, V112, P270; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHRISTOPHER TA, 1994, AM J PHYSIOL, V266, pH867, DOI 10.1152/ajpheart.1994.266.3.H867; DELACADENA RA, 1993, BLOOD, V81, P3313; DHAINAUT JF, 1994, UPD INT CAR, V18, P397; DHAINAUT JFA, 1995, CRIT CARE MED, V23, P1461, DOI 10.1097/00003246-199509000-00004; FIGUEROA CD, 1992, BLOOD, V79, P754; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1994, CRIT CARE MED, V22, P12, DOI 10.1097/00003246-199401000-00008; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V272, P1170; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; GUERRERO R, 1993, J CLIN INVEST, V91, P2754, DOI 10.1172/JCI116516; HIRSCH EF, 1974, J SURG RES, V17, P147, DOI 10.1016/0022-4804(74)90101-2; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1995, J ENDOTOXIN RES, V2, P169, DOI 10.1177/096805199500200305; Maeda H, 1993, Agents Actions Suppl, V42, P159; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; NORONHABLOB L, 1991, INT C KIN 91 SEP 8 1; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; RIDINGS PC, 1995, J INVEST SURG, V8, P115, DOI 10.3109/08941939509016514; TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6; WHALLEY ET, 1992, AGENT ACTION SUPPL, V38, P413; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	27	145	148	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					482	487		10.1001/jama.277.6.482	http://dx.doi.org/10.1001/jama.277.6.482			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020273				2022-12-28	WOS:A1997WG05400036
J	Adkinson, NF; Eggleston, PA; Eney, D; Goldstein, EO; Schuberth, KC; Bacon, JR; Hamilton, RG; Weiss, ME; Arshad, H; Meinert, CL; Tonascia, J; Wheeler, B				Adkinson, NF; Eggleston, PA; Eney, D; Goldstein, EO; Schuberth, KC; Bacon, JR; Hamilton, RG; Weiss, ME; Arshad, H; Meinert, CL; Tonascia, J; Wheeler, B			A controlled trial of immunotherapy for asthma in allergic children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DERMATOPHAGOIDES PTERONYSSINUS; HYPOSENSITIZATION	Background Injections of allergens are widely prescribed for patients with asthma, but little is known about the effectiveness of immunotherapy. Methods We conducted a double-blind, placebo-controlled trial of multiple-allergen immunotherapy in 121 allergic children with moderate-to-severe, perennial (year-round) asthma. The children, who required daily medication for their asthma, were randomly assigned to receive subcutaneous injections of either a mixture of up to seven aeroallergen extracts or a placebo. Maintenance injections were continued for 18 months or longer. Medications were adjusted every two to three weeks on the basis of peak flow rates and symptoms. The principal outcome was the daily medication score. Bronchial sensitivity to methacholine (the concentration provoking a 20 percent decrease in the forced expiratory volume in one second [PC20]) was measured twice yearly. Results The median medication score declined from 5.4 to 4.9 in the immunotherapy group (P<0.001) and from 5.2 to 5.0 in the placebo group (P<0.001), but there was no significant difference between the groups (P>0.6). The number of days on which oral corticosteroids were used was similar in the two groups. Partial or complete remission of asthma occurred in 31 percent of the immunotherapy group and in 28 percent of the placebo group (P>0.5). There was no difference between the groups in the use of medical care, symptoms, or peak flow rates. The median PC20 increased significantly in both groups, but again with no difference between the two groups. Conclusions Immunotherapy with injections of allergens for over two years was of no discernible benefit in allergic children with perennial asthma who were receiving appropriate medical treatment. (C) 1997, Massachusetts Medical Society.	JOHNS HOPKINS UNIV,SCH MED,CTR ASTHMA & ALLERGY,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 21073] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Altman D.G., 1991, PRACTICAL STAT MED R; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P1, DOI 10.1016/0091-6749(94)90064-7; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COLEMAN JW, 1993, CLIN EXP ALLERGY  S3, V23, P3; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Cooke R. A, 1918, NY MED J, V107, P577; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; FRANKLAND AW, 1954, LANCET, V1, P1055; GERN JE, 1994, J ALLERGY CLIN IMMUN, V93, P706, DOI 10.1016/0091-6749(94)90250-X; Hargreave FE, 1985, AIRWAY RESPONSIVENES, P84; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; LOCKEY RF, 1991, ALLERGEN IMMUNOTHERA, P195; MALLING HJ, 1993, ALLERGY, V48, P9; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1990, CL IMMUNOL, V2, P3; NORMAN PS, 1990, J ALLERGY CLIN IMMUN, V85, P522, DOI 10.1016/0091-6749(90)90165-Z; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; *SAS I, 1989, SAS STAT US GUID VER; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; WARNER JO, 1978, LANCET, V2, P912; WEISS ME, 1989, AM REV RESPIR DIS, V139, P67, DOI 10.1164/ajrccm/139.1.67	26	242	249	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					324	331		10.1056/NEJM199701303360502	http://dx.doi.org/10.1056/NEJM199701303360502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011784				2022-12-28	WOS:A1997WG23300002
J	Weller, M				Weller, M			London's mental health problems	LANCET			English	Editorial Material											Weller, M (corresponding author), ST ANNA HOSP,DEPT PSYCHIAT,LONDON N15 3TH,ENGLAND.							Faris Robert E.L, 1939, MENTAL DISORDERS URB; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; JAUHAR P, 1982, BRIT J PSYCHIAT, V140, P231, DOI 10.1192/bjp.140.3.231; JOHNSON S, 1967, LONDONS MENTAL HLTH, P400; ODEGAARD O, 1932, ACTA PSYCHIATRICA S, V4; *ROYAL COLL GEN PR, 1981, 16 RCP; WELLER M, 1989, LANCET, V2, P1509	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					224	224		10.1016/S0140-6736(05)64859-3	http://dx.doi.org/10.1016/S0140-6736(05)64859-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WD906	9014907				2022-12-28	WOS:A1997WD90600007
J	Carpino, N; Wisniewski, D; Strife, A; Marshak, D; Kobayashi, R; Stillman, B; Clarkson, B				Carpino, N; Wisniewski, D; Strife, A; Marshak, D; Kobayashi, R; Stillman, B; Clarkson, B			p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; KIT-LIGAND; C-ABL; BINDING; DOMAINS; SRC; P62; DIFFERENTIATION	Characteristic of chronic myelogenous leukemia (CML) is the presence of the chimeric p210(bcr-abl) protein possessing elevated protein tyrosine kinase activity relative to normal c-abl tyrosine kinase. Hematopoietic progenitors isolated from CML patients in the chronic phase contain a constitutively tyrosine-phosphorylated protein that migrates at 62 kDa by SDS-PAGE and associates with the p120 ras GTPase-activating protein (GAP). We have purified p62(dok) from a hematopoietic cell line expressing p210(bcr-abl). p62(dok) is a novel protein with features of a signaling molecule. Association of p62(dok) with GAP correlates with its tyrosine phosphorylation. p62(dok) is rapidly tyrosine-phosphorylated upon activation of the c-Kit receptor, implicating it as a component of a signal transduction pathway downstream of receptor tyrosine kinases.	SUNY STONY BROOK, PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Memorial Sloan Kettering Cancer Center	Carpino, N (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091	NCI NIH HHS [5P01 CA64593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CHUNG SW, 1995, ONCOGENE, V10, P1261; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALEY GQ, 1991, ADV CANCER RES, V57, P151; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GARRELS J, 1993, METHOD ENZYMOL, V100, P411; GROFFEN J, 1991, CHRONIC MYELOGENOUS, P181; Harlow E., 1988, ANTIBODIES LAB MANUA; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEET K, 1995, MOL CELL BIOL, V15, P4908; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STRIFE A, 1993, CANCER RES, V53, P401; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wisniewski D, 1996, LEUKEMIA, V10, P229; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	335	370	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					197	204		10.1016/S0092-8674(00)81840-1	http://dx.doi.org/10.1016/S0092-8674(00)81840-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008160	hybrid			2022-12-28	WOS:A1997WE97000008
J	Maiti, S; Shear, JB; Williams, RM; Zipfel, WR; Webb, WW				Maiti, S; Shear, JB; Williams, RM; Zipfel, WR; Webb, WW			Measuring serotonin distribution in live cells with three-photon excitation	SCIENCE			English	Article							BASOPHILIC LEUKEMIA-CELLS; MAST-CELLS; FLUORESCENCE; MICROSCOPY; SURFACE; PROTEINS; GRANULES	Tryptophan and serotonin were imaged with infrared illumination by three-photon excitation (3PE) of their native ultraviolet (UV) fluorescence. This technique, established by 3PE cross section measurements of tryptophan and the monoamines serotonin and dopamine, circumvents the limitations imposed by photodamage, scattering, and indiscriminate background encountered in other UV microscopies. Three-dimensionally resolved images are presented along with measurements of the serotonin concentration (similar to 50 mM) and content (up to similar to 5 X 10(8) molecules) of individual secretory granutes.	CORNELL UNIV, SCH APPL & ENGN PHYS, ITHACA, NY 14853 USA	Cornell University			Webb, Watt W./B-5905-2011	Williams, Rebecca/0000-0002-1391-5846	NCRR NIH HHS [RR07719, RR04224] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007719, P41RR004224] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BONIFACINO JS, 1989, J CELL SCI, V92, P701; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GARRIS PA, 1994, J PHYSIOL-LONDON, V478, P239, DOI 10.1113/jphysiol.1994.sp020246; GUILD JB, IN PRESS APPL OPT; LIU G, 1995, NEUROPHARMACOLOGY, V34, P1407, DOI 10.1016/0028-3908(95)00143-T; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; Mertz J, 1995, OPT LETT, V20, P2532, DOI 10.1364/OL.20.002532; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; OLIVER JM, 1988, PROG ALLERGY, V42, P185; PHILLIPS DM, 1985, J ULTRA MOL STRUCT R, V90, P105, DOI 10.1016/0889-1605(85)90120-X; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; SINGH S, 1964, PHYS REV LETT, V12, P612, DOI 10.1103/PhysRevLett.12.612; SPUDICH A, 1995, P NATL ACAD SCI USA, V92, P6976, DOI 10.1073/pnas.92.15.6976; TAMIR H, 1982, J CELL BIOL, V93, P638, DOI 10.1083/jcb.93.3.638; TAN WH, 1995, ANAL CHEM, V67, P2575, DOI 10.1021/ac00111a013; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; THOMAS JL, 1994, J CELL BIOL, V125, P795, DOI 10.1083/jcb.125.4.795; WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Xu C, 1996, J OPT SOC AM B, V13, P481, DOI 10.1364/JOSAB.13.000481; Zerby SE, 1996, BRAIN RES, V712, P1, DOI 10.1016/0006-8993(95)01383-0	26	367	387	5	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1997	275	5299					530	532		10.1126/science.275.5299.530	http://dx.doi.org/10.1126/science.275.5299.530			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999797				2022-12-28	WOS:A1997WE25700044
J	Menard, R; Sultan, AA; Cortes, C; Altszuler, R; vanDijk, MR; Janse, CJ; Waters, AP; Nussenzweig, RS; Nussenzweig, V				Menard, R; Sultan, AA; Cortes, C; Altszuler, R; vanDijk, MR; Janse, CJ; Waters, AP; Nussenzweig, RS; Nussenzweig, V			Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes	NATURE			English	Article							PLASMODIUM-BERGHEI; ANOPHELES-STEPHENSI; THROMBOSPONDIN; EXPRESSION; PARASITE; CELL; TRANSFECTION; HEPATOCYTES	Malaria parasites undergo a sporogonic cycle in the mosquito vector, Sporozoites, the form of the parasite injected into the host during a bloodmeal, develop inside oocysts in the insect midgut, then migrate to and eventually invade the salivary glands, The circumsporozoite protein (CS), one of the major proteins synthesized by salivary gland sporozoites', is a surface-associated molecule which is important in sporozoite infectivity to the host(2). Here, by gene targeting, we created Plasmodium berghei lines in which the single-copy CS gene was disrupted, The CS(-) and wild-type parasites produced similar numbers of oocysts of comparable size in the mosquito midgut, In the CS(-) oocysts, however, sporozoite formation was profoundly inhibited. CS therefore appears to have a pleiotropic role and to be vital for malaria parasites in both the vector and the host: in mosquitoes, CS is essential for sporozoite development within oocysts, and in the vertebrate host it promotes sporozoite attachment to hepatocytes(3-7).	NYU,MED CTR,DEPT MED & MOL PARASITOL,NEW YORK,NY 10016; LEIDEN UNIV,DEPT PARASITOL,NL-2300 RC LEIDEN,NETHERLANDS	New York University; Leiden University; Leiden University - Excl LUMC	Menard, R (corresponding author), NYU MED CTR,KAPLAN CANC CTR,DEPT PATHOL,MICHAEL HEIDELBERGER DIV IMMUNOL,NEW YORK,NY 10016, USA.		Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205; Cortes, Claudio/0000-0003-2870-0028				ARAKAWA RS, 1992, J PROTOZOOL, V39, P333; BOULANGER N, 1995, PARASITOL RES, V81, P58, DOI 10.1007/BF00932418; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; EICHINGER DJ, 1986, MOL CELL BIOL, V6, P3965, DOI 10.1128/MCB.6.11.3965; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; HAMILTON AJ, 1988, PARASITOLOGY, V96, P273, DOI 10.1017/S0031182000058273; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; NAGASAWA H, 1988, EXP PARASITOL, V66, P27, DOI 10.1016/0014-4894(88)90047-1; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; OSAKI LS, 1983, CELL, V34, P815; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; POSTHUMA G, 1988, EUR J CELL BIOL, V46, P18; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SIMONETTI AB, 1993, J EUKARYOT MICROBIOL, V40, P569, DOI 10.1111/j.1550-7408.1993.tb06109.x; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; VANDERBERG J, 1967, J PROTOZOOL, V14, P82, DOI 10.1111/j.1550-7408.1967.tb01452.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; WALLIKER D, 1983, MOL BIOL PARASITES, P53; WU YM, 1995, P NATL ACAD SCI USA, V92, P973, DOI 10.1073/pnas.92.4.973; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225	26	234	241	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					336	340		10.1038/385336a0	http://dx.doi.org/10.1038/385336a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002517				2022-12-28	WOS:A1997WD91400049
J	Lesar, TS; Briceland, L; Stein, DS				Lesar, TS; Briceland, L; Stein, DS			Factors related to errors in medication prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; HOSPITALIZED-PATIENTS; PREVENTABILITY; SYSTEMS; DOCTORS	Objective.-To quantify the type and frequency of identifiable factors associated with medication prescribing errors. Design and Setting.-Systematic evaluation of every third prescribing error detected and averted by pharmacists in a 631-bed tertiary care teaching hospital between July 1, 1994, and June 30, 1995. Each error was concurrently evaluated for the potential to result in adverse patient consequences. Each error was retrospectively evaluated by a physician and 2 pharmacists and a factor likely related to the error was identified. Participants.--All physicians prescribing medications during the study period and all staff pharmacists involved in the routine review of medication orders. Main Outcome Measures.-Frequency of association of factors likely related to medication errors in general and specific to medication classes and prescribing services (needed for medical, pediatric, obstetric-gynecologic, surgical, or emergency department patients); and potential consequences of errors for negative patient outcomes. Results.-A total of 2103 errors thought to have potential clinical importance were detected during the 1-year study period. The overall rate of errors was 3.99 errors per 1000 medication orders, and the error rate varied among medication classes and prescribing services. A total of 696 errors met study criteria (ie, errors with the potential for adverse patient effects) and were evaluated for a likely related factor. The most common specific factors associated with errors were decline in renal or hepatic function requiring alteration of drug therapy (97 errors: 13.9%), patient history of allergy to the same medication class (84 errors, 12.1%): using the wrong drug name, dosage form, or abbreviation (total of 79 errors, 11.4%, for both brand name and generic name orders), incorrect dosage calculations (77 errors, 11.1%), and atypical or unusual and critical dosage frequency considerations (75 errors, 10.8%). The most common groups of factors associated with errors were those related to knowledge and the application of knowledge regarding drug therapy (209 errors, 30%); knowledge and use of knowledge regarding patient fac tors that affect drug therapy (203 errors, 29.2%); use of calculations, decimal points, or unit and rate expression factors (122 errors, 17.5%); and nomenclature factors (incorrect drug name, dosage form, or abbreviation) (93 errors, 13.4%). Conclusions.-Several easily identified factors are associated with a large proportion of medication prescribing errors. By improving the focus of organizational, technological, and risk management educational and training efforts using the factors commonly associated with prescribing errors, risk to patients from adverse drug events should be reduced.	ALBANY COLL PHARM, DEPT PHARM PRACTICE, ALBANY, NY USA; ALBANY MED COLL, DIV MED, ALBANY, NY 12208 USA	Albany College of Pharmacy & Health Sciences; Albany Medical College	Lesar, TS (corresponding author), ALBANY MED CTR HOSP, DEPT PHARM, 43 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.							*AM MED ASS, 1994, AMA BOARD TRUST REP; [Anonymous], 1992, Am J Hosp Pharm, V49, P640; Attilio RM, 1996, HOSP PHARM, V31, P17; BALDWIN L, 1995, BRIT MED J, V310, P1154, DOI 10.1136/bmj.310.6988.1154; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BEERS MH, 1990, J AM GERIATR SOC, V38, P1183, DOI 10.1111/j.1532-5415.1990.tb01496.x; BJORNSON DC, 1993, AM J HOSP PHARM, V50, P1875, DOI 10.1093/ajhp/50.9.1875; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; DAVIS N, 1987, MED ABBREVIATIONS 55; FOLLI HL, 1987, PEDIATRICS, V79, P718; HAIG GM, 1991, AM J HOSP PHARM, V48, P1457, DOI 10.1093/ajhp/48.7.1457; JICK H, 1977, AM J MED, V62, P514, DOI 10.1016/0002-9343(77)90406-5; KIRCHBAUM DW, 1988, DICP ANN PHARMAC, V22, P981; KOREN G, 1994, J CLIN PHARMACOL, V34, P1043, DOI 10.1002/j.1552-4604.1994.tb01978.x; LANDIS SJ, 1990, CAN MED ASSOC J, V143, P611; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEAPE LL, 1995, AM J HEALTH-SYST PH, V52, P379, DOI 10.1093/ajhp/52.4.379; LEBELLE MJ, 1993, CAN MED ASSOC J, V149, P941; Lesar T S, 1994, Hosp Pharm, V29, P935; Lesar TS, 1996, ANN PHARMACOTHER, V30, P31, DOI 10.1177/106002809603000105; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; LESAR TS, 1992, ANN INTERN MED, V117, P537, DOI 10.7326/0003-4819-117-6-537_2; LOMAESTRO BM, 1992, JAMA-J AM MED ASSOC, V268, P2031, DOI 10.1001/jama.1992.03490150083021; LOMAESTRO BM, 1994, ANN INTERN MED, V121, P818, DOI 10.7326/0003-4819-121-10-199411150-00034; MCKENNEY JM, 1979, AM J HOSP PHARM, V36, P1691, DOI 10.1093/ajhp/36.12.1691; MEYERSOHN MB, 1992, APPL PHARMACOKINETIC, P1; Potts MJ, 1996, ARCH PEDIAT ADOL MED, V150, P748, DOI 10.1001/archpedi.1996.02170320094016; Preston SL, 1995, ANN PHARMACOTHER, V29, P1202, DOI 10.1177/106002809502901202; ROLFE S, 1995, BRIT MED J, V310, P1173, DOI 10.1136/bmj.310.6988.1173; VITILLO JA, 1991, DICP ANN PHARMAC, V25, P1388, DOI 10.1177/106002809102501221	35	466	481	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					312	317		10.1001/jama.277.4.312	http://dx.doi.org/10.1001/jama.277.4.312			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002494				2022-12-28	WOS:A1997WC45800031
J	Sheth, SG; Gordon, FD; Chopra, S				Sheth, SG; Gordon, FD; Chopra, S			Nonalcoholic steatohepatitis	ANNALS OF INTERNAL MEDICINE			English	Review							NON-ALCOHOLIC STEATOHEPATITIS; FREE FATTY-ACIDS; MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; EXPANDED CLINICAL ENTITY; MORBID-OBESITY; LIVER-DISEASE; JEJUNOILEAL BYPASS; NATURAL-HISTORY; HEPATIC MORPHOLOGY; DIABETES-MELLITUS	Objective: To determine the clinical relevance of nonalcoholic steatohepatitis (NASH) and to review the available literature on the epidemiology, clinical features, histology, pathogenesis, clinical course, and management of this condition. Data Sources: Pertinent articles in English identified through a MEDLINE search (1966 to the present) and the bibliographies of relevant articles. Study Selection: All studies, including case reports, evaluating the salient features and clinical profile of NASH. Data Extraction: Data were selected from all articles that fit the study selection criteria. Data Synthesis: Nonalcoholic steatohepatitis is a distinct clinical entity characterized by elevated plasma liver enzyme levels and liver biopsy findings that are identical to those seen in alcoholic hepatitis; patients with NASH, however, do not consume alcohol in quantities known to cause liver injury. Patients with NASH are typically obese, middle-aged women with asymptomatic hepatomegaly who are diabetic or hyperlipidemic and present with an unrelated medical problem. Analysis of liver biopsy specimens is the cornerstone of diagnosis; hepatic morphologic findings range from mild fatty degeneration and inflammation to cell degeneration, fibrosis, and cirrhosis with or without the presence of Mallory hyaline bodies. Elevated levels of free fatty acids in the liver are thought to be responsible for the development of steatohepatitis. Although NASH is most often a benign disease with an indolent course, patients with this condition occasionally develop cirrhosis, portal hypertension, and hepatic failure. In some cases, NASH may be reversed with weight reduction. Conclusion: Nonalcoholic steatohepatitis is an important differential diagnosis for asymptomatic patients with chronically elevated plasma liver enzyme levels, especially if obesity, diabetes, or hyperlipidemia are present. Analysis of liver biopsy specimens is necessary for diagnosis and must be done in all patients with unexplained abnormal liver function and negative results on a noninvasive workup. Prognosis is good in most patients. The precise role of weight reduction and ursodeoxycholic acid therapy in the favorable alteration of the natural history of this disorder needs to be addressed in large, well-controlled studies.	BETH ISRAEL DEACONESS MED CTR, DIV GASTROENTEROL, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Sheth, SG (corresponding author), BETH ISRAEL DEACONESS MED CTR, DEPT MED, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ABDELMALEK M, 1995, J CLIN GASTROENTEROL, V20, P127, DOI 10.1097/00004836-199503000-00011; ACOSTA D, 1974, ATHEROSCLEROSIS, V20, P417, DOI 10.1016/0021-9150(74)90023-9; ANDERSEN T, 1984, INT J OBESITY, V8, P97; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; BADDELEY RM, 1985, WORLD J SURG, V9, P842, DOI 10.1007/BF01655388; BALDRIDGE AD, 1995, J PEDIATR-US, V127, P700, DOI 10.1016/S0022-3476(95)70156-7; BLACKARD WG, 1970, DIABETES, V19, P302, DOI 10.2337/diab.19.5.302; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; CAIRNS SR, 1986, J CLIN PATHOL, V39, P647, DOI 10.1136/jcp.39.6.647; CAPRON JP, 1982, DIGEST DIS SCI, V27, P265, DOI 10.1007/BF01296926; CAREY JB, 1966, MEDICINE, V45, P461, DOI 10.1097/00005792-196645060-00009; CARLSON LARS A., 1965, HANDBOOK PHYSIOL, V5, P625; Cello JP, 1990, HEPATOLOGY, P1428, DOI [10.1016/0270-9139(91)90240-v, DOI 10.1016/0270-9139(91)90240-V]; CLAIN DJ, 1987, GASTROENTEROL CLIN N, V16, P239; CRAIG RM, 1980, GASTROENTEROLOGY, V79, P131; DEFRONZO RA, 1982, INT J OBESITY, V6, P73; Dianzani M.U., 1991, HEPATOTOXICOLOGY, P327; DIEHL AM, 1988, GASTROENTEROLOGY, V95, P1056, DOI 10.1016/0016-5085(88)90183-7; DRENICK EJ, 1970, NEW ENGL J MED, V282, P829, DOI 10.1056/NEJM197004092821502; ERIKSSON S, 1986, ACTA MED SCAND, V220, P83; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FALCHUK KR, 1980, GASTROENTEROLOGY, V78, P535; FLETCHER LM, 1991, HEPATOLOGY, V13, P455, DOI 10.1016/0270-9139(91)90298-A; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GALAMBOS JT, 1972, GASTROENTEROLOGY, V63, P1026; GERBER MA, 1972, HUM PATHOL, V3, P199, DOI 10.1016/S0046-8177(72)80073-X; GRIMM IS, 1992, AM J GASTROENTEROL, V87, P775; HAINES NW, 1981, HEPATOLOGY, V1, P161, DOI 10.1002/hep.1840010212; HAMILTON DL, 1983, GASTROENTEROLOGY, V85, P722; HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990; HOFMANN AF, 1990, FALK SYMP, V53, P13; ITOH S, 1982, DIGEST DIS SCI, V27, P341, DOI 10.1007/BF01296754; ITOH S, 1977, ACTA HEPATO-GASTRO, V24, P415; ITOH S, 1987, AM J GASTROENTEROL, V82, P650; KEEFFE EB, 1987, DIGEST DIS SCI, V32, P441, DOI 10.1007/BF01296300; KIMURA H, 1980, GASTROENTEROLOGY, V78, P807; Laurin J, 1996, HEPATOLOGY, V23, P1464; LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9; LEE RG, 1995, HEPATOLOGY, V21, P1742, DOI 10.1002/hep.1840210636; LEE SP, 1981, CLIN SCI, V61, P253, DOI 10.1042/cs0610253; LEE SS, 1975, ARCH PATHOL, V99, P301; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LOMBARDI B, 1966, LAB INVEST, V15, P1; LONARDO A, 1995, AM J GASTROENTEROL, V90, P2072; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; LUMENG L, 1986, HEPATOLOGY, V6, P742, DOI 10.1002/hep.1840060434; MACSWEEN RNM, 1981, LANCET, V1, P707; MACSWEEN RNM, 1986, SEMIN LIVER DIS, V6, P221, DOI 10.1055/s-2008-1040605; MARBET UA, 1987, J HEPATOL, V4, P364, DOI 10.1016/S0168-8278(87)80547-0; MARUBBIO AT, 1976, AM J CLIN PATHOL, V66, P684; MAVRELIS PG, 1983, HEPATOLOGY, V3, P226; MCFARLAND RJ, 1985, BRIT J SURG, V72, P81, DOI 10.1002/bjs.1800720202; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGILL DB, 1972, GASTROENTEROLOGY, V63, P872; MOORHOUSE JA, 1963, J CLIN ENDOCR METAB, V23, P1080, DOI 10.1210/jcem-23-11-1080; MORAN JR, 1983, AM J GASTROENTEROL, V78, P374; MOXLEY RT, 1974, NEW ENGL J MED, V290, P921, DOI 10.1056/NEJM197404252901701; NALPAS B, 1984, HEPATOLOGY, V4, P893, DOI 10.1002/hep.1840040517; NALPAS B, 1986, HEPATOLOGY, V6, P608, DOI 10.1002/hep.1840060410; NASRALLAH SM, 1981, DIGEST DIS SCI, V26, P325, DOI 10.1007/BF01308373; NAZIM M, 1989, HEPATO-GASTROENTEROL, V36, P349; NEUSCHWANDERTETRI BA, 1990, BIOCHEM BIOPH RES CO, V167, P1170, DOI 10.1016/0006-291X(90)90646-5; NONOMURA A, 1992, GASTROENTEROL JPN, V27, P521; PANTEGHINI M, 1984, J CLIN CHEM CLIN BIO, V22, P153; PARTIN JS, 1974, GASTROENTEROLOGY, V67, P107; PESSAYRE D, 1979, GASTROENTEROLOGY, V76, P170; Pinto HC, 1996, DIGEST DIS SCI, V41, P172, DOI 10.1007/BF02208601; POUCELL S, 1984, GASTROENTEROLOGY, V86, P926; POUPON RE, 1989, ALCOHOL CLIN EXP RES, V13, P549, DOI 10.1111/j.1530-0277.1989.tb00376.x; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; POWELL EE, 1989, GASTROENTEROLOGY, V97, P1022, DOI 10.1016/0016-5085(89)91513-8; PRATT DS, 1995, ANN INTERN MED, V123, P236, DOI 10.7326/0003-4819-123-3-199508010-00018; PROPST A, 1995, GASTROENTEROLOGY, V108, P1607, DOI 10.1016/0016-5085(95)90724-6; ROGERS DW, 1992, DIGEST DIS SCI, V37, P1644, DOI 10.1007/BF01299852; ROZENTAL P, 1967, AM J DIG DIS, V12, P198, DOI 10.1007/BF02233443; SCHAFFNER F, 1986, PROG LIVER DIS, V8, P283; SCHELLENBERG F, 1987, ALCOHOL ALCOHOL S1, V22, P624; Seki K, 1983, Gastroenterol Jpn, V18, P197; SHERR HP, 1974, AM J CLIN NUTR, V27, P1369; STIBLER H, 1986, ALCOHOL CLIN EXP RES, V10, P61, DOI 10.1111/j.1530-0277.1986.tb05616.x; STOREY EL, 1987, LANCET, V1, P1292; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; VYBERG M, 1987, LIVER, V7, P271; WANLESS IR, 1989, MODERN PATHOL, V2, P69; WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505	85	472	501	1	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					137	145		10.7326/0003-4819-126-2-199701150-00008	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005748				2022-12-28	WOS:A1997WD29800009
J	Patel, BD; Parekh, SR				Patel, BD; Parekh, SR			Absence of rigor mortis in Indian childhood cirrhosis	LANCET			English	Article									BAI JERBAI WADLA HOSP CHILDREN,MUMBAI,INDIA; INST CHILD HLTH,MUMBAI,INDIA; SETH GS MED COLL,MUMBAI,INDIA	Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital								PATEL BD, 1974, INDIAN PEDIATR, V11, P19; Sen B, 1887, INDIAN MED GAZETTE, V22, P338; SUSHRUTA, 1952, UTTAR TANTRA, pCH27; TSUNEO S, 1976, FORENSIC SCI, V8, P207; WILLIAM B, 1970, TXB PATHOLOGY, P44	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					100	101		10.1016/S0140-6736(05)60883-5	http://dx.doi.org/10.1016/S0140-6736(05)60883-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996425				2022-12-28	WOS:A1997WB80000016
J	Davis, SM; Albers, GW; Diener, HC; Lees, KR; Norris, J				Davis, SM; Albers, GW; Diener, HC; Lees, KR; Norris, J			Termination of acute stroke studies involving selfotel treatment	LANCET			English	Article							ACUTE ISCHEMIC STROKE; GLUTAMATE ANTAGONIST; RANDOMIZED TRIAL				Davis, SM (corresponding author), ROYAL MELBOURNE HOSP,MELBOURNE NEUROSCI CTR,DEPT NEUROL,PARKVILLE,VIC 3050,AUSTRALIA.		Davis, Stephen M/L-5260-2013; Diener, Hans-Christoph/AAF-7275-2019	Davis, Stephen M/0000-0003-0962-2300; Albers, Gregory/0000-0003-0263-4632				CLARK WM, 1994, NEUROLOGY, V44, pA270; GROTTA J, 1995, STROKE, V26, P602, DOI 10.1161/01.STR.26.4.602; MARKABI S, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P635; *SCAND STROK STUD, 1985, STROKE, V16, P885; SPIEGELHALTER DJ, 1986, CONTROL CLIN TRIALS, V7, P8, DOI 10.1016/0197-2456(86)90003-6	5	138	143	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 4	1997	349	9044					32	32		10.1016/S0140-6736(05)62166-6	http://dx.doi.org/10.1016/S0140-6736(05)62166-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WA725	8999265				2022-12-28	WOS:A1997WA72500023
J	Larue, F; Fontaine, A; Colleau, SM				Larue, F; Fontaine, A; Colleau, SM			Underestimation and undertreatment of pain in HIV disease: Multicentre study	BRITISH MEDICAL JOURNAL			English	Article							CANCER PAIN; HOSPITALIZED-PATIENTS; FRANCE; ATTITUDES; MORPHINE; AIDS	Objectives: To measure the prevalence, severity, and impact of pain on quality of life for HIV patients; to identify factors associated with undertreatment of pain. Design: Multicentre cross sectional survey. Settings: 34 HIV treatment facilities, including inpatient hospital wards, day hospitals, and ambulatory care clinics, in 13 cities throughout France. Subjects: 315 HIV patients at different stages of the disease. Main outcome measures: Patients: recorded presence and severity of pain and rated quality of life, Doctors: reported disease status, estimate of pain severity, and analgesic treatment ordered. Results: From 30% (17/56) of outpatients to 62% (73/118) of inpatients reported pain due to HIV disease. Pain severity significantly decreased patients' quality of life. Doctors underestimated pain severity in 52% (70/135) of HIV patients reporting pain. Underestimation of pain severity was more likely for patients who reported moderate (odds ratio 24) or severe pain (165) and less likely for patients whose pain source was identified or who were perceived as more depressed, Of the patients reporting moderate or severe pain, 57% (61/107) did not receive any analgesic treatment; only 22% (23/107) received at least weak opioids. Likelihood of analgesic prescription increased when doctors estimated pain to be more severe and regarded patients as sicker. Conclusions: Pain is a common and debilitating symptom of HIV disease which is gravely underestimated and undertreated.	UNIV PARIS 07, FAC BICHAT, DEPT SANTE PUBL, F-75018 PARIS, FRANCE; UNIV WISCONSIN, SCH MED, WHO, COLLABORATING CTR SYMPTOM EVALUAT CANC CARE, MADISON, WI 53705 USA	UDICE-French Research Universities; Universite Paris Cite; University of Wisconsin System; University of Wisconsin Madison; World Health Organization	Larue, F (corresponding author), INST MUTUALISTE MONTSOURIS, 42 BLVD JOURDAN, F-75014 PARIS, FRANCE.							ANAND A, 1994, J ACQ IMMUN DEF SYND, V7, P52; BREITBART W, 1993, SYMP PAIN R, P49; Breitbart W, 1996, PAIN, V65, P243, DOI 10.1016/0304-3959(95)00217-0; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; DIXON P, 1991, POSTGRAD MED J, V67, pS92; DORMONT J, 1993, PRISE CHARGE PERSONN; Hoyt M J, 1994, J Assoc Nurses AIDS Care, V5, P33; JACOX A, 1994, 9 US DEP HLTH HUM SE; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LARUE F, 1995, CANCER, V76, P2375, DOI 10.1002/1097-0142(19951201)76:11<2375::AID-CNCR2820761129>3.0.CO;2-C; Larue F, 1996, J PAIN SYMPTOM MANAG, V12, P106; LARUE F, 1995, BRIT MED J, V310, P1034, DOI 10.1136/bmj.310.6986.1034; LEBOVITS AH, 1994, CLIN J PAIN, V10, P156, DOI 10.1097/00002508-199406000-00010; MCCORMACK JP, 1993, CLIN J PAIN, V9, P279, DOI 10.1097/00002508-199312000-00010; *MIN SOC AFF, 1994, HLTH CAR AIDS KEY FI; MOSS V, 1991, Palliative Medicine, V5, P112; Newshan G T, 1993, J Assoc Nurses AIDS Care, V4, P53; ONEILL WM, 1993, PAIN, V54, P3, DOI 10.1016/0304-3959(93)90093-5; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SHOFFERMAN J, 1988, J PALLIAT CARE, V4, P46; SINGER EJ, 1993, PAIN, V54, P15, DOI 10.1016/0304-3959(93)90094-6; VAINIO A, 1995, PAIN, V62, P155, DOI 10.1016/0304-3959(94)00264-F; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *WHO, 1990, WHO TECH REP SER, V804	27	141	146	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					23	28		10.1136/bmj.314.7073.23	http://dx.doi.org/10.1136/bmj.314.7073.23			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001475	Green Published			2022-12-28	WOS:A1997WB68400019
J	Roberts, JD; Fineman, JR; Morin, FC; Shaul, PW; Rimar, S; Schreiber, MD; Polin, RA; Zwass, MS; Zayek, MM; Gross, I; Heymann, MA; Zapol, WM				Roberts, JD; Fineman, JR; Morin, FC; Shaul, PW; Rimar, S; Schreiber, MD; Polin, RA; Zwass, MS; Zayek, MM; Gross, I; Heymann, MA; Zapol, WM			Inhaled nitric oxide and persistent pulmonary hypertension of the newborn	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; OXYGENATION; VASOCONSTRICTION; LAMB	Background Persistent pulmonary hypertension of the newborn causes systemic arterial hypoxemia because of increased pulmonary vascular resistance and right-to-left shunting of deoxygenated blood. Inhaled nitric oxide decreases pulmonary vascular resistance in newborns. We studied whether inhaled nitric oxide decreases severe hypoxemia in infants with persistent pulmonary hypertension. Methods In a prospective, multicenter study, 58 full-term infants with severe hypoxemia and persistent pulmonary hypertension were randomly assigned to breathe either a control gas (nitrogen) or nitric oxide (80 parts per million), mixed with oxygen from a ventilator. If oxygenation increased after 20 minutes and systemic blood pressure did not decrease, the treatment was considered successful and was continued at lower concentrations. Otherwise, it was discontinued and alternative therapies, including extracorporeal membrane oxygenation, were used. Results Inhaled nitric oxide successfully doubled systemic oxygenation in 16 of 30 infants (53 percent), whereas conventional therapy without inhaled nitric oxide increased oxygenation in only 2 of 28 infants (7 percent). Long-term therapy with inhaled nitric ox ide sustained systemic oxygenation in 75 percent of the infants who had initial improvement. Extracorporeal membrane oxygenation was required in 71 per cent of the control group and 40 percent of the nitric oxide group (P=0.02). The number of deaths was similar in the two groups. Inhaled nitric oxide did not cause systemic hypotension or increase methemoglobin levels. Conclusions Inhaled nitric oxide improves systemic oxygenation in infants with persistent pulmonary hypertension and may reduce the need for more invasive treatments. (C) 1997, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14260; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX; YALE UNIV,DEPT PEDIAT,NEW HAVEN,CT 06520; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,PHILADELPHIA,PA 19104	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yale University; University of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040473, R01HL041387, R01HL042397] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40473, HL 42397, HL 41387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIGATELLO LM, 1994, ANESTHESIOLOGY, V80, P761, DOI 10.1097/00000542-199404000-00007; CRAWLEY DE, 1992, AM J PHYSIOL, V263, pL325, DOI 10.1152/ajplung.1992.263.3.L325; Day RW, 1996, PEDIATRICS, V98, P698; DOWNES MJ, 1976, ANALYST, V101, P742, DOI 10.1039/an9760100742; FINER NN, 1994, J PEDIATR-US, V124, P302, DOI 10.1016/S0022-3476(94)70324-8; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL C, 1991, CIRCULATION, V84, P2212; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MCQUESTON JA, 1995, AM J PHYSIOL-HEART C, V268, pH288, DOI 10.1152/ajpheart.1995.268.1.H288; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; ROBERTS JD, 1993, CIRCULATION, V87, P447, DOI 10.1161/01.CIR.87.2.447; ROBERTS JD, 1993, CIRC RES, V72, P246, DOI 10.1161/01.RES.72.2.246; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SNEDECOR GW, 1980, STATISTICAL METHODS, P215; STEINHORN RH, 1995, AM J PHYSIOL-HEART C, V268, pH1483, DOI 10.1152/ajpheart.1995.268.4.H1483; TURBOW R, 1995, ACTA PAEDIATR, V84, P1305, DOI 10.1111/j.1651-2227.1995.tb13554.x; ZAYEK M, 1993, J PEDIATR-US, V122, P743, DOI 10.1016/S0022-3476(06)80020-X; ZAYEK M, 1993, J PEDIATR-US, V123, P947, DOI 10.1016/S0022-3476(05)80393-2	19	541	566	2	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					605	610		10.1056/NEJM199702273360902	http://dx.doi.org/10.1056/NEJM199702273360902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032045	Bronze			2022-12-28	WOS:A1997WK02800002
J	Xu, XH; Yeung, ES				Xu, XH; Yeung, ES			Direct measurement of single-molecule diffusion and photodecomposition in free solution	SCIENCE			English	Article							LASER-INDUCED FLUORESCENCE; DNA-MOLECULES; MICRODROPLETS	Continuous monitoring of submillisecond free-solution dynamics of individual rhodamine-6G molecules and 30-base single-stranded DNA tagged with rhodamine was achieved. Fluorescence images were recorded from the same set of isolated molecules excited either through the evanescent field at the quartz-liquid interface or as a thin layer of solution defined by micron-sized wires, giving diffraction-limited resolution of interconnected attoliter volume elements. The single-molecule diffusion coefficients were smaller and the unimolecular photodecomposition lifetimes were longer for the dye-DNA covalent complex as compared with those of the dye molecule itself. Unlike bulk studies, stochastic behavior was found for individual molecules of each type, and smaller diffusion coefficients were observed.	IOWA STATE UNIV SCI & TECHNOL,DEPT CHEM,AMES LAB,US DOE,AMES,IA 50011	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory								ANDERSON LB, 1967, J CHEM EDUC, V44, P9, DOI 10.1021/ed044p9; ATKINS PW, 1982, PHYSICAL CHEM, P823; BARNES MD, 1995, ANAL CHEM, V67, pA418, DOI 10.1021/ac00109a001; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; CASTRO A, 1993, ANAL CHEM, V65, P849, DOI 10.1021/ac00055a004; COLLINSON MM, 1995, SCIENCE, V268, P1883, DOI 10.1126/science.268.5219.1883; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; DOVICHI NJ, 1983, SCIENCE, V219, P845, DOI 10.1126/science.6823553; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FAN FRF, 1995, SCIENCE, V267, P871, DOI 10.1126/science.267.5199.871; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; JETT JH, 1989, J BIOMOL STRUCT DYN, V7, P301, DOI 10.1080/07391102.1989.10507773; LEE YH, 1994, ANAL CHEM, V66, P4142, DOI 10.1021/ac00095a005; Macklin JJ, 1996, SCIENCE, V272, P255, DOI 10.1126/science.272.5259.255; MATHIES RA, 1990, ANAL CHEM, V62, P1786, DOI 10.1021/ac00216a012; Mets U, 1994, J Fluoresc, V4, P259, DOI 10.1007/BF01878461; NG KC, 1992, ANAL CHEM, V64, P2914, DOI 10.1021/ac00047a007; NIE SM, 1995, ANAL CHEM, V67, P2849, DOI 10.1021/ac00113a019; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOPER SA, 1991, ANAL CHEM, V63, P432, DOI 10.1021/ac00005a009; TELLINGHUISEN J, 1994, ANAL CHEM, V66, P64, DOI 10.1021/ac00073a013; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WANG J, 1995, PHYS REV LETT, V74, P4317, DOI 10.1103/PhysRevLett.74.4317; WHITTEN WB, 1991, ANAL CHEM, V63, P1027, DOI 10.1021/ac00010a019; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	27	197	220	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1106	1109		10.1126/science.275.5303.1106	http://dx.doi.org/10.1126/science.275.5303.1106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027307				2022-12-28	WOS:A1997WJ50300038
J	Lam, YA; Xu, W; DeMartino, GN; Cohen, RE				Lam, YA; Xu, W; DeMartino, GN; Cohen, RE			Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome	NATURE			English	Article							ATP-DEPENDENT ACTIVATOR; TERMINAL HYDROLASE; 20-S PROTEASOME; PROTEIN; PROTEOLYSIS; INHIBITION; IDENTIFICATION; PURIFICATION; DEGRADATION; NITRILES	In eukaryotes, ubiquitin (Ub)-dependent proteolysis is essential for bulk protein turnover as well as diverse processes including cell-cycle control, differentiation, antigen presentation, and the stress response(1-3). Generally, multiple ubiquitins are added onto a substrate to form an isopeptide-linked 'polyubiquitin' chain, which targets substrates for degradation by the 26S proteasome(4-7). The specificity of Ub-dependent degradation was thought to depend primarily on the selection of targets for ubiquitination, but recently we have reported evidence(8) for a second level of specificity in which (poly)Ub-protein conjugates are partitioned among two fates: degradation of the protein substrate by the 26S proteasome; and disassembly by Ub isopeptidase(s) to regenerate the protein substrate. Potentially, an isopeptidase could influence degradation by 'editing' (poly)Ub-protein conjugates according to the extent of ubiquitination rather than the structure of the ubiquitination target itself. Here we describe a bovine isopeptidase that is well suited to such an editing function because of its unique localization and specificity, This enzyme is an intrinsic subunit of PA700, the 19S regulatory complex of the 26S proteasome. By disassembling the degradation signal from only the distal end of (poly)Ub chains, this isopeptidase can selectively rescue poorly ubiquitinated or slowly degraded Ub-protein conjugates from proteolysis.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CHATURVEDI RK, 1967, J AM CHEM SOC, V89, P6984, DOI 10.1021/ja01002a029; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUFOUR E, 1995, BIOCHEMISTRY-US, V34, P9136, DOI 10.1021/bi00028a024; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ECKER DJ, 1989, J BIOL CHEM, V264, P1887; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; LIANG TC, 1987, ARCH BIOCHEM BIOPHYS, V252, P626, DOI 10.1016/0003-9861(87)90068-3; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; MOON JB, 1986, J AM CHEM SOC, V108, P1350, DOI 10.1021/ja00266a066; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PICKART CM, 1986, J BIOL CHEM, V261, P210; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Stock D, 1996, CURR OPIN BIOTECH, V7, P376, DOI 10.1016/S0958-1669(96)80111-X	31	360	369	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					737	740		10.1038/385737a0	http://dx.doi.org/10.1038/385737a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034192				2022-12-28	WOS:A1997WJ42300050
J	Lindsay, RS; Toft, AD				Lindsay, RS; Toft, AD			Hypothyroidism	LANCET			English	Article							CORONARY HEART-DISEASE; L-THYROXINE TREATMENT; THYROTROPIN RELEASING HORMONE; SUBCLINICAL HYPOTHYROIDISM; THYROID-FUNCTION; AUTOIMMUNE-THYROIDITIS; REPLACEMENT THERAPY; RISK FACTOR; FOLLOW-UP; LEVOTHYROXINE THERAPY		ROYAL INFIRM EDINBURGH NHS TRUST, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh				Lindsay, Robert/0000-0002-9868-5217				ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; AMINO N, 1977, ANN INTERN MED, V87, P155, DOI 10.7326/0003-4819-87-2-155; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; AUWERX J, 1986, Q J MED, V60, P737; BAGCHI N, 1990, ARCH INTERN MED, V150, P785, DOI 10.1001/archinte.150.4.785; BARAN DT, 1994, J CLIN ENDOCR METAB, V78, P816, DOI 10.1210/jc.78.4.816; BASTENIE PA, 1967, LANCET, V2, P1221; BASTENIE PA, 1971, LANCET, V1, P203; BELL GM, 1985, CLIN ENDOCRINOL, V22, P83, DOI 10.1111/j.1365-2265.1985.tb01068.x; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; BOGNER U, 1993, ACTA ENDOCRINOL-COP, V128, P202, DOI 10.1530/acta.0.1280202; BRAVERMAN LE, 1970, J CLIN INVEST, V49, P855, DOI 10.1172/JCI106304; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; CARON P, 1990, CLIN ENDOCRINOL, V33, P519, DOI 10.1111/j.1365-2265.1990.tb03889.x; CARR D, 1988, CLIN ENDOCRINOL, V28, P325, DOI 10.1111/j.1365-2265.1988.tb01219.x; COMPSTON JE, 1993, CLIN ENDOCRINOL, V39, P519, DOI 10.1111/j.1365-2265.1993.tb02402.x; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; DAVIES PH, 1992, J CLIN ENDOCR METAB, V74, P1189, DOI 10.1210/jc.74.5.1189; Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; ELDER J, 1990, ANN CLIN BIOCHEM, V27, P110, DOI 10.1177/000456329002700204; ENGLER H, 1993, CLIN CHEM, V39, P2466; EVERED D, 1973, BRIT MED J, V3, P131, DOI 10.1136/bmj.3.5872.131; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; FISHER DA, 1991, J CLIN ENDOCR METAB, V72, P523, DOI 10.1210/jcem-72-3-523; FOWLER PBS, 1970, LANCET, V2, P488; FOWLER PBS, 1967, LANCET, V1, P1077; FRANKLYN J, 1994, CLIN ENDOCRINOL, V41, P425, DOI 10.1111/j.1365-2265.1994.tb02572.x; FRANKLYN J, 1995, CLIN ENDOCRINOL, V43, P443, DOI 10.1111/j.1365-2265.1995.tb02615.x; FRANKLYN JA, 1993, CLIN ENDOCRINOL, V38, P453, DOI 10.1111/j.1365-2265.1993.tb00339.x; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GORDIN A, 1981, CLIN ENDOCRINOL, V15, P537, DOI 10.1111/j.1365-2265.1981.tb00699.x; Gull WW, 1874, T CLIN SOC LOND, V7, P180; HARVEY RD, 1919, J CLIN ENDOCR METAB, V721, P72; KAPLAN MM, 1992, THYROID, V2, P147, DOI 10.1089/thy.1992.2.147; KONISHI J, 1985, ANN INTERN MED, V103, P26, DOI 10.7326/0003-4819-103-1-26; KUNG AWC, 1995, CLIN ENDOCRINOL, V43, P445, DOI 10.1111/j.1365-2265.1995.tb02616.x; Lazarus JH, 1996, CLIN ENDOCRINOL, V44, P129, DOI 10.1046/j.1365-2265.1996.d01-1354.x; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LESLIE PJ, 1988, BAILLIERE CLIN ENDOC, V2, P653, DOI 10.1016/S0950-351X(88)80058-2; LITHELL H, 1981, EUR J CLIN INVEST, V11, P3, DOI 10.1111/j.1365-2362.1981.tb01758.x; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MARCOCCI C, 1994, J CLIN ENDOCR METAB, V78, P818, DOI 10.1210/jc.78.4.818; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; Moore DC, 1996, ARCH PEDIAT ADOL MED, V150, P293, DOI 10.1001/archpedi.1996.02170280063012; Murray G R, 1891, Br Med J, V2, P796; NICOLOFF JT, 1993, ENDOCRIN METAB CLIN, V22, P279, DOI 10.1016/S0889-8529(18)30166-X; NILSSON G, 1976, ACTA MED SCAND, V200, P63; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; OPPENHEIMER JH, 1972, J CLIN ENDOCR METAB, V35, P330, DOI 10.1210/jcem-35-2-330; OPPENHEIMER JH, 1995, J CLIN ENDOCR METAB, V80, P2873, DOI 10.1210/jc.80.10.2873; ORD WM, 1879, T CLIN SOC LONDON, V13, P15; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PARLE JV, 1991, LANCET, V337, P171, DOI 10.1016/0140-6736(91)90831-9; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; Roti E, 1996, J CLIN ENDOCR METAB, V81, P1679, DOI 10.1210/jc.81.5.1679; ROTI E, 1993, ENDOCR REV, V14, P401, DOI 10.1210/er.14.4.401; ROTI E, 1994, DRUG THER, V24, P28; ROTI E, 1994, DRUG THER, V24, P32; ROTI E, 1994, DRUG THER, V24, P54; SAWERS JSA, 1980, J CLIN ENDOCR METAB, V50, P226, DOI 10.1210/jcem-50-2-226; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; SOLOMON BL, 1993, THYROID, V3, P17, DOI 10.1089/thy.1993.3.17; SPAULDING SW, 1972, J CLIN ENDOCR METAB, V35, P905, DOI 10.1210/jcem-35-6-905; SPENCER C, 1987, CLIN CHEM, V33, P1391; STAUB JJ, 1992, AM J MED, V92, P631, DOI 10.1016/0002-9343(92)90782-7; STOCK JM, 1974, NEW ENGL J MED, V290, P529, DOI 10.1056/NEJM197403072901001; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; SURKS MI, 1973, J CLIN INVEST, V52, P805, DOI 10.1172/JCI107244; Tanis BC, 1996, CLIN ENDOCRINOL, V44, P643, DOI 10.1046/j.1365-2265.1996.739560.x; TIECHE M, 1981, BRIT HEART J, V46, P202, DOI 10.1136/hrt.46.2.202; TOFT AD, 1994, NEW ENGL J MED, V331, P174; TOFT AD, 1978, NEW ENGL J MED, V298, P643, DOI 10.1056/NEJM197803232981202; TOPLISS DJ, 1980, J CLIN ENDOCR METAB, V50, P52, DOI 10.1210/jcem-50-1-52; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P495, DOI 10.1111/j.1365-2265.1977.tb01341.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VALDEMARSSON S, 1983, ACTA ENDOCRINOL-COP, V104, P50, DOI 10.1530/acta.0.1040050; Vanderpump MPJ, 1996, BMJ-BRIT MED J, V313, P539; WOLFF J, 1969, AM J MED, V47, P101, DOI 10.1016/0002-9343(69)90245-9	84	48	55	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					413	417		10.1016/S0140-6736(97)80050-5	http://dx.doi.org/10.1016/S0140-6736(97)80050-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033482				2022-12-28	WOS:A1997WH29600047
J	Newman, PJ				Newman, PJ			Platelet alloantigens: Cardiovascular as well as immunological risk factors?	LANCET			English	Editorial Material											Newman, PJ (corresponding author), BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,1701 W WISCONSIN AVE,MILWAUKEE,WI 53233, USA.							Carter AM, 1996, LANCET, V348, P485, DOI 10.1016/S0140-6736(05)64592-8; Carter AM, 1996, NEW ENGL J MED, V335, P1072; Goldschmidt-Clermont P. J., 1996, Blood, V88, p26A; GoldschmidtClermont PJ, 1996, LANCET, V347, P1833, DOI 10.1016/S0140-6736(96)91652-9; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Marian AJ, 1996, NEW ENGL J MED, V335, P1071; Maslanka K, 1996, J CLIN INVEST, V98, P1802, DOI 10.1172/JCI118980; NEWMAN PJ, 1995, THROMB HAEMOSTASIS, V74, P234; NEWMAN PJ, 1994, BLOOD, V83, P1447; NEWMAN PJ, 1994, THROMBOSIS HEMORRHAG, P529; NEWMAN PJ, 1995, METABOLIC MOL BASES, P3335; Odawara M, 1996, LANCET, V348, P1310, DOI 10.1016/S0140-6736(05)65786-8; OSBORN SV, 1996, LANCET, V348, P12309; SHULMAN NR, 1964, PROG HEMATOL, V4, P222; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703	15	28	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					370	371		10.1016/S0140-6736(97)80002-5	http://dx.doi.org/10.1016/S0140-6736(97)80002-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033457				2022-12-28	WOS:A1997WH29600002
J	ChoiLundberg, DL; Lin, Q; Chang, YN; Chiang, YL; Hay, CM; Mohajeri, H; Davidson, BL; Bohn, MC				ChoiLundberg, DL; Lin, Q; Chang, YN; Chiang, YL; Hay, CM; Mohajeri, H; Davidson, BL; Bohn, MC			Dopaminergic neurons protected from degeneration by GDNF gene therapy	SCIENCE			English	Article							NEUROTROPHIC FACTOR; IN-VIVO; ADENOVIRUS VECTORS; SURVIVAL FACTOR; GROWTH-FACTOR; LINE; BRAIN; RAT; 6-HYDROXYDOPAMINE; SYSTEM	Glial cell line-derived neurotrophic factor (GDNF) supports growth and survival of dopaminergic (DA) neurons. A replication-defective adenoviral (Ad) vector encoding human GDNF injected near the rat substantia nigra was found to protect DA neurons from the progressive degeneration induced by the neurotoxin 6-hydroxydopamine (6-OHDA) injected into the striatum, Ad GDNF gene therapy reduced loss of DA neurons approximately threefold 6 weeks after 6-OHDA lesion, as compared with no treatment or injection of Ad lacZ or Ad mGDNF (encoding a biologically inactive deletion mutant GDNF). These results suggest that Ad vector-mediated GDNF gene therapy may slow the DA neuronal cell loss in humans with Parkinson's disease.	UNIV ROCHESTER,DEPT NEUROBIOL & ANAT,ROCHESTER,NY 14642; GENET THERAPY,GAITHERSBURG,MD 20878; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Rochester; University of Iowa			Choi-Lundberg, Derek L/J-7670-2014	Choi-Lundberg, Derek L/0000-0002-3594-8585	NIA NIH HHS [T32AG00107] Funding Source: Medline; NINDS NIH HHS [NS31957] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000107] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ANGELOV DN, 1995, GLIA, V13, P113, DOI 10.1002/glia.440130205; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BAJOCCHI G, 1993, NAT GENET, V3, P229, DOI 10.1038/ng0393-229; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CEPKO C, 1990, NEUROMETHODS, V16, P177; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHOILUNDBERG DL, 1995, DEV BRAIN RES, V85, P80, DOI 10.1016/0165-3806(94)00197-8; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EBENDAL T, 1995, J NEUROSCI RES, V40, P276, DOI 10.1002/jnr.490400217; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LU B, 1995, HEPATOLOGY, V21, P752, DOI 10.1016/0270-9139(95)90529-4; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; OLANOW CW, 1993, J NEURAL TRANSM-GEN, V91, P161, DOI 10.1007/BF01245230; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; RINAMAN L, 1991, NEUROSCIENCE, V44, P765, DOI 10.1016/0306-4522(91)90096-7; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SAUER H, 1995, P NATL ACAD SCI USA, V92, P8935, DOI 10.1073/pnas.92.19.8935; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362	37	530	569	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					838	841		10.1126/science.275.5301.838	http://dx.doi.org/10.1126/science.275.5301.838			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012352				2022-12-28	WOS:A1997WG77700063
J	Gu, DF; Philander, SGH				Gu, DF; Philander, SGH			Interdecadal climate fluctuations that depend on exchanges between the tropics and extratropics	SCIENCE			English	Article							UPPER-OCEAN; VARIABILITY; PACIFIC	The unexpected and prolonged persistence of warm conditions over the tropical Pacific during the early 1990s can be attributed to an interdecadal climate fluctuation that involves changes in the properties of the equatorial thermocline arising as a result of an influx of water with anomalous temperatures from higher latitudes, The influx affects equatorial sea-surface temperatures and hence the tropical and extratropical winds that in turn affect the influx, A simple model demonstrates that these processes can give rise to continual interdecadal oscillations.			Gu, DF (corresponding author), PRINCETON UNIV, DEPT GEOSCI, PROGRAM ATMOSPHER & OCEAN SCI, POB CN710, SAYRE HALL, PRINCETON, NJ 08544 USA.							Deser C, 1996, J CLIMATE, V9, P1840, DOI 10.1175/1520-0442(1996)009<1840:UOTVIT>2.0.CO;2; FINE RA, 1987, J PHYS OCEANOGR, V17, P553, DOI 10.1175/1520-0485(1987)017<0553:TPOTIT>2.0.CO;2; GU D, UNPUB; GU DF, 1995, J CLIMATE, V8, P864, DOI 10.1175/1520-0442(1995)008<0864:SCOAAI>2.0.CO;2; Ji M, 1996, J CLIMATE, V9, P3105, DOI 10.1175/1520-0442(1996)009<3105:CMPOED>2.0.CO;2; Jin FF, 1996, SCIENCE, V274, P76, DOI 10.1126/science.274.5284.76; KNUTSON TR, IN PRESS J CLIM; Ladas G., 1991, OSCILLATION THEORY D; LATIF M, 1994, CLIM DYNAM, V9, P167, DOI 10.1007/BF00208250; LATIF M, 1994, SCIENCE, V266, P634, DOI 10.1126/science.266.5185.634; LAU NC, 1994, J CLIMATE, V7, P1184, DOI 10.1175/1520-0442(1994)007<1184:AMSOTR>2.0.CO;2; LIU ZG, 1994, J PHYS OCEANOGR, V24, P2606, DOI 10.1175/1520-0485(1994)024<2606:AGSOTU>2.0.CO;2; LIU ZY, 1995, J PHYS OCEANOGR, V25, P449, DOI 10.1175/1520-0485(1995)025<0449:HDWSPA>2.0.CO;2; LU P, 1995, J PHYS OCEANOGR, V25, P2606; McPhaden M. J., 1993, OCEANOGRAPHY, V6, P36; NEELIN JD, 1994, ANNU REV FLUID MECH, V26, P617, DOI DOI 10.1146/ANNUREV.FL.26.010194.003153; PHILANDER SGH, 1990, NINA SO OSCILLATION; SCHOPF PS, 1988, J ATMOS SCI, V45, P549, DOI 10.1175/1520-0469(1988)045<0549:VIACOM>2.0.CO;2; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; ZHANG Y, IN PRESS J CLIM	21	818	902	4	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 7	1997	275	5301					805	807		10.1126/science.275.5301.805	http://dx.doi.org/10.1126/science.275.5301.805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012341				2022-12-28	WOS:A1997WG77700052
J	Tansey, WP; Herr, W				Tansey, WP; Herr, W			Selective use of TBP and TFIIB revealed by a TATA-TBP-TFIIB array with altered specificity	SCIENCE			English	Article							BOX-BINDING-PROTEIN; ACTIVATION DOMAINS; CRYSTAL-STRUCTURE; IN-VIVO	Interaction between the TATA box-binding protein TBP and TFIIB is critical for transcription in vitro. An altered-specificity TBP-TFIIB interaction was rationally designed and linked in sequence to an altered-specificity TATA box-TBP interaction to study how TBP and TFIIB function together to support transcription in human cells. The activity of this altered-specificity TATA-TBP-TFIIB array demonstrated that many activators use the known TBP-TFIIB interaction to stimulate transcription. One activator, however, derived from a glutamine-rich activation domain of Sp1, activated transcription independently of this interaction. These results reveal that selectivity in activator function in vivo can be achieved through differential use of TBP and TFIIB.			Tansey, WP (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA-13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; STRUBIN M, 1992, CELL, V69, P97; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TANSEY WP, UNPUB; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X	14	38	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					829	831		10.1126/science.275.5301.829	http://dx.doi.org/10.1126/science.275.5301.829			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012349				2022-12-28	WOS:A1997WG77700060
J	Kramer, AM; Steiner, JF; Schlenker, RE; Eilertsen, TB; Hrincevich, CA; Tropea, DA; Ahmad, LA; Eckhoff, DG				Kramer, AM; Steiner, JF; Schlenker, RE; Eilertsen, TB; Hrincevich, CA; Tropea, DA; Ahmad, LA; Eckhoff, DG			Outcomes and costs after hip fracture and stroke - A comparison of rehabilitation settings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; PROPENSITY SCORE; HEALTH-SERVICES; OLDER ADULTS; RECOVERY; DISABILITY; VALIDATION; COMMUNITY; DECLINE; RATES	Objective.-To assess whether outcomes and costs differ for elderly patients admitted to rehabilitation hospitals, subacute nursing homes, and traditional nursing homes. Design.-Inception cohort stratified by provider type and followed prospectively for 6 months. Setting.-A total of 92 hospital-based units and freestanding facilities from 17 states. Patients.-A total of 518 randomly selected patients with hip fracture and 485 stroke patients admitted from November 1991 to February 1994. Main Outcome Measures.-At 6 months comparing community residence, recovery to premorbid levels in 5 activities of daily living (ADLs), Medicare costs, and the number of therapy and physician visits. Outcomes were adjusted for premorbid residence and function, caregiver availability, comorbid illness, admission function, cognition, depression, sensory deficits, and mobility impairments. Results.-On admission, rehabilitation hospital patients were more likely (P<.001) to have caregivers and better cognitive and physical function. Hip fracture patients admitted to rehabilitation hospitals did not differ from patients admitted to nursing homes in returning to the community (adjusted odds ratio [OR], 1.3; 95% confidence interval [Cl], 0.6-2.6) or in the number of ADLs recovered to premorbid level (difference, 0.09 ADL; 95% Cl, -0.27-0.44), but stroke patients admitted to rehabilitation hospitals were more likely to return to the community (adjusted OR, 3.3; 95% Cl, 1.5-7.2) and recover ADLs (difference, 0.63 ADL; 95% CI, 0.201.07). Subacute nursing home patients with stroke were more likely than traditional nursing home patients to return to the community (adjusted OR, 6.8; 95% Cl, 2.2-21 .4), there was no difference in return to the community for patients with hip fracture (adjusted OR, 1.6; 95% Cl, 0.7-3.6), and there were no differences in recovery of ADLs for either condition. Medicare costs were greater (P<.001) for rehabilitation hospital patients than for subacute nursing home patients, and the costs for subacute nursing home patients were greater (P=.03 for stroke and .009 for hip fracture) than for traditional nursing home patients. Conclusions.-Study findings are consistent with enhanced outcomes for elderly patients with stroke treated in rehabilitation hospitals but not for patients with hip fracture. Subacute nursing homes were more effective than traditional nursing homes in returning patients with stroke to the community, despite comparable functional outcomes.	UNIV COLORADO, HLTH SCI CTR, DIV GERIATR, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV GEN INTERNAL MED, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, CTR HLTH SERV RES, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT ORTHOPED, DENVER, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kramer, AM (corresponding author), UNIV COLORADO, HLTH SCI CTR, CTR AGING, 3570 E 12TH AVE, SUITE 300, DENVER, CO 80206 USA.							Ahmad L A, 1994, Orthop Rev, V23, P19; *AUST DAT MAN ASS, 1992, PC GROUP 81992; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BARNES B, 1984, PHYS THER, V64, P317, DOI 10.1093/ptj/64.3.317; BONAR SK, 1990, J AM GERIATR SOC, V38, P1139, DOI 10.1111/j.1532-5415.1990.tb01378.x; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CEDER L, 1980, ACTA ORTHOP SCAND, V51, P157, DOI 10.3109/17453678008990780; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cobeu JC, 1976, CLIN ORTHOP RELAT R, V117, P258; COOK EF, 1989, J CLIN EPIDEMIOL, V42, P317; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P801, DOI 10.1111/j.1532-5415.1988.tb04263.x; DOMBOVY ML, 1987, STROKE, V18, P830, DOI 10.1161/01.STR.18.5.830; FITTI JE, 1987, US DEP HHS PUBLICATI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; GERETY MB, 1989, J GEN INT MED, V149, P2237; GRESHAM GE, 1995, AGENCY HLTH CARE POL; HRINCEVICH CA, 1994, STUDY COST EFFECTIVE; *I HLTH SERV RES, 1994, STUD POST AC CAR FIN; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; JOHNSTON MV, 1986, ARCH PHYS MED REHAB, V67, P581; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEITH RA, 1995, ARCH PHYS MED REHAB, V76, P495, DOI 10.1016/S0003-9993(95)80501-X; KOVAL KJ, 1994, J BONE JOINT SURG AM, V76A, P751, DOI 10.2106/00004623-199405000-00018; KRAMER AM, 1991, POLICY STUDY COST EF; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MAHONEY F I, 1965, Md State Med J, V14, P61; MAROTTOLI RA, 1992, J AM GERIATR SOC, V40, P861, DOI 10.1111/j.1532-5415.1992.tb01980.x; MEADOWS SE, 1991, ORTHOP T, V15, P700; MOSSEY JM, 1990, J GERONTOL, V45, pM163, DOI 10.1093/geronj/45.5.M163; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; *PROSP PAYM ASS CO, 1996, REP REC C MARCH 1 19; *PROSP PAYM ASS CO, 1992, MED AM HLTH CAR SYST; Regensteiner JG, 1990, J VASC MED BIOL, V2, P142; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; STEINER A, 1992, MONITORING CHANGES U; STONE RA, 1995, MED CARE, V33, pAS56; STRAND T, 1985, STROKE, V16, P29, DOI 10.1161/01.STR.16.1.29; Wade D T, 1988, Int Disabil Stud, V10, P64; WOLF PA, 1992, STROKE, V23, P1551, DOI 10.1161/01.STR.23.11.1551; WOLINSKY FD, 1992, MED CARE, V30, P587, DOI 10.1097/00005650-199207000-00002; WOLINSKY FD, 1991, J GERONTOL, V46, pS345, DOI 10.1093/geronj/46.6.S345; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213	48	266	266	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					396	404		10.1001/jama.277.5.396	http://dx.doi.org/10.1001/jama.277.5.396			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE771	9010172				2022-12-28	WOS:A1997WE77100030
J	Browne, GJ; Penna, AS; Phung, X; Soo, M				Browne, GJ; Penna, AS; Phung, X; Soo, M			Randomised trial of intravenous salbutamol in early management of acute severe asthma in children	LANCET			English	Article							NEBULIZED TERBUTALINE; SYSTEMIC ABSORPTION; ALBUTEROL; THERAPY; SCORE	Background The mainstay of treatment for acute asthma in children is nebulised beta(2)-adrenergic agents such as salbutamol, given with corticosteroids. However, penetration of the drug to the small airways is impeded by obstruction so intravenous salbutamol may be more effective. We assessed the use of intravenous salbutamol in the management of children with acute severe asthma in a double-blind randomised study. Methods Children who presented to the Emergency Department of Westmead Hospital, Sydney, Australia with asthma were assessed with a clinical assessment scale, and those with severe acute asthma were given nebulised salbutamol at a dose of 2.5 mg (age less than or equal to 2 years) or 5.0 mg (age >2 years), made up to 4 mL with saline. Children who did not improve were eligible to enter phase one of the study. In this phase (0 h-2 h) treatment was by a standard protocol: nebulised salbutamol at the above dose; 4 L/min or 6 L/min continuous oxygen until oxygen saturation reached 93% in room air for at least 30 min; a bolus of intravenous hydrocortisone 5 mg/kg given over 3 min; and then 15 mu g/kg intravenous salbutamol or saline, depending on randomised allocation. In phase two (2 h-24 h) the children were given nebulised salbutamol continuously then at 30 min, 1 h, 2 h, 3 h, and 4 h, according to need. All children were transferred to the ward once they were ready to start hourly nebulisation. All patients were followed up until discharge. The primary endpoints were recovery time (no longer requiring inhaled salbutamol) and persistent moderate to severe asthma 2 h after randomisation. Analyses were by intention-to-treat although no withdrawals occurred. Findings The recovery time (time to cessation of nebulised salbutamol every 30 min) was 4 h in the 14 children allocated intravenous salbutamol compared with 11.5 h for the 15 children in the control group. 2 (14%) of the intravenous salbutamol group compared with 8 (53%) of the control group needed oxygen to maintain oxygen saturation at 93% room air. The intravenous salbutamol group were ready for discharge from the emergency department 9.7 h earlier than the control group. No clinically significant side-effects were found in either group. Interpretation Addition of a 10 min infusion of salbutamol in the early treatment of children with acute severe asthma has the potential to curtail the clinical progression of asthma, reduce demand placed on hospital resources, and improve the quality of health care provided to the acutely sick child with asthma.	ROYAL ALEXANDRA HOSP CHILDREN,EMERGENCY DEPT,WESTMEAD,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT PAEDIAT,WESTMEAD,NSW 2145,AUSTRALIA; UNIV SYDNEY,WESTERN SYDNEY CLIN SCH,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney; University of Sydney								[Anonymous], 1990, Eur Respir J, V3, P163; BECKER AB, 1984, AM J DIS CHILD, V138, P574, DOI 10.1001/archpedi.1984.02140440058015; BOHN D, 1984, CRIT CARE MED, V12, P892, DOI 10.1097/00003246-198410000-00012; CHEONG B, 1988, BRIT MED J, V297, P448, DOI 10.1136/bmj.297.6646.448; COLACONE A, 1990, CHEST, V97, P693, DOI 10.1378/chest.97.3.693; DAWSON KP, 1992, AUST J HOSP PHARM, V22, P701; GOLDSTEIN DA, 1987, EUR J CLIN PHARMACOL, V32, P631, DOI 10.1007/BF02456001; HENRY RL, 1993, J PAEDIATR CHILD H, V29, P101; JANSON C, 1991, EUR RESPIR J, V4, P544; KELLY HW, 1990, ANN ALLERGY, V64, P229; MOLER FW, 1988, J ALLERGY CLIN IMMUN, V81, P1101, DOI 10.1016/0091-6749(88)90876-7; *NAT ASTHM CAMP, 1993, ASTHM MAN HDB, P30; OBERKLAID F, 1993, MED J AUSTRALIA, V158, P751, DOI 10.5694/j.1326-5377.1993.tb121956.x; PENNA AC, 1993, ACTA PAEDIATR, V82, P963, DOI 10.1111/j.1651-2227.1993.tb12609.x; PENNA AC, 1993, J ASTHMA, V30, P105, DOI 10.3109/02770909309054504; PENNA AC, 1993, AUST J HOSP PHARM, V23, P165; SALMERON S, 1994, AM J RESP CRIT CARE, V149, P1466, DOI 10.1164/ajrccm.149.6.8004299; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; SCHUH S, 1989, PEDIATRICS, V83, P513; SCHUH S, 1990, PEDIATRICS, V3, P50; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P282; STRAUSS RE, 1994, PEDIATRICS, V93, P205	22	79	83	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					301	305		10.1016/S0140-6736(96)06358-1	http://dx.doi.org/10.1016/S0140-6736(96)06358-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024371				2022-12-28	WOS:A1997WF79400007
J	Lazarus, JH				Lazarus, JH			Hyperthyroidism	LANCET			English	Article							AMIODARONE-INDUCED THYROTOXICOSIS; SENSITIVE THYROTROPIN ASSAYS; AUTOIMMUNE THYROID-DISEASE; GRAVES-DISEASE; RECEPTOR GENE; GESTATIONAL THYROTOXICOSIS; RADIOIODINE THERAPY; CLINICAL-EVALUATION; GERMLINE MUTATIONS; IODINE INTAKE				Lazarus, JH (corresponding author), UNIV WALES COLL MED, DEPT MED, LLANDOUGH HOSP, CARDIFF CF64 2XX, S GLAM, WALES.		Rawla, Prashanth/J-1336-2017; Lazarus, John H/H-5108-2017; McMahon, Graham/D-3740-2009	Rawla, Prashanth/0000-0002-4361-8498; Lazarus, John H/0000-0001-8852-704X; McMahon, Graham/0000-0003-4288-6535				ARSCOTT P, 1992, J CLIN ENDOCR METAB, V75, P295, DOI 10.1210/jc.75.1.295; BAHN RS, 1993, NEW ENGL J MED, V329, P1468; BARCLAY ML, 1994, CLIN ENDOCRINOL, V40, P759, DOI 10.1111/j.1365-2265.1994.tb02509.x; BARTALENA L, 1994, J CLIN ENDOCR METAB, V78, P423, DOI 10.1210/jc.78.2.423; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; BORST GC, 1983, ANN INTERN MED, V98, P366, DOI 10.7326/0003-4819-98-3-366; BROWNLIE BEW, 1990, CLIN ENDOCRINOL, V33, P249, DOI 10.1111/j.1365-2265.1990.tb00489.x; BURCH HB, 1993, ENDOCRIN METAB CLIN, V22, P263, DOI 10.1016/S0889-8529(18)30165-8; Cooper D S, 1982, Am J Med, V73, P867; Davies Terry F., 1996, P525; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; FEELY J, 1984, DRUGS, V27, P425, DOI 10.2165/00003495-198427050-00003; FELLS P, 1991, LANCET, V338, P29, DOI 10.1016/0140-6736(91)90014-G; FIGGE J, 1994, AM J MED, V96, P229, DOI 10.1016/0002-9343(94)90147-3; FRADKIN JE, 1983, MEDICINE, V62, P1; FRANKLYN JA, 1993, TRENDS ENDOCRIN MET, V4, P128, DOI 10.1016/1043-2760(93)90036-E; FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731; FURMANIAK J, 1994, DIS THYROID, P117; GARNERO P, 1994, J CLIN ENDOCR METAB, V78, P955, DOI 10.1210/jc.78.4.955; HAMBURGER JI, 1992, THYROID, V2, P219, DOI 10.1089/thy.1992.2.219; HAMILTON CR, 1973, MEDICINE, V52, P195, DOI 10.1097/00005792-197305000-00002; HARDISTY CA, 1990, J ROY COLL PHYS LOND, V24, P36; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; HAYLES AB, 1972, MAYO CLIN PROC, V47, P850; HEDBERG CW, 1987, NEW ENGL J MED, V316, P993, DOI 10.1056/NEJM198704163161605; HENNEMANN G, 1986, LANCET, V1, P1369; KENDALLTAYLOR P, 1992, CLIN ENDOCRINOL, P309; KIMURA M, 1993, CLIN ENDOCRINOL, V38, P345, DOI 10.1111/j.1365-2265.1993.tb00512.x; KLEE GG, 1987, J CLIN ENDOCR METAB, V64, P461, DOI 10.1210/jcem-64-3-461; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KUNG AWC, 1995, CLIN ENDOCRINOL, V42, P303, DOI 10.1111/j.1365-2265.1995.tb01879.x; KUNG AWC, 1994, J CLIN ENDOCR METAB, V79, P542, DOI 10.1210/jc.79.2.542; LANGSTEGER W, 1994, CLIN ENDOCRINOL, V40, P751, DOI 10.1111/j.1365-2265.1994.tb02508.x; LAURBERG P, 1991, J INTERN MED, V229, P415, DOI 10.1111/j.1365-2796.1991.tb00368.x; Lazarus JH, 1996, QJM-INT J MED, V89, P429; LAZARUS JH, 1994, DIAGNOSTIC TESTS END, P39; Lazarus John H., 1996, P577; MARIOTTI S, 1995, ENDOCR REV, V16, P686, DOI 10.1210/er.16.6.686; MARTINO E, 1984, ANN INTERN MED, V101, P28, DOI 10.7326/0003-4819-101-1-28; MCDOUGALL RI, 1992, THYROID DIS CLIN PRA, P83; MCGREGOR AM, 1985, THYROID DISORDERS AS, P209; McIver B, 1996, NEW ENGL J MED, V334, P220, DOI 10.1056/NEJM199601253340403; MCKENZIE JM, 1989, J CLIN ENDOCR METAB, V69, P1093, DOI 10.1210/jcem-69-6-1093; MESTMAN JH, 1995, ENDOCRIN METAB CLIN, V24, P41, DOI 10.1016/S0889-8529(18)30053-7; MEYERGESSNER M, 1994, J ENDOCRINOL INVEST, V17, P29, DOI 10.1007/BF03344959; MONZANI F, 1992, CLIN ENDOCRINOL, V36, P491, DOI 10.1111/j.1365-2265.1992.tb02251.x; MOURITS MP, 1990, OPHTHALMOLOGY, V97, P636; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; NUGENT RA, 1990, RADIOLOGY, V177, P675, DOI 10.1148/radiology.177.3.2243967; PETERS H, 1995, EUR J CLIN INVEST, V25, P186, DOI 10.1111/j.1365-2362.1995.tb01547.x; POLIKAR R, 1993, CIRCULATION, V87, P1435, DOI 10.1161/01.CIR.87.5.1435; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; RAJATANAVIN R, 1988, AM J MED, V85, P237; RATANACHAIYAVONG S, 1985, CLIN ENDOCRINOL META, V14, P449, DOI 10.1016/S0300-595X(85)80042-6; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; REINWEIN D, 1988, J ENDOCRINOL INVEST, V11, P193, DOI 10.1007/BF03350134; REINWEIN D, 1993, J CLIN ENDOCR METAB, V76, P1516; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; ROSS DS, 1984, ANN INTERN MED, V101, P488, DOI 10.7326/0003-4819-101-4-488; SMITH M, 1988, AM SURGEON, V54, P448; Stockigt Jan R., 1996, P377; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; TAMAI H, 1986, IMMUNOLOGY ENDOCRINE, P123; TRIP MD, 1991, AM J MED, V91, P507, DOI 10.1016/0002-9343(91)90187-3; TRZEPACZ PT, 1989, AM J MED, V87, P558; TSURUTA E, 1995, J CLIN ENDOCR METAB, V80, P350, DOI 10.1210/jc.80.2.350; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Vanderpump Mark P. J., 1996, P474; Vanderpump MPJ, 1996, BMJ-BRIT MED J, V313, P539; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WEETMAN AP, 1994, DIS THYROID PATHOPHY, P171; WHEELER MH, 1994, DIS THYROID, P207; WILLIAMS I, 1983, J EPIDEMIOL COMMUN H, V37, P245, DOI 10.1136/jech.37.3.245; YANAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P41, DOI 10.1210/jc.80.1.41; 1993, DRUG THER B, V31, P39; 1982, LANCET, V1, P1286	79	45	45	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	1997	349	9048					339	343		10.1016/S0140-6736(96)08015-4	http://dx.doi.org/10.1016/S0140-6736(96)08015-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024389				2022-12-28	WOS:A1997WF79400042
J	Sporton, SC; Taggart, P; Sutton, PM; Walker, JM; Hardman, SM				Sporton, SC; Taggart, P; Sutton, PM; Walker, JM; Hardman, SM			Acute ischaemia: A dynamic influence on QT dispersion	LANCET			English	Article							VENTRICULAR ARRHYTHMIAS; MYOCARDIAL-ISCHEMIA; CARDIAC DEATH; INFARCTION; INTERVAL; HEART; RECORDINGS	Background The aim of this study was to test the hypothesis that acute myocardial ischaemia increases QT dispersion measured from the 12-lead electrocardiogram. Methods Incremental atrial pacing was used to induce myocardial ischaemia in 18 patients with coronary artery disease and QT dispersion was measured. Six patients with normal coronary arteries served as the control group. Findings All the patients with coronary artery disease developed angina and/or ST depression accompanied by marked increases in QT dispersion (mean increase 38 ms, 95% CI 30 to 45 ms, p<0.001). In contrast patients with normal coronary arteries who without symptoms and without ST changes, there was no significant change in QT dispersion in response to pacing. Baseline QT dispersion did not distinguish those patients with coronary artery disease from those with normal coronary arteries (44 ms [95% CI 39-49 ms] vs 40 ms [25-55 ms]), respectively. Interpretation These results demonstrate that myocardial ischaemia induced by incremental atrial pacing in patients with coronary artery disease causes an acute increase in QT dispersion. Such ''inducible'' QT dispersion may prove more useful than resting QT dispersion in assessing the individual risk of arrhythmic events in patients with coronary artery disease.	UCL, SCH MED, DEPT ACAD & CLIN CARDIOL, LONDON W1N 8AA, ENGLAND; UCL HOSP, DEPT ACAD & CLIN CARDIOL, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London				Walker, John Malcolm/0000-0002-8559-7218				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; DAVIES MJ, 1981, BRIT HEART J, V45, P88; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1992, BRIT HEART J, V67, P39; GLANCY JM, 1995, LANCET, V345, P945, DOI 10.1016/S0140-6736(95)90697-5; HARDMAN SMC, 1995, CIRCULATION S1, V92, P275; HIGHAM P, 1994, BRIT HEART J, V71, P508; HIGHAM PD, 1995, BRIT HEART J, V73, P32; HNATKOVA K, 1994, BRIT HEART J, V72, P390; JANSE MJ, 1989, PHYSIOL REV, V69, P1049, DOI 10.1152/physrev.1989.69.4.1049; JOHN RM, 1991, AM HEART J, V122, P1599, DOI 10.1016/0002-8703(91)90277-O; KLEBER AG, 1978, CIRC RES, V42, P603, DOI 10.1161/01.RES.42.5.603; LINKER NJ, 1992, AM J CARDIOL, V69, P634, DOI 10.1016/0002-9149(92)90155-R; MORENA H, 1980, CIRC RES, V46, P634, DOI 10.1161/01.RES.46.5.634; PYE M, 1994, BRIT HEART J, V71, P511; ZAREBA W, 1994, AM J CARDIOL, V74, P550, DOI 10.1016/0002-9149(94)90742-0	19	141	149	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					306	309		10.1016/S0140-6736(96)06143-0	http://dx.doi.org/10.1016/S0140-6736(96)06143-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024372				2022-12-28	WOS:A1997WF79400008
J	SassoneCorsi, P				SassoneCorsi, P			Transcriptional checkpoints determining the fate of male germ cells	CELL			English	Review							MICE; GENE; DISRUPTION; EXHIBIT; REPAIR; TESTIS; P53				SassoneCorsi, P (corresponding author), INST MOL BIOL & GENET,BP 163,F-67404 ILLKIRCH GRAFFENS,STRASBOURG,FRANCE.							AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BLANDY J, 1996, NATURE, V380, P162; CHRESTA CM, 1996, NAT MED, V2, P744; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; HENRIKSEN K, 1996, NATURE, V380, P159; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MIYASHITA T, 1995, CELL, V80, P293; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; RHEE K, 1995, DEV DYNAM, V204, P406, DOI 10.1002/aja.1002040407; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	22	141	148	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					163	166		10.1016/S0092-8674(00)81834-6	http://dx.doi.org/10.1016/S0092-8674(00)81834-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008156	Bronze			2022-12-28	WOS:A1997WE97000003
J	Velculescu, VE; Zhang, L; Zhou, W; Vogelstein, J; Basrai, MA; Bassett, DE; Hieter, P; Vogelstein, B; Kinzler, KW				Velculescu, VE; Zhang, L; Zhou, W; Vogelstein, J; Basrai, MA; Bassett, DE; Hieter, P; Vogelstein, B; Kinzler, KW			Characterization of the yeast transcriptome	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; GENE-EXPRESSION; ALPHA-FACTOR; FACTOR PHEROMONE; DNA; SEQUENCE; IDENTIFICATION; HYBRIDIZATION; TERMINATION	We have analyzed the set of genes expressed from the yeast genome, herein called the transcriptome, using serial analysis of gene expression. Analysis of 60,633 transcripts revealed 4,665 genes, with expression levels ranging from 0.3 to over 200 transcripts per cell. Of these genes, 1981 had known functions, while 2684 were previously uncharacterized. The integration of positional information with gene expression data allowed for the generation of chromosomal expression maps identifying physical regions of transcriptional activity and identified genes that had not been predicted by sequence information alone. These studies provide insight into global patterns of gene expression in yeast and demonstrate the feasibility of genome-wide expression studies in eukaryotes.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21231; NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Velculescu, VE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,PROGRAM HUMAN & GENET & MOL BIOL,BALTIMORE,MD 21231, USA.		Velculescu, Victor/ABF-4846-2020; Zhang, Lin/A-7389-2009; Vogelstein, Joshua/AAG-5489-2019; Basrai, Munira/AAV-4422-2020	Velculescu, Victor/0000-0003-1195-438X; Zhang, Lin/0000-0003-0018-3903; Vogelstein, Joshua/0000-0003-2487-6237; Vogelstein, R. Jacob/0000-0001-8159-9577; Bassett, Douglas/0000-0002-1619-4618	NATIONAL CANCER INSTITUTE [R01CA057345, R01CA035494, R37CA035494, R37CA057345] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER JE, 1995, CELL, V82, P425, DOI 10.1016/0092-8674(95)90431-X; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; Basrai MA, 1996, MOL CELL BIOL, V16, P2838; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHAMBERS A, 1989, MOL CELL BIOL, V9, P5516, DOI 10.1128/MCB.9.12.5516; DENIS CL, 1983, J BIOL CHEM, V258, P1165; Dick T, 1996, MOL GEN GENET, V251, P38; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; IRNIGER S, 1994, P NATL ACAD SCI USA, V91, P257, DOI 10.1073/pnas.91.1.257; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; MCALISTER L, 1982, J BIOL CHEM, V257, P7181; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHMITT HD, 1983, MOL GEN GENET, V192, P247, DOI 10.1007/BF00327674; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH A, 1983, NUCLEIC ACIDS RES, V11, P4049, DOI 10.1093/nar/11.12.4049; SMITH MM, 1983, J MOL BIOL, V169, P641, DOI 10.1016/S0022-2836(83)80163-6; STJOHN TP, 1979, CELL, V16, P443, DOI 10.1016/0092-8674(79)90020-5; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; [No title captured]; [No title captured]	34	832	1083	15	165	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					243	251		10.1016/S0092-8674(00)81845-0	http://dx.doi.org/10.1016/S0092-8674(00)81845-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008165	hybrid			2022-12-28	WOS:A1997WE97000013
J	Yamanashi, Y; Baltimore, D				Yamanashi, Y; Baltimore, D			Identification of the abl- and rasGAP-associated 62 kDa protein as a docking protein, dok	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; SIGNAL TRANSDUCTION; POINT MUTATIONS; BCR-ABL; C-ABL; V-SRC; PHOSPHORYLATION; INSULIN	A 62 kDa protein is highly phosphorylated in many cells containing activated tyrosine kinases. This protein, characterized mainly by its avid association with rasGAP, has proved elusive. Anti-phosphotyrosine antibody was used to purify p62. From peptide sequence, molecular cloning revealed a cDNA encoding a novel protein, p62(dok), with little homology to others but with a prominent set of tyrosines and nearby sequences suggestive of SH2 binding sites. In cells, v-Abl tyrosine kinase binds and strongly phosphorylates p62(dok), which then binds rasGAP. A monoclonal antibody, 2C4, to the rasGAP-associated p62 reacts with p62(dok). Thus, p62(dok) appears to be the long-sought major substrate of many tyrosine kinases.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Massachusetts Institute of Technology (MIT); University of Tokyo					NCI NIH HHS [CA-51462] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; DARBY C, 1994, J IMMUNOL, V152, P5429; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HAWLEY RG, 1994, GENE THER, V1, P136; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; Ishino M, 1995, ONCOGENE, V11, P2331; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MAA MC, 1994, MOL CELL BIOL, V14, P5466, DOI 10.1128/MCB.14.8.5466; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NEET K, 1995, MOL CELL BIOL, V15, P4908; OGAWA W, 1994, J BIOL CHEM, V269, P29602; Parmar K, 1996, J VIROL, V70, P1009, DOI 10.1128/JVI.70.2.1009-1015.1996; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANCHEZMARGALET V, 1995, ENDOCRINOLOGY, V136, P316, DOI 10.1210/en.136.1.316; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHOU MM, 1995, NATURE, V92, P7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	280	291	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					205	211		10.1016/S0092-8674(00)81841-3	http://dx.doi.org/10.1016/S0092-8674(00)81841-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008161	Bronze			2022-12-28	WOS:A1997WE97000009
J	Hadorn, DC; Holmes, AC				Hadorn, DC; Holmes, AC			The New Zealand priority criteria project .2. Coronary artery bypass graft surgery	BRITISH MEDICAL JOURNAL			English	Article								Priority criteria developed during a national project were used to conduct an audit of all 662 patients on waiting lists for coronary artery bypass surgery in New Zealand during spring 1996. Based on the observed distribution of priority scores, the cost of providing surgery to all patients down to various levels of priority was estimated. Descriptions incorporating life expectancy and quality of life implications of surgery were developed of the kinds of patients who would or would not receive surgery at each of several possible funding levels. Cardiologists and cardiac surgeons agreed that a threshold of 25 points was a reasonable clinical goal but to work with a threshold of 35, which can be sustained with current levels of funding. All agree that the gap between these clinically preferred and currently afforded thresholds is a subject for wider societal dialogue and decision. The ability to measure the size of the gap between clinical desirability and financial sustainability provides a new transparency to the problem of healthcare resource allocation.			Hadorn, DC (corresponding author), MINIST HLTH,NATL ADVISORY COMM HLTH & DISABIL,WELLINGTON,NEW ZEALAND.							AGNEW TM, 1994, NEW ZEAL MED J, V107, P211; ELWOOD PM, 1988, NEW ENGL J MED, V318, P1549; Fraser G, 1993, WAITING LISTS WAITIN; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; *NAT ADV COMM COR, 1993, 2 ANN REP; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	7	68	70	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					135	138		10.1136/bmj.314.7074.135	http://dx.doi.org/10.1136/bmj.314.7074.135			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006478	Green Published			2022-12-28	WOS:A1997WC47900035
J	Morrissey, MM; Chouet, BA				Morrissey, MM; Chouet, BA			Burst conditions of explosive volcanic eruptions recorded on microbarographs	SCIENCE			English	Article							MOUNT-ST-HELENS; WAVES; EXCITATION; PRESSURE; JETS	Explosive volcanic eruptions generate pressure disturbances in the atmosphere that propagate away either as acoustic or as shock waves, depending on the explosivity of the eruption, Both types of waves are recorded on microbarographs as 1- to 0.1-hertz N-shaped signals followed by a longer period coda. These waveforms can be; used to estimate burst pressures and gas concentrations in explosive volcanic eruptions and provide estimates of eruption magnitudes.	US GEOL SURVEY,MENLO PK,CA 94025	United States Department of the Interior; United States Geological Survey	Morrissey, MM (corresponding author), US GEOL SURVEY,DENVER FED CTR,BOX 25046,MS-966,DENVER,CO 80225, USA.			Chouet, Bernard/0000-0001-5527-0532				*AL VOLC OBS, 1993, EOS T AM GEOPHYS UN, V74, P221; Buckingham MJ, 1996, J GEOPHYS RES-SOL EA, V101, P8129, DOI 10.1029/95JB01680; FAGENTS SA, 1993, GEOPHYS J INT, V113, P359, DOI 10.1111/j.1365-246X.1993.tb00892.x; FRANCIS SH, 1973, J GEOPHYS RES, V78, P2278, DOI 10.1029/JA078i013p02278; Fudali R.F., 1971, B VOLCANOL, V35, P383, DOI DOI 10.1007/BF02596963; KANAMORI H, 1994, J GEOPHYS RES-SOL EA, V99, P21947, DOI 10.1029/94JB01475; KANAMORI H, 1982, J GEOPHYS RES, V87, P5422, DOI 10.1029/JB087iB07p05422; KANAMORI H, 1992, GEOPHYS RES LETT, V19, P721, DOI 10.1029/92GL00258; KIEFFER SW, 1984, J GEOPHYS RES, V89, P8253, DOI 10.1029/JB089iB10p08253; KIEFFER SW, 1993, GEOTIMES, V38, P5; McBirney A.R., 1973, B VOLCANOL, V37, P443, DOI [10.1007/BF02597641, DOI 10.1007/BF02597641]; MORRISSEY MM, IN PRESS J GEOPHYS R; NAIRN IA, 1976, NATURE, V259, P190, DOI 10.1038/259190a0; Okada H, 1990, B VOLCANOL SOC JPN 2, V35, P175; POWER JA, 1994, J VOLCANOL GEOTH RES, V62, P69, DOI 10.1016/0377-0273(94)90029-9; REED JW, 1987, J GEOPHYS RES-ATMOS, V92, P11979, DOI 10.1029/JD092iD10p11979; *RUAP SURV GROUP, 1996, EOS T AM GEOPHYS UN, V77, P189; SEIF S, 1979, NATURE, V277, P440; VALENTINE GA, 1989, J GEOPHYS RES-SOLID, V94, P1867, DOI 10.1029/JB094iB02p01867; VALENTINE GA, 1992, GEOL SOC AM BULL, V104, P154, DOI 10.1130/0016-7606(1992)104<0154:EOTOFA>2.3.CO;2; VALENTINE GA, 1988, LA1141T LOS AL LAB; Vergniolle S, 1996, J GEOPHYS RES-SOL EA, V101, P20449, DOI 10.1029/96JB01925; WILSON L, 1980, J VOLCANOL GEOTH RES, V8, P297, DOI 10.1016/0377-0273(80)90110-9; WOHLETZ KH, 1976, MAGMA STORAGE TRANSP, P113; WOODS AW, 1995, EARTH PLANET SC LETT, V131, P189, DOI 10.1016/0012-821X(95)00012-2; [No title captured]	26	50	50	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1290	1293		10.1126/science.275.5304.1290	http://dx.doi.org/10.1126/science.275.5304.1290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036850				2022-12-28	WOS:A1997WK64400037
J	Kong, TQ; Davidson, CJ; Meyers, SN; Tauke, JT; Parker, MA; Bonow, RO				Kong, TQ; Davidson, CJ; Meyers, SN; Tauke, JT; Parker, MA; Bonow, RO			Prognostic implication of creatine kinase elevation following elective coronary artery interventions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIRECTIONAL ATHERECTOMY; ANGIOPLASTY; DISEASE; TRIAL; TRANSIENT; LESIONS; RELEASE; PHASE	Objective.-To determine the prognostic significance of creatine kinase (CK) elevation following elective percutaneous transluminal coronary angioplasty (PTCA). Design.-Retrospective cohort study, Setting.-Tertiary care referral center. Subjects.-A total of 253 consecutive patients with total CK and CK-MB fraction (CK-MB) elevation (case patients) and 120 patients without CK elevation (controls). Control patients had undergone interventions during the same month and year using the same devices. Main Outcome Measures.-In-hospital and late cardiac mortality, subsequent myocardial infarction, and the combined end point of cardiac mortality or myocardial infarction. Results.-Patient groups were similar with respect to age, sex, extent of coronary artery disease, left ventricular function, number of lesions treated by PTCA, and mean duration of follow-up (>3.5 years). Cardiac mortality was significantly greater (P=.02) for patients with CK elevation after PTCA, When patients were categorized according to peak CK elevation, cardiac mortality differed significantly among patient groups (P=.007), with increased cardiac mortality observed for patients with high (>3,0 times normal) and intermediate (1,5 to 3.0 times normal) CK elevations. In multivariate analyses, higher peak CK and lower ejection fraction were the most important predictors of increased cardiac mortality (both, P<.001); the relative risk for cardiac mortality was 1.05 (95% confidence interval, 1.03-1.08) per 100-U/L increment increase in CK. Conclusions.-Creatine kinase elevation following elective PTCA is associated with increased late cardiac mortality. This increase in cardiac mortality is independent of clinical variables, severity of heart disease, coronary artery lesion characteristics, interventional devices, and procedural outcomes. Even patients with lesser degrees of CK elevation are at significantly increased risk for late cardiac death.	NORTHWESTERN UNIV, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, CHICAGO, IL USA	Northwestern University								ABDELMEGUID AE, 1995, CIRCULATION, V91, P2733, DOI 10.1161/01.CIR.91.11.2733; ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; BAIM DS, 1994, CIRCULATION, V90, P214; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; ELLIOTT JM, 1995, CIRCULATION, V91, P2158, DOI 10.1161/01.CIR.91.8.2158; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; HOSMER DW, 1989, APPL LOGISTIC REGRES, P74; KLEIN LW, 1991, J AM COLL CARDIOL, V17, P621, DOI 10.1016/S0735-1097(10)80174-3; KUGELMASS AD, 1994, AM J CARDIOL, V74, P748, DOI 10.1016/0002-9149(94)90427-8; LEON MB, 1994, CIRCULATION, V90, P213; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; OH JK, 1985, AM HEART J, V109, P1225, DOI 10.1016/0002-8703(85)90343-6; RAVKILDE J, 1994, AM HEART J, V127, P13, DOI 10.1016/0002-8703(94)90504-5; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; WAKSMAN R, 1993, CIRCULATION, V88, P299	18	250	258	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					461	466		10.1001/jama.277.6.461	http://dx.doi.org/10.1001/jama.277.6.461			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020269				2022-12-28	WOS:A1997WG05400032
J	Nightingale, SL				Nightingale, SL			Fertility drug shortage over	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					370	370						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010159				2022-12-28	WOS:A1997WE77100007
J	Feldman, HI; Kinman, JL; Berlin, JA; Hennessy, S; Kimmel, SE; Farrar, J; Carson, JL; Strom, BL				Feldman, HI; Kinman, JL; Berlin, JA; Hennessy, S; Kimmel, SE; Farrar, J; Carson, JL; Strom, BL			Parenteral ketorolac: The risk for acute renal failure	ANNALS OF INTERNAL MEDICINE			English	Article						ketorolac; kidney failure, acute; narcotics; anti-inflammatory agents, nonsteroidal; infusions, parenteral	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTRAMUSCULAR KETOROLAC; TUBULAR-NECROSIS; HYPERKALEMIA; IBUPROFEN; INSUFFICIENCY; INDOMETHACIN; SULINDAC; THERAPY	Background: Acute renal failure has been associated with parenteral ketorolac tromethamine, but the risk that is associated with this therapy has not been quantified. Objective: To compare the risk for acute renal failure associated with ketorolac with that associated with opioids. Design: Retrospective cohort study. Setting: 35 hospitals in or near Philadelphia. Patients: Patients receiving 10 219 courses of parenteral ketorolac and patients receiving 10 145 courses of parenteral opioids. Measurements: Acute renal failure was defined by 1) an increase in the serum creatinine concentration of 50% or more and 2) either an absolute increase of 44.2 mu mol/L or more for concentrations that were less than 132.6 mu mol/L at baseline or an absolute increase of 88.4 mu mol/L or more for concentrations that were 132.6 mu mol/L or more at baseline. In addition, a secondary definition required a diagnosis by a physician. Results: The overall incidence of acute renal failure was 1.1% after therapy with either ketorolac or opioids. Multivariate-adjusted rate ratios comparing ketorolac with opioids for acute renal failure were 1.09 (95% CI, 0.83 to 1.42) overall, 1.00 (CI, 0.76 to 1.33) for less than 5 days of thera py, and 2.08 (CI, 1.08 to 4.00; P = 0.03) for more than 5 days of therapy. Similar results were obtained when the secondary definition of acute renal failure was used. Conclusions: Overall, acute renal failure was uncommon in this hospitalized population. Compared with opioids, ketorolac administered for 5 days or less did not increase the rate of renal failure. However, among patients who were treated with analgesics for more than 5 days, ketorolac may be associated with an elevated rate of acute renal failure.	UNIV MED & DENT NEW JERSEY, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Feldman, HI (corresponding author), UNIV PENN, MED CTR, CTR CLIN EPIDEMIOL & BIOSTAT, 423 GUARDIAN DR, 720 BLOCKLEY HALL, PHILADELPHIA, PA 19104 USA.				NIDDK NIH HHS [DK-45191, DK-07006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006, P50DK045191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORASUBER LA, 1992, AM J MED, V92, P450, DOI 10.1016/0002-9343(92)90283-H; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; CORELLI RL, 1993, ANN PHARMACOTHER, V27, P1055, DOI 10.1177/106002809302700908; COX DR, 1972, J R STAT SOC B, V34, P187; FAVRE L, 1982, ANN INTERN MED, V96, P317, DOI 10.7326/0003-4819-96-3-317; FONG HJ, 1982, AM J NEPHROL, V2, P28, DOI 10.1159/000166578; FONG J, 1993, ANN PHARMACOTHER, V27, P510, DOI 10.1177/106002809302700422; GALLER M, 1981, JAMA-J AM MED ASSOC, V246, P154, DOI 10.1001/jama.246.2.154; GONZALO FDE, 1994, REV CLIN ESP, V194, P515; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; HARAGSIM L, 1994, AM J KIDNEY DIS, V24, P578, DOI 10.1016/S0272-6386(12)80215-0; HENANN NE, 1986, DRUG INTEL CLIN PHAR, V20, P860, DOI 10.1177/106002808602001107; KIMBERLY RP, 1979, ARTHRITIS RHEUM, V22, P281, DOI 10.1002/art.1780220311; KLEINKNECHT D, 1986, CLIN NEPHROL, V25, P275; LEE ET, 1980, STATISTICAL METHODS; MARASCO WA, 1987, ARCH INTERN MED, V147, P2107, DOI 10.1001/archinte.147.12.2107; MCCARTHY JT, 1982, MAYO CLIN PROC, V57, P351; MCCARTHY JT, 1982, MAYO CLIN PROC, V57, P289; PERAZELLA MA, 1993, SOUTHERN MED J, V86, P1421, DOI 10.1097/00007611-199312000-00025; QUAN DJ, 1994, J TOXICOL-CLIN TOXIC, V32, P305, DOI 10.3109/15563659409017963; QUINTERO E, 1986, NEPHRON, V42, P298, DOI 10.1159/000183692; REMINGTON RD, 1985, STATISTICS APPLICATI, P187; ROTENBERG FA, 1992, ANN PHARMACOTHER, V26, P778, DOI 10.1177/106002809202600606; SCHLONDORFF D, 1993, KIDNEY INT, V44, P643, DOI 10.1038/ki.1993.293; SCHOCH PH, 1992, ANN PHARMACOTHER, V26, P1233, DOI 10.1177/106002809202601007; SMITH K, 1993, ANAESTH INTENS CARE, V21, P700, DOI 10.1177/0310057X9302100538; Strom BL, 1996, JAMA-J AM MED ASSOC, V275, P376, DOI 10.1001/jama.275.5.376; WHELTON A, 1990, ANN INTERN MED, V112, P568, DOI 10.7326/0003-4819-112-8-568; WHELTON A, 1995, J CLIN PHARMACOL, V35, P454, DOI 10.1002/j.1552-4604.1995.tb04088.x	30	136	138	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					193	+		10.7326/0003-4819-126-3-199702010-00003	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027269				2022-12-28	WOS:A1997WF16800003
J	Snider, GL				Snider, GL			Tuberculosis then and now: A personal perspective on the last 50 years	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DRUG-RESISTANCE	Rates of death from tuberculosis in the United States decreased from 194 per 100 000 persons in 1900 to 40 per 100 000 persons in 1945, in part because the epidemic of tuberculosis in the western world was running its course and in part because of public health initiatives and improved socioeconomic conditions. in 1945, 63 000 persons died of tuberculosis and 115 000 new cases of the disease emerged. Streptomycin and para-aminosalicylic acid had just been discovered; the discovery of isoniazid followed, in 1952. Sanitarium care, nonsurgical and surgical collapse therapy, and resectional surgery were in widespread use. By the middle of the 1950s, it was evident that bedrest did not add to the benefit produced by effective chemotherapy, and sanitariums began to close, a process that was completed by the 1970s. As mortality and morbidity due to tuberculosis rapidly decreased, the U.S. government decreased funding for tuberculosis and many states and cities downgraded their tuberculosis control programs. After 1984, the rate of new cases of tuberculosis, which had decreased to 9.4 per 100 000, began to increase and focal outbreaks of multidrug-resistant tuberculosis were reported. Noncompliance with drug therapy, homelessness, immigration to the United States from developing countries, and human immunodeficiency virus (HIV) infection were invoked as explanations. With the reinstitution of federal funding, improved case-finding and surveillance, and the practice of having patients receive therapy while under direct observation, the rate of new cases of tuberculosis decreased to 8.7 per 100 000 in 1995, the lowest rate since national surveillance was begun in 1953. However, at the end of the 20th century, the worldwide burden of tuberculosis, which is engrafted onto the pandemic of HIV infection, is enormous: an estimated 7.6 million new cases in developing countries and 400 000 new cases in industrial nations.	VET AFFAIRS MED CTR, BOSTON, MA USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University								*AM HOSP ASS, HOSP STAT 1968 1993; *AM LUNG ASS EP ST, 1987, STAT COMP AD LUNG DI; BARNWELL JB, 1948, AM REV TUBERC PULM, V58, P64; BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815; *CDCP, 1995, REP TUB US 1994, P5; DESOPO ND, 1982, AM REV RESPIR DIS, V125, P85; Dubos R, 1952, WHITE PLAGUE TUBERCU; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Kayne GG, 1948, PULMONARY TUBERCULOS, V2nd; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LEHMANN J, 1946, LANCET, V250, P15; LILIENFELD AM, 1982, B HIST MED, V56, P1; LONG ER, 1960, AM REV RESPIR DIS, V81, P481; LOWELL A, 1969, TUBERCULOSIS, P34; MOODIE A S, 1956, Tubercle, V37, P451; MOULDING T, 1995, ANN INTERN MED, V122, P951, DOI 10.7326/0003-4819-122-12-199506150-00010; Murray Christopher J. L., 1994, P583; Pinner M., 1945, PULMONARY TUBERCULOS; ROBITZEK EH, 1952, AM REV TUBERC PULM, V65, P402; Rothman S., 1994, INT J HIST SPORT; RYAN F, 1956, FORGOTTEN PLAGUE BAT, V37, P451; Ryan Frank, 1992, FORGOTTEN PLAGUE BAT; Schatz A, 1944, P SOC EXP BIOL MED, V55, P66, DOI 10.3181/00379727-55-14461; SCHLUGER N, 1995, AM J RESP CRIT CARE, V151, P1486, DOI 10.1164/ajrccm.151.5.7735604; SCHULTZ D, 1994, LUNG DISEASE DATA, P37; SNIDER DE, 1994, TUBERCULOSIS BACK FU, P13; SNIDER DE, 1995, TUBERCULOSIS CLIN MA, P3; SONTAG S, 1990, ILLNESS AS METAPHOR; TAYLOR S, 1986, SARANAC AM MAGIC MOU; *TUB CHEM CTR, 1959, B WORLD HEALTH ORGAN, V21, P51; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097; Young Douglas B., 1994, P559; 1996, MMWR-MORBID MORTAL W, V45, P365	36	47	47	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					237	243		10.7326/0003-4819-126-3-199702010-00011	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027277				2022-12-28	WOS:A1997WF16800011
J	Franke, TF; Kaplan, DR; Cantley, LC; Toker, A				Franke, TF; Kaplan, DR; Cantley, LC; Toker, A			Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TARGET; KINASE	The regulation of the serine-threonine kinase Akt by lipid products of phosphoinositide 3-kinase (PI 3-kinase) was investigated. Akt activity was found to correlate with the amount of phosphatidylinositol-3,4-bisphosphate (PtdIns-3,4-P-2) in vivo, and synthetic PtdIns-3,4-P-2 activated Akt both in vitro and in vivo. Binding of PtdIns-3,4-P-2 occurred within the Akt pleckstrin homology (PH) domain and facilitated dimerization of Akt. Akt mutated in the PH domain was not activated by PI 3-kinase in vivo or by PtdIns-3,4-P-2 in vitro, and it was impaired in binding to PtdIns-3,4-P-2. Examination of the binding to other phosphoinositides revealed that they bound to the Akt PH domain with much lower affinity than did PtdIns-3,4-P-2 and failed to increase Akt activity. Thus, Akt is apparently regulated by the direct interaction of PtdIns-3,4-P-2 with the Akt PH domain.	MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT CELL BIOL,DIV SIGNAL TRANSDUCTION,BOSTON,MA 02115	McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Franke, TF (corresponding author), NCI,ABL BASIC RES PROGRAM,FREDERICK CANC RES FACIL & DEV CTR,FREDERICK,MD 21702, USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM41890, R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DERMAN MP, IN PRESS J BIOL CHEM; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRANKE TF, UNPUB; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304	18	1297	1322	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					665	668		10.1126/science.275.5300.665	http://dx.doi.org/10.1126/science.275.5300.665			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005852				2022-12-28	WOS:A1997WF07700039
J	Wiener, M; Freymann, D; Ghosh, P; Stroud, RM				Wiener, M; Freymann, D; Ghosh, P; Stroud, RM			Crystal structure of colicin Ia	NATURE			English	Article							PORE-FORMING DOMAIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; HELICAL HAIRPIN; CHANNEL; RECEPTOR; PROTEIN; TRANSPORT; GENE; PURIFICATION	The ion-channel forming colicins A, B, E1, Ia, Ib and N all kill bacterial cells selectively by co-opting bacterial active-transport pathways and forming voltage-gated ion conducting channels across the plasma membrane of the target bacterium(1,2). The crystal structure of colicin Ia reveals a molecule 210 Angstrom long with three distinct functional domains arranged along a backbone of two extraordinarily long alpha-helices. A central domain at the bend of the hairpin-like structure mediates specific recognition and binding to an outer-membrane receptor(3). A second domain mediates translocation across the outer membrane via the TonB transport pathway(4); the TonB-box(5) recognition element of colicin Ia is on one side of three 80 Angstrom-long helices arranged as a helical sheet. A third domain is made up of 10 alpha-helices which form a voltage-activated and voltage-gated ion conducting channel across the plasma membrane of the target cell. The two 160 Angstrom-long alpha-helices that link the receptor-binding domain to the other domains enable the colicin Ia molecule to span the periplasmic space and contact both the outer and plasma membranes simultaneously during function(6,7).	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS S964,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015; Freymann, Douglas/0000-0002-5231-8841				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BATY D, 1988, MOL MICROBIOL, V2, P807, DOI 10.1111/j.1365-2958.1988.tb00092.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BENEDETTI H, 1991, J MOL BIOL, V217, P429, DOI 10.1016/0022-2836(91)90747-T; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRUNDEN KR, 1984, J BIOL CHEM, V259, P190; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; DUCHE D, 1995, J BACTERIOL, V177, P4935, DOI 10.1128/jb.177.17.4935-4939.1995; GHOSH P, 1993, J MEMBRANE BIOL, V134, P85; GHOSH P, 1994, NAT STRUCT BIOL, V1, P597, DOI 10.1038/nsb0994-597; JEANTEUR D, 1994, J MOL BIOL, V235, P898, DOI 10.1006/jmbi.1994.1047; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONISKY J, 1970, J BIOL CHEM, V245, P2972; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEDUC M, 1985, J BACTERIOL, V161, P627, DOI 10.1128/JB.161.2.627-635.1985; MEL SF, 1993, BIOCHEMISTRY-US, V32, P9473, DOI 10.1021/bi00087a027; MENDE J, 1990, MOL MICROBIOL, V4, P1523, DOI 10.1111/j.1365-2958.1990.tb02063.x; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; STROUD R, 1995, CURR OPIN STRUC BIOL, V5, P514, DOI 10.1016/0959-440X(95)80037-9	30	222	227	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					461	464		10.1038/385461a0	http://dx.doi.org/10.1038/385461a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009197				2022-12-28	WOS:A1997WF00700059
J	OReilly, MS; Boehm, T; Shing, Y; Fukai, N; Vasios, G; Lane, WS; Flynn, E; Birkhead, JR; Olsen, BR; Folkman, J				OReilly, MS; Boehm, T; Shing, Y; Fukai, N; Vasios, G; Lane, WS; Flynn, E; Birkhead, JR; Olsen, BR; Folkman, J			Endostatin: An endogenous inhibitor of angiogenesis and tumor growth	CELL			English	Article							ENDOTHELIAL-CELL PROLIFERATION; LEWIS-LUNG-CARCINOMA; POTENT INHIBITOR; IN-VIVO; DOMAINS; THROMBOSPONDIN-1; IDENTIFICATION; SUPPRESSION; CHEMOKINE; FRAGMENT	We previously identified the angiogenesis inhibitor angiostatin. Using a similar strategy, we have identified endostatin, an angiogenesis inhibitor produced by hemangioendothelioma. Endostatin is a 20 kDa C-terminal fragment of collagen XVIII. Endostatin specifically inhibits endothelial proliferation and potently inhibits angiogenesis and tumor growth. By a novel method of sustained release, E. coli-derived endostatin was administered as a nonrefolded suspension. Primary tumors were regressed to dormant microscopic lesions. Immunohistochemistry revealed blocked angiogenesis accompanied by high proliferation balanced by apoptosis in tumor cells. There was no toxicity. Together with angiostatin data, these findings validate a strategy for identifying endogenous angiogenesis inhibitors, suggest a theme of fragments of proteins as angiogenesis inhibitors, and demonstrate dormancy therapy.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02115 USA; OSTEOARTHRIT SCI INC, CAMBRIDGE, MA 02139 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University					NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040711, P01HL033014] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA45548] Funding Source: Medline; NHLBI NIH HHS [HL33014, HL 40711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; CHEN C, 1995, CANCER RES, V55, P4230; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; Folkman J, 1985, Important Adv Oncol, P42; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1996, P NATL ACAD SCI USA, V93, P2002; Gately S, 1996, CANCER RES, V56, P4887; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; NELSON J, 1995, CANCER RES, V55, P3772; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; OBESO J, 1990, LAB INVEST, V63, P259; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; SAKAMOTO N, 1991, CANCER RES, V51, P903; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581	41	3685	4180	2	176	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					277	285		10.1016/S0092-8674(00)81848-6	http://dx.doi.org/10.1016/S0092-8674(00)81848-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008168	Bronze			2022-12-28	WOS:A1997WE97000016
J	Semaw, S; Renne, P; Harris, JWK; Feibel, CS; Bernor, RL; Fesseha, N; Mowbray, K				Semaw, S; Renne, P; Harris, JWK; Feibel, CS; Bernor, RL; Fesseha, N; Mowbray, K			2.5-million-year-old stone tools from Gona, Ethiopia	NATURE			English	Article							PLIOCENE HOMINIDS; TURKANA BASIN; LAKE TURKANA; TIME-SCALE; HADAR; KENYA; MA	The Oldowan Stone tool industry was named for 1.8-million-year-old (Mpr) artefacts found near the bottom of Olduvai Gorge, Tanzania. Subsequent archaeological research in the Omo (Ethiopia) and Turkana (Kenya) also yielded stone tools dated to 2.3 Myr. Palaeoanthropological investigations in the Hadar region of the Awash Valley of Ethiopia(1), revealed Oldowan assemblages in the adjacent Gona River drainage(2). We conducted held work in the Gona study area of Ethiopia between 1992 and 1994 which resulted in additional archaeological discoveries as well as radioisotopic age control and a magnetic polarity stratigraphy of the Gona sequence. These occurrences are now securely dated between 2.6-2.5 Myr. The stone tools are thus the oldest known artefacts from anywhere in the world The artefacts show surprisingly sophisticated control of stone fracture mechanics, equivalent to much younger Oldowan assemblages of Early Pleistocene age. This indicates an unexpectedly long period of technological stasis in the Oldowan.	BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; HOWARD UNIV,COLL MED,DEPT ANAT,LAB PALEOBIOL,WASHINGTON,DC 20059	Berkeley Geochronolgy Center; Howard University	Semaw, S (corresponding author), RUTGERS STATE UNIV,DEPT ANTHROPOL,DOUGLASS CAMPUS,NEW BRUNSWICK,NJ 08903, USA.		Klein, Richard G/B-5910-2009; Semaw, Sileshi/M-7021-2018	Renne, Paul/0000-0003-1769-5235; Semaw, Sileshi/0000-0001-8377-8288				ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; Callow P., 1986, STONE AGE PREHISTORY, P243; Chavaillon J., 1976, EARLIEST MAN ENV LAK, P565; CORVINUS G, 1976, ANTHROPOLOGIE, V80, P315; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; Dominguez-Rodrigo M., 1996, COMPLUTUM, V7, P7; Harris J.W.K., 1983, AFR ARCHAEOL REV, V1, P3, DOI DOI 10.1007/BF01116770; HARRIS JWK, 1989, NYAME AKUMA, V31, P19; HILL A, 1992, NATURE, V355, P719, DOI 10.1038/355719a0; ISAAC GL, 1976, EARLIEST MAN ENV LAK, P552; ISAACS GL, 1974, NATURE, V249, P624, DOI 10.1038/249624a0; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; KIBUNJIA M, 1994, J HUM EVOL, V27, P159, DOI 10.1006/jhev.1994.1040; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; Leakey M.D., 1971, OLDUVAI GORGE; MCDOUGALL I, 1992, GEOPHYS RES LETT, V19, P2349, DOI 10.1029/92GL02714; Merrick H.V., 1976, EARLIEST MAN ENV LAK, P574; Piperno M., 1989, P189; RENNE P, 1993, GEOPHYS RES LETT, V20, P1067, DOI 10.1029/93GL00733; ROCHE H, 1977, CR ACAD SCI D NAT, V284, P1871; TOTH N, 1985, J ARCHAEOL SCI, V12, P101, DOI 10.1016/0305-4403(85)90056-1; Vrba E.S., 1988, P405; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0	25	379	391	3	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					333	336		10.1038/385333a0	http://dx.doi.org/10.1038/385333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WD914	9002516				2022-12-28	WOS:A1997WD91400048
J	Stanley, EF; Mirotznik, RR				Stanley, EF; Mirotznik, RR			Cleavage of syntaxin prevents G-protein regulation of presynaptic calcium channels	NATURE			English	Article							CHICK CILIARY GANGLION; ACETYLCHOLINE-RELEASE; SENSORY NEURONS; GIANT SYNAPSE; N-TYPE; CURRENTS; SYNAPTOTAGMIN; MODULATION; INHIBITION	Neurotransmitter release into the synapse is stimulated by calcium influx through ion channels that are closely associated with the transmitter release sites(1,2). This link may involve the membrane protein syntaxin, which is known to be associated with the release sites and to bind to the calcium channels(3,4). There is evidence that presynaptic calcium channels are downregulated by second messenger pathways involving G proteins(5,6). Here we use the patch-clamp technique to test whether calcium current is regulated by G proteins in a vertebrate presynaptic nerve terminal(7), and whether this regulation is affected by the Linkage to syntaxin. The calcium current in the nerve terminal showed typical G-protein-mediated changes in amplitude and activation kinetics which were reversed by a preceding depolarization. These effects of the G protein were virtually eliminated if syntaxin was I first cleaved with botulinum toxin CI. Our findings indicate that this sensitivity of the current to modulation by G proteins requires the association of the presynaptic calcium channel with elements of the transmitter release site, which may ensure that channels tethered at release sites(2,8) are preferentially regulated by the G-protein second messenger pathway.			Stanley, EF (corresponding author), NINCDS, SYNAPT MECH SECT, NIH, BLD 36, RM 5A25, BETHESDA, MD 20892 USA.							BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Kee Y, 1996, J NEUROSCI, V16, P1975; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARCHETTI C, 1989, BIOPHYS J, V56, P1267, DOI 10.1016/S0006-3495(89)82774-2; MOCHIDA S, 1995, NEUROSCIENCE, V65, P905, DOI 10.1016/0306-4522(94)00508-3; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCOTT RH, 1986, NEUROSCI LETT, V69, P59, DOI 10.1016/0304-3940(86)90414-3; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SHIAVO G, 1994, ANN NY ACAD SCI, V710, P65; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; STANLEY EF, 1991, ANN NY ACAD SCI, V635, P70, DOI 10.1111/j.1749-6632.1991.tb36482.x; STANLEY EF, 1991, J NEUROSCI, V11, P985; STANLEY EF, 1989, BRAIN RES, V505, P341, DOI 10.1016/0006-8993(89)91465-0; STANLEY EF, 1991, NEURON, V7, P585, DOI 10.1016/0896-6273(91)90371-6; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	29	153	156	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 23	1997	385	6614					340	343		10.1038/385340a0	http://dx.doi.org/10.1038/385340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002518				2022-12-28	WOS:A1997WD91400050
J	Haley, RW; Hom, J; Roland, PS; Bryan, WW; VanNess, PC; Bonte, FJ; Devous, MD; Matthews, D; Fleckenstein, JL; Wians, FH; Wolfe, GI; Kurt, TL				Haley, RW; Hom, J; Roland, PS; Bryan, WW; VanNess, PC; Bonte, FJ; Devous, MD; Matthews, D; Fleckenstein, JL; Wians, FH; Wolfe, GI; Kurt, TL			Evaluation of neurologic function in gulf war veterans - A blinded case-control study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN; POSTUROGRAPHY	Objective.-To determine whether Gulf War-related illnesses are associated with central or peripheral nervous system dysfunction. Design.-Nested case-control study. Participants.-Twenty-three veterans with factor analysis-derived syndromes (the cases), 10 well veterans deployed to the Gulf War (the deployed controls), and 10 well veterans not deployed to the Gulf War (the nondeployed controls), Method.-With investigators blinded to group identities, participants underwent objective neurophysiological, audiovestibular, neuroradiological, neuropsychological, and blood tests. Main Outcome Measures.-Evidence of neurologic dysfunction. Results.-Compared with the 20 controls, the 23 cases had significantly more neuropsychological evidence of brain dysfunction on the Halstead Impairment Index (P=.01), greater interside asymmetry of the wave I to wave III interpeak latency of brain stem auditory evoked potentials (P=.02), greater interocular asymmetry of nystagmic velocity on rotational testing, increased asymmetry of saccadic Velocity (P=.04), more prolonged interpeak latency of the lumbar-to-cerebral peaks on posterior tibial somatosensory evoked potentials (on right side, P=.03, and on the left side, P=.005), and diminished nystagmic velocity after caloric stimulation bilaterally (P values range from .02 to .04). Cases (n=5) with syndrome 1 (''impaired cognition'') were the most impaired on brain stem auditory evoked potentials (P=.005); those (n=13) with syndrome 2 (''confusion-ataxia'') were the most impaired on the Halstead Impairment Index (P=.006), rotational testing (P=.01), asymmetry of saccadic velocity (P=.03), and somatosensory evoked potentials (P less than or equal to.01); and those (n=5) with syndrome 3 (''arthro-myo-neuropathy'') were the most impaired on caloric stimulation (P less than or equal to.01). Conclusions.-The 3 factor-derived syndromes identified among Gulf War veterans appear to represent variants of a generalized injury to the nervous system.	UNIV TEXAS,SW MED CTR,DEPT OTOLARYNGOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT RADIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235; NEUROPSYCHOL CTR,DALLAS,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Haley, RW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV EPIDEMIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Wolfe, Gil/AAO-2786-2020; Haley, Robert/P-9026-2014	Roland, Peter/0000-0003-4152-7346; Haley, Robert/0000-0001-8849-9579				AbouDonia MB, 1996, J TOXICOL ENV HEALTH, V48, P35, DOI 10.1080/009841096161456; AbouDonia MB, 1996, FUND APPL TOXICOL, V34, P201, DOI 10.1006/faat.1996.0190; ATLAS SW, 1993, J COMPUT ASSIST TOMO, V17, pS1, DOI 10.1097/00004728-199301001-00001; BALOH RW, 1983, CLIN NEUROPHYSIOLOGY; BONTE FJ, 1993, RADIOLOGY, V186, P361, DOI 10.1148/radiology.186.2.8421735; CHIAPPA KH, 1990, EVOKED POTENTIALS CL; DEBLEECKER JL, 1992, CLIN NEUROL NEUROSUR, V94, P93, DOI 10.1016/0303-8467(92)90065-B; DIFABIO RP, 1995, PHYS THER, V75, P290, DOI 10.1093/ptj/75.4.290; ELIAS MF, 1993, J GERONTOL, V48, pP278, DOI 10.1093/geronj/48.6.P278; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; HALL JW, 1992, HDB AUDITORY EVOKED, P350; Jacobson GP., 1993, HDB BALANCE FUNCTION; Jamal GA, 1996, J NEUROL NEUROSUR PS, V60, P449, DOI 10.1136/jnnp.60.4.449; Kleinbaum D. G., 1982, EPIDEMIOLOGIC RES PR, P62; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KRISS A, 1993, EVOKED POTENTIALS CL, P1; LIPP M, 1994, J OTOLARYNGOL, V23, P177; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reitan RM, 1974, CLIN NEUROPSYCHOLOGY; ROLAND PS, 1995, TRAUMATIC BRAIN INJU, P131; RUNGE VM, 1995, TOP MAGN RESON IMAG, V7, P158; SAHA GB, 1994, SEMIN NUCL MED, V24, P324, DOI 10.1016/S0001-2998(05)80022-4; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P75; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P124; SEQUEIRA W, 1994, CLIN EXP RHEUMATOL, V12, P325; Snedecor GW, 1980, STAT METHODS, V7th; *US DEP DEF, 1996, COMPR CLIN EV PROGR; Wechsler D., 2008, WAIS 4 WECHSLER ADUL	32	179	182	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					223	230		10.1001/jama.277.3.223	http://dx.doi.org/10.1001/jama.277.3.223			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB446	9005272				2022-12-28	WOS:A1997WB44600024
J	Harrison, A; Dixon, J; New, B; Judge, K				Harrison, A; Dixon, J; New, B; Judge, K			Funding the NHS: Can the NHS cope in future .2.	BRITISH MEDICAL JOURNAL			English	Article								Four potential pressures are likely to determine whether the NHS will be able to cope in future: the change in population structure, changes in level of morbidity, introduction of new technologies, and increasing expectations of patients and NHS providers. New technology and changes in expectations are likely to have the biggest effect and are also the most difficult to quantify. Nevertheless, these pressures are to some extent amenable to control. If the growth in funding continues as it has in the past there is no convincing evidence that the NHS will not continue to cope.			Harrison, A (corresponding author), KINGS FUND,POLICY INST,LONDON W1M 0AN,ENGLAND.							AARON H, 1996, HLTH CARE REFORM WIL; AARON HJ, 1984, PAINFUL PRESCRIPTION; ABELSMITH B, 1996, HLTH CARE REFORM WIL; ADAMS CBT, 1995, BRIT MED J, V311, P1559, DOI 10.1136/bmj.311.7019.1559; Besley T., 1996, PRIVATE HLTH INSURAN; Bloor K, 1996, BRIT MED J, V313, P33, DOI 10.1136/bmj.313.7048.33; BLOOR K, 1993, 113 U YORK CTR HLTH; BONE M, 1995, HLTH EXPECTANCY ITS; BOSANQUET N, 1995, HLTH CARE UK 1994 95; Bradley C, 1996, BRIT MED J, V312, P835; Calnan M., 1993, GOING PRIVATE WHY PE; Cutler P, 1993, Health Econ, V2, P65, DOI 10.1002/hec.4730020109; *DEP HLTH, 1996, GOV EXP PLANS 1996 9, P47; *DEP HLTH, 1995, ORD DAYC ADM ENGL 19; *DEP HLTH, 1996, NAT HLTH SERV SERV A; DIXON J, 1996, ECONOMIST       0217, P8; DUNNELL K, 1995, POPULATION TRENDS, V82, P12; ELLIOTT L, 1996, GUARDIAN        0531, P2; FRIES JF, 1980, NEW ENGL J MED, V31, P407; GELJINS AC, 1996, C FUND QUEST FUT HLT; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; *HEALTHC 2000, 1995, UK HLTH HEALTHC SERV; *HLTH SEL COMM, 1995, MIN EV PUBL EXP RES, P16; *HOUS COMM HLTH CO, 1995, PRIOR SETT NHS PURCH, V1; JOWELL R, 1996, BRIT SOCIAL ATTITUDE, P230; JUDGE K, 1993, J SOC POLICY, V22, P299, DOI 10.1017/S0047279400019553; LAING W, 1995, LAINGS REV PRIVATE H; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; MCCORMICK A, 1995, HLTH TRENDS, V27, P34; *PARL OFF SCI TECH, 1994, FACT AFF PRESS HLTH; ROBINE JM, 1992, HLTH EXP 1 WORKSH IN; SCHWARTZ WB, 1996, HLTH AFFAIRS     SUM, P71; Sheldon TA, 1996, BRIT MED J, V313, P508; STOCKING B, 1989, FACTORS AFFECTING DI; WORDSWORTH S, 1996, FUTURE CHALLENGES UK; 1996, BRIT MED J, V313, P131; [No title captured]	37	15	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					139	142		10.1136/bmj.314.7074.139	http://dx.doi.org/10.1136/bmj.314.7074.139			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006479	Green Published			2022-12-28	WOS:A1997WC47900036
J	Hoell, T; Oltmanns, F; Schilling, A; Brock, M				Hoell, T; Oltmanns, F; Schilling, A; Brock, M			Precise localisation of single-word retrieval in the left cerebral hemisphere	LANCET			English	Article											Hoell, T (corresponding author), BENJAMIN FRANKLIN UNIV HOSP,DEPT NEUROSURG,D-12200 BERLIN,GERMANY.							Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; OJEMANN GA, 1991, J NEUROSCI, V11, P2281	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					104	104		10.1016/S0140-6736(05)60889-6	http://dx.doi.org/10.1016/S0140-6736(05)60889-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996431				2022-12-28	WOS:A1997WB80000022
J	HemmatiBrivanlou, A; Melton, D				HemmatiBrivanlou, A; Melton, D			Vertebrate embryonic cells will become nerve cells unless told otherwise	CELL			English	Review							NEURAL INDUCTION; XENOPUS EMBRYO; MESODERM INDUCTION; TRUNCATED ACTIVIN; RECEPTOR; ECTODERM; BMP-4; FOLLISTATIN; SIGNALS; PROTEIN	The past few years have witnessed a significant change in the understanding of how the vertebrate nervous system forms during embryogenesis. More than seventy years since Spemann and Mangold first demonstrated the phenomenon of neural induction, the molecular mechanisms underlying neural induction now appear to be at hand. Two independent approaches, one focusing on a ''default'' or ''ground-state'' model for neural induction and the other culminating in the discovery of secreted neural inducing factors (noggin, follistatin, and chordin), have not only brought to a successful conclusion the search for Spemann's neuralizing factor, but also illuminated its mechanism of action. It now appears that neuralization of embryonic cells occurs when cells do not receive other inducing signals telling them to form epidermis, mesoderm, or endoderm. This concept of neuralization allows for a reinterpretation of the classical views on both neural and epidermal specification. The secreted growth factor BMP4 (Bone Morphogenetic Protein) plays a pivotal role wherein BMP signaling induces epidermal differentiation. It is the absence of BMP signaling, accomplished by BMP antagonists including noggin, follistatin, and chordin, that leads to the formation of neural tissue.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	HemmatiBrivanlou, A (corresponding author), ROCKEFELLER UNIV,LAB MOL EMBRYOL,1230 YORK AVE,NEW YORK,NY 10021, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; HANSEN C, 1996, IN PRESS DEVELOPMENT; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	25	265	284	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					13	17		10.1016/S0092-8674(00)81853-X	http://dx.doi.org/10.1016/S0092-8674(00)81853-X			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019398	Bronze			2022-12-28	WOS:A1997WC56900004
J	Savill, J				Savill, J			Science, medicine, and the future - Prospecting for gold in the human genome	BRITISH MEDICAL JOURNAL			English	Review								Doctors struggling with the daily problems of clinical medicine usually have little time for molecular and cell biology But genetic research is producing an explosion of knowledge which doctors will need to understand in order to join in the ethical and financial debates that will inevitably follow the new treatments discovered. There may, indeed, be therapeutic gold hidden in our genes, but the price for it could be more than we can afford. This is the first of three articles introducing a series which aims to convey the excitement and potential power of biomedical science by speculating how current research will impinge on clinical management of common conditions.			Savill, J (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.							Hall IP, 1997, BRIT MED J, V314, P45, DOI 10.1136/bmj.314.7073.45	1	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					43	45		10.1136/bmj.314.7073.43	http://dx.doi.org/10.1136/bmj.314.7073.43			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001481	Green Published, Green Submitted			2022-12-28	WOS:A1997WB68400028
J	Thomas, G; Bonner, S; Gascoigne, A				Thomas, G; Bonner, S; Gascoigne, A			Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): A case report	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,INTENS CARE UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK								CHIN MY, 1992, WESTERN J MED, V156, P380; HUNTER AS, 1971, BRIT J ANAESTH, V43, P620, DOI 10.1093/bja/43.6.620; SHAPIRO H, 1994, INFORMATION DRUG WOR; 1991, JAMA-J AM MED ASSOC, V265, P447; 1991, JAMA-J AM MED ASSOC, V265, P1802	5	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					35	36		10.1136/bmj.314.7073.35	http://dx.doi.org/10.1136/bmj.314.7073.35			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB684	9001478	Green Published			2022-12-28	WOS:A1997WB68400023
J	Davidson, JP; Tepley, FJ				Davidson, JP; Tepley, FJ			Recharge in volcanic systems: Evidence from isotope profiles of phenocrysts	SCIENCE			English	Article							EL-CHICHON VOLCANO; MAGMA CHAMBER; BISHOP-TUFF; LONG-VALLEY; PLAGIOCLASE; EVOLUTION; ERUPTIONS; PETROLOGY; KINETICS; CHIAPAS	Strontium isotope ratios measured from core to rim across plagioclase feldspar crystals can be used to monitor changes in the isotope composition of the magma from which they grew. In samples from three magma systems from convergent margin volcanoes, sudden changes in major element composition, petrographic features, and strontium isotope composition were found to correspond to discrete magmatic events, most likely repeated recharge of more mafic magma with lower ratios of strontium-87 to strontium-86 into a crustally contaminated magma.			Davidson, JP (corresponding author), UNIV CALIF LOS ANGELES, DEPT EARTH & SPACE SCI, LOS ANGELES, CA 90095 USA.							ANDERSON AT, 1983, AM MINERAL, V68, P125; CASHMAN KV, 1990, REV MINERAL, V24, P259; CHRISTENSEN JN, 1993, CONTRIB MINERAL PETR, V113, P100, DOI 10.1007/BF00320834; CLYNNE MA, COMMUNICATION; CLYNNE MA, IN PRESS J PETROL; CLYNNE MA, 1989, NEW MEXICO BUREAU MI, V47, P183; DAVIDSON JP, 1990, J GEOPHYS RES-SOLID, V95, P17661, DOI 10.1029/JB095iB11p17661; DESILVA SL, 1989, J VOLCANOL GEOTH RES, V37, P93, DOI 10.1016/0377-0273(89)90065-6; DRUITT TH, 1989, CONTRIB MINERAL PETR, V101, P245, DOI 10.1007/BF00375310; DUNGAN MA, 1978, CONTRIB MINERAL PETR, V67, P417, DOI 10.1007/BF00383301; EICHELBERGER JC, 1980, NATURE, V288, P446, DOI 10.1038/288446a0; EICHELBERGER JC, 1978, NATURE, V275, P21, DOI 10.1038/275021a0; GILETTI BJ, 1994, GEOCHIM COSMOCHIM AC, V58, P3785, DOI 10.1016/0016-7037(94)90363-8; HAASE CS, 1980, SCIENCE, V209, P272, DOI 10.1126/science.209.4453.272; HAWKESWORTH CJ, 1982, EARTH PLANET SC LETT, V58, P240, DOI 10.1016/0012-821X(82)90197-2; KAY SM, 1985, CONTRIB MINERAL PETR, V90, P276, DOI 10.1007/BF00378268; Kirkpatrick RJ, 1981, REV MINERAL, V8, P321, DOI DOI 10.1017/CBO9781107415324.004; LUHR JF, 1984, J VOLCANOL GEOTH RES, V23, P69, DOI 10.1016/0377-0273(84)90057-X; MCGEE JJ, 1987, GEOFIS INT, V26, P85; OHARA MJ, 1981, J GEOL SOC LONDON, V138, P237, DOI 10.1144/gsjgs.138.3.0237; PALLISTER JS, 1992, NATURE, V356, P426, DOI 10.1038/356426a0; PEARCE TH, 1989, GEOLOGY, V17, P757, DOI 10.1130/0091-7613(1989)017<0757:NICOOT>2.3.CO;2; PEARCE TH, 1990, EARTH-SCI REV, V29, P9, DOI 10.1016/0012-8252(90)90024-P; SINGER BS, 1995, AM MINERAL, V80, P776; SPARKS SRJ, 1977, NATURE, V267, P315, DOI 10.1038/267315a0; SPERA F, 1980, SCIENCE, V207, P299, DOI 10.1126/science.207.4428.299; STAMATELOPOULOUSEYMOUR K, 1990, CONTRIB MINERAL PETR, V104, P73, DOI 10.1007/BF00310647; TILLING RI, 1984, SCIENCE, V224, P747, DOI 10.1126/science.224.4650.747; TILLING RI, 1994, MIDDLE E TECH U DEP, V2; VANDENBOGAARD P, 1995, GEOLOGY, V23, P759, DOI 10.1130/0091-7613(1995)023<0759:AALPAO>2.3.CO;2	30	197	205	3	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 7	1997	275	5301					826	829		10.1126/science.275.5301.826	http://dx.doi.org/10.1126/science.275.5301.826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012348				2022-12-28	WOS:A1997WG77700059
J	Beutler, E				Beutler, E			Genetic irony beyond haemochromatosis: Clinical effects of HLA-H mutations	LANCET			English	Editorial Material											Beutler, E (corresponding author), SCRIPPS RES INST, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA.							Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; Calandro L, 1996, BLOOD CELL MOL DIS, V22, pA194; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; SIMON M, 1974, NOUV PRESSE MED, V4, P1432	7	111	112	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 1	1997	349	9048					296	297		10.1016/S0140-6736(97)22005-2	http://dx.doi.org/10.1016/S0140-6736(97)22005-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024367				2022-12-28	WOS:A1997WF79400002
J	Rinder, MR				Rinder, MR			Doing the little things	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									UNIV MARYLAND, MED CTR, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore									0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					247	247		10.7326/0003-4819-126-3-199702010-00013	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027279				2022-12-28	WOS:A1997WF16800013
J	Yu, XM; Askalan, R; Keil, GJ; Salter, MW				Yu, XM; Askalan, R; Keil, GJ; Salter, MW			NMDA channel regulation by channel-associated protein tyrosine kinase Src	SCIENCE			English	Article							RECEPTOR SUBUNITS; RAT HIPPOCAMPUS; FAMILY; NEURONS; PHOSPHORYLATION; PLASTICITY; GLUTAMATE; PP60C-SRC; CURRENTS; DOMAIN	The N-methyl-D-aspartate (NMDA) receptor mediates synaptic transmission and plasticity in the central nervous system (CNS) and is regulated by tyrosine phosphorylation. In membrane patches excised from mammalian central neurons, the endogenous tyrosine kinase Src was shown to regulate the activity of NMDA channels. The action of Src required a sequence [Src(40-58)] within the noncatalytic, unique domain of Src. In addition, Src coprecipitated with NMDA receptor proteins. Finally, endogenous Src regulated the function of NMDA receptors at synapses. Thus, NMDA receptor regulation by Src may be important in development, plasticity, and pathology in the CNS.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; DEKONINCK Y, 1994, J NEUROPHYSIOL, V71, P1218; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU XQ, 1993, ONCOGENE, V8, P1119; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; PERNEY TM, 1993, SEMIN NEUROSCI, V5, P135; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SORIANO P, 1991, Cell, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; YU X, UNPUB	35	537	560	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					674	678		10.1126/science.275.5300.674	http://dx.doi.org/10.1126/science.275.5300.674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005855				2022-12-28	WOS:A1997WF07700042
J	DeWaard, M; Liu, HY; Walker, D; Scott, VES; Gurnett, CA; Campbell, KP				DeWaard, M; Liu, HY; Walker, D; Scott, VES; Gurnett, CA; Campbell, KP			Direct binding of G-protein beta gamma complex to voltage-dependent calcium channels	NATURE			English	Article							CA2+ CHANNELS; N-TYPE; NEUROTRANSMITTER INHIBITION; SYNAPTIC TRANSMISSION; SYMPATHETIC NEURONS; ALPHA-SUBUNITS; CURRENTS; MODULATION; EXPRESSION; CLONING	Voltage-dependent Ca2+ channels play a central role in controlling neurotransmitter release at the synapse(1,2). They can be inhibited by certain G-protein-coupled receptors, acting by a pathway intrinsic to the membrane(3-6). Here we show that this inhibition results from a direct interaction between the G-protein beta gamma complex and the pore-forming alpha(1) subunits of several types of these channels(7). The interaction is mediated by the cytoplasmic linker connecting the first and second transmembrane repeats. Within this linker, binding occurs both in the alpha(1) interaction domain (AID)(8), which also mediates the interaction between the alpha(1) and beta subunits of tbe channel, and in a second downstream sequence. Further analysis of the binding site showed that several amino-terminal residues in the AID are critical for G beta gamma binding, defining a site distinct from the carboxy-terminal residues shown to be essential for binding the beta-subunit of the Ca2+ channel(9). Mutation of an arginine residue within the N-terminal motif abolished beta gamma binding and rendered the channel refractory to G-protein modulation when expressed in Xenopus oocytes, showing that the interaction is indeed responsible for G-protein-dependent modulation of Ca2+ channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; FAC MED NORD,INST JEAN ROCHE,INSERM,U464,F-13916 MARSEILLE 20,FRANCE	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Walker, Denise/0000-0003-1534-1679; Campbell, Kevin/0000-0003-2066-5889; Gurnett, Christina/0000-0001-9129-315X				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BOLAND LM, 1993, J NEUROSCI, V13, P516; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; DOLPHIN AC, 1986, J PHYSIOL-LONDON, V373, P47, DOI 10.1113/jphysiol.1986.sp016034; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HIRNING LD, 1990, BRAIN RES, V532, P120, DOI 10.1016/0006-8993(90)91751-2; HOLZ GG, 1989, J NEUROSCI, V9, P657; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yassin M, 1996, BIOCHEM BIOPH RES CO, V220, P453, DOI 10.1006/bbrc.1996.0426; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	30	309	314	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					446	450						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009193				2022-12-28	WOS:A1997WF00700055
J	Ulbrandt, ND; Newitt, JA; Bernstein, HD				Ulbrandt, ND; Newitt, JA; Bernstein, HD			The E-coli signal recognition particle is required for the insertion of a subset of inner membrane proteins	CELL			English	Article							ESCHERICHIA-COLI; 4.5S RNA; SEQUENCE RECOGNITION; ALKALINE-PHOSPHATASE; ALPHA-SUBUNIT; GENE; TOPOLOGY; EXPORT; RIBONUCLEOPROTEIN; RECEPTOR	E. coli homologs of the signal recognition particle (SRP) and its receptor are essential for viability, but their role in protein export is unclear. To elucidate their function, we devised a genome-wide screen to identify genes that encode SRP substrates. Inhibition of the SRP pathway sharply blocked the membrane insertion of several polytopic inner membrane proteins (IMPs) that were predicted to be SRP substrates, but had a smaller effect on the insertion of other IMPs and no significant effect on preprotein translocation. Our results suggest that whereas most E. coli preproteins and some IMPs can utilize SRP-independent targeting pathways effectively, the structural features of a subset of IMPs have required the conservation of an SRP-based targeting machinery.			Ulbrandt, ND (corresponding author), NIDDKD, GENET & BIOCHEM BRANCH, NIH, BETHESDA, MD 20892 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; Harlow E., 1988, ANTIBODIES LAB MANUA; ICHO T, 1985, J BIOL CHEM, V260, P2078; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kroll ES, 1996, GENETICS, V143, P95; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; MURPHY CK, 1996, ESCHERICHIA COLI SAL, P967; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SEOL WG, 1993, J BACTERIOL, V175, P565, DOI 10.1128/JB.175.2.565-567.1993; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	47	291	295	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					187	196		10.1016/S0092-8674(00)81839-5	http://dx.doi.org/10.1016/S0092-8674(00)81839-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008159	Bronze			2022-12-28	WOS:A1997WE97000007
J	Bezrukov, SM; Vodyanoy, I				Bezrukov, SM; Vodyanoy, I			Stochastic resonance in non-dynamical systems without response thresholds	NATURE			English	Article							NOISE	The addition of noise to a system can sometimes improve its ability to transfer information reliably. This phenomenon-known as stochastic resonance-was originally proposed to account for periodicity in the Earth's ice ages', but has now been shown to occur in many systems in physics and biology(2-4). Recent experimental and theoretical work has shown that the simplest system exhibiting 'stochastic resonance' consists of nothing more than signal and noise with a threshold-triggered device (when the signal plus noise exceeds the threshold, the system responds momentarily, then relaxes to equilibrium to await the next triggering event)(4-6). Here we introduce a class of non-dynamical and threshold-free systems that also exhibit stochastic resonance. We present and analyse a general mathematical model for such systems, in which a sequence of pulses is generated randomly with a probability (per unit time) that depends exponentially on an input. When this input is a sine-wave masked by additive noise, we observe an increase in the output signal-to-noise ratio as the level of noise increases. This result shows that stochastic resonance can occur in a broad class of thermally driven physico-chemical systems, such as semiconductor p-n junctions, mesoscopic electronic devices and voltage-dependent ion channels(7), in which reaction rates are controlled by activation barriers.	ST PETERSBURG NUCL PHYS INST, GATCHINA 188530, RUSSIA; OFF NAVAL RES EUROPE, LONDON NW1 5TH, ENGLAND; UCL, LONDON, ENGLAND	National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; University of London; University College London	Bezrukov, SM (corresponding author), NIH, DIV COMP RES & TECHNOL, BETHESDA, MD USA.							BENEDICT RR, 1976, ELECT SCI ENG, P80; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BEZRUKOV SM, 1995, NATURE, V378, P362, DOI 10.1038/378362a0; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; COX DR, 1955, J ROY STAT SOC B, V17, P129; COX DR, 1996, STAT ANAL SERIES EVE, P28; GINGL Z, 1995, EUROPHYS LETT, V29, P191, DOI 10.1209/0295-5075/29/3/001; Glasstone S., 1941, THEORY RATE PROCESSE, P1; HILLE B, 1992, IONIC CHANNELS EXCIT, P47; JUNG P, 1995, PHYS LETT A, V207, P93, DOI 10.1016/0375-9601(95)00636-H; LECAR H, 1971, BIOPHYS J, V11, P1048, DOI 10.1016/S0006-3495(71)86277-X; MOSS F, 1994, INT J BIFURCAT CHAOS, V4, P1383, DOI 10.1142/S0218127494001118; NYE JF, 1976, PHYSICAL PROPERTIES, P236; REZNIKOV M, 1995, PHYS REV LETT, V75, P3340, DOI 10.1103/PhysRevLett.75.3340; Rice SO, 1954, SELECTED PAPERS NOIS, P133; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0	17	214	219	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					319	321		10.1038/385319a0	http://dx.doi.org/10.1038/385319a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002515				2022-12-28	WOS:A1997WD91400043
J	Dixon, J; Harrison, A				Dixon, J; Harrison, A			Funding the NHS .3. A little local difficulty?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								The media have been full of reports of crisis in the NHS. Although national analyses suggest that the NHS should be able to cope within the increases in spending it has been given, local pressures can leave parts of the service struggling. Firstly, the change to allocation of funds on the basis of population needs has meant that some authorities and trusts have had effective cuts in their budgets, requiring them to trim services. Secondly, the government's insistence on an annual 3% increase in efficiency may have resulted in authorities taking short term measures that actually decrease efficiency in the long term. Thirdly, health authorities have had to bear the costs of national targets such as reducing waiting lists and junior doctors' hours as well as local problems such as higher numbers of mentally disordered offenders. However, all these factors can be controlled by national or local management and so their impact is not inevitable.			Dixon, J (corresponding author), KINGS FUND INST, POLICY INST, LONDON W1M 0AN, ENGLAND.							ADAMS CBT, 1995, BRIT MED J, V311, P1559, DOI 10.1136/bmj.311.7019.1559; [Anonymous], 1995, BRIT MED J, V310, P1045; APPLEBY J, 1996, MEASURE EFFECTIVENES; Dawson D, 1996, BRIT MED J, V313, P312, DOI 10.1136/bmj.313.7053.312; Dixon J, 1996, BRIT MED J, V312, P1432, DOI 10.1136/bmj.312.7044.1432; EDWARDS N, 1996, HLTH SERVICE J  0502, P24; Ham C, 1988, HLTH CARE VARIATIONS; Harrison A, 1997, BRIT MED J, V314, P139, DOI 10.1136/bmj.314.7074.139; *HC HLTH COMM, 1996, PUBL EXP HLTH SOC SE, V1; HILL RC, 1994, FORMULA DISTRIBUTING; *I FISC STUD, 1995, OPT 1996 GREEN BUDG; MILLS H, 1996, OBSERVER        0922, P5; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT	13	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					216	219		10.1136/bmj.314.7075.216a	http://dx.doi.org/10.1136/bmj.314.7075.216a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022445	Green Published			2022-12-28	WOS:A1997WD91100042
J	Till, SH; Grundman, MJ				Till, SH; Grundman, MJ			Lesson of the week - Prevalence of concomitant disease in patients with iron deficiency anaemia	BRITISH MEDICAL JOURNAL			English	Article							GASTROINTESTINAL-TRACT; COLONIC NEOPLASMS; BARIUM ENEMA; ANEMIA; COLONOSCOPY				Till, SH (corresponding author), CHESTERFIELD & N DERBYSHIRE ROYAL HOSP,DEPT GASTROENTEROL,CHESTERFIELD S44 5BL,DERBY,ENGLAND.							ALDRIDGE MC, 1986, LANCET, V2, P833; COOK IJ, 1986, BRIT MED J, V292, P1380, DOI 10.1136/bmj.292.6532.1380; DODD GD, 1992, CANCER-AM CANCER SOC, V70, P1272, DOI 10.1002/1097-0142(19920901)70:3+<1272::AID-CNCR2820701513>3.0.CO;2-Q; FAGAN PA, 1969, MED J AUSTRALIA, V1, P276, DOI 10.5694/j.1326-5377.1969.tb92124.x; GORDON SR, 1994, AM J GASTROENTEROL, V89, P1963; IRVINE EJ, 1988, GUT, V29, P1188, DOI 10.1136/gut.29.9.1188; KEPCZYK MT, 1995, DIGEST DIS SCI, V40, P1283, DOI 10.1007/BF02065539; LINDSAY DC, 1988, BRIT MED J, V296, P167, DOI 10.1136/bmj.296.6616.167; LUCUS CA, 1996, J R COLL PHYSICIANS, V30, P33; MCINTYRE AS, 1993, GUT, V34, P1102, DOI 10.1136/gut.34.8.1102; *OFF POP CENS SURV, 1988, SER MBI, V16; OREILLY D, 1987, POSTGRAD MED J, V63, P215, DOI 10.1136/pgmj.63.737.215; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; SAHAY R, 1993, GUT, V34, P1427, DOI 10.1136/gut.34.10.1427; SAYER JM, 1993, GUT, V34, P1297, DOI 10.1136/gut.34.10.1297; STEBBING JF, 1995, ANN ROY COLL SURG, V77, P21	16	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					206	208		10.1136/bmj.314.7075.206	http://dx.doi.org/10.1136/bmj.314.7075.206			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022441	Green Published			2022-12-28	WOS:A1997WD91100037
J	Carlson, ES				Carlson, ES			Sexual assault on men in war	LANCET			English	Editorial Material											Carlson, ES (corresponding author), PHYS HUMAN RIGHTS,INT CRIMINAL TRIBUNAL FORMER YUGOSLAVIA,CHURCHILLPLEIN 1,NL-2517 JW THE HAGUE,NETHERLANDS.							AGGER I, 1994, ERA TWILIGHT PSYCHOC, P46; CASEY C, 1993, POLICE REV      0129, P17; LINDHOLM J, 1980, DAN MED B, V27, P243; *MED CTR HUM RIGHT, 1995, CHAR SEX AB MEN WAR; SLOAN I, 1992, RAPE, P7; VANTIENHOVEN H, 1993, TORTURE, V3, P7	6	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					129	129		10.1016/S0140-6736(96)10013-1	http://dx.doi.org/10.1016/S0140-6736(96)10013-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996436				2022-12-28	WOS:A1997WB80000048
J	Pretre, R; Chilcott, M				Pretre, R; Chilcott, M			Blunt trauma to the heart and great vessels	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MYOCARDIAL CONTUSION; THORACIC AORTA; CHEST TRAUMA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; 15-YEAR EXPERIENCE; ARTERIAL INJURIES; RUPTURE; MANAGEMENT; DIAGNOSIS; CT		HOP UNIV GENEVE, DEPT CHIRURG, GENEVA, SWITZERLAND	University of Geneva								BAUMGARTEL ED, 1992, ARCH SURG-CHICAGO, V127, P347; BAXTER BT, 1989, AM J SURG, V158, P557, DOI 10.1016/0002-9610(89)90192-X; BIFFL WL, 1994, AM J SURG, V168, P523, DOI 10.1016/S0002-9610(05)80115-1; BULOCK FA, 1994, EUR HEART J, V15, P1621, DOI 10.1093/oxfordjournals.eurheartj.a060444; CACHECHO R, 1992, J TRAUMA, V33, P68, DOI 10.1097/00005373-199207000-00014; CASTAGNA J, 1975, J THORAC CARDIOV SUR, V69, P521; CATOIRE P, 1995, J TRAUMA, V38, P96, DOI 10.1097/00005373-199501000-00025; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; COWLEY RA, 1990, J THORAC CARDIOV SUR, V100, P652; DUBROW TJ, 1989, SURGERY, V106, P267; DUHAYLONGSOD FG, 1992, J VASC SURG, V15, P331, DOI 10.1016/0741-5214(92)90255-7; EDDY AC, 1990, ARCH SURG-CHICAGO, V125, P1351; FRYKBERG ER, 1991, SURGERY, V109, P85; FULDA G, 1991, J TRAUMA, V31, P167, DOI 10.1097/00005373-199131020-00003; GALAN G, 1992, EUR J CARDIO-THORAC, V6, P284, DOI 10.1016/1010-7940(92)90143-L; GAVANT ML, 1995, RADIOLOGY, V197, P125, DOI 10.1148/radiology.197.1.7568809; GEORGE SM, 1991, WORLD J SURG, V15, P134, DOI 10.1007/BF01658986; JOHNSON SF, 1991, J TRAUMA, V31, P1546, DOI 10.1097/00005373-199111000-00016; KARALIS DG, 1994, J TRAUMA, V36, P53, DOI 10.1097/00005373-199401000-00008; KATO K, 1994, J TRAUMA, V36, P859, DOI 10.1097/00005373-199406000-00017; KIPFER B, 1994, EUR J CARDIO-THORAC, V8, P30, DOI 10.1016/1010-7940(94)90129-5; KRAM HB, 1987, J VASC SURG, V6, P168, DOI 10.1067/mva.1987.avs0060168; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; MATTOX KL, 1992, J TRAUMA, V33, P649; MATTOX KL, 1989, SURG CLIN N AM, V69, P77; MILLER FB, 1989, SURGERY, V106, P596; NEIMAN J, 1992, AM HEART J, V123, P1694, DOI 10.1016/0002-8703(92)90827-I; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; PARMLEY LF, 1958, CIRCULATION, V18, P371, DOI 10.1161/01.CIR.18.3.371; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; POTKIN RT, 1982, CIRCULATION, V66, P627, DOI 10.1161/01.CIR.66.3.627; PRETRE R, 1993, ANN THORAC SURG, V56, P1426, DOI 10.1016/0003-4975(93)90708-P; Pretre R, 1996, SURGERY, V119, P603, DOI 10.1016/S0039-6060(96)80183-8; RAPTOPOULOS V, 1992, RADIOLOGY, V182, P667, DOI 10.1148/radiology.182.3.1535879; RICHARDSON JD, 1990, ANN SURG, V211, P731, DOI 10.1097/00000658-199006000-00012; ROSENBERG JM, 1989, ANN THORAC SURG, V48, P508, DOI 10.1016/S0003-4975(10)66851-8; SANTAVIRTA S, 1992, J TRAUMA, V32, P275, DOI 10.1097/00005373-199203000-00001; SHAMMAS NW, 1992, CRIT CARE MED, V20, P1064, DOI 10.1097/00003246-199207000-00028; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; SMITH DC, 1995, NEW ENGL J MED, V333, P457; SMITH MD, 1995, NEW ENGL J MED, V332, P356, DOI 10.1056/NEJM199502093320603; STURM JT, 1990, AM J EMERG MED, V8, P92, DOI 10.1016/0735-6757(90)90191-2; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; VANSON JAM, 1994, J THORAC CARDIOV SUR, V108, P893, DOI 10.1016/S0022-5223(94)70188-1; VANWAY CW, 1989, SURG CLIN N AM, V69, P143; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; WILLIAMS JS, 1994, ANN THORAC SURG, V57, P726, DOI 10.1016/0003-4975(94)90576-2; WOODRING J H, 1990, Journal of Emergency Medicine, V8, P467; ZEIGER MA, 1990, J CARDIOVASC SURG, V31, P607	49	204	218	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					626	632		10.1056/NEJM199702273360906	http://dx.doi.org/10.1056/NEJM199702273360906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032049				2022-12-28	WOS:A1997WK02800006
J	Cane, MA; Clement, AC; Kaplan, A; Kushnir, Y; Pozdnyakov, D; Seager, R; Zebiak, SE; Murtugudde, R				Cane, MA; Clement, AC; Kaplan, A; Kushnir, Y; Pozdnyakov, D; Seager, R; Zebiak, SE; Murtugudde, R			Twentieth-century sea surface temperature trends	SCIENCE			English	Article							OCEAN-ATMOSPHERE INTERACTION; NINO-SOUTHERN OSCILLATION; SULFATE AEROSOLS; EL-NINO; TROPICAL CLIMATOLOGY; GREENHOUSE GASES; PACIFIC; MODEL; SIMULATION; CO2	An analysis of historical sea surface temperatures provides evidence for global warming since 1900, in line with land-based analyses of global temperature trends, and also shows that over the same period, the eastern equatorial Pacific cooled and the zonal sea surface temperature gradient strengthened. Recent theoretical studies have predicted such a pattern as a response of the coupled ocean-atmosphere system to an exogenous heating of the tropical atmosphere. This pattern, however, is not reproduced by the complex ocean-atmosphere circulation models currently used to simulate the climatic response to increased greenhouse gases. Its presence is likely to lessen the mean 20th-century global temperature change in model simulations.	NASA, GODDARD SPACE FLIGHT CTR, LAB HYDROSPHER PROC, UNIV SPACE RES ASSOC, GREENBELT, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Universities Space Research Association (USRA)	Cane, MA (corresponding author), LAMONT DOHERTY EARTH OBSERV, PALISADES, NY 10964 USA.		Kushnir, Yochanan/B-4472-2013; Cane, Mark/I-8086-2012; , Nobody/M-9571-2019	Seager, Richard/0000-0003-4772-9707; Cane, Mark/0000-0001-5408-2388				BJERKNES J, 1969, MON WEATHER REV, V97, P163, DOI 10.1175/1520-0493(1969)097<0163:ATFTEP>2.3.CO;2; Bottomley M, 1990, GLOBAL OCEAN SURFACE; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; Clement AC, 1996, J CLIMATE, V9, P2190, DOI 10.1175/1520-0442(1996)009<2190:AODT>2.0.CO;2; DIJKSTRA HA, 1995, J CLIMATE, V8, P1343, DOI 10.1175/1520-0442(1995)008<1343:OAIATT>2.0.CO;2; FOLLAND CK, 1995, Q J ROY METEOR SOC, V121, P319, DOI 10.1002/qj.49712152206; FU R, 1992, NATURE, V358, P394, DOI 10.1038/358394a0; Gilbert R. O., 1987, STAT METHODS ENV POL; HANSEN J, 1995, ATMOS RES, V37, P175, DOI 10.1016/0169-8095(94)00077-Q; HARTMANN DL, 1993, J CLIMATE, V6, P2049, DOI 10.1175/1520-0442(1993)006<2049:LSEOTR>2.0.CO;2; JONES A, 1994, NATURE, V370, P450, DOI 10.1038/370450a0; KAPLAN AE, UNPUB; Karl TR, 1995, DAHL WS ENV, V17, P363; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; KNUTSON TR, 1995, J CLIMATE, V8, P2181, DOI 10.1175/1520-0442(1995)008<2181:TMROTT>2.0.CO;2; LATIF M, UNPUB; LAU NC, 1992, J CLIMATE, V5, P284, DOI 10.1175/1520-0442(1992)005<0284:SOELPW>2.0.CO;2; LAU NC, IN PRESS B AM METEOR; LIU Z, 1994, J PHYS OCEANOGR, V24, P1606; Manabe S, 1996, J CLIMATE, V9, P376, DOI 10.1175/1520-0442(1996)009<0376:LFVOSA>2.0.CO;2; MCCREARY JP, 1994, J PHYS OCEANOGR, V24, P466; Meehl GA, 1996, NATURE, V382, P56, DOI 10.1038/382056a0; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; NEELIN JD, 1992, CLIM DYNAM, V7, P73, DOI 10.1007/BF00209610; NEELIN JD, 1995, J CLIMATE, V8, P1325, DOI 10.1175/1520-0442(1995)008<1325:OAIATT>2.0.CO;2; Nicholls, 1991, TELECONNECTIONS LINK, P345; PARKER DE, 1996, NATURAL CLIMATE VARI, P244; PIERREHUMBERT RT, 1995, J ATMOS SCI, V52, P1784, DOI 10.1175/1520-0469(1995)052<1784:TRFATL>2.0.CO;2; RAJAGOPALAN B, UNPUB; RAMANATHAN V, 1991, NATURE, V351, P27, DOI 10.1038/351027a0; SCHNEIDER EK, IN PRESS J CLIM; SEAGER R, IN PRESS J CLIM; Sun DZ, 1996, SCIENCE, V272, P1148, DOI 10.1126/science.272.5265.1148; TETT S, 1995, J CLIMATE, V8, P1473, DOI 10.1175/1520-0442(1995)008<1473:SOENSO>2.0.CO;2; TOGGWEILER JR, 1991, J GEOPHYS RES-OCEANS, V96, P20467, DOI 10.1029/91JC02063; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P521; ZEBIAK SE, 1987, MON WEATHER REV, V115, P2262, DOI 10.1175/1520-0493(1987)115<2262:AMENO>2.0.CO;2; [No title captured]	39	390	406	4	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					957	960		10.1126/science.275.5302.957	http://dx.doi.org/10.1126/science.275.5302.957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020074				2022-12-28	WOS:A1997WH38800039
J	Cooper, PK; Nouspikel, T; Clarkson, SG; Leadon, SA				Cooper, PK; Nouspikel, T; Clarkson, SG; Leadon, SA			RETRACTED: Defective transcription-coupled repair of oxidative base damage in Cockayne syndrome patients from XP group G (Retracted Article. See vol 308, pg 1740, 2005)	SCIENCE			English	Article; Retracted Publication							PIGMENTOSUM GROUP-G; NUCLEOTIDE EXCISION-REPAIR; COMPLEMENTATION GROUP-G; RNA-POLYMERASE-II; DNA-REPAIR; IONIZING-RADIATION; PREFERENTIAL REPAIR; THYMINE GLYCOLS; ACTIVE GENES; YEAST RAD2	In normal human cells, damage due to ultraviolet light is preferentially removed from active genes by nucleotide excision repair (NER) in a transcription-coupled repair (TCR) process that requires the gene products defective in Cockayne syndrome (CS). Oxidative damage, including thymine glycols, is shown to be removed by TCR in cells from normal individuals and from xeroderma pigmentosum (XP)-A, XP-F, and XP-G patients who have NER defects but not from XP-G patients who have severe CS. Thus, TCR of oxidative damage requires an XPG function distinct from its NER endonuclease activity. These results raise the possibility that defective TCR of oxidative damage contributes to the developmental defects associated with CS.	UNIV GENEVA, MED CTR, DEPT GENET & MICROBIOL, CH-1211 GENEVA 4, SWITZERLAND; UNIV N CAROLINA, SCH MED, DEPT RADIAT ONCOL, CHAPEL HILL, NC 27599 USA	University of Geneva; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cooper, PK (corresponding author), UNIV CALIF BERKELEY, LAWRENCE BERKELEY NATL LAB, DIV LIFE SCI, BLDG 934, 1 CYCLOTRON RD, BERKELEY, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA063503, R01CA040453] Funding Source: NIH RePORTER; NCI NIH HHS [CA63503, CA40453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brookman KW, 1996, MOL CELL BIOL, V16, P6553; CHEN DS, 1994, ANN NY ACAD SCI, V726, P306, DOI 10.1111/j.1749-6632.1994.tb52834.x; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; Hamel BCK, 1996, J MED GENET, V33, P607, DOI 10.1136/jmg.33.7.607; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JAEKEN J, 1989, HUM GENET, V83, P339; KOW YW, 1990, MUTAT RES, V235, P147, DOI 10.1016/0921-8777(90)90068-G; LASPIA MF, 1988, J BACTERIOL, V170, P3359, DOI 10.1128/jb.170.8.3359-3366.1988; LEADON SA, 1995, MUTAT RES-DNA REPAIR, V337, P169, DOI 10.1016/0921-8777(95)00021-B; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEADON SA, 1988, DNA REPAIR LABORATOR, V3, P311; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; NOUSPIKEL T, IN PRESS P NATL ACAD; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VERMEULEN W, 1993, AM J HUM GENET, V53, P185; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	46	272	273	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					990	993		10.1126/science.275.5302.990	http://dx.doi.org/10.1126/science.275.5302.990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020084				2022-12-28	WOS:A1997WH38800049
J	Slome, LR; Mitchell, TF; Charlebois, E; Benevedes, JM; Abrams, DI				Slome, LR; Mitchell, TF; Charlebois, E; Benevedes, JM; Abrams, DI			Physician-assisted suicide and patients with human immunodeficiency virus disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS; EUTHANASIA; ATTITUDES; LIFE	Background Data are limited on the attitudes and practices of physicians regarding assisting the suicide of patients with human immunodeficiency virus (HIV) disease. Methods Between November 1994 and January 1995, we used an anonymous, self-administered questionnaire to survey all 228 physicians in the Community Consortium, an association of providers of health care to patients infected with HIV in the San Francisco Bay area. The responses were compared with those in a 1990 survey of consortium physicians. Physician-assisted suicide was defined as ''a physician providing a sufficient dose of narcotics to enable a patient to kill himself.'' Respondents were to ''assume that the patient is a mentally competent, severely ill individual facing imminent death.'' Results One hundred eighteen of the questionnaires were evaluated. Respondents reported a mean of 7.9 ''direct'' and 13.7 ''indirect'' requests from patients for assistance. In responses based on a case vignette, 48 percent of the physicians said they would be likely or very likely to grant the request of a patient with the acquired immunodeficiency syndrome (AIDS) for assistance in a suicide, as compared with 28 percent of the respondents in 1990. Asked to estimate the number of times they had granted the request of a patient with AIDS for assistance in committing suicide, 53 percent said they had done so at least once (mean number of times, 4.2; median, 1.0; range, 0 to 100). In a multivariate analysis, factors positively associated with a physician's having, in fact, assisted a suicide were having had a higher number of patients with AIDS who had died; having received a higher number of indirect requests from patients for assistance; having a stated gay, lesbian, or bisexual orientation him- or herself; and having a higher ''intention to assist'' score (as calculated from the physician's responses to the case vignette). Conclusions Within a group of physicians caring for patients with HIV disease, the acceptance of assisted suicide increased between 1990 and 1995. A majority of respondents in 1995 said they had granted a request for assisted suicide from a patient with AIDS at least once. (C) 1997, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,COMMUNITY CONSORTIUM,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco								Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Bindels PJE, 1996, LANCET, V347, P499, DOI 10.1016/S0140-6736(96)91138-1; Bruni Frank, 1996, N Y Times Web, pB5; CONOVER W. J, 1980, PRACTICAL NONPARAMET; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; GOLDBLUM P, 1989, FACE FACE GUIDE AIDS, P152; HOLDING R, 1976, SAN FRANCISCO C 0307, pA1; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; NELSON B, 1996, HARPERS          MAR, P35; RUSSELL S, 1995, SAN FRANCISCO C 0329; SLOME L, 1992, J ACQ IMMUN DEF SYND, V5, P712; Solomon A., 1995, NEW YORKER      0522, pa154; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L	17	57	57	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					417	421		10.1056/NEJM199702063360606	http://dx.doi.org/10.1056/NEJM199702063360606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010149				2022-12-28	WOS:A1997WF85900006
J	Gostin, LO; Arno, PS; Brandt, AM				Gostin, LO; Arno, PS; Brandt, AM			FDA regulation of tobacco advertising and youth smoking - Historical, social, and constitutional perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE; CHILDREN; ADOLESCENTS; RECOGNITION	Perspectives on tobacco control in American society have shifted markedly. As the view that smoking as a voluntarily assumed health risk has declined, the social and political environment has become more conducive to industry regulation. This transformation can be traced to the mounting evidence of the health risks of secondary smoke; the addictive quality of nicotine; the vulnerability and exploitation of young people; and industry knowledge of the harmful effects of tobacco. Regulation of tobacco advertising and promotions by the Food and Drug Administration (FDA) raises serious concerns about constitutional protection for commercial speech. However, the minimal informational value of tobacco advertising suggests that it should be afforded a low level of constitutional protection. The FDA regulations impose reasonable ''time, place, and manner'' restrictions, leave open alternative channels of communication, restrict messages that are harmful to the public health, do not restrict political speech, prevent misleading messages, and help deter the unlawful sale of tobacco products to miners. The regulations meet the traditional criteria for regulating commercial speech, in that the government's asserted interest is strong, the agency's regulations directly advance that interest, and the regulations are no more extensive than necessary. Thus, the judiciary should defend the FDA's historical social and legislative mission to protect the public health.	GEORGETOWN JOHNS HOPKINS UNIV,PROGRAM LAW & PUBL HLTH,WASHINGTON,DC; GEORGETOWN JOHNS HOPKINS UNIV,PROGRAM LAW & PUBL HLTH,BALTIMORE,MD; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School								Arno PS, 1996, JAMA-J AM MED ASSOC, V275, P1258, DOI 10.1001/jama.275.16.1258; BADGER M, 1980, PROPSERITY ROAD NEW; BEAUCHAMP DE, 1988, HLTH REPUBLIC EPIDEM; BLASI V, 1986, JAMA-J AM MED ASSOC, V256, P502, DOI 10.1001/jama.256.4.502; BLUM A, 1991, NEW ENGL J MED, V324, P913, DOI 10.1056/NEJM199103283241310; BRANDT AM, 1990, DAEDALUS-US, V119, P155; CHAPMAN S, 1989, BRIT J ADDICT, V84, P1267; Chapman S, 1996, BRIT MED BULL, V52, P121, DOI 10.1093/oxfordjournals.bmb.a011520; COYTAUS R, 1995, TOB CONTROL, V4, P253; *CTR DIS CONTR PRE, 1994, MMWR-MORBID MORTAL W, V434, P469; *CTR DIS CONTR PRE, 1996, CDC OFF SMOK HLTH PU; *CTR DIS CONTR PRE, 1993, MORBIDITY MORTALITY, V42, P645; *CTR DIS CONTR PRE, 1994, MMWR-MORBID MORTAL W, V43, P577; *CTR DIS CONTR PRE, 1994, MMWR-MORBID MORTAL W, V43, P925; *CTR DIS CONTR PRE, 1996, MMWR-MORBID MORTAL W, V45, P413; CUMMINGS KM, 1992, MMOWR MORB MORTAL WK, V41, P169; CUMMINGS KM, 1992, MMWR-MORBID MORTAL W, V41, P179; DAVIS RM, 1990, JAMA-J AM MED ASSOC, V263, P2208; DiFranza Joseph R., 1995, TOB CONTROL, V367, P367; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P8149; DUBOW JS, 1992, FOOD BEVER MARKE FEB, V11, P13; ECOBICHON DJ, 1990, P INT MCG U LEX MASS; EVANS N, 1995, J NATL CANCER I, V87, P1538, DOI 10.1093/jnci/87.20.1538; *FED TRAD COMM, 1979, REP C PURS PUBL HLTH; FISCHER PM, 1989, JAMA-J AM MED ASSOC, V261, P84, DOI 10.1001/jama.261.1.84; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; *FOOD DRUG ADM, 1996, NIC CIG SMOK TOB IS; FRITSCHLER AL, 1989, SMOKING POLITICS POL; GEROGE H, 1992, TEENAGE ATTITUDES BE; Glantz S.A., 1996, CIGARETTE PAPERS; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Gold DR, 1996, NEW ENGL J MED, V335, P931, DOI 10.1056/NEJM199609263351304; HENKE LL, 1994, P 1994 AM AC ADV ATH; HILTS PJ, 1996, SMOKESCREEN TRUTH TO; *I MED, 1994, GROW TOB FREE PREV N; JACOBSON PD, 1993, J HEALTH POLIT POLIC, V18, P787; Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; *KWECH MARK RES, 1982, PROJ PLUS MIN 3 CRY; LAW SA, 1992, IOWA LAW REV, V77, P909; LEDWITH F, 1984, HLTH ED Q, V10, P85; LEVIN G, 1992, ADVIERTISING AGE, V68, P12; Lynch BS., 1994, GROWING TOBACCO FREE; MEIER KS, 1991, HEALTH EDUC QUART, V18, P173, DOI 10.1177/109019819101800203; Meiklejohn Alexander, 1948, FREE SPEECH ITS RELA; MEYERS ML, 1981, FEDERAL TRADE COMMIS; MIZERSKI R, 1995, J MARKETING, V59, P58, DOI 10.2307/1252328; National Research Council Committee on Passive Smoking, 1986, ENV TOB SMOK MEAS EX; NELSON DE, 1995, AM J PUBLIC HEALTH, V85, P34, DOI 10.2105/AJPH.85.1.34; Neuberger MB, 1963, SMOKE SCREEN TOBACCO; PARKERPOPE T, 1996, WALL STREET J   1009, pB1; PETO R, 1994, MORTALITY SMOKING; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; Pollay RW, 1996, J MARKETING, V60, P1, DOI 10.2307/1251927; POLLAY RW, 1995, J MARKETING THEORY P, V3, P1, DOI DOI 10.1080/10696679.1995.11501675; RIGOTTI NA, 1991, JAMA-J AM MED ASSOC, V266, P3162; *RJ REYN TOB CO, 1984, TIME MAGAZINE   0409, P91; *ROSW PARK CANC I, 1993, SURV ALC TOB DRUG US; SCHWARTZ J, 1995, WASHINGTON POST 1115, pA2; Slade J, 1995, TOBACCO AND HEALTH, P925; TAIOLI E, 1991, NEW ENGL J MED, V325, P968; THOMPSON EL, 1978, AM J PUBLIC HEALTH, V68, P250, DOI 10.2105/AJPH.68.3.250; Tye J B, 1987, J Public Health Policy, V8, P492, DOI 10.2307/3342275; *US DEP HHS, 1989, CDC US DEP HHS PUBL; *US DEP HHS, 1994, PREV TOB US YOUNG PE; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; US Department of Health and Human Services, 1986, HLTH CONS INV SMOK R; *US DHEW, 1964, US PHS PUBL, V1103; Warner K E, 1986, Circulation, V73, p381A; Zieve AM, 1996, PUBLIC HEALTH REP, V111, P280; ZIEVE AM, 1996, COMMENTS PUBLIC CITI	72	30	30	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					410	418						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE771	9010174				2022-12-28	WOS:A1997WE77100032
J	Kuttner, R				Kuttner, R			Physician-operated networks and the new antitrust guidelines	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGED COMPETITION				Kuttner, R (corresponding author), AMER PROSPECT,6 UNIV RD,CAMBRIDGE,MA 02138, USA.							ARROW KJ, 1963, AM ECON REV, V53, P941; COSTILO LB, 1985, NEW ENGL J MED, V313, P901, DOI 10.1056/NEJM198510033131430; *FAM USA, 1996, HMO CONS RISK STAT R; GREANEY TL, 1994, CORNELL LAW REV, V79, P1507; Havighurst Clark C., 1996, LOY CONSUMER L REP, V8, P78; IGLEHART JK, 1993, NEW ENGL J MED, V328, P1208, DOI 10.1056/NEJM199304223281627; *IL DEP INS, 1996, PROV BAS MARK SYST R; *NAT ASS INS COMM, 1995, BULL; *NC ATT GEN, 1996, ADV OP DURH COUNT HO; *OFF GEN COUNS, 1996, ANT REF, P1; RODWIN MA, 1993, MED MONEY MORALS, P19; STARR P, 1994, LOGIC HLTH CARE REFO; STONE D, IN RESS J HLTH POLIT; 1996, NY TIMES        1225, pA1	14	17	17	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					386	391		10.1056/NEJM199701303360522	http://dx.doi.org/10.1056/NEJM199701303360522			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011808				2022-12-28	WOS:A1997WG23300032
J	Berendes, E; Walter, M; Cullen, P; Prien, T; VanAken, H; Horsthemke, J; Schulte, M; vonWild, K; Scherer, R				Berendes, E; Walter, M; Cullen, P; Prien, T; VanAken, H; Horsthemke, J; Schulte, M; vonWild, K; Scherer, R			Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage	LANCET			English	Article							ANTIDIURETIC-HORMONE; INAPPROPRIATE SECRETION; HYPONATREMIA; HEMORRHAGE; PLASMA	Background Subarachnoid haemorrhage is commonly associated with natriuresis and hyponatraemia. One possible explanation for these features is a defect in the central regulation of renal sodium reabsorption with increased secretion of a natriuretic factor. We investigated whether excess sodium secretion in patients with subarachnoid haemorrhage is related to increased secretion of natriuretic peptides or to the presence of digoxin-like immunoreactive substances. Methods We measured the plasma concentrations of digoxin-like immunoreactive substances (by a fluorescence polarisation immunoassay) and natriuretic peptides, aldosterone, renin, and antidiuretic hormone (by radioimmunoassay) in ten patients with aneurysmal subarachnoid haemorrhage, ten patients undergoing elective craniotomy for cerebral tumours, and 40 healthy controls of similar age and sex distribution. Samples were collected before surgery, 1 h, 4 h, and 12 h after surgery, then daily until 7 days postoperatively in the two groups of patients. Findings All patients with subarachnoid haemorrhage, but none of the tumour patients, showed increased urine output and urinary excretion of sodium (p=0.018 for comparison of means of curves to 7 days). The patients with subarachnoid haemorrhage had much higher plasma concentrations of brain natriuretic peptide (BNP) than controls, on admission (mean 15.1 [SE 3.8] vs 1.6 [1.0] pmol/L, p<0.001) and throughout the study period, accompanied by lower than normal aldosterone concentrations and normal plasma concentrations of atrial and C-type natriuretic peptides (ANP, CNP). The patients with tumours had similar plasma concentrations of ANP, BNP, and CNP to the controls. We did not detect digoxin-like immunoreactive substances in either group of patients. Interpretation Salt-wasting of central origin may induce hyponatraemia in patients with aneurysmal subarachnoid haemorrhage, possibly as a result of increased secretion of BNP with subsequent suppression of aldosterone synthesis.	UNIV MUNSTER,CLEMENSHOSP,KLIN & POLIKLIN ANASTHESIOL & OPERAT INTENS MED,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,INST KLIN CHEM & LAB MED,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,INST ARTERIOSKLEROSEFORSCH,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,NEUROCHIRURG KLIN,D-4400 MUNSTER,GERMANY; UNIV MUNSTER,CLEMENSHOSP,KLIN ANASTHESIOL & OPERAT INTENS MED,D-4400 MUNSTER,GERMANY	University of Munster; University of Munster; University of Munster; University of Munster; University of Munster			Lascola, Christopher D/B-9126-2017	Lascola, Christopher D/0000-0002-8031-782X				AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; BARTTER FC, 1967, AM J MED, V42, P790, DOI 10.1016/0002-9343(67)90096-4; CORT JH, 1954, LANCET, V1, P752; DIRINGER M, 1988, STROKE, V19, P1119, DOI 10.1161/01.STR.19.9.1119; ESPINER EA, 1994, J INTERN MED, V235, P527, DOI 10.1111/j.1365-2796.1994.tb01261.x; GRUBER KA, 1980, NATURE, V287, P743, DOI 10.1038/287743a0; HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118; IIMURA O, 1993, AM HEART J, V125, P635, DOI 10.1016/0002-8703(93)90215-U; ISOTANI E, 1994, STROKE, V25, P2198, DOI 10.1161/01.STR.25.11.2198; JUUL R, 1990, ACTA NEUROCHIR, V106, P18, DOI 10.1007/BF01809328; KROLL M, 1992, J INTERN MED, V232, P291; LANDOLT AM, 1984, J NEUROSURG, V37, P210; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; OELKERS W, 1989, NEW ENGL J MED, V321, P492, DOI 10.1056/NEJM198908243210802; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; RAINE AEG, 1986, NEW ENGL J MED, V315, P533, DOI 10.1056/NEJM198608283150901; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; SHAMISS A, 1993, EUR J PHARMACOL, V233, P113, DOI 10.1016/0014-2999(93)90356-M; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; TAKAHASHI K, 1992, PEPTIDES, V13, P121, DOI 10.1016/0196-9781(92)90149-W; WIJDICKS EFM, 1991, STROKE, V22, P1519, DOI 10.1161/01.STR.22.12.1519; YAMAKI T, 1992, ACTA NEUROCHIR, V115, P156, DOI 10.1007/BF01406376	22	268	282	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					245	249		10.1016/S0140-6736(96)08093-2	http://dx.doi.org/10.1016/S0140-6736(96)08093-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014912				2022-12-28	WOS:A1997WD90600012
J	Stewart, M				Stewart, M			Will glycosylated haemoglobin replace the oral glucose-tolerance test?	LANCET			English	Editorial Material											Stewart, M (corresponding author), MED SCH NEWCASTLE UPON TYNE, HUMAN DIABET & METAB RES CTR, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND.							[Anonymous], 1995, DIABETES, V44, P968; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; *WHO, 1985, TECH REP SER WHO, V727	5	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					223	224		10.1016/S0140-6736(05)64858-1	http://dx.doi.org/10.1016/S0140-6736(05)64858-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014906				2022-12-28	WOS:A1997WD90600006
J	Cool, DR; Normant, E; Shen, FS; Chen, HC; Pannell, L; Zhang, Y; Loh, YP				Cool, DR; Normant, E; Shen, FS; Chen, HC; Pannell, L; Zhang, Y; Loh, YP			Carboxypeptidase E is a regulated secretory pathway sorting receptor: Genetic obliteration leads to endocrine disorders in Cpe(fat) mice	CELL			English	Article							TRANS-GOLGI NETWORK; PITUITARY INTERMEDIATE LOBE; OPIOMELANOCORTIN CONVERTING ENZYME; PRO-OPIOMELANOCORTIN; SECRETOGRANIN-II; DISULFIDE BOND; CHROMOGRANIN-B; PH; PROOPIOMELANOCORTIN; CELLS	A proposed mechanism for sorting secretory proteins into granules for release via the regulated secretory pathway in endocrine-neuroendocrine cells involves binding the proteins to a sorting receptor at the transGolgi network, followed by budding and granule formation. We have identified such a sorting receptor as membrane-associated carboxypeptidase E (CPE) in pituitary Golgi-enriched and secretory granule membranes. CPE specifically bound regulated secretory pathway proteins, including prohormones, but not constitutively secreted proteins. We show that in the Cpe(fat) mutant mouse lacking CPE, the pituitary prohormone, pro-opiomelanocortin, was missorted to the constitutive pathway and secreted in an unregulated manner. Thus, obliteration of CPE, the sorting receptor, leads to multiple endocrine disorders in these genetically defective mice, including hyperproinsulinemia and infertility.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,NIH,BETHESDA,MD 20892; NIDDKD,ANALYT CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cool, DR (corresponding author), NICHHD,CELLULAR NEUROBIOL SECT,NIH,BETHESDA,MD 20892, USA.							BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BIRCH NP, 1989, PROTEOLYTIC ENZYMES, P211; BRENNAN SO, 1978, NATURE, V274, P908, DOI 10.1038/274908a0; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHANDRA S, 1991, J CELL SCI, V100, P747; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1988, J CELL BIOCHEM, V38, P279, DOI 10.1002/jcb.240380407; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LOH YP, 1985, FEBS LETT, V184, P40, DOI 10.1016/0014-5793(85)80648-7; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1977, J GEN PHYSIOL, V70, P37, DOI 10.1085/jgp.70.1.37; LOH YP, 1984, J BIOL CHEM, V259, P8238; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1981, EUR J CELL BIOL, V26, P177; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TILDERS FJH, 1975, EXP BRAIN RES, V23, P198; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WONG SH, 1993, J BIOL CHEM, V268, P22853; YOO SH, 1992, J BIOL CHEM, V267, P11236; ZHOU A, 1993, J BIOL CHEM, V268, P1763	45	374	383	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					73	83		10.1016/S0092-8674(00)81860-7	http://dx.doi.org/10.1016/S0092-8674(00)81860-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019408	Bronze			2022-12-28	WOS:A1997WC56900011
J	Arnon, A; Cook, B; Montell, C; Selinger, Z; Minke, B				Arnon, A; Cook, B; Montell, C; Selinger, Z; Minke, B			Calmodulin regulation of calcium stores in phototransduction of Drosophila	SCIENCE			English	Article							CA2+ RELEASE CHANNEL; LIGHT CHAIN KINASE; RYANODINE RECEPTOR; SKELETAL-MUSCLE; PLASMA-MEMBRANE; BINDING DOMAIN; TUMOR PROMOTER; PHOTORECEPTORS; MYOSIN; THAPSIGARGIN	Phototransduction in Drosophila occurs through the ubiquitous phosphoinositide-mediated signal transduction system. Major unresolved questions in this pathway are the identity and role of the internal calcium stores in light excitation and the mechanism underlying regulation of Ca2+ release from internal stores. Treatment of Drosophila photoreceptors with ryanodine and caffeine disrupted the current induced by light, whereas subsequent application of calcium-calmodulin (Ca-CaM) rescued the inactivated photoresponse. In calcium-deprived wild-type Drosophila and in calmodulin-deficient transgenic flies, the current induced by light was disrupted by a specific inhibitor of Ca-CaM. Furthermore, inhibition of Ca-CaM revealed light-induced release of calcium from intracellular stores. It appears that functional ryanodine-sensitive stores are essential for the photoresponse. Moreover, calcium release from these stores appears to be a component of Drosophila phototransduction, and Ca-CaM regulates this process.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHYSIOL,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,KUHNE MINERVA CTR STUDIES VISUAL TRANSDUCT,IL-91120 JERUSALEM,ISRAEL; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM & NEUROSCI,BALTIMORE,MD 21205; HEBREW UNIV JERUSALEM,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,KUHNE MINERVA CTR STUDIES VISUAL TRANDUCT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Johns Hopkins University; Hebrew University of Jerusalem; Hebrew University of Jerusalem			Montell, Craig/AAH-3357-2021	Montell, Craig/0000-0001-5637-1482	NEI NIH HHS [EY10852, EY03529] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010852, R01EY003529] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLUMENTHAL DK, 1988, BIOCHEM BIOPH RES CO, V156, P860, DOI 10.1016/S0006-291X(88)80923-9; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; EHRLICH BE, 1995, CURR OPIN NEUROBIOL, V5, P304, DOI 10.1016/0959-4388(95)80042-5; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1995, J NEUROSCI, V15, P889; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hofstee CA, 1996, VISUAL NEUROSCI, V13, P897, DOI 10.1017/S0952523800009147; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MESSNER G, 1986, J BIOL CHEM, V261, P6300; Minke B, 1996, CURR OPIN NEUROBIOL, V6, P459, DOI 10.1016/S0959-4388(96)80050-X; MONTELL C, 1988, CELL, V52, P722; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; Pearn MT, 1996, J BIOL CHEM, V271, P4937; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PORTER JA, 1993, J CELL BIOL, V122, P601, DOI 10.1083/jcb.122.3.601; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; WALZ B, 1995, J GEN PHYSIOL, V105, P537, DOI 10.1085/jgp.105.4.537	34	52	54	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1119	1121		10.1126/science.275.5303.1119	http://dx.doi.org/10.1126/science.275.5303.1119			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027311				2022-12-28	WOS:A1997WJ50300042
J	Cooper, A; Penny, D				Cooper, A; Penny, D			Mass survival of birds across the Cretaceous-Tertiary boundary: Molecular evidence	SCIENCE			English	Article							MURINE SARCOMA-VIRUS; MOS PROTO-ONCOGENE; EVOLUTIONARY TREES; EXTINCTION; SEQUENCES; ORIGIN; DIVERSIFICATION; VOLCANISM; MAMMALS; EVENTS	The extent of terrestrial vertebrate extinctions at the end of the Cretaceous is poorly understood, and estimates have ranged from a mass extinction to limited extinctions of specific groups. Molecular and paleontological data demonstrate that modern bird orders started diverging in the Early Cretaceous; at least 22 avian lineages of modern birds cross the Cretaceous-Tertiary boundary. Data for several other terrestrial vertebrate groups indicate a similar pattern of survival and, taken together, favor incremental changes during a Cretaceous diversification of birds and mammals rather than an explosive radiation in the Early Tertiary.	VICTORIA UNIV WELLINGTON,SCH BIOL SCI,WELLINGTON,NEW ZEALAND; SMITHSONIAN INST,NATL ZOOL PK,MOL GENET LAB,WASHINGTON,DC 20008; MASSEY UNIV,SCH BIOL SCI,PALMERSTON NORTH,NEW ZEALAND	Victoria University Wellington; Smithsonian Institution; Smithsonian National Zoological Park & Conservation Biology Institute; Massey University			Penny, David/E-9410-2011; Cooper, Alan/E-8171-2012	Cooper, Alan/0000-0002-7738-7851				ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Archibald J.D., 1996, DINOSAUR EXTINCTION; Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; BENTON MJ, 1995, SCIENCE, V268, P52, DOI 10.1126/science.7701342; BENTON MJ, 1993, FOSSIL RECORD, V2; BOLES WE, 1995, NATURE, V374, P21, DOI 10.1038/374021b0; BUFFETAUT E, 1995, NATURE, V377, P110, DOI 10.1038/377110a0; Charleston M A, 1994, J Comput Biol, V1, P133, DOI 10.1089/cmb.1994.1.133; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; COOPER A, 1995, P ROY SOC B-BIOL SCI, V261, P293, DOI 10.1098/rspb.1995.0150; COOPER A, 1992, P NATL ACAD SCI USA, V89, P8741, DOI 10.1073/pnas.89.18.8741; CRACRAFT J, 1986, PALEOBIOLOGY, V12, P383, DOI 10.1017/S0094837300003122; CRACRAFT J, 1973, J ZOOL, V169, P455; DErchia AM, 1996, NATURE, V381, P597, DOI 10.1038/381597a0; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; Forster CA, 1996, NATURE, V382, P532, DOI 10.1038/382532a0; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; GINGERICH PD, 1994, NATURE, V368, P844, DOI 10.1038/368844a0; HAY JM, 1995, MOL BIOL EVOL, V12, P928; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Hickson RE, 1996, MOL BIOL EVOL, V13, P150, DOI 10.1093/oxfordjournals.molbev.a025552; HOFFMAN A, 1989, J GEOL SOC LONDON, V146, P21, DOI 10.1144/gsjgs.146.1.0021; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; Hou LH, 1996, SCIENCE, V274, P1164, DOI 10.1126/science.274.5290.1164; Houde P., 1987, Palaeovertebrata (Montpellier), V17, P27; Janke A, 1996, J MOL EVOL, V42, P153, DOI 10.1007/BF02198841; JANKE A, 1994, GENETICS, V137, P243; KORNEGAY JR, 1993, J MOL EVOL, V37, P367, DOI 10.1007/BF00178867; LENTO GM, 1995, MOL BIOL EVOL, V12, P28, DOI 10.1093/oxfordjournals.molbev.a040189; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MACLEOD N, 1991, GEOLOGY, V19, P497, DOI 10.1130/0091-7613(1991)019<0497:HDAMEA>2.3.CO;2; MARTIN PG, 1988, TAXON, V37, P364, DOI 10.2307/1222145; Matthew W. D., 1915, Annals of the New York Academy of Sciences, V24; MCGOWAN G, 1995, NATURE, V373, P143, DOI 10.1038/373143a0; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OFFICER CB, 1985, SCIENCE, V227, P1161, DOI 10.1126/science.227.4691.1161; Olson S.L., 1985, Avian Biology, V8, P79; Olson S.L., 1992, Journal of Vertebrate Paleontology, V12, P122; Olson S. L., 1987, SMITHSONIAN CONTRIBU, V63, P1, DOI DOI 10.5479/SI.00810266.63.1; OLSON SL, 1994, P BIOL SOC WASH, V107, P429; PENNY D, 1993, NEW ZEAL J BOT, V31, P275, DOI 10.1080/0028825X.1993.10419505; PRAGER EM, 1980, P INT ORNITHOL C, V17, P1209; PRASAD GVR, 1995, J GEOL SOC LONDON, V152, P289, DOI 10.1144/gsjgs.152.2.0289; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sanz JL, 1996, NATURE, V382, P442, DOI 10.1038/382442a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; Sibley C.G., 1990, PHYLOGENY CLASSIFICA; Simpson George Gaylord, 1946, BULL AMER MUS NAT HIST, V87, P1; Stanhope MJ, 1996, J MOL EVOL, V43, P83, DOI 10.1007/BF02337352; Steel MA, 1996, SYST BIOL, V45, P127, DOI 10.2307/2413610; SUTHERLAND FL, 1994, EARTH-SCI REV, V36, P1, DOI 10.1016/0012-8252(94)90005-1; Swofford David L., 1996, P407; Tarr Cheryl L., 1995, P147; VEEVERS JJ, 1995, GEOLOGY, V23, P1131, DOI 10.1130/0091-7613(1995)023<1131:ELLGVS>2.3.CO;2; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WILLIAMS ME, 1994, J PALEONTOL, V68, P183, DOI 10.1017/S0022336000022770; WILSON AC, 1991, PERSPECTIVES CELLULA, P331; WYLES JS, 1983, P NATL ACAD SCI-BIOL, V80, P4394, DOI 10.1073/pnas.80.14.4394; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	70	368	384	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1109	1113		10.1126/science.275.5303.1109	http://dx.doi.org/10.1126/science.275.5303.1109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027308				2022-12-28	WOS:A1997WJ50300039
J	Bazan, JF; Bacon, KB; Hardiman, G; Wang, W; Soo, K; Rossi, D; Greaves, DR; Zlotnik, A; Schall, TJ				Bazan, JF; Bacon, KB; Hardiman, G; Wang, W; Soo, K; Rossi, D; Greaves, DR; Zlotnik, A; Schall, TJ			A new class of membrane-bound chemokine with a CX(3)C motif	NATURE			English	Article							HEPARAN-SULFATE; CELL-ADHESION; CYTOKINE; INFLAMMATION; SEQUENCE; BINDING	Chemokines direct the trafficking of white blood cells in immune surveillance, playing a key role in inflammatory and infectious diseases such as AIDS(1-5). All chemokines studied so far are secreted proteins of relative molecular mass similar to 7K-15K and fall into:three families that are defined by a cysteine signature motif: CXC, CC and C (refs 3, 6, 7), where C is a cysteine and X any amino-acid residue. We report here the identification and characterization of a fourth human chemokine type, derived from hbn-haemopoietic cells and bearing a new CX(3)C fingerprint. Unlike other chemokine types, the polypeptide chain of the human CX(3)C chemokine is predicted to be part of a 373-amino-acid protein that carries the chemokine domain on top of an extended mucin-like stalk. This molecule can exist in two forms: either membrane-anchored or as a shed 95K glycoprotein. The soluble CX(3)C chemokine has potent chemoattractant activity for T cells and monocytes, and the cell-surface-bound protein, which is induced on activated primary endothelial cells, promotes strong adhesion of those leukocytes. The structure, biochemical features, tissue distribution and chromosomal localization of CX(3)C chemokine all indicate that it represents a unique class of chemokine that may constitute part of the molecular control of leukocyte traffic at the endothelium.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Oxford			Bazan, J. Fernando/B-4562-2010; Zlotnik, Albert/C-3791-2011	Greaves, David/0000-0003-2856-9410; Hardiman, Gary/0000-0003-4558-0400				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BAGGIOLINI M, 1994, IMMUNOL TODAY, V104, P27; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; HANSEN JE, 1995, BIOCHEM J, V308, P601; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; PEMACK BP, 1996, NATURE MED, V2, P1174; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SHIMIZU Y, 1993, NATURE, V366, P630, DOI 10.1038/366630a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Strieter RM, 1996, J IMMUNOL, V156, P3583; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; VYAS P, 1995, GENOMICS, V29, P679, DOI 10.1006/geno.1995.9951; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	23	1590	1690	4	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					640	644		10.1038/385640a0	http://dx.doi.org/10.1038/385640a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024663				2022-12-28	WOS:A1997WH29400052
J	Weber, R; Deplazes, P; Flepp, M; Mathis, A; Baumann, R; Sauer, B; Kuster, H; Luthy, R				Weber, R; Deplazes, P; Flepp, M; Mathis, A; Baumann, R; Sauer, B; Kuster, H; Luthy, R			Cerebral microsporidiosis due to Encephalitozoon cuniculi in a patient with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-VITRO; AIDS; ALBENDAZOLE; CULTURE; URINE		UNIV ZURICH,INST PARASITOL,CH-8057 ZURICH,SWITZERLAND; DIAKONIEWERK BETHANIEN,ANKER HUUS,ZURICH,SWITZERLAND	University of Zurich	Weber, R (corresponding author), UNIV ZURICH HOSP,DEPT MED,DIV INFECT DIS & HOSP EPIDEMIOL,CH-8091 ZURICH,SWITZERLAND.		Kuster, Herbert/A-3912-2013; Weber, Rainer/D-5175-2012	Kuster, Herbert/0000-0001-6873-0091				AARONS EJ, 1994, AIDS, V8, P1119, DOI 10.1097/00002030-199408000-00013; BEAUVAIS B, 1994, ANTIMICROB AGENTS CH, V38, P2440, DOI 10.1128/AAC.38.10.2440; BERGQUIST NR, 1984, BRIT MED J, V288, P902, DOI 10.1136/bmj.288.6421.902; CANNING EU, 1986, MICROSPORIDIA VERTEB; COLBOURN NI, 1994, EUR J PROTISTOL, V30, P211, DOI 10.1016/S0932-4739(11)80031-3; DEGROOTE MA, 1995, J INFECT DIS, V171, P1375, DOI 10.1093/infdis/171.5.1375; Deplazes P, 1996, CLIN INFECT DIS, V22, P557, DOI 10.1093/clinids/22.3.557; Deplazes P, 1996, J EUKARYOT MICROBIOL, V43, pS93, DOI 10.1111/j.1550-7408.1996.tb05018.x; DIDIER ES, 1995, PARASITOLOGY, V111, P411, DOI 10.1017/S0031182000065914; FRANSSEN FF, 1995, ANTIMICROB AGENTS CH, P1265; HOLLISTER WS, 1995, J EUKARYOT MICROBIOL, V42, P367, DOI 10.1111/j.1550-7408.1995.tb01595.x; Joste NE, 1996, ARCH PATHOL LAB MED, V120, P199; KATIYAR SK, 1995, GENE, V152, P27, DOI 10.1016/0378-1119(94)00677-K; KatzwinkelWladarsch S, 1996, TROP MED INT HEALTH, V1, P373, DOI 10.1046/j.1365-3156.1996.d01-51.x; Levaditi C, 1923, CR SOC BIOL, V89, P984; Mathis A, 1996, PARASITOL RES, V82, P727, DOI 10.1007/s004360050192; Mathis A, 1997, PARASITOLOGY, V114, P29, DOI 10.1017/S0031182096008177; MATSUBAYASHI H, 1959, ARCH PATHOL, V67, P181; ORENSTEIN JM, 1996, 11 INT C AIDS VANC J, V2, P265; TERADA S, 1987, ANN INTERN MED, V107, P61, DOI 10.7326/0003-4819-107-1-61; VISVESVARA GS, 1991, J PROTOZOOL, V38, pS105; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; WEBER R, 1994, CLIN MICROBIOL REV, V7, P426, DOI 10.1128/CMR.7.4.426-461.1994; WEBER R, 1993, CLIN INFECT DIS, V17, P415, DOI 10.1093/clinids/17.3.415; Wright JH, 1922, J EXP MED, V36, P135, DOI 10.1084/jem.36.1.135; ZENDER HO, 1989, AM J CLIN PATHOL, V92, P352, DOI 10.1093/ajcp/92.3.352; [No title captured]	27	100	100	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					474	478		10.1056/NEJM199702133360704	http://dx.doi.org/10.1056/NEJM199702133360704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017940				2022-12-28	WOS:A1997WG77600004
J	Guichet, A; Copeland, JWR; Erdelyi, M; Hlousek, D; Zavorszky, P; Ho, J; Brown, S; PercivalSmith, A; Krause, HM; Ephrussi, A				Guichet, A; Copeland, JWR; Erdelyi, M; Hlousek, D; Zavorszky, P; Ho, J; Brown, S; PercivalSmith, A; Krause, HM; Ephrussi, A			The nuclear receptor homologue Ftz-F1 and the homeodomain protein Ftz are mutually dependent cofactors	NATURE			English	Article							DROSOPHILA SEGMENTATION GENE; PAIR-RULE EXPRESSION; FUSHI-TARAZU GENE; LOCALIZATION; EMBRYOS; BINDING; SEQUENCE; CLONING; OSKAR	Nuclear hormone receptors and homeodomain proteins are two classes of transcription factor that regulate major developmental processes. Both depend on interactions with other proteins for specificity and activity. The Drosophila gene fushi tarazu (ftz), which encodes a homeodomain protein(1) (Ftz), is required zygotically for the formation of alternate segments in the developing embryo(2). Here we show that the orphan nuclear receptor alpha Ftz-F1 (ref. 3), which is deposited in the egg during oogenesis(4), is an obligatory cofactor for Ftz. The two proteins interact specifically and directly, both in vitro and in vivo, through a conserved domain in the Ftz polypeptide. This interaction suggests that other nuclear receptor/homeodomain protein interactions may be important and common in developing organisms.	UNIV TORONTO,CHARLES H BEST INST,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA; EUROPEAN MOL BIOL LAB,DEV BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY; UNIV WESTERN ONTARIO,DEPT ZOOL,LONDON,ON N6A 5B7,CANADA; KANSAS STATE UNIV,DIV BIOL,MANHATTAN,KS 66506; UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University of Toronto; European Molecular Biology Laboratory (EMBL); Western University (University of Western Ontario); Kansas State University; University of Toronto			Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020; Ho, Jackie/AAP-1531-2021	Ephrussi, Anne/0000-0002-5061-4620; Ho, Jackie/0000-0001-7115-1381; Brown, Susan/0000-0002-7984-0445; Krause, Henry/0000-0002-6182-7074				BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BROWN SJ, 1994, P NATL ACAD SCI USA, V91, P12922, DOI 10.1073/pnas.91.26.12922; CARROLL SB, 1986, CELL, V45, P113, DOI 10.1016/0092-8674(86)90543-X; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; DAWES R, 1994, DEVELOPMENT, V120, P1561; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; Florence B, 1997, DEVELOPMENT, V124, P839; HAN W, 1993, MOL CELL BIOL, V13, P5549, DOI 10.1128/MCB.13.9.5549; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; JOST W, 1995, ROUX ARCH DEV BIOL, V205, P160, DOI 10.1007/BF00357762; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LAVORGNA G, 1993, P NATL ACAD SCI USA, V90, P3004, DOI 10.1073/pnas.90.7.3004; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; OHNO CK, 1992, MECH DEVELOP, V40, P13; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STEWART JJ, 1991, NATURE, V350, P72; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TSAI CC, 1995, DEVELOPMENT, V121, P453; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; WAKIMOTO BT, 1981, DEV BIOL, V81, P551; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0; YU Y, IN PRESS NATURE	32	158	163	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					548	552		10.1038/385548a0	http://dx.doi.org/10.1038/385548a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020363				2022-12-28	WOS:A1997WG23500051
J	Kessler, DA; Barnett, PS; Witt, A; Zeller, MR; Mande, JR; Schultz, WB				Kessler, DA; Barnett, PS; Witt, A; Zeller, MR; Mande, JR; Schultz, WB			The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NICOTINE; SMOKING; DEPENDENCE	On August 28, 1996, the US Food and Drug Administration (FDA) asserted jurisdiction over cigarettes and smokeless tobacco under the Federal Food, Drug, and Cosmetic Act. Under this Act, a product is a ''drug'' or ''device'' subject to FDA jurisdiction if it is ''intended to affect the structure or any function of the body.'' The FDA determined that nicotine in cigarettes and smokeless tobacco does ''affect the structure or any function of the body'' because nicotine causes addiction and other pharmacological effects. The FDA then determined that these pharmacological effects are ''intended'' because (1) a scientific consensus has emerged that nicotine is addictive; (2) recent studies have shown that most consumers use cigarettes and smokeless tobacco for pharmacological purposes, including satisfying their addiction to nicotine; and (3) newly disclosed evidence from the tobacco manufacturers has revealed that the manufacturers know that nicotine causes pharmacological effects, including addiction, and design their products to provide pharmacologically active doses of nicotine. The FDA thus concluded that cigarettes and smokeless tobacco are subject to FDA jurisdiction because they contain a ''drug,'' nicotine, and a ''device'' for delivering this drug to the body.			Kessler, DA (corresponding author), US FDA,DEPT HLTH & HUMAN SERV,5600 FISHERS LN,14-71 PKLN,ROCKVILLE,MD 20857, USA.							*AM MED ASS, 1993, 1993 AMA POL COMP, P35; *AM PSYCH ASS, 1980, DIAGN STAT MAN MENT, P159; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; COTTLER LB, 1993, ADDICTION, V88, P689, DOI 10.1111/j.1360-0443.1993.tb02082.x; *CTR DIS CONTR, 1994, MMWR-MORBID MORTAL W, V43, P745; *CTR DIS CONTR PRE, 1993, MMWR MROB MORTAL WKL, V43, P925; ELLIS C, 1962, SMOKING HLTH POLICY; GOLDING J, 1982, PSYCHOPHYSIOLOGY, V19, P449, DOI 10.1111/j.1469-8986.1982.tb02504.x; HALE KL, 1993, NIDA RES MONOGRAPH, V182; HUGHES JR, 1987, AM J PSYCHIAT, V144, P205; KOZLOWSKI LT, 1989, JAMA-J AM MED ASSOC, V261, P898; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; *MED RES COUNC, 1994, MRC FIELD REV DRUG D, P11; MORRIS W, 1991, AM HERITAGE DICT ENG, P668; NORTON R, 1992, PSYCHOPHARMACOLOGY, V108, P473, DOI 10.1007/BF02247424; NOVOTNY TE, 1989, NATL CANCER I MONOGR, V8, P25; PRITCHARD WS, 1991, PSYCHOPHARMACOLOGY, V104, P485, DOI 10.1007/BF02245654; *ROY SOC CAN HLTH, 1989, COMM REP, pR5; SEVERSON HH, 1993, NIH MONOGRAPH, V2; SPEARS AW, 1981, RECENT ADV TOBACCO S, V7, P22; United States Department of Energy, 1992, SPIT TOB YOUTH, P8; *US DEP HHS OFF SM, 1988, HLTH CONS SMOK NIC A, P7; *US DEP HHS PHS, 1986, HLTH CONS US SMOK TO, P182; *US FDA, 1991, INT AGR CTR DRUG EV; *US FDA, 1996, FED REG         0828, V61; *WHO, 1992, ICD 10 CLASS MENT BE, P76; WOODY GE, 1993, ADDICTION, V88, P1573, DOI 10.1111/j.1360-0443.1993.tb03144.x; 1996, FED REG         0828, V61, P44396	31	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					405	409		10.1001/jama.277.5.405	http://dx.doi.org/10.1001/jama.277.5.405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE771	9010173				2022-12-28	WOS:A1997WE77100031
J	Kawabe, T; Muslin, AJ; Korsmeyer, SJ				Kawabe, T; Muslin, AJ; Korsmeyer, SJ			HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint	NATURE			English	Article							OKADAIC ACID; HOMEOBOX GENE; KINASE; TRANSCRIPTION; MATURATION; REGULATOR; INHIBITOR; ONCOGENE; SYSTEM; TYPE-1	Hox11 is an orphan homeobox gene that controls the genesis of the spleen(1). HOX11 is also oncogenic, having been isolated from a chromosomal breakpoint in human T-cell leukaemia(2-4). Transgenic mice that redirected HOX11 to the thymus demonstrated cell-cycle aberration and progression to malignancy(5). We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells. Inhibition of PP2A can relate the cell cycle and control the activation of maturation-promoting factor in Xenopus oocytes(6). Microinjection of HOX11 into Xenopus oocytes arrested at the G2. phase of the cell cycle promoted progression to the M phase. G2 arrest can be induced by gamma-irradiation, but is eliminated bt expression oi HOX11 within a T-cell line. Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters(7,8). This interaction suggests a mechanism by which a homeobox can alter the cell cycle.	ST LOUIS UNIV,SCH MED,JEWISH HOSP ST LOUIS,HOWARD HUGHES MED INST,DEPT MED & PATHOL,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,JEWISH HOSP ST LOUIS,DIV CARDIOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Howard Hughes Medical Institute; Saint Louis University; Barnes-Jewish Hospital; Saint Louis University								BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DUBE ID, 1991, BLOOD, V78, P2996; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAHRAEUS R, 1994, EMBO J, V13, P6041, DOI 10.1002/j.1460-2075.1994.tb06950.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, CURR OPIN ONCOL S, V4, P24; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KINOSHITA N, 1993, GENE DEV, V7, P10759; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUMAGAI A, 1992, CELL, V70, P138; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; SHIOMI K, 1994, DEVELOPMENT, V120, P1591; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YANG SI, 1991, MOL CELL BIOL, V64, P1988	30	181	186	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					454	458		10.1038/385454a0	http://dx.doi.org/10.1038/385454a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009195				2022-12-28	WOS:A1997WF00700057
J	Bernstein, BE; Michels, PAM; Hol, WGJ				Bernstein, BE; Michels, PAM; Hol, WGJ			Synergistic effects of substrate-induced conformational changes in phosphoglycerate kinase activation	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; 3-PHOSPHOGLYCERATE KINASE; MOLECULAR REPLACEMENT; CRYSTAL-STRUCTURE; PROTEIN MODELS; COMPLEX; ENZYME; EVOLUTION; SEQUENCE; BINDING	Phosphoglycerate kinase (PGK), a key enzyme in glycolysis, catalyses the transfer of a phosphoryl-group from 1,3-bis-phosphoglycerate to ADP to form 3-phosphoglycerate and ATP. Despite extensive kinetic and structural investigations over more than two decades, the conformation assumed by this enzyme during catalysis remained unknown. Here we present the 2.8 Angstrom crystal structure of a ternary complex of PGK from Trypanosoma brucei, the causative agent of sleeping sickness. This structure determination relied on a procedure in which fragments containing less than 10% of the scattering mass were successively positioned in the unit cell to obtain phases. The PGK ternary complex exhibits a dramatic dosing of the large cleft between the two domains seen in all previous studies(1-6), thereby bringing the two ligands, 3-phosphoglycerate and ADP into dose proximity. Our results demonstrate that PGK is a hinge-bending enzyme, reveal a novel mechanism in which substrate-induced effects combine synergistically to induce major conformational changes and, to our knowledge, afford the first observation of the PGK active site in a catalytic conformation.	UNIV WASHINGTON, DEPT BIOCHEM, BIOMOL STRUCT CTR, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, BIOMOL STRUCT CTR, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV CATHOLIQUE LOUVAIN, INT INST CELLULAR & MOL PATHOL, TROP DIS RES UNIT, B-1200 BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, BIOCHEM LAB, B-1200 BRUSSELS, BELGIUM	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Universite Catholique Louvain; Universite Catholique Louvain			Michels, Paul A/A-5637-2009	Michels, Paul A/0000-0003-3726-6104				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BLAKE CCF, 1974, J MOL BIOL, V84, P585, DOI 10.1016/0022-2836(74)90118-1; BRUNGER AT, 1992, X PLOR VERSION 3 1; DAVIES GJ, 1994, ACTA CRYSTALLOGR D, V50, P202, DOI 10.1107/S0907444993011138; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; GRAHAM HC, 1991, EUR J BIOCHEM, V197, P81, DOI 10.1111/j.1432-1033.1991.tb15885.x; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; May A, 1996, PROTEINS, V24, P292; McPhillips TM, 1996, BIOCHEMISTRY-US, V35, P4118, DOI 10.1021/bi952500o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILDVAN AS, 1981, PHILOS T ROY SOC B, V293, P65, DOI 10.1098/rstb.1981.0061; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OH BH, 1995, ACTA CRYSTALLOGR D, V51, P140, DOI 10.1107/S0907444994010024; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAPPU KM, 1994, ARCH BIOCHEM BIOPHYS, V311, P503, DOI 10.1006/abbi.1994.1268; SCOPES RK, 1978, EUR J BIOCHEM, V85, P503, DOI 10.1111/j.1432-1033.1978.tb12266.x; SHERMAN MA, 1992, PROTEIN SCI, V1, P752, DOI 10.1002/pro.5560010607; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; TOMPA P, 1986, EUR J BIOCHEM, V154, P643, DOI 10.1111/j.1432-1033.1986.tb09446.x; WALKER PA, 1989, EUR J BIOCHEM, V183, P49, DOI 10.1111/j.1432-1033.1989.tb14895.x; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x	29	179	182	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 16	1997	385	6613					275	278		10.1038/385275a0	http://dx.doi.org/10.1038/385275a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000079				2022-12-28	WOS:A1997WC71100054
J	Krude, T; Jackman, M; Pines, J; Laskey, RA				Krude, T; Jackman, M; Pines, J; Laskey, RA			Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system	CELL			English	Article							PROTEIN-KINASE; S-PHASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; CYCLE CONTROL; G(1); TRANSITION; EXPRESSION; INVITRO; NUCLEI	We describe a cell-free system from HeLa cells that initiates DNA replication under cell cycle control. G1 but not G2 phase nuclei initiate replication when coincubated with S phase nuclei in cytosolic extracts from S phase but not from G1 or G2 phase HeLa cells. S phase nuclei or an S phase nuclear extract are required for the initiation of semiconservative DNA replication in G1 nuclei but not for elongation in S phase nuclei. S phase nuclear extract could be replaced by recombinant human cyclins A and E complexed to Cdk2 but not by Cdk2 alone or by human cyclin B1 complexed to CdcP. In S phase cytosol, cyclins A/Cdk2 and E/Cdk2 triggered initiation synergistically.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	Krude, T (corresponding author), WELLCOME TRUST CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.			Krude, Torsten/0000-0002-1842-1933	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELYAEV AS, 1993, NUCLEIC ACIDS RES, V21, P1219, DOI 10.1093/nar/21.5.1219; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HARRIS H, 1966, J CELL SCI, V1, P1; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HEICHMAN KA, 1994, CELL, V79, P577; HEINTZ NH, 1988, MOL CELL BIOL, V8, P1923, DOI 10.1128/MCB.8.5.1923; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Krude T, 1996, J CELL SCI, V109, P309; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LOHKA MJ, 1983, SCIENCE, V220, P79; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WIMMEL A, 1994, ONCOGENE, V9, P995; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	47	265	271	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					109	119		10.1016/S0092-8674(00)81863-2	http://dx.doi.org/10.1016/S0092-8674(00)81863-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019396	Bronze			2022-12-28	WOS:A1997WC56900014
J	Charbonnier, JB; GolinelliPimpaneau, B; Gigant, B; Tawfik, DS; Chap, R; Schindler, DG; Kim, SH; Green, BS; Eshhar, Z; Knossow, M				Charbonnier, JB; GolinelliPimpaneau, B; Gigant, B; Tawfik, DS; Chap, R; Schindler, DG; Kim, SH; Green, BS; Eshhar, Z; Knossow, M			Structural convergence in the active sites of a family of catalytic antibodies	SCIENCE			English	Article							TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; FAB FRAGMENT; IMMUNIZATION	The x-ray structures of three esterase-like catalytic antibodies identified by screening for catalytic activity the entire hybridoma repertoire, elicited in response to a phosphonate transition state analog (TSA) hapten, were analyzed. The high resolution structures account for catalysis by transition state stabilization, and in all three antibodies a tyrosine residue participates in the oxyanion hole. Despite significant conformational differences in their combining sites, the three antibodies, which are the most efficient among those elicited, achieve catalysis in essentially the same mode, suggesting that evolution for binding to a single TSA followed by screening for catalysis lead to antibodies with structural convergence.	HEBREW UNIV JERUSALEM,FAC MED,DEPT PHARMACEUT CHEM,IL-91120 JERUSALEM,ISRAEL; CNRS,LAB ENZYMOL & BIOCHIM STRUCT,F-91198 GIF SUR YVETTE,FRANCE; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Weizmann Institute of Science			Charbonnier, Jean-Baptiste/A-3868-2009; Golinelli, Beatrice/ABB-8347-2021	Charbonnier, Jean-Baptiste/0000-0002-5219-1983; Golinelli, Beatrice/0000-0001-8248-4704; Gigant, Benoit/0000-0002-5946-6759				ALZARI PM, 1990, EMBO J, V9, P3807, DOI 10.1002/j.1460-2075.1990.tb07598.x; ANGELES TS, 1993, BIOCHEMISTRY-US, V32, P12128, DOI 10.1021/bi00096a025; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHARBONNIER JB, 1995, P NATL ACAD SCI USA, V92, P11721, DOI 10.1073/pnas.92.25.11721; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LERNER RA, 1995, INTERFACE CHEM BIOL; Leslie A. G. W.., 1992, PROTEIN CRYSTALLOGR, V26; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MacBeath G, 1996, CHEM BIOL, V3, P433, DOI 10.1016/S1074-5521(96)90091-5; MIYASHITA H, 1994, P NATL ACAD SCI USA, V91, P6045, DOI 10.1073/pnas.91.13.6045; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; TAWFIK DS, 1995, THESIS WEIZMANN I SC; TAWFIK DS, IN PRESS EUR J BIOCH; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; ZEMEL R, 1994, MOL IMMUNOL, V31, P127, DOI 10.1016/0161-5890(94)90085-X; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	26	76	79	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1140	1142		10.1126/science.275.5303.1140	http://dx.doi.org/10.1126/science.275.5303.1140			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027317				2022-12-28	WOS:A1997WJ50300048
J	Zhang, SC				Zhang, SC			A unified theory based on SO(5) symmetry of superconductivity and antiferromagnetism	SCIENCE			English	Article							+ EPSILON-DIMENSIONS; HUBBARD-MODEL; NEUTRON-SCATTERING; CUPRATE SUPERCONDUCTORS; SPIN FLUCTUATIONS; POINTS; STATE	The complex phase diagram of high-critical temperature (T-c) superconductors can be deduced from an SO(5) symmetry principle that unifies antiferromagnetism and d-wave superconductivity. The approximate SO(5) symmetry has been derived from the microscopic Hamiltonian, and it becomes exact under renormalization group flow toward a bicritical point. This symmetry enables the construction of a SO(5) quantum nonlinear sigma model that describes the phase diagram and the effective low-energy dynamics of the system. This model naturally explains the basic phenomenology of the high-T-c superconductors from the insulating to the underdoped and the optimally doped region.	IBM CORP,ALMADEN RES CTR,SAN JOSE,CA 95114	International Business Machines (IBM)	Zhang, SC (corresponding author), STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305, USA.		Zhang, Shou-Cheng/B-2794-2010					ANDERSON PW, 1958, PHYS REV, V112, P1900, DOI 10.1103/PhysRev.112.1900; ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; ANDERSON PW, 1983, BASIC NOTIONS CONDEN; BARZYKIN V, 1995, PHYS REV B, V52, P13585, DOI 10.1103/PhysRevB.52.13585; Batlogg B, 1996, NATURE, V382, P20, DOI 10.1038/382020a0; BICKERS NE, 1989, PHYS REV LETT, V62, P961, DOI 10.1103/PhysRevLett.62.961; CHAKRAVARTY S, 1989, PHYS REV B, V39, P2344, DOI 10.1103/PhysRevB.39.2344; CHUBUKOV AV, 1994, PHYS REV B, V49, P11919, DOI 10.1103/PhysRevB.49.11919; Dai P, 1996, PHYS REV LETT, V77, P5425, DOI 10.1103/PhysRevLett.77.5425; Demler E, 1996, INT J MOD PHYS B, V10, P2137, DOI 10.1142/S0217979296000982; DEMLER E, 1995, PHYS REV LETT, V75, P4126, DOI 10.1103/PhysRevLett.75.4126; DEMLER E, UNPUB; DONIACH S, 1990, PHYS REV B, V41, P6668, DOI 10.1103/PhysRevB.41.6668; DONIACH S, 1996, J PHYS CHEM SOLIDS, V57, P506; EMERY VJ, 1990, PHYS REV LETT, V64, P475, DOI 10.1103/PhysRevLett.64.475; FISHER DS, 1989, PHYS REV B, V39, P11783, DOI 10.1103/PhysRevB.39.11783; FISHER ME, 1974, PHYS REV LETT, V32, P1350, DOI 10.1103/PhysRevLett.32.1350; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Fong HF, 1997, PHYS REV LETT, V78, P713, DOI 10.1103/PhysRevLett.78.713; FRIEDAN DH, 1985, ANN PHYS-NEW YORK, V163, P318, DOI 10.1016/0003-4916(85)90384-7; HALPERIN BI, 1969, PHYS REV, V188, P898, DOI 10.1103/PhysRev.188.898; Harris J., PREPRINT; HIKAMI S, 1974, PROG THEOR PHYS, V52, P369, DOI 10.1143/PTP.52.369; KOHNO H, 1996, P 10 ANN HTS WORKSH; LEE PA, 1987, PHYS REV LETT, V58, P2891; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; MEIXNER S, 9701217 COND NAT; MOOK H, 1994, PHYS REV LETT, V70, P3490; NELSON DR, 1977, PHYS REV B, V16, P2191, DOI 10.1103/PhysRevB.16.2191; PELCOVITS RA, 1976, PHYS LETT A, V57, P23, DOI 10.1016/0375-9601(76)90440-0; PINES D, 1994, PHYSICA C, V235, P113, DOI 10.1016/0921-4534(94)91327-7; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; Scalapino D. J., 1995, Physics Reports, V250, P329, DOI 10.1016/0370-1573(94)00086-I; SCHRIEFFER JR, 1989, PHYS REV B, V39, P11663, DOI 10.1103/PhysRevB.39.11663; TAKIGAWA M, 1994, PHYS REV B, V49, P4158, DOI 10.1103/PhysRevB.49.4158; YANG CN, 1989, PHYS REV LETT, V63, P2144, DOI 10.1103/PhysRevLett.63.2144; YANG CN, 1990, MOD PHYS LETT B, V4, P759, DOI DOI 10.1142/S0217984990000933; ZHANG FC, 1988, PHYS REV B, V37, P3759, DOI 10.1103/PhysRevB.37.3759; ZHANG SC, 1990, PHYS REV LETT, V65, P120, DOI 10.1103/PhysRevLett.65.120; ZHANG SC, 1991, INT J MOD PHYS B, V5, P153, DOI 10.1142/S0217979291000110	41	735	741	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1089	1096		10.1126/science.275.5303.1089	http://dx.doi.org/10.1126/science.275.5303.1089			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027303				2022-12-28	WOS:A1997WJ50300034
J	Schneider, DL; BarrettConnor, EL; Morton, DJ				Schneider, DL; BarrettConnor, EL; Morton, DJ			Timing of postmenopausal estrogen for optimal bone mineral density - The Rancho Bernardo study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONAL REPLACEMENT THERAPY; POST-MENOPAUSAL WOMEN; ELDERLY WOMEN; HIP FRACTURE; OSTEOPOROSIS; PREVENTION; CALCIUM; MASS; GESTAGEN; SPINE	Objective-To determine the effect of the timing of initiation and the duration of postmenopausal estrogen therapy on bone mineral density (BMD). Design.-Cross-sectional study. Setting.-White, middle-class to upper middle-class community-dwelling women, Participants.-A total of 740 women aged 60 to 98 years who participated in a study of osteoporosis. Measurements.-Questionnaire, validated medication use, and height and weight. Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry (SPA) and at the hip and lumbar spine using dual-energy x-ray absorptiometry (DEXA). Results-Of the 740 women, 69% had used oral estrogen after menopause and 30% were current users. Five groups of estrogen use were identified: never users, past users who started at menopause, past users who started after age 60 years, current users who started after age 60 years, and current users who started at menopause, At all 4 bone sites, current users who started at menopause had the highest BMD levels, which were significantly higher than never users or past users who started at menopause (with 10 years' duration of use). These differences persisted after controlling for all major risk factors for osteoporosis. Among current users, there was no significant difference in BMD levels at any site between those who started estrogen at menopause (with 20 years of use) and those who started after age 60 years (with 9 years of use), Conclusions.-Estrogen initiated in the menopausal period and continued into late life is associated with the highest bone density. Nevertheless, estrogen begun after age 60 years and continued appears to offer nearly equal bone-conserving benefit.	UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN JM, 1973, BMJ-BRIT MED J, V3, P515, DOI 10.1136/bmj.3.5879.515; BIRKENHAGER JC, 1992, BONE MINER, V18, P251, DOI 10.1016/0169-6009(92)90811-Q; BRODY JA, 1984, AM J PUBLIC HEALTH, V74, P1397, DOI 10.2105/AJPH.74.12.1397; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; CHRISTIANSEN C, 1981, LANCET, V1, P459; ERDTSIECK RJ, 1994, J BONE MINER RES, V9, P277; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; ETTINGER B, 1994, MENOPAUSE, V1, P19; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; ETTINGER B, 1994, CURRENT THERAPY ENDO, P596; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GREY AB, 1994, CLIN ENDOCRINOL, V40, P671, DOI 10.1111/j.1365-2265.1994.tb03020.x; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HUTCHINSON TA, 1979, LANCET, V2, P705; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOHRT WM, 1995, OSTEOPOROSIS INT, V5, P150, DOI 10.1007/BF02106093; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LINDSAY R, 1980, LANCET, V2, P1151; LINDSAY R, 1976, LANCET, V1, P1038; LINDSAY R, 1978, LANCET, V1, P1325; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARX CW, 1992, J BONE MINER RES, V7, P1275; MAXIM P, 1995, OSTEOPOROSIS INT, V5, P23, DOI 10.1007/BF01623654; NACHTIGALL LE, 1979, OBSTET GYNECOL, V53, P277; NGUYEN TV, 1995, J CLIN ENDOCR METAB, V80, P2709, DOI 10.1210/jc.80.9.2709; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RICHELSON LS, 1984, NEW ENGL J MED, V311, P1273, DOI 10.1056/NEJM198411153112002; *SAS I INC, 1990, SAS STAT US GUID VER, P2; STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756-3282(89)90126-9; SZEJNFELD VL, 1994, SAO PAULO MED J, V112, P514; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	36	181	184	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					543	547		10.1001/jama.277.7.543	http://dx.doi.org/10.1001/jama.277.7.543			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032160				2022-12-28	WOS:A1997WH29700029
J	Lalezari, JP; Stagg, RJ; Kuppermann, BD; Holland, GN; Kramer, F; Ives, DV; Youle, M; Robinson, MR; Drew, WL; Jaffe, HS				Lalezari, JP; Stagg, RJ; Kuppermann, BD; Holland, GN; Kramer, F; Ives, DV; Youle, M; Robinson, MR; Drew, WL; Jaffe, HS			Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						cidofovir; cytomegalovirus retinitis; acquired immunodeficiency syndrome; AIDS-related opportunistic infections; probenecid	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY SYNDROME; CLINICAL PHARMACOKINETICS; ANTIVIRAL ACTIVITY; NUCLEOTIDE ANALOG; VIRUS; GANCICLOVIR; (S)-1-<3-HYDROXY-2-(PHOSPHONYLMETHOXY)PROPYL>CYTOSINE; MANIFESTATIONS; INFECTION	Background: Cytomegalovirus (CMV) retinitis is the most common intraocular infection in patients with the acquired immunodeficiency syndrome (AIDS). If left untreated, it may lead to progressive destruction of retinal tissue and blindness. Cidofovir is a nucleotide analogue of cytosine that has potent, prolonged in vitro and in vivo activity against herpesviruses, including many CMV isolates that are resistant to ganciclovir and foscarnet. Objective: To determine whether intravenous cidofovir delays progression of previously untreated CMV retinitis. Design: Randomized, controlled trial comparing immediate with deferred cidofovir treatment. Patients in the deferred treatment group were eligible to receive cidofovir after progression of CMV retinitis was documented by retinal photography. Setting: Eight academic medical centers and an independent center that read retinal photographs. Patients: 48 patients with AIDS and previously untreated peripheral CMV retinitis who were randomly assigned to immediate (n = 25) or deferred treatment (n = 23). Intervention: Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 weeks and then once every other week. To minimize nephrotoxicity, oral probenecid and intravenous hydration with normal saline were administered with each cidofovir infusion. Measurements: Progression of CMV retinitis was assessed by bilateral, full-field retinal photographs that were read by an ophthalmologist who was masked to treatment assignment. Incidence of side effects, changes in visual acuity, effect on CMV shedding in urine and blood, and mortality were also assessed. Results: The median time to progression of CMV retinitis was 22 days (95% CI, 10 to 27 days) in the deferred treatment group and 120 days (CI, 40 to 134 days) in the immediate treatment group (P < 0.001). Neutropenia (15%) and proteinuria (12%), both asymptomatic, were the most common serious adverse events considered to be possibly related to cidofovir. Cidofovir treatment was discontinued in 10 of 41 patients (24%) because of protocol-defined treatment-limiting nephrotoxicity. Transient reactions to probenecid, including mild to moderate constitutional symptoms or nausea, occurred in 23 of 41 patients (56%) and were dose limiting in 3 (7%). Conclusions: Cidofovir was efficacious in delaying progression of previously untreated CMV retinitis. Treatment was associated with manageable side effects; strict adherence to monitoring of renal function before cidofovir was administered and concomitant administration of probenecid and saline hydration appeared to minimize drug-related nephrotoxicity.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; GILEAD SCI INC, FOSTER CITY, CA 94404 USA; UNIV CALIF IRVINE, IRVINE, CA 92717 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; ST STEPHENS CLIN, LONDON, ENGLAND; UNIV ROCHESTER, MED CTR, ROCHESTER, NY 14642 USA	University of California System; University of California San Francisco; Gilead Sciences; University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of Southern California; Harvard University; Harvard Medical School; University of Rochester								Altman D.G., 1991, PRACTICAL STAT MED R; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; BRONSON JJ, 1989, J MED CHEM, V32, P1457, DOI 10.1021/jm00127a010; COOPER D, 1995, AIDS, V9, P471, DOI 10.1097/00002030-199509050-00009; CUNDY KC, 1995, ANTIMICROB AGENTS CH, V39, P1247, DOI 10.1128/AAC.39.6.1247; CUNNINGHAM RF, 1981, CLIN PHARMACOKINET, V6, P135, DOI 10.2165/00003088-198106020-00004; DECLERCQ E, 1987, ANTIVIR RES, V8, P261; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; HO HT, 1992, MOL PHARMACOL, V41, P197; HOLLAND GN, 1989, ARCH OPHTHALMOL-CHIC, V107, P1759, DOI 10.1001/archopht.1989.01070020841024; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JABS DA, 1994, OPHTHALMOLOGY, V101, P1250; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KORNHAUSER DM, 1989, LANCET, V2, P473; KUPPERMANN BD, 1993, AM J OPHTHALMOL, V115, P575, DOI 10.1016/S0002-9394(14)71453-9; LALEZARI JP, 1994, J INFECT DIS, V170, P570, DOI 10.1093/infdis/170.3.570; LALEZARI JP, 1995, J INFECT DIS, V171, P788, DOI 10.1093/infdis/171.4.788; LEWIS RA, 1995, ARCH INTERN MED, V155, P65, DOI 10.1001/archinte.155.1.65; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; MEINERT CL, 1986, CLIN TRIALS DESIGN C, P198; OBRIEN PC, 1987, BIOMETRICS, V43, P169, DOI 10.2307/2531957; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PEPOSE JS, 1985, OPHTHALMOLOGY, V92, P472; POLIS MA, 1995, ANTIMICROB AGENTS CH, V39, P882, DOI 10.1128/AAC.39.4.882; SNOECK R, 1988, ANTIMICROB AGENTS CH, V32, P1839, DOI 10.1128/AAC.32.12.1839; SNOECK R, 1993, NEW ENGL J MED, V329, P968, DOI 10.1056/NEJM199309233291317; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; TURNER RR, 1987, DIAGN CLIN IMMUNOL, V5, P194	31	267	274	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					257	+		10.7326/0003-4819-126-4-199702150-00001	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036797				2022-12-28	WOS:A1997WH06800003
J	Bao, JX; Kandel, ER; Hawkins, RD				Bao, JX; Kandel, ER; Hawkins, RD			Involvement of pre- and postsynaptic mechanisms in posttetanic potentiation at Aplysia synapses	SCIENCE			English	Article							POST-TETANIC POTENTIATION; TERM SYNAPTIC PLASTICITY; SPONTANEOUS TRANSMITTER RELEASE; DISSOCIATED CELL-CULTURE; MOTOR NEURON SYNAPSES; SENSORIMOTOR SYNAPSES; SENSORY NEURONS; NERVE-TERMINALS; NITRIC-OXIDE; CALCIUM	Posttetanic potentiation (PTP) is a common form of short-term synaptic plasticity that is generally thought to be entirely presynaptic. Consistent with that idea, PTP of evoked excitatory postsynaptic potentials at Aplysia sensory/motor neuron synapses in cell culture was reduced by presynaptic injection of a slow calcium chelator and was accompanied by an increase in the frequency but not the amplitude of spontaneous excitatory postsynaptic potentials. However, PTP was also reduced by postsynaptic injection of a rapid calcium chelator or postsynaptic hyperpolarization. Thus, PTP at these synapses is likely to involve a postsynaptic induction mechanism in addition to the known presynaptic mechanisms.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute					NIMH NIH HHS [MH 26212] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH026212] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ANWYL R, 1989, BRAIN RES, V503, P148, DOI 10.1016/0006-8993(89)91716-2; ATWOOD HL, 1986, INT REV NEUROBIOL, V28, P275, DOI 10.1016/S0074-7742(08)60111-7; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; CASTELLUCCI VF, 1974, P NATL ACAD SCI USA, V71, P5004, DOI 10.1073/pnas.71.12.5004; CLAMANN HP, 1989, J NEUROPHYSIOL, V61, P403, DOI 10.1152/jn.1989.61.2.403; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; CONNOR JA, 1986, J PHYSIOL-LONDON, V375, P625, DOI 10.1113/jphysiol.1986.sp016137; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DELANEY KR, 1989, J NEUROSCI, V9, P3558; ELIOT LS, 1994, J NEUROSCI, V14, P3280; ELIOT LS, 1994, J NEUROSCI, V14, P368; EPSTEIN R, 1970, J PHYSIOL-LONDON, V209, P1; Feng T.P., 1941, CHINESE J PHYSIOL, V16, P341; FROST WN, 1987, THESIS COLUMBIA U NE, P113; GRIFFITH WH, 1990, J NEUROPHYSIOL, V63, P491, DOI 10.1152/jn.1990.63.3.491; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; KRETZ R, 1982, P NATL ACAD SCI-BIOL, V79, P5430, DOI 10.1073/pnas.79.17.5430; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P113, DOI 10.1098/rspb.1994.0016; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P215, DOI 10.1098/rspb.1994.0031; LO YJ, 1994, J NEUROSCI, V14, P4694; MAGLEBY KL, 1975, J PHYSIOL-LONDON, V245, P183, DOI 10.1113/jphysiol.1975.sp010840; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MARTIN AR, 1964, J PHYSIOL-LONDON, V175, P17, DOI 10.1113/jphysiol.1964.sp007500; MURPHEY RK, 1994, J NEUROBIOL, V25, P595, DOI 10.1002/neu.480250602; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHACHER S, 1990, J NEUROSCI, V10, P3286; SCHACHER S, 1985, J NEUROSCI, V5, P2028; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; WALTERS ET, 1984, BRAIN RES, V293, P377, DOI 10.1016/0006-8993(84)91247-2; WAZIRI R, 1969, J NEUROPHYSIOL, V32, P509, DOI 10.1152/jn.1969.32.4.509; YUSTE R, 1995, NEURON, V14, P7, DOI 10.1016/0896-6273(95)90236-8; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1994, NETH J ZOOL, V44, P495	37	87	90	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					969	973		10.1126/science.275.5302.969	http://dx.doi.org/10.1126/science.275.5302.969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020078				2022-12-28	WOS:A1997WH38800043
J	Ewbank, JJ; Barnes, TM; Lakowski, B; Lussier, M; Bussey, H; Hekimi, S				Ewbank, JJ; Barnes, TM; Lakowski, B; Lussier, M; Bussey, H; Hekimi, S			Structural and functional conservation of the Caenorhabditis elegans timing gene clk-1	SCIENCE			English	Article							C-ELEGANS; SACCHAROMYCES-CEREVISIAE; MUTATIONS; OPERONS; COMMON	Mutations in the Caenorhabditis elegans gene clk-1 affect biological timing and extend longevity. The gene clk-1 was identified, and the cloned gene complemented the clk-1 phenotypes and restored normal longevity. The CLK-1 protein was found to be conserved among eukaryotes, including humans, and structurally similar to the yeast metabolic regulator Cat5p (also called Coq7p). These proteins contain a tandem duplication of a core 82-residue domain. clk-1 complemented the phenotype of cat5/coq7 null mutants, demonstrating that clk-1 and CAT5/COQ7 share biochemical function and that clk-1 acts at the level of cellular physiology.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA	McGill University			Ewbank, Jonathan J/G-4948-2010	Ewbank, Jonathan J/0000-0002-1257-6862				Barnes TM, 1996, J NEUROCHEM, V67, P46; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CAMPISI J, 1996, CELL, V86, P9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Creighton T. E., 1993, PROTEINS STRUCTURES; Eeckman FH, 1995, METHOD CELL BIOL, V48, P583; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gems D, 1996, NATURE, V379, P723, DOI 10.1038/379723a0; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HEKIMI S, 1995, GENETICS, V141, P1351; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LAKOWSKI B, UNPUB; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Mello C, 1995, METHOD CELL BIOL, V48, P451; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; PROFT M, 1995, MOL GEN GENET, V246, P367, DOI 10.1007/BF00288610; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1995, 3 INT C INT SYST MOL, P314; ROST B, 1995, PROTEIN FOLDS DISTAN, P132; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG A, 1995, GENETICS, V139, P1247; WONG A, 1994, THESIS MCGILL U MONT; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0; [No title captured]; [No title captured]	34	258	276	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					980	983		10.1126/science.275.5302.980	http://dx.doi.org/10.1126/science.275.5302.980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020081				2022-12-28	WOS:A1997WH38800046
J	Wong, JY; Kuhl, TL; Israelachvili, JN; Mullah, N; Zalipsky, S				Wong, JY; Kuhl, TL; Israelachvili, JN; Mullah, N; Zalipsky, S			Direct measurement of a tethered ligand-receptor interaction potential	SCIENCE			English	Article							LIPOSOMES; CHAINS; FORCES; CELLS	Many biological recognition interactions involve ligands and receptors that are tethered rather than rigidly bound on a cell surface. A surface forces apparatus was used to directly measure the force-distance interaction between a polymer-tethered ligand and its receptor. At separations near the fully extended tether length, the ligands rapidly lock onto their binding sites, pulling the ligand and receptor together. The measured interaction potential and its dynamics can be modeled with standard theories of polymer and colloidal interactions.	SEQUUS PHARMACEUT,MENLO PK,CA 94025		Wong, JY (corresponding author), UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106, USA.		Wong, Joyce Y./AAF-5759-2019; Wong, Joyce Y/F-3732-2011	Wong, Joyce Y./0000-0002-3526-6381; Wong, Joyce Y/0000-0002-3526-6381	NIGMS NIH HHS [GM 47334, GM17876] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334, F32GM017876] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H; [Anonymous], 1992, INTERMOLECULAR SURFA; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3; Cevc G., 1987, PHOSPHOLIPID BILAYER; DeFrees SA, 1996, J AM CHEM SOC, V118, P6101, DOI 10.1021/ja954122g; EVANS E, IN PRESS BIOPHYS J; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; KUHL TL, 1994, BIOPHYS J, V66, P1479, DOI 10.1016/S0006-3495(94)80938-5; LECKBAND DE, 1992, SCIENCE, V255, P1419, DOI 10.1126/science.1542789; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; LEE RJ, 1994, J BIOL CHEM, V269, P3198; MARRA J, 1986, METHOD ENZYMOL, V127, P353; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; Uster PS, 1996, FEBS LETT, V386, P243, DOI 10.1016/0014-5793(96)00452-8; ZALIPSKY S, 1995, BIOCONJUGATE CHEM, V6, P705, DOI 10.1021/bc00036a008; ZALIPSKY S, 1994, FEBS LETT, V353, P71, DOI 10.1016/0014-5793(94)01013-7	18	220	229	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					820	822		10.1126/science.275.5301.820	http://dx.doi.org/10.1126/science.275.5301.820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012346				2022-12-28	WOS:A1997WG77700057
J	Duell, T; vanLint, MT; Ljungman, P; Tichelli, A; Socie, G; Apperley, JF; Weiss, M; Cohen, A; Nekolla, E; Kolb, HJ				Duell, T; vanLint, MT; Ljungman, P; Tichelli, A; Socie, G; Apperley, JF; Weiss, M; Cohen, A; Nekolla, E; Kolb, HJ			Health and functional status of long-term survivors of bone marrow transplantation	ANNALS OF INTERNAL MEDICINE			English	Article						bone marrow transplantation; lymphoma; leukemia; anemia, aplastic; social adjustment	ADULT SURVIVORS; LATE COMPLICATIONS; APLASTIC-ANEMIA; LYMPHOBLASTIC-LEUKEMIA; AVASCULAR NECROSIS; MYELOID-LEUKEMIA; SECONDARY; CHILDHOOD; QUALITY; LIFE	Background: Although many patients now survive the short-term complications of bone marrow transplantation for life-threatening hematologic disease, information on the health and activity of long-term survivors is sparse. Objective: To evaluate the morbidity and mortality of patients surviving more than 5 years after allogeneic bone marrow transplantation. Design: Retrospective, multicenter study. Patients: 798 recipients of bone marrow transplants (477 adults, 321 children) from 43 European centers. Patients had received transplants before December 1985 and had survived at least 5 years. Patients had received allogeneic or syngeneic bone marrow for leukemia, lymphoma, inborn diseases of the hematopoietic and immune systems, and severe aplastic anemia. Measurements: Survival, clinical performance according to Karnofsky score (in increments of 10%), and social reintegration were assessed as outcomes. Patient age and sex, primary disease and status at transplantation, histocompatibility of the donor, conditioning regimen, type of prophylaxis of graft-versus-host disease, and acute and chronic graft-versus-host disease were evaluated as variables. Results: For the 55 5-year survivors, actuarial mortality was 8% at 10 years and 14% at 15 years. The leading causes of death were disease recurrence (21 patients), chronic graft-versus-host disease with complicating infections and lung disease (11 patients), secondary cancer (8 patients), and the acquired immunodeficiency syndrome (AIDS) (5 patients). When patients with recurrent disease were excluded, late death was associated with chronic graft-versus-host disease (P < 0.001), occurrence of secondary cancer (P < 0.001), male sex of the patient (P = 0.05), and female sex of the donor (P = 0.002). Clinical performance was normal (Karnofsky score, 100%) or minimally reduced (Karnofsky score, 90%) in 93% of patients; 89% of patients resumed full-time work or school. Reduced performance status and incomplete resumption of social activity were associated with chronic graft-versus-host disease, recurrent leukemia, AIDS, secondary cancer, organ dysfunction, and neurologic or psychological problems. Other risk factors for incomplete resumption of social activity were female sex (P = 0.002) and alder age at transplantation (P = 0.001). Conclusions: More than 5 years after bone marrow transplantation, most patients were in good health (93%) and had returned to full-time work or school (89%). Recurrence of the primary disease, secondary cancer. and chronic graft-versus-host disease and its sequelae remain problems for some patients.	UNIV MUNICH, KLINIKUM GROSSHADERN, MED KLIN 3, D-81377 MUNICH, GERMANY; OSPED SAN MARTINO GENOVA, GENOA, ITALY; IST GIANNINA GASLINI, GENOA, ITALY; HUDDINGE HOSP, DEPT MED, S-14186 HUDDINGE, SWEDEN; KANTONSSPITAL, DEPT HEMATOL, CH-4031 BASEL, SWITZERLAND; HOP ST LOUIS, BONE MARROW TRANSPLANT UNIT, F-75475 PARIS 10, FRANCE; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; UNIV ULM, INST KLIN PHYSIOL & SOZIALMED, ULM, GERMANY	University of Munich; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS Istituto Giannina Gaslini; Kantonsspital Aarau AG (KSA); University of Basel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Ulm University			Ljungman, Per/M-4946-2019					ANDRYKOWSKI MA, 1989, BONE MARROW TRANSPL, V4, P75; ANDRYKOWSKI MA, 1990, TRANSPLANTATION, V50, P399, DOI 10.1097/00007890-199009000-00009; ANDRYKOWSKI MA, 1994, BONE MARROW TRANSPL, V13, P357; ANDRYKOWSKI MA, 1989, BONE MARROW TRANSPL, V4, P505; APPERLEY JF, 1988, BRIT J HAEMATOL, V69, P239, DOI 10.1111/j.1365-2141.1988.tb07628.x; ATKINSON K, 1987, BONE MARROW TRANSPL, V2, P421; BAKER F, 1994, BONE MARROW TRANSPL, V13, P589; Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; CHRISTIE D, 1994, ARCH DIS CHILD, V70, P275, DOI 10.1136/adc.70.4.275; DEEG HJ, 1984, BRIT J HAEMATOL, V57, P185, DOI 10.1111/j.1365-2141.1984.tb08521.x; DICKE KA, 1994, BONE MARROW TRANSPL, V14, pS11; FELSON DT, 1987, LANCET, V1, P902; FORMAN SJ, 1987, TRANSPLANTATION, V44, P244, DOI 10.1097/00007890-198708000-00014; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V12, pS13; Gratwohl A, 1996, BONE MARROW TRANSPL, V17, P137; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; KOLB HJ, 1990, BONE MARROW TRANSPL, V6, P61; KOLB HJ, 1994, EULEP NEWSLETTER, V75, P13; LIESNER RJ, 1994, J CLIN ONCOL, V12, P916, DOI 10.1200/JCO.1994.12.5.916; Molassiotis A, 1996, BONE MARROW TRANSPL, V17, P249; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; Prieto JM, 1996, BONE MARROW TRANSPL, V17, P1133; SANDERS JE, 1983, TRANSPLANTATION, V36, P252, DOI 10.1097/00007890-198309000-00005; SANDERS JE, 1986, BLOOD, V68, P1129; SCIE G, 1993, BONE MARROW TRANSPL, V12, pS115; SKLAR CA, 1984, CANCER, V53, P1498, DOI 10.1002/1097-0142(19840401)53:7<1498::AID-CNCR2820530712>3.0.CO;2-A; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SULLIVAN KM, 1992, BONE MARROW TRANSPL, V10, P127; SULLIVAN KM, 1984, SEMIN HEMATOL, V21, P53; WINGARD JR, 1991, ANN INTERN MED, V114, P113, DOI 10.7326/0003-4819-114-2-113; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203	32	170	173	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					184	+		10.7326/0003-4819-126-3-199702010-00002	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027268				2022-12-28	WOS:A1997WF16800002
J	Greaves, RRSH; Patchett, SE; Empey, D; Kumar, PJ				Greaves, RRSH; Patchett, SE; Empey, D; Kumar, PJ			A 22-year-old with jaundice and a bit of a cough	LANCET			English	Article							CYSTIC-FIBROSIS		LONDON CHEST HOSP,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London	Greaves, RRSH (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON SCH MED,DIGEST DIS RES CTR,LONDON E1 2AD,ENGLAND.							COHN JA, 1993, GASTROENTEROLOGY, V105, P1857, DOI 10.1016/0016-5085(93)91085-V; COLOMBO C, 1992, HEPATOLOGY, V15, P677, DOI 10.1002/hep.1840150421; MIELES LA, 1989, LANCET, V1, P1073; OBRIEN S, 1992, GUT, V33, P387, DOI 10.1136/gut.33.3.387	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					324	324		10.1016/S0140-6736(97)09001-6	http://dx.doi.org/10.1016/S0140-6736(97)09001-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024377				2022-12-28	WOS:A1997WF79400013
J	McKee, SW; McKee, JD				McKee, SW; McKee, JD			Meningioma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									BETH ISRAEL MED CTR,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center	McKee, SW (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					340	340		10.1056/NEJM199701303360505	http://dx.doi.org/10.1056/NEJM199701303360505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011787				2022-12-28	WOS:A1997WG23300005
J	Gulliford, T; Opomu, M; Wilson, E; Hanham, I; Epstein, R				Gulliford, T; Opomu, M; Wilson, E; Hanham, I; Epstein, R			Popularity of less frequent follow up for breast cancer in randomised study: Initial findings from the hotline study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; RECURRENT	Objective: To compare the experiences of patients with breast cancer who were conventionally monitored with those in whom routine follow up was restricted to the time of mammography. Design: Randomisation to conventional schedule of clinic visits or to visits only after mammography, Both cohorts received identical mammography and were invited to telephone for immediate appointments if they detected symptoms. Setting: Combined breast clinic Chelsea and Westminster Hospital. Subjects: 211 eligible outpatients with a history of breast cancer. Main outcome measures: Acceptability of randomisation, interim use of telephone and general practitioner, satisfaction with allocation to follow up. Results: Of 211 eligible patients, 196 (93%) opted for randomisation in the study, Of these, 55 were under 50 years, 78 were diagnosed fewer than five years before, 90 had stage T2-4 tumours, and 71 had involved axillary nodes, Patients who did not participate were more likely to be under 50 years, to be two to five years after diagnosis, and to have had aggressive primary disease, Twice as many patients in both groups expressed a preference for reducing rather than increasing follow up, No increased use of local practitioner services or telephone triage was apparent in the cohort randomised to less frequent follow up by specialists. Conclusions: Reducing the frequency of routine follow up has so far proved popular among patients with breast cancer at standard risk in this cohort. A multicentre study is needed to determine the effectiveness and cost-effectiveness of routine follow up with respect to disease outcomes.	CHARING CROSS HOSP, DEPT MED ONCOL, CANC RES CAMPAIGN, LONDON W6 8RF, ENGLAND; CHARING CROSS HOSP, DEPT RADIOTHERAPY, LONDON W6 8RF, ENGLAND	Imperial College London; Imperial College London								ABE O, 1992, LANCET, V339, P71; [Anonymous], 1995, ANN ONCOL, V6, P747, DOI 10.1093/oxfordjournals.annonc.a059309; [Anonymous], 1992, Lancet, V339, P1; BRADA M, 1995, EUR J CANCER, V31A, P655, DOI 10.1016/0959-8049(95)00079-X; COOMBES RC, 1980, LANCET, V1, P296; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEWAR J, 1995, BMJ-BRIT MED J, V310, P685, DOI 10.1136/bmj.310.6981.685; EMBERTON M, 1995, BRIT MED J, V311, P1315, DOI 10.1136/bmj.311.7016.1315; GLYNNEJONES R, 1995, BRIT MED J, V311, P1574, DOI 10.1136/bmj.311.7019.1574c; GRUNFELD E, 1995, BMJ-BRIT MED J, V311, P54, DOI 10.1136/bmj.311.6996.54; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P881, DOI 10.1200/JCO.1994.12.5.881; Maher E J, 1995, Clin Oncol (R Coll Radiol), V7, P227, DOI 10.1016/S0936-6555(05)80605-3; MAHER J, 1995, BRIT MED J, V311, P54, DOI 10.1136/bmj.311.6996.54a; MELLINK WAM, 1991, CANCER-AM CANCER SOC, V67, P1844, DOI 10.1002/1097-0142(19910401)67:7<1844::AID-CNCR2820670705>3.0.CO;2-W; NAGLE JP, 1992, BRIT J GEN PRACT, V42, P190; RICHERTBOE KE, 1995, CANCER-AM CANCER SOC, V75, P2605, DOI 10.1002/1097-0142(19950515)75:10<2605::AID-CNCR2820751031>3.0.CO;2-#; Simon MS, 1996, BREAST CANCER RES TR, V37, P39, DOI 10.1007/BF01806630; SPRATT JS, 1990, CANCER, V66, P1351, DOI 10.1002/1097-0142(19900915)66:14+<1351::AID-CNCR2820661410>3.0.CO;2-E; STIERER M, 1989, CANCER, V64, P1128, DOI 10.1002/1097-0142(19890901)64:5<1128::AID-CNCR2820640527>3.0.CO;2-H; TOMIN R, 1987, J CLIN ONCOL, V5, P62, DOI 10.1200/JCO.1987.5.1.62; WAGHORN A, 1995, BRIT MED J, V311, P1344, DOI 10.1136/bmj.311.7016.1344; WERTHEIMER MD, 1991, JAMA-J AM MED ASSOC, V265, P396, DOI 10.1001/jama.265.3.396; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L	23	99	99	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					174	177		10.1136/bmj.314.7075.174	http://dx.doi.org/10.1136/bmj.314.7075.174			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022429	Green Published			2022-12-28	WOS:A1997WD91100022
J	Budetti, PP				Budetti, PP			Health reform for the 21st century? It may have to wait until the 21st century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To assess the likelihood of health care legislation in the forthcoming 105th Congress in 5 areas: health care coverage, tax and Employee Retirement Income Security Act (ERISA) policy, Medicaid, Medicare, and managed care. Design.-Informal, semistructured conversations that took place in the months prior to the 1996 elections. Population.-Congressional health staff and administration officials. Outcome Measures.-Unofficial, off-the-record personal opinions. Results.-Health care coverage initiatives to benefit children and unemployed persons are likely to be proposed, but have little chance of enactment; children are seen as well provided for under current Medicaid law, the strong economy and high employment levels lower concern for unemployed issues, and the effort required to pass the Kassebaum-Kennedy legislation needs time to settle, Tax proposals, such as medical savings accounts (MSAs), and ERISA amendments have no constituency; also, the MSA demonstration in Kassebaum-Kennedy will forestall further action, Medicaid is far less an issue than in the previous Congress, because spending has fallen unexpectedly, the bitter fight over block grants makes them unlikely to be revisited, and the administration is likely to enhance state flexibility through waivers, Medicare will be the subject of substantial action to defer impending insolvency temporarily, but there is virtually no chance that definitive long-term solutions will be enacted even though the underlying fiscal problems are thoroughly understood and recognized. Managed care will be the venue for numerous proposals designed to address specific consumer and quality issues, Conclusions.-Four bitter years of fighting over health care issues has raised awareness of the problems, but has produced a political chemistry that is too rancorous to permit passage of significant legislation in the near future.	NORTHWESTERN UNIV,INST HLTH SERV RES & POLICY STUDIES,EVANSTON,IL	Northwestern University								*BUR LAB STAT, 1996, CONS PRIC IND SUMM S; *C BUDG OFF, 1996, EC BUDG OUTL UPD; *C BUDG OFF, 1996, RED DEF SPEND REV OP; Davis K, 1996, JAMA-J AM MED ASSOC, V276, P831, DOI 10.1001/jama.276.10.831; *NAT ASS INS COMM, 1995, ISS 95; *PROSP PAYM ASS CO, 1996, REP REC C; WINSLOW RSHAL, 1996, WALL STREEET J  1027, P5	7	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					193	198						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB446	9005259				2022-12-28	WOS:A1997WB44600001
J	Glassman, PA; Model, KE; Kahan, JP; Jacobson, PD; Peabody, JW				Glassman, PA; Model, KE; Kahan, JP; Jacobson, PD; Peabody, JW			The role of medical necessity and cost-effectiveness in making medical decisions	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH	The term ''medical necessity'' is used ubiquitously in health care, but its meaning and implementation vary substantially among providers, payers, and patients. This ambiguity has led some to suggest that cost-effectiveness be used as a basis for decision rules. This paper presents an analytical framework that is familiar to clinicians and shows that medical necessity and cost-effectiveness do not provide deterministic rules for clinical decision making. First, 2 x 2 tables are used to show the tradeoff between the sensitivity and specificity of decision rules. Then, the example of asymptomatic abdominal aortic aneurysm is used to show that these tradeoffs can be seen as a continuum of decision rules on a receiver-operating characteristic curve. Society can therefore choose a decision threshold on the basis of medical necessity that optimizes the number of lives saved or any other desired outcome, but the tradeoff between sensitivity and specificity cannot be avoided. Applying cost-effectiveness criteria may change the decision threshold because cost-effectiveness itself involves inherent tradeoffs that create additional ambiguity for clinical decisions. The conclusion is that decision rules based on medical necessity or cost-effectiveness should not be considered deterministic. Rather, decision rules are useful when they make assumptions explicit and specify tradeoffs so that clinicians, patients, and payers can make better decisions.	RAND CORP, SANTA MONICA, CA 90407 USA; W LOS ANGELES VET AFFAIRS MED CTR, DIV GEN INTERNAL MED 111G, LOS ANGELES, CA 90073 USA; EUROPEAN AMER CTR, NL-2628 CE DELFT, NETHERLANDS	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center								ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; Ballard DJ, 1992, ABDOMINAL AORTIC ANE; CULYER AJ, 1995, SOC SCI MED, V40, P727, DOI 10.1016/0277-9536(94)00307-F; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; Eddy DM, 1996, JAMA-J AM MED ASSOC, V275, P650, DOI 10.1001/jama.275.8.650; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; ERNST CB, 1993, NEW ENGL J MED, V328, P1167; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; HALL MA, 1992, U PENN LAW REV, V140, P1637, DOI 10.2307/3312428; JACOBSON PJ, 1995, DEFINING MED NECESSI; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KATZ DA, 1992, JAMA-J AM MED ASSOC, V268, P2678, DOI 10.1001/jama.268.19.2678; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; MARINER WK, 1994, AM J PUBLIC HEALTH, V84, P1515, DOI 10.2105/AJPH.84.9.1515; NEWCOMER LN, 1990, NEW ENGL J MED, V323, P1702, DOI 10.1056/NEJM199012133232411; PARK RE, 1994, NEW ENGL J MED, V330, P432; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238	18	24	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					152	156		10.7326/0003-4819-126-2-199701150-00011	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WD298	9005750				2022-12-28	WOS:A1997WD29800011
J	Lynn, J; Teno, JM; Phillips, RS; Wu, AW; Desbiens, N; Harrold, J; Claessens, MT; Wenger, N; Kreling, B; Connors, AF				Lynn, J; Teno, JM; Phillips, RS; Wu, AW; Desbiens, N; Harrold, J; Claessens, MT; Wenger, N; Kreling, B; Connors, AF			Perceptions by family members of the dying experience of older and seriously ill patients	ANNALS OF INTERNAL MEDICINE			English	Article						terminal care; attitude to death; death; advance directives; decision making	RANDOMIZED CONTROLLED TRIAL; CANCER-PATIENTS; SUPPORT; DYSPNEA; PAIN	Background: Alleviating the problems faced by dying persons and their families has drawn substantial public attention, but little is known about the experience of dying. Objective: To characterize the experience of dying from the perspective of surrogate decision makers, usually close family members (89%). Design: Prospective cohort study. Setting: Five teaching hospitals. Patients: Persons who had one of nine serious medical conditions or were 80 years of age or older who died and for whom a surrogate decision maker completed an interview about the death. Measurements: Medical records were reviewed and surrogate decision makers were interviewed. Results: 4124 of 9105 seriously ill patients died (46%); 408 of 1176 elderly patients died (35%). The patients' family members were interviewed after 3357 persons (73%) had died. Of 1541 patients who survived the enrollment hospitalization, 46% died during a later hospitalization. In the last 3 days of life, 55% of patients were conscious. Among these patients, pain, dyspnea, and fatigue were prevalent. Four in 10 patients had severe pain most of the time. Severe fatigue affected almost 8 in 10 patients. More than 1 in 4 patients had moderate dysphoria. Sixty-three percent of patients had difficulty tolerating physical or emotional symptoms. Overall, 11% of patients had a final resuscitation attempt. A ventilator was used in one fourth of patients, and a feeding tube was used in four tenths of patients. Most patients (59%) were reported to prefer a treatment plan that focused on comfort, but care was reported to be contrary to the preferred approach in 10% of cases. Conclusions: Most elderly and seriously ill patients died in acute care hospitals. Pain and other symptoms were commonplace and troubling to patients. Family members believed that patients preferred comfort, but life-sustaining treatments were often used. These findings indicate important opportunities to improve the care of dying patients.	BETH ISRAEL HOSP, DEPT MED, DEPT CLIN EPIDEMIOL, BOSTON, MA 02215 USA; JOHNS HOPKINS UNIV, SERV RES CTR, BALTIMORE, MD 21205 USA; MARSHFIELD MED RES FDN, DEPT GEN INTERNAL MED, MARSHFIELD, WI 54449 USA; DEPT VET AFFAIRS HOSP, OUTCOMES RES GRP, WHITE RIVER JCT, VT 05009 USA; UNIV CALIF LOS ANGELES, SCH MED, CTR HLTH & ETH, LOS ANGELES, CA 90095 USA; METROHLTH MED CTR, DIV PULM DIS & CRIT CARE, CLEVELAND, OH 44109 USA	Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; MetroHealth System	Lynn, J (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, CTR IMPROVE CARE DYING, 100 22ND ST, SUITE 820, WASHINGTON, DC 20037 USA.		Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; [Anonymous], 1992, J Clin Oncol, V10, P1976; [Anonymous], YEAR DEATH; BROCK DB, 1987, P AM STAT ASS SOC ST, P306; BROWN D, 1994, WASHINGTON POST 1113, pA20; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P365, DOI 10.1016/0885-3924(92)90091-U; Carter Stephen L, 1996, N Y Times Mag, P28; CELLA DF, 1987, J CHRON DIS, V40, P939, DOI 10.1016/0021-9681(87)90143-3; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COHEN MH, 1991, SOUTHERN MED J, V84, P229, DOI 10.1097/00007611-199102000-00019; COLBURN D, 1994, WASHINGTON POST 0510; Doyle D., 1993, OXFORD TXB PALLIATIV; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; KANE RL, 1984, LANCET, V1, P890; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KRELING B, 1990, J CLIN EPIDEMIOL, V43, pS5, DOI 10.1016/0895-4356(90)90212-8; Layde PM, 1996, J CLIN EPIDEMIOL, V49, P835, DOI 10.1016/0895-4356(96)00006-6; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; LYNN J, 1993, NEW ENGL J MED, V328, P964; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; OSLER W, 1908, SCI IMMORTALITY, P18; QUILL TE, 1993, NEW ENGL J MED, V328, P965; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; Rothman, 1995, LIVING SHADOW DEATH; SAUNDERS DC, 1989, TXB PAIN, P624; SCHROEDER SA, 1995, DYING AM, P7; TEASDALE G, 1974, LANCET, V2, P81; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; World Health Organization, 1990, CANC PAIN REL PALL C	36	537	546	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					97	+		10.7326/0003-4819-126-2-199701150-00001	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005760				2022-12-28	WOS:A1997WD29800004
J	Downie, AB; Mulligan, J; Stratford, RJ; Betts, PR; Voss, LD				Downie, AB; Mulligan, J; Stratford, RJ; Betts, PR; Voss, LD			Are short normal children at a disadvantage? The Wessex growth study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT STATURE	Objective: To examine whether short stature through childhood represents a disadvantage at around 12 years. Design: Longitudinal non-intervention study of the physical and psychological development of children recruited from the community in 1986-7 after entry into primary school at age 5-6 years; this is the second psychometric assessment made in 1994-5 after entry into secondary school at age 11-13 years. Setting: Southampton and Winchester health districts. Subjects: 106 short normal children (<3rd centile for height when recruited) and 119 controls of average stature (10th-90th centile). Main outcome measures: Psychometric measures of cognitive development, self concept development, behaviour, and locus of control. Results: The short children did not differ significantly from the control children on measures of self esteem (19.4 v 20.2), self perception (104.2 v 102.4), parents' perception (46.9 v 47.0), or behaviour (6.8 v 5.3). The short children achieved significantly lower scores on measures of intelligence quotient (IQ) (102.6 v 108.6; P<0.005), reading attainment (44.3 v 47.9; P<0.002), and basic number skills (40.2 v 43.5; P<0.003) and displayed less internalisation of control (16.6 v 14.3; P<0.001) and less satisfaction with their height (P<0.0001). More short than control children, however,came fi-om working class homes (P<0.05). Social class was a better predictor than height of all measures except that of body satisfaction Attainment scores were predicted by class and IQ together rather than by height Height accounted for some of the variance in IQ and locus of control scores. Conclusions: These results provide only limited support for the hypothesis that short children are disadvantaged, at least up until 11-13 years old. Social class seems to have more influence than height on children's psychological development.	SOUTHAMPTON GEN HOSP, UNIV HOSP TRUST, DEPT CHILD HLTH, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SOUTHAMPTON, DEPT PSYCHOL, SOUTHAMPTON SO17 1BJ, HANTS, ENGLAND; SOUTHAMPTON UNIV HOSP TRUST, DEPT PAEDIAT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust								ALLEN KD, 1993, CHILD HEALTH CARE, V22, P61; Battle J, 1981, CULTURE FREE SELF ES; DOWDNEY L, 1995, INT J METHOD PSYCH, V5, P29; Downie AB, 1996, ARCH DIS CHILD, V75, P32, DOI 10.1136/adc.75.1.32; Elliot C. D., 1983, BRIT ABILITY SCALES; Harter S., 1985, MANUAL SELF PERCEPTI; Hoare P, 1993, Eur Child Adolesc Psychiatry, V2, P19, DOI 10.1007/BF02098827; HOLMES CS, 1982, CHILD CARE HLTH DEV, V8, P327, DOI 10.1111/j.1365-2214.1982.tb00293.x; LAW CM, 1987, ARCH DIS CHILD, V62, P855, DOI 10.1136/adc.62.8.855; *MARK RES SOC, 1991, OCC GROUP JOB DICT; NOWICKI S, 1973, J CONSULT CLIN PSYCH, V40, P148, DOI 10.1037/h0033978; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; SANDBERG DE, 1994, PEDIATRICS, V94, P832; SCARTH LG, 1994, GROWTH STATURE ADAPT, P107; SIEGEL PT, 1994, GROWTH STATURE ADAPT, P123; SIEGEL PT, 1990, PSYCHONEUROENDOCRINO, P40; SKUSE D, 1994, ACTA PAEDIATR, V83, P11, DOI 10.1111/j.1651-2227.1994.tb13413.x; STABLER B, 1991, ACTA PAEDIATR SCAND, P9; STABLER B, 1987, GROWTH ABNORMALITIES, P255; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400; VOSS LD, 1994, GROWTH STATURE ADAPT, P47; WEINBERG WA, 1974, J PEDIATR-US, V85, P482, DOI 10.1016/S0022-3476(74)80449-X; YOUNG-HYMAN D, 1986, P27; YOUNGHYMAN DL, 1990, PSYCHONEUROENDOCRINO, P40	27	106	107	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	1997	314	7074					97	100		10.1136/bmj.314.7074.97	http://dx.doi.org/10.1136/bmj.314.7074.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC479	9006466	Green Published			2022-12-28	WOS:A1997WC47900018
J	Rennie, AN				Rennie, AN			Prevalence of arm movements in patients with coronary heart disease: Case-control study	BRITISH MEDICAL JOURNAL			English	Article																		RENNIE AN, 1972, BRIT MED J, V1, P380, DOI 10.1136/bmj.1.5796.380-a; ROTH PJ, 1981, J ENG MED, V10, P79	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					122	122		10.1136/bmj.314.7074.122	http://dx.doi.org/10.1136/bmj.314.7074.122			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006473	Green Published			2022-12-28	WOS:A1997WC47900027
J	Hull, HF				Hull, HF			Vaccines - Pax polio	SCIENCE			English	Editorial Material											Hull, HF (corresponding author), WHO,GLOBAL PROGRAMME VACCINES & IMMUNIZAT,CH-1211 GENEVA 27,SWITZERLAND.							BART KJ, 1996, WHO, V74, P35; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; MORRIS W, 1978, AM HERITAGE DICT ENG, P833; 1995, WKLY EPIDEMIOL REC, V71, P189	4	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 3	1997	275	5296					40	41		10.1126/science.275.5296.40	http://dx.doi.org/10.1126/science.275.5296.40			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8999534				2022-12-28	WOS:A1997WA90300037
J	Bechara, A; Damasio, H; Tranel, D; Damasio, AR				Bechara, A; Damasio, H; Tranel, D; Damasio, AR			Deciding advantageously before knowing the advantageous strategy	SCIENCE			English	Article								Deciding advantageously in a complex situation is thought to require overt reasoning on declarative knowledge, namely, on facts pertaining to premises, options for action, and outcomes of actions that embody the pertinent previous experience. An alternative possibility was investigated: that overt reasoning is preceded by a nonconscious biasing step that uses neural systems other than those that support declarative knowledge. Normal participants and patients with prefrontal damage and decision-making defects performed a gambling task in which behavioral, psychophysiological, and self-account measures were obtained in parallel. Normals began to choose advantageously before they realized which strategy worked best, whereas prefrontal patients continued to choose disadvantageously even after they knew the correct strategy. Moreover, normals began to generate anticipatory skin conductance responses (SCRs) whenever they pondered a choice that turned out to be risky, before they knew explicitly that it was a risky choice, whereas patients never developed anticipatory SCRs, although some eventually realized which choices were risky. The results suggest that, in normal individuals, nonconscious biases guide behavior before conscious knowledge does. Without the help of such biases, overt knowledge may be insufficient to ensure advantageous behavior.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROL, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA	University of Iowa; Salk Institute			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389	NINDS NIH HHS [P01 NS19632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS019632] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bechara A., 1995, Society for Neuroscience Abstracts, V21, P1210; Damasio A.R., 2005, DESCARTES ERROR EMOT; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; FUSTER J, 1996, PREFRONTAL CORTEX; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; MONTAGUE PR, 1995, NATURE, V377, P725, DOI 10.1038/377725a0; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Tranel D., 1996, Society for Neuroscience Abstracts, V22, P1108	12	2151	2195	3	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 28	1997	275	5304					1293	1295		10.1126/science.275.5304.1293	http://dx.doi.org/10.1126/science.275.5304.1293			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036851				2022-12-28	WOS:A1997WK64400038
J	Choudhary, VR; Kinage, AK; Choudhary, TV				Choudhary, VR; Kinage, AK; Choudhary, TV			Low-temperature nonoxidative activation of methane over H-galloaluminosilicate (MFI) zeolite	SCIENCE			English	Article							HIGHER HYDROCARBONS	Conversion of methane to higher hydrocarbons by its low-temperature activation without forming undesirable carbon oxides is of great scientific and practical importance. Methane can be highly activated, yielding high rates of conversion to higher hydrocarbons and aromatics (10 to 45 percent) at low temperatures (400 degrees to 600 degrees C), by its reaction over H-galloaluminosilicate ZSM-5 type (MFI) zeolite in the presence of alkenes or higher alkanes. The methane activation results from its hydrogen-transfer reaction with alkenes.			Choudhary, VR (corresponding author), NATL CHEM LAB, DIV CHEM ENGN, PUNE 411008, MAHARASHTRA, INDIA.							AMENOMIYA Y, 1990, CATAL REV, V32, P163, DOI 10.1080/01614949009351351; Choudhary VR, 1996, J CATAL, V158, P23, DOI 10.1006/jcat.1996.0003; Choudhary VR, 1996, J CATAL, V158, P34, DOI 10.1006/jcat.1996.0004; HUTCHINGS GJ, 1989, CHEM SOC REV, V18, P251, DOI 10.1039/cs9891800251; LEE JS, 1988, CATAL REV, V30, P249, DOI 10.1080/01614948808078620; LUKYANOV DB, 1994, J CATAL, V145, P54, DOI 10.1006/jcat.1994.1006; LUKYANOV DB, 1994, J CATAL, V147, P494, DOI 10.1006/jcat.1994.1166; Lunsford J.H., 1990, CATAL TODAY, V6, P235; LUNSFORD JH, 1995, ANGEW CHEM INT EDIT, V34, P970, DOI 10.1002/anie.199509701; SHEPELEV SS, 1989, J CATAL, V117, P362, DOI 10.1016/0021-9517(89)90347-3; Yagita H, 1995, EFCE PUBL S, P639	11	186	200	5	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 28	1997	275	5304					1286	1288		10.1126/science.275.5304.1286	http://dx.doi.org/10.1126/science.275.5304.1286			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WK644	9036848				2022-12-28	WOS:A1997WK64400035
J	vanSteensel, B; deLange, T				vanSteensel, B; deLange, T			Control of telomere length by the human telomeric protein TRF1	NATURE			English	Article							IMMORTAL CELLS; YEAST; GENE; VARIABILITY; ELONGATION; CARCINOMA	Human telomeres, the nucleoprotein complexes at chromosome ends, consist of tandem arrays of TTAGGG repeats bound to specific proteins. In normal human cells, telomeres shorten with successive cell divisions(1,2), probably due to the terminal sequence loss that accompanies DNA replication. In tumours and immortalized cells, this decline is halted through the activation of telomerase(3-5), a reverse transcriptase that extends the telomeric TTAGGG-repeat arrays(6-7). Telomere length is stable in several immortal human-tell lines(3), suggesting that a regulatory mechanism exists for limiting telomere elongation by telomerase. Here we show that the human telomeric-repeat binding factor TRF1 (ref. 8) is involved in this regulation, Long-term overexpression of TRF1 in the telomerase-positive tumour-cell Line HT1080 resulted in a gradual and progressive telomere shortening, Conversely, telomere elongation was induced by expression of a dominant-negative TRF1 mutant that inhibited binding of endogenous TRF1 to telomeres. Our results identify TRF1 as a suppressor of telomere elongation and indicate that TRF1 is involved in the negative feedback mechanism that stabilizes telomere length. As TRF1 does not detectably affect the expression of telomerase, we propose that the binding of TRF1 controls telomere length in cis by inhibiting the action of telomerase at the ends of individual telomeres.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University			de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X				BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BIANCHI A, IN PRESS EMBO J; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; BRYAN TM, IN PRESS EUR J CANC; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; INSTIG AJ, 1990, SCIENCE, V250, P549; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P347; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MARCAND S, IN PRESS SCIENCE; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	29	1003	1039	0	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					740	743		10.1038/385740a0	http://dx.doi.org/10.1038/385740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034193				2022-12-28	WOS:A1997WJ42300051
J	George, JN; Woolf, SH; Raskob, GE; Wasser, JS; Aledort, LM; Ballem, PJ; Blanchette, VS; Bussel, JB; Cines, DB; Kelton, JG; Lichtin, AE; McMillan, R; Okerbloom, JA; Regan, DH; Warrier, I				George, JN; Woolf, SH; Raskob, GE; Wasser, JS; Aledort, LM; Ballem, PJ; Blanchette, VS; Bussel, JB; Cines, DB; Kelton, JG; Lichtin, AE; McMillan, R; Okerbloom, JA; Regan, DH; Warrier, I			Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American Society of Hematology	ANNALS OF INTERNAL MEDICINE			English	Article								To develop guidelines for the diagnosis and management of idiopathic thrombocytopenic purpura (ITP) and to document the extent to which these guidelines are based on either scientific evidence or opinion, the American Society of Hematology established a panel composed of 13 hematologists with expertise in ITP, a clinical epidemiologist, and a practice guidelines methodologist. A comprehensive review was done of all published English-language studies that met explicit inclusion criteria and that evaluated the natural history of ITP or the effectiveness of testing and treatment options for ITP. The quality of each study was graded by two reviewers using formal methodologic rules. In subject areas for which data were inadequate, recommendations were based on opinion and were derived by using a formal scoring procedure. Confidential questionnaires were used to survey the hematologists on the panel about the appropriateness of testing and treatment options in hundreds of clinical scenarios. Practice recommendations were derived from the mean appropriateness scores for each indication. Voting was kept confidential to give each panel member an equal voice and to limit biases introduced by group dynamics. The recommendations were peer reviewed by eight outside experts. This report focuses on data on and recommendations for adults with ITP. Little high-quality scientific evidence with which to assess the efficacy of diagnostic tests and treatments for ITP is available. The opinion of the panel was that most diagnostic tests are unnecessary in the routine work-ups of patients suspected of having ITP and that ITP accompanied by severe bleeding requires treatment with glucocorticoids, intravenous immunoglobulin, and other measures. However, treatment and hospitalization are often unnecessary when patients have only mild or moderate thrombocytopenia or minimal bleeding. Special therapeutic measures are sometimes indicated in pregnant women with ITP.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, FAIRFAX, VA USA; WATKINS CTR HEMATOL ONCOL, MANCHESTER, CT USA; MT SINAI SCH MED, NEW YORK, NY USA; UNIV BRITISH COLUMBIA, VANCOUVER, BC V5Z 1M9, CANADA; UNIV TORONTO, TORONTO, ON M5S 1A1, CANADA; CORNELL UNIV, COLL MED, ITHACA, NY 14853 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; MCMASTER UNIV, HAMILTON, ON, CANADA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; SCRIPPS CLIN, LA JOLLA, CA 92037 USA; HEARTLAND ONCOL HEMATOL, COUNCIL BLUFFS, IA USA; HEMATOL ONCOL GRP, PORTLAND, OR USA; WAYNE STATE UNIV, DETROIT, MI 48202 USA	Virginia Commonwealth University; Icahn School of Medicine at Mount Sinai; University of British Columbia; University of Toronto; Cornell University; University of Pennsylvania; McMaster University; Cleveland Clinic Foundation; Scripps Research Institute; Wayne State University	George, JN (corresponding author), UNIV OKLAHOMA, HLTH SCI CTR, HEMATOL ONCOL SECT, POB 26901, OKLAHOMA CITY, OK 73190 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; BROOK RH, 1991, N3376HHS RAND; Burrows R F, 1993, Obstet Gynecol Surv, V48, P781, DOI 10.1097/00006254-199312000-00003; BURROWS RF, 1990, AM J OBSTET GYNECOL, V163, P1147, DOI 10.1016/0002-9378(90)90675-W; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; CORTELAZZO S, 1991, BLOOD, V77, P31; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; GARMEL SH, 1995, PRENATAL DIAG, V15, P439, DOI 10.1002/pd.1970150506; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1994, NEW ENGL J MED, V331, P1207, DOI 10.1056/NEJM199411033311807; GEORGE JN, 1995, WILLIAMS HEMATOLOGY, P1315; GUTHRIE TH, 1988, AM J MED SCI, V296, P17, DOI 10.1097/00000441-198807000-00004; JACOBS P, 1994, AM J MED, V97, P55, DOI 10.1016/0002-9343(94)90048-5; LACEY JV, 1977, SEMIN THROMB HEMOST, V3, P160; RASMUS KT, 1989, OBSTET GYNECOL, V73, P943	15	97	101	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					319	326						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036806				2022-12-28	WOS:A1997WH06800012
J	Klein, AL; Grimm, RA; Black, IW; Leung, DY; Chung, MK; Vaughn, SE; Murray, RD; Miller, DP; Arheart, KL				Klein, AL; Grimm, RA; Black, IW; Leung, DY; Chung, MK; Vaughn, SE; Murray, RD; Miller, DP; Arheart, KL			Cardioversion guided by transesophageal echocardiography: The ACUTE pilot study - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						electric countershock; atrial fibrillation; echocardiography, transesophageal; thromboembolism; anticoagulants	TWO-DIMENSIONAL ECHOCARDIOGRAPHY; ATRIAL MECHANICAL FUNCTION; SPONTANEOUS ECHO CONTRAST; MITRAL-VALVE DISEASE; ELECTRICAL CARDIOVERSION; ANATOMIC CORRELATIONS; CLINICAL-APPLICATIONS; THROMBOEMBOLIC COMPLICATIONS; IMAGE ORIENTATION; FIBRILLATION	Background: Electrical cardioversion in patients with atrial fibrillation is associated with an increased risk for embolic stroke. Screening for atrial thrombi with transesophageal echocardiography (TEE) before cardioversion should, in many patients, safely permit cardioversion to be done earlier than would be possible with prolonged conventional, anticoagulation therapy. Objective: To compare the feasibility and safety of TEE-guided early cardioversion with those of conventional management of cardioversion in patients with atrial fibrillation. Design: Randomized, multicenter clinical trial. Setting: 10 hospitals in the United States, Europe, and Australia. Patients: 126 patients who had atrial fibrillation lasting longer than 2 days and were having electrical cardioversion. Intervention: Conventional therapy or early, TEE-guided cardioversion with short-term anticoagulation therapy. Outcome Measures: Feasibility outcome variables were frequency of cardioversion and times to cardioversion and sinus rhythm. Safety outcomes were ischemic stroke, transient ischemic attack, systemic embolization, bleeding, and detected episodes of clinical hemodynamic instability occurring as long as 4 weeks after cardioversion. Results: 62 patients were randomly assigned to receive TEE-guided cardioversion; IEE was done in 56 (90%) of these patients. Atrial thrombi were detected in 7 patients (13%) and led to the postponement of cardioversion. Cardioversion was successful in 38 of 45 patients (84%) who had early cardioversion. No embolization occurred with this strategy. Of the 64 patients receiving conventional therapy, 37 (58%) had cardioversion, which was successful in 28 patients (76%). One patient had a peripheral embolic event. The time to cardioversion was shorter in the TEE group (0.6 weeks [95% Cl, 0.3 to 0.9 weeks] compared with 4.8 weeks [Cl, 3.8 to 5.7 weeks]; P < 0.01). The incidence of clinical hemodynamic instability and bleeding complications tended to be greater in the conventional therapy group. Conclusions: These results suggest that TEE-guided cardioversion with short-term anticoagulation therapy is feasible and safe. The use of TEE may allow cardioversion to be done earlier, may decrease the risk for embolism associated with cardioversion, and may be associated with less clinical instability than conventional therapy. A large multicenter study to confirm these findings is currently under way.	UNIV NEBRASKA, OMAHA, NE USA; RIVERSIDE METHODIST HOSP, COLUMBUS, OH 43214 USA; OHIO STATE UNIV, COLUMBUS, OH 43210 USA; UNIV CALIF SAN FRANCISCO, MED CTR, SAN FRANCISCO, CA 94143 USA; UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA; TEXAS HEART INST, HOUSTON, TX 77025 USA; PRINCE HENRY HOSP, SYDNEY, NSW, AUSTRALIA; BRONX VET AFFAIRS MED CTR, BRONX, NY USA; UNIV ESSEN GESAMTHSCH, ESSEN, GERMANY	University of Nebraska System; University System of Ohio; Ohio State University; University of California System; University of California San Francisco; University of Louisville; Texas Heart Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; University of Duisburg Essen			Leung, Dominic/ABB-4492-2020	Miller, Dave/0000-0003-2947-152X; Leung, Dominic/0000-0002-5626-7236				ABERG H, 1968, ACTA MED SCAND, V183, P415; ALPERT JS, 1988, ANNU REV MED, V39, P41, DOI 10.1146/annurev.med.39.1.41; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; Balslov J T, 1968, Nord Med, V79, P243; BEPPU S, 1985, J AM COLL CARDIOL, V6, P744, DOI 10.1016/S0735-1097(85)80476-9; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; BLACK IW, 1994, CIRCULATION, V89, P2509, DOI 10.1161/01.CIR.89.6.2509; BLACK IW, 1991, BRIT HEART J, V66, P302; CHAN M, 1992, J AM SOC ECHOCARDIOG, V5, P308; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; FATKIN D, 1994, J AM COLL CARDIOL, V23, P307, DOI 10.1016/0735-1097(94)90412-X; FORFAR JC, 1979, BRIT HEART J, V42, P128; GOLDMAN MJ, 1960, PROG CARDIOVASC DIS, V2, P465, DOI 10.1016/S0033-0620(60)80005-9; GRIMM RA, 1993, J AM COLL CARDIOL, V22, P1359, DOI 10.1016/0735-1097(93)90543-A; GRIMM RA, 1993, NEW ENGL J MED, V329, P577; GRIMM RA, 1995, AM HEART J, V130, P174, DOI 10.1016/0002-8703(95)90253-8; GRIMM RA, 1994, J AM COLL CARDIOL, V23, P533, DOI 10.1016/0735-1097(94)90443-X; HALMOS PB, 1966, BRIT HEART J, V28, P302; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; HENRY WL, 1976, CIRCULATION, V53, P273, DOI 10.1161/01.CIR.53.2.273; HURST JW, 1964, AM J MED, V37, P728, DOI 10.1016/0002-9343(64)90021-X; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KLEIN AL, 1994, J AM COLL CARDIOL, pA128; KLEIN AL, 1994, CIRCULATION, V90, P21; KLEIN AL, 1996, J AM SOC ECHOCARDIOG, V9, P387; Klein Allan L., 1993, Journal of the American College of Cardiology, V21, p28A; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LEUNG DY, 1994, CIRCULATION, V90, P224; Leung DY, 1996, PROG CARDIOVASC DIS, V39, P21, DOI 10.1016/S0033-0620(96)80038-7; LOWN B, 1967, BRIT HEART J, V29, P469; LOWN B, 1963, NEW ENGL J MED, V269, P325, DOI 10.1056/NEJM196308152690701; MANNING WJ, 1994, J AM COLL CARDIOL, V23, P1535, DOI 10.1016/0735-1097(94)90652-1; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1989, J AM COLL CARDIOL, V13, P617, DOI 10.1016/0735-1097(89)90602-5; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MOREYRA E, 1995, AM HEART J, V129, P71, DOI 10.1016/0002-8703(95)90045-4; ORSINELLI DA, 1993, AM J CARDIOL, V72, P1337, DOI 10.1016/0002-9149(93)90315-4; Orsinelli DA, 1996, AM HEART J, V131, P622, DOI 10.1016/S0002-8703(96)90553-0; PEARSON AC, 1995, J AM COLL CARDIOL, V25, P1362, DOI 10.1016/0735-1097(95)00064-B; PETERSEN P, 1989, LANCET, V1, P175; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; QUINONES MA, 1981, CIRCULATION, V64, P744, DOI 10.1161/01.CIR.64.4.744; RESNEKOV L, 1967, BRIT HEART J, V29, P926; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SELZER A, 1966, PROG CARDIOVASC DIS, V9, P90; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1993, MAYO CLIN PROC, V68, P523, DOI 10.1016/S0025-6196(12)60367-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHAPIRO EP, 1988, AM J CARDIOL, V62, P1202, DOI 10.1016/0002-9149(88)90260-3; Stein B, 1990, Cardiovasc Clin, V21, P231; STODDARD MF, 1995, AM HEART J, V129, P1204, DOI 10.1016/0002-8703(95)90405-0; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	57	167	172	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					200	+		10.7326/0003-4819-126-3-199702010-00004	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027270				2022-12-28	WOS:A1997WF16800004
J	Lorenz, RD; McKay, CP; Lunine, JI				Lorenz, RD; McKay, CP; Lunine, JI			Photochemically driven collapse of Titan's atmosphere	SCIENCE			English	Article							SURFACE; MODEL; EQUILIBRIUM; CLIMATE; LIQUID; MARS	Saturn's giant moon Titan has a thick (1.5 bar) nitrogen atmosphere, which has a temperature structure that is controlled by the absorption of solar and thermal radiation by methane, hydrogen, and organic aerosols into which methane is irreversibly converted by photolysis. Previous studies of Titan's climate evolution have been done with the assumption that the methane abundance was maintained against photolytic depletion throughout Titan's history, either by continuous supply from the interior or by buffering by a surface or near surface reservoir. Radiative-convective and radiative-saturated equilibrium models of Titan's atmosphere show that methane depletion may have allowed Titan's atmosphere to cool so that nitrogen, its main constituent, condenses onto the surface, collapsing Titan into a Triton-like frozen state with a thin atmosphere.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Lorenz, RD (corresponding author), UNIV ARIZONA,DEPT PLANETARY SCI,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.		Lorenz, Ralph D/B-8759-2016	Lorenz, Ralph D/0000-0001-8528-4644				BERTAUX JL, 1983, J GEOPHYS RES-SPACE, V88, P8716, DOI 10.1029/JA088iA11p08716; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; DEMOTT SF, 1995, NATURE, V374, P238; DUBOULOZ N, 1989, ICARUS, V82, P81, DOI 10.1016/0019-1035(89)90025-0; ENGEL S, 1995, PLANET SPACE SCI, V43, P1059, DOI 10.1016/0032-0633(95)00044-6; GIERASCH PJ, 1973, J ATMOS SCI, V30, P1502, DOI 10.1175/1520-0469(1973)030<1502:APVATC>2.0.CO;2; GRIFFITH CA, 1991, ICARUS, V93, P362, DOI 10.1016/0019-1035(91)90219-J; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KOUVARIS LC, 1991, ICARUS, V91, P112, DOI 10.1016/0019-1035(91)90131-C; LARA LM, 1994, PLANET SPACE SCI, V42, P5, DOI 10.1016/0032-0633(94)90135-X; LEMMON MT, 1995, ICARUS, V113, P27, DOI 10.1006/icar.1995.1003; Lorenz RD, 1995, J GEOPHYS RES-PLANET, V100, P26377, DOI 10.1029/95JE02708; LORENZ RD, 1993, PLANET SPACE SCI, V41, P647, DOI 10.1016/0032-0633(93)90048-7; Lorenz RD, 1996, PLANET SPACE SCI, V44, P1021, DOI 10.1016/0032-0633(95)00139-5; LORENZ RD, 1994, PLANET SPACE SCI, V42, P1, DOI 10.1016/0032-0633(94)90134-1; Lorenz RD, 1996, ICARUS, V122, P79, DOI 10.1006/icar.1996.0110; LUNINE JI, 1985, NATURE, V317, P238, DOI 10.1038/317238a0; LUNINE JI, 1989, ICARUS, V80, P370, DOI 10.1016/0019-1035(89)90147-4; McIlveen R., 1992, FUNDAMENTALS WEATHER; MCKAY CP, 1991, SCIENCE, V253, P1118, DOI 10.1126/science.11538492; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; MCKAY CP, 1993, ICARUS, V102, P88, DOI 10.1006/icar.1993.1034; MORRISON D, 1986, SATELLITES, P764; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; SAMUELSON RE, 1983, ICARUS, V53, P364, DOI 10.1016/0019-1035(83)90156-2; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; THOMPSON WR, 1992, ICARUS, V97, P187, DOI 10.1016/0019-1035(92)90127-S; TOON OB, 1992, ICARUS, V95, P24, DOI 10.1016/0019-1035(92)90188-D; TOUBLANC D, 1995, ICARUS, V113, P2, DOI 10.1006/icar.1995.1002; YUNG YL, 1984, ASTROPHYS J SUPPL S, V55, P465, DOI 10.1086/190963	30	76	76	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					642	644		10.1126/science.275.5300.642	http://dx.doi.org/10.1126/science.275.5300.642			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005844				2022-12-28	WOS:A1997WF07700031
J	Levine, MM				Levine, MM			Oral vaccines against cholera: Lessons from Vietnam and elsewhere	LANCET			English	Editorial Material							TOXIN-COREGULATED PILI; FIELD TRIAL; BANGLADESH				Levine, MM (corresponding author), UNIV MARYLAND,SCH MED,CTR VACCINE DEV,BALTIMORE,MD 21201, USA.							BATSON A, 1994, VACCINE, V12, P963, DOI 10.1016/0264-410X(94)90328-X; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; HALL RH, 1991, INFECT IMMUN, V59, P2508, DOI 10.1128/IAI.59.7.2508-2512.1991; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837	7	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					220	221		10.1016/S0140-6736(97)22004-0	http://dx.doi.org/10.1016/S0140-6736(97)22004-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014902				2022-12-28	WOS:A1997WD90600002
J	Payne, N; Saul, C				Payne, N; Saul, C			Variations in use of cardiology services in a health authority: Comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality	BRITISH MEDICAL JOURNAL			English	Article							BYPASS-SURGERY; CARE; QUESTIONNAIRE; DEPRIVATION; MORBIDITY; SYMPTOMS; EQUITY; ACCESS; CASS	Objective: To explore the relation between rates of coronary artery revascularisation and prevalence of angina to assess whether use of health services reflects need. Design: Prevalence of angina symptoms determined by postal questionnaire on 16 750 subjects (18 to 94 years), Comparison of data on use of coronary artery revascularisation with prevalence of symptoms and mortality from coronary heart disease. Setting: Health authority with population of 530 000. Subjects: Patients admitted to hospital for coronary heart disease; patients who died; and patients undergoing angiography, angioplasty, or coronary artery bypass graft Cohort of 491 people with symptoms from survey. Main outcome measures: Pearson's product moment correlation coefficients for relation between variables. Results: Overall, 4.0% (95% confidence interval 3.7% to 4.4%) of subjects had symptoms, Prevalences varied widely between electoral wards and were positively associated with Townsend score (r = 0.79; P < 0.001), as was mortality, but the correlation between admission rates and Townsend score was less clear (r = 0.47; P < 0.01), Revascularisation rate and Townsend score were not associated. The ratio of revascularisation to number experiencing symptoms was inversely related to Townsend score (r = -0.67; P < 0.001), The most deprived wards had only about half the number of revascularisations per head of population with angina than did the more affluent wards, In affluent wards 11% (13/116) of those with symptoms had coronary angiograms compared with only 4% (9/216) in poorer wards (chi(2) = 4.96; P = 0.026). Townsend score also inversely correlated with revascularisations per public health premature death from coronary heart disease Carol Saul, (r = -0.55; P < 0.01) and revascularisations per admission for myocardial infarction (r = -0.47; P < 0.01). Conclusion: The use of interventional cardiology services is not commensurate with need, thus exhibiting the inverse care law.			Payne, N (corresponding author), SHEFFIELD HLTH,SHEFFIELD S10 3TG,S YORKSHIRE,ENGLAND.		Payne, Nick/A-3073-2010					*AUD COMM, 1995, DEAR OUR HEARTS COMM; BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; CAMERON AAC, 1995, J AM COLL CARDIOL, V26, P895, DOI 10.1016/0735-1097(95)00280-4; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; *CENTR HLTH MON UN, 1994, COR HEART DIS EP OV; *CLIN STAND ADV GR, 1993, COR ART BYP GRAFT CO; COLHOUN H, 1996, HLTH SURVEY ENGLAND; DEAN AG, EPIINFO VERSION 5 WO; ELDER AT, 1991, BRIT MED J, V303, P950, DOI 10.1136/bmj.303.6808.950; GARBER CE, 1992, J CLIN EPIDEMIOL, V45, P715, DOI 10.1016/0895-4356(92)90048-R; HARRIS RB, 1991, J CLIN EPIDEMIOL, V44, P1071, DOI 10.1016/0895-4356(91)90009-X; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; KEE F, 1993, BRIT MED J, V307, P1305, DOI 10.1136/bmj.307.6915.1305; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MCCORMICK A, 1995, MORBIDITY STAT GEN P; McKee M, 1993, Qual Health Care, V2, P104, DOI 10.1136/qshc.2.2.104; *OFF POP CENS SURV, 1984, GEN HOUS SURV 1982; Office of Population Censuses and Surveys, 1990, TAB LIST CLASS SURG; PAYNE JN, 1993, J PUBLIC HEALTH MED, V15, P161; ROBERTS H, 1994, TRENT HLTH LIFESTYLE; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; THOMAS M, 1994, OPCS SERIES GHS, V23; TOWNSEND P, 1987, J SOC POLICY, V16, P125, DOI 10.1017/S0047279400020341; UNDERWOOD MJ, 1993, BMJ-BRIT MED J, V306, P1047, DOI 10.1136/bmj.306.6884.1047; *VAR SUBGR CHIEF M, 1995, VAR HLTH WHAT CAN DE; Voors AA, 1996, CIRCULATION, V93, P42, DOI 10.1161/01.CIR.93.1.42; WENNBERG D, 1995, C ABSTRACTS SCI BASI; *WORK GROUP BRIT C, 1994, BRIT HEART J, V72, P303	28	85	87	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					257	261		10.1136/bmj.314.7076.257	http://dx.doi.org/10.1136/bmj.314.7076.257			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022488	Green Published			2022-12-28	WOS:A1997WE63300023
J	Williams, DM; Kasting, JF; Wade, RA				Williams, DM; Kasting, JF; Wade, RA			Habitable moons around extrasolar giant planets	NATURE			English	Article							MARS; ATMOSPHERE; COMPANION; CONSTRAINTS; TITANS	Possible planetary objects have now been discovered(1-9) orbiting nine different main-sequence stars. These companion objects (some of which might actually be brown dwarfs) all have a mass at least half that of Jupiter, and are therefore unlikely to be hospitable to Earth-like Life: jovian planets and brown dwarfs support neither a solid nor a liquid surface near which organisms might dwell. Here we argue that redry moons orbiting these companions could be habitable if the planet-moon system orbits the parent star within the so-called 'habitable zone'(10), where life- supporting liquid water(11) could be present. The companions to the stars 16 Cygni B and 47 Ursae Majoris might satisfy this criterion. Such a moon would, however, need to be large enough (>0.12 Earth masses) to retain a substantial and long-lived atmosphere, and would also need to possess a strong magnetic field in order to prevent its atmosphere from being sputtered away by the constant bombardment of energetic ions from the planet's magnetosphere.	PENN STATE UNIV, DEPT GEOSCI, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Williams, DM (corresponding author), PENN STATE UNIV, DEPT ASTRON & ASTROPHYS, 525 DAVEY LAB, UNIVERSITY PK, PA 16802 USA.		Kasting, James/AAF-6851-2020					Boss AP, 1996, NATURE, V379, P397, DOI 10.1038/379397a0; BRACK A, 1993, ORIGINS LIFE EVOL B, V23, P3, DOI 10.1007/BF01581985; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; BUTLER RP, UNPUB ASTROPHYS J; CHYBA CF, 1990, NATURE, V343, P129, DOI 10.1038/343129a0; COCHRAN WD, 1991, ASTROPHYS J, V380, pL35; Cochran WD., 1996, B AM ASTRON SOC, V28, P1111; FOX JL, 1993, J GEOPHYS RES-PLANET, V98, P3297, DOI 10.1029/92JE02289; FRANCIS PW, 1982, J GEOPHYS RES, V87, P9881, DOI 10.1029/JB087iB12p09881; Gatewood G., 1996, B AM ASTRON SOC, V28, P885; GRIFFITH CA, 1995, J GEOPHYS RES-PLANET, V100, P16907, DOI 10.1029/95JE01135; Gurnett DA, 1996, NATURE, V384, P535, DOI 10.1038/384535a0; KASS DM, 1995, SCIENCE, V268, P697, DOI 10.1126/science.7732377; KASTING JF, 1988, SCI AM, V258, P90, DOI 10.1038/scientificamerican0288-90; KASTING JF, 1993, ICARUS, V101, P1; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; Lin DNC, 1996, NATURE, V380, P606, DOI 10.1038/380606a0; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MARCY GW, UNPUB ASTROPHYS J; MCELROY MB, 1972, SCIENCE, V175, P443, DOI 10.1126/science.175.4020.443; MCKAY CP, 1991, NATURE, V352, P489, DOI 10.1038/352489a0; Peale S. J., 1977, IAU C, P87; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PRINN RG, 1981, ASTROPHYS J, V249, P308, DOI 10.1086/159289; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; ROY AE, 1988, ORBITAL MOTION, P239; Saumon D, 1996, ASTROPHYS J, V460, P993, DOI 10.1086/177027; SOLOMON SC, 1990, J GEOPHYS RES-SOLID, V95, P11073, DOI 10.1029/JB095iB07p11073; STROBEL DF, 1992, ICARUS, V100, P512, DOI 10.1016/0019-1035(92)90114-M; Turcotte DL, 1996, J GEOPHYS RES-PLANET, V101, P4765, DOI 10.1029/95JE02295; TURCOTTE DL, 1982, GEODYNAMICS APPL CON, P137; VANALLEN JA, 1976, JUPITER; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; WATSON A, 1978, BIOSYSTEMS, V10, P293, DOI 10.1016/0303-2647(78)90012-6	36	158	159	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					234	236		10.1038/385234a0	http://dx.doi.org/10.1038/385234a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000072				2022-12-28	WOS:A1997WC71100040
J	Mahajan, R; Delphin, C; Guan, TL; Gerace, L; Melchior, F				Mahajan, R; Delphin, C; Guan, TL; Gerace, L; Melchior, F			A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2	CELL			English	Article							RNA1 GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; TRANSPORT FACTORS; RCC1 PROTEIN; IMPORT; RAN/TC4; GTP; IDENTIFICATION; ENCODES	We have found that the mammalian Ran GTPase-activating protein RanGAP1 is highly concentrated at the cytoplasmic periphery of the nuclear pore complex (NPC), where it associates with the 358-kDa Ran-GTP-binding protein RanBP2. This interaction requires the ATP-dependent posttranslational conjugation of RanGAP1 with SUMO-1 (for small ubiquitin-related modifier), a novel protein of 101 amino acids that contains low but significant homology to ubiquitin. SUMO-1 appears to represent the prototype for a novel family of ubiquitin-related protein modifiers. Inhibition of nuclear protein import resulting from antibodies directed at NPC-associated RanGAP1 cannot be overcome by soluble cytosolic RanGAP1, indicating that GTP hydrolysis by Ran at RanBP2 is required for nuclear protein import.			Mahajan, R (corresponding author), Scripps Res Inst, DEPT CELL BIOL, 10555 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Melchior, Frauke/E-2014-2014; Christian, Delphin/P-9284-2017	Melchior, Frauke/0000-0001-9546-8797; Christian, Delphin/0000-0003-3240-8695				Bastos R, 1995, INT REV CYTOL, V162B, P257; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; SWEET DJ, 1995, TRENDS CELL BIOL, V5, P444, DOI 10.1016/S0962-8924(00)89108-4; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	45	933	977	3	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					97	107		10.1016/S0092-8674(00)81862-0	http://dx.doi.org/10.1016/S0092-8674(00)81862-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019411	Bronze			2022-12-28	WOS:A1997WC56900013
J	Gotto, AM				Gotto, AM			The Multiple Risk Factor Intervention Trial (MRFIT) - A return to a landmark trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; DEATH				Gotto, AM (corresponding author), CORNELL UNIV,COLL MED,OFF DEAN,1300 YORK AVE,NEW YORK,NY 10021, USA.							*AM HEART ASS, 1995, HEART STROK FACTS 19; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; KIRCHSTEIN R, 1993, JAMA-J AM MED ASSOC, V270, P1521; *MULT RISK FACT IN, 1990, JAMA-J AM MED ASSOC, V263, P1795; *MULT RISK FACT IN, 1986, AM J CARDIOL, V58, P1; *MULT RISK FACT IN, 1982, JAMA-J AM MED ASSOC, V248, P1465; *MULT RISK FACT IN, 1996, CIRCULATION, V94, P946; *NAT I HLTH, 1971, NIH US DHEW PUBL; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823	10	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					595	597		10.1001/jama.277.7.595	http://dx.doi.org/10.1001/jama.277.7.595			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032169				2022-12-28	WOS:A1997WH29700038
J	Hunink, MGM; Goldman, L; Tosteson, ANA; Mittleman, MA; Goldman, PA; Williams, LW; Tsevat, J; Weinstein, MC				Hunink, MGM; Goldman, L; Tosteson, ANA; Mittleman, MA; Goldman, PA; Williams, LW; Tsevat, J; Weinstein, MC			The recent decline in mortality from coronary heart disease, 1980-1990 - The effect of secular trends in risk factors and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; DENSITY LIPOPROTEIN CHOLESTEROL; NUTRITION EXAMINATION SURVEYS; MYOCARDIAL-INFARCTION; UNITED-STATES; CARDIOVASCULAR-DISEASE; NATIONAL-HEALTH; ALAMEDA COUNTY; SURVIVAL; MINNESOTA	Objective.-To examine whether secular trends in risk factor levels and improvements in treatment can account for the observed decline in coronary heart disease mortality in the United States from 1980 to 1990 and to analyze the proportional contribution of these changes. Data Sources.-Literature review, US statistics, health surveys, and ongoing clinical trials. Study Selection.-Data representative of the US situation nationwide reported in adequate detail. Data Extraction.-A computer-simulation state-transition model of the US population between the ages of 35 and 84 years was developed to forecast coronary mortality. The input variables were estimated such that the combination of values led to an adequate agreement with reported coronary mortality figures. Subsequently, secular trends were modeled. Data Synthesis.-Actual coronary mortality in 1990 was 34% (127 000 deaths) lower than would be predicted if risk factor levels, case-fatality rates, and event rates in those with and without coronary disease remained the same as in 1980. When secular changes in these factors were included in the model, predicted coronary mortality in 1990 was within 3% (in 000 deaths) of the observed mortality and explained 92% of the decline; only 25% of the decline was explained by primary prevention, while 29% was explained by secondary reduction in risk factors in patients with coronary disease and 43% by other improvements in treatment in patients with coronary disease. Conclusions. These results suggest that primary and Secondary risk factor reductions explain about 50% of the striking decline in coronary mortality in the United States between 1980 and 1990 but that more than 70% of the overall decline in mortality has occurred among patients with coronary disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT MED, BOSTON, MA 02215 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94143 USA; DARTMOUTH HITCHCOCK MED CTR, DEPT CLIN RES, LEBANON, NH 03766 USA; UNIV CINCINNATI, MED CTR, DIV GEN INTERNAL MED, CINCINNATI, OH 45267 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Dartmouth College; University System of Ohio; University of Cincinnati	Hunink, MGM (corresponding author), UNIV GRONINGEN, DEPT HLTH SCI, ANTONIUS DEUSINGLAAN 1, NL-9713 AV GRONINGEN, NETHERLANDS.			Mittleman, Murray/0000-0001-9788-7274	AHRQ HHS [R01HS06258] Funding Source: Medline; NHLBI NIH HHS [1RO1HL46315] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006258] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046315] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; BURKE GL, 1989, INT J EPIDEMIOL, V18, pS73; COHN BA, 1988, AM J EPIDEMIOL, V127, P1143, DOI 10.1093/oxfordjournals.aje.a114908; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; ELVEBACK LR, 1985, MAYO CLIN PROC, V60, P305, DOI 10.1016/S0025-6196(12)60537-0; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; FEINLEIB M, 1989, CIRCULATION, V79, P13; FIORE MC, 1989, JAMA-J AM MED ASSOC, V261, P49, DOI 10.1001/jama.261.1.49; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON D J, 1990, Journal of Drug Development, V3, P11; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JAMROZIK K, 1989, MED J AUSTRALIA, V150, P14; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAPLAN GA, 1988, AM J EPIDEMIOL, V127, P1131, DOI 10.1093/oxfordjournals.aje.a114907; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MCGOVERN PG, 1992, JAMA-J AM MED ASSOC, V268, P753; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; *NAT CTR HLTH STAT, 1994, VITA STAT US 1990, V2; *NAT CTR HLTH STAT, 1987, US DEP HLTH HUM S 10, V164; *NAT CTR HLTH STAT, 1989, VIT HLTH STAT, V10; *NAT CTR HLTH STAT, 1985, VIT STAT US 1980, V2; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988, V2; *NAT CTR HLTH STAT, 1989, VIT STAT US 1986, V2; *NAT CTR HLTH STAT, 1990, NAT HLTH NUTR EX SUR; *NAT CTR HLTH STAT, 1992, MMWR-MORBID MORTAL W, V41, P354; *NAT HEART LUNG BL, 1990, MORB COR HEART DIS U, P45; PEDERSEN TR, 1994, LANCET, V344, P1383; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; SCHAFFER WA, 1975, NEW ENGL J MED, V293, P259, DOI 10.1056/NEJM197508072930601; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TOSTESON ANA, 1990, AM J PUBLIC HEALTH, V80, P1481, DOI 10.2105/AJPH.80.12.1481; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; *US BUR CENS, 1990, CURR POP REP US P25, V1057; *US DEPT HHS, 1992, VIT HLTH STAT, V13; *US DEPT HHS, 1991, VIT HLTH STAT, V13; *US DEPT HHS, 1988, VIT HLTH STAT, V13; *US DEPT HHS, NIH PUBL; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003	55	503	514	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					535	542		10.1001/jama.277.7.535	http://dx.doi.org/10.1001/jama.277.7.535			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH297	9032159				2022-12-28	WOS:A1997WH29700028
J	Xu, WQ; Harrison, SC; Eck, MJ				Xu, WQ; Harrison, SC; Eck, MJ			Three-dimensional structure of the tyrosine kinase c-Src	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; SH3 DOMAIN; CRYSTAL-STRUCTURE; TRANSFORMING PROTEIN; HOMOLOGY-2 DOMAIN; BINDING-SITE; P60C-SRC; IDENTIFICATION; ACTIVATION; MECHANISM	The structure of a large fragment of the c-Src tyrosine kinase, comprising the regulatory and kinase domains and the carboxy-terminal tail, has been determined at 1.7 Angstrom resolution in a closed, inactive state. Interactions among domains, stabilized by binding of the phosphorylated tail to the SH2 domain, lock the molecule in a conformation that simultaneously disrupts the kinase active site and sequesters the binding surfaces of the SH2 and SH3 domains. The structure shows how appropriate cellular signals, or transforming mutations in v-Src, could break these interactions to produce an open, active kinase.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, LAB MOL MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Xu, Wenqing/0000-0002-2884-3101				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELLIS B, 1994, J CELL BIOCH B S, V18, P276; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Koegl M, 1995, ONCOGENE, V11, P2317; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, IN PRESS ANN REV BIO; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OKADA M, 1993, J BIOL CHEM, V268, P18070; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; 1994, ATA CRYSTALLOGR D, V50, P760	52	1220	1253	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					595	602		10.1038/385595a0	http://dx.doi.org/10.1038/385595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024657				2022-12-28	WOS:A1997WH29400040
J	Bush, ABG				Bush, ABG			Numerical simulation of the cretaceous tethys circumglobal current	SCIENCE			English	Article							UPPER-OCEAN; VARIABILITY; PACIFIC	Certain paleobiogeographical reconstructions of ocean currents during the Cretaceous (about 144 to 65 million years ago) suggest that a circumglobal tropical current flowed westward through the continental configuration of that time. Although some numerical climate models failed in initial attempts to simulate this current, simulations with a coupled atmosphere-ocean model with relatively high spatial resolution and a late Cretaceous continental distribution show that a circumglobal current is a robust feature even though local surface currents in the Tethys Seaway reverse during the south Eurasian monsoon months.			Bush, ABG (corresponding author), PRINCETON UNIV, ATMOSPHER & OCEAN SCI PROGRAM, POB CN710, SAYRE HALL, PRINCETON, NJ 08544 USA.							Deser C, 1996, J CLIMATE, V9, P1840, DOI 10.1175/1520-0442(1996)009<1840:UOTVIT>2.0.CO;2; FINE RA, 1987, J PHYS OCEANOGR, V17, P553, DOI 10.1175/1520-0485(1987)017<0553:TPOTIT>2.0.CO;2; GU D, UNPUB; GU DF, 1995, J CLIMATE, V8, P864, DOI 10.1175/1520-0442(1995)008<0864:SCOAAI>2.0.CO;2; Ji M, 1996, J CLIMATE, V9, P3105, DOI 10.1175/1520-0442(1996)009<3105:CMPOED>2.0.CO;2; Jin FF, 1996, SCIENCE, V274, P76, DOI 10.1126/science.274.5284.76; KNUTSON TR, IN PRESS J CLIM; Ladas G., 1991, OSCILLATION THEORY D; LATIF M, 1994, CLIM DYNAM, V9, P167, DOI 10.1007/BF00208250; LATIF M, 1994, SCIENCE, V266, P634, DOI 10.1126/science.266.5185.634; LAU NC, 1994, J CLIMATE, V7, P1184, DOI 10.1175/1520-0442(1994)007<1184:AMSOTR>2.0.CO;2; LIU ZG, 1994, J PHYS OCEANOGR, V24, P2606, DOI 10.1175/1520-0485(1994)024<2606:AGSOTU>2.0.CO;2; LIU ZY, 1995, J PHYS OCEANOGR, V25, P449, DOI 10.1175/1520-0485(1995)025<0449:HDWSPA>2.0.CO;2; LU P, 1995, J PHYS OCEANOGR, V25, P2606; McPhaden M. J., 1993, OCEANOGRAPHY, V6, P36; NEELIN JD, 1994, ANNU REV FLUID MECH, V26, P617, DOI DOI 10.1146/ANNUREV.FL.26.010194.003153; Philander S.G., 1990, NINO NINA SO OSCILLA; SCHOPF PS, 1988, J ATMOS SCI, V45, P549, DOI 10.1175/1520-0469(1988)045<0549:VIACOM>2.0.CO;2; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; ZHANG Y, IN PRESS J CLIM	21	54	56	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 7	1997	275	5301					807	810		10.1126/science.275.5301.807	http://dx.doi.org/10.1126/science.275.5301.807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012342				2022-12-28	WOS:A1997WG77700053
J	KauffmanZeh, A; RodriguezViciana, P; Ulrich, E; Gilbert, C; Coffer, P; Downward, J; Evan, G				KauffmanZeh, A; RodriguezViciana, P; Ulrich, E; Gilbert, C; Coffer, P; Downward, J; Evan, G			Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB	NATURE			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE; ACTIVATION; DOMAIN; GTPASE; LOCALIZATION; AKT	The viability of vertebrate cells depends on survival factors which activate signal transduction pathways that suppress apoptosis. Defects in anti-apoptotic signalling pathways are implicated in many pathologies including cancer, in which apoptosis induced by deregulated oncogenes must be forestalled for a tumour to become established. Phosphatidylinositol-3-kinase (PI(3)K) is involved in the intracellular signal transduction of many receptors and has been implicated in the transduction of survival signals in neuronal cells(1). We therefore examined the role of PI(3)K, its upstream effector Ras(2), and its putative downstream protein kinase effecters PKB/Akt(3,4) and p70(S6K) (ref. 5) in the modulation of apoptosis induced in fibroblasts by the oncoprotein c-Myc. Here we show that Ras activation of PI(3)K suppresses c-Myc-induced apoptosis through the activation of PKB/Akt but not p70(S6K). However, we also found that Ras is an effective promoter of apoptosis, through the Raf pathway. Thus Ras activates contradictory intracellular pathways that modulate cell viability. Induction of apoptosis by Ras may be an important factor in limiting the expansion of somatic cells that sustain oncogenic ras mutations.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNIV UTRECHT HOSP,DEPT PULM DIS,NL-3584 CX UTRECHT,NETHERLANDS	Cancer Research UK; Utrecht University; Utrecht University Medical Center			Coffer, Paul/AAF-7970-2020; Downward, Julian/A-3251-2012; Coffer, Paul J/A-5769-2009	Downward, Julian/0000-0002-2331-4729				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FLORES VJ, 1995, J BIOL CHEM, V270, P22473; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Park SH, 1995, ONCOGENE, V11, P2349; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VICIANA PR, 1994, NATURE, V370, P5527; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P5533; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	1029	1071	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					544	548		10.1038/385544a0	http://dx.doi.org/10.1038/385544a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020362				2022-12-28	WOS:A1997WG23500050
J	Nachtigall, LB; Boepple, PA; Pralong, FP; Crowley, WF				Nachtigall, LB; Boepple, PA; Pralong, FP; Crowley, WF			Adult-onset idiopathic hypogonadotropic hypogonadism - A treatable form of male infertility	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING HORMONE; MEN; SECRETION; TESTOSTERONE; RESPONSES; PATTERNS; PUBERTY; DEFECT; GNRH	Background Men with isolated gonadotropin-releasing hormone (GnRH) deficiency typically present with an absence of pubertal development. We describe an adult-onset form of idiopathic hypogonadotropic hypogonadism that develops after puberty. Methods We studied 10 men (age, 27 to 57 years) with normal sexual maturation, idiopathic infertility, sexual dysfunction, low serum testosterone concentrations, and apulsatile secretion of luteinizing hormone on frequent blood sampling. All the men had otherwise normal anterior pituitary hormone secretion and sellar anatomy. We compared the results of semen analyses and measurements of testicular volume, serum testosterone, inhibin B, and gonadotropins in these men with the results in 24 men with classic GnRH deficiency before and during GnRH-replacement therapy and in 29 normal men of similar age. Results Serum gonadotropin concentrations in the men with adult-onset GnRH deficiency were similar before and during pulsatile GnRH administration to those in the men with classic GnRH deficiency. However, as compared with men with classic GnRH deficiency, men with adult-onset hypogonadotropic hypogonadism had larger mean (+/-SD) testicular volumes (18+/-5 vs. 3+/-2 ml, P<0.001), serum testosterone concentrations (78+/-34 vs. 49+/-20 ng per deciliter [2.7+/-1.2 vs. 1.7+/-0.7 nmol per liter], P=0.004), and serum inhibin B concentrations (119+/-52 vs. 60+/-21 pg per milliliter, P<0.001). Treatment with GnRH reversed the hypogonadism and restored fertility in each of the five men who received long-term therapy. Conclusions The recognition of adult-onset hypogonadotropic hypogonadism in men as a distinct disorder expands the spectrum of GnRH deficiency and identifies a treatable form of male infertility. (C) 1997, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, REPROD ENDOCRINE UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, NATL CTR INFERTIL RES, BOSTON, MA 02114 USA; CHU VAUDOIS, DIV ENDOCRINOL, LAUSANNE, SWITZERLAND	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015788, U54HD028138] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164, P30HD028138] Funding Source: NIH RePORTER; NICHD NIH HHS [P30 HD028138, R01 HD015788, U54 HD029164, U54-HD29164, R01-HD-15788, U54 HD028138, P30-HD28138] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARKAN AL, 1985, J CLIN ENDOCR METAB, V61, P1118, DOI 10.1210/jcem-61-6-1118; BRAUNSTEIN GD, 1981, AM J PEDIAT HEMATOL, V3, P67; CAMERON JL, 1991, J CLIN ENDOCR METAB, V73, P35, DOI 10.1210/jcem-73-1-35; CARISKI AT, 1981, JAMA-J AM MED ASSOC, V245, P62, DOI 10.1001/jama.245.1.62; CHARBONNEL B, 1981, ACTA ENDOCRINOL-COP, V98, P178, DOI 10.1530/acta.0.0980178; DURANTEAU L, 1993, ACTA ENDOCRINOL-COP, V128, P351, DOI 10.1530/acta.0.1280351; FILICORI M, 1984, J CLIN INVEST, V73, P1638, DOI 10.1172/JCI111370; FOK ACK, 1989, AUST NZ J MED, V19, P354, DOI 10.1111/j.1445-5994.1989.tb00279.x; Georgopoulos NA, 1997, J CLIN ENDOCR METAB, V82, P213, DOI 10.1210/jc.82.1.213; HARDJASUDARMA M, 1994, SOUTHERN MED J, V87, P340, DOI 10.1097/00007611-199403000-00008; HOFFMAN AR, 1982, NEW ENGL J MED, V307, P1237, DOI 10.1056/NEJM198211113072003; JENKINS JS, 1976, J CLIN ENDOCR METAB, V43, P394, DOI 10.1210/jcem-43-2-394; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; MCLEOD JF, 1993, J CLIN ENDOCR METAB, V77, pA599, DOI 10.1210/jcem.77.3.8370682; Nachtigall LB, 1996, J CLIN ENDOCR METAB, V81, P3520, DOI 10.1210/jc.81.10.3520; PAXSON CL, 1976, PEDIATRICS, V57, P893; RANJAN A, 1994, BRIT J NEUROSURG, V8, P179, DOI 10.3109/02688699409027964; RAO PN, 1976, STEROIDS, V28, P101, DOI 10.1016/0039-128X(76)90129-X; ROBERTS AC, 1993, FERTIL STERIL, V60, P686; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; SANTEN RJ, 1973, J CLIN ENDOCR METAB, V36, P47, DOI 10.1210/jcem-36-1-47; SNYDER PJ, 1987, ENDOCRIN METAB CLIN, V16, P755, DOI 10.1016/S0889-8529(18)30472-9; SPITZ IM, 1974, NEW ENGL J MED, V290, P10, DOI 10.1056/NEJM197401032900103; SPRATT DI, 1987, J CLIN ENDOCR METAB, V64, P283, DOI 10.1210/jcem-64-2-283; SPRATT DI, 1986, ANN INTERN MED, V105, P848, DOI 10.7326/0003-4819-105-6-848; TAKEUCHI J, 1978, J NEUROSURG, V49, P41, DOI 10.3171/jns.1978.49.1.0041; THODOU E, 1995, J CLIN ENDOCR METAB, V80, P2302, DOI 10.1210/jc.80.8.2302; VALK TW, 1980, J CLIN ENDOCR METAB, V51, P730, DOI 10.1210/jcem-51-4-730; VANTHIEL DH, 1974, GASTROENTEROLOGY, V67, P1188; Waldstreicher J, 1996, J CLIN ENDOCR METAB, V81, P4388, DOI 10.1210/jc.81.12.4388; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; WU FCW, 1990, J CLIN ENDOCR METAB, V70, P629, DOI 10.1210/jcem-70-3-629; YEN SSC, 1993, ENDOCRIN METAB CLIN, V22, P29, DOI 10.1016/S0889-8529(18)30179-8	33	141	144	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					410	415		10.1056/NEJM199702063360604	http://dx.doi.org/10.1056/NEJM199702063360604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010147				2022-12-28	WOS:A1997WF85900004
J	Yu, Y; Li, W; Su, K; Yussa, M; Han, W; Perrimon, N; Pick, L				Yu, Y; Li, W; Su, K; Yussa, M; Han, W; Perrimon, N; Pick, L			The nuclear hormone receptor Ftz-F1 is a cofactor for the Drosophila homeodomain protein Ftz	NATURE			English	Article							GENE FUSHI-TARAZU; DNA-BINDING SPECIFICITY; EXPRESSION; ACTIVATION; REGULATOR; ELEMENT	Homeobox genes specify cell fate and positional identity in embryos throughout the animal kingdom(1). Paradoxically, although each has a specific function in vivo, the in vitro DNA-binding specificities of homeodomain proteins are overlapping and relatively weak. A current model is that homeodomain proteins interact with cofactors that increase specificity in vivo(2,3). Here we use a native binding site for the homeodomain protein Fushi tarazu (Ftz) to isolate Ftz-F1, a protein of the nuclear hormone-receptor superfamily and a new Ftz cofactor. Ftz and Ftz-F1 are present in a complex in Drosophila embryos. Ftz-F1 facilitates the binding of Ftz to DNA, allowing interactions with weak-affinity sites at concentrations of Ftz that alone bind only high-affinity sites. Embryos lacking Ftz-F1 display ftz-like pair-rule cuticular defects. This phenotype is a result of abnormal ftz function because it is expressed but fails to activate downstream target genes. Cooperative interaction between homeodomain proteins and cofactors of different classes may serve as a general mechanism to increase HOX protein specificity and to broaden the range of target sites they regulate.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOL BIOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Li, Willis X/AAL-7212-2020; Li, Willis/ABC-5695-2020	Li, Willis X/0000-0001-9041-7341; Li, Willis/0000-0001-9041-7341; Perrimon, Norbert/0000-0001-7542-472X				AYER S, 1993, NUCLEIC ACIDS RES, V21, P1619, DOI 10.1093/nar/21.7.1619; Chou TB, 1996, GENETICS, V144, P1673; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; FURUKUBOTOKUNAGA K, 1992, GENE DEV, V6, P1082, DOI 10.1101/gad.6.6.1082; HAN W, 1993, MOL CELL BIOL, V13, P5549, DOI 10.1128/MCB.13.9.5549; HAN W, UNPUB J BIOL CHEM; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; Hyduk D, 1996, GENETICS, V142, P481; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; MAIER D, 1990, EMBO J, V9, P3957, DOI 10.1002/j.1460-2075.1990.tb07616.x; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; OHNO CK, 1994, MOL CELL BIOL, V14, P3166, DOI 10.1128/MCB.14.5.3166; Perrimon N, 1996, GENETICS, V144, P1681; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; TREISMAN J, 1989, CELL, V59, P553; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; YU Y, 1995, MECH DEVELOP, V50, P163, DOI 10.1016/0925-4773(94)00333-I	28	163	164	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					552	555		10.1038/385552a0	http://dx.doi.org/10.1038/385552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020364				2022-12-28	WOS:A1997WG23500052
J	Lipkin, WI				Lipkin, WI			European consensus on viral encephalitis	LANCET			English	Editorial Material							HERPES-SIMPLEX ENCEPHALITIS				Lipkin, WI (corresponding author), UNIV CALIF IRVINE,DEPT NEUROL,LAB NEUROVIROL,IRVINE,CA 92697, USA.		Lipkin, W. Ian/ABE-6216-2020	Lipkin, W. Ian/0000-0002-8768-9386				Cinque P, 1996, J NEUROL NEUROSUR PS, V61, P339, DOI 10.1136/jnnp.61.4.339; DAVIS LE, 1979, ANN NEUROL, V5, P2, DOI 10.1002/ana.410050103; DRACHMAN DA, 1962, ARCH NEUROL-CHICAGO, V7, P45, DOI 10.1001/archneur.1962.04210010051005; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857; NAHMIAS AJ, 1982, J INFECT DIS, V145, P829, DOI 10.1093/infdis/145.6.829; OLSON LC, 1967, NEW ENGL J MED, V277, P1271, DOI 10.1056/NEJM196712142772401; SKOLDENBERG B, 1984, LANCET, V2, P707; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WHITLEY RJ, 1991, INFECT CENTRAL NERVO, V1, P41	9	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					299	300		10.1016/S0140-6736(05)62821-8	http://dx.doi.org/10.1016/S0140-6736(05)62821-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024370				2022-12-28	WOS:A1997WF79400005
J	Dudek, H; Datta, SR; Franke, TF; Birnbaum, MJ; Yao, RJ; Cooper, GM; Segal, RA; Kaplan, DR; Greenberg, ME				Dudek, H; Datta, SR; Franke, TF; Birnbaum, MJ; Yao, RJ; Cooper, GM; Segal, RA; Kaplan, DR; Greenberg, ME			Regulation of neuronal survival by the serine-threonine protein kinase Akt	SCIENCE			English	Article							GROWTH-FACTOR-I; MOLECULAR-CLONING; MAP KINASE; C-AKT; INSULIN; ACTIVATION; IDENTIFICATION; SYSTEM; RAS; INHIBITION	A signaling pathway was delineated by which insulin-like growth factor 1 (IGF-1) promotes the survival of cerebellar neurons. IGF-1 activation of phosphoinositide 3-kinase (PI3-K) triggered the activation of two protein kinases, the serine-threonine kinase Akt and the p70 ribosomal protein S6 kinase (p70(S6K)). Experiments with pharmacological inhibitors, as well as expression of wild-type and dominant-inhibitory forms of Akt, demonstrated that Akt but not p70(S6K) mediates PI3-K-dependent survival. These findings suggest that in the developing nervous system, Akt is a critical mediator of growth factor-induced neuronal survival.	CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; MCGILL UNIV,MONTREAL NEUROL INST,MONTREAL,PQ H3A 2B4,CANADA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV SIGNAL TRANSDUCTION,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV MOL GENET,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; McGill University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Pennsylvania; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute				Datta, Sandeep/0000-0002-8068-3862; Birnbaum, Morris/0000-0001-9972-8680	NATIONAL CANCER INSTITUTE [R01CA018689, R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689, R01 CA43855] Funding Source: Medline; NIDDK NIH HHS [DK39519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED NN, 1993, ONCOGENE, V8, P1957; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BORASIO GD, 1989, NEURON, V2, P1087; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEPABLO F, 1995, TRENDS NEUROSCI, V18, P143, DOI 10.1016/0166-2236(95)93892-2; DUDEK HJ, UNPUB; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRANKE TF, UNPUB; GALLI C, 1995, J NEUROSCI, V15, P1172; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GRAVEL C, 1987, J NEUROSCI METH, V21, P145, DOI 10.1016/0165-0270(87)90112-9; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Nobes CD, 1996, NEUROSCIENCE, V70, P1067, DOI 10.1016/0306-4522(95)00420-3; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Schulz JB, 1996, J NEUROSCI, V16, P4696; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	41	2120	2194	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					661	665		10.1126/science.275.5300.661	http://dx.doi.org/10.1126/science.275.5300.661			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005851				2022-12-28	WOS:A1997WF07700038
J	Wyszynski, M; Lin, J; Rao, A; Nigh, E; Beggs, AH; Craig, AM; Sheng, M				Wyszynski, M; Lin, J; Rao, A; Nigh, E; Beggs, AH; Craig, AM; Sheng, M			Competitive binding of alpha-actinin and calmodulin to the NMDA receptor	NATURE			English	Article							POSTSYNAPTIC DENSITY FRACTION; TUMOR-SUPPRESSOR PROTEIN; RAT-BRAIN; SUBUNIT; CHANNEL; MEMBRANE; NEURONS; CLONING; DOMAIN	The mechanisms by which neurotransmitter receptors are immobilized at postsynaptic sites in neurons are largely unknown. The activity of NMDA (N-methyl-D-aspartate) receptors is mechano-sensitive(1) and dependent on the integrity of actin(2), suggesting a functionally important interaction between NMDA receptors and the postsynaptic cytoskeleton, alpha-Actinin-2, a member of the spectrin/dystrophin family of actin-binding proteins, is identified here as a brain postsynaptic density protein that colocalizes in dendritic spines with NMDA receptors and the putative NMDA receptor-clustering molecule PSD-95, alpha-Actinin-2 binds by its central rod domain to the cytoplasmic tail of both NR1 and NR2B subunits of the NMDA receptor, and can be immunoprecipitated with NMDA receptors and PSD-95 from rat brain. Intriguingly, NR1-alpha-actinin binding is directly antagonized by Ca2+/calmodulin. Thus alpha-actinin may play a role in both the localization of NMDA receptors and their modulation by Ca2+.	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROBIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Illinois System; University of Illinois Urbana-Champaign; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Craig, Ann Marie/M-2054-2014	Sheng, Morgan/0000-0002-8703-5366; Beggs, Alan/0000-0001-8818-0568				BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q	27	508	523	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					439	442		10.1038/385439a0	http://dx.doi.org/10.1038/385439a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009191				2022-12-28	WOS:A1997WF00700053
J	Dobson, AP; Rodriguez, JP; Roberts, WM; Wilcove, DS				Dobson, AP; Rodriguez, JP; Roberts, WM; Wilcove, DS			Geographic distribution of endangered species in the United States	SCIENCE			English	Article							BIODIVERSITY; CONSERVATION; DIVERSITY; RICHNESS; HOTSPOTS	Geographic distribution data for endangered species in the United States were used to locate ''hot spots'' of threatened biodiversity. The hot spots for different species groups rarely overlap, except where anthropogenic activities reduce natural habitat in centers of endemism. Conserving endangered plant species maximizes the incidental protection of all other species groups. The presence of endangered birds and herptiles, however, provides a more sensitive indication of overall endangered biodiversity within any region. The amount of land that needs to be managed to protect currently endangered and threatened species in the United States is a relatively small proportion of the land mass.			Dobson, AP (corresponding author), PRINCETON UNIV,DEPT ECOL & EVOLUT BIOL,PRINCETON,NJ 08544, USA.		Rodriguez, Jon P/A-1491-2009; Rodriguez, Jon P/G-7224-2012	Rodriguez, Jon P/0000-0001-5019-2870; Wilcove, David S./0000-0002-1354-0503				Adams J. M., 1989, PLANTS TODAY, V2, P183; Banarescu P, 1992, ZOOGEOGRAPHY FRESH W, V2; Bibby C.J., 1992, PUTTING BIODIVERSITY; DINERSTEIN E, 1993, CONSERV BIOL, V7, P53, DOI 10.1046/j.1523-1739.1993.07010053.x; FLATHER CH, 1994, RM241 USDA ROCK MOUN; Gentry A.H., 1986, CONSERVATION BIOL SC, P153; *GOLD SOFTW, 1995, MAPV; KIESTER AR, IN PRESS CONSERV BIO; MacArthur R.H., 1972, pvii; PEARSON DL, 1992, CONSERV BIOL, V6, P376, DOI 10.1046/j.1523-1739.1992.06030376.x; PRENDERGAST JR, 1993, NATURE, V365, P335, DOI 10.1038/365335a0; Pressey RL, 1996, BIOL CONSERV, V76, P259, DOI 10.1016/0006-3207(95)00120-4; PRESSEY RL, 1993, TRENDS ECOL EVOL, V8, P124, DOI 10.1016/0169-5347(93)90023-I; PRESSEY RL, 1994, CONSERV BIOL, V8, P662, DOI 10.1046/j.1523-1739.1994.08030662.x; SCOTT JM, 1987, BIOSCIENCE, V37, P782, DOI 10.2307/1310544; SCOTT JM, 1993, WILDLIFE MONOGR, V123, P1; STEIN BA, 1996, PRIORITIES CONSERVAT; US Bureau of the Census, 1991, STAT ABSTR US; *US EPA, 1995, END SPEC COUNT DAT; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; WILCOVE DS, 1993, CONSERV BIOL, V7, P87, DOI 10.1046/j.1523-1739.1993.07010087.x; Williams P, 1996, CONSERV BIOL, V10, P155, DOI 10.1046/j.1523-1739.1996.10010155.x	22	491	531	4	155	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					550	553		10.1126/science.275.5299.550	http://dx.doi.org/10.1126/science.275.5299.550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999803				2022-12-28	WOS:A1997WE25700050
J	Sellers, PJ; Dickinson, RE; Randall, DA; Betts, AK; Hall, FG; Berry, JA; Collatz, GJ; Denning, AS; Mooney, HA; Nobre, CA; Sato, N; Field, CB; Henderson-Sellers, A				Sellers, PJ; Dickinson, RE; Randall, DA; Betts, AK; Hall, FG; Berry, JA; Collatz, GJ; Denning, AS; Mooney, HA; Nobre, CA; Sato, N; Field, CB; Henderson-Sellers, A			Modeling the exchanges of energy, water, and carbon between continents and the atmosphere	SCIENCE			English	Review							GENERAL-CIRCULATION MODEL; SIMPLE BIOSPHERE MODEL; LAND-SURFACE; CLIMATE MODELS; TROPICAL DEFORESTATION; STOMATAL CONDUCTANCE; AMAZONIAN DEFORESTATION; CANOPY REFLECTANCE; JULY CIRCULATION; REGIONAL CLIMATE	Atmospheric general circulation models used for climate simulation and weather forecasting require the fluxes of radiation, heat, water vapor, and momentum across the land-atmosphere interlace to be specified. These fluxes are calculated by submodels called land surface parameterizations. Over the last 20 years, these parameterizations have evolved from sim pie, unrealistic schemes into credible representations of the global soil-vegetation-atmosphere transfer system as advances in plant physiological and hydrological research, advances in satellite data interpretation, and the results of large-scale field experiments have been exploited. Some modem schemes incorporate biogeochemical and ecological knowledge and, when coupled with advanced climate and ocean models, will be capable of modeling the biological and physical responses of the Earth system to global change, for example, increasing atmospheric carbon dioxide.	UNIV ARIZONA, DEPT ATMOSPHER SCI, TUCSON, AZ 85721 USA; COLORADO STATE UNIV, DEPT ATMOSPHER SCI, FT COLLINS, CO 80523 USA; ATMOSPHER RES, PITTSFORD, VT 05763 USA; NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; CARNEGIE INST WASHINGTON, DEPT PLANT BIOL, STANFORD, CA 94305 USA; UNIV CALIF SANTA BARBARA, SCH ENVIRONM SCI & MANAGEMENT, SANTA BARBARA, CA 93106 USA; STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; INPE, CPTEC, BR-12630000 CACHOEIRA PAULISTA, SP, BRAZIL; JAPAN METEOROL AGCY, DIV NUMER PREDICT, CHIYODA KU, TOKYO 100, JAPAN; ROYAL MELBOURNE INST TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA	University of Arizona; Colorado State University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Carnegie Institution for Science; University of California System; University of California Santa Barbara; Stanford University; Instituto Nacional de Pesquisas Espaciais (INPE); Japan Meteorological Agency; Royal Melbourne Institute of Technology (RMIT)	Sellers, PJ (corresponding author), NASA, LYNDON B JOHNSON SPACE CTR, MAIL CODE CB, HOUSTON, TX 77058 USA.		Henderson-Sellers, Ann/H-5323-2011; collatz, george j/D-5381-2012; Randall, David A/E-6113-2011; Denning, Scott/F-4974-2011; Noojipady, Praveen/B-2511-2010; Betts, Alan K/H-5282-2011; Berry, Joseph/B-8211-2009; Berry, Joseph/ABA-8496-2020	Randall, David A/0000-0001-6935-4112; Denning, Scott/0000-0003-3032-7875; Betts, Alan K/0000-0003-2749-5333; Berry, Joseph/0000-0002-5849-6438; Berry, Joseph/0000-0002-5849-6438				ANDRE JC, 1988, ANN GEOPHYS, V6, P477; ASRAR G, 1984, AGRON J, V76, P300, DOI 10.2134/agronj1984.00021962007600020029x; Ball J. T., 1988, THESIS; Beljaars ACM, 1996, MON WEATHER REV, V124, P362, DOI 10.1175/1520-0493(1996)124<0362:TAROTU>2.0.CO;2; Betts AK, 1996, J GEOPHYS RES-ATMOS, V101, P7209, DOI 10.1029/95JD02135; Bj÷rkman O., 1981, ENCY PLANT PHYSL A, P57; BOLLE HJ, 1993, ANN GEOPHYS, V11, P173; BONAN GB, 1995, J GEOPHYS RES-ATMOS, V100, P2817, DOI 10.1029/94JD02961; BRUBAKER KL, 1993, J CLIMATE, V6, P1077, DOI 10.1175/1520-0442(1993)006<1077:EOCPR>2.0.CO;2; Budyko MI., 1974, CLIMATE LIFE; CARSON DJ, 1981, NUMERICAL EXPT PROGR; CARSON DJ, 1981, P JSC STUD C LAND SU, P67; CHAMEY JG, 1977, J ATMOS SCI, V34, P1366; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; COLLATZ GJ, 1992, AUST J PLANT PHYSIOL, V19, P519, DOI 10.1071/PP9920519; COLLATZ GJ, 1991, AGR FOREST METEOROL, V54, P107, DOI 10.1016/0168-1923(91)90002-8; Cowan I R, 1977, Symp Soc Exp Biol, V31, P471; DEARDORFF JW, 1978, J GEOPHYS RES-OCEANS, V83, P1889, DOI 10.1029/JC083iC04p01889; DEERING D, UNPUB; Denning AS, 1996, TELLUS B, V48, P521, DOI 10.1034/j.1600-0889.1996.t01-2-00009.x; Denning AS, 1996, TELLUS B, V48, P543, DOI 10.1034/j.1600-0889.1996.t01-1-00010.x; DENNING AS, 1995, NATURE, V376, P240, DOI 10.1038/376240a0; Dickinson R.E., 1984, CLIM PROCESS CLIM SE, V29, P58, DOI DOI 10.1029/GM029P0058; DICKINSON RE, 1991, AGR FOREST METEOROL, V54, P373, DOI 10.1016/0168-1923(91)90014-H; DICKINSON RE, 1988, Q J ROY METEOR SOC, V114, P439, DOI 10.1002/qj.49711448009; DICKINSON RE, 1995, REV GEOPHYS, V33, P917, DOI 10.1029/95RG00284; DICKINSON RE, UNPUB; Dickinson RE, 1988, J CLIMATE, V1, P1086, DOI 10.1175/1520-0442(1988)001<1086:TFMFST>2.0.CO;2; DORMAN JL, 1989, J APPL METEOROL, V28, P833, DOI 10.1175/1520-0450(1989)028<0833:AGCOAR>2.0.CO;2; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Field C., 1986, EC PLANT FORM FUNCTI, P22; GARRATT JR, 1993, J CLIMATE, V6, P419, DOI 10.1175/1520-0442(1993)006<0419:SOCSTL>2.0.CO;2; GASH JC, CONCISE PLAN LARGE S; *GEWEX CONT SCAL I, 1996, J GEOPHYS RES, V101; GOUTORBE JP, 1994, ANN GEOPHYS-ATM HYDR, V12, P53, DOI 10.1007/s00585-994-0053-0; Hall FG, 1995, J GEOPHYS RES-ATMOS, V100, P25383, DOI 10.1029/95JD03300; HALL FG, 1992, J GEOPHYS RES-ATMOS, V97, P19061, DOI 10.1029/92JD02189; HALL FG, 1990, REMOTE SENS ENVIRON, V32, P47, DOI 10.1016/0034-4257(90)90097-6; HENDERSON-SELLERS A, 1984, CLIMATIC CHANGE, V6, P231, DOI 10.1007/BF00142475; HENDERSON-SELLERS A, 1993, J GEOPHYS RES-ATMOS, V98, P7289, DOI 10.1029/92JD02830; HIROSE T, 1987, OECOLOGIA, V72, P520, DOI 10.1007/BF00378977; Intergovt Panel Climate Change, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P1; JARVIS PG, 1976, PHILOS T ROY SOC B, V273, P593, DOI 10.1098/rstb.1976.0035; KEELING CD, 1995, NATURE, V375, P666, DOI 10.1038/375666a0; KOSTER RD, 1992, J GEOPHYS RES-ATMOS, V97, P2697, DOI 10.1029/91JD01696; KUCHLER AW, 1983, GOODES WORLD ATLAS, P16; LEAN J, 1989, NATURE, V342, P411, DOI 10.1038/342411a0; LEAN J, 1993, Q J ROY METEOR SOC, V119, P509, DOI 10.1002/qj.49711951109; LOS SO, 1994, INT J REMOTE SENS, V15, P3493, DOI 10.1080/01431169408954342; MANABE S, 1969, MON WEATHER REV, V97, P739, DOI 10.1175/1520-0493(1969)097<0739:CATOC>2.3.CO;2; MANABE S, 1975, J GEOPHYS RES, V80, P1617, DOI 10.1029/JC080i012p01617; MANABE S, 1987, J ATMOS SCI, V44, P1211, DOI 10.1175/1520-0469(1987)044<1211:LSCOSW>2.0.CO;2; MATTHEWS E, 1983, J CLIM APPL METEOROL, V22, P474, DOI 10.1175/1520-0450(1983)022<0474:GVALUN>2.0.CO;2; MEEHL GA, 1988, J ATMOS SCI, V45, P1476, DOI 10.1175/1520-0469(1988)045<1476:ACOSMS>2.0.CO;2; MEESON BW, 1995, ISLSCP INITIATIVE, V1; Mintz Y., 1984, Global climate, P79; MITCHELL JFB, 1983, VARIATIONS GLOBAL WA, P429; MONTEITH JL, 1973, PRINCIPLES ENV PHYSI; MYNENI RB, 1992, IEEE T GEOSCI REMOTE, V30, P302, DOI 10.1109/36.134080; Nobel P.S., 1974, INTRO BIOPHYSICAL PL; NOBRE CA, 1991, J CLIMATE, V4, P957, DOI 10.1175/1520-0442(1991)004<0957:ADARCC>2.0.CO;2; NOILHAN J, 1991, MON WEATHER REV, V119, P2393, DOI 10.1175/1520-0493(1991)119<2393:AEWAAS>2.0.CO;2; Olson J.S., 1983, CARBON LIVE VEGETATI; Paulson C.A., 1970, J APPL METEOROL, V9, P857, DOI [10.1175/1520-0450(1970)0092.0.co;2, DOI 10.1175/1520-0450(1970)009<0857:TMROWS>2.0.CO;2, 10.1175/1520-0450(1970)009, DOI 10.1175/1520-0450(1970)009]; PIELKE RA, 1990, LANDSCAPE ECOL, V4, P133, DOI 10.1007/BF00132857; PRINCE SD, 1995, REMOTE SENS ENVIRON, V51, P215, DOI 10.1016/0034-4257(94)00076-Y; Randall DA, 1996, J CLIMATE, V9, P738, DOI 10.1175/1520-0442(1996)009<0738:ARLSPF>2.0.CO;2; RASOOL SI, 1983, 1 NAT CTR ATM RES; RAUPACH MR, 1981, ANNU REV FLUID MECH, V13, P97, DOI 10.1146/annurev.fl.13.010181.000525; SATO N, 1989, J ATMOS SCI, V46, P2757, DOI 10.1175/1520-0469(1989)046<2757:EOITSB>2.0.CO;2; SCHNEIDER SH, 1974, REV GEOPHYS, V12, P447, DOI 10.1029/RG012i003p00447; SELLERS P, 1995, B AM METEOROL SOC, V76, P1549, DOI 10.1175/1520-0477(1995)076<1549:TBESAO>2.0.CO;2; Sellers P.J., 1992, J GEOPHYS RES, V97; Sellers PJ, 1996, J CLIMATE, V9, P706, DOI 10.1175/1520-0442(1996)009<0706:ARLSPF>2.0.CO;2; Sellers PJ, 1996, J CLIMATE, V9, P676, DOI 10.1175/1520-0442(1996)009<0676:ARLSPF>2.0.CO;2; Sellers PJ, 1996, SCIENCE, V271, P1402, DOI 10.1126/science.271.5254.1402; SELLERS PJ, 1985, INT J REMOTE SENS, V6, P1335, DOI 10.1080/01431168508948283; SELLERS PJ, 1987, REMOTE SENS ENVIRON, V21, P143, DOI 10.1016/0034-4257(87)90051-4; SELLERS PJ, 1995, REMOTE SENS ENVIRON, V51, P3, DOI 10.1016/0034-4257(94)00061-Q; Sellers PJ, 1996, B AM METEOROL SOC, V77, P1987, DOI 10.1175/1520-0477(1996)077<1987:TIIIGD>2.0.CO;2; SELLERS PJ, 1986, J ATMOS SCI, V43, P505, DOI 10.1175/1520-0469(1986)043<0505:ASBMFU>2.0.CO;2; SELLERS PJ, 1992, REMOTE SENS ENVIRON, V42, P187, DOI 10.1016/0034-4257(92)90102-P; Sellers PJ, 1995, J GEOPHYS RES-ATMOS, V100, P25607, DOI 10.1029/95JD02205; SELLERS PJ, 1992, J GEOPHYS RES-ATMOS, V97, P19033, DOI 10.1029/92JD01096; SHUKLA J, 1982, SCIENCE, V215, P1498, DOI 10.1126/science.215.4539.1498; SHUTTLEWORTH WJ, 1984, Q J ROY METEOR SOC, V110, P1143, DOI 10.1002/qj.49711046622; SHUTTLEWORTH WJ, 1984, Q J ROY METEOR SOC, V110, P1163, DOI 10.1002/qj.49711046623; SUD YC, 1982, J CLIMATOL, V2, P105, DOI 10.1002/joc.3370020202; SUD YC, 1985, BOUND-LAY METEOROL, V33, P15, DOI 10.1007/BF00137034; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; TRENBERTH K, 1992, CLIMATE SYSTEMS MODE; TUCKER CJ, 1981, REMOTE SENS ENVIRON, V11, P171, DOI 10.1016/0034-4257(81)90018-3; TUCKER CJ, 1986, NATURE, V319, P195, DOI 10.1038/319195a0; VITERBO P, 1995, J CLIMATE, V8, P2716, DOI 10.1175/1520-0442(1995)008<2716:AILSPS>2.0.CO;2; VONCAEMMERER S, 1985, 1983 P C TALL, P46; WALKER J, 1977, Q J ROY METEOR SOC, V103, P29, DOI 10.1002/qj.49710343503; WARRILOW DA, 1989, ANN GEOPHYS-ATM HYDR, V7, P439; WARRILOW DA, 1986, ESA SP248, P143; WARRILOW DA, 1986, 38 UK MET OFF; Washington W. M., 1986, INTRO 3 DIMENSIONAL; WILLMOTT CJ, 1986, SP248 ESA, P109; WILSON MF, 1985, J CLIMATOL, V5, P119, DOI 10.1002/joc.3370050202; XUE Y, 1991, J CLIMATE, V6, P2232; [No title captured]	104	1080	1180	29	423	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 24	1997	275	5299					502	509		10.1126/science.275.5299.502	http://dx.doi.org/10.1126/science.275.5299.502			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999789	Green Submitted			2022-12-28	WOS:A1997WE25700036
J	Song, ZW; McCall, K; Steller, H				Song, ZW; McCall, K; Steller, H			DCP-1, a Drosophila cell death protease essential for development	SCIENCE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; GENE CED-3; CYSTEINE PROTEASES; MOLECULAR-CLONING; MAMMALIAN HOMOLOG; NERVOUS-SYSTEM; MICE DEFICIENT; APOPTOSIS	Apoptosis, a form of cellular suicide, involves the activation of CED-3-related cysteine proteases (caspases), The regulation of caspases by apoptotic signals and the precise mechanism by which they kill the cell remain unknown. In Drosophila, different death-inducing stimuli induce the expression of the apoptotic activator reaper. Cell killing by reaper and two genetically linked apoptotic activators, hid and grim, requires caspase activity. A Drosophila caspase, named Drosophila caspase-1 (DCP-1), was identified and found to be structurally and biochemically similar to Caenorhabditis elegans CED-3. Loss of zygotic DCP-1 function in Drosophila caused larval lethality and melanotic tumors, showing that this gene is essential for normal development.	MIT,DEPT BRAIN & COGNIT SCI,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)								ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDEZALNEMR.T, 1994, J BIOL CHEM, V269, P30764; Fraser Andrea, 1993, COMMUNICATION; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LIPKE JA, 1996, J BIOL CHEM, V271, P1825; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; Song Z., UNPUB; SPARROW J, 1978, GENETICS BIOL DROSOP; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STELLER H, 1994, NEURON, V13, P1269, DOI 10.1016/0896-6273(94)90413-8; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATSON KL, 1991, DEV GENET, V12, P173, DOI 10.1002/dvg.1020120302; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; XUE D, 1996, GENE DEV, V10, P1973; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHOU L, 1995, CURR BIOL, V5, P784, DOI 10.1016/S0960-9822(95)00155-2	61	250	259	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					536	540		10.1126/science.275.5299.536	http://dx.doi.org/10.1126/science.275.5299.536			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999799				2022-12-28	WOS:A1997WE25700046
J	Hinterberger, W; Rowlings, PA; HinterbergerFischer, M; Gibson, J; Jacobsen, N; Klein, JP; Kolb, HJ; Stevens, DA; Horowitz, MM; Gale, RP				Hinterberger, W; Rowlings, PA; HinterbergerFischer, M; Gibson, J; Jacobsen, N; Klein, JP; Kolb, HJ; Stevens, DA; Horowitz, MM; Gale, RP			Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia	ANNALS OF INTERNAL MEDICINE			English	Article						anemia, aplastic; twins, monozygotic; bone marrow transplantation; cyclophosphamide; outcome and process assessment (health care)	SOLID MALIGNANT-TUMORS; VERSUS-HOST DISEASE; TERM FOLLOW-UP; LYMPHOKINE OVERPRODUCTION; GRAFT FAILURE; INVITRO; CYCLOPHOSPHAMIDE; HEMATOPOIESIS; CYCLOSPORINE; INTERFERON	Background: Aplastic anemia is caused by several diverse factors, including a lack of or defective hematopoietic stem cells, immune abnormalities, and disorders of the bone marrow microenvironment. The outcome of transplanting bone marrow from genetically identical twins into patients with aplastic anemia may help define how frequently these factors play a role in this condition. Objective: To determine the outcome of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Design: Observational study. Setting: 31 centers participating in the International Bone Marrow Transplant Registry. Patients: 40 patients with aplastic anemia who received bone marrow transplants from their genetically identical twins between 1964 and 1992. Intervention: 23 patients received their first bone marrow transplant without pretransplantation conditioning; 17 received it after pretransplantation conditioning with cyclophosphamide alone or combined with other drugs or radiation. Six patients received post-transplantation immunosuppressive therapy with methotrexate, cyclosporine, and corticosteroids, alone or in combination. Measurements: Outcomes of transplantation, including hematologic recovery and survival. Results: Seven of 23 patients who received their first transplant without receiving conditioning had sustained complete hematologic recovery. One of 16 patients who did not have complete recovery after the first transplantation recovered after a second transplantation, which was not preceded by conditioning. The other 15 patients had two to five transplantations that were preceded by conditioning; in 13 patients, sustained bone marrow function was recovered. Twelve of 17 patients whose first transplantation was preceded by conditioning had sustained complete hematologic recovery. The likelihood of hema tologic recovery was greater in patients who had conditioning before the first transplantation (P = 0.033). The actuarial 10-year survival rate for the 40 patients was 78% (95% CI, 59% to 92%). The survival rate was higher in patients who did not have conditioning before the first transplantation (patients without conditioning, 87% [range, 65% to 99%]; patients with conditioning, 70% [range, 47% to 89%]; P = 0.037). Conclusions: Most patients with aplastic anemia recover bone marrow function after receiving a transplant from a genetically identical twin. Pretransplantation conditioning may increase the chance of bone marrow recovery but does not seem to improve survival.	MED COLL WISCONSIN, INT BONE MARROW TRANSPLANT REGISTRY, MILWAUKEE, WI 53226 USA; DONAUSPITAL SOZIALMED, ZENTRUM OST 2, MED ABT, A-1220 VIENNA, AUSTRIA; ROYAL PRINCE ALFRED HOSP, DEPT HAEMATOL, CAMPERDOWN, NSW 2050, AUSTRALIA; RIGSHOSP, DEPT HAEMATOL L4042, DK-2100 COPENHAGEN, DENMARK; UNIV MUNICH, KLINIKUM GROSSHADERN, MED KLIN 3, D-8000 MUNICH 70, GERMANY; UNIV LOUISVILLE, CTR CANC, LOUISVILLE, KY 40292 USA; SALICK HLTH CARE INC, BONE MARROW & STEM CELL TRANSPLANTAT, LOS ANGELES, CA 90048 USA	Medical College of Wisconsin; Donauspital; University of Sydney; Rigshospitalet; University of Copenhagen; University of Munich; University of Louisville			horowitz, Mary/ABH-2173-2021		NCI NIH HHS [CP-21161, P01-CA-40053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELBAUM FR, 1980, BLOOD, V55, P1033; APPELBAUM FR, 1985, BLOOD, V65, P553; BORGAN O, 1990, SCAND J STAT, V17, P35; CAMITTA BM, 1976, BLOOD, V48, P63; CHAMPLIN RE, 1989, BLOOD, V73, P606; DEPLANQUE MM, 1988, BRIT J HAEMATOL, V70, P55; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GASCON P, 1986, BLOOD, V67, P1349; GLUCKMAN E, 1991, BLOOD, V78, P2451; GLUCKMAN E, 1992, BLOOD, V79, P269; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; HINTERBERGER W, 1989, BLOOD, V74, P2713; HINTERBERGER W, 1988, BLOOD, V72, P266; HINTERBERGER W, 1985, EXP HEMATOL, V13, P66; HINTERBERGERFISCHER M, 1989, EUR J HAEMATOL, V43, P136; LU DP, 1981, EXP HEMATOL, V9, P257; MARSH JCW, 1990, BLOOD, V76, P1748; MILLS SD, 1964, JAMA-J AM MED ASSOC, V188, P85; NAJEAN Y, 1990, BLOOD, V76, P2222; NISTICO A, 1994, ANN INTERN MED, V120, P463, DOI 10.7326/0003-4819-120-6-199403150-00003; SINGER JW, 1979, BLOOD, V54, P180; SINGER JW, 1978, BLOOD, V52, P37; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; TOROKSTORB B, 1984, BLOOD, V63, P349; VANKAMP H, 1991, BLOOD, V78, P3209; WITHERSPOON RP, 1992, BLOOD, V79, P289; Wolin MJ, 1996, BONE MARROW TRANSPL, V17, P125; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; ZOUMBOS NC, 1985, P NATL ACAD SCI USA, V82, P188, DOI 10.1073/pnas.82.1.188; 1977, LANCET, V2, P742	35	50	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					116	+		10.7326/0003-4819-126-2-199701150-00004	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005745				2022-12-28	WOS:A1997WD29800006
J	Li, LM; Li, X; Francke, U; Cohen, SN				Li, LM; Li, X; Francke, U; Cohen, SN			The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer	CELL			English	Article							MULTIPLE SIGNAL-TRANSDUCTION; CELL LUNG-CANCER; OVARIAN-CANCER; FREQUENT LOSS; ALLELIC LOSS; HETEROZYGOSITY; IDENTIFICATION; DNA; CLONING; REGIONS	Recent work has identified a mouse gene (tsg101) whose inactivation in fibroblasts results in cellular transformation and the ability to produce metastatic tumors in nude mice. Here, we report that the human homolog, TSG101, which we isolated and mapped to chromosome 11, bands 15.1-15.2, a region proposed to contain tumor suppressor gene(s), is mutated at high frequency in human breast cancer. In 7 of 15 uncultured primary human breast carcinomas, intragenic deletions were shown in TSG101 genomic DNA and transcripts by gel and sequence analysis, and mutations affecting two TSG101 alleles were identified in four of these cancers. No TSG101 defects were found in matched normal breast tissue from the breast cancer patients. These findings strongly implicate TSG101 mutations in human breast cancer.	STANFORD UNIV,DEPT GENET,SCH MED,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,SCH MED,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Baffa R, 1996, CANCER RES, V56, P268; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BOOTH PM, 1994, GENE, V146, P303, DOI 10.1016/0378-1119(94)90310-7; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; BYRNE JA, 1993, GENE CHROMOSOME CANC, V8, P104, DOI 10.1002/gcc.2870080207; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COWELL JK, 1993, BRIT J CANCER, V67, P1259, DOI 10.1038/bjc.1993.235; DERRY JMJ, 1995, GENOMICS, V30, P361, DOI 10.1006/geno.1995.0031; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; FERTIPASSANTONOPOULOU A, 1991, CANCER GENET CYTOGEN, V51, P183, DOI 10.1016/0165-4608(91)90130-M; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; FRANCKE U, 1986, COLD SPRING HARB SYM, V51, P855, DOI 10.1101/SQB.1986.051.01.099; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1277; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1994, ONCOGENE, V9, P3063; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; LI X, 1993, GENOMICS, V18, P667, DOI 10.1016/S0888-7543(05)80371-4; LI X, 1995, CYTOGENET CELL GENET, V68, P185, DOI 10.1159/000133910; LI X, 1995, CYTOGENET CELL GENET, V71, P301, DOI 10.1159/000134132; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Miyagi Mutsuko, 1992, Human Molecular Genetics, V1, P705, DOI 10.1093/hmg/1.9.705; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NEGRINI M, 1995, CANCER RES, V55, P3003; Phillips KK, 1996, CANCER RES, V56, P1222; PRESTI JC, 1991, CANCER RES, V51, P5405; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; ROOS G, 1993, LEUKEMIA, V7, P1538; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P10080; SELLAR GC, 1994, GENOMICS, V19, P221, DOI 10.1006/geno.1994.1051; SMITH RC, 1995, J UROLOGY, V153, P1684, DOI 10.1016/S0022-5347(01)67504-9; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKITA K, 1992, GENOMICS, V13, P1296, DOI 10.1016/0888-7543(92)90049-X; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WINQVIST R, 1995, CANCER RES, V55, P2660; WINQVIST R, 1993, CANCER RES, V53, P4486; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; ZHANG RD, 1991, INVAS METAST, V11, P204	57	130	148	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					143	154		10.1016/S0092-8674(00)81866-8	http://dx.doi.org/10.1016/S0092-8674(00)81866-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019400	Bronze			2022-12-28	WOS:A1997WC56900017
J	Brown, JE; Jacobs, DR; Hartman, TJ; Barosso, GM; Stang, JS; Gross, MD; Zeuske, MA				Brown, JE; Jacobs, DR; Hartman, TJ; Barosso, GM; Stang, JS; Gross, MD; Zeuske, MA			Predictors of red cell folate level in women attempting pregnancy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURAL-TUBE DEFECTS; PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; FOLIC-ACID SUPPLEMENTATION; DIETARY-FOLATE; ZINC STATUS; PREVENTION; RISK; METABOLISM; RECURRENCE	Objective.-To identify predictors of red cell folate level in women attempting to become pregnant. Design.-Cohort study, Setting.-A health maintenance organization serving the Minneapolis-St Paul, Minn, area. Participants.-A total of 189 healthy, primarily white women aged 22 to 35 years enrolled in the Diana Project, a population-based prospective study of preconceptional and prenatal risks to reproductive outcomes. The sample represents 189 of 219 enrolled women who were sequentially selected from the total Diana Project sample to receive additional laboratory analyses, Main Outcome Measure.-Red cell folate level. Results.-Folic acid supplements, folic acid intake from fortified cereals, vitamin C supplements, and serum zinc level (inverse) were found to predict red cell folate levels. Previous research has shown that red cell folate levels higher than 906 nmol/L (400 ng/mL) may be optimal for the prevention of folate-responsive neural tube defects. For folic acid supplement users, folate intakes of 450 mu g per day and higher corresponded to these protective levels of red cell folate, In nonusers of supplements, intakes of more than 500 mu g of folate per day from foods and folio acid-fortified cereals may be needed to attain red cell folate levels higher than 906 nmol/L (400 ng/mL). Red cell folate levels higher than 906 nmol/L (400 ng/m L) were primarily found in women who took folio acid supplements, Only 1 in 4 women had red cell folate levels higher than 906 nmol/L (400 ng/mL), while 1 in 8 had red cell folate levels indicative of a negative folate balance. Addition of a daily, 400-mu g folic acid supplement to the usual diet would result in red cell folate levels over 906 nmol/L (400 ng/mL) in a majority of women in this study. Conclusions.-Supplementation of diets of women of childbearing potential with 400 mu g of folic acid per day would effectively raise red cell folate to levels associated with a low risk of folate-responsive neural tube defects. Protective levels of red cell folate may also be obtained by ample consumption of vegetables, fruits, and folic acid-fortified breakfast cereals. Efforts to increase folic acid supplement use and folate consumption among women of childbearing potential must go beyond fortification of refined cereal and grain products and reach women within all educational and income groups.			Brown, JE (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST,SUITE 300,MINNEAPOLIS,MN 55454, USA.			Stang, Jamie/0000-0003-2607-190X; Jacobs, David/0000-0002-7232-0543	NICHD NIH HHS [HD19724] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019724] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILEY LB, 1992, J AM DIET ASSOC, V92, P463; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Brown JE, 1996, J AM DIET ASSOC, V96, P262, DOI 10.1016/S0002-8223(96)00078-8; BROWN JE, IN PRESS PAEDIAT PER; BUNDUKI V, 1995, BIOL NEONATE, V67, P154, DOI 10.1159/000244157; BUTTERWORTH CE, 1989, AM J CLIN NUTR, V50, P353, DOI 10.1093/ajcn/50.2.353; BUTTERWORTH CE, 1993, J AM COLL NUTR, V12, P438, DOI 10.1080/07315724.1993.10718334; COLMAN N, 1982, NUTR REV, V40, P225, DOI 10.1111/j.1753-4887.1982.tb05319.x; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; DANSKY LV, 1992, NEUROLOGY, V42, P32; FULLER NJ, 1992, EUR J PEDIATR, V151, P51, DOI 10.1007/BF02073892; GHISHAN FK, 1986, AM J CLIN NUTR, V43, P258, DOI 10.1093/ajcn/43.2.258; HAMBIDGE M, 1993, BRIT J OBSTET GYNAEC, V100, P746, DOI 10.1111/j.1471-0528.1993.tb14266.x; Herbert V, 1994, MODERN NUTR HLTH DIS, V1, P402; HERBERT VD, 1988, MODERN NUTRITION HLT, P388; HIGASHI A, 1988, J PEDIATR GASTR NUTR, V7, P430, DOI 10.1097/00005176-198805000-00020; Hinman AR, 1992, MMWR, V41, P1; KAUWELL GPA, 1995, J NUTR, V125, P66; KIRKE PN, 1993, Q J MED, V86, P703; KRUMDIECK CL, 1978, AM J CLIN NUTR, V31, P88, DOI 10.1093/ajcn/31.1.88; LAURENCE KM, 1980, BRIT MED J, V281, P1592, DOI 10.1136/bmj.281.6255.1592; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; LAZEBNIK N, 1989, AM J OBSTET GYNECOL, V161, P437, DOI 10.1016/0002-9378(89)90538-3; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MILNE D B, 1989, Journal of Trace Elements in Experimental Medicine, V2, P297; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; *MRC VIT STUD RES, 1991, LANCET, V338, P131; MUKHERJEE MD, 1984, AM J CLIN NUTR, V40, P496, DOI 10.1093/ajcn/40.3.496; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; OKEEFE CA, 1995, J NUTR, V125, P2717; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; Shaw GM, 1996, JAMA-J AM MED ASSOC, V275, P1093, DOI 10.1001/jama.275.14.1093; SMITHELLS RW, 1976, ARCH DIS CHILD, V51, P944, DOI 10.1136/adc.51.12.944; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; SMITHELLS RW, 1982, PEDIATRICS, V69, P498; SMITHELLS RW, 1983, NUTR PREGNANCY, P155; SOLTAN MH, 1982, BRIT J OBSTET GYNAEC, V89, P56, DOI 10.1111/j.1471-0528.1982.tb04635.x; STEEGERSTHEUNISSEN RP, 1995, EUR J OBSTET GYN R B, V61, P39, DOI 10.1016/0028-2243(95)02151-H; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; Werler MM, 1996, JAMA-J AM MED ASSOC, V275, P1089, DOI 10.1001/jama.275.14.1089; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; YATES JRW, 1987, CLIN GENET, V31, P279; YETLEY E, 1996, FOLATE; ZIMMERMANN MB, 1993, AM J CLIN NUTR, V58, P127, DOI 10.1093/ajcn/58.2.127	46	54	56	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					548	552		10.1001/jama.277.7.548	http://dx.doi.org/10.1001/jama.277.7.548			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032161				2022-12-28	WOS:A1997WH29700030
J	Etchells, E; Bell, C; Robb, K				Etchells, E; Bell, C; Robb, K			Does this patient have an abnormal systolic murmur?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MITRAL-VALVE PROLAPSE; DOPPLER ECHOCARDIOGRAPHY; AORTIC-STENOSIS; REGURGITANT MURMURS; BEDSIDE DIAGNOSIS; CONTROLLED TRIAL; SEVERITY; PREVALENCE; HISTORY; RISK	Our objective was to review the available evidence of the precision and accuracy of the clinical examination for abnormal systolic murmurs. We conducted a MEDLINE search, manually reviewed all reference lists,and contacted authors of published studies. Each study was independently reviewed by 2 observers and graded for methodologic quality. We found that most studies were conducted using cardiologist examiners. In the clinical setting, the reliability of detecting systolic murmurs was fair (kappa, 0.30-0.48). The most useful findings for ruling in aortic stenosis are a slow rate of rise of the carotid pulse (positive likelihood ratio, 2.8-130), mid to late peak intensity of the murmur (positive likelihood ratio, 8.0-101), and decreased intensity of the second heart sound (positive likelihood ratio, 3.1-50). The most useful finding for ruling out aortic stenosis is the absence of murmur radiation to the right carotid artery (negative likelihood ratio, 0.05-0.10). Smaller, lower-quality studies indicate that cardiologists can accurately rule in and rule out mitral regurgitation, tricuspid regurgitation, hypertrophic cardiomyopathy, and echocardiographic mitral valve prolapse. We conclude that the clinical examination by cardiologists is accurate for detecting various causes of abnormal systolic murmurs. Studies of the clinical examination by noncardiologists are needed.	UNIV TORONTO, DEPT MED, DIV GEN INTERNAL MED & CLIN EPIDEMIOL, TORONTO, ON M5S 1A1, CANADA	University of Toronto	Etchells, E (corresponding author), TORONTO GEN HOSP, 200 ELIZABETH ST, ENG-248, TORONTO, ON M5G 2C4, CANADA.		Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469				ABBASI AS, 1983, J AM COLL CARDIOL, V2, P1219, DOI 10.1016/S0735-1097(83)80354-4; ABELLA M, 1992, J ACOUST SOC AM, V91, P2224, DOI 10.1121/1.403655; Ahuja I M, 1982, Indian Heart J, V34, P241; ARONOW WS, 1987, AM J CARDIOL, V60, P399, DOI 10.1016/0002-9149(87)90262-1; Ballard D J, 1989, Int J Technol Assess Health Care, V5, P249; BARRON JT, 1988, CLIN CARDIOL, V11, P401, DOI 10.1002/clc.4960110608; BARTALL H, 1978, CHEST, V74, P77, DOI 10.1378/chest.74.1.77; BATTLE WE, 1977, GERIATRICS, V32, P61; BETHEL CS, 1963, AM J CARDIOL, V11, P763, DOI 10.1016/0002-9149(63)90104-8; BRAUNWALD E, 1964, CIRCULATION, V29, P422, DOI 10.1161/01.CIR.29.3.422; BRUNS DL, 1958, BRIT HEART J, V20, P370; BUDA A, 1977, CIRCULATION S3, V56, P111; BUJACK W, 1976, JAMA-J AM MED ASSOC, V235, P2417, DOI 10.1001/jama.235.22.2417; CASSIDY J, 1975, CHEST, V67, P395, DOI 10.1378/chest.67.4.395; CHATTERJEE K, 1991, CARDIOLOGY ILLUSTRAT, V1; CHUN PKC, 1982, ARCH INTERN MED, V142, P2284, DOI 10.1001/archinte.142.13.2284; CONSTANT J, 1985, BEDSIDE CARDIOLOGY; COTTER L, 1980, J ROY COLL PHYS LOND, V14, P128; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; DEVEREUX RB, 1986, J AM COLL CARDIOL, V8, P767; DOBROW RJ, 1964, MED ANN DIST COL JUL; EWY GA, 1987, J MED EDUC, V62, P738; FORSSELL G, 1985, ACTA MED SCAND, V218, P397; Freeman AR, 1933, ANN INTERN MED, V6, P1371, DOI 10.7326/0003-4819-6-11-1371; GAASCH WH, 1995, CHEST, V108, P842, DOI 10.1378/chest.108.3.842; GRIFFITHS R A, 1975, Age and Ageing, V4, P99, DOI 10.1093/ageing/4.2.99; HOAGLAND PM, 1986, AM J MED, V80, P1041, DOI 10.1016/0002-9343(86)90663-7; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; JAFFE WM, 1988, CIRCULATION, V78, P267, DOI 10.1161/01.CIR.78.2.267; KINNEY EL, 1988, J GEN INTERN MED, V3, P429, DOI 10.1007/BF02595918; KLEIN HO, 1988, CHEST, V93, P814, DOI 10.1378/chest.93.4.814; KNIGHT PV, 1986, AGE AGEING, V15, P169, DOI 10.1093/ageing/15.3.169; KRAMER DS, 1986, ANN INTERN MED, V104, P772, DOI 10.7326/0003-4819-104-6-772; LEACH RM, 1990, LANCET, V335, P1199, DOI 10.1016/0140-6736(90)92709-Q; LEHMANN KG, 1992, ANN INTERN MED, V117, P10, DOI 10.7326/0003-4819-117-1-10; LEMBO NJ, 1986, ANN INTERN MED, V105, P368, DOI 10.7326/0003-4819-105-3-368; LEMBO NJ, 1988, NEW ENGL J MED, V318, P1572, DOI 10.1056/NEJM198806163182404; Levine SA, 1933, J AMER MED ASSOC, V101, P436, DOI 10.1001/jama.1933.02740310020005; LOCKHART PB, 1989, J AM DENT ASSOC, V119, P417, DOI 10.14219/jada.archive.1989.0060; MAISEL AS, 1984, ANN INTERN MED, V101, P781, DOI 10.7326/0003-4819-101-6-781; MARKIEWICZ W, 1976, CIRCULATION, V53, P464, DOI 10.1161/01.CIR.53.3.464; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; MARRIOT HJ, 1991, BEDSIDE CARDIAC DIAG, P19; MCCRACKEN D, 1976, PRACTITIONER, V216, P308; MCKILLOP GM, 1991, POSTGRAD MED J, V67, P1059, DOI 10.1136/pgmj.67.794.1059; MEYERS DG, 1986, J CLIN ULTRASOUND, V14, P117, DOI 10.1002/jcu.1870140207; MISHRA M, 1992, BRIT MED J, V304, P1413, DOI 10.1136/bmj.304.6839.1413; NELLEN M, 1967, BMJ-BRIT MED J, V3, P140, DOI 10.1136/bmj.3.5558.140; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; NORTHCOTE RJ, 1985, CLIN CARDIOL, V8, P327, DOI 10.1002/clc.4960080604; ODDONE EZ, 1993, AM J MED, V95, P389, DOI 10.1016/0002-9343(93)90308-C; OLIVE KE, 1990, SOUTHERN MED J, V83, P1266, DOI 10.1097/00007611-199011000-00008; ORENCIA AJ, 1995, STROKE, V26, P7, DOI 10.1161/01.STR.26.1.7; ORTON D, 1986, JAMA-J AM MED ASSOC, V256, P2817, DOI 10.1001/jama.1986.03380200055013; PANIDIS IP, 1986, J AM COLL CARDIOL, V7, P975, DOI 10.1016/S0735-1097(86)80214-5; PEREZ GL, 1976, J AM GERIATR SOC, V24, P29, DOI 10.1111/j.1532-5415.1976.tb03250.x; PERLOFF JK, 1986, AM J CARDIOL, V57, P1124, DOI 10.1016/0002-9149(86)90686-7; PETRIN TJ, 1979, J AM GERIATR SOC, V27, P43, DOI 10.1111/j.1532-5415.1979.tb01720.x; RAFTERY EB, 1967, AM J EPIDEMIOL, V85, P438, DOI 10.1093/oxfordjournals.aje.a120705; RAHKO PS, 1989, ANN INTERN MED, V111, P466, DOI 10.7326/0003-4819-111-6-466; RAVIN A, 1977, AUSCULTATION HEART, V2, P45; RETCHIN SM, 1987, MED CARE, V25, P652, DOI 10.1097/00005650-198707000-00008; RIVERO CARVALLO J M, 1946, Arch Inst Cardiol Mex, V16, P531; ROSENBLUM R, 1965, AM J CARDIOL, V15, P868, DOI 10.1016/0002-9149(65)90393-0; RUSHMER RF, 1952, AMA AM J DIS CHILD, V83, P740, DOI 10.1001/archpedi.1952.02040100038003; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SENEVIRATNE B, 1994, BRIT HEART J, V72, P63; SHARPEYSCHAFER EP, 1956, BRIT MED J, V1, P1072, DOI 10.1136/bmj.1.4975.1072; SPODICK DH, 1982, AM J CARDIOL, V49, P159, DOI 10.1016/0002-9149(82)90290-9; STEFADOUROS MA, 1976, AM J CARDIOL, V37, P89, DOI 10.1016/0002-9149(76)90505-1; STEWART IMG, 1951, BRIT HEART J, V13, P561; TAN C C, 1988, SMJ Singapore Medical Journal, V29, P337; TARANTA A, 1964, DATA ACQUISITION PRO, V3, P23; TOFLER OB, 1990, AM J CARDIOL, V66, P1355, DOI 10.1016/0002-9149(90)91167-5; VAUGHAN JP, 1979, B WORLD HEALTH ORGAN, V57, P89; XU M, 1993, NEW ZEAL MED J, V106, P54; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	78	97	98	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					564	571		10.1001/jama.277.7.564	http://dx.doi.org/10.1001/jama.277.7.564			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032164				2022-12-28	WOS:A1997WH29700033
J	Kasting, G; Rollin, PE				Kasting, G; Rollin, PE			Wound care following needlestick injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							B-VIRUS		CTR DIS CONTROL & PREVENT,SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	Kasting, G (corresponding author), CTR DIS CONTROL & PREVENT,OCCUPAT HLTH CLIN,ATLANTA,GA 30333, USA.			Rollin, Pierre/0000-0002-4608-2641				GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; HOLMES GP, 1995, CLIN INFECT DIS, V20, P421, DOI 10.1093/clinids/20.2.421; *MICR INC, 1995, TOX OCC MED ENV SER, P27; WEIGLER BJ, 1992, CLIN INFECT DIS, V14, P555, DOI 10.1093/clinids/14.2.555	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					517	517		10.1001/jama.1997.03540310015007	http://dx.doi.org/10.1001/jama.1997.03540310015007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032142				2022-12-28	WOS:A1997WH29700002
J	Collman, JP; Fu, L; Herrmann, PC; Zhang, XM				Collman, JP; Fu, L; Herrmann, PC; Zhang, XM			A functional model related to cytochrome c oxidase and its electrocatalytic four-electron reduction of O-2	SCIENCE			English	Article							PROTON PUMP; DIOXYGEN; ISSUES	A cytochrome c oxidase model that consists of a cobalt(II) porphyrin with a copper(I) triazacyclononane macrocycle fastened on the distal face and an imidazole covalently attached to the proximal face has been synthesized and characterized. Redox titrations with molecular oxygen (O-2) and cobaltocene were carried out, and O-2 was found to bind irreversibly in a 1:1 ratio to the model compound. This O-2 adduct (a bridged peroxide) can be fully reduced to the deoxygenated form with four equivalents of cobaltocene. The model compound was adsorbed on an edge-plane graphite electrode, and rotating ring-disk voltammetry was used to monitor the electrocatalytic reduction of O-2. Four-electron reduction of O-2 was observed at physiological pH.			Collman, JP (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.		Zhang, Xumu/K-8746-2013	Zhang, Xumu/0000-0001-5700-0608	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017880] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 04122] Funding Source: Medline; NIGMS NIH HHS [5R37 GM-17880-26] Funding Source: Medline; PHS HHS [CHE9123187-A2] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHAN SI, 1990, BIOCHEMISTRY-US, V29, P1, DOI 10.1021/bi00453a001; COLLMAN JP, 1995, INORG CHEM, V34, P1311, DOI 10.1021/ic00110a006; COLLMAN JP, 1994, J AM CHEM SOC, V116, P2681, DOI 10.1021/ja00085a083; COLLMAN JP, 1994, ANGEW CHEM INT EDIT, V33, P1537, DOI 10.1002/anie.199415371; COLLMAN JP, UNPUB; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jameson GB, 1996, METAL-CONTAINING POLYMERIC MATERIALS, P421; KOUTECKY J, 1958, ZH FIZ KHIM+, V32, P1565; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OLIVEBERG M, 1992, BIOCHEMISTRY-US, V31, P3560, DOI 10.1021/bi00129a002; PALMER G, 1993, J BIOENERG BIOMEMBR, V25, P145, DOI 10.1007/BF00762856; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; [No title captured]	20	171	173	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					949	951		10.1126/science.275.5302.949	http://dx.doi.org/10.1126/science.275.5302.949			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020071				2022-12-28	WOS:A1997WH38800036
J	Alper, PR				Alper, PR			Learning to accentuate the positive in managed care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		1996, WALL STREET J   0801, pA1	1	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					508	509		10.1056/NEJM199702133360713	http://dx.doi.org/10.1056/NEJM199702133360713			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017948				2022-12-28	WOS:A1997WG77600012
J	Horton, B; Smith, O				Horton, B; Smith, O			Diverse opportunities for immunologists	NATURE			English	Article																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					657	658						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024667				2022-12-28	WOS:A1997WH29400056
J	Starr, JM; Rogers, TR; Impallomeni, M				Starr, JM; Rogers, TR; Impallomeni, M			Hospital-acquired Clostridium difficile diarrhoea and herd immunity	LANCET			English	Article							RISK-FACTORS; ANTIBIOTICS; DISEASE	Clostridium difficile diarrhoea represents a significant hearth-service burden. We recently experienced an outbreak of C difficile diarrhoea associated with increased use of cefotaxime. The question we pose in this paper is how did the introduction and withdrawal of a single antibiotic so greatly affect rates of C difficile diarrhoea? Other antibiotics had nearly as high a risk of causing diarrhoea as cefotaxime, and the majority of patients never received cefotaxime. We believe that such outbreaks of C difficile diarrhoea are best understood in terms of a population model, and that taking antibiotics like cefotaxime should be thought of as a population rather than an individual risk factor. We postulate a herd-immunity model of C difficile diarrhoea, and examine the implications of this hypothesis.	HAMMERSMITH HOSP, DEPT INFECT DIS, LONDON, ENGLAND; HAMMERSMITH HOSP, DIV GERIATR MED, LONDON, ENGLAND	Imperial College London; Imperial College London	Starr, JM (corresponding author), UNIV EDINBURGH, ROYAL VICTORIA HOSP, DEPT GERIATR MED, EDINBURGH EH4 2DN, MIDLOTHIAN, SCOTLAND.		Starr, John/C-8951-2011	Rogers, Thomas/0000-0003-4336-7729				AMBROSE NS, 1985, J ANTIMICROB CHEMOTH, V15, P319, DOI 10.1093/jac/15.3.319; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; *DEP HLTH PHLS JOI, 1994, CLOSTR DIFF INF PREV; FINCH R, 1993, BRIT J HOSP MED, V49, P346; Funada H, 1984, Jpn J Antibiot, V37, P555; Gibson GJ, 1996, PLANT PATHOL, V45, P172, DOI 10.1046/j.1365-3059.1996.d01-116.x; HEARD SR, 1988, EPIDEMIOL INFECT, V100, P63, DOI 10.1017/S0950268800065560; IMPALLOMENI M, 1995, BRIT MED J, V311, P1345, DOI 10.1136/bmj.311.7016.1345; LEUNG ACT, 1985, CLIN NEPHROL, V24, P242; MCFARLAND LV, 1990, J INFECT DIS, V162, P678, DOI 10.1093/infdis/162.3.678; MCFARLAND LV, 1994, JAMA-J AM MED ASSOC, V271, P1913, DOI 10.1001/jama.271.24.1913; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; Rhodes CJ, 1996, NATURE, V381, P600, DOI 10.1038/381600a0; Ross R, 1915, BRIT MED J, V1915, P546, DOI 10.1136/bmj.1.2830.546; SCHWAN A, 1984, SCAND J INFECT DIS, V16, P211, DOI 10.3109/00365548409087145; WALKER KJ, 1993, J AM GERIATR SOC, V41, P940, DOI 10.1111/j.1532-5415.1993.tb06759.x	16	50	51	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					426	428		10.1016/S0140-6736(97)80053-0	http://dx.doi.org/10.1016/S0140-6736(97)80053-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033485				2022-12-28	WOS:A1997WH29600050
J	Tuckerman, ME; Marx, D; Klein, ML; Parrinello, M				Tuckerman, ME; Marx, D; Klein, ML; Parrinello, M			On the quantum nature of the shared proton in hydrogen bonds	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATION; DENSITY-FUNCTIONAL THEORY; ENZYME CATALYSIS; WATER CLUSTERS; THERMAL CONDITIONS; HYDROXIDE ION; SPECTROSCOPY; HYDRONIUM; SOLVATION; SYSTEMS	The relative influence of thermal and quantum fluctuations on the proton transfer properties of the charged water complexes H5O2+ and H3O2- was investigated with the use of ab initio techniques. These small systems can be considered as prototypical representatives of strong and intermediate-strength hydrogen bonds. The shared proton in the strongly hydrogen bonded H5O2+ behaved in an essentially classical manner, whereas in the H3O2- low-barrier hydrogen bond, quantum zero-point motion played a crucial role even at room temperature. This behavior can be traced back to a small difference in the oxygen-oxygen separation and hence to the strength of the hydrogen bond.	UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA; MAX PLANCK INST FESTKORPERFORSCH, D-70569 STUTTGART, GERMANY	University of Pennsylvania; Max Planck Society	Tuckerman, ME (corresponding author), UNIV PENN, CTR MOL MODELING, PHILADELPHIA, PA 19104 USA.							AKESON M, 1991, BIOPHYS J, V60, P101, DOI 10.1016/S0006-3495(91)82034-3; ANDO K, 1995, J MOL LIQ, V64, P25, DOI 10.1016/0167-7322(95)92818-V; BARNETT RN, 1993, PHYS REV B, V48, P2081, DOI 10.1103/PhysRevB.48.2081; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Benderskii V.A., 1994, ADV CHEM PHYS, V<bold>88</bold>, DOI 10.1002/9780470141472; Bountis T., 1992, PROTON TRANSFER HYDR; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; CHANDLER D, 1981, J CHEM PHYS, V74, P4078, DOI 10.1063/1.441588; CHENG HP, 1995, CHEM PHYS LETT, V237, P161, DOI 10.1016/0009-2614(95)00282-9; CLELAND WW, 1995, SCIENCE, V269, P104, DOI 10.1126/science.269.5220.104; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cruzan JD, 1996, SCIENCE, V271, P59, DOI 10.1126/science.271.5245.59; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Feynman R. P., 2018, STAT MECH SET LECT; FREY PA, 1995, SCIENCE, V269, P104, DOI 10.1126/science.269.5220.104-a; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GRIMM AR, 1995, MOL PHYS, V86, P369, DOI 10.1080/00268979509413619; HALLE B, 1983, J CHEM SOC FARAD T 2, V79, P1031, DOI 10.1039/f29837901031; LAASONEN K, 1992, CHEM PHYS LETT, V194, P172, DOI 10.1016/0009-2614(92)85529-J; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Liu K, 1996, SCIENCE, V271, P62, DOI 10.1126/science.271.5245.62; Liu K, 1996, NATURE, V381, P501, DOI 10.1038/381501a0; Lobaugh J, 1996, J CHEM PHYS, V104, P2056, DOI 10.1063/1.470962; LUTH K, 1992, INT J QUANTUM CHEM, P817; Marx D, 1996, SCIENCE, V271, P179, DOI 10.1126/science.271.5246.179; MARX D, 1995, NATURE, V375, P216, DOI 10.1038/375216a0; Marx D, 1996, J CHEM PHYS, V104, P4077, DOI 10.1063/1.471221; MARX D, 1994, Z PHYS B CON MAT, V95, P143, DOI 10.1007/BF01312185; OJAMAE L, 1995, INT J QUANTUM CHEM, P657; OKUMURA M, 1990, J PHYS CHEM-US, V94, P3416, DOI 10.1021/j100372a014; Pomes R, 1996, J PHYS CHEM-US, V100, P2519, DOI 10.1021/jp9525752; PUDZIANOWSKI AT, 1995, J CHEM PHYS, V102, P8029, DOI 10.1063/1.469001; REID C, 1959, J CHEM PHYS, V30, P182, DOI 10.1063/1.1729873; Sagnella DE, 1996, BIOPHYS J, V71, P1172, DOI 10.1016/S0006-3495(96)79321-9; SAYKALLY RJ, 1988, SCIENCE, V239, P157, DOI 10.1126/science.239.4836.157; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; SHI Z, 1993, J CHEM PHYS, V99, P8009, DOI 10.1063/1.465678; SIM F, 1992, J AM CHEM SOC, V114, P4391, DOI 10.1021/ja00037a055; Sprik M, 1996, J CHEM PHYS, V105, P1142, DOI 10.1063/1.471957; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; TUCKERMAN M, 1995, J CHEM PHYS, V103, P150, DOI 10.1063/1.469654; TUCKERMAN M, 1995, J PHYS CHEM-US, V99, P5749, DOI 10.1021/j100016a003; TUCKERMAN ME, 1993, J CHEM PHYS, V99, P2796, DOI 10.1063/1.465188; TUCKERMAN ME, 1994, J PHYS-CONDENS MAT, V6, pA93, DOI 10.1088/0953-8984/6/23A/010; Tuckerman ME, 1996, J CHEM PHYS, V104, P5579, DOI 10.1063/1.471771; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; XANTHEAS SS, 1995, J AM CHEM SOC, V117, P10373, DOI 10.1021/ja00146a023; XIE YM, 1994, J CHEM PHYS, V101, P4878, DOI 10.1063/1.467409; YANG X, 1990, J PHYS CHEM-US, V94, P8500, DOI 10.1021/j100386a003; YANG XL, 1989, J AM CHEM SOC, V111, P6845, DOI 10.1021/ja00199a056; YEH LI, 1989, J CHEM PHYS, V91, P7319, DOI 10.1063/1.457305; YEH LI, 1994, J MOL SPECTROSC, V164, P473, DOI 10.1006/jmsp.1994.1090	56	630	635	6	187	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 7	1997	275	5301					817	820		10.1126/science.275.5301.817	http://dx.doi.org/10.1126/science.275.5301.817			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9012345				2022-12-28	WOS:A1997WG77700056
J	Simon, AM; Goodenough, DA; Li, E; Paul, DL				Simon, AM; Goodenough, DA; Li, E; Paul, DL			Female infertility in mice lacking connexin 37	NATURE			English	Article							GAP JUNCTION PROTEINS; CUMULUS-OOCYTE COMPLEX; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GENE; MUTATIONS; LETHALITY; CELLS	The signals regulating ovarian follicle development and the mechanisms by which they are communicated are largely undefined(1). At birth, the ovary contains primordial follicles consisting of meiotically arrested oocytes surrounded by a single layer of supporting (granulosa) cells. Periodically, subsets of primordial follicles undergo further development during which the oocyte increases in size and the granulosa cells proliferate, stratify and develop a fluid-filled antrum. After ovulation, oocytes resume meiosis and granulosa cells retained in the follicle differentiate into steroidogenic cells, forming the corpus luteum(1,2). It has been proposed that intercellular signalling through gap junction channels may influence aspects of follicular development(3,4). Gap junctions are aggregations of intercellular channels composed of connexins, a family of at least 13 related proteins that directly connect adjacent cells allowing the diffusional movement of ions, metabolites, and other potential signalling molecules(5). Here we show that connexin 37 is present in gap junctions between oocyte and granulosa cells and that connexin-37-deficient mice lack mature (Graafian) follicles, fail to ovulate and develop numerous inappropriate corpora lutea. In addition, oocyte development arrests before meiotic competence is achieved. Thus, cell-cell signalling through intercellular channels critically regulates the highly coordinated set of cellular interactions required for successful oogenesis and ovulation.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ANDERSON E, 1976, J CELL BIOL, V71, P680, DOI 10.1083/jcb.71.2.680; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BJORKMAN N, 1962, ACTA ANAT, V51, P125, DOI 10.1159/000141943; BORNSLAEGER EA, 1985, BIOL REPROD, V66, P698; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CHO WK, 1974, J EXP ZOOL, V187, P383, DOI 10.1002/jez.1401870307; DEKEL N, 1978, P NATL ACAD SCI USA, V75, P4369, DOI 10.1073/pnas.75.9.4369; EOFOULU MA, 1970, ENDOCRINOLOGY, V87, P286; EPPIG JJ, 1991, BIOESSAYS, V13, P569, DOI 10.1002/bies.950131105; GILULA NB, 1978, J CELL BIOL, V78, P58, DOI 10.1083/jcb.78.1.58; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MATTSON BA, 1990, MOL REPROD DEV, V25, P374, DOI 10.1002/mrd.1080250411; MEYER EC, 1989, J CELL BIOL, V108, P596; NELSON LM, 1994, J CLIN ENDOCR METAB, V79, P1470, DOI 10.1210/jc.79.5.1470; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; SORENSEN RA, 1976, DEV BIOL, V50, P5531; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALDIMARSSON G, 1993, MOL REPROD DEV, V36, P7, DOI 10.1002/mrd.1080360103; Wassarman Paul M., 1994, P79; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049	24	530	546	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					525	529		10.1038/385525a0	http://dx.doi.org/10.1038/385525a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020357				2022-12-28	WOS:A1997WG23500045
J	Brown, MA				Brown, MA			Pre-eclampsia: A case of nerves?	LANCET			English	Editorial Material							PREECLAMPSIA; PREGNANCY		ST GEORGE HOSP,DEPT OBSTET,KOGARAH,NSW 2217,AUSTRALIA; UNIV NEW S WALES,KOGARAH,NSW 2217,AUSTRALIA	St George Hospital; University of New South Wales Sydney	Brown, MA (corresponding author), ST GEORGE HOSP,DEPT MED,KOGARAH,NSW 2217,AUSTRALIA.							*AUSTR SOC STUD HY, 1995, AUST NZ J OBSTET GYN, V35, P39; BROWN MA, 1995, CLIN EXP PHARMACOL P, V22, P781, DOI 10.1111/j.1440-1681.1995.tb01937.x; Chesley LC, 1978, HYPERTENSIVE DISORDE, P17; HEESCH CM, 1995, CLIN EXP PHARMACOL P, V22, P136, DOI 10.1111/j.1440-1681.1995.tb01970.x; PEDERSEN EB, 1988, HDB HYPERTENSION, V10, P152; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Schobel HP, 1996, NEW ENGL J MED, V335, P1480, DOI 10.1056/NEJM199611143352002	7	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					297	298		10.1016/S0140-6736(05)62819-X	http://dx.doi.org/10.1016/S0140-6736(05)62819-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024368				2022-12-28	WOS:A1997WF79400003
J	Nakano, N; Rooke, R; Benoist, C; Mathis, D				Nakano, N; Rooke, R; Benoist, C; Mathis, D			Positive selection of T cells induced by viral delivery of neopeptides to the thymus	SCIENCE			English	Article							INVARIANT CHAIN; RECEPTOR REPERTOIRE; NEGATIVE SELECTION; ANTIGEN; PEPTIDE; MICE; RECOGNITION; LIGANDS; LYMPHOCYTES; SPECIFICITY	The relation between an antigenic peptide that can stimulate a mature T cell and the natural peptide that promoted selection of this cell in the thymus is still unknown. An experimental system was devised to address this issue in vivo-mice expressing neopeptides in thymic stromal cells after adenovirus-mediated delivery of invariant chain-peptide fusion proteins. In this system, selection of T cells capable of responding to a given antigenic peptide could be promoted by the peptide itself, by closely related analogs lacking agonist and antagonist activity, or by ostensibly unrelated peptides. However, the precise repertoire of T cells selected was dictated by the particular neopeptide expressed.			Nakano, N (corresponding author), UNIV STRASBOURG 1,CU STRASBOURG,INSERM,CNRS,INST GENET & BIOL MOL CELLULAIRE,1 RUE LAURENT FRIES,F-67404 ILLKIRCH GRAFFENS,FRANCE.							ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CASANOVA JL, 1993, IMMUNOL TODAY, V14, P391, DOI 10.1016/0167-5699(93)90140-G; COCHET M, 1992, EUR J IMMUNOL, V22, P2639, DOI 10.1002/eji.1830221025; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FINK PJ, 1990, J EXP MED, V172, P139, DOI 10.1084/jem.172.1.139; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kaye J, 1991, Semin Immunol, V3, P269; KOOP BF, 1994, GENOMICS, V19, P478, DOI 10.1006/geno.1994.1097; LIANG HE, 1994, EUR J IMMUNOL, V24, P1604, DOI 10.1002/eji.1830240723; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; NAKANO N, UNPUB; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Oehen S, 1996, J EXP MED, V183, P2617, DOI 10.1084/jem.183.6.2617; Pawlowski TJ, 1996, EUR J IMMUNOL, V26, P851, DOI 10.1002/eji.1830260419; ROOKE R, UNPUB; SANDERSON S, 1995, P NATL ACAD SCI USA, V92, P7217, DOI 10.1073/pnas.92.16.7217; SCHUMACHER TNM, 1994, IMMUNITY, V1, P721, DOI 10.1016/S1074-7613(94)80013-8; Sebzda E, 1996, J EXP MED, V183, P1093, DOI 10.1084/jem.183.3.1093; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; TOURNE S, 1995, EUR J IMMUNOL, V25, P1851, DOI 10.1002/eji.1830250709; TOURNE S, UNPUB; VANSANTEN HM, 1995, J EXP MED, V181, P787, DOI 10.1084/jem.181.2.787; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	40	98	100	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					678	683		10.1126/science.275.5300.678	http://dx.doi.org/10.1126/science.275.5300.678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005856				2022-12-28	WOS:A1997WF07700043
J	Start, RD; Bury, JP; Strachan, AG; Cross, SS; Underwood, JCE				Start, RD; Bury, JP; Strachan, AG; Cross, SS; Underwood, JCE			Evaluating the reliability of causes of death in published clinical research	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,SCH MED,DEPT PATHOL,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of Sheffield				Cross, Simon/0000-0003-2044-1754				BANGDIWALA SI, 1989, CONTROL CLIN TRIALS, V12, P876; Britton M, 1993, Qual Assur Health Care, V5, P299; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, ANN INTERN MED, V121, P894; 1994, LANCET, V344, P1517	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					271	271		10.1136/bmj.314.7076.271	http://dx.doi.org/10.1136/bmj.314.7076.271			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022491	Green Published			2022-12-28	WOS:A1997WE63300026
J	Savill, J				Savill, J			Science medicine, and the future .3. Role of molecular cell biology in understanding disease	BRITISH MEDICAL JOURNAL			English	Article								Molecular techniques have revolutionised our knowledge of cell and tissue function in both health and disease, We already have new and powerful treatments based on an understanding of communication between cells by messenger molecules called cytokines, Furthermore, there is great therapeutic promise in defining molecules which regulate cell adhesion, motility, proliferation, survival, and death, Rational manipulation of cell and tissue function for therapeutic ends may be much closer than you think.			Savill, J (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					203	206		10.1136/bmj.314.7075.203	http://dx.doi.org/10.1136/bmj.314.7075.203			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022440	Green Published, Green Submitted			2022-12-28	WOS:A1997WD91100036
J	Kristensen, GB; Trope, C				Kristensen, GB; Trope, C			Epithelial ovarian carcinoma	LANCET			English	Article							DEOXYRIBONUCLEIC-ACID PLOIDY; EPIDERMAL GROWTH-FACTOR; LYMPH-NODE INVOLVEMENT; ORAL-CONTRACEPTIVE USE; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; POSTMENOPAUSAL WOMEN; SERUM CA-125; CANCER				Kristensen, GB (corresponding author), NORWEGIAN RADIUM HOSP,DEPT GYNAECOL ONCOL,N-0310 OSLO,NORWAY.							*ADV OV CANC TRIAL, 1991, BRIT MED J, V303, P884; ALBERTS DS, 1995, P AN M AM SOC CLIN, V14, P273; Allen D. G., 1995, European Journal of Gynaecological Oncology, V16, P349; BARTER FB, 1993, OVARIAN CANC, P269; BERCHUCK A, 1990, CANCER RES, V50, P4087; BEREK JS, 1995, CANCER-AM CANCER SOC, V76, P2092, DOI 10.1002/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T; BOLIS G, 1992, P AN M AM SOC CLIN, V11, P225; Bookman MA, 1996, J CLIN ONCOL, V14, P1895, DOI 10.1200/JCO.1996.14.6.1895; BORING CC, 1991, CA CANC J CLIN, V44, P7; BUIST MR, 1994, GYNECOL ONCOL, V52, P191, DOI 10.1006/gyno.1994.1030; BURGHARDT E, 1991, GYNECOL ONCOL, V40, P103, DOI 10.1016/0090-8258(91)90099-Q; Conte PF, 1996, J CLIN ONCOL, V14, P351, DOI 10.1200/JCO.1996.14.2.351; DAVIES AP, 1993, BRIT J OBSTET GYNAEC, V100, P927, DOI 10.1111/j.1471-0528.1993.tb15109.x; DEPRIEST PD, 1994, GYNECOL ONCOL, V55, P174, DOI 10.1006/gyno.1994.1273; DIETL J, 1993, GYNECOL OBSTET INVES, V35, P129, DOI 10.1159/000292682; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; EISENKOP SM, 1992, GYNECOL ONCOL, V47, P203, DOI 10.1016/0090-8258(92)90107-T; ENGELAND A, 1995, APMIS S, V49, P81; FANNING J, 1992, OBSTET GYNECOL, V80, P954; FATHALLA MF, 1971, LANCET, V2, P163; FELIP E, 1995, CANCER, V75, P2147, DOI 10.1002/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FRANCESCHI S, 1991, INT J CANCER, V49, P61, DOI 10.1002/ijc.2910490112; FREIDMAN JB, 1990, NEW ENGL J MED, V322, P1079; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; Granberg S, 1991, ACTA OBSTET GYN SCAN, V70, P385, DOI 10.3109/00016349109007896; HARTGE P, 1994, OBSTET GYNECOL, V84, P760; HEINTZ APM, 1986, OBSTET GYNECOL, V67, P783, DOI 10.1097/00006250-198606000-00007; HENRIKSEN R, 1995, BRIT J CANCER, V72, P1324, DOI 10.1038/bjc.1995.509; Herod JJO, 1996, CANCER RES, V56, P2178; HOSKINS PJ, 1995, CRIT REV ONCOL HEMAT, V20, P41, DOI 10.1016/1040-8428(94)00148-M; HOSKINS WJ, 1993, OVARIAN CANC, P241; HUNTER RW, 1992, AM J OBSTET GYNECOL, V166, P504; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JACQUET P, 1993, CANCER, V72, P1631, DOI 10.1002/1097-0142(19930901)72:5<1631::AID-CNCR2820720523>3.0.CO;2-I; KAERN J, 1993, INT J GYNECOL CANCER, V3, P349, DOI 10.1046/j.1525-1438.1993.03060349.x; KAERN J, 1994, AM J OBSTET GYNECOL, V170, P479, DOI 10.1016/S0002-9378(94)70215-2; KATSAROS D, 1995, ANTICANCER RES, V15, P1501; Kaye SB, 1996, J CLIN ONCOL, V14, P2113, DOI 10.1200/JCO.1996.14.7.2113; KERLIKOWSKE K, 1992, OBSTET GYNECOL, V80, P700; LEVESQUE MA, 1995, CANCER-AM CANCER SOC, V75, P1327, DOI 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P; MACKEY SE, 1995, J CLIN ONCOL, V13, P783, DOI 10.1200/JCO.1995.13.3.783; MAGGINO T, 1994, GYNECOL ONCOL, V54, P117, DOI 10.1006/gyno.1994.1179; MAKAR AP, 1993, GYNECOL ONCOL, V49, P73, DOI 10.1006/gyno.1993.1089; MAKAR AP, 1995, GYNECOL ONCOL, V56, P175, DOI 10.1006/gyno.1995.1027; MAKER AP, 1994, INT J GYNECOL CANC, V4, P194; MARKMAN M, 1993, INTRAPERITONEAL CHEM; MCGOWAN L, 1985, OBSTET GYNECOL, V65, P568; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MOLLER P, 1993, J CANC CARE, V2, P94; NIWA K, 1994, BRIT J CANCER, V70, P1191, DOI 10.1038/bjc.1994.472; OZOLS RF, 1995, SEMIN ONCOL, V22, P61; PETTERSSON F, 1995, ANN REPORT RESULTS T, V23; ROSENBERG L, 1994, AM J EPIDEMIOL, V139, P654, DOI 10.1093/oxfordjournals.aje.a117055; Rustin GJS, 1996, J CLIN ONCOL, V14, P1545, DOI 10.1200/JCO.1996.14.5.1545; SCAMBIA G, 1995, BRIT J CANCER, V72, P361, DOI 10.1038/bjc.1995.339; Scambia G, 1996, J CLIN ONCOL, V14, P334, DOI 10.1200/JCO.1996.14.2.334; SCHUTTER EMJ, 1994, CANCER-AM CANCER SOC, V74, P1398, DOI 10.1002/1097-0142(19940815)74:4<1398::AID-CNCR2820740433>3.0.CO;2-J; SCHWARTZ PE, 1995, ANN MED, V27, P519, DOI 10.3109/07853899509002463; SHARP F, 1995, INT J GYNECOL CANCER, V5, P449, DOI 10.1046/j.1525-1438.1995.05060449.x; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TSURUCHI N, 1993, GYNECOL ONCOL, V49, P51, DOI 10.1006/gyno.1993.1085; VANDAM PA, 1994, J CLIN PATHOL, V47, P914, DOI 10.1136/jcp.47.10.914; VANDERBURG MEL, 1995, NEW ENGL J MED, V332, P629, DOI 10.1056/NEJM199503093321002; VANNAGELL JR, 1995, CANCER, V76, P2086, DOI 10.1002/1097-0142(19951115)76:10+<2086::AID-CNCR2820761330>3.0.CO;2-L; VERGOTE IB, 1993, AM J OBSTET GYNECOL, V169, P40, DOI 10.1016/0002-9378(93)90129-7; VERMORKEN JB, 1993, ANN ONCOL, V4, P41; VESSEY MP, 1995, BRIT J CANCER, V71, P1340, DOI 10.1038/bjc.1995.260; WHITTEMORE AS, 1994, GYNECOL ONCOL, V55, pS15, DOI 10.1006/gyno.1994.1334; WILLIAMS SD, 1992, GYNECOL ONCOL, V47, P5, DOI 10.1016/0090-8258(92)90066-R; YOUNG RC, 1995, SEMIN ONCOL, V22, P76; ZALOUDEK C, 1994, PATHOLOGY GYNECOLOGY, P330; ZANETTA G, 1995, INT J GYNECOL OBSTET, V51, P133, DOI 10.1016/0020-7292(95)02455-L; 1995, JAMA-J AM MED ASSOC, V273, P491	74	124	129	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					113	117		10.1016/S0140-6736(96)06071-0	http://dx.doi.org/10.1016/S0140-6736(96)06071-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996432				2022-12-28	WOS:A1997WB80000043
J	Maynard, A				Maynard, A			Evidence-based medicine: An incomplete method for informing treatment choices	LANCET			English	Editorial Material							CLINICAL FREEDOM; HEALTH; COLLABORATION; NEED; END				Maynard, A (corresponding author), UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							Freemantle N, 1995, Qual Health Care, V4, P45, DOI 10.1136/qshc.4.1.45; FUCHS V, 1974, WHO SHALL LIVE, P148; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAMPTON JR, 1983, BRIT MED J, V287, P1237, DOI 10.1136/bmj.287.6401.1237; LOEWY EH, 1980, NEW ENGL J MED, V302, P697; MAXWELL RJ, 1984, BRIT MED J, V288, P1470, DOI 10.1136/bmj.288.6428.1470; SACKET DL, 1996, DOCTORS ETHICAL EC D; SACKETT DL, 1995, HEALTH ECON, V4, P249, DOI 10.1002/hec.4730040401; Sackett DL, 1995, J ROY SOC MED, V88, P620; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SACKETT DL, 1995, J PUBLIC HEALTH MED, V17, P330; SACKETT DL, 1994, BRIT MED J, V309, P1514, DOI 10.1136/bmj.309.6967.1514c; SHELDON T, 1994, HEALTH ECON, V3, P201, DOI 10.1002/hec.4730030308; Stewart AL, 1992, MEASURING FUNCTIONIN; *U LEEDS YORK, 1994, EFF HLTH CAR B, V8; WILLIAMS A, 1988, BRIT MED J, V297, P1183, DOI 10.1136/bmj.297.6657.1183; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WILLIAMS A, 1996, WORLD C HLTH EC VANC	18	161	163	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					126	128		10.1016/S0140-6736(96)05153-7	http://dx.doi.org/10.1016/S0140-6736(96)05153-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB800	8996435				2022-12-28	WOS:A1997WB80000046
J	Moayyedi, P; Carter, AM; Catto, A; Heppell, RM; Grant, PJ; Axon, ATR				Moayyedi, P; Carter, AM; Catto, A; Heppell, RM; Grant, PJ; Axon, ATR			Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection	BRITISH MEDICAL JOURNAL			English	Article							SEROLOGY		UNIV LEEDS,RES SCH MED,UNIT MOL VASC MED,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds	Moayyedi, P (corresponding author), GEN INFIRM,CTR DIGEST DIS,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Moayyedi, Paul/M-6178-2014	Moayyedi, Paul/0000-0002-3616-9292; Catto, Andrew/0000-0002-5934-3054				GLUPCZYNSKI Y, 1993, ZBL BAKT-INT J MED M, V280, P150, DOI 10.1016/S0934-8840(11)80951-5; MOAYYEDI P, 1994, LANCET, V344, P1016; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4	3	67	67	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					119	119		10.1136/bmj.314.7074.119	http://dx.doi.org/10.1136/bmj.314.7074.119			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006471	Green Published			2022-12-28	WOS:A1997WC47900025
J	Cookson, WOCM; Moffatt, MF				Cookson, WOCM; Moffatt, MF			Immunology - Asthma: An epidemic in the absence of infection?	SCIENCE			English	Editorial Material							REACTIVITY; CHILDREN; CELL				Cookson, WOCM (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT MED, OXFORD OX3 9DU, ENGLAND.		Cookson, William/HHC-1790-2022					ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; LACOUR M, 1994, DERMATOLOGY, V188, P255, DOI 10.1159/000247161; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; Sartono E, 1996, EUR J IMMUNOL, V26, P501, DOI 10.1002/eji.1830260233; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692	14	249	264	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 3	1997	275	5296					41	42		10.1126/science.275.5296.41	http://dx.doi.org/10.1126/science.275.5296.41			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WA903	8999535				2022-12-28	WOS:A1997WA90300038
J	Kolb, DM; Ullmann, R; Will, T				Kolb, DM; Ullmann, R; Will, T			Nanofabrication of small copper clusters on gold(111) electrodes by a scanning tunneling microscope	SCIENCE			English	Article							ELECTROCHEMICAL DEPOSITION; TIP; SURFACES; STM	The use of scanning tunneling microscopy in an electrochemical environment as a tool for the nanoscale modification of gold electrodes was demonstrated. Small copper clusters, typically two to four atomic layers in height, were precisely positioned on a gold(111) electrode by a process in which copper was first deposited onto the tip of the scanning tunneling microscope, which then acted as a reservoir from which copper could be transferred to the surface during an appropriate approach of the tip to the surface. Tip approach and position were controlled externally by a microprocessor unit, allowing the fabrication of various patterns, cluster arrays, and ''conducting wires'' in avery flexible and convenient manner.			Kolb, DM (corresponding author), UNIV ULM,DEPT ELECTROCHEM,D-89069 ULM,GERMANY.							BATINA N, 1992, FARADAY DISCUSS, V94, P93, DOI 10.1039/fd9929400093; BECKER RS, 1987, NATURE, V325, P419, DOI 10.1038/325419a0; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; CIRACI S, 1993, SPRINGER SERIES SURF, V29, P179; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; GOMER R, 1986, IBM J RES DEV, V30, P428, DOI 10.1147/rd.304.0428; KUIPERS L, 1995, SURF SCI, V340, P231, DOI 10.1016/0039-6028(95)00702-4; LAGRAFF JR, 1994, J PHYS CHEM-US, V98, P11246, DOI 10.1021/j100095a003; LANDMAN U, 1993, SPRINGER SERIES SURF, V29, P207; LI WJ, 1992, J PHYS CHEM-US, V96, P6529, DOI 10.1021/j100195a005; LI WJ, 1992, APPL PHYS LETT, V60, P1181, DOI 10.1063/1.107398; MAMIN HJ, 1991, J VAC SCI TECHNOL B, V9, P1398, DOI 10.1116/1.585205; MAMIN HJ, 1990, PHYS REV LETT, V65, P2418, DOI 10.1103/PhysRevLett.65.2418; QUATE CF, 1991, NATO ADV SCI I B-PHY, V285, P573; ULLMANN R, 1993, CHEM PHYS LETT, V209, P238, DOI 10.1016/0009-2614(93)80100-4; ULLMANN R, 1995, BER BUNSEN PHYS CHEM, V99, P1414, DOI 10.1002/bbpc.199500094	17	299	310	2	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 21	1997	275	5303					1097	1099		10.1126/science.275.5303.1097	http://dx.doi.org/10.1126/science.275.5303.1097			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027304				2022-12-28	WOS:A1997WJ50300035
J	Kurahashi, T; Menini, A				Kurahashi, T; Menini, A			Mechanism of odorant adaptation in the olfactory receptor cell	NATURE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; NUCLEOTIDE-GATED CHANNELS; ADAPTIVE PROPERTIES; NEURONS; CALCIUM; NEWT; PHOSPHORYLATION; TRANSDUCTION; SENSITIVITY; CONDUCTANCE	Adaptation to odorants begins at the level of sensory receptor cells(1-5), presumably through modulation of their transduction machinery, The olfactory signal transduction involves the activation of the adenylyl cyclase/cyclic AMP second messenger system which leads to the sequential opening of cAMP-gated channels and Ca2+-activated chloride ion channels(4-7). Several reports of results obtained from in vitro preparations describe the possible molecular mechanisms involved in odorant adaptation; namely, ordorant receptor phosphorylation(8,9), activation of phosphodiesterase(10), and ion channel regulation(11-14). However, it is still unknown whether these putative mechanisms work in the intact olfactory receptor cell. Here we investigate the nature of the adaptational mechanism in intact olfactory cells by using a combination of odorant stimulation and caged cAMP photolysis(15) which produces current responses that bypass the early stages of signal transduction (involving the receptor, G protein and adenylyl cyclase). Odorant- and cAMP-induced responses showed the same adaptation in a Ca2+-dependent manner, indicating that adaptation occurs entirely downstream of the cyclase. Moreover, we show that phosphodiesterase activity remains constant during adaptation and that an affinity change of the cAMP-gated channel for ligands accounts well for our results. We conclude that the principal mechanism underlying odorant adaptation is actually a modulation of the cAMP-gated channel by Ca2+ feedback.	OSAKA UNIV, DEPT BIOL, TOYOAKE, AICHI 560, JAPAN; CNR, IST CIBERNET & BIOFIS, I-16149 GENOA, ITALY	Osaka University; Consiglio Nazionale delle Ricerche (CNR)	Kurahashi, T (corresponding author), NATL INST PHYSIOL SCI, OKAZAKI, AICHI 444, JAPAN.			Menini, Anna/0000-0001-9304-0412				Balasubramanian S, 1996, J MEMBRANE BIOL, V152, P13, DOI 10.1007/s002329900081; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BORISY FF, 1992, J NEUROSCI, V12, P915; BREER H, 1992, SOC GEN PHY, V47, P93; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P541, DOI 10.1113/jphysiol.1978.sp012480; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; Kawamura S, 1996, J BIOL CHEM, V271, P21359, DOI 10.1074/jbc.271.35.21359; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1994, CURR BIOL, V4, P256, DOI 10.1016/S0960-9822(00)00058-0; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LYNCH JW, 1994, J GEN PHYSIOL, V103, P87, DOI 10.1085/jgp.103.1.87; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NERBONNE JM, 1984, NATURE, V310, P74, DOI 10.1038/310074a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Torre V, 1995, J NEUROSCI, V15, P7757; YAMAGATA K, 1990, NEURON, V4, P469, DOI 10.1016/0896-6273(90)90059-O; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	30	259	263	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					725	729		10.1038/385725a0	http://dx.doi.org/10.1038/385725a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034189				2022-12-28	WOS:A1997WJ42300047
J	Asahara, T; Murohara, T; Sullivan, A; Silver, M; vanderZee, R; Li, T; Witzenbichler, B; Schatteman, G; Isner, JM				Asahara, T; Murohara, T; Sullivan, A; Silver, M; vanderZee, R; Li, T; Witzenbichler, B; Schatteman, G; Isner, JM			Isolation of putative progenitor endothelial cells for angiogenesis	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; PLASMINOGEN-ACTIVATOR; ADHESION MOLECULES; VASCULOGENESIS; HEMATOPOIESIS; EXPRESSION; IDENTIFICATION; LIMB	Putative endothelial cell (EC) progenitors or angioblasts were isolated from human peripheral blood by magnetic bead selection on the basis of cell surface antigen expression. In vitro, these cells differentiated into ECs. In animal models of ischemia, heterologous, homologous, and autologous EC progenitors incorporated into sites of active angiogenesis. These findings suggest that EC progenitors may be useful for augmenting collateral vessel growth to ischemic tissues (therapeutic angiogenesis) and for delivering anti- or pro-angiogenic agents, respectively, to sites of pathologic or utilitarian angiogenesis.	TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED CARDIOL, BOSTON, MA 02135 USA; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University			Mordwinkin, Nicholas M/A-4347-2010; Asahara, Takayuki/AAH-5990-2021; Murohara, Toyoaki/M-4958-2014; Witzenbichler, Bernhard/ABC-2525-2021		PHS HHS [57516, 2824, 53354] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREWS RG, 1986, BLOOD, V67, P842; BAFFOUR R, 1992, J VASC SURG, V16, P181, DOI 10.1016/0741-5214(92)90106-I; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BRUGGER W, 1995, NEW ENGL J MED, V333, P283, DOI 10.1056/NEJM199508033330503; CIVIN CI, 1984, J IMMUNOL, V133, P157; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FINA L, 1990, BLOOD, V75, P2417; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; His W, 1900, ABHANDL KS GES WISS, V22, P171; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; ITO A, 1995, LAB INVEST, V72, P532; KATZ FE, 1985, LEUKEMIA RES, V9, P191, DOI 10.1016/0145-2126(85)90082-7; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Noishiki Y, 1996, NAT MED, V2, P90, DOI 10.1038/nm0196-90; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; RISAU W, 1988, DEVELOPMENT, V102, P471; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SATO Y, 1993, EXP CELL RES, V204, P223, DOI 10.1006/excr.1993.1028; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; Senger DR, 1996, AM J PATHOL, V149, P293; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHI Q, 1994, J VASC SURG, V20, P546, DOI 10.1016/0741-5214(94)90279-8; SOLIGO D, 1991, LEUKEMIA, V5, P1026; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tschudi MR, 1996, J CLIN INVEST, V98, P899, DOI 10.1172/JCI118872; VANDERZEE R, IN PRESS CIRCULATION; Weiss MJ, 1996, J CLIN INVEST, V97, P591, DOI 10.1172/JCI118454; WU MHD, 1995, J VASC SURG, V21, P862, DOI 10.1016/S0741-5214(05)80019-9; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	37	6846	7824	13	451	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					964	967		10.1126/science.275.5302.964	http://dx.doi.org/10.1126/science.275.5302.964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020076				2022-12-28	WOS:A1997WH38800041
J	Marcand, S; Gilson, E; Shore, D				Marcand, S; Gilson, E; Shore, D			A protein-counting mechanism for telomere length regulation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; CHROMOSOME STABILITY; RAP1; DNA; IDENTIFICATION; TRANSCRIPTION; LOCALIZATION; TETRAHYMENA; INTERACTS	In the yeast Saccharomyces cerevisiae, telomere elongation is negatively regulated by the telomere repeat-binding protein Rap1p, such that a narrow length distribution of telomere repeat tracts is observed, This length regulation was shown to function independently of the orientation of the telomere repeats. The number of repeats at an individual telomere was reduced when hybrid proteins containing the Rap1p carboxyl terminus were targeted there by a heterologous DNA-binding domain. The extent of this telomere tract shortening was proportional to the number of targeted molecules, consistent with a feedback mechanism of telomere length regulation that can discriminate the precise number of Rap1p molecules bound to the chromosome end.	UNIV GENEVA,DEPT MOL BIOL,CH-1211 GENEVA 4,SWITZERLAND; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; ECOLE NORMALE SUPER LYON,LAB BIO MOL & CELLULAIRE,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR 49,F-69364 LYON 07,FRANCE	University of Geneva; Columbia University; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X; Marcand, Stephane/0000-0001-5199-1885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040094] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40094] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Boscheron C, 1996, EMBO J, V15, P2184, DOI 10.1002/j.1460-2075.1996.tb00572.x; BUCK S, 1996, THESIS COLUMBIA U; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1994, NUCLEIC ACIDS RES, V22, P5310, DOI 10.1093/nar/22.24.5310; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANDIN N, IN PRESS GENES DEV; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARDY CFJ, 1991, THESIS COLUMBIA U; HARLEY CB, 1995, TELOMERES, P247; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Liu C, 1996, GENETICS, V143, P81; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; MARCAND S, UNPUB; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; SANDELL LL, 1994, P NATL ACAD SCI USA, V91, P12061, DOI 10.1073/pnas.91.25.12061; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VANSTEENSEL B, IN PRESS NATURE; WALMSLEY RM, 1985, P NATL ACAD SCI USA, V82, P506, DOI 10.1073/pnas.82.2.506; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WOTTON D, IN PRESS GENES DEV; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	45	429	436	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					986	990		10.1126/science.275.5302.986	http://dx.doi.org/10.1126/science.275.5302.986			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020083				2022-12-28	WOS:A1997WH38800048
J	Fanucchi, M; Glaspy, J; Crawford, J; Garst, J; Figlin, R; Sheridan, W; Menchaca, D; Tomita, D; Ozer, H; Harker, L				Fanucchi, M; Glaspy, J; Crawford, J; Garst, J; Figlin, R; Sheridan, W; Menchaca, D; Tomita, D; Ozer, H; Harker, L			Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-MPL LIGAND; COLONY-STIMULATING FACTOR; ACTIVATION IN-VITRO; INDUCED THROMBOCYTOPENIA; PHASE-I; THROMBOPOIETIN; CARBOPLATIN; PURIFICATION; INTERLEUKIN-3; AGGREGATION	Background Polyethylene glycol (PEG)-conjugated recombinant human megakaryocyte growth and development factor (MGDF, also known as PEG-rHuMGDF), a recombinant molecule related to thrombopoietin, specifically stimulates megakaryopoiesis and platelet production and reduces the severity of thrombocytopenia in animals receiving myelosuppressive chemotherapy. Methods We conducted a randomized, double-blind, placebo-controlled dose-escalation study of MGDF in 53 patients with lung cancer who were treated with carboplatin and paclitaxel. The patients were randomly assigned in blocks of 4 in a 1:3 ratio to receive either placebo or MGDF (0.03, 0.1, 0.3, 1.0, 3.0, or 5.0 mu g per kilogram of body weight per day), injected subcutaneously. No other marrow-active cytokines were given. Results In the 38 patients who received MGDF after chemotherapy, the median nadir platelet count was 188,000 per cubic millimeter (range, 68,000 to 373,000), as compared with 111,000 per cubic millimeter (range, 21,000 to 307,000) in 12 patients receiving placebo (P=0.013). The platelet count recovered to base-line levels in 14 days in the treated patients as compared with more than 21 days in those receiving placebo (P<0.001). Among all 40 patients treated with MGDF, 1 had deep venous thrombosis and pulmonary embolism, and another had superficial thrombophlebitis. Conclusions MGDF has potent stimulatory effects on platelet production in patients with chemotherapy-induced thrombocytopenia. (C) 1997, Massachusetts Medical Society.	EMORY UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; DUKE UNIV,CTR COMPREHENS CANC,DURHAM,NC; DUKE UNIV,DEPT MED,DURHAM,NC; AMGEN INC,THOUSAND OAKS,CA 91320	Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University; Duke University; Amgen	Fanucchi, M (corresponding author), EMORY UNIV,SCH MED,WINSHIP CANC CTR,1365 CLIFTON RD,BLDG B,RM B6204,ATLANTA,GA 30322, USA.			Sheridan, William/0000-0001-8320-1323				Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; BARTLEY TD, 1994, MPL CELL, V77, P1117; Basser RL, 1996, LANCET, V348, P1279, DOI 10.1016/S0140-6736(96)04471-6; BICK RL, 1992, SEMIN THROMB HEMOST, V18, P353, DOI 10.1055/s-2007-1002575; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; CHOI ES, 1995, STEM CELLS, V13, P317, DOI 10.1002/stem.5530130313; DECOSTER G, 1994, FILGRASTIM R METHUG, P267; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; deSauvage FJ, 1996, J EXP MED, V183, P651, DOI 10.1084/jem.183.2.651; DHONDT V, 1995, BLOOD, V85, P2347, DOI 10.1182/blood.V85.9.2347.bloodjournal8592347; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; Farese AM, 1996, J CLIN INVEST, V97, P2145, DOI 10.1172/JCI118652; FARESE AM, 1995, BLOOD, V86, P54, DOI 10.1182/blood.V86.1.54.bloodjournal86154; FOSTER D, 1996, THROMBOPOIESIS THROM, P203; Glaspy J, 1996, Curr Opin Hematol, V3, P223; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; GRABAREK J, 1994, J BIOL CHEM, V269, P21718; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Harker LA, 1996, BLOOD, V88, P511, DOI 10.1182/blood.V88.2.511.bloodjournal882511; HOKOM MM, 1995, BLOOD, V86, P4486, DOI 10.1182/blood.V86.12.4486.bloodjournal86124486; HUNT P, 1995, BLOOD, V86, P540, DOI 10.1182/blood.V86.2.540.bloodjournal862540; KATO T, 1995, J BIOCHEM-TOKYO, V118, P229, DOI 10.1093/oxfordjournals.jbchem.a124883; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; LANGER CJ, 1995, J CLIN ONCOL, V13, P1860, DOI 10.1200/JCO.1995.13.8.1860; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MENITOVE JE, 1991, HEMATOLOGY BASIC PRI, P1651; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Molineux G, 1996, BLOOD, V88, P1509, DOI 10.1182/blood.V88.4.1509.bloodjournal8841509; Molineux G, 1996, BLOOD, V88, P366; NICHOL JL, 1995, J CLIN INVEST, V95, P2973, DOI 10.1172/JCI118005; OMalley CJ, 1996, BLOOD, V88, P3288, DOI 10.1182/blood.V88.9.3288.bloodjournal8893288; POSTMUS PE, 1992, J CLIN ONCOL, V10, P1131, DOI 10.1200/JCO.1992.10.7.1131; ROGERS JS, 1988, J CLIN ONCOL, V6, P276, DOI 10.1200/JCO.1988.6.2.276; ROWINSKY EK, 1995, SEMIN ONCOL, V22, P48; SHIMODA K, 1993, J CLIN INVEST, V91, P1310, DOI 10.1172/JCI116330; Slichter SJ, 1991, HEMATOLOGY BASIC PRI, P1610; SMITH JW, 1993, NEW ENGL J MED, V328, P756, DOI 10.1056/NEJM199303183281103; TOOMBS CF, 1995, THROMB RES, V80, P23, DOI 10.1016/0049-3848(95)00147-J; Ulich TR, 1996, BLOOD, V87, P5006, DOI 10.1182/blood.V87.12.5006.bloodjournal87125006; VADHANRAJ S, 1995, BLOOD, V86, P2098, DOI 10.1182/blood.V86.6.2098.bloodjournal8662098; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; Zar JH., 1999, BIOSTAT ANAL; [No title captured]	46	233	245	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					404	409		10.1056/NEJM199702063360603	http://dx.doi.org/10.1056/NEJM199702063360603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010146				2022-12-28	WOS:A1997WF85900003
J	Zangwill, KM; Schuchat, A; Riedo, FX; Pinner, RW; Koo, DT; Reeves, MW; Wenger, JD				Zangwill, KM; Schuchat, A; Riedo, FX; Pinner, RW; Koo, DT; Reeves, MW; Wenger, JD			School-based clusters of meningococcal disease in the United States - Descriptive epidemiology and a case-control analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEISSERIA-MENINGITIDIS; RISK-FACTORS; OUTBREAK; TRANSMISSION; POPULATION; CLASSROOM; INFECTION; CONTACTS	Objective.-To evaluate the epidemiologic features and risk factors for multiple cases of meningococcal disease in schools. Design.-Population-based prospective evaluation and case-control study of clusters of meningococcal disease that occurred in schools from January 1989 to June 1994. Setting.-Surveillance conducted through state health departments in the United States. Main Outcome Measures.-Descriptive epidemiology of school-based clusters of meningococcal disease and determinants of their occurrence. Results.-We identified 22 clusters of meningococcal disease in 15 states. The estimated incidence of secondary meningococcal disease among schoolchildren aged 5 to 18 years was 2.5 per 100 000 population, a relative risk of 2.3 (95% confidence interval [Cl], 1.6-3.3). The median number of students per cluster was 2 (range, 2-4), Of 30 subsequent cases, 10 (33%) occurred 2 or fewer days after the index case, and 22 (79%) occurred 14 or fewer days after the index case. Among the 8 schools with 2 or more cases, 50% of the additional cases occurred 2 or more days after the Second case. Secondary schools (grades 7 through 12) accounted for 15 (75%) of 20 cluster schools compared with 9 (45%) of 20 matched control schools (P<.05). In 16 (73%) of 22 clusters, interaction between case patients was noted. The index patient in cluster schools was more likely than the controls to have participated in a-school-based group activity 14 or fewer days before illness (matched odds ratio, 7.0; 95% Cl, 0.9-57). Conclusions.-Three quarters of the school clusters occurred in secondary schools, with over 70% of subsequent cases occurring within 2 weeks of the index case. Rapid initiation of a chemoprophylaxis program after 2 cases of meningococcal disease in a school would have potentially prevented 50% of subsequent cases in the clusters described.	CTR DIS CONTROL & PREVENT,CHILDHOOD & RESP DIS BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ALEXANDER JP, 1993, J INFECT DIS, V167, P1201, DOI 10.1093/infdis/167.5.1201; CHEEK JE, 1995, ARCH PEDIAT ADOL MED, V149, P774, DOI 10.1001/archpedi.1995.02170200064010; COUNTS GW, 1984, REV INFECT DIS, V6, P640; *CTR DIS CONTR, 1985, MMWR-MORBID MORTAL W, V34, P255; *CTR DIS CONTR PRE, 1995, MMWR MORBID MORTAL W, V44, P121; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; FAVOROVA L A, 1975, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, V6, P15; FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007; GAUNT PN, 1988, J ANTIMICROB CHEMOTH, V21, P489, DOI 10.1093/jac/21.4.489; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; HUDSON PJ, 1986, PEDIATR INFECT DIS J, V5, P213, DOI 10.1097/00006454-198603000-00011; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1837; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1834; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; JACOBSON JA, 1976, AM J EPIDEMIOL, V104, P552, DOI 10.1093/oxfordjournals.aje.a112329; *MEN DIS SURV GROU, 1976, JAMA-J AM MED ASSOC, V235, P261; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MORROW HW, 1990, PEDIATR INFECT DIS J, V9, P394, DOI 10.1097/00006454-199006000-00005; MUNFORD RS, 1994, LANCET, V343, P1275; OLIVARES R, 1992, EUR J EPIDEMIOL, V8, P737, DOI 10.1007/BF00145393; SAS, 1996, SAS STAT SOFTW CHANG; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SCHWARTZ B, 1988, LANCET, V1, P1239; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320	27	60	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					389	395		10.1001/jama.277.5.389	http://dx.doi.org/10.1001/jama.277.5.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010171				2022-12-28	WOS:A1997WE77100029
J	Merson, MH; Feldman, EA; Bayer, R; Stryker, J				Merson, MH; Feldman, EA; Bayer, R; Stryker, J			Rapid self testing for HIV infection	LANCET			English	Editorial Material							HOME		YALE UNIV,INST SOCIAL & POLICY STUDIES,NEW HAVEN,CT; COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA	Yale University; Columbia University; University of California System; University of California San Francisco	Merson, MH (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 208034,NEW HAVEN,CT 06520, USA.							ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BAYER R, 1995, NEW ENGL J MED, V332, P1296, DOI 10.1056/NEJM199505113321911; BERRIOS DC, 1993, JAMA-J AM MED ASSOC, V270, P1576, DOI 10.1001/jama.270.13.1576; BRANSON BM, 1996, AIDS SOC NEWSLET MAR; NIGHTINGALE SL, 1995, JAMA-J AM MED ASSOC, V273, P613; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; Schopper D, 1996, AIDS, V10, P1455, DOI 10.1097/00002030-199611000-00002; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; WALL PG, 1993, AIDS, V7, P1523, DOI 10.1097/00002030-199311000-00018; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; 1995, FED REG         0223, V60, P10087	11	23	23	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					352	353		10.1016/S0140-6736(96)08260-8	http://dx.doi.org/10.1016/S0140-6736(96)08260-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024392				2022-12-28	WOS:A1997WF79400045
J	Kupfer, DJ; Reynolds, CF				Kupfer, DJ; Reynolds, CF			Management of insomnia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BENZODIAZEPINE HYPNOTICS; DOUBLE-BLIND; SLEEP; ZOLPIDEM; MELATONIN; DISORDERS; PREVENTION; PLACEBO; ZURICH; TIME				Kupfer, DJ (corresponding author), UNIV PITTSBURGH,MED CTR,WESTERN PSYCHIAT INST & CLIN,DEPT PSYCHIAT,3811 OHARA ST,PITTSBURGH,PA 15213, USA.				NIMH NIH HHS [MH-52247, MH-30915, MH-24652] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH024652, R37MH024652, P30MH030915, P30MH052247, P50MH030915] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALDHOUS M, 1985, BRIT J CLIN PHARMACO, V19, P517, DOI 10.1111/j.1365-2125.1985.tb02679.x; *AM SOC HLTH SYST, 1996, AM HOSP FORM SERV DR, P1536; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANGST J, 1989, EUR ARCH PSY CLIN N, V238, P285, DOI 10.1007/BF00449810; BEZCHLIBNUKBUTL.KZ, 1995, CLIN HDB PSYCHOTROPI; BOOTZIN RR, 1992, J CLIN PSYCHIAT, V53, P37; CRISMON ML, 1993, HDB NONPRESCRIPTION, P135; CRISMON ML, 1992, APPL THERAPEUTICS CL; DEW MA, 1994, J GERONTOL, V49, pP8, DOI 10.1093/geronj/49.1.P8; Diagnostic Classification Steering Committee American Sleep Disorders Association., 1990, INT CLASS SLEEP DIS; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; Drugs and Insomnia: NIH Consensus Development Conference, 1984, DRUGS INS NIH CONS D, V4, P1; EATON WW, 1995, AM J PSYCHIAT, V152, P967; FAIRWEATHER DB, 1992, EUR J CLIN PHARMACOL, V43, P597, DOI 10.1007/BF02284957; FARNEY RJ, 1995, MED CLIN N AM, V79, P391, DOI 10.1016/S0025-7125(16)30075-X; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FRIEDMAN L, 1991, J GERONTOL PSYCHOL S, V46, pPU; Ganguli M, 1996, J AM GERIATR SOC, V44, P778, DOI 10.1111/j.1532-5415.1996.tb03733.x; GANZONI E, 1995, J INT MED RES, V23, P61, DOI 10.1177/030006059502300108; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; GARZONE PD, 1989, CLIN PHARMACOKINET, V16, P337, DOI 10.2165/00003088-198916060-00002; GILLIN JC, 1990, NEW ENGL J MED, V322, P239; GREENBLATT DJ, 1992, J CLIN PSYCHIAT, V53, P7; GREENBLATT DJ, 1991, J CLIN PSYCHIAT, V52, P4; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; HAURI P, 1981, ARCH GEN PSYCHIAT, V38, P752; HOEHNS JD, 1993, CLIN PHARMACY, V12, P814; HOEHNS JD, 1993, CLIN PHARMACY, V12, P881; HOHAGEN F, 1994, EUR ARCH PSY CLIN N, V244, P65, DOI 10.1007/BF02193521; KARACAN I, 1983, AM FAM PHYSICIAN, V27, P143; LACY C, 1995, DRUG INFORMATION HDB; MACFARLANE JG, 1991, BIOL PSYCHIAT, V30, P371, DOI 10.1016/0006-3223(91)90293-U; MENDELSON WB, 1995, SLEEP, V18, P698, DOI 10.1093/sleep/18.8.698; MONTI JM, 1994, PHARMACOPSYCHIATRY, V27, P166, DOI 10.1055/s-2007-1014298; MORIN CM, 1989, PSYCHOL AGING, V4, P290, DOI 10.1037/0882-7974.4.3.290; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; *NAT SLEEP FDN, 1991, SLEEP AM NAT SURV US; Nofzinger EA, 1996, AM J PSYCHIAT, V153, P941; NOWELL PD, IN PRESS PSYCHOTHERA; REITE M, 1995, SLEEP, V18, P58, DOI 10.1093/sleep/18.1.58; REYNOLDS CF, 1991, J GERONTOL, V46, pM39, DOI 10.1093/geronj/46.2.M39; REYNOLDS CF, IN PRESS CLIN GERIAT; Reynolds Charles F. Iii, 1995, P1617; SCHARF MB, 1994, J CLIN PSYCHIAT, V55, P192; SHARPLEY AL, 1995, BIOL PSYCHIAT, V37, P85, DOI 10.1016/0006-3223(94)00135-P; SHAW SH, 1992, J INT MED RES, V20, P150, DOI 10.1177/030006059202000207; SHAW SH, 1992, J INT MED RES, V20, P494; SPIELMAN AJ, 1987, SLEEP, V10, P45; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; VOLLRATH M, 1989, EUR ARCH PSY CLIN N, V239, P113, DOI 10.1007/BF01759584; WALSH JK, 1992, J CLIN PSYCHIAT, V53, P10; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	52	206	217	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					341	346		10.1056/NEJM199701303360506	http://dx.doi.org/10.1056/NEJM199701303360506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WG233	9011788				2022-12-28	WOS:A1997WG23300006
J	Burnett, AK; Eden, OB				Burnett, AK; Eden, OB			The treatment of acute leukaemia	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; BONE-MARROW TRANSPLANTATION; MDR1 GENE-EXPRESSION; CYTOGENETIC ABNORMALITIES; DRUG-SENSITIVITY; IN-VITRO; CHEMOTHERAPY	Developments in supportive care, new regimens for induction of remission and consolidation therapy, and bone-marrow transplantation have improved the outlook for patients with acute leukaemia. The outlook, though, is influenced by age and factors related to the biology of the disease. In acute myeloid leukaemia age is such an important factor that it determines approach to therapy. Overcoming resistance to chemotherapy is an area that needs much attention.	ROYAL MANCHESTER CHILDRENS HOSP,ACAD DEPT PAEDIAT ONCOL,MANCHESTER M27 4HD,LANCS,ENGLAND	Royal Manchester Children's Hospital	Burnett, AK (corresponding author), UNIV WALES COLL MED,DEPT HAEMATOL,CARDIFF CF4 4XN,S GLAM,WALES.							APPELBAUM FR, 1988, BLOOD, V72, P179; ARLIN Z, 1990, LEUKEMIA, V4, P177; AUR RJA, 1971, BLOOD-J HEMATOL, V37, P272, DOI 10.1182/blood.V37.3.272.272; BEGG CB, 1984, J CLIN ONCOL, V2, P369, DOI 10.1200/JCO.1984.2.5.369; BERMAN E, 1991, BLOOD, V77, P1666; BIONDI A, 1992, LEUKEMIA, V6, P282; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; Burnett A. K., 1996, British Journal of Haematology, V93, P313; CAMPOS L, 1993, BLOOD, V81, P3091; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; CHESSELLS JM, IN PRESS J CLIN ONCO; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; DEMIRER T, 1995, BONE MARROW TRANSPL, V15, P915; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; GALE RP, 1995, BONE MARROW TRANSPL, V16, P203; GALE RP, 1983, LANCET, V2, P663; GOKER E, 1993, LEUKEMIA, V7, P1000; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; KASPERS GJL, 1995, BLOOD, V85, P751, DOI 10.1182/blood.V85.3.751.bloodjournal853751; KEATING MJ, 1988, LEUKEMIA, V2, P403; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; MARIE JP, 1991, BLOOD, V78, P586; MAUNG ZT, 1995, BRIT J HAEMATOL, V91, P93, DOI 10.1111/j.1365-2141.1995.tb05251.x; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; NACHMAN J, 1993, CANCER, V71, P3377, DOI 10.1002/1097-0142(19930515)71:10+<3377::AID-CNCR2820711741>3.0.CO;2-8; PATTE C, 1992, MED PEDIATR ONCOL, V20, P405; PIRKER R, 1991, J NATL CANCER I, V83, P708, DOI 10.1093/jnci/83.10.708; Ravindranath Y, 1996, NEW ENGL J MED, V334, P1428, DOI 10.1056/NEJM199605303342203; READING CL, 1993, BLOOD, V81, P3083; Rees JKH, 1996, BRIT J HAEMATOL, V94, P89, DOI 10.1046/j.1365-2141.1996.d01-1769.x; Rowe JM, 1996, LEUKEMIA, V10, pS40; RUUTU T, 1994, LEUKEMIA, V8, P11; SCHIFFER CA, 1989, BLOOD, V73, P263; Veerman A J, 1990, Haematol Blood Transfus, V33, P473; Wheatley K., 1995, Blood, V86, p434A; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WOODS WG, 1994, BLOOD, V84, pA232; WORMANN B, 1994, HEMATOL BLOOD TRANSF, V36, P5; YUNIS JJ, 1984, NEW ENGL J MED, V311, P812, DOI 10.1056/NEJM198409273111302; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	40	63	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					270	275		10.1016/S0140-6736(96)08086-5	http://dx.doi.org/10.1016/S0140-6736(96)08086-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014927				2022-12-28	WOS:A1997WD90600046
J	Cockwell, P; Savage, COS; Owen, JJT; Thompson, RA; Gordon, C; Adu, D; Howie, AJ; Sheppard, MC; Stewart, PM; Littler, WA; Langman, MJS; Holmes, J				Cockwell, P; Savage, COS; Owen, JJT; Thompson, RA; Gordon, C; Adu, D; Howie, AJ; Sheppard, MC; Stewart, PM; Littler, WA; Langman, MJS; Holmes, J			Grand Round - Queen Elizabeth Medical Centre, Birmingham - Systemic lupus erythematosus - Complicated by lupus nephritis and antiphospholipid antibody syndrome	BRITISH MEDICAL JOURNAL			English	Editorial Material							PULSE CYCLOPHOSPHAMIDE				Cockwell, P (corresponding author), QUEEN ELIZABETH MED CTR,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.			Cockwell, Paul/0000-0003-1975-266X				ADU D, 1982, CLIN RHEUM DIS, V8, P153; [Anonymous], 1992, SEMIN ARTHRITIS RHEU, P275; BOUMPAS DT, 1993, ANN INTERN MED, V119, P366, DOI 10.7326/0003-4819-119-5-199309010-00003; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; Johnson AE, 1996, LANCET, V347, P367, DOI 10.1016/S0140-6736(96)90539-5; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; PONTCELLI C, 1992, OXFORD TXB CLIN NEPH, V1, P646; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; 1994, DRUG THER B, V32, P66	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					292	295		10.1136/bmj.314.7076.292	http://dx.doi.org/10.1136/bmj.314.7076.292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022497	Green Published			2022-12-28	WOS:A1997WE63300034
J	Rai, R; Cohen, H; Dave, M; Regan, L				Rai, R; Cohen, H; Dave, M; Regan, L			Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)	BRITISH MEDICAL JOURNAL			English	Article							LUPUS-ANTICOAGULANT; ANTICARDIOLIPIN ANTIBODIES; FETAL DEATH; PREDNISONE	Objective: To determine whether treatment with low dose aspirin and heparin leads to a higher rate of live births than that achieved with low dose aspirin alone in women with a history of recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies), lupus anticoagulant, and cardiolipin antibodies (or anticardiolipin antibodies). Design: Randomised controlled trial. Setting: Specialist clinic for recurrent miscarriages. Subjects: 90 women (median age 33 (range 22-43)) with a history of recurrent miscarriage (median number 4 (range 3-15)) and persistently positive results for phospholipid antibodies. Intervention: Either low dose aspirin (75 mg daily) or low dose aspirin and 5000 U of unfractionated heparin subcutaneously 12 hourly. All women started treatment with low dose aspirin when they had a positive urine pregnancy test Women were randomly allocated an intervention when fetal heart activity was seen on ultrasonography. Treatment was stopped at the time of miscarriage or at 34 weeks' gestation. Main outcome measures: Rate oflive births with the two treatments. Results: There was no significant difference in the two groups in age or the number and gestation of previous miscarriages. The rate oflive births with low dose aspirin and heparin was 71% (32/45 pregnancies) and 42% (19/45 pregnancies) with low dose aspirin alone (odds ratio 3.37 (95% confidence interval 1.40 to 8.10)). More than 90% of miscarriages occurred in the first trimester. There was no difference in outcome betwveen the two treatments in pregnancies that advanced beyond 13 weeks' gestation. Twelve of the 51 successful pregnancies (24%) were delivered before 37 weeks' gestation. Women randomly allocated aspirin and heparin had a median decrease in lumbar spine bone density of 5.4% (range -8.6% to 1.7%). Conclusion: Treatment with aspirin and heparin leads to a significantly higher rate of live births in women with a history of recurrent miscarriage associated with phospholipid antibodies than that achieved with aspirin alone.	ST MARYS HOSP,SCH MED,IMPERIAL COLL,DEPT OBSTET & GYNAECOL,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,IMPERIAL COLL,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London								BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1597; CARRERAS LO, 1988, LANCET, V2, P393; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DEWOLF F, 1982, AM J OBSTET GYNECOL, V142, P829, DOI 10.1016/S0002-9378(16)32527-3; HARRIS EN, 1987, BRIT J RHEUMATOL, V26, P324; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; KHAMASHTA MA, 1993, J CLIN PATHOL, V46, P104, DOI 10.1136/jcp.46.2.104; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LUBBE WF, 1983, LANCET, V1, P1361; *LUP ANT WORK PART, 1991, J CLIN PATHOL, V44, P885; LYDEN TW, 1992, J REPROD IMMUNOL, V22, P1, DOI 10.1016/0165-0378(92)90002-L; MCINTYRE JA, 1993, HAEMOSTASIS, V23, P202; OUT HJ, 1991, EUR J OBSTET GYN R B, V41, P179, DOI 10.1016/0028-2243(91)90021-C; PEACEMAN AM, 1995, AM J OBSTET GYNECOL, V173, P1391, DOI 10.1016/0002-9378(95)90622-3; Rai RS, 1995, HUM REPROD, V10, P3301, DOI 10.1093/oxfordjournals.humrep.a135907; RAI RS, 1996, HUM REPROD, V11, P27; RAI RS, 1995, HUM REPROD, V10, P101; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; ROTE NS, 1992, AM J REPROD IMMUNOL, V28, P31, DOI 10.1111/j.1600-0897.1992.tb00753.x; SILVER RK, 1993, AM J OBSTET GYNECOL, V169, P1411, DOI 10.1016/0002-9378(93)90410-K; SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130; STRAYPEDERSEN B, 1984, AM J OBSTET GYNECOL, V148, P140, DOI 10.1016/S0002-9378(84)80164-7; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WATSON H, 1993, HUM REPROD, V8, P829, DOI 10.1093/oxfordjournals.humrep.a138149	27	803	822	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					253	257		10.1136/bmj.314.7076.253	http://dx.doi.org/10.1136/bmj.314.7076.253			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022487	Green Published			2022-12-28	WOS:A1997WE63300022
J	Shu, LJ; Nesheim, JC; Kauffmann, K; Munck, E; Lipscomb, JD; Que, L				Shu, LJ; Nesheim, JC; Kauffmann, K; Munck, E; Lipscomb, JD; Que, L			An (Fe2O2)-O-IV diamond core structure for the key intermediate Q of methane monooxygenase	SCIENCE			English	Article							METHYLOCOCCUS-CAPSULATUS-BATH; RIBONUCLEOTIDE REDUCTASE; MAGNETIC-PROPERTIES; CATALYTIC CYCLE; DIIRON CENTER; HYDROXYLASE; COMPONENT; OXIDATION; CLUSTER; PURIFICATION	A new paradigm for oxygen activation is required for enzymes such as methane monooxygenase (MMO), for which catalysis depends on a nonheme diiron center instead of the more familiar Fe-porphyrin cofactor. On the basis of precedents from synthetic diiron complexes, a high-valent Fe-2(mu-O)(2) diamond core has been proposed as the key oxidizing species for MMO and other nonheme diiron enzymes such as ribonucleotide reductase and fatty acid desaturase. The presence of a single short Fe-O bond (1.77 angstroms) per Fe atom and an Fe-Fe distance of 2.46 angstroms in MMO reaction intermediate Q, obtained from extended x-ray absorption fine structure and Mossbauer analysis, provides spectroscopic evidence that the diiron center in Q has an (Fe2O2)-O-IV, diamond core.	UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR MET BIOCATALYSIS,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Carnegie Mellon University				Lipscomb, John/0000-0002-8158-5594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008277, R01GM040466, R01GM022701] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040466, GM-08277, GM-22701, GM-40466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1982, IRON SULFUR PROTEINS, P3; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLLINS TJ, 1990, J AM CHEM SOC, V112, P5637, DOI 10.1021/ja00170a037; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEWITT JG, 1995, INORG CHEM, V34, P2505, DOI 10.1021/ic00114a007; DONG YH, 1995, J AM CHEM SOC, V117, P2778, DOI 10.1021/ja00115a013; Dong YH, 1996, ANGEW CHEM INT EDIT, V35, P618, DOI 10.1002/anie.199606181; DONG YH, 1995, J AM CHEM SOC, V117, P11377, DOI 10.1021/ja00150a051; ELANGO N, IN PRESS PROTEIN SCI; FOX BG, 1989, J BIOL CHEM, V264, P10023; Halfen JA, 1996, SCIENCE, V271, P1397, DOI 10.1126/science.271.5254.1397; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LIU KE, 1995, J AM CHEM SOC, V117, P4997, DOI 10.1021/ja00122a032; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU KE, 1995, ADV INORG CHEM RAD, V42, P263; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; MAHAPATRA S, 1995, J AM CHEM SOC, V117, P8865, DOI 10.1021/ja00139a026; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Ookubo T, 1996, J AM CHEM SOC, V118, P701, DOI 10.1021/ja953705n; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PECORARO VL, 1994, CHEM REV, V94, P807, DOI 10.1021/cr00027a012; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; Que L, 1996, ACCOUNTS CHEM RES, V29, P190, DOI 10.1021/ar950146g; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; REDDY KR, 1994, INORG CHEM, V33, P428, DOI 10.1021/ic00081a008; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; ROE AL, 1984, J AM CHEM SOC, V106, P1676, DOI 10.1021/ja00318a021; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; SCARROW RC, 1987, J AM CHEM SOC, V109, P7857, DOI 10.1021/ja00259a039; Shu LJ, 1996, J BIOL INORG CHEM, V1, P297, DOI 10.1007/s007750050057; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; ZANG Y, 1995, J AM CHEM SOC, V117, P1169, DOI 10.1021/ja00108a050	38	527	534	5	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					515	518		10.1126/science.275.5299.515	http://dx.doi.org/10.1126/science.275.5299.515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999792				2022-12-28	WOS:A1997WE25700039
J	CroninStubbs, D; Beckett, LA; Scherr, PA; Field, TS; Chown, MJ; Pilgrim, DM; Bennett, DA; Evans, DA				CroninStubbs, D; Beckett, LA; Scherr, PA; Field, TS; Chown, MJ; Pilgrim, DM; Bennett, DA; Evans, DA			Weight loss in people with Alzheimer's disease: A prospective population based analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									CTR DIS CONTROL & PREVENT, HLTH CARE & AGING STUDIES BRANCH, ATLANTA, GA USA; HARVARD UNIV, SCH MED, DIV MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, HARVARD COMMUNITY HLTH PLAN, BOSTON, MA USA	Centers for Disease Control & Prevention - USA; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	CroninStubbs, D (corresponding author), RUSH INST AGING, 1645 W JACKSON BLVD, SUITE 675, CHICAGO, IL 60612 USA.				NATIONAL INSTITUTE ON AGING [P30AG010161, N01AG012106, N01AG002107] Funding Source: NIH RePORTER; NIA NIH HHS [AG-10161, N01-AG-02107, N01-AG-12106] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM HOSP ASS DIV Q, 1989, INT CLASS DIS; GALANOS AN, 1994, J AM GERIATR SOC, V42, P368, DOI 10.1111/j.1532-5415.1994.tb07483.x; RHEAUME Y, 1987, Journal of Nutrition for the Elderly, V7, P43, DOI 10.1300/J052v07n01_05; SPARKS DL, 1988, ARCH NEUROL-CHICAGO, V45, P994, DOI 10.1001/archneur.1988.00520330084014; Wolf-Klein G P, 1994, Int Psychogeriatr, V6, P135, DOI 10.1017/S1041610294001705	5	87	89	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					178	179		10.1136/bmj.314.7075.178	http://dx.doi.org/10.1136/bmj.314.7075.178			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WD911	9022430	Green Published, Green Submitted			2022-12-28	WOS:A1997WD91100024
J	Neal, KR; Dornan, J; Irving, WL				Neal, KR; Dornan, J; Irving, WL			Prevalence of hepatitis C antibodies among healthcare workers of two teaching hospitals. Who is at risk?	BRITISH MEDICAL JOURNAL			English	Article							VIRUS; TRANSMISSION		QUEENS MED CTR,NOTTINGHAM OCCUPAT HLTH,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	Neal, KR (corresponding author), UNIV NOTTINGHAM,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND.			Irving, William/0000-0002-7268-3168	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLANDER T, 1995, LANCET, V345, P603, DOI 10.1016/S0140-6736(95)90518-9; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; NEAL KR, 1994, EPIDEMIOL INFECT, V112, P595, DOI 10.1017/S0950268800051293; SUZUKI K, 1994, J INFECT DIS, V170, P1575, DOI 10.1093/infdis/170.6.1575; ZUCKERMAN J, 1994, LANCET, V343, P1618, DOI 10.1016/S0140-6736(94)93064-3	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					179	180		10.1136/bmj.314.7075.179	http://dx.doi.org/10.1136/bmj.314.7075.179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022431	Green Published			2022-12-28	WOS:A1997WD91100025
J	Ahlgren, U; Pfaff, SL; Jessell, TM; Edlund, T; Edlund, H				Ahlgren, U; Pfaff, SL; Jessell, TM; Edlund, T; Edlund, H			Independent requirement for ISL1 in formation of pancreatic mesenchyme and islet cells	NATURE			English	Article							ENDOCRINE PANCREAS; PROTEIN ISL-1; INSULIN GENE; HOMEODOMAIN; NEURONS; POLYPEPTIDE; EXPRESSION; ELEGANS; LINEAGE	The mammalian pancreas is a specialized derivative of the primitive gut endoderm and controls many homeostatic functions through the activity of its component exocrine acinar and endocrine islet cells. The LIM homeodomain protein ISL1 is expressed in all classes of islet cells in the adult(1,2) and its expression in the embryo is initiated soon after the islet cells have left the cell cycle. ISL1 is also expressed in mesenchymal cells that surround the dorsal but not ventral evagination of the gut endoderm, which together comprise the pancreatic anlagen. To define the role of ISL1 in the development of the pancreas, we have now analysed acinar and islet cell differentiation in mice deficient in ISL1 function(3). Dorsal pancreatic mesenchyme does not form in ISL1-mutant embryos and there is an associated failure of exocrine cell differentiation in the dorsal but not the ventral pancreas. There is also a complete loss of differentiated islet cells. Exocrine, but not endocrine, cell differentiation in the dorsal pancreas can be rescued in vitro by provision of mesenchyme derived from wild-type embryos. These results indicate that ISL1, by virtue of its requirement for the formation of dorsal mesenchyme, is necessary for the development of the dorsal exocrine pancreas, and also that ISL1 function in pancreatic endodermal cells is required for the generation of all endocrine islet cells.	UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN; COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Umea University; Columbia University; Howard Hughes Medical Institute				Edlund, Helena/0000-0002-3553-7348; Ahlgren, Ulf/0000-0001-5923-8572				Ahlgren U, 1996, DEVELOPMENT, V122, P1409; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOLOSOW N, 1962, DEV BIOL, V4, P242, DOI 10.1016/0012-1606(62)90042-8; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LUNDGREN FE, 1995, DEVELOPMENT, V121, P1769; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Offield MF, 1996, DEVELOPMENT, V122, P983; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2	22	552	579	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					257	260		10.1038/385257a0	http://dx.doi.org/10.1038/385257a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000074				2022-12-28	WOS:A1997WC71100049
J	Verstraete, M				Verstraete, M			Fortnightly review: Prophylaxis of venous thromboembolism	BRITISH MEDICAL JOURNAL			English	Review							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; UNFRACTIONATED HEPARIN; RANDOMIZED TRIAL; PREVENTION; THROMBOPROPHYLAXIS; STROKE; ORG-10172; SURGERY				Verstraete, M (corresponding author), CTR MOL & VASC BIOL,CAMPUS GASTHUISBERG O&N,B-3000 LOUVAIN,BELGIUM.							BERGQVIST D, 1991, SURGERY, V109, P617; BERGQVIST D, 1993, HAEMOSTASIS, V23, P15; *BRIT SOC HAEM, 1993, J CLIN PATHOL, V46, P489; CLAGETT GP, 1995, CHEST S, V108, P312; COOK DJ, 1995, CHEST, V108, P227; DAHAN R, 1986, HAEMOSTASIS, V16, P159; *DAN EN STUD GROUP, 1991, ARCH INTERN MED, V151, P1621; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; Eriksson BI, 1996, LANCET, V347, P635, DOI 10.1016/S0140-6736(96)91200-3; *EUR CONS STAT, 1992, INT ANGIOL, V11, P151; GINSBERG JS, 1994, CIRCULATION, V90, P2385, DOI 10.1161/01.CIR.90.5.2385; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; HIRSH J, 1992, BLOOD, V79, P1; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; KOCK HJ, 1995, LANCET, V346, P459, DOI 10.1016/S0140-6736(95)91320-3; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; LEYVRAZ P, 1992, BRIT J SURG, V79, P911, DOI 10.1002/bjs.1800790919; Pineo GF, 1996, DRUGS, V52, P71, DOI 10.2165/00003495-199652010-00006; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; PRINS MH, 1987, THROMB HAEMOSTASIS, V58, P117; *SCOTT INT GUID NE, 1996, PROPH VEN THROMB; THOMAS DP, 1989, THROMB HAEMOSTASIS, V62, P648; *THROMB RISK FACT, 1992, BRIT MED J, V305, P567; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; TURPIE AGG, 1987, LANCET, V1, P523; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	27	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					123	125		10.1136/bmj.314.7074.123	http://dx.doi.org/10.1136/bmj.314.7074.123			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006474	Green Published			2022-12-28	WOS:A1997WC47900028
J	Choquet, D; Felsenfeld, DP; Sheetz, MP				Choquet, D; Felsenfeld, DP; Sheetz, MP			Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages	CELL			English	Article							LOCOMOTING CELLS; TYROSINE PHOSPHORYLATION; TRACTION FORCES; GROWTH CONE; FIBRONECTIN; DOMAIN; REARRANGEMENT; FIBROBLASTS; ATTACHMENT; EXPRESSION	To move forward, migrating cells must generate traction forces through surface receptors bound to extracellular matrix molecules coupled to a rigid structure. We investigated whether cells sample and respond to the rigidity of the anchoring matrix. Movement of beads coated with fibronectin or an anti-integrin antibody was restrained with an optical trap on fibroblasts to mimic extracellular attachment sites of different resistance. Cells precisely sense the restraining force on fibronectin beads and respond by a localized, proportional strengthening of the cytoskeleton linkages, allowing stronger force to be exerted on the integrins. This strengthening was absent or transient with antibody beads, but restored with soluble fibronectin. Hence, ligand binding site occupancy was required. Finally, phenylarsine oxide inhibited strengthening of cytoskeletal linkages, indicating a role for dephosphorylation. Thus, the strength of integrin-cytoskeleton linkages is dependent on matrix rigidity and on its biochemical composition. Matrix rigidity may, therefore, serve as a guidance cue in a process of mechanotaxis.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University			Choquet, Daniel/K-7893-2018; Ladoux, Benoit/A-9879-2013; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/E-4203-2013	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; 				ASHKIN A, 1992, BIOPHYS J, V61, P569, DOI 10.1016/S0006-3495(92)81860-X; CARNEMOLLA B, 1992, J BIOL CHEM, V267, P24689; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; DALTON SL, 1992, J BIOL CHEM, V267, P8186; DEMBO M, 1981, J CELL BIOL, V91, P528, DOI 10.1083/jcb.91.2.528; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MANDEVILLE JTH, 1996, IN PRESS J LEUKOC BI; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; OLIVER T, 1995, CELL MOTIL CYTOSKEL, V31, P225, DOI 10.1002/cm.970310306; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROMER LH, 1992, COLD SPRING HARB SYM, V57, P193, DOI 10.1101/SQB.1992.057.01.024; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SATO M, 1987, ARTERIOSCLEROSIS, V7, P276, DOI 10.1161/01.ATV.7.3.276; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; SHIRINSKY VP, 1989, J CELL BIOL, V109, P331, DOI 10.1083/jcb.109.1.331; Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1; SIMS JR, 1992, J CELL SCI, V103, P1215; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; STOPAK D, 1985, P NATL ACAD SCI USA, V82, P2804, DOI 10.1073/pnas.82.9.2804; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WANG N, 1994, BIOPHYS J, V66, P2181, DOI 10.1016/S0006-3495(94)81014-8; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; ZHELEV DV, 1995, BIOPHYS J, V68, P2004, DOI 10.1016/S0006-3495(95)80377-2	46	993	1011	2	93	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					39	48		10.1016/S0092-8674(00)81856-5	http://dx.doi.org/10.1016/S0092-8674(00)81856-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019403	Bronze			2022-12-28	WOS:A1997WC56900007
J	Zapun, A; Petrescu, SM; Rudd, PM; Dwek, RA; Thomas, DY; Bergeron, JJM				Zapun, A; Petrescu, SM; Rudd, PM; Dwek, RA; Thomas, DY; Bergeron, JJM			Conformation-independent binding of monoglucosylated ribonuclease B to calnexin	CELL			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; HIGH MANNOSE OLIGOSACCHARIDES; PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN GLUCOSYLTRANSFERASE; RAT-LIVER; LINKED OLIGOSACCHARIDES; UDP-GLC; ASSOCIATION; RECOGNITION	Calnexin is a membrane protein of the endoplasmic reticulum that associates transiently with newly synthesized N-linked glycoproteins in vivo. Using defined components, the binding of ribonuclease B (RNase B) Man(7)-Man(9) glycoforms to the luminal domain of calnexin was observed in vitro only if RNase B was monoglucosylated. Binding was independent of the conformation of the glycoprotein. Calnexin protected monoglucosylated RNase B from the action of glucosidase II and PNGase F but not from that of Endo H, which completely released the protein from calnexin. These observations directly demonstrate that calnexin can act exclusively as a lectin.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,GENET GRP,MONTREAL,PQ H4P 2R2,CANADA; UNIV OXFORD,DEPT BIOCHEM,OXFORD GLYCOBIOL INST,OXFORD OX1 3QU,ENGLAND; INST BIOCHEM,BUCHAREST 77700,ROMANIA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA	National Research Council Canada; University of Oxford; Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; McGill University	Zapun, A (corresponding author), MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3A 2B2,CANADA.		Petrescu, Stefana M/I-9240-2012; Petrescu, Stefana/AAJ-9505-2021; Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Petrescu, Stefana M/0000-0002-4047-0811; Petrescu, Stefana/0000-0002-4047-0811; Thomas, David/0000-0002-8854-762X; Zapun, Andre/0000-0001-8953-4399				ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CHU FK, 1986, J BIOL CHEM, V261, P172; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DATEMA R, 1982, P NATL ACAD SCI-BIOL, V79, P6787, DOI 10.1073/pnas.79.22.6787; GRAFL R, 1987, J BIOL CHEM, V262, P10624; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARODI AJ, 1984, J BIOL CHEM, V259, P6351; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WANG FFC, 1977, J BIOL CHEM, V252, P8358; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WATANABE D, 1994, J BIOL CHEM, V269, P7744; WILLIAMS RL, 1987, J BIOL CHEM, V262, P16020; YEO KT, 1989, BIOCHEM BIOPH RES CO, V161, P1013, DOI 10.1016/0006-291X(89)91344-2; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	43	174	178	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					29	38		10.1016/S0092-8674(00)81855-3	http://dx.doi.org/10.1016/S0092-8674(00)81855-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019402	Bronze			2022-12-28	WOS:A1997WC56900006
J	Yang, J; Liu, XS; Bhalla, K; Kim, CN; Ibrado, AM; Cai, JY; Peng, TI; Jones, DP; Wang, XD				Yang, J; Liu, XS; Bhalla, K; Kim, CN; Ibrado, AM; Cai, JY; Peng, TI; Jones, DP; Wang, XD			Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; PROTEIN; CED-3; INHIBITION; SURVIVAL; ENCODES; HOMOLOG	Bcl-2 is an integral membrane protein located mainly on the outer membrane of mitochondria. Overexpression of Bcl-2 prevents cells from undergoing apoptosis in response to a variety of stimuli. Cytosolic cytochrome c is necessary for the initiation of the apoptotic program, suggesting a possible connection between Bcl-2 and cytochrome c, which is normally located in the mitochondrial intermembrane space. Cells undergoing apoptosis were found to have an elevation of cytochrome c in the cytosol and a corresponding decrease in the mitochondria. Overexpression of Bcl-2 prevented the efflux of cytochrome c from the mitochondria and the initiation of apoptosis. Thus, one possible role of Bcl-2 in prevention of apoptosis is to block cytochrome c release from mitochondria.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED,WINSHIP CANC CTR,DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University; Emory University; Emory University				Wang, Xiaodong/0000-0001-9885-356X; Bhalla, Kapil/0000-0001-5209-5126				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bullock G, 1996, LEUKEMIA, V10, P1731; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; FISHER WR, 1973, J BIOL CHEM, V248, P3188; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; HANDE KR, 1984, CANCER RES, V44, P379; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; KAMESAKI S, 1993, CANCER RES, V53, P4251; KAUFMANN SH, 1989, CANCER RES, V53, P4251; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEMASTERS JJ, 1993, METHODS TOXICOL, V2, P404; Liu X.-W., UNPUB; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODWYER PJ, 1985, NEW ENGL J MED, V312, P692, DOI 10.1056/NEJM198503143121106; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SENIOR AE, 1970, ARCH BIOCHEM BIOPHYS, V140, P257, DOI 10.1016/0003-9861(70)90030-5; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J., UNPUB; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	37	4163	4433	14	286	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1129	1132		10.1126/science.275.5303.1129	http://dx.doi.org/10.1126/science.275.5303.1129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027314				2022-12-28	WOS:A1997WJ50300045
J	Masala, A; Faedda, R; Alagna, S; Satta, A; Chiarelli, G; Rovasio, PP; Ivaldi, R; Taras, MS; Lai, E; Bartoli, E				Masala, A; Faedda, R; Alagna, S; Satta, A; Chiarelli, G; Rovasio, PP; Ivaldi, R; Taras, MS; Lai, E; Bartoli, E			Use of testosterone to prevent cyclophosphamide-induced azoospermia	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; HORMONE-RELEASING HORMONE; LUTEINIZING-HORMONE; TESTICULAR FUNCTION; GONADAL-FUNCTION; CHEMOTHERAPY; ANALOGS; DAMAGE; PROTECTION; FERTILITY	Background: Prepubertal patients receiving chemotherapy are relatively resistant to cyclophosphamide-induced germinal cell alterations. Objective: To study the possible protective effect of testosterone used to inhibit germinal cell activity in men who are receiving cyclophosphamide. Design: Randomized, clinical trial. Setting: University medical center. Patients: 15 patients with the nephrotic syndrome who were treated with cyclophosphamide for 6 to 8 months. Intervention: Five patients received daily oral cyclophosphamide, five received cyclophosphamide in monthly bolus injections, and five received monthly intravenous boluses of cyclophosphamide plus testosterone (100 mg intramuscularly every 15 days). Measurements: Sperm counts, serum follicle-stimulating hormone levels, and serum luteinizing hormone levels were measured before, during, and after treatment with cyclophosphamide alone or cyclophosphamide plus testosterone. Results: The 10 patients who did not receive testosterone became azoospermic during cyclophosphamide therapy. In only 1 of the 10 patients did the sperm count return to norma 1 6 months after discontinuation of therapy. Follicle-stimulating hormone levels were elevated in these patients (mean +/- SE, 19.20 +/- 1.28 IU/L in patients receiving oral cyclophosphamide and 16.04 +/- 2.22 IU/L in patients receiving intravenous cyclophosphamide alone). All 5 patients who received testosterone became azoospermic or severely oligospermic during treatment but had a normal sperm count 6 months after the discontinuation of therapy. In these patients, the mean sperm count was 45.78 +/- 3.89 x 10(6)/mL and follicle-stimulating hormone levels were normal (5.08 +/- 0.56 IU/L). Conclusion: Testosterone given to men before and during an 8-month cycle of cyclophosphamide therapy for the nephrotic syndrome may preserve fertility.	POLICLIN UNIV, I-33100 UDINE, ITALY; UNIV SASSARI, I-07100 SASSARI, ITALY	Hospital Santa Maria della Misericordia; University of Sassari			Chiarelli, Giorgio/E-8953-2012	Chiarelli, Giorgio/0000-0001-9851-4816				AVERETTE HE, 1990, CA-CANCER J CLIN, V40, P199, DOI 10.3322/canjclin.40.4.199; BOGDANOVIC R, 1990, PEDIATR NEPHROL, V4, P451, DOI 10.1007/BF00869818; CARDE P, 1989, CONTRACEPT FERTIL S, V17, P445; CHAPMAN RM, 1981, BLOOD, V58, P849; COHEN A, 1991, BONE MARROW TRANSPL, V8, P16; CUNNINGHAM GR, 1979, J CLIN ENDOCR METAB, V49, P520, DOI 10.1210/jcem-49-4-520; Faedda R, 1995, CLIN NEPHROL, V44, P367; FAEDDA R, 1995, J NEPHROL, V8, P107; FAIRLEY KF, 1972, LANCET, V1, P568; GOODPASTURE JC, 1988, CANCER RES, V48, P2174; HEIMPEL H, 1991, BONE MARROW TRANSPL, V8, P21; JOHNSON DH, 1985, BLOOD, V65, P832; KARASHIMA T, 1988, P NATL ACAD SCI USA, V85, P2329, DOI 10.1073/pnas.85.7.2329; KREUSER ED, 1993, EUR UROL, V23, P157; MASALA A, 1994, J NUCL BIOL MED, V38, P266; MATSUMOTO AM, 1990, J CLIN ENDOCR METAB, V70, P282, DOI 10.1210/jcem-70-1-282; RIVKEES SA, 1988, JAMA-J AM MED ASSOC, V259, P2123; SHALET SM, 1988, HORM RES, V30, P53, DOI 10.1159/000181029; SKLAR CA, 1982, AM J MED, V73, P688, DOI 10.1016/0002-9343(82)90411-9; WATSON AR, 1985, BRIT MED J, V291, P1457, DOI 10.1136/bmj.291.6507.1457	20	107	111	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					292	295		10.7326/0003-4819-126-4-199702150-00005	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036801				2022-12-28	WOS:A1997WH06800007
J	Bolton, PF; Griffiths, PD				Bolton, PF; Griffiths, PD			Association of tuberous sclerosis of temporal lobes with autism and atypical autism	LANCET			English	Article							EPIDEMIOLOGY	Background Tuberous sclerosis (TS) is a multisystem genetic disorder that is associated with mental retardation, autism, and atypical autism. We investigated the basis for these associations by examining whether the liability to mental retardation and autism or atypical autism is related to the number and distribution of hamartomatous brain growths (cortical tubers) that characterise TS. Methods 18 patients consecutively referred to our clinic were assessed for the presence of autism or atypical autism, and their IQs were estimated (without awareness of brain-scan results). Brain scans were reviewed by a neuroradiologist (unaware of clinical diagnoses), and the number and location of cortical tubers was examined in relation to the liability to psychopathology. Findings Nine of the 18 patients had autism or atypical autism (two with IQ greater than or equal to 70; four with IQ 51-69, three with IQ less than or equal to 50; eight with a history of epilepsy). The remaining patients had various other psychiatric disorders (five with IQ greater than or equal to 70; four with IQ 51-69; seven had a history of epilepsy). In the group as a whole, the number of tubers was significantly greater (p=0.005) in patients with mental retardation (median 6 [IQR 4-9]) than in those of normal intelligence (1 [0-3]), and the degree of mental retardation was significantly correlated with the number of brain tubers (r(s)0.64; p=0.008). Similarly, the number of tubers was significantly greater (p=0.02) in individuals with a diagnosis of autism or atypical autism (6 [4-8]) than in those without this diagnosis (2 [1-4]). Eight of the nine patients with autism or atypical autism, but none of the non-autistic individuals, had tubers located in the temporal robes (p=0.0004). Otherwise, no particular distribution of cortical tubers was associated with a diagnosis of autism or atypical autism. Interpretation Our investigation provides evidence of an association between a gross, focal brain abnormality. detectable on neuroimaging and autism or atypical autism. The results show the importance of scan findings in the prognosis of TS, and also suggest that temporal lobe neurodevelopmental abnormalities may create a risk for autism or atypical autism.	ADDENBROOKES NHS TRUST, DEPT RADIOL, CAMBRIDGE, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Bolton, PF (corresponding author), UNIV CAMBRIDGE, DEPT PSYCHIAT, SECT DEV PSYCHIAT, CAMBRIDGE CB2 2AH, ENGLAND.							Baron -Cohen S., 1997, MINDBLINDNESS ESSAY; Bauman M.L, 1994, NEUROBIOLOGY AUTISM, P119; Chugani HT, 1996, ANN NEUROL, V39, P643, DOI 10.1002/ana.410390514; Clarke A, 1996, DEV MED CHILD NEUROL, V38, P139; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; CURATOLO P, 1991, ANN NY ACAD SCI, V615, P8; DELONG GR, 1992, NEUROSCI BIOBEHAV R, V16, P63, DOI 10.1016/S0149-7634(05)80052-1; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; GILLBERG IC, 1994, DEV MED CHILD NEUROL, V36, P50; Gomez MR, 1988, TUBEROUS SCLEROSIS; GONZALEZ RC, 1994, GAC MED MEX, V130, P374; HOON AH, 1992, DEV MED CHILD NEUROL, V34, P252; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; JAMBAQUE I, 1991, DEV MED CHILD NEUROL, V33, P698; MENOR F, 1992, PEDIATR RADIOL, V22, P485, DOI 10.1007/BF02012989; Minshew N.J., 1994, NEUROBIOLOGY AUTISM, P66; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; Piven J, 1996, J AM ACAD CHILD PSY, V35, P530, DOI 10.1097/00004583-199604000-00020; ROACH ES, 1987, ARCH NEUROL-CHICAGO, V44, P301, DOI 10.1001/archneur.1987.00520150047020; SHEPHERD CW, 1995, AM J NEURORADIOL, V16, P149; SMALLEY S, 1995, PSYCHIAT GENET, V5, pS88; Webb DW, 1996, DEV MED CHILD NEUROL, V38, P146; WILLIAMSON DA, 1995, J AUTISM DEV DISORD, V25, P435, DOI 10.1007/BF02179377; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; Young AW, 1996, NEUROPSYCHOLOGIA, V34, P31, DOI 10.1016/0028-3932(95)00062-3; [No title captured]; [No title captured]	28	195	198	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 8	1997	349	9049					392	395		10.1016/S0140-6736(97)80012-8	http://dx.doi.org/10.1016/S0140-6736(97)80012-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033466				2022-12-28	WOS:A1997WH29600012
J	Shoham, D; Hubener, M; Schulze, S; Grinvald, A; Bonhoeffer, T				Shoham, D; Hubener, M; Schulze, S; Grinvald, A; Bonhoeffer, T			Spatio-temporal frequency domains and their relation to cytochrome oxidase staining in cat visual cortex	NATURE			English	Article							ISO-ORIENTATION DOMAINS; STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; CONTRAST SENSITIVITY; INTRINSIC SIGNALS; NEURONS; ORGANIZATION; AREA-17; BLOBS	Spatial and temporal frequencies are important attributes of the visual scene. It is a long-standing question whether these attributes are represented in a spatially organized way in cat primary visual cortex(1-4). Using optical imaging of intrinsic signals(5-10), we show here that grating stimuli of different spatial frequencies drifting at various speeds produce distinct activity patterns. Rather than observing a map of continuously changing spatial frequency preference across the cortical surface, we found only two distinct sets of domains, one preferring low spatial frequency and high speed, and the other high spatial frequency and low speed. We compared the arrangement of these spatio-temporal frequency domains with the cytochrome oxidase staining pattern, which, based on work in primate striate cortex, is thought to reflect the partition of the visual cortex into different processing streams. We found that the cytochrome oxidase blobs in cat striate cortex coincide with domains engaged in the processing of low spatial and high temporal frequency contents of the visual scene. Together with other recent results(11), our data suggest that spatiotemporal frequency domains are a manifestation of parallel streams in cat visual cortex, with distinct patterns of thalamic inputs and extrastriate projections.	MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Max Planck Society; Weizmann Institute of Science			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				BERARDI N, 1982, J PHYSIOL-LONDON, V323, P603, DOI 10.1113/jphysiol.1982.sp014094; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bonhoeffer Tobias, 1996, P55; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7066, DOI 10.1073/pnas.88.16.7066; Boyd J. D., 1992, Society for Neuroscience Abstracts, V18, P298; Boyd JD, 1996, J COMP NEUROL, V365, P659; CAMPBELL FW, 1969, J PHYSIOL-LONDON, V203, P223, DOI 10.1113/jphysiol.1969.sp008861; DeValois RL, 1988, SPATIAL VISION; DYCK RH, 1993, P NATL ACAD SCI USA, V90, P9066, DOI 10.1073/pnas.90.19.9066; EDWARDS DP, 1995, VISION RES, V35, P1501, DOI 10.1016/0042-6989(94)00253-I; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GLEZER VD, 1973, VISION RES, V13, P1875, DOI 10.1016/0042-6989(73)90061-8; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBENER M, 1992, J COMP NEUROL, V324, P67, DOI 10.1002/cne.903240106; HUBENER M, 1996, SOC NEUR ABSTR, V22, P951; MAFFEI L, 1977, VISION RES, V17, P257, DOI 10.1016/0042-6989(77)90089-X; MAFFEI L, 1973, VISION RES, V13, P1255, DOI 10.1016/0042-6989(73)90201-0; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Matsubara Joanne, 1994, Society for Neuroscience Abstracts, V20, P1742; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P101, DOI 10.1113/jphysiol.1978.sp012490; MURPHY K M, 1990, Society for Neuroscience Abstracts, V16, P292; MURPHY KM, 1995, J NEUROSCI, V15, P4196; POLLEN DA, 1971, SCIENCE, V173, P74, DOI 10.1126/science.173.3991.74; ROBSON JG, 1975, HDB PERCEPTION, V5, P81; SHOHAM D, 1996, ISRAEL J MED SCI, V32, pS7; SILVERMAN MS, 1989, P NATL ACAD SCI USA, V86, P711, DOI 10.1073/pnas.86.2.711; TOLHURST DJ, 1982, EXP BRAIN RES, V48, P217; TOLHURST DJ, 1981, PROC R SOC SER B-BIO, V213, P183, DOI 10.1098/rspb.1981.0061; TOOTELL RB, 1981, SCIENCE, V214, P813, DOI 10.1126/science.7292014; TOOTELL RBH, 1988, J NEUROSCI, V8, P1610; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5	33	117	118	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					529	533		10.1038/385529a0	http://dx.doi.org/10.1038/385529a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020358				2022-12-28	WOS:A1997WG23500046
J	Charlier, JC; DeVita, A; Blase, X; Car, R				Charlier, JC; DeVita, A; Blase, X; Car, R			Microscopic growth mechanisms for carbon nanotubes	SCIENCE			English	Article							ARC-DISCHARGE; PSEUDOPOTENTIALS; MICROTUBULES; FULLERENES	The uncatalyzed edge growth of carbon nanotubes was investigated by first-principles molecular dynamics simulations. At experimental temperatures the open end of single-walled nanotubes closed spontaneously into a graphitic dome, which may explain why these nanotubes do not grow in the absence of transition metal catalysts, On the other hand, chemical bonding between the edges of adjacent coaxial tubes (''lip-lip'' interactions) trapped the end oi a double-walled nanotube in a metastable energy minimum, thus preventing dome closure. These calculations show that this end geometry exhibits a high degree of chemical activity and easily accommodates incoming carbon fragments, supporting a model of growth by chemisorption from the vapor phase.	PHB ECUBLENS,INST ROMAND RECH NUMER PHYS MAT,CH-1015 LAUSANNE,SWITZERLAND; UNIV CATHOLIQUE LOUVAIN,UNITE PHYSICOCHIM & PHYS MAT,B-1348 LOUVAIN,BELGIUM; UNIV LYON 1,DEPT PHYS MAT,UA 172,F-69622 VILLEURBANNE,FRANCE	Universite Catholique Louvain; UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Blase, Xavier/H-3588-2018	Blase, Xavier/0000-0002-0201-9093				BACHELET GB, 1982, PHYS REV B, V26, P4199, DOI 10.1103/PhysRevB.26.4199; BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0; BLASE X, 1994, PHYS REV LETT, V72, P1878, DOI 10.1103/PhysRevLett.72.1878; Charlier JC, 1996, PHYS REV B, V54, pR8377, DOI 10.1103/PhysRevB.54.R8377; Charlier JC, 1996, PHYS REV B, V53, P11108, DOI 10.1103/PhysRevB.53.11108; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; DEVITA A, 1994, EPFL SUPERCOMPUT J, V6, P22; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; Ebbesen TW, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881603; Eggen BR, 1996, SCIENCE, V272, P87, DOI 10.1126/science.272.5258.87; ENDO M, 1992, J PHYS CHEM-US, V96, P6941, DOI 10.1021/j100196a017; GAMALY EG, 1995, PHYS REV B, V52, P2083, DOI 10.1103/PhysRevB.52.2083; GUO T, 1995, J PHYS CHEM-US, V99, P10694, DOI 10.1021/j100027a002; HAMADA N, 1992, PHYS REV LETT, V68, P1579, DOI 10.1103/PhysRevLett.68.1579; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; IIJIMA S, 1993, MAT SCI ENG B-SOLID, V19, P172, DOI 10.1016/0921-5107(93)90184-O; IIJIMA S, 1992, PHYS REV LETT, V69, P3100, DOI 10.1103/PhysRevLett.69.3100; IIJIMA S, 1992, NATURE, V356, P776, DOI 10.1038/356776a0; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Kiang CH, 1996, PHYS REV LETT, V76, P2515, DOI 10.1103/PhysRevLett.76.2515; LOU L, 1995, PHYS REV B, V52, P1429, DOI 10.1103/PhysRevB.52.1429; MAITI A, 1994, PHYS REV LETT, V73, P2468, DOI 10.1103/PhysRevLett.73.2468; Nose S., 1991, PROG THEOR PHYS SUPP, V103, P1, DOI DOI 10.1143/PTP.103.1; SAITO R, 1992, CHEM PHYS LETT, V195, P537, DOI 10.1016/0009-2614(92)85559-S; Saito R, 1996, PHYS REV B, V53, P2044, DOI 10.1103/PhysRevB.53.2044; SAITO Y, 1993, CHEM PHYS LETT, V204, P277, DOI 10.1016/0009-2614(93)90009-P; SERAPHIN S, 1994, MICROSC ACTA, V3, P64; Service RF, 1996, SCIENCE, V271, P1232, DOI 10.1126/science.271.5253.1232; SMALLEY RE, 1993, MAT SCI ENG B-SOLID, V19, P1, DOI 10.1016/0921-5107(93)90156-H; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; WAGNER RS, 1964, APPL PHYS LETT, V4, P89, DOI 10.1063/1.1753975; ZHANG XF, 1993, J CRYST GROWTH, V130, P368, DOI 10.1016/0022-0248(93)90522-X	36	215	220	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					646	649						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005846				2022-12-28	WOS:A1997WF07700033
J	Guo, LJ; Leobandung, E; Chou, SY				Guo, LJ; Leobandung, E; Chou, SY			A silicon single-electron transistor memory operating at room temperature	SCIENCE			English	Article							BEAM LITHOGRAPHY	A single-electron memory, in which a bit of information is stored by one electron, is demonstrated at room temperature, The memory is a floating gate metal-oxide-semiconductor transistor in silicon with a channel width (similar to 10 nanometers) smaller than the Debye screening length of a single electron and a nanoscale polysilicon dot (similar to 7 nanometers by 7 nanometers) as the floating gate embedded between the channel and the control gate, Storing one electron on the floating gate screens the entire channel from the potential on the control gate and leads to (i) a discrete shift in the threshold voltage, (ii) a staircase relation between the charging voltage and the shift, and (iii) a self-limiting charging process. The structure and fabrication of the memory should be compatible with future ultralarge-scale integrated circuits.	UNIV MINNESOTA,DEPT ELECT ENGN,NANOSTRUCT LAB,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								CHOU ST, UNPUB; DAVIS JR, 1980, INSTABILITIES MOS DE; FISCHER PB, 1993, APPL PHYS LETT, V62, P2989, DOI 10.1063/1.109166; FISCHER PB, 1993, J VAC SCI TECHNOL B, V11, P2524, DOI 10.1116/1.586659; Leobandung E, 1995, J VAC SCI TECHNOL B, V13, P2865, DOI 10.1116/1.588306; LIU HI, 1994, APPL PHYS LETT, V64, P1383, DOI 10.1063/1.111914; Tiwari S, 1996, APPL PHYS LETT, V68, P1377, DOI 10.1063/1.116085; YANO K, 1994, IEEE T ELECTRON DEV, V41, P1628, DOI 10.1109/16.310117	8	318	358	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					649	651		10.1126/science.275.5300.649	http://dx.doi.org/10.1126/science.275.5300.649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005847				2022-12-28	WOS:A1997WF07700034
J	Roberts, WM; Estrov, Z; Ouspenskaia, MV; Johnston, DA; McClain, KL; Zipf, TF				Roberts, WM; Estrov, Z; Ouspenskaia, MV; Johnston, DA; McClain, KL; Zipf, TF			Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; ACUTE MYELOID-LEUKEMIA; CLINICAL-SIGNIFICANCE; FOLLOW-UP; DISEASE; CHILDREN; PERSISTENCE; THERAPY; CELLS; CHEMOTHERAPY	Background Complete remission of B-precursor acute lymphoblastic leukemia (ALL) has traditionally been defined as the near absence of lymphoblasts in a light-microscopical examination of stained bone marrow smears, but a patient in remission may still harbor up to 10(10) leukemia cells. We investigated whether there is a relation between the outcome of treatment and submicroscopic evidence of residual disease. Methods We conducted a prospective study of patients during a first clinical remission using a quantitative polymerase-chain-reaction (PCR) assay capable of detecting 1 viable leukemia cell among 200,000 normal marrow mononuclear cells and a clonogenic blast-colony assay. Bone marrow specimens from 24 children were sequentially evaluated during a five-year period, and the results were compared with the clinical outcome. Results Seven patients relapsed and 17 remained in remission 2 to 35 months after the completion of treatment. The levels of residual leukemia-cell DNA in the two groups were significantly different (P<0.001; 95 percent confidence interval for the difference in the mean log-transformed ratio of leukemia-cell DNA to normal bone marrow-cell DNA, 0.38 to 1.28). Autoregression analyses identified trends for individual patients that were associated with relapse. Despite continued remission in 17 patients, evidence of residual leukemia was detected by PCR in 15 and by both PCR and blast-colony assays in 7. Conclusions Molecular signs of residual leukemia can persist up to 35 months after the cessation of chemotherapy in children with ALL in remission. This suggests that eradication of all leukemia cells may not be a prerequisite for cure. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,MD ANDERSON CANCER CTR,DIV PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOIMMUNOTHERAPY,DIV MED,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOMATH,HOUSTON,TX 77030; BAYLOR COLL MED,TEXAS CHILDRENS CANC CTR,HOUSTON,TX 77030; BAYLOR COLL MED,SERV HEMATOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine				McClain, Kenneth/0000-0003-0725-6263	NATIONAL CANCER INSTITUTE [P30CA016672, K08CA001546] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA01546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1993, CLIN CHIM ACTA, V217, P75, DOI 10.1016/0009-8981(93)90239-Z; BENNETT JM, 1981, BRIT J HAEMATOL, V47, P553, DOI 10.1111/j.1365-2141.1981.tb02684.x; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CHANG KS, 1993, ONCOGENE, V8, P983; DEANE M, 1990, EUR J IMMUNOL, V20, P2209, DOI 10.1002/eji.1830201009; ESTROV Z, 1986, NEW ENGL J MED, V315, P538, DOI 10.1056/NEJM198608283150902; ESTROV Z, 1994, LEUKEMIA, V8, P46; GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z; GEORGE SL, 1979, NEW ENGL J MED, V300, P269, DOI 10.1056/NEJM197902083000601; ITO Y, 1994, LEUKEMIA LYMPHOMA, V16, P57, DOI 10.3109/10428199409114140; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; Jurlander J, 1996, BLOOD, V88, P2183, DOI 10.1182/blood.V88.6.2183.bloodjournal8862183; KWOK S, 1989, NATURE, V339, P490; MONTAGNA D, 1995, CANCER RES, V55, P3835; NIZET Y, 1991, BRIT J HAEMATOL, V79, P205, DOI 10.1111/j.1365-2141.1991.tb04523.x; NIZET Y, 1993, BLOOD, V82, P1618; NUCIFORA G, 1993, BLOOD, V82, P712; OUSPENSKAIA MV, 1995, LEUKEMIA, V9, P321; PINKEL D, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P211; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; PUI CH, 1991, J CLIN ONCOL, V9, P1341, DOI 10.1200/JCO.1991.9.8.1341; ROBERTS WM, 1995, CYTOKINES MOL THER, V1, P65; Roberts WM, 1996, LEUKEMIA LYMPHOMA, V20, P181, DOI 10.3109/10428199609051607; SHAHANGIAN S, 1989, CLIN CHEM, V35, P972; SKIPPER H E, 1964, Cancer Chemother Rep, V35, P1; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; Wu NH, 1996, PEDIATR HEMAT ONCOL, V13, P257, DOI 10.3109/08880019609030825; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705	29	162	166	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					317	323		10.1056/NEJM199701303360501	http://dx.doi.org/10.1056/NEJM199701303360501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011783				2022-12-28	WOS:A1997WG23300001
J	Brandt, CJ; Christiansen, L; Christoffersen, G; Ellegaard, H; Joensen, M; Madsen, A; Kallan, FV; Sorknaes, AD; Tougaard, L				Brandt, CJ; Christiansen, L; Christoffersen, G; Ellegaard, H; Joensen, M; Madsen, A; Kallan, FV; Sorknaes, AD; Tougaard, L			Effect of diagnosis of ''smoker's lung''	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; TRIAL				Brandt, CJ (corresponding author), FAABORG SYGEHUS,CTR MIDT,SYGEHUS FYN,DEPT INTERNAL MED,DK-5600 FABORG,DENMARK.							CROWLEY TJ, 1995, PSYCHOPHARMACOLOGY, V119, P193, DOI 10.1007/BF02246161; JARVIS MJ, 1995, THORAX S1, V50, P522; PEDERSON LL, 1991, INT J ADDICT, V26, P107, DOI 10.3109/10826089109056242; TOUGAARD L, 1992, LANCET, V339, P1517, DOI 10.1016/0140-6736(92)91274-C	4	29	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					253	253		10.1016/S0140-6736(05)64863-5	http://dx.doi.org/10.1016/S0140-6736(05)64863-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014918				2022-12-28	WOS:A1997WD90600018
J	Itzhaki, RF; Lin, WR; Shang, DH; Wilcock, GK; Faragher, B; Jamieson, GA				Itzhaki, RF; Lin, WR; Shang, DH; Wilcock, GK; Faragher, B; Jamieson, GA			Herpes simplex virus type 1 in brain and risk of Alzheimer's disease	LANCET			English	Article							APOLIPOPROTEIN-E; REACTIVATION; ASSOCIATION; ETIOLOGY; DNA; PCR	Background The apolipoprotein E epsilon 4 (APOE-epsilon 4) allele is a risk factor for Alzheimer's disease (AD), but it is neither essential nor sufficient for development of the disease. Other factors-genetic or environmental-must therefore have a role. By means of a PCR we have detected herpes simplex virus type 1 (HSV1) in latent form in brains of elderly people with and without AD. We have postulated that limited reactivation of the virus causes more damage in AD patients than in elderly people without AD because of a difference in the hosts. We now report the APOE genotypes of AD patients and non-AD sufferers with and without HSV1 in brain. Methods DNA was extracted from 84 samples of brain from 46 AD patients (39 temporal lobe, 39 frontal lobe, three hippocampus) and from 75 samples of brain from 44 non-AD elderly people (33 temporal lobe, 36 frontal lobe, six hippocampus). PCR amplification was used to detect HSV1 thymidine kinase gene and the host APOE gene. Findings By multiple logistic regression, the APOE-epsilon 4 allele frequency was significantly higher in the patients positive for HSV1 in brain than in the HSV1-negative AD group, the HSV1-positive non-AD group, or the HSV1-negative non-AD group (52.8% vs 10.0%, 3.6%, and 6.3%, respectively). The odds ratio for APOE-epsilon 4 in the HSV1-positive AD group compared with HSV1-negative non-AD group was 16.8 (95% CI 3.61-77.8) and in the HSV1-negative AD group, 1.67 (0.21-13.4). We also compared APOE genotypes of 40 people who had recurrent cold sores and 33 non-sufferers; the APOE-epsilon 4 allele frequencies were 36% and 9%, respectively (p<0.0001). Interpretation These findings suggest that the combination of HSV1 in brain and carriage of an APOE-epsilon 4 allele is a strong risk factor for AD, whereas either of these features alone does not increase the risk of AD. The findings in people with cold sores support our hypothesis that APOE-epsilon 4 and HSV1 together are damaging in the nervous system.	FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND; UNIV MANCHESTER,DEPT MED BIOPHYS,MED STAT RES SUPPORT UNIT,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Manchester	Itzhaki, RF (corresponding author), UNIV MANCHESTER,INST SCI & TECHNOL,DEPT OPTOMETRY & VIS SCI,MOL NEUROBIOL LAB,MANCHESTER M60 1QD,LANCS,ENGLAND.							BALL UJ, 1982, CANAD J NEUROL SCI, V9, P303; BARINGER JR, 1994, ANN NEUROL, V36, P823, DOI 10.1002/ana.410360605; BEYER CF, 1989, CURR EYE RES, V8, P1287, DOI 10.3109/02713688909013908; BLYTH WA, 1984, IMMUNOBIOLOGY HERPES, P10; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CAULEY JA, 1993, GENET EPIDEMIOL, V10, P27, DOI 10.1002/gepi.1370100104; ESIRI MM, 1982, J NEUROL NEUROSUR PS, V45, P759, DOI 10.1136/jnnp.45.8.759; Gordon L, 1996, CLIN DIAGN VIROL, V6, P33, DOI 10.1016/0928-0197(95)00203-0; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; Itzhaki R., 1993, ALZHEIMERS DIS ADV C, P97; ITZHAKI RF, 1994, MOL NEUROBIOL, V9, P1, DOI 10.1007/BF02816099; JAMIESON GA, 1991, J MED VIROL, V33, P224, DOI 10.1002/jmv.1890330403; JAMIESON GA, 1992, J PATHOL, V167, P365, DOI 10.1002/path.1711670403; JI ZS, 1994, J BIOL CHEM, V269, P2764; KLAPPER PE, 1984, J NEUROL NEUROSUR PS, V47, P1247, DOI 10.1136/jnnp.47.11.1247; Lin WR, 1995, BIOCHEM SOC T, V23, pS594, DOI 10.1042/bst023594s; Lin WR, 1996, MOL CHEM NEUROPATHOL, V28, P135, DOI 10.1007/BF02815215; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; ROBERTS GW, 1986, J NEUROL NEUROSUR PS, V49, P216, DOI 10.1136/jnnp.49.2.216; SALDANHA J, 1986, J NEUROL NEUROSUR PS, V49, P613, DOI 10.1136/jnnp.49.6.613; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; TANAKA S, 1994, J GEN VIROL, V75, P2691, DOI 10.1099/0022-1317-75-10-2691; Tyler KL, 1995, NEUROLOGY, V45, P2246, DOI 10.1212/WNL.45.12.2246; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WILCOCK GK, 1989, J NEUROL NEUROSUR PS, V52, P693, DOI 10.1136/jnnp.52.6.693	26	459	468	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					241	244		10.1016/S0140-6736(96)10149-5	http://dx.doi.org/10.1016/S0140-6736(96)10149-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014911				2022-12-28	WOS:A1997WD90600011
J	McShane, R; Keene, J; Gedling, K; Fairburn, C; Jacoby, R; Hope, T				McShane, R; Keene, J; Gedling, K; Fairburn, C; Jacoby, R; Hope, T			Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; PSYCHOGERIATRIC PATIENTS; BEHAVIORAL DISTURBANCE; EXTRAPYRAMIDAL SIGNS; GERIATRIC-PATIENTS; SENILE DEMENTIA; PSYCHOSIS; HALOPERIDOL; SYMPTOMS; THIORIDAZINE	Objective: To investigate the contribution of neuroleptic drugs to cognitive decline in dementia. Design: Two year prospective, longitudinal study consisting of interviews every four months, with necropsy follow up. Setting: Community settings in Oxfordshire. Subjects: 71 subjects with dementia, initially living at home with informant. Main outcome measures: Cognitive function (score from expanded minimental state examination); behavioural problems (physical aggression, hallucinations, persecutory ideas, and disturbance of diurnal rhythm); and postmortem neuropathological assessment (cortical Lewy body pathology). Results: The mean (SE) decline in cognitive score in the 16 patients who took neuroleptics was twice that in the patients who did not (20.7 (2.9) v 9.3 (1.3), P=0.002). An increased rate of decline was also associated with aggression, disturbed diurnal rhythm, and persecutory ideas, However, only use of neuroleptics and severity of persecutory ideas were independently associated with more rapid cognitive decline when all other variables were adjusted for, The start of neuroleptic treatment coincided with more rapid cognitive decline: median rate of decline was 5 (interquartile range 8.5) points per year before treatment and 11 (12) points per year after treatment (P=0.02), Cortical Lewy body pathology did not account for association between neuroleptic use and more rapid decline. Conclusions: Neuroleptic drugs that are sometimes used to treat behavioural complications of dementia may worsen already poor cognitive function, Randomised controlled trials are needed to confirm a causal relation.			McShane, R (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OLD AGE PSYCHIAT SECT, OXFORD OX3 7JX, ENGLAND.		Fairburn, Christopher/AAM-9792-2020; Fairburn, Christopher/AAG-6234-2019	Fairburn, Christopher/0000-0002-9673-9795; 				BARNES R, 1982, AM J PSYCHIAT, V139, P1170; BARTON R, 1966, BRIT J PSYCHIAT, V112, P989, DOI 10.1192/bjp.112.491.989; BROWN JW, 1993, J NERV MENT DIS, V181, P695, DOI 10.1097/00005053-199311000-00008; BURNS A, 1990, BRIT J PSYCHIAT, V157, P76, DOI 10.1192/bjp.157.1.76; CHAKOS MH, 1994, AM J PSYCHIAT, V151, P1430; Chen CPLH, 1996, J NEUROCHEM, V66, P1592, DOI 10.1046/j.1471-4159.1996.66041592.x; CHUI HC, 1994, ARCH NEUROL-CHICAGO, V51, P676, DOI 10.1001/archneur.1994.00540190056015; COWLEY LM, 1979, J CLIN PSYCHIAT, V40, P411; DAVIE JW, 1981, ARCH GEN PSYCHIAT, V38, P463; DEVANAND DP, 1989, ARCH NEUROL-CHICAGO, V46, P854, DOI 10.1001/archneur.1989.00520440036018; DEVANAND DP, 1988, COMPR PSYCHIAT, V29, P387, DOI 10.1016/0010-440X(88)90020-X; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; DREVETS WC, 1989, BIOL PSYCHIAT, V25, P39, DOI 10.1016/0006-3223(89)90145-5; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; Esiri MM, 1996, J NEUROL NEUROSUR PS, V61, P127, DOI 10.1136/jnnp.61.2.127; Figiel G S, 1991, J Geriatr Psychiatry Neurol, V4, P86, DOI 10.1177/089198879100400206; FORSTL H, 1993, ACTA PSYCHIAT SCAND, V87, P395, DOI 10.1111/j.1600-0447.1993.tb03394.x; Foster P, 1989, PHARM J, V243, P431; GALASKO D, 1994, ARCH NEUROL-CHICAGO, V51, P888, DOI 10.1001/archneur.1994.00540210060013; GILLEARD CJ, 1983, ACTA PSYCHIAT SCAND, V68, P419, DOI 10.1111/j.1600-0447.1983.tb00950.x; GOTESTAM KG, 1981, ACTA PSYCHIAT SCAND, P46; HAMILTON LD, 1962, J AM GERIATR SOC, V10, P140, DOI 10.1111/j.1532-5415.1962.tb00266.x; HOPE T, 1992, PSYCHOL MED, V22, P223, DOI 10.1017/S0033291700032888; Jellinger K., 1977, NEUROTOXICOLOGY, P25; Lehmann H E, 1967, Laval Med, V38, P588; MANN AH, 1984, PSYCHOL MED, V14, P891, DOI 10.1017/S0033291700019851; MAYEUX R, 1985, NEUROLOGY, V35, P453, DOI 10.1212/WNL.35.4.453; McGrath AM, 1996, BRIT MED J, V312, P611; MCKEITH I, 1992, BRIT MED J, V305, P673, DOI 10.1136/bmj.305.6855.673; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; NYTH AL, 1992, ACTA PSYCHIAT SCAND, V86, P138, DOI 10.1111/j.1600-0447.1992.tb03242.x; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; ROSEN HJ, 1979, J CLIN PSYCHIAT, V40, P17; ROSEN J, 1991, BIOL PSYCHIAT, V29, P224, DOI 10.1016/0006-3223(91)91284-X; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; SCHNEIDER LS, 1992, PSYCHOPHARMACOL BULL, V28, P71; SMITH DA, 1992, ANN PHARMACOTHER, V26, P1400, DOI 10.1177/106002809202601114; SMITH GR, 1974, PSYCHOSOMATICS, V15, P134; STERN Y, 1994, NEUROLOGY, V44, P2300, DOI 10.1212/WNL.44.12.2300; SUGERMAN AA, 1964, AM J PSYCHIAT, V120, P1190, DOI 10.1176/ajp.120.12.1190; TOBIN JM, 1970, GERIATRICS, V25, P119; WILCOCK GK, 1989, J NEUROL NEUROSUR PS, V52, P693, DOI 10.1136/jnnp.52.6.693; WISNIEWSKI HM, 1994, ALZ DIS ASSOC DIS, V8, P211, DOI 10.1097/00002093-199408040-00001	43	186	189	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	1997	314	7076					266	270		10.1136/bmj.314.7076.266	http://dx.doi.org/10.1136/bmj.314.7076.266			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE633	9022490	Green Published			2022-12-28	WOS:A1997WE63300025
J	Classen, DC; Pestotnik, SL; Evans, RS; Lloyd, JF; Burke, JP				Classen, DC; Pestotnik, SL; Evans, RS; Lloyd, JF; Burke, JP			Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED ILLNESS; SURVEILLANCE; INFORMATION; ADMISSIONS; INFECTIONS; SERVICES; SYSTEM	Objective.-To determine the excess length of stay, extra costs, and mortality attributable to adverse drug events (ADEs) in hospitalized patients. Design.-Matched case-control study. Setting.-The LDS Hospital, a tertiary care health care institution. Patients.-All patients admitted to LDS Hospital from January 1, 1990, to December 31, 1993, were eligible. Cases were defined as patients with ADEs that occurred during hospitalization; controls were selected according to matching variables in a stepwise fashion. Methods.-Controls were matched to cases on primary discharge diagnosis related group (DRG), age, sex, acuity, and year of admission; varying numbers of controls were matched to each case. Matching was successful for 71% of the cases, leading to 1580 cases and 20197 controls. Main Outcome Measures.-Crude and attributable mortality, crude and attributable length of stay, and cost of hospitalization. Results.-ADEs complicated 2.43 per 100 admissions to the LDS Hospital during the study period. The crude mortality rates for the cases and matched controls were 3.5% and 1.05%, respectively (P<.001). The mean length of hospital stay significantly differed between the cases and matched controls (7.69 vs 4.46 days; P<.001) as did the mean cost of hospitalization ($10 010 vs $5355; P<.001). The extra length of hospital stay attributable to an ADE was 1.74 days (P<.001). The excess cost of hospitalization attributable to an ADE was $2013 (P<.001). A linear regression analysis for length of stay and cost controlling for all matching variables revealed that the occurrence of an ADE was associated with increased length of stay of 1.91 days and an increased cost of $2262 (P<.001). In a similar logistic regression analysis for mortality, the increased risk of death among patients experiencing an ADE was 1.88 (95% confidence interval, 1.54-2.22; P<.001). Conclusion.-The attributable lengths of stay and costs of hospitalization for ADEs are substantial. An ADE is associated with a significantly prolonged length of stay, increased economic burden, and an almost 2-fold increased risk of death.			Classen, DC (corresponding author), LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, 8TH AVE & C ST, SALT LAKE CITY, UT 84143 USA.							BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Bloom B S, 1988, Am J Med, V84, P20, DOI 10.1016/0002-9343(88)90250-1; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; CLASSEN D, 1993, THESIS U UTAH SALT L; Classen D C, 1992, Hosp Pharm, V27, P776; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CLASSEN DC, 1992, HOSP PHARM, V27, P776; Classen DC, 1992, HOSP PHARM, V27, P783; CLUFF LE, 1975, MAJOR PROBLEMS INTER, V5; COLLEY CA, 1993, J GEN INTERN MED, V8, P278, DOI 10.1007/BF02600099; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; Evans R S, 1992, Proc Annu Symp Comput Appl Med Care, P437; Evans R S, 1995, Proc Annu Symp Comput Appl Med Care, P651; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; HALEY RW, 1991, AM J MED, V91, pS32, DOI 10.1016/0002-9343(91)90341-T; HALEY RW, 1992, HOSP INFECT, P507; *INT HLTH CAR INC, 1987, STAND COST MAN US GU; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KNOX RA, 1995, BOSTON GLOBE    0323, P1; KUPERMAN G, 1990, HELP SYSTEM DYNAMIC; *LDS HOSP, 1990, NURS CAR MAN; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lovett R B, 1991, J Pediatr Oncol Nurs, V8, P122, DOI 10.1177/104345429100800305; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; MEYER D, 1978, GRASP PATIENT INFORM; MILLER RR, 1974, ARCH INTERN MED, V134, P219, DOI 10.1001/archinte.134.2.219; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; Powe NR, 1995, CONTROL CLIN TRIALS, V16, P377, DOI 10.1016/S0197-2456(95)00075-5; PRINCE BS, 1992, AM J HOSP PHARM, V49, P1696, DOI 10.1093/ajhp/49.7.1696; SCHNEIDER PJ, 1995, AM J HEALTH-SYST PH, V52, P2415, DOI 10.1093/ajhp/52.21.2415; SLOAN FA, 1993, MED CARE, V31, P851, DOI 10.1097/00005650-199310000-00001; TALLEY RB, 1974, JAMA-J AM MED ASSOC, V229, P1043, DOI 10.1001/jama.1974.03230460011003; VANRUISWYK J, 1990, NURS MANAG, V23, P44; WHALEN KL, 1990, CRIT CARE MED, V18, P505, DOI 10.1097/00003246-199005000-00009	42	1281	1338	2	53	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					301	306		10.1001/jama.277.4.301	http://dx.doi.org/10.1001/jama.277.4.301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC458	9002492				2022-12-28	WOS:A1997WC45800029
J	Scott, SK; Young, AW; Calder, AJ; Hellawell, DJ; Aggleton, JP; Johnson, M				Scott, SK; Young, AW; Calder, AJ; Hellawell, DJ; Aggleton, JP; Johnson, M			Impaired auditory recognition of fear and anger following bilateral amygdala lesions	NATURE			English	Article							VOICE RECOGNITION; TEMPORAL-LOBE; EMOTION; FACES; NEURONS; MONKEY	The amygdalar complex is a medial temporal lobe structure in the brain which is widely considered to be involved in the neural substrates of emotion, Selective bilateral damage to the human amygdala is rare, offering a unique insight into its functions. There is impairment of social perception after amygdala damage, with defective recognition of facial expressions of emotion(1-4). Among the basic emotions, the processing of fear and anger has been shown to be disrupted by amygdala damage(1,2,5). Although it remains puzzling why this not found in all cases(6), the importance of the amygdala in negative emotion, and especially fear, has been confirmed by conditioning(7), memory(8) and positron emission tomography (PET) experiments(9,10). Central to our understanding of these findings is the question of whether the amygdala is involved specifically in the perception of visual signals of emotion emanating from the face, or more widely in the perception of emotion in all sensory modalities(11). We report here a further investigation of one of these rare cases, a woman (D.R) who has impaired perception of the intonation patterns that are essential to the perception of vocal affect, despite normal hearing, As is the case for recognition of facial expressions, it is recognition of fear and anger that is most severely affected in the auditory domain, This shows that the amygdala's role in the recognition of certain emotions is not confined to vision, which is consistent with its being involved in the appraisal of danger and the emotion of fear(12,13).	MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND; ASTLEY AINSLIE HOSP,REHABIL STUDIES UNIT,EDINBURGH EH9 2HL,MIDLOTHIAN,SCOTLAND; UNIV WALES COLL CARDIFF,SCH PSYCHOL,CARDIFF CF1 3YG,S GLAM,WALES; ST JAMES UNIV HOSP,DEPT NEUROL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	University of Cambridge; Cardiff University; Saint James's University Hospital			Scott, Sophie K/A-1843-2010; Young, Andy/G-2189-2011	Scott, Sophie K/0000-0001-7510-6297; Young, Andy/0000-0002-1202-6297; Aggleton, John/0000-0002-5573-1308	Wellcome Trust [090961] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADOLPHS R, 1995, J NEUROSCI, V15, P5879; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AGGLETON JP, 1992, AMYGDALA; ALLMAN J, 1994, NATURE, V372, P613, DOI 10.1038/372613a0; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BROTHERS L, 1989, AM J PSYCHIAT, V146, P10; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; CAHILL L, 1995, NATURE, V377, P295, DOI 10.1038/377295a0; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Ekman P., 1972, NEBRASKA S MOTIVATIO, P207, DOI DOI 10.1037/0022-3514.53.4.712; Ekman P., 1976, PICTURES FACIAL AFFE; Ekman Paul, 1973, DARWIN FACIAL EXPRES; FRICK RW, 1985, PSYCHOL BULL, V97, P412, DOI 10.1037/0033-2909.97.3.412; Hamann SB, 1996, NATURE, V379, P497, DOI 10.1038/379497a0; Kay J., 1992, PSYCHOLINGUISTIC ASS; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LEONARD CM, 1985, BEHAV BRAIN RES, V15, P159, DOI 10.1016/0166-4328(85)90062-2; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; MURRAY IR, 1993, J ACOUST SOC AM, V93, P1097, DOI 10.1121/1.405558; NAKAMURA K, 1992, J NEUROPHYSIOL, V67, P1447, DOI 10.1152/jn.1992.67.6.1447; Nolan F, 1983, PHONETIC BASES SPEAK; REID I, 1993, BEHAV NEUROL, V6, P225, DOI 10.3233/BEN-1993-6409; ROLLS ET, 1984, HUM NEUROBIOL, V3, P209; SEECK M, 1993, ANN NEUROL, V34, P369, DOI 10.1002/ana.410340311; VANLANCKER D, 1985, J PHONETICS, V13, P39, DOI 10.1016/S0095-4470(19)30724-7; Young AW, 1996, NEUROPSYCHOLOGIA, V34, P31, DOI 10.1016/0028-3932(95)00062-3; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15	29	415	425	5	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					254	257		10.1038/385254a0	http://dx.doi.org/10.1038/385254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WC711	9000073				2022-12-28	WOS:A1997WC71100048
J	Hadorn, DC; Holmes, AC				Hadorn, DC; Holmes, AC			The New Zealand priority criteria project .1. Overview	BRITISH MEDICAL JOURNAL			English	Article								New Zealand restructured its health system in 1992 with the aim of achieving greater levels of assessment and accountability in the publicly funded health sector. A committee was established specifically to advise the minister of health on the kinds, and relative priorities, of health services that should be publicly funded. One of its projects has been to develop standardised sets of criteria to assess the extent of benefit expected from elective surgical procedures. These have been developed with the help of professional advisory groups using a modified Delphi technique to reach consensus. So far the committee has developed criteria for cataract surgery, coronary artery bypass grafting, hip and knee replacement, cholecystectomy, and tympanostomy tubes for odds media with effusion. These criteria incorporate both clinical and social factors. Use of priority criteria to ensure consistency and transparency regarding patients' priority for surgery is required for access to a dedicated NZ$ 130m (f57m; US$90m) pool of money, created to help eliminate surgical waiting lists and move to booking systems. The criteria will also be used in surgical outcome studies, currently in the planning phase.			Hadorn, DC (corresponding author), MINIST HLTH,NATL ADVISORY COMM HLTH & DISABIL,WELLINGTON,NEW ZEALAND.							Ashton T, 1993, Health Care Anal, V1, P57, DOI 10.1007/BF02196972; DAWES RM, 1974, PSYCHOL BULL, V81, P95, DOI 10.1037/h0037613; ELWOOD PM, 1988, NEW ENGL J MED, V318, P1549; Fraser G, 1993, WAITING LISTS WAITIN; MEEHL PE, 1954, CLIN VERSUS STATISTI; *NAT ADV COMM COR, 1993, 2 ANN REP; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; Tversky A., 1982, JUDGMENT UNCERTAINTY, P8498; 1996, DOMINION        0510, P8	9	231	232	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					131	134		10.1136/bmj.314.7074.131	http://dx.doi.org/10.1136/bmj.314.7074.131			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006477	Green Published			2022-12-28	WOS:A1997WC47900032
J	Ridsdale, L; Robins, D; Cryer, C; Williams, H; Close, J; Free, A; Hughes, C; Hart, Y; Ogden, J; OrmeSmith, A; Stoy, N; Stott, P				Ridsdale, L; Robins, D; Cryer, C; Williams, H; Close, J; Free, A; Hughes, C; Hart, Y; Ogden, J; OrmeSmith, A; Stoy, N; Stott, P			Feasibility and effects of nurse run clinics for patients with epilepsy in general practice: Randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective: To test the feasibility and effect of nurse run epilepsy clinics in primary care. Design: A randomised controlled trial of nurse run clinics versus ''usual care.'' Setting: Six general practices in the South Thames region. Subjects: 251 patients aged over 15 years who were taking anti-epileptic drugs or had a diagnosis of epilepsy and an attack in the past two years who met specified inclusion criteria and had responded to a questionnaire. Main outcome measures: Questionnaire responses and recording of key variables extracted from the clinical records before and after the intervention. Results: 127 patients were randomised to a nurse run clinic, of whom 106 (83%) attended. The nurse wrote 28 letters to the general practitioners suggesting changes in epilepsy management. For this intervention group compared with the usual care group there was a highly significant improvement in the level of advice recorded as having been given on drug compliance, adverse drug effects, driving, alcohol intake, and self help groups. Conclusions: Nurse run clinics for patients with epilepsy were feasible and well attended, Such clinics can significantly improve the level of advice and drug management recorded.	SE INST PUBL HLTH,TUNBRIDGE WELLS TN3 0XT,ENGLAND		Ridsdale, L (corresponding author), UNITED MED & DENT SCH,DIV GEN PRACTICE & PRIMARY CARE,LONDON SE11 6SP,ENGLAND.			Ridsdale, Leone/0000-0002-2234-2859				*BRIT EP ASS, 1996, NEW UND; Ridsdale L, 1996, BRIT J GEN PRACT, V46, P11; Ridsdale L, 1996, BRIT J GEN PRACT, V46, P365; Shorvon SD, 1993, CLIN NURSE SPECIALIS	4	53	53	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					120	122		10.1136/bmj.314.7074.120	http://dx.doi.org/10.1136/bmj.314.7074.120			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006472	Green Published			2022-12-28	WOS:A1997WC47900026
J	Jacobson, DR; Pastore, RD; Yaghoubian, R; Kane, I; Gallo, G; Buck, FS; Buxbaum, JN				Jacobson, DR; Pastore, RD; Yaghoubian, R; Kane, I; Gallo, G; Buck, FS; Buxbaum, JN			Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SENILE SYSTEMIC AMYLOIDOSIS; CLINICAL-SIGNIFICANCE; LIVER-TRANSPLANTATION; POLYNEUROPATHY; FREQUENCY; HEART; GENE; PCR; POPULATION; AUTOPSY	Background After the age of 60, isolated cardiac amyloidosis is four times more common among blacks than whites in the United States; 3.9 percent of blacks are heterozygous for an amyloidogenic allele of the normal serum carrier protein transthyretin in which isoleucine is substituted for valine at position 122 (Ile 122). We hypothesized that the high prevalence of transthyretin lie 122 is at least partially responsible for the increased frequency of senile cardiac amyloidosis among blacks. Methods Paraffin blocks of cardiac tissue were obtained from an earlier study of 52,370 autopsies in Los Angeles and were examined by immunohistochemical and DNA analyses. Samples were available from 32 of 55 blacks and 20 of 78 whites over 60 years of age with isolated cardiac amyloidosis and from two control groups (228 cases). Results Transthyretin amyloidosis was identified in 31 of the 32 cardiac-tissue samples from the black patients and in 19 of the 20 samples from the white patients. Six of the 26 analyzable DNA samples (23 percent) from the black patients and none of the 19 samples from the white patients were heterozygous for the lie 122 variant, Four of 125 DNA samples obtained at autopsy (3.2 percent) from a second, more recent, age-matched cohort of blacks without amyloidosis at the same institution were heterozygous for the transthyretin lie 122 allele. On reexamination the cardiac tissue from these four patients contained small amounts of amyloid not detected at the initial autopsies. All subjects with the lie 122 variant had ventricular amyloid. Conclusions The assessment of elderly black patients with unexplained heart disease should include a consideration of transthyretin amyloidosis, particularly that related to the lie 122 allele. (C)1997, Massachusetts Medical Society.	VET AFFAIRS MED CTR, RES SERV, NEW YORK, NY 10010 USA; NYU, SCH MED, DEPT MED, NEW YORK, NY USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY USA; UNIV SO CALIF, LOS ANGELES CTY MED CTR, DEPT PATHOL, LOS ANGELES, CA 90033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; New York University; University of Southern California					PHS HHS [34900] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALMEIDA MD, 1991, BIOCHIM BIOPHYS ACTA, V1097, P224; Alves Isabel L., 1993, Journal of Rheumatology, V20, P185; [Anonymous], 1993, Bull World Health Organ, V71, P105; BARTALENA L, 1992, THYROID, V2, P237, DOI 10.1089/thy.1992.2.237; Beneke R, 1908, BEITR PATHOL ANAT AL, V44, P362; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; BUCK FS, 1989, MODERN PATHOL, V2, P372; CHRISTMANSON L, 1991, FEBS LETT, V281, P177, DOI 10.1016/0014-5793(91)80387-I; COELHO T, 1994, J MED GENET, V31, P293, DOI 10.1136/jmg.31.4.293; GALLO G, 1988, MODERN PATHOL, V1, P453; GALLO GR, 1986, CLIN IMMUNOL IMMUNOP, V39, P479, DOI 10.1016/0090-1229(86)90175-3; GERTZ MA, 1985, AM J CARDIOL, V55, P1645, DOI 10.1016/0002-9149(85)90995-6; GOREVIC PD, 1989, J CLIN INVEST, V83, P836, DOI 10.1172/JCI113966; GRATEAU G, 1993, CLIN GENET, V43, P143, DOI 10.1111/j.1399-0004.1993.tb04439.x; Greer C E, 1991, PCR Methods Appl, V1, P46; GRIFFITHS BE, 1982, THORAX, V37, P711, DOI 10.1136/thx.37.9.711; GUSTAVSSON A, 1995, LAB INVEST, V73, P703; HODKINSON HM, 1977, Q J MED, V46, P381; HUSBY G, 1992, J INTERN MED, V232, P511, DOI 10.1111/j.1365-2796.1992.tb00626.x; Jacobson D R, 1991, Adv Hum Genet, V20, P69; JACOBSON DR, 1990, AM J HUM GENET, V47, P127; Jacobson DR, 1996, HUM GENET, V98, P236, DOI 10.1007/s004390050199; JACOBSON DR, 1992, AM J HUM GENET, V50, P195; JACOBSON DR, 1991, AM J HUM GENET, V49, P192; JACOBSON DR, 1994, HUM MUTAT, V3, P254, DOI 10.1002/humu.1380030313; JACOBSON DR, 1994, AMYLOID AMYLOIDOSIS, P474; JACOBSON DR, 1991, ADV HUM GENET, V20, P309; JACOBSON DR, IN PRESS TEXAS HEART; JONES RS, 1950, ARCH PATHOL, V50, P366; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; Kwok S, 1990, PCR PROTOCOLS GUIDE, P142; KYLE RA, 1994, AMYLOID AMYLOIDOSIS, P648; LIE JT, 1988, MAYO CLIN PROC, V63, P552, DOI 10.1016/S0025-6196(12)64885-X; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; NAVIDI W, 1992, AM J HUM GENET, V50, P347; NICHOLS WC, 1991, J LAB CLIN MED, V117, P175; *PHS, 1991, DHHS PUBL, P46; POMERANCE A, 1991, CARDIOVASC PATHOL, P155; RUBINOW A, 1981, CIRCULATION, V63, P1285, DOI 10.1161/01.CIR.63.6.1285; RUSSELL C, 1996, OFFICIAL GUIDE RACIA, P71; SARAIVA MJM, 1990, SCAND J IMMUNOL, V32, P341, DOI 10.1111/j.1365-3083.1990.tb02928.x; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SMITH TJ, 1984, MAYO CLIN PROC, V59, P547, DOI 10.1016/S0025-6196(12)61493-1; Soyka J, 1876, PRAG MED WOCHENSCH, V1, P165; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009; WRIGHT JR, 1975, J AM GERIATR SOC, V23, P97, DOI 10.1111/j.1532-5415.1975.tb00968.x; WRIGHT JR, 1969, MEDICINE, V48, P39, DOI 10.1097/00005792-196901000-00002	48	392	417	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					466	473		10.1056/NEJM199702133360703	http://dx.doi.org/10.1056/NEJM199702133360703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017939	Bronze			2022-12-28	WOS:A1997WG77600003
J	Sicheri, F; Moarefi, I; Kuriyan, J				Sicheri, F; Moarefi, I; Kuriyan, J			Crystal structure of the Src family tyrosine kinase Hck	NATURE			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; PROLINE-RICH PEPTIDES; SH3 DOMAIN; BINDING; PROTEIN; PP60C-SRC; DEPHOSPHORYLATION; PHOSPHORYLATION; RECOGNITION; SPECIFICITY	The crystal structure of the haematopoietic cell kinase Hck has been determined at 2.6/2.9 Angstrom resolution. Inhibition of enzymatic activity is a consequence of intramolecular interactions of the enzyme's Src-homology domains SH2 and SH3, with concomitant displacement of elements of the catalytic domain. The conformation of the active site has similarities with that of Inactive cyclln-dependent protein kinases.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, LAB MOL BIOPHYS, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University			Sicheri, Frank/F-8856-2013					ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CUNNINGHAM BDM, 1992, ANTI-CANCER DRUG DES, V7, P365; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUREY W, 1990, P AM CRYSTALLOGRAPHI, P73; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUFFREY PD, 1995, NATURE, V376, P294; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KURIYAN J, IN PRESS ANN REV BIO; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, BLOOD, V87, P1780; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; [No title captured]	46	1031	1066	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					602	609		10.1038/385602a0	http://dx.doi.org/10.1038/385602a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024658				2022-12-28	WOS:A1997WH29400041
J	Laupacis, A; Sekar, N; Stiell, IG				Laupacis, A; Sekar, N; Stiell, IG			Clinical prediction rules - A review and suggested modifications of methodological standards	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-ARTERY DISEASE; ACUTE ANKLE INJURIES; MYOCARDIAL-INFARCTION; NONCARDIAC SURGERY; PROSPECTIVE VALIDATION; MEDICAL PATIENTS; PROSTATE-CANCER; DECISION RULES; NEURAL NETWORK; LOW-RISK	Background-Clinical prediction rules are decision-making tools for clinicians, containing variables from the history, physical examination, or simple diagnostic tests. Objective.-To review the quality of recently published clinical prediction rules and to suggest methodological standards for their development and evaluation. Data Sources.-Four general medical journals were manually searched for clinical prediction rules published from 1991 through 1994. Study Selection.-Four hundred sixty potentially eligible reports were identified, of which 30 were clinical prediction rules eligible for study. Most methodological standards could only be evaluated in 29 studies. Data Abstraction-Two investigators independently evaluated the quality of each report using a standard data sheet. Disagreements were resolved by consensus. Data Synthesis.-The mathematical technique was used to develop the rule, and the results of the rule were described in 100% (29/29) of the reports. All the rules but 1 (97% [28/29]) were felt to be clinically sensible. The outcomes and predictive variables were clearly defined in 83% (24/29) and 59% (17/29) of the reports, respectively. Blind assessment of outcomes and predictive variables occurred in 41% (12/29) and 79% (23/29) of the reports, respectively, and the rules were prospectively validated in 79% (11/14). Reproducibility of predictive variables was assessed in only 3% (1/29) of the reports, and the effect of the rule on clinical use was prospectively measured in only 3% (1/30). Forty-one percent (12/29) of the rules were felt to be easy to use. Conclusions.-Although clinical prediction rules comply with some methodological criteria, for other criteria, better compliance is needed.	UNIV OTTAWA, DEPT EPIDEMIOL & COMMUNITY MED, OTTAWA, ON, CANADA; OTTAWA CIVIC HOSP, LOEB MED RES INST, CLIN EPIDEMIOL UNIT, OTTAWA, ON K1Y 4E9, CANADA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Laupacis, A (corresponding author), UNIV OTTAWA, DEPT MED, 451 SMYTH RD, OTTAWA, ON, CANADA.		Burls, Amanda J.E./D-7641-2011	Stiell, Ian/0000-0002-2583-6408				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BATES DW, 1992, JAMA-J AM MED ASSOC, V267, P1962, DOI 10.1001/jama.267.14.1962; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; CELANI MG, 1994, BRIT MED J, V308, P1674, DOI 10.1136/bmj.308.6945.1674; CHADWICK D, 1993, BRIT MED J, V306, P1374; CHODAK GW, 1991, JAMA-J AM MED ASSOC, V265, P618, DOI 10.1001/jama.265.5.618; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; Ciampi A., 1987, TIME SERIES ECONOMET, P23; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; COOPERPATRICK L, 1994, JAMA-J AM MED ASSOC, V272, P1757, DOI 10.1001/jama.272.22.1757; DRAMAIX M, 1993, BMJ-BRIT MED J, V307, P710, DOI 10.1136/bmj.307.6906.710; Fackler ML, 1996, ANN INTERN MED, V124, P741, DOI 10.7326/0003-4819-124-8-199604150-00007; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; Feinstein AR, 1987, CLINIMETRICS; Fleiss JL, 1981, STAT METHODS RATES P; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; JUTRAS D, 1993, CAN MED ASSOC J, V148, P905; KERR L, 1994, NEW ZEAL MED J, V107, P294; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MAROTTOLI RA, 1994, ANN INTERN MED, V121, P842, DOI 10.7326/0003-4819-121-11-199412010-00003; MORROW K, 1993, ANN INTERN MED, V118, P689, DOI 10.7326/0003-4819-118-9-199305010-00005; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; NOURI FM, 1993, BRIT MED J, V307, P482, DOI 10.1136/bmj.307.6902.482; PARSONS RW, 1994, BMJ-BRIT MED J, V308, P1006, DOI 10.1136/bmj.308.6935.1006; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RIFKIN MD, 1990, NEW ENGL J MED, V323, P621, DOI 10.1056/NEJM199009063231001; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P179; SAUVE JS, 1994, ANN INTERN MED, V120, P633, DOI 10.7326/0003-4819-120-8-199404150-00002; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHUFFLEBARGER CM, 1992, ANN EMERG MED, V21, P1461, DOI 10.1016/S0196-0644(05)80060-5; SILVER MT, 1994, ANN INTERN MED, V121, P750, DOI 10.7326/0003-4819-121-10-199411150-00004; SKENE AI, 1992, BRIT MED J, V305, P1119, DOI 10.1136/bmj.305.6862.1119; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1995, NEW ZEAL MED J, V108, P111; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS M, 1995, THROMB HAEMOSTASIS, V73, P953; ZARCHY TM, 1991, ANN INTERN MED, V114, P137, DOI 10.7326/0003-4819-114-2-137	56	882	889	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					488	494		10.1001/jama.277.6.488	http://dx.doi.org/10.1001/jama.277.6.488			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020274				2022-12-28	WOS:A1997WG05400037
J	Barrett, T; Xiao, B; Dodson, EJ; Dodson, G; Ludbrook, SB; Nurmahomed, K; Gamblin, SJ; Musacchio, A; Smerdon, SJ; Eccleston, JF				Barrett, T; Xiao, B; Dodson, EJ; Dodson, G; Ludbrook, SB; Nurmahomed, K; Gamblin, SJ; Musacchio, A; Smerdon, SJ; Eccleston, JF			The structure of the GTPase-activating domain from p50rhoGAP	NATURE			English	Article							PROTEIN; BINDING; RHO; BCR; REGION	Members of the Rho family of small G proteins transduce signals from plasma-membrane receptors and control cell adhesion, motility and shape by actin cytoskeleton formation(1-4), They also activate other kinase cascades, Like all other GTPases, Rho proteins act as molecular switches, with an active GTP-bound form and an inactive GDP-bound form(5), The active conformation is promoted by guanine-nucleotide exchange factors, and the inactive state by GTPase-activating proteins (GAPs) which stimulate the intrinsic GTPase activity of small G proteins(6), Rho-specific GAP domains are found in a wide variety of large, multi-functional proteins(7), Here we report the crystal structure of an active 242-residue C-terminal fragment of human p50rhoGAP(8), The structure is an unusual arrangement of nine alpha-helices, the core of which includes a four-helix bundle, Residues conserved across the rhoGAP family are largely confined to one face of this bundle, which may be an interaction site for target G protein, In particular, we propose that Arg 85 and Asn 194 are involved in binding G proteins and enhancing GTPase activity.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND; CHILDRENS HOSP, MOL MED LAB, BOSTON, MA 02115 USA	MRC National Institute for Medical Research; University of York - UK; Harvard University; Boston Children's Hospital				Smerdon, Stephen/0000-0001-5688-8465; Musacchio, Andrea/0000-0003-2362-8784				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, J CELL SCI, P127; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	22	94	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 30	1997	385	6615					458	461		10.1038/385458a0	http://dx.doi.org/10.1038/385458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009196				2022-12-28	WOS:A1997WF00700058
J	Preziosi, MP; Yam, A; Ndiaye, M; Simaga, A; Simondon, F; Wassilak, SGF				Preziosi, MP; Yam, A; Ndiaye, M; Simaga, A; Simondon, F; Wassilak, SGF			Practical experiences in obtaining informed consent for a vaccine trial in rural Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ETHICS		INST FRANCAIS RECH SCI DEV & COOPERAT,DAKAR,SENEGAL; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA				Simondon, Francois/0000-0003-0395-1314				AABY P, 1993, AM J EPIDEMIOL, V138, P746, DOI 10.1093/oxfordjournals.aje.a116912; ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BRANDON S, 1991, J ROY SOC MED, V84, P575; *COM CONS NAT ETH, 1993, 41 COM CONS NAT ETH; DICKINSON RE, 1991, CLIMATIC CHANGE, V19, P175, DOI 10.1007/BF00142224; FREEMAN TR, 1992, FAM PRACT, V9, P36, DOI 10.1093/fampra/9.1.36; HOFFMASTER B, 1992, SOC SCI MED, V35, P1421, DOI 10.1016/0277-9536(92)90045-R; *I SUP SAN, 1995, 11 INT S PERT VACC T; IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212; Levine R J, 1991, Law Med Health Care, V19, P207; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; MEISEL A, 1992, ARTHRITIS RHEUM, V35, P1264, DOI 10.1002/art.1780351104; MILLER B, 1992, AM BOOK REV, V14, P7; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P771, DOI 10.1016/0895-4356(91)90129-W; SIMONDON F, 1994, 34 INT C ANT AG CHEM, P188; Singer P A, 1990, J Clin Ethics, V1, P95; SPAETH GL, 1992, OPHTHALMIC SURG LAS, V23, P648; *WHO, 1982, PROP INT GUID BIOM R; *WHO, 1993, WHO GUID GOOD CLIN P; World Health Organization, 1993, INT ETH GUID BIOM RE	21	62	63	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 30	1997	336	5					370	373		10.1056/NEJM199701303360511	http://dx.doi.org/10.1056/NEJM199701303360511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG233	9011793				2022-12-28	WOS:A1997WG23300011
J	Arvanitakis, L; GerasRaaka, E; Varma, A; Gershengorn, MC; Cesarman, E				Arvanitakis, L; GerasRaaka, E; Varma, A; Gershengorn, MC; Cesarman, E			Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation	NATURE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; KAPOSIS-SARCOMA; DNA-SEQUENCES; GENE-EXPRESSION; CHEMOKINES; CYTOKINES; SAIMIRI; CLONING	Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8, or HHV 8) is a virus that is consistently present in Kaposi's sarcoma(1,2) and in primary-effusion (body-cavity-based) lymphomas(3), malignancies that occur frequently, but not exclusively in AIDS patients. KSHV is a gamma herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus(1,4), both of which can transform lymphocytes(5). Cloning of a KSHV genome fragment revealed the presence of an open reading frame encoding a putative G-protein-coupled receptor(6) that is homologous to a G-protein-coupled receptor encoded by herpesvirus Saimiri(7,8) and to human interleukin-8 receptors(9,10). Here we show that the KSHV G-protein-coupled receptor is a bona fide signalling receptor which has constitutive (agonist-independent) activity in the phosphoinositide-inositoltrisphosphate-protein kinase C pathway. Furthermore, the KSHV G-protein-coupled receptor stimulates cellular proliferation, making it a candidate viral oncogene.	CORNELL UNIV MED COLL,DEPT MED,DIV MOL MED,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University								AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DOTTO GP, 1985, NATURE, V318, P472; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LOYTER A, 1982, P NATL ACAD SCI-BIOL, V79, P422, DOI 10.1073/pnas.79.2.422; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; Roizman B, 1996, FIELDS VIROLOGY, P2221; SANDE JV, 1995, J CLIN ENDOCR METAB, V80, P2577; SCHADLOW VC, 1992, MOL BIOL CELL, V3, P941, DOI 10.1091/mbc.3.8.941; SCIACCA FL, 1994, J IMMUNOL, V153, P4816; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	28	529	554	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					347	350		10.1038/385347a0	http://dx.doi.org/10.1038/385347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002520				2022-12-28	WOS:A1997WD91400052
J	Roter, DL; Stewart, M; Putnam, SM; Lipkin, M; Stiles, W; Inui, TS				Roter, DL; Stewart, M; Putnam, SM; Lipkin, M; Stiles, W; Inui, TS			Communication patterns of primary care physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT COMMUNICATION; INTERVIEW STYLE; OUTCOMES; SATISFACTION	Objectives.-To use audiotape analysis to describe communication patterns in primary care, to relate these to ideal relationship types as described in the literature, and to explore the patterns' relationships with physician and patient characteristics and satisfaction. Design.-Description of routine communication in primary care based on audiotape analysis and patient and physician exit questionnaires. Setting.-A total of 11 ambulatory clinics and private practices. Participants.-The participants were 127 physicians and 537 patients coping with ongoing problems related to disease. Main Outcomes Measures.-Roter Interactional Analysis System (RIAS) and patient and physician exit satisfaction questionnaires. Results.-Cluster analysis revealed 5 distinct communication patterns: (1) ''narrowly biomedical,'' characterized by closed-ended medical questions and biomedical talk occurring in 32% of visits; (2) ''expanded biomedical,'' like the restricted pattern but with moderate levels of psychosocial discussion occurring in 33% of the visits; (3) ''biopsychosocial,'' reflecting a balance of psychosocial and biomedical topics (20% of the visits); (4) ''psychosocial,'' characterized by psychosocial exchange (8% of visits), and (5) ''consumerist,'' characterized primarily by patient questions and physician information giving (8% of visits). Biomedically focused visits were used more often with more sick, older, and lower income patients by younger, male physicians. Physician satisfaction was lowest in the narrowly biomedical pattern and highest in the consumerist pattern, while patient satisfaction was highest in the psychosocial pattern. Conclusions.-Primary care communication patterns range from narrowly biomedical to consumerist patterns and parallel the ideal forms of patient-physician relationships described in the literature.	UNIV WESTERN ONTARIO,DEPT FAMILY PRACTICE,LONDON,ON,CANADA; BOSTON UNIV,MED CTR,DEPT MED,BOSTON,MA; NYU MED CTR,DEPT MED,NEW YORK,NY 10016; MIAMI UNIV,OXFORD,OH 45056; HARVARD UNIV,BOSTON,MA 02115	Western University (University of Western Ontario); Boston University; New York University; University System of Ohio; Miami University; Harvard University	Roter, DL (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,624 N BROADWAY,BALTIMORE,MD 21205, USA.		Roter, Debra L/N-8830-2014	Stiles, William/0000-0001-7740-0609; Stewart, Moira/0000-0002-5552-0762; Lipkin, Mack/0000-0001-9970-0725				BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; BRENT EE, 1986, MED CARE, V24, P981, DOI 10.1097/00005650-198611000-00002; BRIDGES KW, 1985, J PSYCHOSOM RES, V29, P563, DOI 10.1016/0022-3999(85)90064-9; BUIJS R, 1984, SOC SCI MED, V7, P683; Byrne P.S., 1976, DOCTORS TALKING PATI; CAMPBELL JD, 1990, SOC SCI MED, V12, P1359; Cohen-Cole SA, 1991, MED INTERVIEW 3 FUNC; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; ENGEL GL, 1988, TASK MED DIALOGUE WI; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HALL JA, 1994, HEALTH PSYCHOL, V13, P384, DOI 10.1037/0278-6133.13.5.384; INUI TS, 1985, MED CARE, V23, P521, DOI 10.1097/00005650-198505000-00013; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; Lazare A., 1995, MED INTERVIEW CLIN C, P422; LIPKIN M, 1994, OFFICE PRACTICE MED, P1287; ORMEL J, 1990, PSYCHOL DISORDERS GE, P146; ROTER D, 1987, MED CARE, V25, P399; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Stewart M, 1995, PATIENT CTR MED TRAN; STEWART MA, 1984, SOC SCI MED, V19, P167, DOI 10.1016/0277-9536(84)90284-3; SUCHMAN AL, 1993, MED CARE, V31, P1083, DOI 10.1097/00005650-199312000-00002; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; WISSOW LS, 1994, PEDIATRICS, V93, P289; 1982, PRESIDENTS COMMISSIO, P1	24	715	725	2	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					350	356		10.1001/jama.277.4.350	http://dx.doi.org/10.1001/jama.277.4.350			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC458	9002500				2022-12-28	WOS:A1997WC45800037
J	Eke, T; Talbot, JF; Lawden, MC				Eke, T; Talbot, JF; Lawden, MC			Severe persistent visual field constriction associated with vigabatrin	BRITISH MEDICAL JOURNAL			English	Article									LEICESTER ROYAL INFIRM,DEPT OPHTHALMOL,LEICESTER LE1 5WW,LEICS,ENGLAND; LEICESTER ROYAL INFIRM,DEPT NEUROL,LEICESTER LE1 5WW,LEICS,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT OPHTHALMOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Leicester; University of Leicester; University of Sheffield								BUTLER WH, 1987, TOXICOL PATHOL, V15, P143, DOI 10.1177/019262338701500203; DIETERLE L, 1994, NERVENARZT, V65, P122; Faeda MT, 1993, GIORN NEUROPSICOFARM, V15, P105; GRAHAM DG, 1989, BR J CLIN PHARM S, V27, P43; *MAR MERR DOW PHAR, ABPI DAT SHEET COMP, P956	5	362	367	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					180	181		10.1136/bmj.314.7075.180	http://dx.doi.org/10.1136/bmj.314.7075.180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022432	Green Published			2022-12-28	WOS:A1997WD91100026
J	McCrory, PR; Bladin, PF; Berkovic, SF				McCrory, PR; Bladin, PF; Berkovic, SF			Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: Phenomenology, aetiology, and outcome	BRITISH MEDICAL JOURNAL			English	Article							SYNCOPE	Objectives: To study the ictal phenomenology, aetiology, and outcome of convulsions occurring within seconds of impact in violent collision sport. Design: Retrospective identification of convulsions associated with concussive brain injury from case records fi-om medical officers of football clubs over a 15 year period. Subjects: Elite Australian rules and rugby league footballers. Main outcome measures: Neuroimaging studies, electroencephalography, neuropsychological test data, and statistics on performance in matches to determine presence of structural or functional brain injury Clinical follow up and electroencephalography for evidence of epilepsy. Results: Twenty two cases of concussive convulsions were identified with four events documented on television videotape. Convulsions began within 2 seconds of impact and comprised an initial period of tonic stiffening followed by myoclonic jerks of all limbs lasting up to 150 seconds. Some asymmetry in the convulsive manifestations was common, and recovery of consciousness was rapid. No structural or permanent brain injury was present on clinical assessment neuropsychological testing, or neuroimaging studies. All players returned to elite competition within two weeks of the incident Epilepsy did not develop in any player over a mean (range) follow up of 3.5 (1-13) years. Conclusions: These concussive or impact convulsions are probably a non-epileptic phenomenon, somewhat akin to convulsive syncope. The mechanism may be a transient traumatic functional decerebration. In concussive convulsions the outcome is universally good, antiepileptic treatment is not indicated, and prolonged absence from sport is unwarranted.	UNIV MELBOURNE,DEPT MED NEUROL,AUSTIN,AUSTRALIA; REPATRIAT MED CTR,HEIDELBERG,VIC 3084,AUSTRALIA	University of Melbourne			jiang, yu/HGU-0029-2022; McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X				AMINOFF MJ, 1988, ANN INTERN MED, V108, P791, DOI 10.7326/0003-4819-108-6-791; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; DUVOISIN RC, 1962, ARCH NEUROL-CHICAGO, V7, P219, DOI 10.1001/archneur.1962.04210030057008; GASTAUT H, 1957, LANCET, V2, P1018; GASTAUT H, 1974, HDB CLIN NEUROLOGY, V5, P815; GASTAUT H, 1972, EPILEPTIC SEIZURES C, P197; GOWERS WR, 1881, EPILEPSY CHRONIC CON, P26; GOWERS WR, 1907, BORDERLAND EPILEPSY, P1; HOWARD P, 1951, BRIT MED J, V2, P382, DOI 10.1136/bmj.2.4728.382; JENNETT B, 1975, EPILEPSY NON MISSILE; LEMPERT T, 1994, ANN NEUROL, V36, P233, DOI 10.1002/ana.410360217; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; MADDOCKS D, 1991, J CLIN EXP NEUROPSYC, V3, P439; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, IN PRESS BRAIN INJ; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Seward H. G., 1992, AUST J SCI MED SPORT, V24, P51; Stephenson J., 1990, FITS FAINTS, P41; WALKER AE, 1969, LATE EFFECTS HEAD IN	21	77	78	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					171	174		10.1136/bmj.314.7075.171	http://dx.doi.org/10.1136/bmj.314.7075.171			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022428	Green Published			2022-12-28	WOS:A1997WD91100021
J	McKinley, RK; Cragg, DK; Hastings, AM; French, DP; MankuScott, TK; Campbell, SM; Van, F; Roland, MO; Roberts, C				McKinley, RK; Cragg, DK; Hastings, AM; French, DP; MankuScott, TK; Campbell, SM; Van, F; Roland, MO; Roberts, C			Comparison of out of hours care provided by patients' own general practitioners and commercial deputising services: A randomised controlled trial .1. The outcome of care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH SURVEY QUESTIONNAIRE; SATISFACTION	Objective: To compare the outcome of out of hours care given by general practitioners from patients' own practices and by commercial deputising services. Design: Randomised controlled trial. Setting: Four urban areas in Manchester, Salford, Stockport, and Leicester. Subjects: 2152 patients who requested out of hours care, and 49 practice doctors and 183 deputising doctors (61% local principals in general practice) who responded to the requests. Main outcome measures: Health status outcome, patient satisfaction, and subsequent health sen ice use. Results: Patients seen by deputising doctors were less satisfied with the care they received. The mean overall satisfaction score for practice doctors was 70.7 (95% confidence interval 68.1 to 73.2) and for deputising doctors 61.8 (59.9 to 63.7), The greatest difference in satisfaction was with the delay in visiting. There were no differences in the change in health or overall health status measured 24 to 120 hours after the out of hours call or subsequent use of the health service in the two groups. Conclusions: Patients are more satisfied with the out of hours care provided by practice doctors than that provided by deputising doctors, Organisation of doctors into large groups ma) produce lower levels of patient satisfaction, especially when associated with increased delays in the time taken to visit There seem to be no appreciable differences in health outcome between the two types of service.	UNIV MANCHESTER, RUSHOLME HLTH CTR, DEPT GEN PRACTICE, MANCHESTER M14 5NP, LANCS, ENGLAND; UNIV MANCHESTER, NATL PRIMARY CARE RES & DEV CTR, MANCHESTER M13 9PL, LANCS, ENGLAND	University of Manchester; University of Manchester	McKinley, RK (corresponding author), UNIV LEICESTER, LEICESTER GEN HOSP, DEPT GEN PRACTICE & PRIMARY HLTH CARE, LEICESTER LE5 4PW, LEICS, ENGLAND.		French, David P/K-7283-2012; McKinley, Robert Kee/H-9211-2013	French, David P/0000-0002-7663-7804; McKinley, Robert Kee/0000-0002-3684-3435; Campbell, Stephen/0000-0002-2328-4136				BAKER R, 1995, BRIT J GEN PRACT, V45, P654; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BAKER R, 1995, BRIT MED J, V310, P533, DOI 10.1136/bmj.310.6978.533c; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Cragg DK, 1997, BMJ-BRIT MED J, V314, P187, DOI 10.1136/bmj.314.7075.187; CREIGHTON PA, 1982, BRIT MED J, V284, P1090, DOI 10.1136/bmj.284.6322.1090; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; FITZPATRICK R, 1993, BRIT J RHEUMATOL, V32, P807; Garratt A M, 1994, Qual Health Care, V3, P186, DOI 10.1136/qshc.3.4.186; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; MAXWELL RBH, 1993, BRIT J GEN PRACT, V43, P226; McKinley RK, 1997, BMJ-BRIT MED J, V314, P193, DOI 10.1136/bmj.314.7075.193; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PRINGLE M, 1990, BRIT J GEN PRACT, V40, P455; PRUDHOE RH, 1984, BRIT MED J, V288, P718, DOI 10.1136/bmj.288.6418.718-a; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; STEVENSON JSK, 1982, BRIT MED J, V284, P947, DOI 10.1136/bmj.284.6320.947; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; Ware J. E., 1993, SF36 HLTH SURVEY MAN	25	43	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					190	193		10.1136/bmj.314.7075.190	http://dx.doi.org/10.1136/bmj.314.7075.190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022435	Green Published			2022-12-28	WOS:A1997WD91100030
J	Russell, SCS; Doyle, E				Russell, SCS; Doyle, E			Recent advances - Paediatric anaesthesia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CAUDAL ANALGESIA; VENOUS CANNULATION; EMLA CREAM; TOPICAL ANESTHESIA; CHILDREN; HALOTHANE; SEVOFLURANE; BUPIVACAINE; CLONIDINE; KETAMINE		ROYAL HOSP SICK CHILDREN, DEPT ANAESTHESIA, EDINBURGH EH9 1LF, MIDLOTHIAN, SCOTLAND									BJERRING P, 1989, BRIT J ANAESTH, V63, P655, DOI 10.1093/bja/63.6.655; BJERRING P, 1990, BRIT J ANAESTH, V64, P173, DOI 10.1093/bja/64.2.173; Black A, 1996, ANAESTHESIA, V51, P539, DOI 10.1111/j.1365-2044.1996.tb12559.x; BROCKMEYER DM, 1995, BRIT J ANAESTH, V74, P79, DOI 10.1093/bja/74.1.79; COOK B, 1995, BRIT J ANAESTH, V75, P698, DOI 10.1093/bja/75.6.698; DOI M, 1987, ANESTH ANALG, V66, P241; DOYLE E, 1993, ANAESTHESIA, V48, P1050; Eger Edmond I. Ii, 1993, Canadian Journal of Anaesthesia, V40, pR3; EHRENSTROMREIZ G, 1983, ACTA ANAESTH SCAND, V27, P510, DOI 10.1111/j.1399-6576.1983.tb01997.x; FISHER DM, 1985, ANESTHESIOLOGY, V63, P647, DOI 10.1097/00000542-198512000-00015; FRINK EJ, 1994, ANAESTH PHARM REV, V2, P61; HALLEN B, 1984, ANAESTHESIA, V39, P969, DOI 10.1111/j.1365-2044.1984.tb08884.x; Imamura S, 1987, J Anesth, V1, P62; JAMALI S, 1994, ANESTH ANALG, V78, P663; KAMAL RS, 1995, PAEDIATR ANAESTH, V5, P101, DOI 10.1111/j.1460-9592.1995.tb00253.x; KENNA JG, 1987, BRIT MED J, V294, P1209, DOI 10.1136/bmj.294.6581.1209; KRISTENSEN JD, 1995, BRIT J ANAESTH, V74, P193, DOI 10.1093/bja/74.2.193; LANDAIS A, 1995, PAEDIATR ANAESTH, V5, P297, DOI 10.1111/j.1460-9592.1995.tb00309.x; LAWSON RA, 1995, BRIT J ANAESTH, V75, P282, DOI 10.1093/bja/75.3.282; LEE JJ, 1994, BRIT J ANAESTH, V72, P258, DOI 10.1093/bja/72.3.258; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; MANNER T, 1987, ACTA ANAESTH SCAND, V31, P735, DOI 10.1111/j.1399-6576.1987.tb02655.x; Mori N, 1996, PAEDIATR ANAESTH, V6, P95, DOI 10.1111/j.1460-9592.1996.tb00368.x; NAGUIB M, 1991, BRIT J ANAESTH, V67, P559, DOI 10.1093/bja/67.5.559; NAITO Y, 1991, BRIT J ANAESTH, V67, P387, DOI 10.1093/bja/67.4.387; PHILLIPS AJ, 1988, ANAESTHESIA, V43, P927, DOI 10.1111/j.1365-2044.1988.tb05653.x; PIAT V, 1994, ANESTH ANALG, V79, P840; Ray DC, 1996, BRIT J ANAESTH, V77, P404, DOI 10.1093/bja/77.3.404; SARNER JB, 1995, ANESTHESIOLOGY, V82, P38, DOI 10.1097/00000542-199501000-00006; SEMPLE D, IN PRESS ANAESTHESIA; Shiraishi Y, 1990, J Clin Anesth, V2, P381, DOI 10.1016/0952-8180(90)90024-W; Sury MRJ, 1996, ANAESTHESIA, V51, P543, DOI 10.1111/j.1365-2044.1996.tb12560.x; WARK HJ, 1983, ANAESTHESIA, V38, P237, DOI 10.1111/j.1365-2044.1983.tb13983.x; WARNER LO, 1984, ANESTH ANALG, V63, P838; WOLF AR, 1990, BRIT J ANAESTH, V64, P430, DOI 10.1093/bja/64.4.430	35	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					201	203		10.1136/bmj.314.7075.201	http://dx.doi.org/10.1136/bmj.314.7075.201			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022439	Green Published			2022-12-28	WOS:A1997WD91100035
J	Hardingham, GE; Chawla, S; Johnson, CM; Bading, H				Hardingham, GE; Chawla, S; Johnson, CM; Bading, H			Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression	NATURE			English	Article							C-FOS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; ACTIVATION; KINASE; SERUM; TRANSCRIPTION; STIMULATION; SEQUENCES; PATHWAYS	Calcium entry into neuronal cells through voltage or ligand-gated ion channels triggers neuronal affinity-dependent gene expression critical for adaptive changes in the nervous system(1-5). Cytoplasmic calcium transients are often accompanied by an increase in the concentration of nuclear calcium(6-9), but the functional significance of such spatially distinct calcium signals is unknown. Here we show that gene expression is differentially controlled by nuclear and cytoplasmic calcium signals which enable a single second messenger to generate diverse transcriptional responses, We used nuclear microinjection of a nondiffusible calcium chelator to block increases in nuclear, but not cytoplasmic, calcium concentrations following activation of L-type voltage-gated calcium channels, We showed that increases in nuclear calcium concentration control calcium-activated gene expression mediated by the cyclic-AMP-response element (CRE), and demonstrated that the CRE-binding protein CREB can function as a nuclear calcium-responsive transcription factor. A second signalling pathway, activating transcription through the serum-response element (SRE), is triggered by a rise in cytoplasmic calcium and does not require an increase in nuclear calcium.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Hardingham, Giles/0000-0002-7629-5314; Johnson, Claire/0000-0003-4428-3594				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MINTA A, 1989, J BIOL CHEM, V264, P8171; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; OMALLEY DM, 1994, J NEUROSCI, V14, P5741; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SEGAL M, 1992, J PHYSIOL-LONDON, V448, P655, DOI 10.1113/jphysiol.1992.sp019063; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WORLEY PE, 1994, J NEUROSCI, V13, P4776; ZHENG W, 1991, MOL PHARMACOL, V40, P734	27	627	650	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 16	1997	385	6613					260	265		10.1038/385260a0	http://dx.doi.org/10.1038/385260a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WC711	9000075				2022-12-28	WOS:A1997WC71100050
J	Doney, K; Leisenring, W; Storb, R; Appelbaum, FR				Doney, K; Leisenring, W; Storb, R; Appelbaum, FR			Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy	ANNALS OF INTERNAL MEDICINE			English	Article						outcome and process assessment (health care); anemia, aplastic; bone marrow transplantation; immunosuppression; age factors	VERSUS-HOST DISEASE; ANTITHYMOCYTE GLOBULIN ATG; HLA-HAPLOIDENTICAL MARROW; COLONY-STIMULATING FACTOR; ANTI-THYMOCYTE GLOBULIN; SAA WORKING PARTY; RANDOMIZED TRIAL; ANTILYMPHOCYTE GLOBULIN; MALIGNANT-TUMORS; GRAFT	Background: Both immunosuppressive therapy and bone marrow transplantation are accepted treatments for patients with aplastic anemia. Choosing one of these therapies for a given patient depends not only on donor availability but also on such factors as patient age. Objective: io compare survival rates and long-term complications after bone marrow transplantation or immunosuppressive therapy in patients with acquired aplastic anemia and to identify prognostic factors associated with improved survival. Design: Center-based, retrospective analysis. Setting: Referral center for patients with aplastic anemia. Patients: 395 patients with acquired aplastic anemia. Intervention: Bone marrow transplant from an HLA-identical, related donor or immunosuppressive therapy. Measurements: Kaplan-Meier survival curves, results of log-rank tests, and cumulative incidence curves. Results: Of 168 bone marrow transplant recipients, 89% had sustained engraftment. Forty-six patients developed grade II to IV acute graft-versus-host disease, and 68 developed chronic graft-versus-host disease that required therapy. Of 227 patients who received immunosuppressive therapy, 44% achieved a complete, partial, or minimal response. Fifty-four percent died or had no response to therapy. Actuarial survival at 15 years was 69% for bone marrow transplant recipients and 38% for patients receiving immunosuppressive therapy (P < 0.001). Improved survival was associated with having bone marrow transplantation as primary therapy, being younger, having no transfusion before transplantation, and having a higher absolute neutrophil count. Disease duration, year of therapy, sex, refractoriness to platelet transfusions, and previous treatment with androgens or corticosteroids did not significantly affect survival. Conclusions: Data from this center suggest that bone marrow transplantation may be preferred for younger patients with acquired aplastic anemia who have matched, related donors. Long-term survival is excellent for patients who respond to either form of therapy.	SEATTLE VET ADM MED CTR, SEATTLE, WA USA		Doney, K (corresponding author), UNIV WASHINGTON, FRED HUTCHINSON CANC RES CTR,SCH MED,DIV CLIN RES, 1124 COLUMBIA ST, M-120, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [P30CA015704, P01CA018221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER; NCI NIH HHS [CA 18221, CA 15704] Funding Source: Medline; NHLBI NIH HHS [HL 36444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACIGALUPO A, 1995, BLOOD, V85, P1348, DOI 10.1182/blood.V85.5.1348.bloodjournal8551348; BACIGALUPO A, 1988, BRIT J HAEMATOL, V70, P177, DOI 10.1111/j.1365-2141.1988.tb02460.x; CAMITTA B, 1983, BLOOD, V62, P883; CAMITTA BM, 1976, BLOOD, V48, P63; CRUMP M, 1992, AM J MED, V92, P596, DOI 10.1016/0002-9343(92)90776-8; DEEG HJ, 1985, TRANSPLANTATION, V40, P162, DOI 10.1097/00007890-198508000-00011; DEEG HJ, 1986, TRANSPLANT P, V18, P791; DONEY K, 1987, EXP HEMATOL, V15, P239; DONEY K, 1984, BLOOD, V63, P342; DONEY K, 1992, BLOOD, V79, P2566; DONEY K, 1993, BRIT J HAEMATOL, V85, P182, DOI 10.1111/j.1365-2141.1993.tb08665.x; DONEY KC, 1981, EXP HEMATOL, V9, P829; DONEY KC, 1981, AM J HEMATOL, V11, P1, DOI 10.1002/ajh.2830110102; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY MS, 1985, AM J MED, V78, P978, DOI 10.1016/0002-9343(85)90221-9; MARSH JCW, 1987, BLOOD, V70, P1046; PAQUETTE RL, 1995, BLOOD, V85, P283, DOI 10.1182/blood.V85.1.283.bloodjournal851283; PEPE MS, 1993, BRIT J HAEMATOL, V83, P602, DOI 10.1111/j.1365-2141.1993.tb04697.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; STORB R, 1994, BLOOD, V83, P2749; STORB R, 1980, ANN INTERN MED, V92, P30, DOI 10.7326/0003-4819-92-1-30; STORB R, 1982, BLOOD, V59, P236; STORB R, 1986, BLOOD, V68, P119; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; SULLIVAN KM, 1988, BLOOD, V72, P546; SULLIVAN KM, 1988, BLOOD, V72, P555; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x	30	128	135	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					107	+		10.7326/0003-4819-126-2-199701150-00003	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005744				2022-12-28	WOS:A1997WD29800005
J	Haley, RW; Kurt, TL				Haley, RW; Kurt, TL			Self-reported exposure to neurotoxic chemical combinations in the Gulf War - A cross-sectional epidemiologic study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Research Conference on the Gulf War Illness	OCT 26, 1995	CTR DIS CONTROL & PREVENT, ATLANTA, GA		CTR DIS CONTROL & PREVENT		INDUCED DELAYED POLYNEUROPATHY; NERVE AGENTS; PYRIDOSTIGMINE; ORGANOPHOSPHORUS; SOMAN; PRETREATMENT; NEUROPATHY; SARIN; ANTAGONISM; PROTECTION	Objective.-To identify risk factors of factor analysis-derived Gulf War-related syndromes. Design.-A cross-sectional survey. Participants.-A total of 249 Gulf War veterans from the Twenty-fourth Reserve Naval Mobile Construction Battalion. Data Collection.-Participants completed standardized booklets measuring self-reported wartime exposures and present symptoms. Main Outcome Measures.-Associations of factor analysis-derived syndromes with risk factors for chemical interactions that inhibit butyrylcholinesterase and neuropathy target esterase. Results.-Risk of syndrome 1 (''impaired cognition'') was greater in veterans who reported wearing flea collars during the war (5 of 20, 25%) than in those who never wore them (7 of 229, 3%; relative risk [RR], 8.7; 95% confidence interval [CI], 3.0-24.7; P<.001). Risk of syndrome 2 (''confusion-ataxia'') increased with a scale of advanced adverse effects from pyridostigmine bromide (chi(2) for trend, P<.001), was greater among veterans who believed they had been involved in chemical weapons exposure (18 of 108, 17%) than in those who did not (3 of 141, 2%; RR, 7.8; 95% CI, 2.3-25.9; P<.001), and was increased in veterans who had been in a sector of far northeastern Saudi Arabia on the fourth day of the air war (6 of 21, 29%) than in those who had not been (15 of 228, 7%; RR, 4.3; 95% CI, 1.9-10.0; P=.004). Effects of perceived chemical weapons exposure and advanced adverse effects from pyridostigmine were synergistic (Rothman S, 5.3; 95% CI, 1.04-26.7), Risk of syndrome 3 (''arthro-myo-neuropathy'') increased with an index of frequency and amount of government-issued insect repellent containing 75% DEET (N,N-diethyl-m-toluamide) in ethanol applied during the war (chi(2) for trend, P<.001) and with advanced adverse effects from pyridostigmine (chi(2) for trend, P<.001). Conclusion.-Some Gulf War Veterans may have delayed, chronic neurotoxic syndromes from wartime exposure to combinations of chemicals that inhibit butyrylcholinesterase and neuropathy target esterase.			Haley, RW (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DIV EPIDEMIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Haley, Robert/P-9026-2014	Haley, Robert/0000-0001-8849-9579				AbouDonia MB, 1996, J TOXICOL ENV HEALTH, V48, P35, DOI 10.1080/009841096161456; AbouDonia MB, 1996, FUND APPL TOXICOL, V34, P201, DOI 10.1006/faat.1996.0190; ABOUDONIA MB, 1990, ANNU REV PHARMACOL, V30, P405, DOI 10.1146/annurev.pa.30.040190.002201; [Anonymous], 1994, JAMA, V272, P391; [Anonymous], 1990, SAS STAT US GUID VER; BAKER DB, 1988, ARCH ENVIRON HEALTH, V43, P325; BOULDIN TW, 1979, AM J PATHOL, V94, P241; BROOMFIELD CA, 1991, J PHARMACOL EXP THER, V259, P633; CAPODICASA E, 1991, ARCH TOXICOL, V65, P150, DOI 10.1007/BF02034943; Cattell R.B., 1978, SCI USE FACTOR ANAL, DOI [DOI 10.1007/978-1-4684-2262-7_5, 10.1007/978-1-4684-2262-7_5]; COOK JE, 1992, MIL MED, V157, P250, DOI 10.1093/milmed/157.5.250; DEBLEECKER JL, 1992, CLIN NEUROL NEUROSUR, V94, P93, DOI 10.1016/0303-8467(92)90065-B; *DEF SCI BOARD, 1994, REP DEF SCI BOARD TA; DIRNHUBER P, 1978, J PHARM PHARMACOL, V30, P419, DOI 10.1111/j.2042-7158.1978.tb13278.x; DOCTOR BP, 1993, CHEM-BIOL INTERACT, V87, P285, DOI 10.1016/0009-2797(93)90056-5; DUFFY FH, 1979, TOXICOL APPL PHARM, V47, P161, DOI 10.1016/0041-008X(79)90083-8; DUNN MA, 1989, JAMA-J AM MED ASSOC, V262, P649, DOI 10.1001/jama.262.5.649; ECOBICHON DJ, 1994, PESTICIDES NEUROLOGI, P171; Goldberg J, 1992, Ann Epidemiol, V2, P841, DOI 10.1016/1047-2797(92)90078-5; GORDON JJ, 1983, ARCH TOXICOL, V52, P71, DOI 10.1007/BF00354767; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P223, DOI 10.1001/jama.277.3.223; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; Hayes WJ., 1991, HDB PESTICIDE TOXICO; HOGAN MD, 1978, AM J EPIDEMIOL, V108, P60; HOSMER DW, 1989, APPL LOGISTIC REGRES; Husain K., 1995, Indian Journal of Physiology and Pharmacology, V39, P47; HUSAIN K, 1993, J APPL TOXICOL, V13, P143, DOI 10.1002/jat.2550130212; *I MED MED FOLL UP, 1995, HLTH CONS SERV PERS; IDSON B, 1975, J PHARM SCI-US, V64, P901, DOI 10.1002/jps.2600640604; Jamal GA, 1996, J NEUROL NEUROSUR PS, V60, P449, DOI 10.1136/jnnp.60.4.449; JOHNSON MK, 1970, BIOCHEM J, V120, P523, DOI 10.1042/bj1200523; JOHNSON MK, 1987, TRENDS PHARMACOL SCI, V8, P174, DOI 10.1016/0165-6147(87)90161-1; KAPLAN JG, 1993, NEUROLOGY, V43, P2193, DOI 10.1212/WNL.43.11.2193; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P284; KOPLOVITZ I, 1992, FUND APPL TOXICOL, V18, P102, DOI 10.1016/0272-0590(92)90201-R; La Du BN, 1992, PHARMACOGENETICS DRU, P51; LEESHALEY PR, 1992, PERCEPT MOTOR SKILL, V75, P531, DOI 10.2466/PMS.75.5.531-544; LOTTI M, 1992, CRIT REV TOXICOL, V21, P465, DOI 10.3109/10408449209089884; MANTEL N, 1959, J NATL CANCER I, V22, P719; *MICR HEALTHC SERV, 1995, POISINDEX CD ROM VER; MILLER SA, 1993, PHARMACOL BIOCHEM BE, V44, P343, DOI 10.1016/0091-3057(93)90472-6; MORGAN JP, 1978, ARCH NEUROL-CHICAGO, V35, P530, DOI 10.1001/archneur.1978.00500320050011; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; MOUNT ME, 1991, VET HUM TOXICOL, V33, P19; OSIMITZ TG, 1995, J AM MOSQUITO CONTR, V11, P274; PETTY CS, 1958, AM J MED, V24, P467, DOI 10.1016/0002-9343(58)90332-2; POPE CN, 1990, J TOXICOL ENV HEALTH, V31, P261, DOI 10.1080/15287399009531455; RICHARDSON RJ, 1992, ORGANOPHOSPHATES CHE, P299; ROBBINS PJ, 1986, J TOXICOL ENV HEALTH, V18, P503, DOI 10.1080/15287398609530891; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252; RUMMEL RJ, 1970, APPLIED FACTOR ANAL; SABRI MI, 1980, EXPT CLIN NEUROTOXIC, P206; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; SHARABI Y, 1991, ISRAEL J MED SCI, V27, P656; SIDELL FR, 1992, ANN EMERG MED, V21, P865, DOI 10.1016/S0196-0644(05)81036-4; SIDELL FR, 1974, CLIN TOXICOL, V7, P1; Smith MI, 1930, PUBLIC HEALTH REP, V45, P2509, DOI 10.2307/4579816; Snedecor GW, 1980, STAT METHODS, V7th; SPIEGELBERG U, 1961, WERHRDIENST GESUNDHE, V3; Stockholm International Peace Research Institute, 1975, DEL TOX EFF CHEM WAR; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; *US SEN, 1994, US CHEM BIOL WARF RE; WENGER B, 1993, AVIAT SPACE ENVIR MD, V64, P905; WILLEMS JL, 1984, ARCH TOXICOL, V55, P76, DOI 10.1007/BF00316591; WINDHEUSER JJ, 1982, J PHARM SCI-US, V71, P1211, DOI 10.1002/jps.2600711107	69	269	274	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					231	237		10.1001/jama.277.3.231	http://dx.doi.org/10.1001/jama.277.3.231			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WB446	9005273				2022-12-28	WOS:A1997WB44600025
J	Magnusson, S				Magnusson, S			Oh, for a little humanity	BRITISH MEDICAL JOURNAL			English	Article																			0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1601	1603		10.1136/bmj.313.7072.1601	http://dx.doi.org/10.1136/bmj.313.7072.1601			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011288	Green Published			2022-12-28	WOS:A1996VZ81100028
J	Cochran, ST				Cochran, ST			Determination of serum creatinine level prior to administration of radiographic contrast media	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NEPHROTOXICITY				Cochran, ST (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIOL SCI,LOS ANGELES,CA 90024, USA.							BARRETT BJ, 1993, RADIOLOGY, V188, P171, DOI 10.1148/radiology.188.1.8511292; BYRD L, 1979, MEDICINE, V58, P270, DOI 10.1097/00005792-197905000-00006; CIGARROA RG, 1989, AM J MED, V86, P649, DOI 10.1016/0002-9343(89)90437-3; COCHRAN ST, 1983, AM J ROENTGENOL, V141, P1027, DOI 10.2214/ajr.141.5.1027; LEE JKT, 1995, INVEST RADIOL, V12, P700; MUDGE GH, 1980, KIDNEY INT, V18, P540, DOI 10.1038/ki.1980.172	6	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					517	518		10.1001/jama.1997.03540310015008	http://dx.doi.org/10.1001/jama.1997.03540310015008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032143				2022-12-28	WOS:A1997WH29700003
J	Friedman, E				Friedman, E			California public hospitals - The buck has stopped	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Andrulis DP, 1996, JAMA-J AM MED ASSOC, V276, P946, DOI 10.1001/jama.276.12.946; *CAL ASS PUBL HOSP, 1996, COUNT HOSP HLTH SYST; Cornwell EE, 1996, JAMA-J AM MED ASSOC, V276, P940, DOI 10.1001/jama.276.12.940; *EMPL BEN RES I, 1996, SOURC HLTH INS CHAR; HERSHEY R, 1996, NY TIMES        0528, pC1; *INT STUD, 1996, INT COMP EDG IND REP; Tranquada RE, 1996, JAMA-J AM MED ASSOC, V276, P945, DOI 10.1001/jama.276.12.945; Trunkey D, 1996, JAMA-J AM MED ASSOC, V276, P944, DOI 10.1001/jama.276.12.944; LOS ANGELES TIME SEP	9	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					577	581		10.1001/jama.277.7.577	http://dx.doi.org/10.1001/jama.277.7.577			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH297	9032167				2022-12-28	WOS:A1997WH29700036
J	Levinson, W; Roter, DL; Mullooly, JP; Dull, VT; Frankel, RM				Levinson, W; Roter, DL; Mullooly, JP; Dull, VT; Frankel, RM			Physician-patient communication - The relationship with malpractice claims among primary care physicians and surgeons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENTS SATISFACTION; NONSUED PHYSICIANS; MEDICAL-CARE; BAD-NEWS; SKILLS; QUALITY; IMPROVEMENT; LITIGATION; OUTCOMES; BEHAVIOR	Objective.-To identify specific communication behaviors associated with malpractice history in primary care physicians and surgeons. Design.-Comparison of communication behaviors of ''claims'' vs ''no-claims'' physicians using audiotapes of 10 routine office visits per physician. Settings.-One hundred twenty-four physician offices in Oregon and Colorado. Participants-Fifty-nine primary care physicians (general internists and family practitioners) and 65 general and orthopedic Surgeons and their patients. Physicians were classified into no-claims or claims (greater than or equal to 2 lifetime claims) groups based on insurance company records and were stratified by years in practice and specialty. Main Outcome Measures.-Audiotape analysis using the Roter Interaction Analysis System. Results-Significant differences in communication behaviors of no-claims and claims physicians were identified in primary care physicians but not in surgeons. Compared with claims primary care physicians, no-claims primary care physicians used more statements of orientation (educating patients about what to expect and the flow of a visit), laughed and used humor more, and tended to use more facilitation (soliciting patients' opinions, checking understanding, and encouraging patients to talk). No-claims primary care physicians spent longer in routine visits than claims primary care physicians (mean, 13.3 vs 15.0 minutes), and the length of the visit had an independent effect in predicting claims status. The multivariable model for primary care improved the prediction of claims status by 57% above chance (90% confidence interval, 33%-73%). Multivariable models did not significantly improve prediction of claims status for surgeons. Conclusions.-Routine physician-patient communication differs in primary care physicians with vs without prior malpractice claims. In contrast, the study did not find communication behaviors to distinguish between claims vs no-claims surgeons. The study identifies specific and teachable communication behaviors associated with fewer malpractice claims for primary care physicians. Physicians can use these findings as they seek to improve communication and decrease malpractice risk, Malpractice insurers can use this information to guide malpractice risk prevention and education for primary care physicians but should not assume that it is appropriate to teach similar behaviors to other specialty groups.	OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; LEGACY GOOD SAMARITAN HOSP & MED CTR,PORTLAND,OR; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218; KAISER FDN HOSP,CTR HLTH RES,PORTLAND,OR; PORTLAND STATE UNIV,DEPT PSYCHOL,PORTLAND,OR 97207; UNIV ROCHESTER,HIGHLAND HOSP,DEPT MED,ROCHESTER,NY 14627	Oregon Health & Science University; Johns Hopkins University; Kaiser Permanente; Portland State University; University of Rochester			Roter, Debra L/N-8830-2014		PHS HHS [R01 07289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON TE, 1989, WESTERN J MED, V150, P356; APPLEGATE WB, 1986, ARCH INTERN MED, V146, P2249, DOI 10.1001/archinte.146.11.2249; BECKMAN H, 1990, J GEN INTERN MED, V5, P42, DOI 10.1007/BF02602308; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BROYARD A, 1992, INTOXICATED MY ILLNE, P33; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; CHARLES SC, 1992, WESTERN J MED, V157, P433; CHARLES SC, 1988, BEHAV MED, V14, P148, DOI 10.1080/08964289.1988.9935139; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; COHEN SM, 1991, PROG EXP TUMOR RES, V33, P21; Efron B., 1993, INTRO BOOTSTRAP, P237; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P823; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1995, FRONT PR CA, P316; GASK L, 1987, MED EDUC, V21, P362, DOI 10.1111/j.1365-2923.1987.tb00377.x; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; HALL J, 1981, J HEALTH SOC BEHAV, V11, P18; HALL JA, 1994, HEALTH PSYCHOL, V13, P384, DOI 10.1037/0278-6133.13.5.384; HALL JA, 1988, SOC SCI MED, V27, P637, DOI 10.1016/0277-9536(88)90012-3; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; INUI TS, 1982, MED CARE, V20, P535, DOI 10.1097/00005650-198206000-00001; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; LESTER GW, 1993, WESTERN J MED, V158, P268; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEVINSON W, 1994, JAMA-J AM MED ASSOC, V272, P1619, DOI 10.1001/jama.272.20.1619; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; PENCHANSKY R, 1994, MED CARE, V32, P813, DOI 10.1097/00005650-199408000-00005; ROLPH JE, 1991, JAMA-J AM MED ASSOC, V266, P2093, DOI 10.1001/jama.266.15.2093; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; ROTER DL, 1991, ROTER INTERACTION AN; SHAPIRO RS, 1989, ARCH INTERN MED, V149, P2190, DOI 10.1001/archinte.149.10.2190; SNEDECOR GW, 1989, STAT METHODS, P185; STEWART M, 1989, CAN FAM PHYSICIAN, V35, P159; STRAUSS RP, 1995, PEDIATRICS, V96, P82; TARAGIN MI, 1994, MED CARE, V32, P661, DOI 10.1097/00005650-199407000-00001; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; WHITE J, 1993, J GEN INTERN MED, V9, P24; WISSOW LS, 1994, PEDIATRICS, V93, P289; WOLRAICH ML, 1986, MED CARE, V24, P891, DOI 10.1097/00005650-198610000-00003	48	1144	1162	0	94	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 19	1997	277	7					553	559		10.1001/jama.277.7.553	http://dx.doi.org/10.1001/jama.277.7.553			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH297	9032162				2022-12-28	WOS:A1997WH29700031
J	Aronson, D; Rayfield, EJ; Chesebro, JH				Aronson, D; Rayfield, EJ; Chesebro, JH			Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Review							PLASMINOGEN-ACTIVATOR INHIBITOR; CORONARY-ARTERY-DISEASE; LEFT-VENTRICULAR FUNCTION; HEART-RATE-VARIABILITY; THROMBOLYTIC THERAPY; CARDIOVASCULAR-DISEASE; AUTONOMIC NEUROPATHY; REPERFUSION THERAPY; SYSTOLIC FUNCTION; BETA-BLOCKERS	Purpose: To review the pathogenic mechanisms that lead to the poor prognosis of diabetic patients after myocardial infarction and to determine the efficacy of current interventions for myocardial infarction in these patients. Data Sources: Search of the MEDLINE database from 1985 to 1995, using the keywords diabetes, myocardial infarction, and cardiomyopathy, and a search of the reference citations of relevant articles. Study Selection: Experimental and clinical studies on myocardial infarction in diabetic patients and basic research studies relevant to this topic. Data Synthesis: The excess in-hospital mortality of diabetic patients results primarily from an increased incidence of congestive heart failure. Several combined mechanisms reduce the compensatory ability of the noninfarcted myocardium; such mechanisms include preexisting congestive heart failure caused by diabetic cardiomyopathy, severe coronary artery disease, decreased vasodilatory reserve of epicardial and resistance arteries, and possibly abnormal metabolism of myocardial substrate. Late mortality results from increased reinfarction rates caused by the diffuse nature of the atherosclerotic disease and hypercoagulable state. Platelet hyperactivity, reduced fibrinolytic capacity, increased concentrations of hemostatic proteins, and endothelial dysfunction promote thrombosis at the site of plaque rupture. Autonomic neu neuropathy predisposes patients to ventricular arrhythmias. Thrombolytic agents, aspirin, p-blockers, and angiotensin-converting enzyme inhibitors are effective in patients with diabetes. Conclusions: In the thrombolytic era, mortality rates of diabetic patients who have had acute myocardial infarction remain 1.5 to 2 times higher than those in nondiabetic patients. This increased mortality rate is caused by diverse mechanisms that affect myocardial function and blood supply and by the tendency toward thrombosis in diabetic patients. Current therapies for myocardial infarction are effective in these patients. Improved metabolic control may also decrease mortality rates.	MT SINAI MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, NEW YORK, NY 10029 USA; MT SINAI MED CTR, DEPT MED, DIV CARDIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Aronson, D (corresponding author), JOSLIN DIABET CTR, RES INST, METAB SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA.		Aronson, Doron/F-3390-2010					ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; ABBUD ZA, 1995, AM HEART J, V130, P51, DOI 10.1016/0002-8703(95)90235-X; Alderman EL, 1996, NEW ENGL J MED, V335, P217; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; ANDERSON JL, 1993, CIRCULATION, V87, P1829, DOI 10.1161/01.CIR.87.6.1829; [Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Aronson D, 1996, J AM COLL CARDIOL, V27, P528, DOI 10.1016/0735-1097(95)00496-3; Aronson D., 1993, DIABETES CARE, V16, P72, DOI [10.2337/diacare.16.2.72, DOI 10.2337/DIACARE.16.2.72]; BARBASH GI, 1993, J AM COLL CARDIOL, V22, P707, DOI 10.1016/0735-1097(93)90180-9; BARBASH GI, 1989, AM J CARDIOL, V64, P1231, DOI 10.1016/0002-9149(89)90559-6; BARZILAY JI, 1994, AM J CARDIOL, V74, P334, DOI 10.1016/0002-9149(94)90399-9; BERNARDI L, 1992, CIRCULATION, V86, P1443, DOI 10.1161/01.CIR.86.5.1443; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; Bloomgarden ZT, 1996, DIABETES CARE, V19, P187, DOI 10.2337/diacare.19.2.187; BRAUNWALD E, 1993, NEW ENGL J MED, V329, P1650, DOI 10.1056/NEJM199311253292211; Braunwald E, 1996, NEW ENGL J MED, V334, P51, DOI 10.1056/NEJM199601043340113; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; CAPONE RJ, 1991, J AM COLL CARDIOL, V18, P1434, DOI 10.1016/0735-1097(91)90671-U; CHESEBRO JH, 1991, CIRCULATION, V83, P1815, DOI 10.1161/01.CIR.83.5.1815; CLARK RS, 1985, BRIT MED J, V291, P303, DOI 10.1136/bmj.291.6491.303; CLEMENTS IP, 1991, AM J CARDIOL, V67, P1245, DOI 10.1016/0002-9149(91)90935-E; COHEN RA, 1993, CIRCULATION, V87, P67; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; COOPER J, 1991, FIBRINOLYSIS, V5, P105, DOI 10.1016/0268-9499(91)90051-5; CURB JD, 1995, CIRCULATION, V91, P2591, DOI 10.1161/01.CIR.91.10.2591; CZYZK A, 1980, DIABETES CARE, V3, P526, DOI 10.2337/diacare.3.4.526; DAHL JV, 1993, CIRCULATION, V88, P395, DOI 10.1161/01.CIR.88.2.395; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; DEFEO P, 1991, J CLIN INVEST, V88, P833, DOI 10.1172/JCI115384; DIMINNO G, 1986, BLOOD, V68, P886; EBERLI FR, 1991, CIRC RES, V68, P466, DOI 10.1161/01.RES.68.2.466; EPSTEIN M, 1992, HYPERTENSION, V19, P403, DOI 10.1161/01.HYP.19.5.403; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; EWING DJ, 1976, LANCET, V1, P601, DOI 10.1016/S0140-6736(76)90413-X; FAVA S, 1993, DIABETES CARE, V16, P1615, DOI 10.2337/diacare.16.12.1615; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GANDA OP, 1992, DIABETES CARE, V15, P1245, DOI 10.2337/diacare.15.10.1245; GERIELLO A, 1988, DIABETOLOGIA, V31, P889; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GILPIN E, 1991, AM HEART J, V121, P457, DOI 10.1016/0002-8703(91)90712-Q; GINSBERG HN, 1991, DIABETES CARE, V14, P839, DOI 10.2337/diacare.14.9.839; GRANGER CB, 1993, J AM COLL CARDIOL, V21, P920, DOI 10.1016/0735-1097(93)90348-5; GRAY RP, 1993, BRIT HEART J, V70, P530; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; GRINES CL, 1989, CIRCULATION, V80, P245, DOI 10.1161/01.CIR.80.2.245; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grossman E, 1996, ANN INTERN MED, V125, P304, DOI 10.7326/0003-4819-125-4-199608150-00009; GRUDEN G, 1994, DIABETES, V43, P426, DOI 10.2337/diabetes.43.3.426; GUNDERSEN T, 1983, DIABETES CARE, V6, P285, DOI 10.2337/diacare.6.3.285; GWILT DJ, 1984, BRIT HEART J, V51, P626; GWILT DJ, 1985, BRIT HEART J, V54, P466; HAMSTEN A, 1987, LANCET, V2, P3; HARRISON JK, 1993, CIRCULATION, V87, P1531, DOI 10.1161/01.CIR.87.5.1531; HERLITZ J, 1988, ACTA MED SCAND, V224, P31; HERLITZ J, 1992, CARDIOLOGY, V80, P237, DOI 10.1159/000175008; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; IWASAKA T, 1992, DIABETES CARE, V15, P1522, DOI 10.2337/diacare.15.11.1522; IWASAKA T, 1994, CORONARY ARTERY DIS, V5, P237, DOI 10.1097/00019501-199403000-00009; JAARSMA W, 1986, AM J CARDIOL, V58, P394, DOI 10.1016/0002-9149(86)90002-0; JACOBY RM, 1992, J AM COLL CARDIOL, V20, P736, DOI 10.1016/0735-1097(92)90033-J; JAFFE AS, 1984, AM HEART J, V108, P31, DOI 10.1016/0002-8703(84)90541-6; JANSSON JH, 1991, BRIT HEART J, V66, P351; JOHNSON M, 1979, LANCET, V1, P325; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; JUHANVAGUE I, 1991, DIABETOLOGIA, V34, P457, DOI 10.1007/BF00403280; KANNEL WB, 1990, AM HEART J, V120, P672, DOI 10.1016/0002-8703(90)90026-T; KARLSON BW, 1993, DIABETIC MED, V10, P449, DOI 10.1111/j.1464-5491.1993.tb00097.x; KEEGAN A, 1995, DIABETOLOGIA, V38, P1475, DOI 10.1007/BF00400609; KENDALL MJ, 1995, ANN INTERN MED, V123, P358, DOI 10.7326/0003-4819-123-5-199509010-00007; KERSTEN JR, 1995, AM J PHYSIOL-HEART C, V268, pH1667, DOI 10.1152/ajpheart.1995.268.4.H1667; KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KLEIN HH, 1993, AM J CARDIOL, V71, P518, DOI 10.1016/0002-9149(93)90505-7; KOUVARAS G, 1988, JPN HEART J, V29, P1; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEHTO S, 1994, J INTERN MED, V236, P291, DOI 10.1111/j.1365-2796.1994.tb00799.x; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIEDTKE AJ, 1981, PROG CARDIOVASC DIS, V23, P321, DOI 10.1016/0033-0620(81)90019-0; LINCOFF AM, 1993, CIRCULATION, V88, P1361, DOI 10.1161/01.CIR.88.3.1361; LIU YG, 1993, CIRCULATION, V88, P1273, DOI 10.1161/01.CIR.88.3.1273; LOMUSCIO A, 1991, ACTA CARDIOL, V46, P543; LYNCH M, 1994, DIABETIC MED, V11, P162, DOI 10.1111/j.1464-5491.1994.tb02013.x; MALMBERG K, 1989, EUR HEART J, V10, P423, DOI 10.1093/oxfordjournals.eurheartj.a059505; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MALMBERG K, 1988, EUR HEART J, V9, P259, DOI 10.1093/oxfordjournals.eurheartj.a062494; MALPAS SC, 1990, DIABETES, V39, P1177, DOI 10.2337/diabetes.39.10.1177; MCGILL JB, 1994, DIABETES, V43, P104, DOI 10.2337/diabetes.43.1.104; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILDENBERGER RR, 1984, J AM COLL CARDIOL, V4, P234, DOI 10.1016/S0735-1097(84)80207-7; MILO C, 1994, AM J CARDIOL, V74, P1275, DOI 10.1016/0002-9149(94)90564-9; MOLITERNO DJ, 1995, J AM COLL CARDIOL, V25, pA155; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; MULLER DWM, 1991, AM HEART J, V121, P1042, DOI 10.1016/0002-8703(91)90661-Z; MURPHY JF, 1995, AM J CARDIOL, V76, P827, DOI 10.1016/S0002-9149(99)80237-9; MUSTONEN JN, 1994, AM J CARDIOL, V73, P1202, DOI 10.1016/0002-9149(94)90182-1; NAHSER PJ, 1995, CIRCULATION, V91, P635, DOI 10.1161/01.CIR.91.3.635; NITENBERG A, 1993, DIABETES, V42, P1017, DOI 10.2337/diabetes.42.7.1017; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; NORDT TK, 1993, ARTERIOSCLER THROMB, V13, P1822, DOI 10.1161/01.ATV.13.12.1822; OBRIEN JA, 1991, Q J MED, V79, P495; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; OHTAKE T, 1995, J NUCL MED, V36, P456; ORLANDER PR, 1994, DIABETES, V43, P897, DOI 10.2337/diabetes.43.7.897; OSWALD GA, 1984, LANCET, V1, P1264; OURIEL K, 1994, RADIOLOGY, V193, P561, DOI 10.1148/radiology.193.2.7972780; PAILLOLE C, 1989, AM J CARDIOL, V64, P1010, DOI 10.1016/0002-9149(89)90799-6; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEIFER MA, 1984, DIABETES CARE, V7, P447, DOI 10.2337/diacare.7.5.447; PIEPER GM, 1995, DIABETES, V44, P1106, DOI 10.2337/diabetes.44.9.1106; PITT B, 1995, CIRCULATION, V91, P1855, DOI 10.1161/01.CIR.91.6.1855; RAEV DC, 1994, DIABETES CARE, V17, P633, DOI 10.2337/diacare.17.7.633; REINER JS, 1994, J AM COLL CARDIOL, V24, P1439, DOI 10.1016/0735-1097(94)90137-6; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; RIGGS TW, 1990, AM J CARDIOL, V65, P899, DOI 10.1016/0002-9149(90)91433-7; RODRIGUES B, 1995, J MOL CELL CARDIOL, V27, P169, DOI 10.1016/S0022-2828(08)80016-8; ROLLINS MD, 1992, DIABETOLOGIA, V35, P452, DOI 10.1007/BF02342443; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUNNMAN EM, 1990, J CLIN INVEST, V86, P1222, DOI 10.1172/JCI114828; RYTTER L, 1985, DIABETES CARE, V8, P230, DOI 10.2337/diacare.8.3.230; SAMPSON MJ, 1990, Q J MED, V75, P635; SANE DC, 1991, THROMB HAEMOSTASIS, V65, P275; SAVAGE MP, 1988, AM J CARDIOL, V62, P665, DOI 10.1016/0002-9149(88)91199-X; SCHULMAN SP, 1988, J AM COLL CARDIOL, V11, P1164, DOI 10.1016/0735-1097(88)90277-X; SEBBAG L, 1994, EUR J CLIN INVEST, V24, P686, DOI 10.1111/j.1365-2362.1994.tb01061.x; SHAPIRO LM, 1981, BRIT HEART J, V45, P129; SILVA JA, 1995, CIRCULATION, V92, P1731, DOI 10.1161/01.CIR.92.7.1731; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S; STEIN B, 1995, CIRCULATION, V91, P979, DOI 10.1161/01.CIR.91.4.979; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; SUN DQ, 1994, CIRCULATION, V89, P793, DOI 10.1161/01.CIR.89.2.793; TAKAHASHI N, 1989, DIABETES CARE, V12, P630, DOI 10.2337/diacare.12.9.630; TANI M, 1988, CIRC RES, V62, P931, DOI 10.1161/01.RES.62.5.931; TANSEY MJB, 1977, BRIT MED J, V1, P1624, DOI 10.1136/bmj.1.6077.1624; TAYLOR GJ, 1992, AM J CARDIOL, V70, P26, DOI 10.1016/0002-9149(92)91384-G; TESFAMARIAM B, 1992, AM J PHYSIOL, V263, pH321, DOI 10.1152/ajpheart.1992.263.2.H321; TESFAMARIAM B, 1994, FREE RADICAL BIO MED, V16, P383, DOI 10.1016/0891-5849(94)90040-X; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; TRIP MD, 1990, NEW ENGL J MED, V322, P1549, DOI 10.1056/NEJM199005313222201; TSCHOEPE D, 1995, DIABETES, V44, P890, DOI 10.2337/diabetes.44.8.890; TSCHOEPE D, 1993, SEMIN THROMB HEMOST, V19, P122, DOI 10.1055/s-2007-994015; TSCHOEPE D, 1991, SEMIN THROMB HEMOST, V17, P433, DOI 10.1055/s-2007-1002650; TSE WY, 1994, DIABETIC MED, V11, P137, DOI 10.1111/j.1464-5491.1994.tb02009.x; ULVENSTAM G, 1985, DIABETES, V34, P787, DOI 10.2337/diabetes.34.8.787; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011; UMEDA F, 1989, ATHEROSCLEROSIS, V75, P61, DOI 10.1016/0021-9150(89)90207-4; UUSITUPA M, 1988, DIABETOLOGIA, V31, P783; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; VERED Z, 1984, AM J CARDIOL, V54, P633, DOI 10.1016/0002-9149(84)90263-7; VIGORITO C, 1980, AM HEART J, V100, P782, DOI 10.1016/0002-8703(80)90056-3; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5; WHEELER TJ, 1988, J BIOL CHEM, V263, P19447; WINOCOUR PD, 1992, DIABETES, V41, P26, DOI 10.2337/diab.41.2.S26; WOO KS, 1994, ANNU REV MED, V45, P325; YUDKIN JS, 1988, DIABETES CARE, V11, P351, DOI 10.2337/diacare.11.4.351; ZANINETTI D, 1988, DIABETOLOGIA, V31, P108, DOI 10.1007/BF00395557; ZARICH S, 1994, J AM COLL CARDIOL, V24, P956, DOI 10.1016/0735-1097(94)90855-9; ZARICH SW, 1988, J AM COLL CARDIOL, V12, P114, DOI 10.1016/0735-1097(88)90364-6; ZARICH SW, 1989, AM HEART J, V118, P1000, DOI 10.1016/0002-8703(89)90236-6; ZILJSTRA F, 1993, NEW ENGL J MED, V328, P680; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S; Zuanetti Giulio, 1996, Journal of the American College of Cardiology, V27, p319A	174	236	247	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					296	306		10.7326/0003-4819-126-4-199702150-00006	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH068	9036802				2022-12-28	WOS:A1997WH06800008
J	Peterson, ED; Shaw, LK; DeLong, ER; Pryor, DB; Califf, RM; Mark, DB				Peterson, ED; Shaw, LK; DeLong, ER; Pryor, DB; Califf, RM; Mark, DB			Racial variation in the use of coronary-revascularization procedures - Are the differences real? Do they matter?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BYPASS GRAFT-SURGERY; OF-VETERANS-AFFAIRS; ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC HEART-DISEASE; ARTERY DISEASE; CARDIAC PROCEDURES; RACE; RATES; CARE; SURVIVAL	Background Studies have reported that blacks undergo fewer coronary-revascularization procedures than whites, but it is not clear whether the clinical characteristics of the patients account for these differences or whether they indicate underuse of the procedures in blacks or overuse in whites. Methods In a study at Duke University of 12,402 patients (10.3 percent of whom were black) with coronary disease, we calculated unadjusted and adjusted rates of angioplasty and bypass surgery in blacks and whites after cardiac catheterization. We also examined patterns of treatment after stratifying the patients according to the severity of disease, angina status, and estimated survival benefit due to revascularization. Finally, we compared five-year survival rates in blacks and whites. Results After adjustment for the severity of disease and other characteristics, blacks were 13 percent less likely than whites to undergo angioplasty and 32 percent less likely to undergo bypass surgery. The adjusted black:white odds ratios for receiving these procedures were 0.87 (95 percent confidence interval, 0.73 to 1.03) and 0.68 (95 percent confidence interval, 0.56 to 0.82), respectively. The racial differences in rates of bypass surgery persisted among those with severe anginal symptoms (31 percent of blacks underwent surgery, vs. 45 percent of whites; P<0.001) and among those predicted to have the greatest survival benefit from revascularization (42 percent vs. 61 percent, P<0.001). Finally, unadjusted and adjusted rates of survival for five years were significantly lower in blacks than in whites. Conclusions Blacks with coronary disease were significantly less likely than whites to undergo coronary revascularization, particularly bypass surgery - a difference that could not be explained by the clinical features of their disease. The differences in treatment were most pronounced among those predicted to benefit the most from revascularization. Since these differences also correlated with a lower survival rate in blacks, we conclude that coronary revascularization appears to be underused in blacks. (C)1997, Massachusetts Medical Society.	DUKE UNIV,MED CTR,DEPT COMMUNITY & FAMILY MED,DIV BIOMETRY,DURHAM,NC 27710	Duke University	Peterson, ED (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,BOX 3236,DURHAM,NC 27710, USA.		Peterson, Eric David/ABF-5033-2021	Mark, Daniel/0000-0001-6340-8087	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670] Funding Source: NIH RePORTER; AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-17670] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; CALDWELL SH, 1995, ANN INTERN MED, V122, P614, DOI 10.7326/0003-4819-122-8-199504150-00010; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MCBEAN AM, 1994, AM HEART J, V127, P287, DOI 10.1016/0002-8703(94)90115-5; MIRVIS DM, 1994, J AM COLL CARDIOL, V24, P1297, DOI 10.1016/0735-1097(94)90112-0; OKELO SO, 1995, CIRCULATION S1, V92, P437; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1989, J AM COLL CARDIOL, V14, P1016, DOI 10.1016/0735-1097(89)90484-1; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; Schecter AD, 1996, AM J CARDIOL, V78, P996, DOI 10.1016/S0002-9149(96)00523-1; SMITH LR, 1991, CIRCULATION, V84, P245; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; TRASK N, 1984, J AM COLL CARDIOL, V3, P1145, DOI 10.1016/S0735-1097(84)80171-0; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; White E H, 1977, Nurs Clin North Am, V12, P27; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson-Ford V, 1992, Health Soc Work, V17, P28; Yusuf, 1994, LANCET, V344, P1446; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	35	438	438	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					480	486		10.1056/NEJM199702133360706	http://dx.doi.org/10.1056/NEJM199702133360706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017942				2022-12-28	WOS:A1997WG77600006
J	Stern, RC				Stern, RC			Current concepts - The diagnosis of cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSMEMBRANE CONDUCTANCE REGULATOR; EXOCRINE PANCREATIC FUNCTION; POTENTIAL DIFFERENCE; LUNG-DISEASE; RESPIRATORY EPITHELIA; GENE-TRANSFER; INFLAMMATION; AMILORIDE; MUTATIONS; INFANTS		CASE WESTERN RESERVE UNIV, DEPT PEDIAT, CLEVELAND, OH 44106 USA; LEROY W MATTHEWS CYST FIBROSIS CTR, CLEVELAND, OH 44106 USA	Case Western Reserve University	Stern, RC (corresponding author), UNIV HOSP CLEVELAND, RAINBOW BABIES & CHILDRENS HOSP, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NIDDK NIH HHS [P30DK 27651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAN SH, 1991, J PEDIATR-US, V119, P211, DOI 10.1016/S0022-3476(05)80729-2; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; ARMSTRONG DS, 1995, BRIT MED J, V310, P1571, DOI 10.1136/bmj.310.6994.1571; Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K; BARASCH J, 1993, J CELL SCI, P229; BARBERO GJ, 1966, AM J DIS CHILD, V112, P536, DOI 10.1001/archpedi.1966.02090150080005; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; BIRNKRANT DJ, 1991, AM J ASTHMA ALLERGY, V4, P194; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVIS PB, 1980, AM J MED, V69, P643, DOI 10.1016/0002-9343(80)90482-9; DELMARCO A, 1996, ISR J MED SCI S32, V32, pS183; DORK T, 1991, HUM GENET, V87, P441; Dumur V, 1996, HUM GENET, V97, P7; GHARIB R, 1964, AM J DIS CHILD, V108, P499, DOI 10.1001/archpedi.1964.02090010501009; GRAHAM A, 1993, EUR RESPIR J, V6, P1243; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; LANKISCH PG, 1982, GUT, V23, P777, DOI 10.1136/gut.23.9.777; NOUSIAARVANITAKIS S, 1978, J PEDIATR-US, V92, P734, DOI 10.1016/S0022-3476(78)80139-5; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSENSTEIN BJ, 1990, J RESPIR DIS, V11, P519; SAUDER RA, 1987, J PEDIATR-US, V111, P353, DOI 10.1016/S0022-3476(87)80453-5; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHWACHMAN H, 1975, PEDIATRICS, V55, P86; SILVERMAN BL, 1985, J PEDIATR-US, V106, P953, DOI 10.1016/S0022-3476(85)80250-X; STERN RC, 1995, LANCET, V346, P274, DOI 10.1016/S0140-6736(95)92165-6; STERN RC, 1986, J PEDIATR GASTR NUTR, V5, P35, DOI 10.1097/00005176-198601000-00007; STERN RC, 1978, JAMA-J AM MED ASSOC, V239, P2676, DOI 10.1001/jama.239.25.2676; STERN RC, 1982, LANCET, V1, P1401; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	40	190	194	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					487	491		10.1056/NEJM199702133360707	http://dx.doi.org/10.1056/NEJM199702133360707			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017943				2022-12-28	WOS:A1997WG77600007
J	Palmer, JD				Palmer, JD			Organelle genomes: Going, going, gone!	SCIENCE			English	Editorial Material							GIARDIA-LAMBLIA; MITOCHONDRIA; PROTEINS; HYDROGENOSOMES; CHLOROPLASTS; ANTIBODIES; EVOLUTION; PROTOZOA				Palmer, JD (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.		Palmer, Jeffrey/P-6747-2014	Palmer, Jeffrey/0000-0002-4626-2220				Bozner P, 1996, J PARASITOL, V82, P103, DOI 10.2307/3284124; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; Edlind TD, 1996, MOL PHYLOGENET EVOL, V5, P359; EMBLEY TM, 1995, P ROY SOC B-BIOL SCI, V262, P87, DOI 10.1098/rspb.1995.0180; FENCHEL T, 1995, OXFORD SERIES ECOLOG, P1; FINLAY BJ, 1989, FEMS MICROBIOL LETT, V65, P311; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; GOCKEL G, 1994, CURR GENET, V26, P256, DOI 10.1007/BF00309557; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; JOHNSON PH, UNPUB; Keeling PJ, 1996, MOL BIOL EVOL, V13, P1297, DOI 10.1093/oxfordjournals.molbev.a025576; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; MARVINSIKKEMA FD, 1993, EUR J CELL BIOL, V61, P86; MCFADDEN G, 1995, TRENDS ECOL EVOL, V10, P12, DOI 10.1016/S0169-5347(00)88954-5; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; Muller M., 1980, The eukaryotic microbial cell.  (30th Symp. Soc. Gen. Microbiol., Univ. Cambridge, March 1980)., P127; MULLER M, IN PRESS PARASITOL T; Palmer JD, 1996, P NATL ACAD SCI USA, V93, P7432, DOI 10.1073/pnas.93.15.7432; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; REINER DS, 1992, INFECT IMMUN, V60, P5312, DOI 10.1128/IAI.60.12.5312-5315.1992; REITH M, 1995, ANNU REV PLANT PHYS, V46, P549, DOI 10.1146/annurev.arplant.46.1.549; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; SCHELGEL M, 1994, TRENDS ECOL EVOL, V9, P330; SOLTYS BJ, 1994, J PARASITOL, V80, P580, DOI 10.2307/3283195; vanderGiezen M, 1997, MOL MICROBIOL, V23, P11, DOI 10.1046/j.1365-2958.1997.1891553.x; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648	32	94	96	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 7	1997	275	5301					790	791		10.1126/science.275.5301.790	http://dx.doi.org/10.1126/science.275.5301.790			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG777	9036544				2022-12-28	WOS:A1997WG77700045
J	Malinin, NL; Boldin, MP; Kovalenko, AV; Wallach, D				Malinin, NL; Boldin, MP; Kovalenko, AV; Wallach, D			MAP3K-related kinase involved in NF-kappa B induction by TNF, CD95 and IL-1	NATURE			English	Article							PUTATIVE PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; SIGNAL TRANSDUCTION; DOMAIN; YEAST; STE11; GENE; ACTIVATION; ENCODES; FAMILY	Several members of the tumour-necrosis/nerve-growth factor (TNF/NGF) receptor family activate the transcription factor NF-kappa B through a common adaptor protein, Traf2 (refs 1-5), whereas the interleukin 1 type-I receptor activates NF-kappa B independently of Traf2 (ref. 4). We have now cloned a new protein kinase, NIK, which binds to Traf2 and stimulates NF-kappa B activity. This kinase shares sequence similarity with several MAPKK kinases. Expression in cells of kinase-deficient NIK mutants fails to stimulate NF-kappa B and blocks its induction by TNF, by either of the two TNF receptors or by the receptor CD95 (Fas/Apo-1), and by TRADD, RIP and MORT1/FADD, which are adaptor proteins that bind to these receptors. It also blocked NF-kappa B induction by interleukin-l. Our findings indicate that NIK participates in an NF-kappa B-inducing signalling cascade common to receptors of the TNF/NGF family and to the interleukin-1 type-I receptor.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Malinin, Nikolay/Z-5308-2019; Malinin, Nikolay/J-4271-2012	Malinin, Nikolay/0000-0002-2654-1783; Boldin, Mark/0000-0003-4593-0669				BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; HAHN T, 1985, P NATL ACAD SCI USA, V82, P3814, DOI 10.1073/pnas.82.11.3814; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STYRKARSDOTTIR U, 1992, MOL GEN GENET, V235, P122, DOI 10.1007/BF00286189; Wallach D, 1996, EUR CYTOKINE NETW, V7, P713; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	31	1148	1193	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 6	1997	385	6616					540	544		10.1038/385540a0	http://dx.doi.org/10.1038/385540a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WG235	9020361				2022-12-28	WOS:A1997WG23500049
J	Greenberger, NJ				Greenberger, NJ			Update in gastroenterology	ANNALS OF INTERNAL MEDICINE			English	Article											Greenberger, NJ (corresponding author), UNIV KANSAS, MED CTR, DEPT MED, 39TH ST & RAINBOW BLVD, KANSAS CITY, KS 66103 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					221	225		10.7326/0003-4819-126-3-199702010-00008	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027274				2022-12-28	WOS:A1997WF16800008
J	Pouchot, J; Grasland, A; Collet, C; Coste, J; Esdaile, JM; Vinceneux, P				Pouchot, J; Grasland, A; Collet, C; Coste, J; Esdaile, JM; Vinceneux, P			Reliability of tuberculin skin test measurement	ANNALS OF INTERNAL MEDICINE			English	Article							REACTION MANTOUX TEST; PEN METHOD; PALPATION	Background: Important management decisions depend on results of the tuberculin skin test. However, the test is subject to several potential errors, and its reliability has not been adequately studied. Objective: To ascertain the reliability of tuberculin skin testing. Design: Cross-sectional study. Setting: University hospital. Participants: 96 persons who received a tuberculin skin test. Measurements: Ballpoint-pen and palpation measures of induration. Results: Global intra- and interobserver reliability coefficients of the ballpoint-pen technique were high. Five percent of the time, however, a second measurement by the same observer could be at least 2.7 mm less to 3.0 mm more than the first measurement and the measurement from the second observer could be at least 3.4 mm less to 3.7 mm more than the measurement from the first observer. This could lead to the reclassification of a positive test result as negative or vice versa. The area of imprecision was 38% less broad for the ballpoint-pen technique than for the palpation technique. Conclusion: Reading of tuberculin skin tests may frequently result in misclassifications when measurements are close to the cutoff point that separates negative from positive results.	HOP COCHIN, DEPT BIOSTAT, F-75674 PARIS, FRANCE; UNIV BRITISH COLUMBIA, VANCOUVER HOSP, VANCOUVER, BC B5Z 1L7, CANADA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of British Columbia	Pouchot, J (corresponding author), HOP LOUIS MOURIER, SERV MED INTERNE 5, 178 RUE RENOUILLERS, F-92701 COLOMBES, FRANCE.							*AM THOR SOC, 1981, AM REV RESPIR DIS, V124, P356; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BEARMAN JE, 1964, AM REV RESPIR DIS, V90, P913; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BOUROS D, 1992, RESP MED, V86, P219, DOI 10.1016/S0954-6111(06)80059-4; BOUROS D, 1991, CHEST, V99, P416, DOI 10.1378/chest.99.2.416; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DECOCK KM, 1995, LANCET, V345, P833, DOI 10.1016/S0140-6736(95)92967-3; HOWARD TP, 1988, ARCH INTERN MED, V148, P2457, DOI 10.1001/archinte.148.11.2457; JORDAN TJ, 1987, CHEST, V92, P234, DOI 10.1378/chest.92.2.234; LOUDON RG, 1963, AM REV RESPIR DIS, V87, P852; Mantoux C., 1910, PRESSE MED, V18, P10; MEYER SN, 1951, PUBLIC HEALTH REP, V66, P561, DOI 10.2307/4587713; ORMEROD LP, 1992, BRIT MED J, V304, P1231; SAS Institute, 1990, SAS STAT US GUID VER, P893; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013	18	97	99	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					210	214		10.7326/0003-4819-126-3-199702010-00005	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027271				2022-12-28	WOS:A1997WF16800005
J	Folkner, WM; Preston, RA; Border, JS; Navarro, J; Wilson, WE; Oestreich, M				Folkner, WM; Preston, RA; Border, JS; Navarro, J; Wilson, WE; Oestreich, M			Earth-based radio tracking of the Galileo probe for Jupiter wind estimation	SCIENCE			English	Article							BALLOONS	Although the Galileo probe was designed to communicate only to the orbiter, the probe radio signal was detected at two Earth-based radio observatories where the signal was a billion times weaker. The measured signal frequency was used to derive a vertical profile of the jovian zonal wind speed, Due to the mission geometry, the Earth-based wind estimates are less sensitive to descent trajectory errors than estimates based on probe-orbiter Doppler measurements. The two estimates of wind profiles agree qualitatively; both show high wind speeds at all depths sampled.	NATL RADIO ASTRON OBSERV,SOCORRO,NM 87801; CSIRO,AUSTRALIA TELESCOPE NATL FACIL,EPPING,NSW 2121,AUSTRALIA	National Radio Astronomy Observatory (NRAO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Folkner, WM (corresponding author), CALTECH,JET PROP LAB,PASADENA,CA 91109, USA.							Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; ATKINSON DH, 1989, THESIS WASHINGTON ST; Beebe RF, 1996, SCIENCE, V272, P841, DOI 10.1126/science.272.5263.841; BUSSE FH, 1976, ICARUS, V29, P255, DOI 10.1016/0019-1035(76)90053-1; BUSSE FH, 1970, ASTROPHYS J, V159, P620; Counselman CC, 1980, J GEOPHYS RES-SPACE, V85, P8026, DOI 10.1029/JA085iA13p08026; GIERASCH PJ, 1976, ICARUS, V29, P445, DOI 10.1016/0019-1035(76)90064-6; INGERSOLL AP, 1982, ICARUS, V52, P62, DOI 10.1016/0019-1035(82)90169-5; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; Kerzhanovich V. V., 1983, Venus, P766; LIMAYE SS, 1986, ICARUS, V65, P335, DOI 10.1016/0019-1035(86)90142-9; LIMAYE SS, 1982, J ATMOS SCI, V39, P1413, DOI 10.1175/1520-0469(1982)039<1413:JWFVPI>2.0.CO;2; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; POLLACK JB, 1992, SPACE SCI REV, V60, P143, DOI 10.1007/BF00216853; PRESTON RA, 1986, SCIENCE, V231, P1414, DOI 10.1126/science.231.4744.1414; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; SAGDEYEV RZ, 1992, ASTRON ASTROPHYS, V254, P387; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; WOO R, COMMUNICATION; Zhang KK, 1996, SCIENCE, V273, P941, DOI 10.1126/science.273.5277.941	21	25	25	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					644	646		10.1126/science.275.5300.644	http://dx.doi.org/10.1126/science.275.5300.644			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005845				2022-12-28	WOS:A1997WF07700032
J	Greisman, HA; Pabo, CO				Greisman, HA; Pabo, CO			A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites	SCIENCE			English	Article							BINDING-SPECIFICITY; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; RECOGNITION; SEQUENCES; RULES; REVEALS; COMPLEX; DESIGN; PHAGE	A method is described for selecting DNA-binding proteins that recognize desired sequences. The protocol involves gradually extending a new zinc finger protein across the desired 9- or 10-base pair target site, adding and optimizing one finger at a time. This procedure was tested with a TATA box, a p53 binding site, and a nuclear receptor element, and proteins were obtained that bind with nanomolar dissociation constants and discriminate effectively (greater than 20,000-fold) against nonspecific DNA. This strategy may provide important information about protein-DNA recognition as well as powerful tools for biomedical research.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Wilson, Matthew H/K-3193-2013					BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CHENG C, 1995, J MOL BIOL, V251, P1, DOI 10.1006/jmbi.1995.0410; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1994, P NATL ACAD SCI USA, V91, P11099, DOI 10.1073/pnas.91.23.11099; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DESJARLAIS JR, 1992, PROTEINS, V13, P272; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; GREISMAN HA, 1997, THEIS MIT CAMBRIDGE; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NEKLUDOVA L, COMMUNICATION; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Rebar EJ, 1996, METHOD ENZYMOL, V267, P129; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; TAYLOR WE, 1995, BIOCHEMISTRY-US, V34, P3222, DOI 10.1021/bi00010a011; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; ZIFF EB, 1978, CELL, V15, P1463, DOI 10.1016/0092-8674(78)90070-3; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	35	314	416	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 31	1997	275	5300					657	661		10.1126/science.275.5300.657	http://dx.doi.org/10.1126/science.275.5300.657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF077	9005850				2022-12-28	WOS:A1997WF07700037
J	Garred, P; Madsen, HO; Balslev, U; Hofmann, B; Pedersen, C; Gerstoft, J; Svejgaard, A				Garred, P; Madsen, HO; Balslev, U; Hofmann, B; Pedersen, C; Gerstoft, J; Svejgaard, A			Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN GENE; NULL ALLELES; RECOGNITION; CD4; POLYMORPHISM; ASSOCIATION; ACTIVATION; MUTATIONS; FREQUENCY	Background Low serum concentrations of mannose-binding lectin (MBL) are associated with increased susceptibility to recurrent infection. Three variant alleles in the MBL gene (B, C, and D), cause low serum concentrations of the protein. We investigated whether variant alleles of MBL affect susceptibility to infection with HIV and progression of AIDS. Methods Between 1983 and 1986, all men who attended two clinics in Copenhagen for HIV screening were invited to take part in our study. We investigated the prevalence of variant alleles of MBL (detected by PCR) and assessed the prognostic value of these alleles and the corresponding serum MBL concentrations (measured by ELISA) in 96 homosexual men with HIV infection and in two control groups (123 healthy adults and 36 HIV-negative homosexual men at high risk of HIV infection because of their sexual behaviour). Follow-up was for up to 10 years. Findings Eight (8%) of the HIV-infected men were homozygous for the variant MBL alleles compared with one (0.8%) of the healthy controls (p=0.005) and none of the high-risk homosexual controls (p=0.05). We found no significant association between MBL genotype and time from first positive HIV test to progression of AIDS (p=0.8). However, in the 61 HIV-infected men who developed AIDS, the median survival time was significantly shorter after the AIDS diagnosis for men who were carriers of the variant alleles (both homozygous and heterozygous) than for men homozygous for the normal MBL allele (11 [IQR 4-21] vs 18 months [9-44], p=0.007). Among men who developed AIDS, there was a significant difference in survival time between those with serum MBL concentrations below the lower quartile, those within the IQR, and those above the upper quartile (p=0.02). Multivariate analysis showed that men who developed AIDS and had low serum concentrations had an increased rate of rapid independently of CD4 T-cell counts at AIDS diagnosis. Interpretation Our findings suggest that homozygous carriers of variant MBL alleles are at increased risk of HIV infection, either directly or indirectly because of increased susceptibility to coinfections. These alleles are also associated with a significantly shorter survival time after a diagnosis of AIDS.	RIGSHOSP, DEPT MED M, DK-2200 COPENHAGEN, DENMARK; HVIDOVRE UNIV HOSP, DEPT INFECT DIS, COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen; University of Copenhagen	Garred, P (corresponding author), RIGSHOSP, DEPT CLIN IMMUNOL, TISSUE TYPING LAB, SECT 7631, DK-2200 COPENHAGEN, DENMARK.		Madsen, Hans O/Q-2035-2015	Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				Bradbury J, 1996, LANCET, V348, P463, DOI 10.1016/S0140-6736(05)64540-0; CAMERON PU, 1990, HUM IMMUNOL, V29, P282, DOI 10.1016/0198-8859(90)90042-N; CAMERON PU, 1988, BRIT MED J, V296, P1627, DOI 10.1136/bmj.296.6637.1627; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; GARRED P, 1992, CLIN EXP IMMUNOL, V90, P517; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GARRED P, 1992, EUR J IMMUNOGENET, V19, P403, DOI 10.1111/j.1744-313X.1992.tb00083.x; GARREDD P, 1995, LANCET, V346, P1630; HAURUM JS, 1993, AIDS, V7, P1307, DOI 10.1097/00002030-199310000-00002; HENTGES F, 1992, CLIN EXP IMMUNOL, V88, P237, DOI 10.1111/j.1365-2249.1992.tb03067.x; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; NIELSEN SL, 1995, CLIN EXP IMMUNOL, V100, P219; ROBINSON WE, 1990, VIROLOGY, V175, P600, DOI 10.1016/0042-6822(90)90449-2; SADLON TA, 1994, IMMUNOL CELL BIOL, V72, P461, DOI 10.1038/icb.1994.70; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SENALDI G, 1995, J INFECTION, V31, P145, DOI 10.1016/S0163-4453(95)92185-0; SNOWDEN N, 1995, LANCET, V346, P1629, DOI 10.1016/S0140-6736(95)91963-5; STEEL CM, 1988, LANCET, V1, P1185; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; Sullivan BL, 1996, J IMMUNOL, V157, P1791; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; SVEJGAARD A, 1995, AIDS RES EC LEVEL, P288; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; VANEMMERIK LC, 1994, CLIN EXP IMMUNOL, V97, P411	36	323	344	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					236	240		10.1016/S0140-6736(96)08440-1	http://dx.doi.org/10.1016/S0140-6736(96)08440-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014910				2022-12-28	WOS:A1997WD90600010
J	Harrison, A; Dixon, J; New, B; Judge, K				Harrison, A; Dixon, J; New, B; Judge, K			Funding the NHS: Is the NHS sustainable?	BRITISH MEDICAL JOURNAL			English	Article								The survival of the NHS lies largely in the hands of government, and this article suggests steps that it should take to deal with pressures on the NHS in terms of funding, managing efficiency, and demands. Changes to the system of funding may be unfeasible, but management could be improved by research to allow greater understanding of the local effects of national policies. Alternatively health authorities could be given more freedom to manage funds, although this would have to be accompanied by stiff sanctions for those who failed. Demand could be contained by strengthening policies to ensure that new technologies are cost effective. The government could try to reduce demands arising from increased expectations by encouraging informed public debate about priorities and influencing the availability of private health care. All these efforts should be guided by the values underpinning the NHS, which should be debated and decided collectively and confirmed in a new charter for NHS's 50th anniversary in 1998.			Harrison, A (corresponding author), KINGS FUND,POLICY INST,LONDON W1M 0AN,ENGLAND.							BLOOR K, 1996, HLTH CARE UK 1995 96; *DEP HLTH, 1996, NAT HLTH SERV SERV A; *DEP HLTH NHS EX, 1996, PLANN PRIOR GUID NHS; *DEP HLTH NHS EX, 1996, EL9474 NHS EX; Dixon J, 1997, BRIT MED J, V314, P58, DOI 10.1136/bmj.314.7073.58; Dixon J, 1997, BMJ-BRIT MED J, V314, P216, DOI 10.1136/bmj.314.7075.216a; Harrison A, 1997, BRIT MED J, V314, P139, DOI 10.1136/bmj.314.7074.139; HARRISON AJ, 1994, HLTH CARE UK 1993 94, P25; *HEALTHC 2000, 1995, UK HLTH HEALTHC SERV; HOFFMEYER UK, 1994, FINANCING HLTH CARE; JONES A, 1995, HYPOTHECTED HLTH TAX; *NAT AUD OFF, 1996, HLTH NAT PROGR REP; Russell LB., 1986, IS PREVENTION BETTER; Sheldon TA, 1996, BRIT MED J, V313, P508; Stewart J., 1994, CITIZENS JURIES	15	12	12	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					296	298		10.1136/bmj.314.7076.296	http://dx.doi.org/10.1136/bmj.314.7076.296			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022498	Green Published			2022-12-28	WOS:A1997WE63300036
J	McCracken, S; Fong, N; Yankulov, K; Ballantyne, S; Pan, GH; Greenblatt, J; Patterson, SD; Wickens, M; Bentley, DL				McCracken, S; Fong, N; Yankulov, K; Ballantyne, S; Pan, GH; Greenblatt, J; Patterson, SD; Wickens, M; Bentley, DL			The C-terminal domain of RNA polymerase II couples mRNA processing to transcription	NATURE			English	Article							MAMMALIAN NUCLEI; GLOBIN GENE; POLYADENYLATION; INITIATION; PROTEIN; SITE; SUBUNIT; INVITRO; INTRON; SIGNAL	Messenger RNA is produced by RNA polymerase II (pol II) transcription, followed by processing of the primary transcript. Transcription, splicing, and cleavage-polyadenylation can occur independently in vitro, but we demonstrate here that these processes are intimately linked in vivo. We show that the carboxy-terminal domain (CTD) of the pol II large subunit is required for efficient RNA processing. Splicing, processing of the 3' end and termination of transcription downstream of the poly(A) site, are all inhibited by truncation of the CTD. We found that the cleavage-polyadenylation factors CPSF and CstF specifically bound to CTD affinity columns and copurified with pol II in a high-molecular-mass complex. Our demonstration of an association between the CTD and 3'-processing factors, considered together with reports of a similar interaction with splicing factors(1,2), suggests that an mRNA 'factory' exists which carries out coupled transcription, splicing and cleavage-polyadenylation of mRNA precursors.	AMGEN INST,TORONTO,ON M5G 2C1,CANADA; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320	University of Wisconsin System; University of Wisconsin Madison; University of Toronto; University of Toronto; Amgen				Yankulov, Krassimir/0000-0001-9440-9234; Bentley, David/0000-0002-8414-4647				BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; Blau J, 1996, MOL CELL BIOL, V16, P2044; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GREENLEAF AL, 1993, TRENDS BIOCHEM SCI, V18, P117, DOI 10.1016/0968-0004(93)90016-G; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; LIEBER A, 1989, NUCLEIC ACIDS RES, V17, P8485, DOI 10.1093/nar/17.21.8485; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; MIFFLIN RC, 1991, J BIOL CHEM, V266, P19593; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; Schul W, 1996, EMBO J, V15, P2883, DOI 10.1002/j.1460-2075.1996.tb00649.x; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SMALE ST, 1985, MOL CELL BIOL, V5, P5352; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEST ML, 1995, GENETICS, V140, P1223; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHANG GH, 1994, NATURE, V372, P809	30	735	745	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					357	361		10.1038/385357a0	http://dx.doi.org/10.1038/385357a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002523				2022-12-28	WOS:A1997WD91400055
J	Jessopp, L; Beck, I; Hollins, L; Shipman, C; Reynolds, M; Dale, J				Jessopp, L; Beck, I; Hollins, L; Shipman, C; Reynolds, M; Dale, J			Changing the pattern out of hours: A survey of general practice cooperatives	BRITISH MEDICAL JOURNAL			English	Article							CARE		MAIDDOC,NATL ASSOC GEN PRACTICE COOPERAT,AYLESFORD ME20 7SE,KENT,ENGLAND		Jessopp, L (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,LAMBETH SOUTHWARK & LEWISHAM OUT HOURS PROJECT,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553				Court BV, 1996, BRIT MED J, V312, P1401; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; Hallam L, 1996, BRIT MED J, V312, P1402; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; REYNOLDS M, 1995, GUIDANCE NATL ASS GP, P6	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					199	200		10.1136/bmj.314.7075.199	http://dx.doi.org/10.1136/bmj.314.7075.199			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022438	Green Published			2022-12-28	WOS:A1997WD91100033
J	Roll, C; Luboldt, HJ; Winter, A; Volt, T; Erhard, J				Roll, C; Luboldt, HJ; Winter, A; Volt, T; Erhard, J			Hepatoblastoma in a 2-year-old child of a liver-transplanted mother	LANCET			English	Article							RECIPIENTS		UNIV HOSP,DEPT UROL,D-45122 ESSEN,GERMANY; UNIV HOSP,DEPT SURG,D-45122 ESSEN,GERMANY	University of Duisburg Essen; University of Duisburg Essen	Roll, C (corresponding author), UNIV HOSP,DEPT PAEDIAT,D-45122 ESSEN,GERMANY.							Luboldt HJ, 1996, CANCER RES, V56, P826; RADOMSKI JS, 1995, TRANSPLANT P, V27, P1089; VILLE Y, 1993, AM J OBSTET GYNECOL, V168, P896, DOI 10.1016/S0002-9378(12)90841-8	3	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					103	103		10.1016/S0140-6736(05)60887-2	http://dx.doi.org/10.1016/S0140-6736(05)60887-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996429				2022-12-28	WOS:A1997WB80000021
J	Kalmijn, S; Feskens, EJM; Launer, LJ; Kromhout, D				Kalmijn, S; Feskens, EJM; Launer, LJ; Kromhout, D			Longitudinal study of the effect of apolipoprotein e4 allele on the association between education and cognitive decline in elderly men	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE				Kalmijn, S (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,NL-3720 BA BILTHOVEN,NETHERLANDS.		Kromhout, Daan/A-8566-2014; Feskens, Edith/ABI-1446-2020; Feskens, Edith JM/A-3757-2012	Feskens, Edith/0000-0001-5819-2488; 				FESKENS EJM, 1994, BRIT MED J, V309, P1202, DOI 10.1136/bmj.309.6963.1202; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; SWAAB DF, 1991, NEUROBIOL AGING, V12, P317, DOI 10.1016/0197-4580(91)90008-8; WHITE L, 1994, J CLIN EPIDEMIOL, V47, P363, DOI 10.1016/0895-4356(94)90157-0	5	17	18	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 4	1997	314	7073					34	35		10.1136/bmj.314.7073.34	http://dx.doi.org/10.1136/bmj.314.7073.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB684	9001477	Green Published			2022-12-28	WOS:A1997WB68400022
J	Black, RA; Rauch, CT; Kozlosky, CJ; Peschon, JJ; Slack, JL; Wolfson, MF; Castner, BJ; Stocking, KL; Reddy, P; Srinivasan, S; Nelson, N; Boiani, N; Schooley, KA; Gerhart, M; Davis, R; Fitzner, JN; Johnson, RS; Paxton, RJ; March, CJ; Cerretti, DP				Black, RA; Rauch, CT; Kozlosky, CJ; Peschon, JJ; Slack, JL; Wolfson, MF; Castner, BJ; Stocking, KL; Reddy, P; Srinivasan, S; Nelson, N; Boiani, N; Schooley, KA; Gerhart, M; Davis, R; Fitzner, JN; Johnson, RS; Paxton, RJ; March, CJ; Cerretti, DP			A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells	NATURE			English	Article							MOLECULAR-CLONING; SURFACE; PROTEIN; INHIBITOR; PRECURSOR; RECEPTOR; FUSION; TNF	Mammalian cells proteolytically release (shed) the extracellular domains of many cell-surface proteins(1). Modification of the cell surface in this way can alter the cell's responsiveness to its environment(2) and release potent soluble regulatory factors'. The release of soluble tumour-necrosis factor-alpha (TNF-alpha) from its membrane-bound precursor(4,5) is one of the most intensively studied shedding events because this inflammatory cytokine is so physiologically important(6,7). The inhibition of TNF-alpha release (and many other shedding phenomena) by hydroxamic acid-based inhibitors indicates that one or more metalloproteinases is involved(3,8,9). We have now purified and cloned a metalloproteinase that specifically cleaves precursor TNF-alpha. Inactivation of the gene in mouse cells caused a marked decrease in soluble TNF-alpha production. This enzyme (called the TNF-alpha-converting enzyme, or TACE) is a new member of the family of mammalian adamalysins (or ADAMs)(10), for which no physiological catalytic function has previously been identified. Our results should facilitate the development of therapeutically useful inhibitors of TNF-alpha release, and they indicate that an important function of adamalysins may be to shed cell-surface proteins.			Black, RA (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DECKER T, 1987, J IMMUNOL, V138, P957; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LIBBY P, 1986, J CLIN INVEST, V77, P127, DOI 10.1172/JCI112266; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; STOCKER W, 1995, PROTEIN SCI, V4, P823; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; WARNER SJC, 1989, J IMMUNOL, V142, P100; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	30	2551	2651	6	104	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 20	1997	385	6618					729	733		10.1038/385729a0	http://dx.doi.org/10.1038/385729a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ423	9034190				2022-12-28	WOS:A1997WJ42300048
J	Rampino, N; Yamamoto, H; Ionov, Y; Li, Y; Sawai, H; Reed, JC; Perucho, M				Rampino, N; Yamamoto, H; Ionov, Y; Li, Y; Sawai, H; Reed, JC; Perucho, M			Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype	SCIENCE			English	Article							REPEATED SEQUENCES REVEAL; TUMOR-SUPPRESSOR P53; CELL-DEATH; COLORECTAL TUMORIGENESIS; BINDING-PROTEIN; DNA-DAMAGE; INSTABILITY; RECEPTOR; EXPRESSION; MECHANISM	Cancers of the microsatellite mutator phenotype (MMP) show exaggerated genomic instability at simple repeat sequences. More than 50 percent (21 out of 41) of human MMP(+) colon adenocarcinomas examined were found to have frameshift mutations in a tract of eight deoxyguanosines [(G)(8)] within BAX, a gene that promotes apoptosis. These mutations were absent in MMP tumors and were significantly less frequent in (G), repeats from other genes. Frameshift mutations were present in both BAX alleles in some MMP(+) colon tumor cell lines and in primary tumors. These results suggest that inactivating BAX mutations are selected for during the progression of colorectal MMP(+) tumors and that the wild-type BAX gene plays a suppressor role in a p53-independent pathway for colorectal carcinogenesis.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Perucho, Manuel/0000-0002-2169-2662	NATIONAL CANCER INSTITUTE [R37CA063585, R01CA063585, R01CA038579] Funding Source: NIH RePORTER; NCI NIH HHS [CA63585, CA38579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Casares S, 1995, ONCOGENE, V11, P2303; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM HG, 1994, AM J PATHOL, V145, P148; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krajewski S, 1996, ANAL BIOCHEM, V236, P221, DOI 10.1006/abio.1996.0160; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOEB LA, 1994, CANCER RES, V54, P5059; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	34	1170	1201	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					967	969		10.1126/science.275.5302.967	http://dx.doi.org/10.1126/science.275.5302.967			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020077				2022-12-28	WOS:A1997WH38800042
J	Young, JL; Cooke, AR				Young, JL; Cooke, AR			Intussusception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Young, JL (corresponding author), UNIV KANSAS,MED CTR,KANSAS CITY,KS 66160, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 13	1997	336	7					479	479		10.1056/NEJM199702133360705	http://dx.doi.org/10.1056/NEJM199702133360705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG776	9017941				2022-12-28	WOS:A1997WG77600005
J	Gottlieb, A				Gottlieb, A			Safety of minocycline for acne	LANCET			English	Editorial Material											Gottlieb, A (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DIV DERMATOL,NEW BRUNSWICK,NJ 08901, USA.							Gough A, 1996, BRIT MED J, V312, P169; Knowles SR, 1996, ARCH DERMATOL, V132, P934, DOI 10.1001/archderm.132.8.934; MIN DI, 1992, PHARMACOTHERAPY, V12, P66	3	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					374	374		10.1016/S0140-6736(97)80006-2	http://dx.doi.org/10.1016/S0140-6736(97)80006-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033461				2022-12-28	WOS:A1997WH29600006
J	Lainhart, JE				Lainhart, JE			Developmental abnormalities in autism	LANCET			English	Editorial Material											Lainhart, JE (corresponding author), UNIV UTAH,INST NEUROPSYCHIAT,SALT LAKE CITY,UT 84108, USA.							BACHEVALIER J, 1994, NEUROPSYCHOLOGIA, V32, P627, DOI 10.1016/0028-3932(94)90025-6; Bauman ML, 1996, J AUTISM DEV DISORD, V26, P199, DOI 10.1007/BF02172012; Chugani HT, 1996, ANN NEUROL, V39, P643, DOI 10.1002/ana.410390514; Dawson G, 1996, J AUTISM DEV DISORD, V26, P179, DOI 10.1007/BF02172008; Piven J, 1996, J AM ACAD CHILD PSY, V35, P530, DOI 10.1097/00004583-199604000-00020; REISS AL, 1994, NEUROLOGY, V44, P1317, DOI 10.1212/WNL.44.7.1317; ZILBOVICIUS M, 1995, AM J PSYCHIAT, V152, P248	7	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					373	374		10.1016/S0140-6736(97)80005-0	http://dx.doi.org/10.1016/S0140-6736(97)80005-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WH296	9033460				2022-12-28	WOS:A1997WH29600005
J	Ronkainen, A; Hernesniemi, J; Puranen, M; Niemitukia, L; Vanninen, R; Ryynanen, M; Kuivaniemi, H; Tromp, G				Ronkainen, A; Hernesniemi, J; Puranen, M; Niemitukia, L; Vanninen, R; Ryynanen, M; Kuivaniemi, H; Tromp, G			Familial intracranial aneurysms	LANCET			English	Article							MAGNETIC-RESONANCE ANGIOGRAPHY; UNRUPTURED CEREBRAL ANEURYSMS; POLYCYSTIC KIDNEY-DISEASE; SUBARACHNOID HEMORRHAGE; CEREBROVASCULAR-DISEASE; UNKNOWN ETIOLOGY; NATURAL-HISTORY; SURGERY; RISK; IMPACT	Background We set out to determine the prevalence of incidental intracranial aneurysms in first-degree relatives aged 30 years or more of people with intracranial aneurysms, and to see if polycystic kidney disease contributes to the aggregation of familial intracranial aneurysms. Methods 91 families with two or more affected members had previously been identified from a 14 year series of 1150 intracranial aneurysm patients treated at the University Hospital of Kuopio, Finland. Magnetic resonance angiography was used as a preliminary screening method, followed by conventional four-vessel angiography to verify suspected aneurysms. Participants were also screened for polycystic kidneys by ultrasonography. Findings Incidental aneurysms were detected in 40 individuals: 38 of 438 individuals from 85 families without polycystic kidney disease or other diagnosed heritable disorders, and two of 22 individuals from six families known to have polycystic kidney disease. The crude and age-adjusted prevalence of incidental intracranial aneurysms among screened first-degree relatives was 8.7 (SE 1.3)% (95% CI 6.2-11.7) and 9.1(1.4)% (6.2-11.7), respectively, for the familial group and the crude prevalence for the polycystic kidney group was 9.1 (6.1)% (1.1-29.2). Interpretation Our results demonstrate a high prevalence of incidental intracranial aneurysms among first-degree relatives aged 30 years or older of patients with the condition and indicate that the risk of having an aneurysm is about four times higher for a close relative than for someone from the general population. Also, polycystic kidney disease families are a small fraction of the familial intracranial aneurysm families.	KUOPIO UNIV HOSP,DEPT CLIN RADIOL,KUOPIO 70210,FINLAND; KUOPIO UNIV HOSP,DEPT OBSTET & GYNAECOL,KUOPIO 70210,FINLAND; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Wayne State University	Ronkainen, A (corresponding author), KUOPIO UNIV HOSP,DEPT NEUROSURG,PL 1777,KUOPIO 70210,FINLAND.		Tromp, Gerard/B-2677-2017; Kuivaniemi, Helena/Q-8178-2019	Tromp, Gerard/0000-0002-7761-0806; Kuivaniemi, Helena/0000-0001-5753-8766				ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z; ATLAS SW, 1994, RADIOLOGY, V193, P1; Awad Issam A., 1992, Neurological Research, V14, P360; CHALOUPKA JC, 1995, CLIN PLAST SURG, V22, P417; CHAPMAN AB, 1993, AM J KIDNEY DIS, V22, P526, DOI 10.1016/S0272-6386(12)80924-3; Donner T R, 1994, J La State Med Soc, V146, P54; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HARBAUGH RE, 1992, J NEUROSURG, V76, P408, DOI 10.3171/jns.1992.76.3.0408; HERNESNIEMI J, 1993, ACTA NEUROCHIR, V122, P1, DOI 10.1007/BF01446980; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; KING JT, 1994, J NEUROSURG, V81, P837, DOI 10.3171/jns.1994.81.6.0837; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; LOZANO AM, 1987, J NEUROSURG, V66, P522, DOI 10.3171/jns.1987.66.4.0522; LOZANO AM, 1992, CAN J NEUROL SCI, V19, P222, DOI 10.1017/S031716710004230X; MEYER FB, 1995, MAYO CLIN PROC, V70, P153, DOI 10.4065/70.2.153; NAKAGAWA T, 1994, J NEUROSURG, V80, P217, DOI 10.3171/jns.1994.80.2.0217; NORRGARD O, 1987, NEUROSURGERY, V20, P236, DOI 10.1227/00006123-198702000-00006; RONKAINEN A, 1995, RADIOLOGY, V195, P35, DOI 10.1148/radiology.195.1.7892491; RONKAINEN A, 1992, ACTA NEUROCHIR, V119, P29, DOI 10.1007/BF01541778; RONKAINEN A, 1995, NEUROSURGERY, V37, P43, DOI 10.1227/00006123-199507000-00006; RONKAINEN A, 1994, NEUROSURGERY, V35, P208, DOI 10.1227/00006123-199408000-00005; RONKAINEN A, 1993, NEUROSURGERY, V33, P787; SCHIEVINK WI, 1994, STROKE, V25, P2028, DOI 10.1161/01.STR.25.10.2028; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; Vanninen RL, 1996, NEUROSURGERY, V38, P838, DOI 10.1227/00006123-199604000-00041; WARNOCK NG, 1993, BRIT J RADIOL, V66, P855, DOI 10.1259/0007-1285-66-790-855; WEIR B, 1985, NEUROSURGERY, P1308; WIEBERS DO, 1992, STROKE, V23, P1416, DOI 10.1161/01.STR.23.10.1416	30	189	197	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					380	384		10.1016/S0140-6736(97)80009-8	http://dx.doi.org/10.1016/S0140-6736(97)80009-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033463				2022-12-28	WOS:A1997WH29600009
J	Simioni, P; Prandoni, P; Lensing, AWA; Scudeller, A; Sardella, C; Prins, MH; Villalta, S; Dazzi, F; Girolami, A				Simioni, P; Prandoni, P; Lensing, AWA; Scudeller, A; Sardella, C; Prins, MH; Villalta, S; Dazzi, F; Girolami, A			The risk of recurrent venous thromboembolism in patients with an Arg(506)->Gln mutation in the gene for factor V (factor V Leiden)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; DEEP-VEIN THROMBOSIS; POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; RESISTANCE; DIAGNOSIS; THROMBOPHILIA	Background A recently discovered mutation in coagulation factor V (Arg(506)-->Gln, referred to as factor V Leiden), which results in resistance to activated protein C, is found in approximately one fifth of patients with venous thromboembolism. However, the risk of recurrent thromboembolism in heterozygous carriers of this genetic abnormality is unknown. Methods We searched for factor V Leiden in 251 unselected patients with a first episode of symptomatic deep-vein thrombosis diagnosed by venography. The patients were followed prospectively for a mean of 3.9 years to determine the frequency of recurrent venous thrombosis and pulmonary embolism. Results Factor V Leiden was found in 41 of the patients (16.3 percent; 95 percent confidence interval, 11.8 to 20.9 percent). The cumulative incidence of recurrent venous thromboembolism after follow-up of up to eight years was 39.7 percent (95 percent confidence interval, 22.8 to 56.5 percent) among carriers of the mutation, as compared with 18.3 percent (95 percent confidence interval, 12.3 to 24.3 percent) among patients without the mutation (hazard ratio, 2.4; 95 percent confidence interval, 1.3 to 4.5; P<0.01). Conclusions The risk of recurrent thromboembolic events is significantly higher in carriers of factor V Leiden than in patients without this abnormality. Large trials assessing the risk-benefit ratio of long-term anticoagulation in carriers of the mutation who have had a first episode of venous thromboembolism are indicated. (C) 1997, Massachusetts Medical Society.	UNIV AMSTERDAM, ACAD MED CTR, CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV HOSP PADUA, INST MED SEMEIOT, PADUA, ITALY; UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL, NL-1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Amsterdam; Academic Medical Center Amsterdam			SIMIONI, PAOLO/AAC-5438-2022; Dazzi, Francesco/ABD-6171-2021; Simioni, Paolo/AAC-5416-2022	SIMIONI, PAOLO/0000-0002-6744-383X; Dazzi, Francesco/0000-0003-2407-236X; 				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GIROLAMI A, 1993, BRIT J HAEMATOL, V85, P521; GRIFFIN JH, 1993, BLOOD, V82, P1989; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1993, HEMOSTASIS THROMBOSI, P1322; HUISMAN MV, 1988, ARCH INTERN MED, V148, P681, DOI 10.1001/archinte.148.3.681; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LENSING AWA, 1992, THROMB HAEMOSTASIS, V68, P245; LENSING AWA, 1993, HEMOSTASIS THROMBOSI, P1297; PABINGER I, 1992, BLOOD COAGUL FIBRIN, V3, P547, DOI 10.1097/00001721-199210000-00005; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TRIPLETT DA, 1995, THROMB RES, V78, P1, DOI 10.1016/0049-3848(95)00001-1; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	22	323	327	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					399	403		10.1056/NEJM199702063360602	http://dx.doi.org/10.1056/NEJM199702063360602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010145	Green Published, Bronze			2022-12-28	WOS:A1997WF85900002
J	LaCombe, MA				LaCombe, MA			On bedside teaching	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL DIAGNOSIS; ACCURACY; HISTORY	Actual teaching at the bedside during attending rounds, with emphasis on history taking and physical diagnosis, has declined from an incidence of 75% in the 1960s to an incidence of less than 16% today. Profound advances in technology, in imaging, and in laboratory testing and our fascination for these aspects of patient care, account for part of this decline, but faculty must also assume responsibility for the present lack of bedside teaching. If we are to reverse this trend, we will need to realize the barriers to bedside teaching, both real and imagined, and overcome them. And if we are to become effective bedside teachers, as were our mentors, we will need to sharpen our own physical diagnostic skills. We will need to learn how to be gentle with students and housestaff, how to better communicate with patients, and how to teach ethics and professionalism with the patient at hand.										CHIMOWITZ MI, 1990, ANN NEUROL, V28, P78, DOI 10.1002/ana.410280114; COLLINS GF, 1978, J MED EDUC, V53, P429; COPE Z, 1979, COPES EARLY DIAGNOSI; DEGOWIN EL, 1993, DEGOWIN DEGOWINS BED; Duus P, 1989, TOPICAL DIAGNOSIS NE; FITZGERALD FT, 1990, WESTERN J MED, V152, P377; GRADY MJ, 1990, AM J MED, V88, P519, DOI 10.1016/0002-9343(90)90432-D; LEHRER S, 1993, UNDERSTANDING LUND S; MANGIONE S, 1994, J GEN INTERN MED, V9, P213, DOI 10.1007/BF02600127; MANGIONE S, 1993, ANN INTERN MED, V119, P47, DOI 10.7326/0003-4819-119-1-199307010-00009; Marriott HJL., 1993, BEDSIDE CARDIAC DIAG; MEIDL EJ, 1993, J GEN INTERN MED, V8, P635, DOI 10.1007/BF02599724; PERLOFF JK, 1990, PHYSICAL EXAMINATION; PETERSON MC, 1992, WESTERN J MED, V156, P163; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; REICHSMAN F, 1964, J Med Educ, V39, P147; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SAMMAN PD, 1965, NAILS DIS; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCHNEIDERMAN H, 1992, BEDSIDE DIAGNOSIS AN; SCHROEDER S A, 1988, Journal of General Internal Medicine, V3, pS5, DOI 10.1007/BF02600247; SIEGLER M, 1978, JAMA-J AM MED ASSOC, V239, P951, DOI 10.1001/jama.239.10.951	22	161	169	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1997	126	3					217	220		10.7326/0003-4819-126-3-199702010-00007	http://dx.doi.org/10.7326/0003-4819-126-3-199702010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF168	9027273				2022-12-28	WOS:A1997WF16800007
J	Ganesan, V; Kirkham, FJ				Ganesan, V; Kirkham, FJ			Lesson of the week - Carotid dissection causing stroke in a child with migraine	BRITISH MEDICAL JOURNAL			English	Article							RISK; ARTERIES				Ganesan, V (corresponding author), INST CHILD HLTH,WOLFSON CTR,NEUROSCI UNIT,LONDON WC1N 2AP,ENGLAND.		Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958				BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012; DANGLEJANCHATILLON J, 1989, HEADACHE, V29, P560, DOI 10.1111/j.1526-4610.1989.hed2909560.x; SCHIEVINK WI, 1994, NEUROLOGY, V44, P1607, DOI 10.1212/WNL.44.9.1607; STURZENEGGER M, 1995, J NEUROL, V242, P231, DOI 10.1007/BF00919596; TZOURIO C, 1995, BMJ-BRIT MED J, V310, P830, DOI 10.1136/bmj.310.6983.830; WELCH KMA, 1994, NEUROLOGY S7, V4, pD33	6	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					291	292		10.1136/bmj.314.7076.291	http://dx.doi.org/10.1136/bmj.314.7076.291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE633	9022496	Green Published			2022-12-28	WOS:A1997WE63300033
J	Touze, JE; Perret, JL; Nicolas, X; Fourcade, L; Bernard, J; Keundjian, A; Soares, JM; Doury, JC				Touze, JE; Perret, JL; Nicolas, X; Fourcade, L; Bernard, J; Keundjian, A; Soares, JM; Doury, JC			Efficacy of low dose halofantrine for second treatment of uncomplicated falciparum malaria	LANCET			English	Article									LARREYS HOSP,TOULOUSE,FRANCE		Touze, JE (corresponding author), TROP MED INST FRENCH ARMY,LE PHARO,F-13998 MARSEILLE,FRANCE.							COULAUD JP, 1986, T ROY SOC TROP MED H, V80, P615, DOI 10.1016/0035-9203(86)90158-6; KARBWANG J, 1991, BRIT J CLIN PHARMACO, V31, P484, DOI 10.1111/j.1365-2125.1991.tb05567.x; Matson PA, 1996, AM J TROP MED HYG, V54, P229, DOI 10.4269/ajtmh.1996.54.229; NOSTEN F, 1993, LANCET, V341, P1054, DOI 10.1016/0140-6736(93)92412-M; Touze JE, 1996, AM J TROP MED HYG, V54, P225, DOI 10.4269/ajtmh.1996.54.225	5	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					255	256		10.1016/S0140-6736(05)64867-2	http://dx.doi.org/10.1016/S0140-6736(05)64867-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014922				2022-12-28	WOS:A1997WD90600022
J	Penmetsa, RV; Cook, DR				Penmetsa, RV; Cook, DR			A legume ethylene-insensitive mutant hyperinfected by its rhizobial symbiont	SCIENCE			English	Article							L CV SPARKLE; ARABIDOPSIS-THALIANA; INHIBITOR AMINOETHOXYVINYLGLYCINE; SIGNAL-TRANSDUCTION; NODULE FORMATION; PLANT DEFENSE; NODULATION; MELILOTI; ALFALFA; MUTATION	Development of the Rhizobium-legume symbiosis is controlled by the host plant, although the underlying mechanisms have remained obscure. A mutant in the annual legume Medicago truncatula exhibits an increase of more than an order of magnitude in the number of persistent rhizobial infections. Physiological and genetic analyses indicate that this same mutation confers insensitivity to the plant hormone ethylene for multiple aspects of plant development, including nodulation. These data support the hypothesis that ethylene is a component of the signaling pathway controlling rhizobial infection of legumes.	TEXAS A&M UNIV,DEPT PLANT PATHOL & MICROBIOL,CROP BIOTECHNOL CTR,COLLEGE STN,TX 77843; TEXAS A&M UNIV,GRAD PROGRAM GENET,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station								BENT AF, 1992, MOL PLANT MICROBE IN, V5, P372, DOI 10.1094/MPMI-5-372; BHUVANESWARI TV, 1981, PLANT PHYSIOL, V68, P1144, DOI 10.1104/pp.68.5.1144; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BOIVIN C, 1990, PLANT CELL, V2, P1157, DOI 10.1105/tpc.2.12.1157; CAETANOANOLLES G, 1988, PLANTA, V175, P546, DOI 10.1007/BF00393078; CAETANOANOLLES G, 1992, J PLANT PHYSL, V138, P765; CARROLL BJ, 1985, P NATL ACAD SCI USA, V82, P4162, DOI 10.1073/pnas.82.12.4162; CARROLL BJ, 1985, PLANT PHYSIOL, V78, P34, DOI 10.1104/pp.78.1.34; CHANG C, 1995, P NATL ACAD SCI USA, V92, P4129, DOI 10.1073/pnas.92.10.4129; CHAUBET N, 1992, J MOL BIOL, V225, P569, DOI 10.1016/0022-2836(92)90943-E; DEBILLY F, 1991, PLANT J, V1, P27, DOI 10.1111/j.1365-313X.1991.00027.x; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FEAM JC, 1991, PLANT PHYSIOL, V96, P239; GUINEL FC, 1991, PLANT PHYSIOL, V97, P1206, DOI 10.1104/pp.97.3.1206; GUINEL FC, 1992, PLANT PHYSIOL, V99, P515, DOI 10.1104/pp.99.2.515; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; KNIGHT LI, 1910, SCIENCE, V31, P635; LANAHAN MB, 1994, PLANT CELL, V6, P521, DOI 10.1105/tpc.6.4.521; Lawton K, 1995, MOL PLANT MICROBE IN, V8, P863, DOI 10.1094/MPMI-8-0863; LEE KH, 1992, PLANT PHYSIOL, V100, P1759, DOI 10.1104/pp.100.4.1759; LEE KH, 1992, PLANT PHYSIOL, V100, P1334, DOI 10.1104/pp.100.3.1334; LEONG SA, 1985, NUCLEIC ACIDS RES, V13, P5965, DOI 10.1093/nar/13.16.5965; LIGERO F, 1991, PLANT PHYSIOL, V97, P1221, DOI 10.1104/pp.97.3.1221; MASUCCI JD, 1994, PLANT PHYSIOL, V106, P1335, DOI 10.1104/pp.106.4.1335; Masucci JD, 1996, PLANT CELL, V8, P1505, DOI 10.1105/tpc.8.9.1505; MAUCH F, 1992, PLANTA, V186, P367, DOI 10.1007/BF00195317; NIEHAUS K, 1993, PLANTA, V190, P415; PENMETSA RV, UNPUB; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PETERS NK, 1989, PLANT PHYSIOL, V91, P690, DOI 10.1104/pp.91.2.690; ROMAN G, 1995, GENETICS, V139, P1393; RUAN XA, 1992, J BACTERIOL, V174, P3467, DOI 10.1128/JB.174.11.3467-3473.1992; SILVERMAN P, 1993, MOL PLANT MICROBE IN, V6, P775, DOI 10.1094/MPMI-6-775; SOMASEGARAN P, 1994, HDB RHIZOBIA METHODS, P392; Tanimoto M, 1995, PLANT J, V8, P943, DOI 10.1046/j.1365-313X.1995.8060943.x; VASSE J, 1993, PLANT J, V4, P555, DOI 10.1046/j.1365-313X.1993.04030555.x	38	438	456	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					527	530		10.1126/science.275.5299.527	http://dx.doi.org/10.1126/science.275.5299.527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999796				2022-12-28	WOS:A1997WE25700043
J	Perkins, ND; Felzien, LK; Betts, JC; Leung, KY; Beach, DH; Nabel, GJ				Perkins, ND; Felzien, LK; Betts, JC; Leung, KY; Beach, DH; Nabel, GJ			Regulation of NF-kappa B by cyclin-dependent kinases associated with the p300 coactivator	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; LONG TERMINAL REPEAT; CELL-CYCLE; DNA-BINDING; E1A-ASSOCIATED P300; HUMAN FIBROBLASTS; GENE-EXPRESSION; PROTEIN P300; G(1) ARREST	The nuclear factor kappa B (NF-kappa B) transcription factor is responsive to specific cytokines and stress and is often activated in association with cell damage and growth arrest in eukaryotes. NF-kappa B is a heterodimeric protein, typically composed of 50- and 65-kilodalton subunits of the Rel family, of which RelA(p65) stimulates transcription of diverse genes. Specific cyclin-dependent kinases (CDKs) were found to regulate transcriptional activation by NF-kappa B through interactions with the coactivator p300. The transcriptional activation domain of RelA(p65) interacted with an amino-terminal region of p300 distinct from a carboxyl-terminal region of p300 required for binding to the cyclin E-Cdk2 complex. The CDK inhibitor p21 or a dominant negative Cdk2,which inhibited p300-associated cyclin E-Cdk2 activity, stimulated kappa B-dependent gene expression which was also enhanced by expression of p300 in the presence of p21. The interaction of NF-kappa B and CDKS through the p300 and CBP coactivators provides a mechanism for the coordination of transcriptional activation with cell cycle progression.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute					NIAID NIH HHS [R01 AI29179] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BANERJEE AC, 1994, ONCOGENE, V9, P1733; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Janknecht R, 1996, ONCOGENE, V12, P1961; JIANG HP, 1994, ONCOGENE, V9, P3397; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI Y, 1994, ONCOGENE, V9, P2261; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN WC, 1991, BIOTECHNIQUES, V11, P344; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muraoka M, 1996, ONCOGENE, V12, P1565; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARKER SF, IN PRESS J VIROL; PERKINS N, UNPUB; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; THEVENIN C, 1990, New Biologist, V2, P793; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	65	659	682	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					523	527		10.1126/science.275.5299.523	http://dx.doi.org/10.1126/science.275.5299.523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999795				2022-12-28	WOS:A1997WE25700042
J	Montoya, G; Svensson, C; Luirink, J; Sinning, I				Montoya, G; Svensson, C; Luirink, J; Sinning, I			Crystal structure of the NG domain from the signal-recognition particle receptor FtsY	NATURE			English	Article							ESCHERICHIA-COLI; GTP HYDROLYSIS; MOLECULAR SWITCH; PROTEIN MODELS; RAS PROTEIN; RESOLUTION; MECHANISM; SUBUNIT; PROGRAM; SRP	Newly synthesized proteins destined either for secretion or incorporation into membranes are targeted to the membrane translocation machinery by a ubiquitous system consisting of a signal recognition particle (SRP) and its receptor(1,2). Both the SRP receptor and the protein within the SRP that binds the signal sequence contain GTPases(3,4). These two proteins, together with the RNA component of the SRP, form a complex(5-7) and thereby regulate each other's GTPase activity(8). Here we report the structure of the GTPase-containing portion of FtsY, the functional homologue of the SRP receptor of Escherichia coli(9), at 2.2 Angstrom resolution without bound nucleotide. This so-called NG domain displays similarities to the Ras-related GTPases, as well as features unique to the SRP-type GTPases(10), such as a separate aminoterminal domain, an insertion within the p21(ras) (Ras) effector domain(11), and a wide-open GTP-binding region. The structure explains the low affinity of FtsY for GTP, and suggests rearrangements that may occur on nucleotide binding. It also identifies regions potentially involved in the transmission of signals between domains and in interactions with regulatory proteins.	EUROPEAN MOL BIOL LAB, STRUCT BIOL PROGRAMME, D-69117 HEIDELBERG, GERMANY; BIOCTR AMSTERDAM, INST MOL BIOL SCI, DEPT MICROBIOL, NL-1081 HV AMSTERDAM, NETHERLANDS	European Molecular Biology Laboratory (EMBL); University of Amsterdam			Sinning, Irmgard/A-2982-2010; Luirink, Joen/AAB-8658-2021					Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER TA, 1993, XPLOR VERSION 3 1; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYST ASS 40 AN M; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSTERS R, 1995, FEBS LETT, V372, P253, DOI 10.1016/0014-5793(95)00997-N; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MONTOYA G, IN PRESS PROTEINS ST; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Schmidt G, 1996, ONCOGENE, V12, P87; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	30	181	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 23	1997	385	6614					365	368		10.1038/385365a0	http://dx.doi.org/10.1038/385365a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002525				2022-12-28	WOS:A1997WD91400057
J	Paice, E; Moss, F; West, G; Grant, J				Paice, E; Moss, F; West, G; Grant, J			Association of use of a log book and experience as a preregistration house officer: Interview survey	BRITISH MEDICAL JOURNAL			English	Article							EDUCATION	Objective: To determine whether use of a log book improved the experiences of preregistration house officers. Design: Confidential questionnaire and interview survey of preregistration house officers carried out as part of University of London inspection process. Measures: Preregistration house officers were asked to rate educational and pastoral elements of their posts and about the use made of previously distributed log books. Subjects and setting: Preregistration house officers in North Thames. Results: The incumbents of 535 of 560 (95%) preregistration house officer posts in the region were surveyed between June 1994 and July 1995, 490 by questionnaire and interview, 45 by questionnaire alone, House officers Who had discussed the log book with their consultant expressed more satisfaction with their induction, consultant supervision and feedback, and formal and informal education and were more likely to recommend their job to a friend. Conclusion: Preregistration house officers who had discussed the log book with their consultant expressed more satisfaction with the educational elements of their jobs. The structured discussion with their consultant about the job and their performance seemed to make the difference.	JOINT CTR EDUC,LONDON WC1N 3EJ,ENGLAND	University of London	Paice, E (corresponding author), N THAMES DEPT POSTGRAD MED & DENT EDUC,LONDON WC1N 3EJ,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIGGS JSG, 1989, MED EDUC, V23, P526, DOI 10.1111/j.1365-2923.1989.tb01579.x; CALMAN KC, 1991, MED EDUC, V25, P51, DOI 10.1111/j.1365-2923.1991.tb00026.x; *COPMED, 1993, PRER HOUS OFF EXP IM; DENT THS, 1990, BRIT MED J, V300, P713, DOI 10.1136/bmj.300.6726.713; DOWLING S, 1993, DOCTORS MAKING EXPER; *GEN MED COUNC, 1992, REC GEN CLIN TRAIN; *JOINT CTR ED MED, 1991, PRER HOUS OFF TRAIN; KING RC, 1989, BRIT J HOSP MED, V41, P111; PAICE E, 1994, BRIT J HOSP MED, V51, P63; WILSON DH, 1993, BRIT MED J, V306, P194, DOI 10.1136/bmj.306.6871.194	10	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					213	215		10.1136/bmj.314.7075.213	http://dx.doi.org/10.1136/bmj.314.7075.213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022443	Green Published			2022-12-28	WOS:A1997WD91100040
J	Cantekin, EI				Cantekin, EI			Treatment of glue ear in general practice	LANCET			English	Letter							OTITIS-MEDIA; EFFUSION				Cantekin, EI (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213, USA.							BAILAR JC, 1995, J CLIN EPIDEMIOL, V48, P149, DOI 10.1016/0895-4356(94)00149-K; CANTEKIN EI, 1991, JAMA-J AM MED ASSOC, V266, P3309; CANTEKIN EI, 1994, JAMA-J AM MED ASSOC, V272, P203, DOI 10.1001/jama.1994.03520030043025; MANDEL EM, 1991, PEDIATR INFECT DIS J, V10, P899, DOI 10.1097/00006454-199112000-00004; vanBalen FAM, 1996, LANCET, V348, P713, DOI 10.1016/S0140-6736(96)02511-1	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					133	134		10.1016/S0140-6736(05)60917-8	http://dx.doi.org/10.1016/S0140-6736(05)60917-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996444				2022-12-28	WOS:A1997WB80000056
J	Lynch, T				Lynch, T			Don't leave a mess. Call Triple S!	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1603	1605		10.1136/bmj.313.7072.1603	http://dx.doi.org/10.1136/bmj.313.7072.1603			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011289	Green Published			2022-12-28	WOS:A1996VZ81100029
J	Roberts, TJ; Marsh, RL; Weyand, PG; Taylor, CR				Roberts, TJ; Marsh, RL; Weyand, PG; Taylor, CR			Muscular force in running turkeys: The economy of minimizing work	SCIENCE			English	Article							TREADMILL LOCOMOTION; MEDIAL GASTROCNEMIUS; MUSCLE FORCE; CAT; SPEED; PERFORMANCE; ENERGETICS; LENGTH; POWER	During running, muscles and tendons must absorb and release mechanical work to maintain the cyclic movements of the body and limbs, while also providing enough force to support the weight of the body. Direct measurements of force and fiber length in the lateral gastrocnemius muscle of running turkeys revealed that the stretch and recoil of tendon and muscle springs supply mechanical work while active muscle fibers produce high forces. During level running, the active muscle shortens little and performs little work but provides the force necessary to support body weight economically. Running economy is improved by muscles that act as active struts rather than working machines.	HARVARD UNIV, MUSEUM COMPARAT ZOOL, CONCORD FIELD STN, BEDFORD, MA 01730 USA	Harvard University	Roberts, TJ (corresponding author), NORTHEASTERN UNIV, DEPT BIOL, 360 HUNTINGTON AVE, BOSTON, MA 02115 USA.			Marsh, Richard/0000-0002-4264-9890	NIAMS NIH HHS [AR39318, AR18140] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039318, R01AR018140, R01AR039318] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Basmajian J., 1985, MUSCLES ALIVE THEIR; Biewener A. A., 1992, BIOMECHANICS STRUCTU; BIEWENER AA, 1992, J EXP BIOL, V164, P1; CAVAGNA GA, 1964, J APPL PHYSIOL, V19, P249, DOI 10.1152/jappl.1964.19.2.249; GREGOR RJ, 1994, MED SCI SPORT EXER, V26, P1359; GRIFFITHS RI, 1991, J PHYSIOL-LONDON, V436, P219, DOI 10.1113/jphysiol.1991.sp018547; GRIFFITHS RI, 1987, J NEUROSCI METH, V21, P159, DOI 10.1016/0165-0270(87)90113-0; HEGLUND NC, 1982, J EXP BIOL, V97, P57; Hill A. V., 1950, Science Progress London, V38, P209; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOFFER JA, 1989, PROG BRAIN RES, V80, P75; KER RF, 1987, NATURE, V325, P147, DOI 10.1038/325147a0; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; LUTZ GJ, 1994, SCIENCE, V263, P370, DOI 10.1126/science.8278808; MARSH RL, 1994, J EXP BIOL, V188, P131; MARSH RL, 1992, NATURE, V357, P411, DOI 10.1038/357411a0; Prilutsky BI, 1996, J EXP BIOL, V199, P801; PUGH LGCE, 1971, J PHYSIOL-LONDON, V213, P255, DOI 10.1113/jphysiol.1971.sp009381; SHERIF MH, 1983, J BIOMECH, V16, P691, DOI 10.1016/0021-9290(83)90079-9; TAYLOR CR, 1980, J EXP BIOL, V86, P9; TAYLOR CR, 1985, J EXP BIOL, V115, P253; WALMSLEY B, 1978, J NEUROPHYSIOL, V41, P1203, DOI 10.1152/jn.1978.41.5.1203; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WHITING WC, 1984, J BIOMECH, V17, P685, DOI 10.1016/0021-9290(84)90122-2	24	548	557	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1113	1115		10.1126/science.275.5303.1113	http://dx.doi.org/10.1126/science.275.5303.1113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027309				2022-12-28	WOS:A1997WJ50300040
J	Hedlund, J				Hedlund, J			Should pneumococcal infections continue to be classified as a single disease?	LANCET			English	Editorial Material							STREPTOCOCCUS-PNEUMONIAE				Hedlund, J (corresponding author), KAROLINSKA INST,DANDERYD HOSP,DEPT INFECT DIS,S-18288 DANDERYD,SWEDEN.							AUSTRIAN R, 1981, REV INFECT DIS, V3, P183; BARNES DM, 1995, J INFECT DIS, V171, P890, DOI 10.1093/infdis/171.4.890; BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251, DOI 10.1093/clinids/14.1.251; HEDLUND J, 1995, CLIN INFECT DIS, V21, P948, DOI 10.1093/clinids/21.4.948; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; Scott JAG, 1996, CLIN INFECT DIS, V22, P973, DOI 10.1093/clinids/22.6.973; WATSON DA, 1995, EUR J CLIN MICROBIOL, V14, P479, DOI 10.1007/BF02113425	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 8	1997	349	9049					371	372		10.1016/S0140-6736(97)80003-7	http://dx.doi.org/10.1016/S0140-6736(97)80003-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WH296	9033458				2022-12-28	WOS:A1997WH29600003
J	Goodwin, CS; Mendall, MM; Northfield, TC				Goodwin, CS; Mendall, MM; Northfield, TC			Helicobacter pylori infection	LANCET			English	Article							QUALITY-OF-LIFE; DUODENAL-ULCER; DYSPEPTIC PATIENTS; GASTRODUODENAL DISEASE; GASTRIC-CARCINOMA; PEPTIC-ULCER; BREATH TEST; ERADICATION; RISK; TRANSMISSION				Goodwin, CS (corresponding author), ST GEORGE HOSP, SCH MED, DIV GASTROENTEROL ENDOCRINOL & METAB, CRANMER TERRACE, LONDON SW17 0RE, ENGLAND.							Axon ATR, 1996, SCAND J GASTROENTERO, V31, P47, DOI 10.3109/00365529609094518; BATESON MC, 1993, POSTGRAD MED J, V69, P41, DOI 10.1136/pgmj.69.807.41; BLASER MJ, 1995, CANCER RES, V55, P562; BLASER MJ, 1995, CANCER RES, V55, P2111; BLUM A, 1996, GASTROENTEROL S, V214, P24; Bourke B, 1996, PEDIATR INFECT DIS J, V15, P1, DOI 10.1097/00006454-199601000-00002; Bujanover Y, 1996, PEDIATR CLIN N AM, V43, P213, DOI 10.1016/S0031-3955(05)70403-X; Bytzer P, 1996, GASTROENTEROLOGY, V110, P302, DOI 10.1053/gast.1996.v110.agast960302; CALAM J, 1995, EUR J GASTROEN HEPAT, V7, P310; Chey WD, 1996, AM J GASTROENTEROL, V91, P89; CULLEN DJE, 1993, GUT, V34, P1681, DOI 10.1136/gut.34.12.1681; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; CUTLER AF, 1995, GASTROENTEROLOGY, V109, P136, DOI 10.1016/0016-5085(95)90278-3; CUTLER AF, 1993, AM J GASTROENTEROL, V88, P1359; De Koster E, 1994, Eur J Cancer Prev, V3, P247; DEBOER WA, 1995, SCAND J GASTROENTERO, V30, P401, DOI 10.3109/00365529509093298; DIXON M, 1993, LANCET, V342, P384, DOI 10.1016/0140-6736(93)92808-7; Forman D, 1996, SCAND J GASTROENTERO, V31, P31, DOI 10.3109/00365529609094513; Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290, DOI 10.1093/oxfordjournals.aje.a008924; GOODWIN CS, 1993, GUT, V34, P293, DOI 10.1136/gut.34.3.293; GOODWIN CS, 1993, GASTROENTEROL CLIN N, V22, P5; Gormally SM, 1996, GUT, V38, P513, DOI 10.1136/gut.38.4.513; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Graham DY, 1996, GASTROENTEROLOGY, V110, P1647, DOI 10.1053/gast.1996.v110.agast961647; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HARRIS AW, 1995, EUR J GASTROEN HEPAT, V7, P595; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; International Agency for Research on Cancer, 1994, IARC MON EV CARC RIS, V61, P177; Isaacson PG, 1996, AM J SURG PATHOL, V20, pS1; ISRAEL DM, 1993, J PEDIATR-US, V123, P53, DOI 10.1016/S0022-3476(05)81536-7; KOLTS BE, 1993, AM J GASTROENTEROL, V88, P650; Kuipers EJ, 1996, EUR J GASTROEN HEPAT, V8, P153, DOI 10.1097/00042737-199602000-00012; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; Lee A, 1996, GASTROENTEROLOGY, V110, P2003, DOI 10.1053/gast.1996.v110.agast962003; Lee A, 1996, HELICOBACTER PYLORI, P50; LOUW JA, 1995, GUT, V36, P544, DOI 10.1136/gut.36.4.544; LUZZA F, 1995, AM J GASTROENTEROL, V90, P1820; LYNCH DAF, 1995, EUR J GASTROEN HEPAT, V7, pS17; MACARTHUR C, 1995, JAMA-J AM MED ASSOC, V273, P729, DOI 10.1001/jama.273.9.729; MADAN E, 1990, ANN CLIN LAB SCI, V20, P329; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1994, AM J GASTROENTEROL, V89, pS116; MARSHALL BJ, 1984, LANCET, V1, P1311; MCCARTHY C, 1995, DIGEST DIS SCI, V40, P114, DOI 10.1007/BF02063953; McColl KEL, 1996, GUT, V39, P615, DOI 10.1136/gut.39.4.615; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; MEGRAUD F, 1995, ALIMENT PHARM THERAP, V9, P85; MENDALL MA, 1995, GUT, V36, P330, DOI 10.1136/gut.36.3.330; MENDALL MA, 1995, GUT, V37, P1, DOI 10.1136/gut.37.1.1; MOAYYEDI P, 1995, CURR OPIN INFECT DIS, V8, P374, DOI 10.1097/00001432-199510000-00010; MULLER AF, 1995, GUT, V36, P679, DOI 10.1136/gut.36.5.679; NEWELL DG, 1991, J CLIN PATHOL, V44, P385, DOI 10.1136/jcp.44.5.385; NGUYEN AMH, 1995, ORAL SURG ORAL MED O, V79, P705, DOI 10.1016/S1079-2104(05)80304-X; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PATEL P, 1994, LANCET, V344, P511, DOI 10.1016/S0140-6736(94)91899-6; PATEL P, 1995, LANCET, V346, P1315, DOI 10.1016/S0140-6736(95)92340-3; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Peura D A, 1996, Am J Med, V100, p19S; PEURA DA, 1995, GASTROENTEROLOGY, V109, P313, DOI 10.1016/0016-5085(95)90299-6; Pounder RE, 1996, GASTROENTEROLOGY, V110, P947, DOI 10.1053/gast.1996.v110.agast960947; REILLY TG, 1995, ALIMENT PHARM THERAP, V9, P483; Rosengren H, 1996, BRIT J GEN PRACT, V46, P177; Sahay P, 1996, Helicobacter, V1, P175, DOI 10.1111/j.1523-5378.1996.tb00035.x; Santander C, 1996, AM J GASTROENTEROL, V91, P1549; Sheu BS, 1996, AM J GASTROENTEROL, V91, P441; SIPPONEN P, 1994, SCAND J GASTROENTERO, V29, P24, DOI 10.3109/00365529409105356; SOBALA GM, 1993, J CLIN PATHOL, V46, P235, DOI 10.1136/jcp.46.3.235; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; TALLEY NJ, 1994, GASTROENTEROLOGY, V106, P1174, DOI 10.1016/0016-5085(94)90007-8; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THIJS WJ, 1995, EUR J GASTROEN HEPAT, V7, P603; TREPSI E, 1994, SCAND J GASTROENTERO, V29, P884; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; TYTGAT GNJ, 1994, SCAND J GASTROENTERO, V29, P38, DOI 10.3109/00365529409091408; VALLE J, 1991, SCAND J GASTROENTERO, V26, P1057, DOI 10.3109/00365529109003956; WALSH JH, 1995, NEW ENGL J MED, V333, P984, DOI 10.1056/NEJM199510123331508; WEAVER LT, 1995, T ROY SOC TROP MED H, V89, P347, DOI 10.1016/0035-9203(95)90002-0; WILHELMSEN I, 1994, SCAND J GASTROENTERO, V29, P874, DOI 10.3109/00365529409094856; WITTEMAN EM, 1995, J CLIN PATHOL, V48, P250, DOI 10.1136/jcp.48.3.250; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	84	166	175	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 25	1997	349	9047					265	269		10.1016/S0140-6736(96)07023-7	http://dx.doi.org/10.1016/S0140-6736(96)07023-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014926				2022-12-28	WOS:A1997WD90600045
J	Hallowell, N; Murton, F; Statham, H; Green, JM; Richards, MPM				Hallowell, N; Murton, F; Statham, H; Green, JM; Richards, MPM			Women's need for information before attending genetic counselling for familial breast or ovarian cancer: A questionnaire, interview, and observational study	BRITISH MEDICAL JOURNAL			English	Article							WRITTEN	Objectives: To describe women's information needs prior to genetic counselling for familial breast or ovarian cancer. Design: Prospective study including semistructured telephone interviews before genetic counselling, observations of consultations, completion of postal questionnaires, and face-to face interviews within two months of counselling. Subjects: 46 women attending genetic counselling for familial breast or ovarian cancer. Main outcome measures: Subjects' understanding of process and content of genetic counselling before attending and attitudes about their preparation for the counselling session. Results: Although all women interviewed before the clinic expected to discuss their risk of developing cancer and risk management options, there was evidence of a lack of knowledge about the process and content of genetic counselling; 17 (37%) women said they did not know what else would happen, Most women interviewed after counselling viewed it positively, but 26 (65%) felt they had been inadequately prepared and 11 (28%) felt that their lack of preparation meant that they could not be given an accurate estimation of their risk of cancer. Conclusions: Some women felt that they did not obtain optimum benefit from genetic counselling because they were inadequately prepared for it We suggest that cancer family history clinics should provide women with written information about the process and content of genetic counselling before their clinic attendance.	UNIV LEEDS,DEPT MIDWIFERY STUDIES,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds	Hallowell, N (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,FAC SOC & POLIT SCI,CAMBRIDGE CB2 3RF,ENGLAND.		Green, Josephine M/A-2443-2010					Austoker J, 1994, J Med Screen, V1, P238; GIBBS S, 1990, J ROY SOC MED, V83, P292, DOI 10.1177/014107689008300505; HJELMKARLSSON K, 1989, INT J NURS STUD, V26, P53, DOI 10.1016/0020-7489(89)90046-1; JulianReynier C, 1996, EUR J CANCER, V32A, P398, DOI 10.1016/0959-8049(95)00601-X; Michie S, 1996, PSYCHOL HEALTH, V11, P797, DOI 10.1080/08870449608400276; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Richards M P, 1995, J Genet Couns, V4, P219, DOI 10.1007/BF01408411; WEINMAN J, 1990, J ROY SOC MED, V83, P303, DOI 10.1177/014107689008300508	8	63	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 25	1997	314	7076					281	283		10.1136/bmj.314.7076.281	http://dx.doi.org/10.1136/bmj.314.7076.281			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WE633	9022494	Green Published			2022-12-28	WOS:A1997WE63300030
J	Bycroft, M; Hubbard, TJP; Proctor, M; Freund, SMV; Murzin, AG				Bycroft, M; Hubbard, TJP; Proctor, M; Freund, SMV; Murzin, AG			The solution structure of the S1 RNA binding domain: A member of an ancient nucleic acid-binding fold	CELL			English	Article							RIBOSOMAL-PROTEIN S1; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MESSENGER-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; THERMUS-THERMOPHILUS; SECONDARY STRUCTURE; NUSA PROTEIN; SEQUENCE; RECOGNITION	The S1 domain, originally identified in ribosomal protein S1, is found in a large number of RNA-associated proteins. The structure of the S1 RNA-binding domain from the E. coli polynucleotide phosphorylase has been determined using NMR methods and consists of a five-stranded antiparallel beta barrel. Conserved residues on one face of the barrel and adjacent loops form the putative RNA-binding site. The structure of the S1 domain is very similar to that of cold shock protein, suggesting that they are both derived from an ancient nucleic acid-binding protein. Enhanced sequence searches reveal hitherto unidentified S1 domains in RNase E, RNase II, NusA, EMB-5, and other proteins.	UNIV CAMBRIDGE, CTR MRC, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	Bycroft, M (corresponding author), UNIV CAMBRIDGE, CTR PROT ENGN, DEPT CHEM, LENSFIELD RD, CAMBRIDGE CB2 1EW, ENGLAND.		Bycroft, Mark/D-9446-2017; Hubbard, Tim J/C-2567-2008; Hubbard, Tim J.P./AAT-4571-2020	Hubbard, Tim J/0000-0002-1767-9318; Hubbard, Tim J.P./0000-0002-1767-9318; Bycroft, Mark/0000-0002-0673-2216				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BLEASBY AJ, 1994, NUCLEIC ACIDS RES, V22, P3574; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Brunger A. T., 1993, X PLOR MANUAL VERSIO; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CLEMENS MJ, 1994, MOL BIOL REP, V19, P201, DOI 10.1007/BF00986962; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; EKLUND EA, 1995, GENE, V155, P231, DOI 10.1016/0378-1119(94)00898-3; Fuchs TM, 1996, J BACTERIOL, V178, P4445, DOI 10.1128/jb.178.15.4445-4452.1996; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; Hubbard EJA, 1996, SCIENCE, V273, P112, DOI 10.1126/science.273.5271.112; HUBBARD TJ, 1995, PROTEINS, V23, P398, DOI 10.1002/prot.340230313; ITO K, 1991, J BACTERIOL, V173, P1492, DOI 10.1128/jb.173.4.1492-1501.1991; Jaishree TN, 1996, BIOCHEMISTRY-US, V35, P2845, DOI 10.1021/bi951062i; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGER D, 1994, NUCLEIC ACIDS RES, V22, P694, DOI 10.1093/nar/22.4.694; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATTAJ IW, 1995, NAT STRUCT BIOL, V2, P518, DOI 10.1038/nsb0795-518; MOSYAK L, 1995, NAT STRUCT BIOL, V2, P537, DOI 10.1038/nsb0795-537; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8; OKADA Y, 1994, J BACTERIOL, V176, P917, DOI 10.1128/jb.176.3.917-922.1994; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; REGNIER P, 1987, J BIOL CHEM, V262, P63; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STONEHOUSE J, 1995, J MAGN RESON SER A, V112, P43, DOI 10.1006/jmra.1995.1008; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TEPLYAKOV A, 1994, PROTEIN SCI, V3, P1098, DOI 10.1002/pro.5560030713; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; VENKATESH TV, 1993, J BACTERIOL, V175, P1844, DOI 10.1128/JB.175.6.1844-1846.1993; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; ZILHAO R, 1993, MOL MICROBIOL, V8, P43, DOI 10.1111/j.1365-2958.1993.tb01201.x	66	347	354	2	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 24	1997	88	2					235	242		10.1016/S0092-8674(00)81844-9	http://dx.doi.org/10.1016/S0092-8674(00)81844-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008164	Bronze			2022-12-28	WOS:A1997WE97000012
J	Freed, EO; Englund, G; Maldarelli, F; Martin, MA				Freed, EO; Englund, G; Maldarelli, F; Martin, MA			Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection	CELL			English	Letter							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEAR-LOCALIZATION SIGNAL; NONDIVIDING CELLS; PRODUCTIVE INFECTION; PROTEIN; INVITRO; DOMAIN				Freed, EO (corresponding author), NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892, USA.		Maldarelli, Frank/O-2428-2016					Berthold E, 1996, J VIROL, V70, P4667, DOI 10.1128/JVI.70.7.4667-4682.1996; Bukrinskaya AG, 1996, P NATL ACAD SCI USA, V93, P367, DOI 10.1073/pnas.93.1.367; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; ENGLUND G, 1995, J VIROL, V69, P3216, DOI 10.1128/JVI.69.5.3216-3219.1995; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; FREED EO, 1994, NATURE, V369, P107, DOI 10.1038/369107b0; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; KORNBLUTH RS, 1989, J EXP MED, V169, P1137, DOI 10.1084/jem.169.3.1137; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992	16	61	61	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					171	173		10.1016/S0092-8674(00)81836-X	http://dx.doi.org/10.1016/S0092-8674(00)81836-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008157	Bronze			2022-12-28	WOS:A1997WE97000004
J	Hale, CA; deBoer, PAJ				Hale, CA; deBoer, PAJ			Direct binding of FtsZ to ZipA, an essential component of the septal ring structure that mediates cell division in E-coli	CELL			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PROTEIN FTSZ; GENE; IDENTIFICATION; INHIBITION; INTERACTS; MEMBRANE; REGIONS; RATIO	FtsZ is a soluble, tubulin-like GTPase that forms a membrane-associated ring at the division site of bacterial cells. While this ring is thought to drive cell constriction, it is not well understood how it is assembled or how it affects cell wall invagination. Here we report that FtsZ binds directly to a novel integral inner-membrane protein in E. coli that we call ZipA. We present genetic and morphological evidence indicating that this interaction is required for cell division, and show that a fluorescent ZipA-Gfp fusion protein is located in a ring structure at the division site, both before and during cell wall invagination. ZipA is an essential component of the division machinery, and, by binding to both FtsZ and the cytoplasmic membrane, is likely to be directly involved in the assembly and/or function of the FtsZ ring.			Hale, CA (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.			de Boer, Piet/0000-0002-5375-6317				Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; Baumann P, 1996, P NATL ACAD SCI USA, V93, P6726, DOI 10.1073/pnas.93.13.6726; BEGG KJ, 1995, J BACTERIOL, V177, P6211, DOI 10.1128/jb.177.21.6211-6222.1995; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; DAI K, 1992, J BACTERIOL, V174, P6145, DOI 10.1128/JB.174.19.6145-6151.1992; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DESCOTEAUX A, 1987, J BACTERIOL, V169, P1938, DOI 10.1128/jb.169.5.1938-1942.1987; DEWAR SJ, 1992, J BACTERIOL, V174, P6314, DOI 10.1128/JB.174.19.6314-6316.1992; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIGASHITANI A, 1995, BIOCHEM BIOPH RES CO, V209, P198, DOI 10.1006/bbrc.1995.1489; Huang J, 1996, J BACTERIOL, V178, P5080, DOI 10.1128/jb.178.17.5080-5085.1996; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KHATTAR MM, 1994, J BACTERIOL, V176, P7140, DOI 10.1128/JB.176.23.7140-7147.1994; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; LUTKENHAUS J, 1996, ESCHERICHIA COLI SAL, P1615; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; OSTERYOUNG KW, 1995, NATURE, V376, P473, DOI 10.1038/376473b0; Park JT, 1996, ESCHERICHIA COLI SAL, P48; PLA J, 1991, MOL MICROBIOL, V5, P1681, DOI 10.1111/j.1365-2958.1991.tb01915.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; SANCHEZ M, 1994, EMBO J, V13, P4919, DOI 10.1002/j.1460-2075.1994.tb06819.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Wang X, 1996, MOL MICROBIOL, V21, P313, DOI 10.1046/j.1365-2958.1996.6421360.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHAO CR, 1995, P NATL ACAD SCI USA, V92, P4314	46	391	402	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					175	185		10.1016/S0092-8674(00)81838-3	http://dx.doi.org/10.1016/S0092-8674(00)81838-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008158	Bronze			2022-12-28	WOS:A1997WE97000006
J	Sylvester, PJ; Campbell, IH; Bowyer, DA				Sylvester, PJ; Campbell, IH; Bowyer, DA			Niobium/uranium evidence for early formation of the continental crust	SCIENCE			English	Article							CONTAMINATED KOMATIITES; KAMBALDA VOLCANICS; WESTERN-AUSTRALIA; ISOTOPIC EVIDENCE; MANTLE EVOLUTION; SM-ND; BASALTS; CONSTRAINTS; PETROGENESIS; GEOCHEMISTRY	Niobium/uranium ratios in greenstone-belt basalts and gabbros indicate that parts of the Late Archean mantle beneath Western Australia underwent a level of melt extraction, resulting in formation of the continental crust, comparable to that seen in the present mantle. The implication is either that (i) the amount of continental crust that formed before 2.7 x 10(9) years ago was much greater than generally thought or (ii) crustal growth occurred by severe depletion of small volumes of the mantle rather than by moderate depletion of a large volume of mantle.			Sylvester, PJ (corresponding author), AUSTRALIAN NATL UNIV,RES SCH EARTH SCI,GPO BOX 4,CANBERRA,ACT 0200,AUSTRALIA.		Campbell, Ian/A-4941-2008	Campbell, Ian/0000-0001-8578-0154				ABOUCHAMI W, 1990, J GEOPHYS RES-SOLID, V95, P17605, DOI 10.1029/JB095iB11p17605; ALLEGRE CJ, 1986, CHEM GEOL, V56, P219, DOI 10.1016/0009-2541(86)90005-7; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; ARMSTRONG RL, 1968, REV GEOPHYS, V6, P175, DOI 10.1029/RG006i002p00175; ARMSTRONG RL, 1991, AUST J EARTH SCI, V38, P613, DOI 10.1080/08120099108727995; ARNDT NT, 1986, CHEM GEOL, V56, P229, DOI 10.1016/0009-2541(86)90006-9; CAMPBELL IH, 1989, NATURE, V339, P697, DOI 10.1038/339697a0; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; CHAUVEL C, 1985, EARTH PLANET SC LETT, V74, P315, DOI 10.1016/S0012-821X(85)80003-0; COMPSTON W, 1986, EARTH PLANET SC LETT, V76, P299, DOI 10.1016/0012-821X(86)90081-6; DEPAOLO DJ, 1983, GEOPHYS RES LETT, V10, P705, DOI 10.1029/GL010i008p00705; EGGINS SM, IN PRESS CHEM GEOL; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; GHADERI M, UNPUB; HEMOND C, 1994, CHEM GEOL, V115, P7, DOI 10.1016/0009-2541(94)90143-0; HOFMANN AW, 1986, EARTH PLANET SC LETT, V79, P33, DOI 10.1016/0012-821X(86)90038-5; HURLEY PM, 1969, SCIENCE, V164, P1229, DOI 10.1126/science.164.3885.1229; JOCHUM KP, 1991, EARTH PLANET SC LETT, V107, P272, DOI 10.1016/0012-821X(91)90076-T; LESHER CM, 1995, LITHOS, V34, P127, DOI 10.1016/0024-4937(94)00036-2; MCCULLOCH MT, 1978, SCIENCE, V200, P1003, DOI 10.1126/science.200.4345.1003; MILLER RG, 1986, CHEM GEOL, V57, P87, DOI 10.1016/0009-2541(86)90095-1; MOORBATH S, 1978, PHILOS T R SOC A, V288, P401, DOI 10.1098/rsta.1978.0024; MOORBATH S, 1977, CHEM GEOL, V20, P151, DOI 10.1016/0009-2541(77)90042-0; NELSON BK, 1985, GEOL SOC AM BULL, V96, P746, DOI 10.1130/0016-7606(1985)96<746:RPOCCT>2.0.CO;2; PATCHETT PJ, 1986, EARTH PLANET SC LETT, V78, P329, DOI 10.1016/0012-821X(86)90001-4; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; SIMS KWW, 1995, SCIENCE, V267, P508, DOI 10.1126/science.267.5197.508	28	95	106	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					521	523		10.1126/science.275.5299.521	http://dx.doi.org/10.1126/science.275.5299.521			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999794				2022-12-28	WOS:A1997WE25700041
J	Jonas, EA; Knox, RJ; Smith, TCM; Wayne, NL; Connor, JA; Karzmarek, LK				Jonas, EA; Knox, RJ; Smith, TCM; Wayne, NL; Connor, JA; Karzmarek, LK			Regulation by insulin of a unique neuronal Ca2+ pool and of neuropeptide secretion	NATURE			English	Article							EGG-LAYING HORMONE; BAG CELL NEURONS; ELECTRICAL AFTERDISCHARGE; INOSITOL TRISPHOSPHATE; NEUROENDOCRINE CELLS; APLYSIA; CALCIUM; CHANNELS; RELEASE; THAPSIGARGIN	The insulin receptor is a tyrosine kinase receptor that is found in mammalian brain(1) and at high concentrations in the bag cell neurons of Aplysia(2). We show here that insulin causes an acute rise in intracellular Ca2+ concentration ([Ca2+](i)) in these neurons and triggers release of neuropeptide. The insulin-sensitive intracellular Ca2+ pool differs pharmacologically from previously described Ca2+ stores that are sensitive to inositol trisphosphate and from mitochondrial Ca2+ stores(3-7). Insulin, but not thapsigargin, stimulates Ca2+ release at the distal tips of neurites, the presumed site of neuropeptide secretion(8,9). The effects of insulin on intracellular Ca2+ release and neuropeptide secretion occur without triggering spontaneous action potentials. The insulin-sensitive rise in [Ca2+](i) moves into the distal tips of neurites after exposure to a cyclic AMP analogue, a treatment that causes a similar translocation of neuronal vesicles(10-12). Our data indicate that Ca2+ release from a distinct intracellular pool associated with secretory vesicles may contribute to secretion of neuropeptide in the absence of neuronal discharge.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90025; LOVELACE BIOMED & ENVIRONM RES INST,ALBUQUERQUE,NM 87108	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Lovelace Respiratory Research Institute	Jonas, EA (corresponding author), YALE UNIV,SCH MED,DEPT PHARMACOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.							ARCH S, 1976, J GEN PHYSIOL, V68, P197, DOI 10.1085/jgp.68.2.197; AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FINK LA, 1988, J NEUROSCI, V8, P2544; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FRAZIER WT, 1967, J NEUROPHYSIOL, V30, P1288, DOI 10.1152/jn.1967.30.6.1288; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HASKINS JT, 1981, J NEUROCYTOL, V10, P729, DOI 10.1007/BF01262650; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; Jonas EA, 1996, J NEUROSCI, V16, P1645; KNOX RJ, 1992, NEURON, V8, P883, DOI 10.1016/0896-6273(92)90202-O; Knox RJ, 1996, J PHYSIOL-LONDON, V494, P627, DOI 10.1113/jphysiol.1996.sp021520; LOECHNER KJ, 1990, J NEUROPHYSIOL, V63, P738, DOI 10.1152/jn.1990.63.4.738; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAYERI E, 1985, J NEUROSCI, V5, P2060; MEECH RW, 1980, J PHYSIOL-LONDON, V298, P111, DOI 10.1113/jphysiol.1980.sp013070; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; STUART DK, 1980, J NEUROPHYSIOL, V43, P488, DOI 10.1152/jn.1980.43.2.488; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WAYNE NL, 1994, ENDOCRINOLOGY, V134, P1046, DOI 10.1210/en.134.3.1046; WAYNE NL, 1995, ENDOCRINOLOGY, V136, P369, DOI 10.1210/en.136.1.369; YAMAMOTO H, 1990, N-S ARCH PHARMACOL, V341, P273	25	105	108	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 23	1997	385	6614					343	346		10.1038/385343a0	http://dx.doi.org/10.1038/385343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WD914	9002519				2022-12-28	WOS:A1997WD91400051
J	Machin, D				Machin, D			Educational initiatives deserve randomised controlled trials - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Machin, D (corresponding author), SINGAPORE GEN HOSP, CLIN TRIALS & EPIDEMIOL RES UNIT, NATL MED RES COUNCIL, SINGAPORE 169608, SINGAPORE.							[Anonymous], 1995, STAT MED, V14, P1659	1	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					216	216		10.1136/bmj.314.7075.216	http://dx.doi.org/10.1136/bmj.314.7075.216			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022444	Green Published			2022-12-28	WOS:A1997WD91100041
J	Schwartz, DA; Doebbeling, BN; Merchant, JA; Barrett, DH; Black, DW; Burmeister, LF; Clarke, WR; Falter, KH; Hall, DB; Jones, MF; Saag, KG; Snyders, TL; Thorne, PS; Torner, JC; Wolson, RF; Ballas, ZK; Barrash, J; Casale, TB; Chrischilles, E; Falk, H; Hansen, MD; Kathol, RG; Kelly, JR; Pfohl, BM; Piette, WW; Quinlisk, P; Rohrer, JE; Sprince, NL; Talby, PM; Zwerling, C				Schwartz, DA; Doebbeling, BN; Merchant, JA; Barrett, DH; Black, DW; Burmeister, LF; Clarke, WR; Falter, KH; Hall, DB; Jones, MF; Saag, KG; Snyders, TL; Thorne, PS; Torner, JC; Wolson, RF; Ballas, ZK; Barrash, J; Casale, TB; Chrischilles, E; Falk, H; Hansen, MD; Kathol, RG; Kelly, JR; Pfohl, BM; Piette, WW; Quinlisk, P; Rohrer, JE; Sprince, NL; Talby, PM; Zwerling, C			Self-reported illness and health status among gulf war veterans - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIFFERENTIAL RECALL; BIAS; QUESTIONNAIRE; IMPACT; SCALE	Objective.-To assess the prevalence of self-reported symptoms and illnesses among military personnel deployed during the Persian Gulf War (PGW) and to compare the prevalence of these conditions with the prevalence among military personnel on active duly at the same time, but not deployed to the Persian Gulf (non-PGW). Design.-Cross-sectional telephone interview survey of PGW and non-PGM, military personnel. The study instrument consisted of validated questions, validated questionnaires, and investigator-derived questions designed to assess relevant medical and psychiatric conditions. Setting.-Population-based sample of military personnel from Iowa. Study Participants.-A total of 4886 study subjects were randomly selected from 1 of 4 study domains (PGW regular military, PGW National Guard/Reserve, non-PGW regular military, and non-PGW National Guard/Reserve), stratifying for age, sex, race, rank, and branch of military service. Main Outcome Measures.-Self-reported symptoms and symptoms of medical illnesses and psychiatric conditions. Results.-Overall, 3695 eligible study subjects (76%) and 91% of the located subjects completed the telephone interview. Compared with non-PGW military personnel, PGW military personnel reported a significantly higher prevalence of symptoms of depression (17.0% vs 10.9%; Cochran-Mantel-Haenszel test statistic, P<.001), posttraumatic stress disorder (PTSD) (1.9% vs 0.8%, P=.007), chronic fatigue (1.3% vs 0.3%, P<.001), cognitive dysfunction (18.7% vs 7.6%, P<.001), bronchitis (3.7% vs 2.7%, P<.001), asthma (7.2% vs 4.1%, P=.004), fibromyalgia (19.2% vs 9.6%, P<.001), alcohol abuse (17.4% vs 12.6%, P=.02), anxiety (4.0% vs 1.8%, P<.001), and sexual discomfort (respondent, 1.5% vs 1.1%, P=.009; respondent's female partner, 5.1% vs 2.4%, P<.001). Assessment of health-related quality of life demonstrated diminished mental and physical functioning scores for PGW military personnel. In almost all cases, larger differences between PGW and non-PGW military personnel were observed in the National Guard/Reserve comparison. Within the PGW military study population, compared with veterans in the regular military, Veterans in the National Guard/Reserve only reported more symptoms of chronic fatigue (2.9% vs 1.0%, P=.03) and alcohol abuse (19.4% vs 17.0%, P=.004). Conclusions.-Military personnel who participated in the PGW have a higher self-reported prevalence of medical and psychiatric conditions than contemporary military personnel who were not deployed to the Persian Gulf. These findings establish the need to further investigate the potential etiologic, clinical, pathogenic, and public health implications of the increased prevalence of multiple medical and psychiatric conditions in populations of military personnel deployed to the Persian Gulf.	CTR DIS CONTROL & PREVENT, NATL CTR ENVIRONM HLTH, ATLANTA, GA 30333 USA; IOWA DEPT PUBL HLTH, DES MOINES, IA 50319 USA	Centers for Disease Control & Prevention - USA	Schwartz, DA (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, SE318 GH, IOWA CITY, IA 52242 USA.		Casale, Thomas B/K-4334-2013; Doebbeling, Bradley/L-9155-2019; Doebbeling, Bradley/AAC-1063-2022; Doebbeling, Bradley/C-6620-2009	Casale, Thomas B/0000-0002-3149-7377; Doebbeling, Bradley/0000-0003-3504-3468; 	PHS HHS [U50/CCU711513] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AbouDonia MB, 1996, J TOXICOL ENV HEALTH, V48, P35, DOI 10.1080/009841096161456; [Anonymous], 1988, JAMA, V259, P2701; [Anonymous], 1994, JAMA, V272, P391; [Anonymous], 1995, Arch Intern Med, V155, P262; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BOYLE CA, 1987, JAMA-J AM MED ASSOC, V257, P790; CALLE EE, 1988, JAMA-J AM MED ASSOC, V259, P2715, DOI 10.1001/jama.1988.03720180041030; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P443; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CHOUINARD E, 1995, J CLIN EPIDEMIOL, V48, P245, DOI 10.1016/0895-4356(94)00132-A; *COMM REV HLTH CON, 1994, HLTH CONS SERV PERS; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; *CTR DIS CONTR PRE, 1995, BEH RISK FACT SURV S; *CTR ENV HLTH INJ, 1989, HLTH  STAT VIETN VET, V2; DECOUFLE P, 1992, AM J EPIDEMIOL, V135, P312, DOI 10.1093/oxfordjournals.aje.a116285; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DREWS CD, 1990, INT J EPIDEMIOL, V19, P1107, DOI 10.1093/ije/19.4.1107; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEISS JL, 1991, STATISTICAL METHODS; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Gray GC, 1996, NEW ENGL J MED, V335, P1505, DOI 10.1056/NEJM199611143352007; Greenland S, 1982, Stat Med, V1, P217, DOI 10.1002/sim.4780010304; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; *NAT CTR HLTH SERV, 1989, PUBL PHS; *NAT CTR INF DIS C, 1994, ILLN PERS GULF VET L; NEUGEBAUER R, 1990, J CLIN EPIDEMIOL, V43, P1337, DOI 10.1016/0895-4356(90)90100-4; *OFF ASS SECR DEF, 1996, COMPR CLIN EV PROGR; *OFF UND SECR DEF, 1994, REP DEF SCI BOARD TA; Penman AD, 1996, MIL MED, V161, P1; *PRES ADV COMM GUL, 1996, INT REP; REYNOLDS CF, 1988, PSYCHIAT RES, V24, P231, DOI 10.1016/0165-1781(88)90106-0; *SAS I INC, 1990, SAS IML SOFTW US REF; SATO T, 1990, ENVIRON HEALTH PERSP, V87, P95, DOI 10.2307/3431011; SHAH BV, 1992, SUDAAN USERS MANUAL; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; STRAHAN R, 1972, J CLIN PSYCHOL, V28, P191, DOI 10.1002/1097-4679(197204)28:2<191::AID-JCLP2270280220>3.0.CO;2-G; *U CAL, 1994, COMP ASS SURV EX SYS; *U IOW, 1993, FEM FAM HLTH QUEST A; Ware JE, 1993, SF36 HLTH SURVEY MAN; Weathers FW, 1993, ANN M INT SOC, V1, P548; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; 1993, VITAL HLTH STAT, V1	47	410	413	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 15	1997	277	3					238	245						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WB446	9005274				2022-12-28	WOS:A1997WB44600026
J	McBride, SR; Lawrence, CM; Pape, SA; Reid, CA				McBride, SR; Lawrence, CM; Pape, SA; Reid, CA			Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis	LANCET			English	Article							MALARIA PROPHYLAXIS; TRAVELERS		ROYAL VICTORIA INFIRM,DEPT PLAST SURG,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK	McBride, SR (corresponding author), ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.		Pape, Sarah A./AAG-1350-2020	McBride, Sandy/0000-0002-8449-1809				BRADLEY DJ, 1995, BRIT MED J, V310, P709, DOI 10.1136/bmj.310.6981.709; LENCH P, 1995, BRIT MED J, V311, P192, DOI 10.1136/bmj.311.6998.192; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; VANDENENDEN E, 1991, LANCET, V337, P683, DOI 10.1016/0140-6736(91)92509-Z	4	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					101	101		10.1016/S0140-6736(05)60884-7	http://dx.doi.org/10.1016/S0140-6736(05)60884-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996426				2022-12-28	WOS:A1997WB80000018
J	Stark, H; Orlova, EV; RinkeAppel, J; Junke, N; Mueller, F; Rodnina, M; Wintermeyer, W; Brimacombe, R; vanHeel, M				Stark, H; Orlova, EV; RinkeAppel, J; Junke, N; Mueller, F; Rodnina, M; Wintermeyer, W; Brimacombe, R; vanHeel, M			Arrangement of tRNAs in pre- and posttranslocational ribosomes revealed by electron cryomicroscopy	CELL			English	Article							ESCHERICHIA-COLI RIBOSOMES; FLUORESCENCE ENERGY-TRANSFER; PHENYLALANINE TRANSFER-RNA; MESSENGER-RNA; P-SITE; ANGULAR RECONSTITUTION; DECODING REGION; CROSS-LINKING; EXIT SITE; 16S RNA	The three-dimensional structure of the translating 70S E. coli ribosome is presented in its two main conformations: the pretranslocational and the posttranslocational states. Using electron cryomicroscopy and angular reconstitution, structures at 20 Angstrom resolution were obtained, which, when compared with our earlier reconstruction of ''empty'' ribosomes, showed densities corresponding to tRNA molecules-at the P and E sites for posttranslocational ribosomes and at the A and P sites for pretranslocational ribosomes. The P-site tRNA lies directly above the bridge connecting the two ribosomal subunits, with the A-site tRNA fitted snugly against it at an angle of similar to 50 degrees, toward the L7/L12 side of the ribosome. The E-site tRNA appears to lie between the side robe of the 30S subunit and the L1 protuberance.	MAX PLANCK INST MOL GENET, D-14195 BERLIN, GERMANY; UNIV WITTEN HERDECKE, INST MOL BIOL, D-58453 WITTEN, GERMANY; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AY, ENGLAND	Max Planck Society; Witten Herdecke University; Imperial College London	Stark, H (corresponding author), MAX PLANCK GESELL, FRITZ HABER INST, FARADAYWEG 4-6, D-14195 BERLIN, GERMANY.		Rodnina, Marina V./AAD-4667-2019; Orlova, Elena/CAF-8290-2022	Rodnina, Marina V./0000-0003-0105-3879; Holger, Stark/0000-0002-6161-1118; Orlova, Elena/0000-0003-3371-415X				Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CHIU W, 1986, ANNU REV BIOPHYS BIO, V15, P237; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GORNICKI P, 1984, J BIOL CHEM, V259, P493; HARAUZ G, 1986, OPTIK, V73, P146; Hawkes P W., 1980, COMPUTER PROCESSING, P1; HENDERSON R, 1995, Q REV BIOPHYS, V28, P171, DOI 10.1017/S003358350000305X; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; LILL R, 1988, J MOL BIOL, V203, P699, DOI 10.1016/0022-2836(88)90203-3; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOORE PB, 1995, STRUCTURE, V3, P851, DOI 10.1016/S0969-2126(01)00219-2; Mueller F, 1995, BIOCHEM CELL BIOL, V73, P767, DOI 10.1139/o95-085; NOLLER HF, 1990, RIBOSOME, P73; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OFVERSTEDT LG, 1994, CELL, V79, P629, DOI 10.1016/0092-8674(94)90548-7; PAULSEN H, 1986, BIOCHEMISTRY-US, V25, P2749, DOI 10.1021/bi00358a002; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; REMME J, 1989, EUR J BIOCHEM, V183, P281, DOI 10.1111/j.1432-1033.1989.tb14925.x; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RHEINBERGER HJ, 1986, FEBS LETT, V204, P97, DOI 10.1016/0014-5793(86)81393-X; RinkeAppel J, 1995, RNA, V1, P1018; ROBERTSON JM, 1987, J MOL BIOL, V196, P525, DOI 10.1016/0022-2836(87)90030-1; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SIRDESHMUKH R, 1985, NUCLEIC ACIDS RES, V13, P1185, DOI 10.1093/nar/13.4.1185; SMITH D, 1989, P NATL ACAD SCI USA, V86, P4397, DOI 10.1073/pnas.86.12.4397; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANHEEL M, 1992, SCANNING MICROSCOPY, V6, P23; WALLECZEK J, 1990, J BIOL CHEM, V265, P11338; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; YONATH A, 1993, CURR OPIN STRUC BIOL, V3, P175, DOI 10.1016/S0959-440X(05)80149-6	54	216	217	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 10	1997	88	1					19	28		10.1016/S0092-8674(00)81854-1	http://dx.doi.org/10.1016/S0092-8674(00)81854-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019401	Bronze			2022-12-28	WOS:A1997WC56900005
J	Genovese, BJ				Genovese, BJ			And God will fill the bullet holes with candy	BRITISH MEDICAL JOURNAL			English	Article											Genovese, BJ (corresponding author), HLTH SCI PROGRAM,SANTA MONICA,CA 90407, USA.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1585	1587		10.1136/bmj.313.7072.1585	http://dx.doi.org/10.1136/bmj.313.7072.1585			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011287	Green Published			2022-12-28	WOS:A1996VZ81100015
J	Mittal, V; Hernandez, N				Mittal, V; Hernandez, N			Role for the amino-terminal region of human TBP in U6 snRNA transcription	SCIENCE			English	Article							RNA-POLYMERASE-III; TATA-BINDING-PROTEIN; PROXIMAL SEQUENCE ELEMENT; CONSERVED CORE DOMAIN; ACTIVATES TRANSCRIPTION; GENE INVITRO; COMPLEX; PROMOTERS; MOUSE; EXPRESSION	Basal transcription from the human RNA polymerase III U6 promoter depends on a TATA box that recruits the TATA box-binding protein (TBP) and a proximal sequence element that recruits the small nuclear RNA (snRNA)-activating protein complex (SNAP(c)). TBP consists of a conserved carboxyl-terminal domain that performs all known functions of the protein and a nonconserved amino-terminal region of unknown function. Here, the aminoterminal region is shown to down-regulate binding oi TBP to the U6 TATA box, mediate cooperative binding with SNAP(c) to the U6 promoter, and enhance U6 transcription.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute				Hernandez, Nouria/0000-0003-1465-4585	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM38810] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GOOMER RS, 1994, GENE, V148, P269, DOI 10.1016/0378-1119(94)90698-X; HANCOCK JM, 1993, NUCLEIC ACIDS RES, V21, P2823, DOI 10.1093/nar/21.12.2823; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; IMBERT G, 1994, GENOMICS, V21, P667, DOI 10.1006/geno.1994.1335; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; NAKASHIMA K, 1995, GENE, V152, P209, DOI 10.1016/0378-1119(94)00681-H; Pendergrast PS, 1996, J VIROL, V70, P5025, DOI 10.1128/JVI.70.8.5025-5034.1996; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REDDY R, 1988, J BIOL CHEM, V263, P15980; RUDLOFF U, 1994, P NATL ACAD SCI USA, V91, P8229, DOI 10.1073/pnas.91.17.8229; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; YOON JB, 1995, MOL CELL BIOL, V15, P2019; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	41	79	81	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1136	1140		10.1126/science.275.5303.1136	http://dx.doi.org/10.1126/science.275.5303.1136			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027316				2022-12-28	WOS:A1997WJ50300047
J	Perry, G; Brown, E; Thornton, R; Shiva, T; Hubbard, J; Reddy, KR; Doherty, JE; Cardello, FP; Fast, A; Radford, MJ; Folger, JS; Bhaskar, G; Zoble, RG; Sridharan, V; Sridharan, MR; Loungani, RR; Gheorghiade, M; Hsieh, A; Tommaso, C; Mansuri, M; Guess, MA; Akhtar, S; Wagner, S; Hagan, K; McIntyre, KM; Ruble, P; Moten, M; Riley, A; Pierpont, G; Anand, I; Patel, G; Puram, BS; Eladasari, BR; Karnegis, J; Gillie, E; Crawford, MH; Graettinger, WF; Shah, A; Sacco, J; Chaudhry, MA; Dolen, D; ElSherif, N; BekheitSaad, S; Campos, EE; Greene, JG; Khanijo, V; Kumar, U; Mallis, GI; Mookherjee, S; DibnerDunlap, M; Gupta, SC; Danisa, K; Thadani, U; Tan, A; Rajachar, M; Amidi, M; OReilly, MV; Hassapoyannes, CA; Davies, ML; Kumar, VA; Okerson, D; Ramanathan, KB; Putatunda, B; Gollapudi, A; Montero, A; Mohanty, PK; Lui, C; Thagirisa, S; Lee, RW; Glatter, TR; Bodine, K; Roberts, D; Bertoglio, M; Dennish, GW; Sarma, RJ; Gregoratos, G; Rausch, DC; Pitt, WA; Kennelly, BM; Fahrenholtz, D; Gordon, R; Horwitz, L; Rothbart, R; Nutting, P; Lutz, L; Copen, DL; Rashkow, A; Babb, J; VanVoorhees, L; Silverman, A; Stillabower, ME; Miller, AB; NguyenPho, HT; Safford, RE; Fishman, S; Neiman, JC; Stein, M; Dominguez, JC; Abernathy, GT; Nair, PH; Goodman, LS; Cook, TH; Wickemeyer, WJ; Berkson, DM; Mathew, J; Richman, HG; Lubell, DL; Lang, R; Zajac, EJ; Rosenstein, R; Silver, MA; Shanes, JG; Kelly, KJ; Pequignot, MH; Campbell, R; Kirlin, PC; Ziperman, DB; Denny, DM; Gamble, L; Weiss, M; Kaimal, PK; Dhurandhar, RW; Ventura, H; Godley, ML; Pu, C; Schick, EC; Barbour, DJ; Salmon, D; Goldstein, M; Effron, MB; Fleg, JL; Baughman, KL; Weiss, R; Ericson, K; Sturrock, WA; Heinsimer, J; Timmis, GC; Smith, S; Shrestha, DD; Duvernoy, WFC; Hickner, J; Lewis, BK; OBrien, TK; Yarows, SA; Willens, HJ; Mast, DJ; Johnson, TH; Rodeheffer, RJ; Siefert, M; Swenson, L; Denes, P; Gudapati, R; Charles, FR; Rich, MW; Beckham, V; Hamilton, WP; Abele, PB; Harper, DM; OKelly, RL; Forker, AD; Kahl, FR; Garrou, BW; Klang, TE; Popio, K; Mohiuddin, S; Pollak, EM; Chiaramida, A; Gregory, JJ; Papa, LA; Abrams, J; Ung, S; Jutila, CK; Croke, RP; Chiaramida, S; Lucariello, R; Rim, DA; Goldberger, MH; Kohn, RM; Graham, S; Philbin, EF; Sheesley, K; Nafziger, A; Macina, G; Hsueh, JT; Zoneraich, S; Binder, A; Weinstein, C; Morrison, J; Cameron, A; Vanderbush, E; Brown, J; Pande, PN; Lader, E; Kay, R; Bloomfield, D; Costantino, T; Heiselman, DE; Radwany, S; Smith, MR; Hobbs, RE; Fraker, TD; Frerking, TR; DeLeon, AC; Christie, LG; Toren, M; Grover, J; McBarron, FD; Harris, DE; McLean, RW; Morris, L; Zatuchni, J; Boehmer, JP; Clemson, BS; Lipshutz, H; Small, RS; Ufret, R; LugoRodriquez, JE; Khan, AH; Yousefian, M; Friesinger, GC; Ely, D; Farmer, JA; Young, JB; Payne, RM; Fowles, RE; Lee, AB; Shalev, Y; AlBitar, I; Schroeder, GS; Radant, L; Hankey, TL; Rezkalla, S; Groden, DL; Teo, KK; Humen, DP; Wong, D; Greenwood, PV; Talibi, T; Hui, W; Klinke, WP; Senaratne, MPJ; Goeres, M; Hughes, DF; Sayeed, MAR; Roth, DL; Belenkie, I; Manyari, DE; Borgersen, K; Read, L; Kinloch, D; Reid, R; Barber, NC; Horner, BA; Kenefick, G; Kuritzky, RA; Imrie, JR; Wagner, KR; Rabkin, SW; Mizgala, HF; Tarry, L; Dodek, A; Kornder, JM; Ashton, T; Barr, D; Dufton, J; Sweeny, R; Morris, A; Bessoudo, R; Marr, D; Milton, JR; Thompson, B; Robinson, V; Sussex, BA; Tobin, M; McMahon, DP; Folkins, D; Crowell, R; Lalonde, LD; Koilpillai, C; Hatheway, RJ; OReilly, MG; Machel, T; Hack, I; Stewart, JW; Tanser, PH; Sullivan, B; Hagar, S; Quinn, B; Davies, RA; Baird, MG; Williams, WL; LeMay, M; Higginson, L; Turek, M; Sochowski, RA; Weeks, A; Jacobs, MH; Baigrie, R; DeVilla, MA; Vertes, G; Bozek, B; Goode, JE; Ricci, AJ; Swan, J; Fell, DA; LevinoffRoth, SN; Arnold, JMO; Patrick, L; Southern, RF; Rinne, C; Brisbin, D; DeYoung, JP; Baitz, T; Vizel, S; Minkowitz, J; Letarte, P; Chan, YK; Kwok, KK; Nawaz, S; Ganjavi, F; Yao, L; Misterski, J; Raco, DL; Hess, AR; Kuruvilla, G; Silverberg, L; Borts, D; Fulop, JC; Weingert, ME; Carter, RP; Sahay, BM; Hickey, JE; Lalonde, G; Gosselin, G; Bourassa, MG; Goulet, C; Joyal, M; Methe, M; Honos, G; Fitchett, D; Serpa, A; Sestier, F; Roberge, G; Latour, Y; Rondeau, C; Gossard, D; Lenis, JHF; Brossoit, R; Simard, L; Delage, F; Auger, P; Saulnier, D; Talbot, P; Beaudoin, J; Campeau, J; Pruneau, G; Tamilia, M; Boutros, G; Comeau, B; Starra, R; StHilaire, R; Veilleux, J; Mercier, M; Poulin, JF; Maclellan, K; Lepage, S; Rouleau, JL; Bruinsma, N; Levesque, C; DeLarochelliere, R; LeBlanc, M; Kouz, S; Kiwan, GS; Laforest, M; Brooks, J; Bouchard, G; Gervais, PB; Brophy, J; Gagnon, J; Habib, N; Basu, AK; Lutterodt, AT; Khouri, M; Gorlin, R; Egan, D; Garg, R; Yusuf, S; Montague, T; Smith, TW; Cohn, JN; Dagenais, GR; Davies, R; Johnstone, DE; Fye, C; Sather, MR; Deykin, D; Francis, G; Collins, JF; Williford, WO; Singh, BN				Perry, G; Brown, E; Thornton, R; Shiva, T; Hubbard, J; Reddy, KR; Doherty, JE; Cardello, FP; Fast, A; Radford, MJ; Folger, JS; Bhaskar, G; Zoble, RG; Sridharan, V; Sridharan, MR; Loungani, RR; Gheorghiade, M; Hsieh, A; Tommaso, C; Mansuri, M; Guess, MA; Akhtar, S; Wagner, S; Hagan, K; McIntyre, KM; Ruble, P; Moten, M; Riley, A; Pierpont, G; Anand, I; Patel, G; Puram, BS; Eladasari, BR; Karnegis, J; Gillie, E; Crawford, MH; Graettinger, WF; Shah, A; Sacco, J; Chaudhry, MA; Dolen, D; ElSherif, N; BekheitSaad, S; Campos, EE; Greene, JG; Khanijo, V; Kumar, U; Mallis, GI; Mookherjee, S; DibnerDunlap, M; Gupta, SC; Danisa, K; Thadani, U; Tan, A; Rajachar, M; Amidi, M; OReilly, MV; Hassapoyannes, CA; Davies, ML; Kumar, VA; Okerson, D; Ramanathan, KB; Putatunda, B; Gollapudi, A; Montero, A; Mohanty, PK; Lui, C; Thagirisa, S; Lee, RW; Glatter, TR; Bodine, K; Roberts, D; Bertoglio, M; Dennish, GW; Sarma, RJ; Gregoratos, G; Rausch, DC; Pitt, WA; Kennelly, BM; Fahrenholtz, D; Gordon, R; Horwitz, L; Rothbart, R; Nutting, P; Lutz, L; Copen, DL; Rashkow, A; Babb, J; VanVoorhees, L; Silverman, A; Stillabower, ME; Miller, AB; NguyenPho, HT; Safford, RE; Fishman, S; Neiman, JC; Stein, M; Dominguez, JC; Abernathy, GT; Nair, PH; Goodman, LS; Cook, TH; Wickemeyer, WJ; Berkson, DM; Mathew, J; Richman, HG; Lubell, DL; Lang, R; Zajac, EJ; Rosenstein, R; Silver, MA; Shanes, JG; Kelly, KJ; Pequignot, MH; Campbell, R; Kirlin, PC; Ziperman, DB; Denny, DM; Gamble, L; Weiss, M; Kaimal, PK; Dhurandhar, RW; Ventura, H; Godley, ML; Pu, C; Schick, EC; Barbour, DJ; Salmon, D; Goldstein, M; Effron, MB; Fleg, JL; Baughman, KL; Weiss, R; Ericson, K; Sturrock, WA; Heinsimer, J; Timmis, GC; Smith, S; Shrestha, DD; Duvernoy, WFC; Hickner, J; Lewis, BK; OBrien, TK; Yarows, SA; Willens, HJ; Mast, DJ; Johnson, TH; Rodeheffer, RJ; Siefert, M; Swenson, L; Denes, P; Gudapati, R; Charles, FR; Rich, MW; Beckham, V; Hamilton, WP; Abele, PB; Harper, DM; OKelly, RL; Forker, AD; Kahl, FR; Garrou, BW; Klang, TE; Popio, K; Mohiuddin, S; Pollak, EM; Chiaramida, A; Gregory, JJ; Papa, LA; Abrams, J; Ung, S; Jutila, CK; Croke, RP; Chiaramida, S; Lucariello, R; Rim, DA; Goldberger, MH; Kohn, RM; Graham, S; Philbin, EF; Sheesley, K; Nafziger, A; Macina, G; Hsueh, JT; Zoneraich, S; Binder, A; Weinstein, C; Morrison, J; Cameron, A; Vanderbush, E; Brown, J; Pande, PN; Lader, E; Kay, R; Bloomfield, D; Costantino, T; Heiselman, DE; Radwany, S; Smith, MR; Hobbs, RE; Fraker, TD; Frerking, TR; DeLeon, AC; Christie, LG; Toren, M; Grover, J; McBarron, FD; Harris, DE; McLean, RW; Morris, L; Zatuchni, J; Boehmer, JP; Clemson, BS; Lipshutz, H; Small, RS; Ufret, R; LugoRodriquez, JE; Khan, AH; Yousefian, M; Friesinger, GC; Ely, D; Farmer, JA; Young, JB; Payne, RM; Fowles, RE; Lee, AB; Shalev, Y; AlBitar, I; Schroeder, GS; Radant, L; Hankey, TL; Rezkalla, S; Groden, DL; Teo, KK; Humen, DP; Wong, D; Greenwood, PV; Talibi, T; Hui, W; Klinke, WP; Senaratne, MPJ; Goeres, M; Hughes, DF; Sayeed, MAR; Roth, DL; Belenkie, I; Manyari, DE; Borgersen, K; Read, L; Kinloch, D; Reid, R; Barber, NC; Horner, BA; Kenefick, G; Kuritzky, RA; Imrie, JR; Wagner, KR; Rabkin, SW; Mizgala, HF; Tarry, L; Dodek, A; Kornder, JM; Ashton, T; Barr, D; Dufton, J; Sweeny, R; Morris, A; Bessoudo, R; Marr, D; Milton, JR; Thompson, B; Robinson, V; Sussex, BA; Tobin, M; McMahon, DP; Folkins, D; Crowell, R; Lalonde, LD; Koilpillai, C; Hatheway, RJ; OReilly, MG; Machel, T; Hack, I; Stewart, JW; Tanser, PH; Sullivan, B; Hagar, S; Quinn, B; Davies, RA; Baird, MG; Williams, WL; LeMay, M; Higginson, L; Turek, M; Sochowski, RA; Weeks, A; Jacobs, MH; Baigrie, R; DeVilla, MA; Vertes, G; Bozek, B; Goode, JE; Ricci, AJ; Swan, J; Fell, DA; LevinoffRoth, SN; Arnold, JMO; Patrick, L; Southern, RF; Rinne, C; Brisbin, D; DeYoung, JP; Baitz, T; Vizel, S; Minkowitz, J; Letarte, P; Chan, YK; Kwok, KK; Nawaz, S; Ganjavi, F; Yao, L; Misterski, J; Raco, DL; Hess, AR; Kuruvilla, G; Silverberg, L; Borts, D; Fulop, JC; Weingert, ME; Carter, RP; Sahay, BM; Hickey, JE; Lalonde, G; Gosselin, G; Bourassa, MG; Goulet, C; Joyal, M; Methe, M; Honos, G; Fitchett, D; Serpa, A; Sestier, F; Roberge, G; Latour, Y; Rondeau, C; Gossard, D; Lenis, JHF; Brossoit, R; Simard, L; Delage, F; Auger, P; Saulnier, D; Talbot, P; Beaudoin, J; Campeau, J; Pruneau, G; Tamilia, M; Boutros, G; Comeau, B; Starra, R; StHilaire, R; Veilleux, J; Mercier, M; Poulin, JF; Maclellan, K; Lepage, S; Rouleau, JL; Bruinsma, N; Levesque, C; DeLarochelliere, R; LeBlanc, M; Kouz, S; Kiwan, GS; Laforest, M; Brooks, J; Bouchard, G; Gervais, PB; Brophy, J; Gagnon, J; Habib, N; Basu, AK; Lutterodt, AT; Khouri, M; Gorlin, R; Egan, D; Garg, R; Yusuf, S; Montague, T; Smith, TW; Cohn, JN; Dagenais, GR; Davies, R; Johnstone, DE; Fye, C; Sather, MR; Deykin, D; Francis, G; Collins, JF; Williford, WO; Singh, BN			The effect of digoxin on mortality and morbidity in patients with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WITHDRAWAL; DIGITALIS; TRIAL	Background The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and hospitalization in a randomized, double-blind clinical trial. Methods In the main trial, patients with left ventricular ejection fractions of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo. Results In the main trial, mortality was unaffected. There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P = 0.80). In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95 percent confidence interval, 0.77 to 1.01; P = 0.06). There were 6 percent fewer hospitalizations overall in that group than in the placebo group, and fewer patients were hospitalized for worsening heart failure (26.8 percent vs. 34.7 percent; risk ratio, 0.72; 95 percent confidence interval, 0.66 to 0.79; P < 0.001). In the ancillary trial, the findings regarding the primary combined outcome of death or hospitalization due to worsening heart failure were consistent with the results of the main trial. Conclusions Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure. These findings define more precisely the role of digoxin in the management of chronic heart failure. (C) 1997, Massachusetts Medical Society.	MT SINAI MED CTR,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai			Arnold, Malcolm/G-2869-2011; Rich, Michael/AAD-6167-2022; brophy, james/H-6673-2019; Effron, Mark B./P-9300-2015; Harper, Diane M./I-2180-2014; Sarma, Radha/AAK-1026-2020	Rich, Michael/0000-0002-4243-9391; brophy, james/0000-0001-8049-6875; Effron, Mark B./0000-0003-4050-5030; Harper, Diane M./0000-0001-7648-883X; 				*DIG INV GROUP, 1996, CONTROLLED CLIN TRIA, V17, P77; JAESCHKE R, 1990, AM J MED, V88, P279, DOI 10.1016/0002-9343(90)90154-6; JELLIFFE RW, 1974, AM J MED, V57, P63, DOI 10.1016/0002-9343(74)90769-4; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; YUSUF S, 1990, CIRCULATION, V82, P673; YUSUF S, 1992, AM J CARDIOL, V69, pG64, DOI 10.1016/0002-9149(92)91255-3; YUSUF S, 1986, CIRCULATION, V73, P14, DOI 10.1161/01.CIR.73.1.14; YUSUF S, 1990, HEART FAILURE ARRHYT, P147	11	1963	2031	1	72	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 20	1997	336	8					525	533						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WJ240	9036306				2022-12-28	WOS:A1997WJ24000001
J	Harrington, L; McPhail, T; Mar, V; Zhou, W; Oulton, R; Bass, MB; Arruda, I; Robinson, MO				Harrington, L; McPhail, T; Mar, V; Zhou, W; Oulton, R; Bass, MB; Arruda, I; Robinson, MO			A mammalian telomerase-associated protein	SCIENCE			English	Article							TETRAHYMENA-TELOMERASE; RNA TEMPLATE; SECONDARY STRUCTURE; IMMORTAL CELLS; NUCLEAR RNAS; YEAST; ELONGATION; VECTORS; RIBONUCLEOPROTEIN; SENESCENCE	The telomerase ribonucleoprotein catalyzes the addition of new telomeres onto chromosome ends. A gene encoding a mammalian telomerase homolog called TP1 (telomerase-associated protein 1) was identified and cloned. TP1 exhibited extensive amino acid similarity to the Tetrahymena telomerase protein p80 and was shown to interact specifically with mammalian telomerase RNA. Antiserum to TP1 immunoprecipitated telomerase activity from cell extracts,suggesting that TP1 is associated with telomerase in vivo. The identification of TP1 suggests that telomerase-associated proteins are conserved from ciliates to humans.	AMGEN INC, AMGEN EST PROGRAM, THOUSAND OAKS, CA 91320 USA	Amgen	Harrington, L (corresponding author), UNIV TORONTO, ONTARIO CANC INST, AMGEN INST, DEPT MED BIOPHYS, 620 UNIV AVE, TORONTO, ON M5G 2C1, CANADA.			Robinson, Murray/0000-0003-4462-0685				ARES M, 1986, CELL, V47, P49, DOI 10.1016/0092-8674(86)90365-X; ARRUDA I, UNPUB; AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DEUTSCHER SL, 1988, P NATL ACAD SCI USA, V85, P9479, DOI 10.1073/pnas.85.24.9479; DING SW, 1989, VIROLOGY, V172, P555, DOI 10.1016/0042-6822(89)90198-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; GOOD PD, 1994, GENE, V151, P209, DOI 10.1016/0378-1119(94)90658-0; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARPER JW, 1993, CELL, V75, P805; HARRINGTON L, 1995, J BIOL CHEM, V270, P8893, DOI 10.1074/jbc.270.15.8893; Kaiser C., 1994, METHODS YEAST GENETI; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; Lendvay TS, 1996, GENETICS, V144, P1399; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MCCORMICKGRAHAM M, 1995, NUCLEIC ACIDS RES, V23, P1091, DOI 10.1093/nar/23.7.1091; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TENDAM E, 1991, NUCLEIC ACIDS RES, V19, P6951; TOLLERVEY D, 1983, CELL, V35, P753, DOI 10.1016/0092-8674(83)90108-3; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAUG AJ, 1995, RNA, V1, P363; ZHOU WJ, UNPUB	49	614	664	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 14	1997	275	5302					973	977		10.1126/science.275.5302.973	http://dx.doi.org/10.1126/science.275.5302.973			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020079				2022-12-28	WOS:A1997WH38800044
J	Smiley, ST; Kaplan, MH; Grusby, MJ				Smiley, ST; Kaplan, MH; Grusby, MJ			Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells	SCIENCE			English	Article							II-DEFICIENT MICE; NK1.1(+) T-CELLS; IN-VIVO; THYMOCYTES; CD1; CD4(+); IL-4; CD4+; EXPRESSION; MOLECULES	A lymphocyte population that expresses surface markers found on T cells and natural killer (NK) cells secretes large amounts of interleukin-4 (IL-4) immediately after T cell receptor ligation. These NK-like T cells are thus thought to be important for the initiation of type 2 T helper cell (T(H)2) responses. CD1-deficient mice were found to lack this lymphocyte subset, but they could nevertheless mount a protypical T(H)2 response; after immunization with antibody to immunoglobulin D (IgD), CD1-deficient mice produced IgE. Thus, although dependent on CD1 for their development, IL-4-secreting NK-like T cells are not required for T(H)2 responses.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School					PHS HHS [R01 A140171] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BALK SP, 1991, J IMMUNOL, V146, P768; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BRADBURY A, 1988, EMBO J, V7, P3081, DOI 10.1002/j.1460-2075.1988.tb03173.x; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; COLES MC, 1994, J EXP MED, V180, P395, DOI 10.1084/jem.180.1.395; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MACDONALD HR, 1995, J EXP MED, V182, P633, DOI 10.1084/jem.182.3.633; SEDER RA, 1992, J IMMUNOL, V148, P1652; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; YOSHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P11931, DOI 10.1073/pnas.92.25.11931; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	28	427	437	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 14	1997	275	5302					977	979		10.1126/science.275.5302.977	http://dx.doi.org/10.1126/science.275.5302.977			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH388	9020080				2022-12-28	WOS:A1997WH38800045
J	Scanziani, M; Salin, PA; Vogt, KE; Malenka, RC; Nicoll, RA				Scanziani, M; Salin, PA; Vogt, KE; Malenka, RC; Nicoll, RA			Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors	NATURE			English	Article							GUINEA-PIG HIPPOCAMPUS; METHYL-D-ASPARTATE; MOSSY FIBER LTP; TRANSMISSION; ACID; INHIBITION; RESPONSES; SYNAPSES; NEURONS	The classical view of fast chemical synaptic transmission is that released neurotransmitter acts locally on postsynaptic receptors and is cleared from the synaptic cleft within a few milliseconds by diffusion and by specific reuptake mechanisms. This rapid clearance restricts the spread of neurotransmitter and, combined with the low affinities of many ionotropic receptors, ensures that synaptic transmission occurs in a point-to-point fashion(1). We now show, however, that when transmitter release is enhanced at hippocampal messy fibre synapses, the concentration of glutamate increases and its clearance is delayed; this allows it to spread away from the synapse and to activate presynaptic inhibitory metabotropic glutamate receptors (mGluRs). At normal levels of glutamate release during low-frequency activity, these presynaptic receptors are not activated. When glutamate concentration is increased by higher-frequency activity or by blocking glutamate uptake, however, these receptors become activated, leading to a rapid inhibition of transmitter release. This effect may be related to the long-term depression of messy fibre synaptic responses that has recently been shown after prolonged activation of presynaptic mGluRs (refs 2, 3). The use-dependent activation of presynaptic mGluRs that we describe here thus represents a negative feedback mechanism for controlling the strength of synaptic transmission.	UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Salin, Paul/0000-0001-5221-9109; Vogt, Kaspar/0000-0002-0859-876X				BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BERGLES DE, 1996, NEUR ABSTR, V22, P797; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CHICUREL ME, 1992, J COMP NEUROL, V323, P1; Conn PJ., 1994, METABOTROPIC GLUTAMA; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GLAUM SR, 1993, J NEUROPHYSIOL, V70, P2669, DOI 10.1152/jn.1993.70.6.2669; HAMLYN LH, 1962, J ANAT, V96, P112; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HSIA AY, 1995, NEUROPHARMACOLOGY, V34, P1567, DOI 10.1016/0028-3908(95)00115-M; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; Kobayashi K, 1996, SCIENCE, V273, P648, DOI 10.1126/science.273.5275.648; Kullmann DM, 1996, NEURON, V17, P461, DOI 10.1016/S0896-6273(00)80178-6; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P17, DOI 10.1016/0306-4522(88)90124-8; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; Shigemoto R., 1995, Society for Neuroscience Abstracts, V21, P846; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; YAMAMOTO C, 1983, EXP BRAIN RES, V51, P128; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645	28	391	416	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 13	1997	385	6617					630	634		10.1038/385630a0	http://dx.doi.org/10.1038/385630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024660				2022-12-28	WOS:A1997WH29400049
J	Hauptman, PJ; OConnor, KJ				Hauptman, PJ; OConnor, KJ			Medical programs - Procurement and allocation of solid organs for transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEART-BEATING DONORS; WALL-MOTION ABNORMALITIES; HEALTH-CARE PROFESSIONALS; LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; CARDIAC TRANSPLANTATION; KIDNEY-TRANSPLANTATION; UNITED-STATES; INTRAVASCULAR ULTRASOUND; SUBARACHNOID HEMORRHAGE		HARVARD UNIV, SCH MED, BOSTON, MA USA; NEW ENGLAND ORGAN BANK INC, NEWTON, MA USA	Harvard University; Harvard Medical School	Hauptman, PJ (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA.							ABOUNA GM, 1993, TRANSPLANT P, V25, P2310; ALEXANDER JW, 1994, TRANSPLANTATION, V57, P871, DOI 10.1097/00007890-199403270-00018; ALEXANDER JW, 1991, TRANSPLANTATION, V51, P135, DOI 10.1097/00007890-199101000-00021; ALTSHULER JS, 1992, JAMA-J AM MED ASSOC, V267, P2037, DOI 10.1001/jama.1992.03480150043029; ANDRES A, 1993, NEW ENGL J MED, V328, P1644, DOI 10.1056/NEJM199306033282220; ANGSTWURM H, 1984, TRANSPLANT P, V16, P95; ASCHER NL, 1996, ORGAN PROCUREMENT PR; BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; BARGER B, 1992, TRANSPLANTATION, V53, P770, DOI 10.1097/00007890-199204000-00013; BARKOUKIS TJ, 1993, TRANSPLANTATION, V55, P1434; BART KJ, 1979, TRANSPLANT P, V11, P455; BART KJ, 1981, TRANSPLANTATION, V31, P383, DOI 10.1097/00007890-198105010-00016; BOTAS J, 1995, CIRCULATION, V92, P1126, DOI 10.1161/01.CIR.92.5.1126; BROELSCH CE, 1994, HEPATOLOGY, V20, pS49, DOI 10.1016/0270-9139(94)90273-9; BURGESS BL, 1994, TRANSPLANTATION, V58, P734; CACCIARELLI TV, 1993, TRANSPLANT P, V25, P3140; Callender C O, 1982, J Natl Med Assoc, V74, P807; CALLENDER CO, 1991, NEW ENGL J MED, V325, P442, DOI 10.1056/NEJM199108083250631; CASAVILLA A, 1995, TRANSPLANT P, V27, P710; CECKA JM, 1995, TRANSPLANT P, V27, P801; Cho Y W, 1994, Clin Transpl, P435; CLARKSON K, 1991, ANN INTERN MED, V115, P877, DOI 10.7326/0003-4819-115-11-877; CLERICI M, 1992, NEW ENGL J MED, V327, P564, DOI 10.1056/NEJM199208203270813; COHEN RG, 1994, ANN THORAC SURG, V57, P1423, DOI 10.1016/0003-4975(94)90095-7; *COUNC TRANSPL SOC, 1985, LANCET, V82, P715; CUTLER JA, 1993, TRANSPLANTATION, V56, P225; Daemen JHC, 1996, TRANSPL P, V28, P105; DALESSANDRO AM, 1995, TRANSPLANTATION, V59, P977, DOI 10.1097/00007890-199504150-00009; DAlmeida P, 1996, TRANSPLANT P, V28, P93; DARBY JM, 1989, JAMA-J AM MED ASSOC, V261, P2222, DOI 10.1001/jama.261.15.2222; DAWIDSON I, 1993, TRANSPLANT P, V25, P3139; DEBY T, 1991, TRANSPLANT P, V23, P2665; DEFARIA JBL, 1993, TRANSPLANTATION, V56, P1583; DETROZ B, 1991, TRANSPLANT P, V23, P2657; DEVITA MA, 1995, PROCURING ORGANS TRA, P33; DOMINGUEZROLDAN JM, 1992, TRANSPLANT P, V24, P29; DONALDSON P, 1993, HEPATOLOGY, V17, P1008, DOI 10.1002/hep.1840170611; DOUTRELEPONT JM, 1995, TRANSPLANT P, V27, P1789; ECKHOFF DE, 1996, ORGAN PROCUREMENT PR; Eggers P W, 1995, Health Care Financ Rev, V17, P89; ERICZON BG, 1987, TRANSPLANT P, V19, P3862; EVANS RW, 1993, JAMA-J AM MED ASSOC, V269, P3113, DOI 10.1001/jama.269.24.3113; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; FERNANDEZ M, 1991, TRANSPL P, V23, P1799; Fishman JA, 1996, TRANSPLANTATION, V62, P147, DOI 10.1097/00007890-199607270-00001; Friedlaender MM, 1996, TRANSPLANTATION, V61, P1549, DOI 10.1097/00007890-199605270-00024; GABER AO, 1990, TRANSPLANT P, V22, P313; GARRISON RN, 1991, SURG GYNECOL OBSTET, V173, P391; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; GLASSON J, 1994, JAMA-J AM MED ASSOC, V272, P809, DOI 10.1001/jama.1994.03520100071036; GOMEZ E, 1995, TRANSPLANTATION, V59, P156, DOI 10.1097/00007890-199501150-00031; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; HAUPTMAN PJ, 1995, J HEART LUNG TRANSPL, V14, P654; HAUPTMAN PJ, 1994, NEW ENGL J MED, V331, P404; HAUPTMAN PJ, 1993, CIRCULATION, V88, P287; HEBERT MJ, 1992, NEW ENGL J MED, V326, P1571; HEINEMAN E, 1995, TRANSPLANT P, V27, P2895; HIMES L, 1995, J TRANSPLANT COORD, V5, P87; HO JK, 1994, TRANSPL P, V26, P2269; HO M, 1990, PRINCIPLES PRACTICE, P2284; HOLZER BR, 1985, TRANSPLANTATION, V39, P315, DOI 10.1097/00007890-198503000-00023; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; IWAKI Y, 1993, TRANSPLANTATION, V56, P1528; Jacobbi LM, 1995, TRANSPLANTATION, V60, P1491, DOI 10.1097/00007890-199560120-00021; JEEVANANDAM V, 1994, J HEART LUNG TRANSPL, V13, P681; KAPPEL DF, 1993, TRANSPLANT P, V25, P2489; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Kirkman R L, 1993, Clin Transpl, P317; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; KRON IL, 1993, ANN SURG, V217, P518, DOI 10.1097/00000658-199305010-00012; LAKS H, 1993, J HEART LUNG TRANSPL, V12, P810; Laks Hillel, 1996, Journal of Heart and Lung Transplantation, V15, pS41; LAPUMA J, 1995, MANAGED CARE, V4, P49; LASKE A, 1992, TRANSPLANT P, V24, P2679; LAZDA VA, 1991, TRANSPLANT P, V23, P901; Love Robert B., 1995, Journal of Heart and Lung Transplantation, V14, pS88; MALININ T, 1996, ORGAN PROCUREMENT PR; MARKIN RS, 1993, TRANSPLANTATION, V56, P1403, DOI 10.1097/00007890-199312000-00025; MATHER PJ, 1995, J AM COLL CARDIOL, V26, P737, DOI 10.1016/0735-1097(95)00216-Q; MERRILL JP, 1956, JAMA-J AM MED ASSOC, V160, P277, DOI 10.1001/jama.1956.02960390027008; MILFRED SK, 1994, TRANSPLANTATION, V57, P568; MOR E, 1992, TRANSPLANTATION, V53, P383, DOI 10.1097/00007890-199202010-00022; MORENO EG, 1991, BRIT J SURG, V78, P813, DOI 10.1002/bjs.1800780715; *NAT HIGHW TRAFF S, 1996, TRAFF SAF FACTS COMP; NATHAN HM, 1991, TRANSPLANTATION, V51, P142, DOI 10.1097/00007890-199101000-00022; Nathan HM, 1996, ANN INTERN MED, V124, P374, DOI 10.7326/0003-4819-124-3-199602010-00029; *NEW ENGL ORG BANK, 1988, ANN REP; NOVITZKY D, 1990, TRANSPLANTATION, V49, P311, DOI 10.1097/00007890-199002000-00017; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; ORLOFF MS, 1994, ANN SURG, V220, P578; PASIC M, 1993, NEW ENGL J MED, V328, P319, DOI 10.1056/NEJM199302043280505; PENN I, 1991, TRANSPLANT P, V23, P2629; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; PEREZ LM, 1988, TRANSPLANTATION, V46, P553, DOI 10.1097/00007890-198810000-00017; PEREZ MS, 1993, TRANSPLANT P, V25, P2492; PHILLIPS MG, 1996, ORGAN PROCUREMENT PR; Pierce GA, 1996, TRANSPLANT P, V28, P12; PIRSCH JD, 1992, NEW ENGL J MED, V326, P412; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; PROTTAS J, 1988, AM J PUBLIC HEALTH, V78, P642, DOI 10.2105/AJPH.78.6.642; Provoost A P, 1993, Curr Opin Nephrol Hypertens, V2, P521; QUNIBI W, 1995, CLIN TRANSPLANT, V9, P317; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P176, DOI 10.1001/jama.1991.03460020020005; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P1227, DOI 10.1001/jama.265.10.1227; RANDALL T, 1991, JAMA-J AM MED ASSOC, V265, P1223, DOI 10.1001/jama.265.10.1223; RAPAPORT FT, 1993, TRANSPLANT P, V25, P1507; RENE AA, 1995, TRANSPL P, V27, P1893; Renoult E, 1996, TRANSPLANT P, V28, P181; RUBIN RH, 1990, REV INFECT DIS, V12, pS754; RUIZ JC, 1993, TRANSPLANTATION, V55, P682; SAVARIA DT, 1990, TRANSPLANT P, V22, P316; SCHLUMPF R, 1995, TRANSPLANT P, V27, P2942; SCHUTT GR, 1995, TRANSPLANT P, V27, P1450; SELLS RA, 1992, TRANSPLANT P, V24, P2198; SHAFER T, 1994, JAMA-J AM MED ASSOC, V272, P1607, DOI 10.1001/jama.272.20.1607; Sheehy E, 1996, TRANSPLANT P, V28, P139; SHROYER TW, 1996, ORGAN PROCUREMENT PR; SIMINOFF LA, 1995, ANN INTERN MED, V123, P10, DOI 10.7326/0003-4819-123-1-199507010-00037; SIMONDS RJ, 1992, NEW ENGL J MED, V326, P726, DOI 10.1056/NEJM199203123261102; SOIFER BE, 1989, ANN INTERN MED, V111, P189; SOIFER BE, 1989, ANN INTERN MED, V110, P814, DOI 10.7326/0003-4819-110-10-814; SOULILLOU JP, 1995, NEW ENGL J MED, V333, P379, DOI 10.1056/NEJM199508103330610; SPEES EK, 1990, TRANSPLANT P, V22, P374; SPITAL A, 1991, NEW ENGL J MED, V325, P1243, DOI 10.1056/NEJM199110243251710; SPITAL A, 1990, TRANSPLANT P, V22, P2414; STEIN A, 1995, BMJ-BRIT MED J, V310, P1149, DOI 10.1136/bmj.310.6988.1149; STERNECK MR, 1995, TRANSPLANTATION, V60, P667, DOI 10.1097/00007890-199510150-00009; STEVENSON LW, 1991, J AM COLL CARDIOL, V18, P919, DOI 10.1016/0735-1097(91)90747-W; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106; SUMRANI N, 1991, TRANSPLANTATION, V51, P305, DOI 10.1097/00007890-199102000-00005; SWEENEY MS, 1990, ANN THORAC SURG, V50, P7, DOI 10.1016/0003-4975(90)90071-D; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TAKEMOTO S, 1994, NEW ENGL J MED, V331, P760, DOI 10.1056/NEJM199409223311202; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; TUZCU EM, 1995, CIRCULATION, V91, P1706, DOI 10.1161/01.CIR.91.6.1706; *UN NETW ORG SHAR, 1994, REP CTR SPC GRAFT PA; *UN NETW ORG SHAR, 1995, 1995 ANN REP US SCI; *UNOS, 1996, UNOS B           NOV, V1; VALERO R, 1995, TRANSPLANT P, V27, P2899; VIRNIG BA, 1992, TRANSPLANT P, V24, P2155; WALLER JA, 1993, TRANSPLANTATION, V55, P542, DOI 10.1097/00007890-199303000-00016; WARREN J, 1996, TRANSPLANT NEWS, V6, P1; Wekerle Thomas, 1996, Journal of Heart and Lung Transplantation, V15, pS52; WERKMAN HA, 1991, TRANSPLANT P, V23, P2553; WICK L, 1995, TRANSPL P, V27, P2539; WIJNEN RMH, 1995, TRANSPLANT P, V27, P2945; YANG SL, 1993, TRANSPLANT P, V25, P2487; YOUNG JB, 1994, J HEART LUNG TRANSPL, V13, P353; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; 1987, MMWR-MORBID MORTAL W, V36, P306	151	100	100	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					422	431		10.1056/NEJM199702063360607	http://dx.doi.org/10.1056/NEJM199702063360607			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010150				2022-12-28	WOS:A1997WF85900007
J	Ghali, WA; Ash, AS; Hall, RE; Moskowitz, MA				Ghali, WA; Ash, AS; Hall, RE; Moskowitz, MA			Statewide quality improvement initiatives and mortality after cardiac surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE	Background.-Recent reports from New York and northern New England claim that statewide quality improvement initiatives and outcome reporting are leading to decreased mortality following coronary artery bypass graft (CABG) surgery. Objective.-To compare trends in mortality after CABG surgery in Massachusetts (a state that has not instituted statewide outcome reporting) with the decreases reported from New York and northern New England. Design.-Surgical cohorts from 1990, 1992, and 1994 were used to evaluate the risk-adjusted mortality trend for Massachusetts. We present this trend along with the published trends from New York and northern New England. For comparison, we also present unadjusted Medicare mortality trends from Massachusetts, New York, northern New England, and the entire United States. Setting.-All 12 Massachusetts hospitals performing cardiac surgery (excluding a Veterans Affairs hospital). Patients and Data Sets.-Massachusetts administrative data were used to identify all patients undergoing isolated CABG surgery in 1990, 1992, and 1994. Main Outcome Measures.-Observed and risk-adjusted in-hospital mortality. Results.-Observed mortality rates in Massachusetts decreased from 4.7% in 1990 to 3.5% in 1992 and to 3.3% in 1994. The corresponding risk-adjusted mortality reductions for 1992 and 1994 (relative to 1990) were 35% and 42%, respectively. The mortality reduction seen in Massachusetts is comparable to the reductions seen in New York and northern New England over similar periods. Unadjusted Medicare mortality trends were generally similar in the states under study, and in the United States as a whole. Conclusions.-In-hospital mortality after CABG surgery has decreased in Massachusetts despite the absence of statewide outcome reporting. Direct program evaluations are needed to better characterize the efficacy of the ongoing statewide outcome studies in New York and northern New England.	BOSTON MED CTR, DEPT MED, GEN INTERNAL MED SECT, HLTH CARE RES UNIT, BOSTON, MA 02118 USA	Boston Medical Center			Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253				*3M HLTH INF SYST, 1992, DIAGN REL GROUPS VER; CAIRNS JA, 1992, CHEST, V102, pS482, DOI 10.1378/chest.102.4_Supplement.482S; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; DENSEN PM, 1980, NEW ENGL J MED, V302, P171, DOI 10.1056/NEJM198001173020311; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Ghali WA, 1996, J CLIN EPIDEMIOL, V49, P273, DOI 10.1016/0895-4356(95)00564-1; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Kasper J F, 1992, QRB Qual Rev Bull, V18, P129; KIRKLIN JW, 1989, CIRCULATION, V79, P81; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; *US DEP HHS PHS, 1988, INT CLASS DIS 9 REV; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	20	153	154	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 5	1997	277	5					379	382		10.1001/jama.277.5.379	http://dx.doi.org/10.1001/jama.277.5.379			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WE771	9010169				2022-12-28	WOS:A1997WE77100027
J	Aurigemma, G				Aurigemma, G			Has thrombolytic therapy changed the equation for postinfarction risk stratification?	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION				Aurigemma, G (corresponding author), UNIV MASSACHUSETTS,DIV CARDIOVASC MED,WORCESTER,MA 01655, USA.							Basu S, 1996, BMJ-BRIT MED J, V313, P844; DIAMOND GA, 1993, JAMA-J AM MED ASSOC, V269, P2418, DOI 10.1001/jama.269.18.2418; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; MARX BE, 1995, AM J MED, V98, P550; MOSS AJ, 1993, JAMA-J AM MED ASSOC, V269, P2379, DOI 10.1001/jama.269.18.2379; RYAN TJ, REPORT AM COLEGE CAR; SHAW IJ, 1996, AM J CARDIOL, V78, P1327; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					298	299		10.1016/S0140-6736(05)62820-6	http://dx.doi.org/10.1016/S0140-6736(05)62820-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024369				2022-12-28	WOS:A1997WF79400004
J	Greaves, MF				Greaves, MF			Aetiology of acute leukaemia	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD LEUKEMIA; INFECTIOUS ETIOLOGY; MULTIPLE-SCLEROSIS; MYELOID-LEUKEMIA; INFANT LEUKEMIAS; MLL GENE; CANCER; EPIDEMIOLOGY; TRANSMISSION	Ionising radiation. In high dose and with acute exposure, is a factor that has been implicated in leukaemogenesis, but what is the evidence for leukaemogenesis and exposure to diagnostic X-rays, to natural terrestrial or cosmic ionising radiation, to electromagnetic fields, or to nuclear energy? Why is population mixing and infection a possible explanation for the clusters of childhood acute leukaemias around the nuclear processing plants of Sellafield and Dounreay? These questions, as well as how chemical agents, including therapeutic substances, might contribute to leukaemogenesis, are discussed in this last article in the leukaemia series.			Greaves, MF (corresponding author), INST CANC RES,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND.							Alexander FE, 1997, BRIT J CANCER, V75, P457, DOI 10.1038/bjc.1997.77; ALVORD EC, 1987, J CHILD NEUROL, V2, P313, DOI 10.1177/088307388700200418; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; BACKETT EM, 1957, LANCET, V1, P778; Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713; Boice J. D., 1996, LEUKEMIA, P195; BRIDGES BA, 1996, 4 COMARE COMM MED AS; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Darby S. C., 1995, RAD TOXICOLOGY BONE, P337; DOLL R, 1995, BRIT J CANCER, V72, P1339, DOI 10.1038/bjc.1995.513; DOLL R, IN PRESS BR J RADIOL; DRAPER G, 1993, BRIT MED J, V307, P884, DOI 10.1136/bmj.307.6909.884; DWORSKY M, 1983, PEDIATRICS, V72, P295; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GREAVES M, 1996, LEUKEMIA, P34; Greaves MF, 1996, LEUKEMIA, V10, P372; GREAVES MF, 1993, LEUKEMIA, V7, P349; GRUNWALD H, 1996, LEUKEMIA, P179; GUTENSOHN N, 1981, NEW ENGL J MED, V304, P135, DOI 10.1056/NEJM198101153040302; HEATH CW, 1963, AM J MED, V34, P796, DOI 10.1016/0002-9343(63)90088-3; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KURTZKE JF, 1986, NEUROLOGY, V36, P307, DOI 10.1212/WNL.36.3.307; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; Petridou E, 1996, NATURE, V382, P352, DOI 10.1038/382352a0; PETRIDOU E, 1993, BRIT MED J, V307, P774, DOI 10.1136/bmj.307.6907.774; Poirel H, 1996, BLOOD, V87, P2496, DOI 10.1182/blood.V87.6.2496.bloodjournal8762496; PRESTON DL, 1994, RADIAT RES, V137, pS68, DOI 10.2307/3578893; Pui CH, 1995, LEUKEMIA, V9, P1990; PUI CH, 1995, LEUKEMIA, V9, P762; ROBISON LL, 1995, ENVIRON HEALTH PERSP, V103, P111, DOI 10.2307/3432358; ROSS JA, 1994, J NATL CANCER I, V86, P1678, DOI 10.1093/jnci/86.22.1678; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; Shu XO, 1996, JNCI-J NATL CANCER I, V88, P24, DOI 10.1093/jnci/88.1.24; Smith MA, 1996, JNCI-J NATL CANCER I, V88, P407, DOI 10.1093/jnci/88.7.407; TAYLOR GM, 1995, LEUKEMIA, V9, P440; Taylor GM, 1996, LEUKEMIA, P210; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; UNSCEAR 1994. United Nations Scientific Committee on the Effects of Atomic Radiation, 1994, E94IX11 UNSCEAR; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	45	357	362	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					344	349		10.1016/S0140-6736(96)09412-3	http://dx.doi.org/10.1016/S0140-6736(96)09412-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024390				2022-12-28	WOS:A1997WF79400043
J	Jeffery, KJM; Read, SJ; Peto, TEA; MayonWhite, RT; Bangham, CRM				Jeffery, KJM; Read, SJ; Peto, TEA; MayonWhite, RT; Bangham, CRM			Diagnosis of viral infections of the central nervous system: Clinical interpretation of PCR results	LANCET			English	Article							POLYMERASE CHAIN-REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; BARR-VIRUS DNA; CEREBROSPINAL-FLUID; ENTEROVIRAL MENINGITIS; MEDICAL LITERATURE; USERS GUIDES; AIDS; ENCEPHALITIS; MANAGEMENT	Background Standard laboratory techniques, such as viral culture and serology, provide only circumstantial or retrospective evidence of viral infections of the central nervous system (CNS). We assessed the diagnostic accuracy of PCR of cerebrospinal fluid (CSF) in the diagnosis of viral infections of the CNS. Methods We examined all the CSF samples that were received at our diagnostic virology laboratory between May, 1994, and May, 1996, by nested PCR for viruses associated with CNS infections in the UK. We collected clinical and laboratory data for 410 patients from Oxford city hospitals (the Oxford cohort) whose CSF was examined between May, 1994, and May, 1995. These patients were classified according to the likelihood of a viral infection of the CNS. We used stratified logistic regression analysis to identify the clinical factors independently associated with a positive PCR result. We calculated likelihood ratios to estimate the clinical usefulness of PCR amplification of CSF. Findings We tested 2233 consecutive CSF samples from 2162 patients. A positive PCR result was obtained in 143 patients, including 22 from the Oxford cohort. Logistic regression analysis of the Oxford cohort showed that fever, a virus-specific rash, and a CSF white-cell count of 5/mu L or more were independent predictors of a positive PCR result. The likelihood ratio for a definite diagnosis of viral infection of the CNS ir? a patient with a positive PCR result, relative to a negative PCR result, was 88.2 (95% CI 20.6-378). The likelihood ratio for a possible diagnosis of viral infection of the CNS in a patient with a negative PCR result, relative to a positive PCR result, was 0.10 (0.03-0.39). Interpretation A patient with a positive PCR result was 88 times as likely to have a definite diagnosis of viral infection of the CNS as a patient with a negative PCR result. A negative PCR result can be used with moderate confidence to rule out a diagnosis of viral infection of the CNS. We believe that PCR will become the first-line diagnostic test for viral meningitis and encephalitis.	JOHN RADCLIFFE HOSP,PUBL HLTH LAB SERV,DEPT MICROBIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; OXFORDSHIRE HLTH AUTHOR,DIRECTORATE PUBL HLTH & POLICY,OXFORD OX3 9DZ,ENGLAND	University of Oxford; University of Oxford	Jeffery, KJM (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT IMMUNOL,PRAED ST,LONDON W2 1PG,ENGLAND.			Bangham, Charles/0000-0003-2624-3599				ARRIBAS JR, 1995, J CLIN MICROBIOL, V33, P1580, DOI 10.1128/JCM.33.6.1580-1583.1995; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; Dallal GE, 1988, AM STAT, V42, P272; DEAN AG, 1994, EPI INFO 6 VERSION 6; ECHEVARRIA JM, 1994, J MED VIROL, V43, P331, DOI 10.1002/jmv.1890430403; FONG IW, 1995, J CLIN MICROBIOL, V33, P484, DOI 10.1128/JCM.33.2.484-486.1995; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GOZLAN J, 1995, AIDS, V9, P253, DOI 10.1097/00002030-199509030-00006; GUFFOND T, 1994, CLIN INFECT DIS, V18, P744, DOI 10.1093/clinids/18.5.744; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Jeffery KJM, 1996, CURR OPIN INFECT DIS, V9, P132, DOI 10.1097/00001432-199604000-00018; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857; READ SJ, 1997, IN PRESS J CLIN MICR; RICE SK, 1995, CLIN INFECT DIS, V20, P931, DOI 10.1093/clinids/20.4.931; SAWYER MH, 1994, PEDIATR INFECT DIS J, V13, P177, DOI 10.1097/00006454-199403000-00002; SCHLESINGER Y, 1995, CLIN INFECT DIS, V20, P842, DOI 10.1093/clinids/20.4.842; SCHLESINGER Y, 1994, PEDIATRICS, V94, P157; TEDDER DG, 1994, ANN INTERN MED, V121, P334, DOI 10.7326/0003-4819-121-5-199409010-00004; THOREN A, 1994, SCAND J INFECT DIS, V26, P249, DOI 10.3109/00365549409011792; WEBER T, 1994, J INFECT DIS, V169, P1138, DOI 10.1093/infdis/169.5.1138	21	119	124	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 1	1997	349	9048					313	317		10.1016/S0140-6736(96)08107-X	http://dx.doi.org/10.1016/S0140-6736(96)08107-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF794	9024374				2022-12-28	WOS:A1997WF79400010
J	Chaimanee, Y; Suteethorn, V; Jaeger, JJ; Ducrocq, S				Chaimanee, Y; Suteethorn, V; Jaeger, JJ; Ducrocq, S			A new Late Eocene anthropoid primate from Thailand	NATURE			English	Article							EARLY OLIGOCENE; DISCOVERY; SULTANATE; PROVINCE; ORIGINS; OMAN	The fossil record of anthropoid primates from the Middle Eocene of South Asia is so far restricted to two genera (Pondaungia cotteri Pilgrim, 1937 and Amphipithecus mogaungensis Colbert, 1937 from the Eocene Pondaung deposits of Burma) whose anthropoid status and phylogenetic position have long been under debate(1-6) because they represent the oldest highly derived fossil primates of anthropoid grade. Moreover, several new African taxa(7-10), some of which are even older, have been recently included in the suborder Anthropoidea, suggesting an African origin for this group. Conversely, new fossil primates recently discovered in China (Eosimias) have been related to the most primitive representatives of Anthropoidea, alternatively suggesting an Asian origin and a probable Asian radiation centre(11). We report here the discovery of a new anthropoid from the Thai Late Eocene locality of Krabi(12,13), which displays several additional anthropoid characters with regard to those of the Eocene Burmese genera. This species, which is about the size of the Fayum Aegyptopithecus, can be related to the Burmese forms, and it further provides strong additional evidence for a southeast Asian evolutionary centre for anthropoids.	UNIV MONTPELLIER 2,INST SCI EVOLUT,CNRS,UMR 5554,F-34095 MONTPELLIER 5,FRANCE; DEPT MINERAL RESOURCES,GEOL SURVEY DIV,PALEONTOL SECT,BANGKOK 10400,THAILAND	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Department of Mineral Resources - Thailand			Klein, Richard G/B-5910-2009	chaimanee, yaowalak/0000-0002-8432-3880				Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1991, AM J PHYS ANTHROPOL, V85, P159, DOI 10.1002/ajpa.1330850205; CHOW M, 1961, VERTEBRAT PALASIATIC, V1, P1; CIOCHON RL, 1985, SCIENCE, V229, P756, DOI 10.1126/science.229.4715.756; Ciochon Russell L., 1994, P143; Ducrocq S, 1995, J SOUTHE ASIAN EARTH, V12, P65, DOI 10.1016/0743-9547(95)00021-6; DUCROCQ S, 1995, J HUM EVOL, V28, P477, DOI 10.1006/jhev.1995.1035; Ducrocq Stephane, 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Monatshefte, V6, P355; GINGERICH PD, 1980, AM J PHYS ANTHROPOL, V52, P231; Gingerich Philip D., 1994, P163; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; Holroyd Patricia A., 1994, P297; HUSSAIN S T, 1978, Proceedings of the Koninklijke Nederlandse Akademie van Wetenschappen Series B Physical Sciences, V81, P74; Jaeger J.-J., 1985, EVOLUTIONARY RELATIO, P567; Kay Richard F., 1994, P361; Legendre S., 1989, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V16, P1; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1971, NATURE, V232, P489, DOI 10.1038/232489a0; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; SIMONS EL, 1991, INT J PRIMATOL, V1, P163; Simons Elwyn L., 1994, P179; SZALAY FS, 1972, NATURE, V236, P179, DOI 10.1038/236179a0; SZALAY FS, 1970, NATURE, V227, P355, DOI 10.1038/227355a0; THOMAS H, 1991, J HUM EVOL, V20, P33, DOI 10.1016/0047-2484(91)90044-V; THOMAS H, 1989, GEOBIOS-LYON, V22, P101, DOI 10.1016/S0016-6995(89)80091-9; Vianey-Liaud Monique, 1994, Palaeovertebrata (Montpellier), V23, P93; Zdansky O., 1930, Palaeontologia Sinica, V6C, P1	29	83	86	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					429	431		10.1038/385429a0	http://dx.doi.org/10.1038/385429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	WF007	9009188				2022-12-28	WOS:A1997WF00700050
J	McCarthy, MC; Travers, MJ; Kovacs, A; Chen, W; Novick, SE; Gottlieb, CA; Thaddeus, P				McCarthy, MC; Travers, MJ; Kovacs, A; Chen, W; Novick, SE; Gottlieb, CA; Thaddeus, P			Detection and characterization of the cumulene carbenes H2C5 and H2C6	SCIENCE			English	Article							CARBON-CHAIN CARBENE; LABORATORY DETECTION; PROPADIENYLIDENE	Two cumulene carbenes, H2C5 and H2C6, were detected in a supersonic molecular beam by Fourier transform microwave spectroscopy. Their rotational and leading centrifugal distortion constants were determined with high accuracy, such that the entire radio spectrum can now be calculated. Like the known carbenes H2C2 and H2C4, both molecules have singlet electronic ground states and linear carbon-chain backbones. They can be produced in sufficiently high concentrations in the laboratory that their electronic spectra, expected to lie in the visible, should be readily detectable by laser spectroscopy. The microwave spectra of other, more exotic isomers may be detectable as well.	HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; WESLEYAN UNIV,DEPT CHEM,MIDDLETOWN,CT 06459	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Wesleyan University	McCarthy, MC (corresponding author), HARVARD UNIV,DIV ENGN & APPL SCI,29 OXFORD ST,CAMBRIDGE,MA 02138, USA.		Kovacs, Attila/C-1171-2010	Kovacs, Attila/0000-0001-8991-9088; McCarthy, Michael/0000-0001-9142-0008				AVERY LW, 1980, IAU S, V87, P47; BALLE TJ, 1981, REV SCI INSTRUM, V52, P33, DOI 10.1063/1.1136443; BOTSCHWINA P, COMMUNICATION; BROWN RD, 1985, J AM CHEM SOC, V107, P4109, DOI 10.1021/ja00300a001; CEMICHARO J, 1991, ASTROPHYS J, V368, pL43; CEMICHARO J, 1991, ASTROPHYS J, V368, pL39; DOUGLAS AE, 1977, NATURE, V269, P130, DOI 10.1038/269130a0; GOTTLIEB CA, 1986, ASTRON ASTROPHYS, V164, pL5; GOTTLIEB CA, 1993, J CHEM PHYS, V98, P4478, DOI 10.1063/1.465007; HERBIG GH, 1995, ANNU REV ASTRON ASTR, V33, P19, DOI 10.1146/annurev.aa.33.090195.000315; KENNEY JW, 1978, J AM CHEM SOC, V100, P6930, DOI 10.1021/ja00490a027; KIEFER JH, 1992, COMBUST SCI TECHNOL, V82, P101, DOI 10.1080/00102209208951815; KILLIAN TC, 1990, ASTROPHYS J, V365, pL89, DOI 10.1086/185895; LANGER W, UNPUB; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; MALUENDES SA, 1992, CHEM PHYS LETT, V200, P511, DOI 10.1016/0009-2614(92)80083-N; McCarthy MC, 1996, ASTROPHYS J, V467, pL125, DOI 10.1086/310208; McMahon Richard, COMMUNICATION; MILLER JA, 1992, COMBUST FLAME, V91, P21, DOI 10.1016/0010-2180(92)90124-8; OSWALD M, 1995, J MOL SPECTROSC, V169, P181, DOI 10.1006/jmsp.1995.1013; PEARSON JC, 1988, ASTRON ASTROPHYS, V189, pL13; SALEM L, 1992, MOL ORBITAL THEORY C; SMALLEY RE, 1992, ACCOUNTS CHEM RES, V25, P98, DOI 10.1021/ar00015a001; STANTON JF, IN PRESS J AM CHEM S; THADDEUS P, 1993, J CHEM SOC FARADAY T, V89, P2125, DOI 10.1039/ft9938902125; Townes CH., 1955, MICROWAVE SPECTROSCO, V1; Travers MJ, 1996, J MOL SPECTROSC, V180, P75, DOI 10.1006/jmsp.1996.0225; VRTILEK JM, 1990, ASTROPHYS J, V364, pL53, DOI 10.1086/185873; WATSON JKG, 1977, VIBRATIONAL SPECTRA, V6, pCH1; WOON DE, 1995, CHEM PHYS LETT, V244, P45, DOI 10.1016/0009-2614(95)00906-K	31	99	100	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					518	520		10.1126/science.275.5299.518	http://dx.doi.org/10.1126/science.275.5299.518			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999793				2022-12-28	WOS:A1997WE25700040
J	Wang, YB; Martinez, I; Guyot, F; Liebermann, RC				Wang, YB; Martinez, I; Guyot, F; Liebermann, RC			The breakdown of olivine to perovskite and magnesiowustite	SCIENCE			English	Article							SPINEL TRANSFORMATION; HIGH-PRESSURE; SYSTEM MG2SIO4-FE2SIO4; SUBDUCTING LITHOSPHERE; ELECTRON-MICROSCOPY; NATURAL OLIVINE; LOWER MANTLE; BETA-PHASE; MECHANISM; KINETICS	San Carlos olivine crystals under laboratory conditions of 26 gigapascals and 973 to 1473 kelvin (conditions typical of subducted slabs at a depth of 720 kilometers) for periods of a few minutes to 19 hours transformed to the phase assemblage of perovskite and magnesiowustite in two stages: (i) the oxygen sublattice transformed into a cubic close-packed lattice, forming a metastable spinelloid, and (ii) at higher temperatures or longer run durations, this spinelloid broke down to perovskite and magnesiowustite by redistributing silicon and magnesium while maintaining the general oxygen framework. The breakdown was characterized by a blocking temperature of 1000 kelvin, below which olivine remained metastable, and by rapid kinetics once the reaction was activated.	SUNY STONY BROOK,INST MINERAL PHYS,STONY BROOK,NY 11794; SUNY STONY BROOK,CTR HIGH PRESSURE RES,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			GUYOT, François J/C-3824-2016; Martinez, Isabelle/K-7178-2012	GUYOT, François J/0000-0003-4622-2218; Wang, Yanbin/0000-0001-5716-3183				BOLAND JN, 1983, NATURE, V303, P233, DOI 10.1038/303233a0; BREARLEY AJ, 1994, PHYS EARTH PLANET IN, V86, P45, DOI 10.1016/0031-9201(94)05061-9; Burnley PC, 1995, AM MINERAL, V80, P1293; BURNLEY PC, 1989, NATURE, V338, P753, DOI 10.1038/338753a0; BURNLEY PC, 1991, J GEOPHYS RES-SOLID, V96, P425, DOI 10.1029/90JB01937; GREEN HW, 1989, NATURE, V341, P733, DOI 10.1038/341733a0; GREEN HW, 1990, NATURE, V348, P720, DOI 10.1038/348720a0; GREEN HW, 1992, HIGH PRESSURE RES AP, P229; HYDE BG, 1982, Z KRISTALLOGR, V160, P53, DOI 10.1524/zkri.1982.160.1-2.53; ITO E, 1991, NATURE, V351, P140, DOI 10.1038/351140a0; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; ITO E, 1987, HIGH PRESSURE RES MI, P211; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; Kerschhofer L, 1996, SCIENCE, V274, P79, DOI 10.1126/science.274.5284.79; KIRBY SH, 1987, J GEOPHYS RES-SOLID, V92, P13789, DOI 10.1029/JB092iB13p13789; Kirby SH, 1996, REV GEOPHYS, V34, P261, DOI 10.1029/96RG01050; KOHLSTEDT DL, 1976, PHYS CHEM MINER, P35; LACAM A, 1980, NATURE, V228, P155; Liebermann RC, 1992, HIGH PRESSURE RES AP, P19; MADON M, 1989, PHYS CHEM MINER, V16, P320; MADON M, 1983, PHYS EARTH PLANET IN, V33, P31, DOI 10.1016/0031-9201(83)90005-5; MARTINEZ I, IN PRESS J GEOPHYS R; POIRIER JP, 1981, PHYS EARTH PLANET IN, V26, P179, DOI 10.1016/0031-9201(81)90006-6; POIRIER JP, 1981, GEODYNAMICS SERIES, V4, P113; RINGWOOD AE, 1968, EARTH PLANET SC LETT, V5, P67, DOI 10.1016/S0012-821X(68)80015-9; RUBIE DC, 1984, NATURE, V308, P505, DOI 10.1038/308505a0; RUBIE DC, 1994, PHYS EARTH PLANET IN, V86, P223, DOI 10.1016/0031-9201(94)05070-8; SUNG CM, 1976, TECTONOPHYSICS, V31, P1; WANG Y, 1994, EOS, V75, P613; WANG YB, 1992, J GEOPHYS RES-SOL EA, V97, P12327, DOI 10.1029/92JB00870; WANG YB, 1990, SCIENCE, V248, P468, DOI 10.1126/science.248.4954.468; Wyckoff R., 1965, CRYSTAL STRUCTURES, V3	32	36	36	3	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 24	1997	275	5299					510	513		10.1126/science.275.5299.510	http://dx.doi.org/10.1126/science.275.5299.510			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WE257	8999790				2022-12-28	WOS:A1997WE25700037
J	Cambau, E; Perani, E; Guillemin, I; Jamet, P; Ji, BH				Cambau, E; Perani, E; Guillemin, I; Jamet, P; Ji, BH			Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae	LANCET			English	Article							LEPROSY		INST MARCHOUX,BAMAKO,MALI		Cambau, E (corresponding author), UNIV PARIS 06,FAC MED PITIE SALPETRIERE,SERV BACTERIOL,LAB RECH MOL ANTIBIOT,F-75234 PARIS 13,FRANCE.		Cambau, Emmanuelle/G-7385-2014	Cambau, Emmanuelle/0000-0001-5944-2530				Cambau E, 1996, RES MICROBIOL, V147, P52, DOI 10.1016/0923-2508(96)80204-X; GROSSET JH, 1990, INT J LEPROSY, V58, P281; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; JI BH, 1985, LEPROSY REV, V56, P265; TSUKAMURA M, 1985, AM REV RESPIR DIS, V131, P352	5	79	81	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 11	1997	349	9045					103	104		10.1016/S0140-6736(05)60888-4	http://dx.doi.org/10.1016/S0140-6736(05)60888-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WB800	8996430				2022-12-28	WOS:A1997WB80000020
J	Hiom, K; Gellert, M				Hiom, K; Gellert, M			A stable RAG1-RAG2-DNA complex that is active in V(D)J Cleavage	CELL			English	Article							BROKEN DNA-MOLECULES; MOUSE THYMOCYTES; STRAND TRANSFER; CODING ENDS; RECOMBINATION; MECHANISM; SEQUENCE; REARRANGEMENT; INTEGRATION; INITIATION	The RAG1 and RAG2 proteins initiate V(D)J recombination by making specific double-strand DNA breaks at recombination signal sequences. We show here that RAG1 and RAG2 bind specifically to this sequence, forming a stable protein-DNA complex. The complex requires the conserved heptamer and nonamer motifs of the recombination signal as well as both the RAG1 and RAG2 proteins. This complex is able to either nick or form hairpins at the V(D)J signal sequence, depending on the divalent cation present. A complex trapped using Ca2+ is subsequently active when transferred to Mg2+ or Mn2+. After cleavage, the complex is destabilized and the RAG proteins dissociate. We term this early precursor in the V(D)J recombination reaction a ''stable cleavage complex.''			Hiom, K (corresponding author), NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892, USA.		Hiom, Kevin/B-4374-2009					BOUBNOV NV, 1995, NUCLEIC ACIDS RES, V23, P1060, DOI 10.1093/nar/23.6.1060; Craig NL, 1996, SCIENCE, V271, P1512, DOI 10.1126/science.271.5255.1512; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; EZEKIEL UR, 1995, IMMUNITY, V2, P381, DOI 10.1016/1074-7613(95)90146-9; GELLERT M, 1992, ANNU REV GENET, V22, P425; GERSTEIN RM, 1993, GENE DEV, V7, P1459, DOI 10.1101/gad.7.7b.1459; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Roman CAJ, 1996, P NATL ACAD SCI USA, V93, P2333, DOI 10.1073/pnas.93.6.2333; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	30	169	170	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 10	1997	88	1					65	72		10.1016/S0092-8674(00)81859-0	http://dx.doi.org/10.1016/S0092-8674(00)81859-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WC569	9019407	Bronze			2022-12-28	WOS:A1997WC56900010
J	Zhang, YQ; Kiel, DP; Kreger, BE; Cupples, LA; Ellison, RC; Dorgan, JF; Schatzkin, A; Levy, D; Felson, DT				Zhang, YQ; Kiel, DP; Kreger, BE; Cupples, LA; Ellison, RC; Dorgan, JF; Schatzkin, A; Levy, D; Felson, DT			Bone mass and the risk of breast cancer among postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; HORMONE-BINDING GLOBULIN; MINERAL DENSITY; ELDERLY WOMEN; SEX-HORMONES; ENDOGENOUS HORMONES; MENSTRUAL-CYCLE; HIP-FRACTURES; METAANALYSIS; COMMUNITY	Background Recent studies have shown a direct relation between serum estrogen levels assessed at a single point in time and the risk of breast cancer, but no evidence links estrogen levels assessed repeatedly over an extended interval to the risk of breast cancer. Bone mass has been proposed as a marker of cumulative exposure to estrogen in women. We therefore studied the association between bone mass and the incidence of breast cancer. Methods Between 1967 and 1970, 1373 women who were 47 to 80 years old and had no history of breast cancer underwent posteroanterior hand radiography in the Framingham Study. We used radiogrametry to measure the cortical width cif each woman's second metacarpal. Participants were followed until the end of 1993. All incident cases of breast cancer were confirmed by pathological reports. We used a Cox proportional-hazards model to examine the relation of metacarpal bone mass to the risk of postmenopausal breast cancer. Results Postmenopausal breast cancer developed in 91 subjects. Incidence rates per 1000 person-years increased from 2.0 among the women in the lowest age-specific quartile of metacarpal bone mass to 2.6, 2.71 and 7.0 among the women in the second, third, and highest quartiles, respectively. After adjustments for age and other potential confounding factors, the rate ratios for the risk of breast cancer were 1.0, 1.3, 1.3, and 3.5 from the lowest quartile to the highest (P for trend, <0.001). Conclusions Women in the highest quartile of bone mass are at higher risk for postmenopausal breast cancer than those in the lowest quartile. The mechanisms underlying this relation are not understood, but cumulative exposure to estrogen may play a part. (C) 1997, Massachusetts Medical Society.	BOSTON UNIV,SCH MED,EVANS DEPT MED,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,GEN INTERNAL MED SECT,BOSTON,MA 02118; HARVARD UNIV,SCH MED,HEBREW REHABIL CTR AGED,BOSTON,MA; HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02115; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA; NCI,DIV CANC PREVENT & CONTROL,BETHESDA,MD 20892; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA; NHLBI,BETHESDA,MD 20892	Boston University; Boston University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zhang, YQ (corresponding author), BOSTON UNIV,MED CTR,CTR ARTHRITIS,RM B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.		Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Kiel, Douglas/0000-0001-8474-0310; Zhang, Yuqing/0000-0001-7954-1149; Kreger, Bernard/0000-0002-8593-3795; Ellison, Robert Curtis/0000-0002-0582-7467; Felson, David/0000-0002-2668-2447	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NIAMS NIH HHS [AR20613, AR41398] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041398, P60AR020613] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AITKEN JM, 1974, J BONE JOINT SURG BR, VB 56, P370, DOI 10.1302/0301-620X.56B2.370; Anttila L, 1991, ACTA OBSTET GYN SCAN, V70, P475, DOI 10.3109/00016349109007163; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; Bonjour J P, 1993, Osteoporos Int, V3 Suppl 1, P67, DOI 10.1007/BF01621867; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; BUCHANAN JR, 1988, J BONE MINER RES, V3, P673, DOI 10.1002/jbmr.5650030613; BULBROOK RD, 1986, ANN NY ACAD SCI, V464, P378, DOI 10.1111/j.1749-6632.1986.tb16017.x; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; CAULEY JA, 1994, AM J EPIDEMIOL, V139, P1035, DOI 10.1093/oxfordjournals.aje.a116943; CAULEY JA, 1986, AM J EPIDEMIOL, V124, P752, DOI 10.1093/oxfordjournals.aje.a114451; CAULEY JA, 1989, JAMA-J AM MED ASSOC, V261, P1154; CAULEY JA, 1988, JAMA-J AM MED ASSOC, V260, P3150, DOI 10.1001/jama.260.21.3150; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DEWAARD F, 1988, INT J CANCER, V41, P666, DOI 10.1002/ijc.2910410505; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; EGELAND GM, 1988, PREV MED, V17, P403, DOI 10.1016/0091-7435(88)90039-4; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; EXTONSMITH AN, 1969, LANCET, V2, P1153; FALCH JA, 1990, BONE, V11, P425, DOI 10.1016/8756-3282(90)90138-O; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GARLAND CF, 1992, AM J EPIDEMIOL, V135, P1220, DOI 10.1093/oxfordjournals.aje.a116228; GARN SM, 1967, AM J PHYS ANTHROPOL, V26, P313, DOI 10.1002/ajpa.1330260306; GARN SM, 1964, RELATIONS DEVELOPMEN, P41; GENANT HK, 1982, ANN INTERN MED, V97, P699, DOI 10.7326/0003-4819-97-5-699; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HELZLSOUER KJ, 1994, CANCER DETECT PREV, V18, P79; HORSMAN A, 1975, BRIT J RADIOL, V48, P471, DOI 10.1259/0007-1285-48-570-470; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KREGER BE, 1991, CANCER, V67, P1, DOI 10.1002/1097-0142(19910101)67:1<1::AID-CNCR2820670102>3.0.CO;2-W; LEE ET, 1980, STATISTICAL METHODS; LEONARD PJ, 1976, HORMONE ASSAYS THEIR, P657; MADIGAN MP, 1995, J NATL CANCER I, V87, P1681, DOI 10.1093/jnci/87.22.1681; MAZZUOLI G, 1990, J STEROID BIOCHEM, V37, P457, DOI 10.1016/0960-0760(90)90498-A; MCINTOSH JEA, 1980, FERTIL STERIL, V34, P125; MEEMA HE, 1974, J AM GERIATR SOC, V22, P443, DOI 10.1111/j.1532-5415.1974.tb04812.x; MURPHY S, 1992, POSTGRAD MED J, V68, P908, DOI 10.1136/pgmj.68.805.908; OLSSON H, 1992, AM J EPIDEMIOL, V136, P422, DOI 10.1093/oxfordjournals.aje.a116515; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PERSSON I, 1994, CANCER CAUSE CONTROL, V5, P523, DOI 10.1007/BF01831380; PLYMATE SR, 1985, J CLIN ENDOCR METAB, V61, P993, DOI 10.1210/jcem-61-5-993; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V266, P1362; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STEINBERG KK, 1994, EPIDEMIOLOGY, V5, P415, DOI 10.1097/00001648-199407000-00007; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499; VANHEMERT AM, 1990, J CLIN EPIDEMIOL, V43, P579, DOI 10.1016/0895-4356(90)90162-I; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; World Health Organization, 1976, ICD O INT CLASS DIS; WYSOWSKI DK, 1987, AM J EPIDEMIOL, V125, P791, DOI 10.1093/oxfordjournals.aje.a114596; ZIEGLER R, 1995, J NUTR, V125, pS2033, DOI 10.1093/jn/125.suppl_7.2033S	60	228	231	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 27	1997	336	9					611	617		10.1056/NEJM199702273360903	http://dx.doi.org/10.1056/NEJM199702273360903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WK028	9032046				2022-12-28	WOS:A1997WK02800003
J	Clifton, KE				Clifton, KE			Mass spawning by green algae on coral reefs	SCIENCE			English	Article							SEXUAL REPRODUCTION; HALIMEDA BIOHERMS; SEA-URCHIN; DEFENSES; GAMETOGENESIS; COMMUNITIES; CHLOROPHYTA; RECRUITMENT; HERBIVORES; SEDIMENTS	Predawn episodes of mass spawning by green algae (up to nine species in five genera on a single morning) intermittently cloud Caribbean waters. Species- and sex-specific bouts of anisogamous gamete release occurred synchronously and predictably on a given morning, with closely related species spawning al different times. Algal sexual reproduction was seasonal, but, unlike the mass-spawning behavior of other sessile marine organisms, showed no lunar or tidal cycling. The discovery of mass-spawning behavior by these algae has important implications for future studies of the reproductive ecology and speciation of a vital, yet poorly understood, component of the coral reef community.	SMITHSONIAN TROP RES INST, BALBOA, PANAMA	Smithsonian Institution; Smithsonian Tropical Research Institute								ADEY WH, 1978, SCIENCE, V202, P831, DOI 10.1126/science.202.4370.831; [Anonymous], 1980, ADV MAR BIOL; Babcock R, 1995, REPROD FERT DEVELOP, V7, P943, DOI 10.1071/RD9950943; BABCOCK R, 1992, INVERTEBR REPROD DEV, V22, P213, DOI 10.1080/07924259.1992.9672274; Braga JC, 1996, GEOLOGY, V24, P35, DOI 10.1130/0091-7613(1996)024<0035:ISOSRH>2.3.CO;2; BRAWLEY SH, 1992, BRIT PHYCOL J, V27, P233, DOI 10.1080/00071619200650241; BRAZEAU DA, 1990, MAR BIOL, V104, P465, DOI 10.1007/BF01314351; CARPENTER RC, 1988, P NATL ACAD SCI USA, V85, P511, DOI 10.1073/pnas.85.2.511; CARPENTER RC, 1986, ECOL MONOGR, V56, P345, DOI 10.2307/1942551; CHRISTIE AO, 1962, NATURE, V193, P193, DOI 10.1038/193193a0; CUBIT JD, 1989, CORAL REEFS, V8, P59, DOI 10.1007/BF00301804; Done TJ, 1995, CORAL REEFS, V14, P183, DOI 10.1007/BF00334340; DREW EA, 1988, CORAL REEFS, V6, P207, DOI 10.1007/BF00302017; FELDMANN J, 1951, CR HEBD ACAD SCI, V233, P1309; Fischel JL, 1995, ANTICANCER RES, V15, P2155; FORNOS JJ, 1992, SEDIMENT GEOL, V75, P283, DOI 10.1016/0037-0738(92)90097-B; FREILE D, 1995, CORAL REEFS, V14, P27, DOI 10.1007/BF00304068; GOLDSTEIN M, 1970, ANN NY ACAD SCI, V175, P660, DOI 10.1111/j.1749-6632.1970.tb45183.x; GUSTAVSON TC, 1992, J PALEONTOL, V66, P160, DOI 10.1017/S0022336000033564; Harrison P.L., 1990, ECOSYSTEMS WORLD, V25, P133; HARRISON PL, 1984, SCIENCE, V223, P1186, DOI 10.1126/science.223.4641.1186; HAY ME, 1994, ECOLOGY, V75, P1714, DOI 10.2307/1939631; HAY ME, IN PRESS CORAL REEFS; Hillis Llewellya, 1996, Journal of Phycology, V32, P21; HUGHES TP, 1987, J EXP MAR BIOL ECOL, V113, P39, DOI 10.1016/0022-0981(87)90081-5; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; IRVINE DEG, 1984, SYSTEMATICS GREEN AL, P271; ISASSI GD, 1995, CRYPTOGAMIE ALGOL, V16, P199; KNOWLTON N, 1993, SCIENCE, V260, P1629, DOI 10.1126/science.8503007; Knowlton N, 1990, SMITHSON CONTR MAR S, V31, P1, DOI DOI 10.5479/SI.01960768.31.1; Lasker HR, 1996, BIOL BULL, V190, P45, DOI 10.2307/1542674; Littler M.M., 1994, SEAWEED ECOLOGY PHYS, P72, DOI DOI 10.1017/CB0; LITTLER MM, 1989, OECOLOGIA, V80, P331, DOI 10.1007/BF00379034; MACINTYRE IG, 1995, J SEDIMENT RES A, V65, P143; MARSHALL JF, 1988, CORAL REEFS, V6, P139, DOI 10.1007/BF00302010; MEINESZ A, 1980, PHYCOLOGIA, V19, P82, DOI 10.2216/i0031-8884-19-1-82.1; MEINESZ A, 1975, ANN MUS HIST NAT NIC, V3, P1920; MORRISON D, 1988, ECOLOGY, V69, P1367, DOI 10.2307/1941634; NIAM O, 1988, CORAL REEFS, V6, P237, DOI DOI 10.1007/BF00302020; ODUM HT, 1955, ECOL MONOGR, V25, P291, DOI 10.2307/1943285; ORME GR, 1988, CORAL REEFS, V6, P131, DOI 10.1007/BF00302009; Paul V.J., 1992, ECOLOGICAL ROLES MAR; PAUL VJ, 1988, CORAL REEFS, V6, P263, DOI 10.1007/BF00302022; PAUL VJ, 1988, J EXP MAR BIOL ECOL, V119, P15, DOI 10.1016/0022-0981(88)90149-9; PAWLIK JR, 1993, CHEM REV, V93, P1911, DOI 10.1021/cr00021a012; PRICE I R, 1972, Phycologia, V11, P217, DOI 10.2216/i0031-8884-11-2-217b.1; RAO VP, 1994, MAR GEOL, V121, P293, DOI 10.1016/0025-3227(94)90036-1; REED DC, 1990, ECOLOGY, V71, P776, DOI 10.2307/1940329; ROBERTSON DR, 1987, COPEIA, P637, DOI 10.2307/1445655; SANTELICES B, 1990, OCEANOGR MAR BIOL, V28, P177; Serrao EA, 1996, P NATL ACAD SCI USA, V93, P5286, DOI 10.1073/pnas.93.11.5286; Stachowicz JJ, 1996, OECOLOGIA, V105, P377, DOI 10.1007/BF00328741; WALTERS LJ, 1994, J EXP MAR BIOL ECOL, V175, P105, DOI 10.1016/0022-0981(94)90178-3; WOODLEY JD, 1981, SCIENCE, V214, P749, DOI 10.1126/science.214.4522.749; Wynne MJ, 1985, INTRO ALGAE	55	109	116	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 21	1997	275	5303					1116	1118		10.1126/science.275.5303.1116	http://dx.doi.org/10.1126/science.275.5303.1116			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WJ503	9027310				2022-12-28	WOS:A1997WJ50300041
J	Falagas, ME; Syndman, DR; Griffith, J; Ruthazer, R; Werner, BG; Rohrer, R; Freeman, R; Fairchild, R; Fawaz, K; Hoffman, MA; Kaplan, M; Gill, M; Rubin, RH; Dienstag, JL; Doran, M; ORourke, E; Vacanti, J; Jenkins, R; Lewis, WD; Hammer, S; Martin, M; Grady, GF; Leszczynski, J; Dougherty, N; Katz, A; Fausett, G; Platt, R; Cheeseman, SH; Pasternack, M; Gorbach, SL				Falagas, ME; Syndman, DR; Griffith, J; Ruthazer, R; Werner, BG; Rohrer, R; Freeman, R; Fairchild, R; Fawaz, K; Hoffman, MA; Kaplan, M; Gill, M; Rubin, RH; Dienstag, JL; Doran, M; ORourke, E; Vacanti, J; Jenkins, R; Lewis, WD; Hammer, S; Martin, M; Grady, GF; Leszczynski, J; Dougherty, N; Katz, A; Fausett, G; Platt, R; Cheeseman, SH; Pasternack, M; Gorbach, SL			Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	33rd Interscience Conference on Antimicrobial Agents and Chemotherapy	OCT 17-20, 1993	NEW ORLEANS, LA	Amer Soc Microbiol		cytomegalovirus infections; liver transplantation; mortality; cytomegaloviruses; serology	LABORATORY DATA; SURVIVAL; DIAGNOSIS; IMPACT	Background: To reduce the mortality rate associated with liver transplantation, it is important to identify the risk factors for increased mortality among liver transplant recipients. It has been suggested that cytomegalovirus (CMV) infection is one such risk factor, but no studies have examined mortality rates associated with the CMV serologic status of the donor and recipient by using multivariate techniques. Objective: To study the elect of CMV on 1-year mortality rates in orthotopic liver transplant recipients. Design: Intention-to-treat analysis of a cohort. Patients: 146 liver transplant recipients who were enrolled in a multicenter, randomized, placebo-controlled, intervention trial. Setting: Four university-affiliated transplantation centers. Results: 1-year mortality rates for the four strata of donor and recipient CMV serologic status before transplantation were as follows: seronegative donor and recipient, 11%, seronegative donor and seropositive recipient, 22%; seropositive donor and recipient, 30%; and seropositive donor and seronegative recipient, 44% (P = 0.0091). Multivariate analysis using a time-dependent Cox proportional hazards model showed that retransplantation (relative risk, 4.6 [95% CI, 1.9 to 10.7]; P < 0.001); total number of units of blood products administered during transplantation (relative risk, 1.006 per unit [CI, 1.003 to 1.010]; P < 0.001); and presence of CMV disease (relative risk, 3.9 [CI, 1.8 to 8.5]; P < 0.001), invasive fungal disease (relative risk, 3.3 [CI, 1.5 to 7.1]; P = 0.0020), and bacteremia (relative risk, 2.5 [CI, 1.2 to 5.2]; P = 0.0136) were independently associated with higher mortality rates. If post-transplantation variables that were highly correlated with donor and recipient CMV serologic status were restricted from the model, donor and recipient CMV serologic status was the only pretransplantation variable independently associated with higher mortality rates (P = 0.002). Conclusion: Donor and recipient CMV serologic status is a significant pretransplantation determinant for death in liver transplant recipients.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; MASSACHUSETTS STATE LAB INST, BOSTON, MA USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; CHILDRENS HOSP, BOSTON, MA USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA	Tufts Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital			Snydman, David R/O-3889-2014	Snydman, David R/0000-0003-0119-3978	NIDDK NIH HHS [R10 DK31389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER M, 1988, ANN SURG, V208, P196, DOI 10.1097/00000658-198808000-00011; [Anonymous], 1990, SAS STAT US GUID VER; BALIGA P, 1992, SURGERY, V112, P704; COLLINS LA, 1994, J INFECT DIS, V170, P644, DOI 10.1093/infdis/170.3.644; CUERVASMONS V, 1986, HEPATOLOGY, V6, P922, DOI 10.1002/hep.1840060519; DELMONICO FL, 1992, ARCH SURG-CHICAGO, V127, P579; ETTINGER NA, 1993, AM REV RESPIR DIS, V147, P1017, DOI 10.1164/ajrccm/147.4.1017; Falagas ME, 1996, CLIN INFECT DIS, V23, P468, DOI 10.1093/clinids/23.3.468; GONWA TA, 1995, TRANSPLANTATION, V59, P361, DOI 10.1097/00007890-199502150-00010; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; MARKUS BH, 1988, TRANSPLANTATION, V46, P372; MOTSCHMAN TL, 1989, MAYO CLIN PROC, V64, P346, DOI 10.1016/S0025-6196(12)65256-2; Patel R, 1996, TRANSPLANTATION, V61, P1279, DOI 10.1097/00007890-199605150-00001; PIKUL J, 1994, TRANSPLANTATION, V57, P469, DOI 10.1097/00007890-199402150-00030; SNYDMAN DR, 1993, ANN INTERN MED, V119, P984, DOI 10.7326/0003-4819-119-10-199311150-00004; STRATTA RJ, 1992, DIGEST DIS SCI, V37, P673, DOI 10.1007/BF01296422; TODO S, 1994, ANN SURG, V220, P297, DOI 10.1097/00000658-199409000-00006; WIESNER RH, 1993, GASTROENTEROL CLIN N, V22, P351; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9	19	87	90	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1997	126	4					275	+		10.7326/0003-4819-126-4-199702150-00003	http://dx.doi.org/10.7326/0003-4819-126-4-199702150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	WH068	9036799				2022-12-28	WOS:A1997WH06800005
J	Yin, CY; Knudson, CM; Korsmeyer, SJ; VanDyke, T				Yin, CY; Knudson, CM; Korsmeyer, SJ; VanDyke, T			Bax suppresses tumorigenesis and stimulates apoptosis in vivo	NATURE			English	Article							PROGRAMMED CELL-DEATH; VIRUS-40 T-ANTIGEN; WILD-TYPE P53; IN-VIVO; GENE AMPLIFICATION; TRANSGENIC MICE; EXPRESSION; DEFICIENT; MUTANT; BCL-2	The protein p53 is a key tumour-suppressor, as evidenced by its frequent inactivation in human cancers. Animal models have indicated that attenuation of p53-dependent cell death (apoptosis) can contribute to both the initiation and progression of cancer, but the molecular mechanisms are unknown, Although p53-mediated transcriptional activation is one possible explanation, none of the known p53-responsive genes has been shown to function in p53-dependent apoptosis. Here we test the role of the death-promoting gene bax in a transgenic mouse brain tumour, a model in which p53-mediated apoptosis attenuates tumour growth, Inactivation of p53 causes a dramatic acceleration of tumour growth owing to a reduction in apoptosis of over ninety per cent(1). We show that p53-dependent expression of bax is induced in slow-growing apoptotic tumours. Moreover, tumour growth is accelerated and apoptosis drops by fifty per cent in Bax-deficient mice, indicating that it is required for a full p53-mediated response. To our knowledge this is the first demonstration that Bax acts as a tumour suppressor, and our findings indicate that Bax could be a component of the p53-mediated apoptotic response in this system.	UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DIV MOL ONCOL, ST LOUIS, MO 63110 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Knudson, Charles Michael/0000-0003-3964-5466				Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCCURRACH ME, UNPUB P NATL ACAD SC; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; Van Dyke Terry A., 1993, P287; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	21	556	590	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 13	1997	385	6617					637	640		10.1038/385637a0	http://dx.doi.org/10.1038/385637a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WH294	9024662				2022-12-28	WOS:A1997WH29400051
J	Johansson, JE; Holmberg, L; Johansson, S; Bergstrom, R; Adami, HO				Johansson, JE; Holmberg, L; Johansson, S; Bergstrom, R; Adami, HO			Fifteen-year survival in prostate cancer - A prospective, population-based study in Sweden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVAL; NATURAL-HISTORY; FOLLOW-UP; DIAGNOSIS; ANTIGEN; MEN; ESTRAMUSTINE; MANAGEMENT; ASPIRATION; CARCINOMA	Objective.-To describe the natural history of initially untreated early-stage prostate cancer. A key secondary objective was to calculate long-term survival rates by stage, grade, and age at diagnosis. Design.-Prospective cohort study, Setting.-Population-based in 1 county of Sweden, without screening for prostate cancer. Patients.-A group of 642 patients with prostate cancer of any stage, consecutively diagnosed between 1977 and 1984 at a mean age of 72 years with complete follow-up to 1994. Main Outcome Measures.-Proportion of patients who died from prostate cancer, and 15-year survival (with 95% confidence interval [CI]), corrected for causes of death other than prostate cancer. Results.-In the entire cohort, prostate cancer accounted for 201 (37%) of all 541 deaths. Among 300 patients with a diagnosis of localized disease (T0-T2), 33 (11%) died of prostate cancer. In this group, the corrected 15-year survival rate was similar in 223 patients with deferred treatment (81%; 95% CI, 72%-89%) and in 77 who received initial treatment (81%; 95% CI, 67%-95%). The corrected 15-year survival was 57% (95% CI, 45%-68%) in 183 patients with locally advanced cancer (T3-T4) and 6% (95% CI, 0%-12%) in those 159 who had distant metastases at the time of diagnosis. Conclusion.-Patients with localized prostate cancer have a favorable outlook following watchful waiting, and the number of deaths potentially avoidable by radical initial treatment is limited. Without reliable prognostic indicators, an aggressive approach to all patients with early disease would entail substantial overtreatment. In contrast, patients with locally advanced or metastatic disease need trials of aggressive therapy to improve their poor prognosis.	UNIV UPPSALA HOSP, DEPT CANC EPIDEMIOL, UPPSALA, SWEDEN; UPPSALA UNIV, DEPT STAT, UPPSALA, SWEDEN; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CTR CANC PREVENT, BOSTON, MA 02115 USA	Uppsala University; Uppsala University Hospital; Uppsala University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Johansson, JE (corresponding author), OREBRO MED CTR HOSP, DEPT UROL, S-70185 OREBRO, SWEDEN.							ABRAHAMSSON PA, 1996, J UROLOGY, V155, P296; ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; AUSTENFELD MS, 1994, J UROLOGY, V152, P1866, DOI 10.1016/S0022-5347(17)32403-5; Cancer Registry of Norway, 1980, SURV CANC PAT CAS DI; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHODAK GW, 1984, J UROLOGY, V132, P480, DOI 10.1016/S0022-5347(17)49699-6; CHODAK GW, 1993, UROLOGY, V42, P116, DOI 10.1016/0090-4295(93)90633-L; CHODAK GW, 1995, J UROLOGY, V154, P2132, DOI 10.1016/S0022-5347(01)66714-4; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; FRACCHIA JA, 1993, PRIM CARE CANC, V13, P31; FRANZEN S, 1960, Br J Urol, V32, P193, DOI 10.1111/j.1464-410X.1960.tb03763.x; GRAVERSEN PH, 1990, UROLOGY, V36, P493, DOI 10.1016/0090-4295(90)80184-O; GRONBERG H, 1995, THESIS UMEA U UMEA; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; HAKULINEN T, 1981, ANN CLIN RES, V13, P1; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; *INT UN CANC, 1978, TNM CLASS MAL TUM; IVERSEN P, 1995, SCAND J UROL NEPHROL, P65; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JOHANSSON JE, 1987, UROLOGY, V29, P55, DOI 10.1016/0090-4295(87)90599-1; JOHANSSON JE, 1991, BRIT J UROL, V68, P67, DOI 10.1111/j.1464-410X.1991.tb15259.x; JOHANSSON JE, 1991, J UROLOGY, V145, P519, DOI 10.1016/S0022-5347(17)38385-4; JOHANSSON JE, 1995, 126 SWED COUNC TECHN; LEVI F, 1992, EUR J CANCER, V28A, P1490, DOI 10.1016/0959-8049(92)90551-C; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; NITTI V, 1995, LANCET S26, V346; OTNES B, 1995, BRIT J UROL, V76, P587, DOI 10.1111/j.1464-410X.1995.tb07783.x; PEARSON JD, 1994, J UROLOGY, V152, P1743, DOI 10.1016/S0022-5347(17)32375-3; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHRODER FH, 1995, BRIT MED J, V310, P140, DOI 10.1136/bmj.310.6973.140; STENBECK M, 1995, ACTA ONCOL, V34, P61, DOI 10.3109/02841869509094060; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; TIBBLIN G, 1995, J UROLOGY, V154, P1386, DOI 10.1016/S0022-5347(01)66872-1; Tretli S, 1996, J NATL CANCER I, V88, P128, DOI 10.1093/jnci/88.2.128; WAISMAN J, 1991, UROLOGY, V37, P301, DOI 10.1016/0090-4295(91)80253-4; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WATERBOR JW, 1995, CANCER CAUSE CONTROL, V6, P267, DOI 10.1007/BF00051798; *WHO, 1980, INT HIST CLASS TUM H; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8	46	335	346	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					467	471		10.1001/jama.277.6.467	http://dx.doi.org/10.1001/jama.277.6.467			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020270				2022-12-28	WOS:A1997WG05400033
J	Kedes, DH; Ganem, D; Ameli, N; Bacchetti, P; Greenblatt, R				Kedes, DH; Ganem, D; Ameli, N; Bacchetti, P; Greenblatt, R			The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTED WOMEN; HOMOSEXUAL MEN; DNA-SEQUENCES; FORMS; AIDS; TRANSMISSION	Objective.-To determine the prevalence of human herpesvirus 8 (HHV-8) seropositivity among women who are known to be infected with human immunodeficiency virus type 1 (HIV-1) or who are at high risk for HIV infection. Design.-A cross-sectional and blinded study of the prevalence of serological reactivity to HHV-8 infection as determined by an indirect immunofluorescence assay using nuclei from cells latently infected with HHV-8. Data and specimens were collected at baseline assessments of a longitudinal natural history cohort study. Setting.-Four San Francisco Bay Area outpatient HIV specialty clinics participating in the cohort study. Patients.-A total of 387 participants in the Women's Interagency HIV Study whose HIV infection status was documented and serum was available in a local specimen repository. Main Outcome Measure.-Serological reactivity to HHV-8. Results.-Serological reactivity to latent HHV-8 antigens was uncommon among study participants: 13 (3.4%) demonstrated serum antibodies. HHV-8 reactivity was more common among HIV-infected women; 12 (4.0%; 95% confidence interval [CI], 2.1%-6.9%) of the 302 HIV-infected participants vs 1 (1.2%; 95% CI, 0.03%-6.4%) of the 84 HIV-uninfected participants were seropositive for HHV-8, though the difference did not attain statistical significance (odds ratio=3.43; 95% CI, 0.49-148.6). Two of the HIV-infected women had Kaposi sarcoma lesions and both were seropositive. Conclusions.-The prevalence of HHV-8 seropositivity among the group of HIV-infected women was dramatically lower than that recently reported among HIV-infected homosexual and bisexual men (30%-35%). This finding parallels the lower prevalence of Kaposi sarcoma among women in contrast to men with HIV infection. These data further extend the correlation of HHV-8 serological reactivity with risk of Kaposi sarcoma and are consistent with an important role for HHV-8 infection in development of Kaposi sarcoma.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV INFECT DIS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					NIAID NIH HHS [U01-AI-34989] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034989] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT H, 1994, GENITOURIN MED, V70, P394; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER HIV AIDS, P5; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; Corbellino M, 1996, NEW ENGL J MED, V335, P1237, DOI 10.1056/NEJM199610173351614; FRANCESCHI S, 1995, J ACQ IMMUN DEF SYND, V9, P313, DOI 10.1097/00042560-199507000-00016; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; GEDDES M, 1994, BRIT J CANCER, V69, P333, DOI 10.1038/bjc.1994.60; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; Jacobson Lisa P., 1995, Current Opinion in Oncology, V7, P450, DOI 10.1097/00001622-199509000-00011; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; MOORE P, 1995, AIDS, V10, P175; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MORLAT P, 1992, AIDS, V6, P1187, DOI 10.1097/00002030-199210000-00020; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RABKIN CS, 1993, INT J CANCER, V55, P208, DOI 10.1002/ijc.2910550207; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SERRAINO D, 1995, AIDS, V9, P971, DOI 10.1097/00002030-199508000-00022; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Tasaka T, 1996, NEW ENGL J MED, V335, P1237; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; ZIEGLER JL, 1984, SEMIN ONCOL, V11, P47	30	122	125	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 12	1997	277	6					478	481		10.1001/jama.277.6.478	http://dx.doi.org/10.1001/jama.277.6.478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WG054	9020272				2022-12-28	WOS:A1997WG05400035
J	Schulman, S; Granqvist, S; Holmstrom, M; Carlsson, A; Lindmarker, P; Nicol, P; Eklund, SG; Nordlander, S; Larfars, G; Leijd, B; Linder, O; Loogna, E; Gustafsson, C; Grondahl, A; Rhedin, AS; Tornebohm, E; Lockner, D; Johnsson, H; Kobosko, J; Malmros, B; Arcini, N; Saaw, J; Stig, R; Viering, S; Ljungberg, B; Wilhelmsson, S; Ohlsson, A; Walter, H; Malmqvist, K; AlKhalili, F; Petrescu, A; Brohult, J; Hulting, J; Svensson, E; Dahlin, L; Boberg, J; Marjanovics, B; Jonsson, KA; Malm, C; Hjorth, M; Lindgren, A; Fagrell, B; Kallner, M; Wadman, B; Snyder, M				Schulman, S; Granqvist, S; Holmstrom, M; Carlsson, A; Lindmarker, P; Nicol, P; Eklund, SG; Nordlander, S; Larfars, G; Leijd, B; Linder, O; Loogna, E; Gustafsson, C; Grondahl, A; Rhedin, AS; Tornebohm, E; Lockner, D; Johnsson, H; Kobosko, J; Malmros, B; Arcini, N; Saaw, J; Stig, R; Viering, S; Ljungberg, B; Wilhelmsson, S; Ohlsson, A; Walter, H; Malmqvist, K; AlKhalili, F; Petrescu, A; Brohult, J; Hulting, J; Svensson, E; Dahlin, L; Boberg, J; Marjanovics, B; Jonsson, KA; Malm, C; Hjorth, M; Lindgren, A; Fagrell, B; Kallner, M; Wadman, B; Snyder, M			The duration of oral anticoagulant therapy after a second episode of venous thromboembolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background A consensus has not been reached about the optimal duration of oral anticoagulant therapy after a second episode of venous thromboembolism. Methods In a multicenter trial, we compared six months of oral anticoagulant therapy with anticoagulant therapy continued indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 patients enrolled, 111 were randomly assigned to six months of anticoagulation and 116 were assigned to receive anticoagulant therapy indefinitely; for both groups, the target international normalized ratio was 2.0 to 2.85. The initial episodes of deep-vein thrombosis (n = 193) and pulmonary embolism (n = 34), as well as recurrent episodes, were all objectively confirmed. Results After four years of follow-up, there were 26 recurrences of venous thromboembolism that fulfilled the diagnostic criteria, 23 in the group assigned to six months of therapy (20.7 percent) and 3 in the group assigned to continuing therapy (2.6 percent). The relative risk of recurrence in the group assigned to six months of therapy, as compared with the group assigned to therapy of indefinite duration, was 8.0 (95 percent confidence interval, 2.5 to 25.9). There were 13 major hemorrhages, 3 in the six-month group (2.7 percent) and 10 in the indefinite-treatment group (8.6 percent). The relative risk of major hemorrhage in the six-month group, as compared with the indefinite-treatment group, was 0.3 (95 percent confidence interval, 0.1 to 1.1). There was no difference in mortality between the two groups. Conclusions Prophylactic oral anticoagulation that was continued for an indefinite period after a second episode of venous thromboembolism was associated with a much lower rate of recurrence during four years of follow-up than treatment for six months. However, there was a trend toward a higher risk of major hemorrhage when anticoagulation was continued indefinitely. (C) 1997, Massachusetts Medical Society.	HUDDINGE HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN; DANDERYD HOSP,DEPT INTERNAL MED,S-18288 DANDERYD,SWEDEN; KOPING HOSP,DEPT INTERNAL MED,KOPING,SWEDEN; SODERTALJE HOSP,DEPT INTERNAL MED,SODERTALJE,SWEDEN; VASTERAS HOSP,DEPT INTERNAL MED,VASTERAS,SWEDEN; SODER SJUKHUSET,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; ST GORANS UNIV HOSP,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; OREBRO REG HOSP,DEPT INTERNAL MED,OREBRO,SWEDEN; NACKA HOSP,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; ERSTA HOSP,DEPT RADIOL,STOCKHOLM,SWEDEN; SABBATSBERGS HOSP,S-11382 STOCKHOLM,SWEDEN; NORRTALJE HOSP,NORRTALJE,SWEDEN; LIDKOPING HOSP,LINKOPING,SWEDEN; UPPSALA ACAD HOSP,UPPSALA,SWEDEN; KAROLINSKA HOSP,S-10401 STOCKHOLM,SWEDEN; NYKOPING HOSP,NYKOPING,SWEDEN; LINKOPING REG HOSP,LINKOPING,SWEDEN; LOWENSTROMSKA HOSP,UPPLANDS VASBY,SWEDEN; TADIRAN INFORMAT SYST,GIVAT SHMUEL,ISRAEL	Danderyds Hospital; Vasteras Central Hospital; Sodersjukhuset Hospital; Saint Goran's Hospital; Ersta Sjukhus; Uppsala University; Uppsala University Hospital; Karolinska Institutet; Karolinska University Hospital	Schulman, S (corresponding author), KAROLINSKA HOSP,DEPT INTERNAL MED,S-17176 STOCKHOLM,SWEDEN.		Schulman, Sam/I-7559-2019; Holmström, Margareta/AAJ-2628-2021; Miranda, Fausto/N-9780-2018	Schulman, Sam/0000-0002-8512-9043; Miranda, Fausto/0000-0003-2954-8638				HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HYERS TM, 1992, CHEST, V102, pS408, DOI 10.1378/chest.102.4_Supplement.408S; HYERS TM, 1993, CHEST, V103, P1636, DOI 10.1378/chest.103.5.1636a; Johansson J, 1987, Lakartidningen, V84, P22; *RES COMM BRIT THO, 1992, LANCET, V340, P873; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SCHULMAN S, 1988, ACTA MED SCAND, V224, P425	8	483	491	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 6	1997	336	6					393	398		10.1056/NEJM199702063360601	http://dx.doi.org/10.1056/NEJM199702063360601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WF859	9010144				2022-12-28	WOS:A1997WF85900001
J	Chen, DF; Schneider, GE; Martinou, JC; Tonegawa, S				Chen, DF; Schneider, GE; Martinou, JC; Tonegawa, S			Bcl-2 promotes regeneration of severed axons in mammalian CNS	NATURE			English	Article							RETINAL GANGLION-CELLS; TRANSGENIC MICE; NERVOUS-SYSTEM; IN-VITRO; DEATH; APOPTOSIS; SURVIVAL; PROTEIN; NEURONS; GROWTH	Most neurons of the mammalian central nervous system (CNS) lose the ability to regenerate severed axons in vivo after a certain point in development(1). At least part of this loss in regenerative potential is intrinsic to neuron(2-4). Although embryonic retinal ganglion cells (RGCs) can grow axons into tectum of any age, most RGCs from older animals fail to extend axons into CNS tissue derived from donors of any age, including the embryonic tectum(2). Here we report that the proto-oncogene bcl-2 plays a key role in this developmental change by promoting the growth and regeneration of retinal axons. This effect does not seem to be an indirect consequence of its well-known anti-apoptotic activity. Another anti-apoptotic drug, ZVAD, supported neuronal survival but did noe promote axon regeneration in culture. This finding could lead to new strategies for the treatment of injuries to the CNS.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; GLAXO INST MOL BIOL SA,CH-1228 GENEVA,SWITZERLAND	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); GlaxoSmithKline	Chen, DF (corresponding author), MIT,HOWARD HUGHES MED INST,CTR LEARNING & MEMORY,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			martinou, Jean-claude/0000-0002-9847-2051				AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Angelucci A, 1996, J NEUROSCI METH, V65, P101, DOI 10.1016/0165-0270(95)00155-7; AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CHEN DF, 1995, P NATL ACAD SCI USA, V92, P7287, DOI 10.1073/pnas.92.16.7287; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MERRY DE, 1994, DEVELOPMENT, V120, P301; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PERRY VH, 1983, J COMP NEUROL, V219, P3546; Sagot Y, 1996, J NEUROSCI, V16, P2335; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SHEWAN D, 1995, J NEUROSCI, V15, P2057, DOI 10.1523/JNEUROSCI.15-03-02057.1995; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG HG, 1994, ONCOGENE, V9, P2751; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	30	404	440	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 30	1997	385	6615					434	439		10.1038/385434a0	http://dx.doi.org/10.1038/385434a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WF007	9009190				2022-12-28	WOS:A1997WF00700052
J	Donnan, GA; Darby, DG; Saling, MM				Donnan, GA; Darby, DG; Saling, MM			Identification of brain region for coordinating speech articulation	LANCET			English	Editorial Material											Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR,NEUROSCI CLIN SERV UNIT,HEIDELBERG,VIC 3084,AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008	Donnan, Geoffrey/0000-0001-6324-3403				Broca P. A., 1865, B SOC ANTHROPOL PAR, V6, P493; Dronkers NF, 1996, NATURE, V384, P159, DOI 10.1038/384159a0; HUERTA MF, 1993, TRENDS NEUROSCI, V16, P436, DOI 10.1016/0166-2236(93)90069-X; OJEMANN GA, 1978, BRAIN LANG, V6, P239, DOI 10.1016/0093-934X(78)90061-5; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; TOGNOLA G, 1980, NEUROPSYCHOLOGIA, V18, P257, DOI 10.1016/0028-3932(80)90122-0	6	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 25	1997	349	9047					221	222		10.1016/S0140-6736(05)64855-6	http://dx.doi.org/10.1016/S0140-6736(05)64855-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD906	9014903				2022-12-28	WOS:A1997WD90600003
J	Lewis, SM; Wu, GE				Lewis, SM; Wu, GE			The origins of V(D)J recombination	CELL			English	Review							SITE-SPECIFIC RECOMBINATION; HIN RECOMBINASE; DNA; SEQUENCE		UNIV TORONTO,WELLESLEY HOSP,RES INST,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Lewis, SM (corresponding author), HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,555 UNIV AVE,TORONTO,ON M5S 1A8,CANADA.		wu, ge/ABE-3285-2020					Blakely G, 1996, GENE DEV, V10, P762, DOI 10.1101/gad.10.6.762; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; FENG JA, 1994, SCIENCE, V263, P348, DOI 10.1126/science.8278807; Gellert M, 1996, GENES CELLS, V1, P269, DOI 10.1046/j.1365-2443.1996.22023.x; HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x; HUGHES KT, 1992, EMBO J, V11, P2695, DOI 10.1002/j.1460-2075.1992.tb05335.x; IIDA S, 1990, MOL MICROBIOL, V4, P991, DOI 10.1111/j.1365-2958.1990.tb00671.x; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KLOBUTCHER LA, 1995, NUCLEIC ACIDS RES, V23, P2006, DOI 10.1093/nar/23.11.2006; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; Pyle AM, 1996, NATURE, V381, P280, DOI 10.1038/381280a0; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SIMON M, 1980, SCIENCE, V209, P1370, DOI 10.1126/science.6251543; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; Steen SB, 1996, GENES CELLS, V1, P543; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	20	46	47	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 24	1997	88	2					159	162		10.1016/S0092-8674(00)81833-4	http://dx.doi.org/10.1016/S0092-8674(00)81833-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	WE970	9008155	Bronze			2022-12-28	WOS:A1997WE97000002
J	Geltman, P; Stover, E				Geltman, P; Stover, E			Genocide and the plight of children in Rwanda	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REFUGEE CHILDREN; ORPHANAGE; COMMUNITY; HEALTH; ZAIRE		BOSTON UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02118 USA; BOSTON MED CTR, BOSTON, MA USA; UNIV CALIF BERKELEY, HUMAN RIGHTS CTR, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA	Boston University; Boston Medical Center; University of California System; University of California Berkeley; University of California System; University of California Berkeley				Geltman, Paul/0000-0002-9704-7782	BHP HRSA HHS [5 T32 PE10014.02] Funding Source: Medline	BHP HRSA HHS		AJDUKOVIC M, 1993, CHILD ABUSE NEGLECT, V17, P843, DOI 10.1016/S0145-2134(08)80014-2; ALLODI F, 1980, DANISH MED J, V22, P229; Allodi Federico, 1985, BREAKING BODIES MIND, P58; [Anonymous], 1995, Lancet, V345, P339; AUGUSTYN M, 1995, CONT PEDIAT, V12, P35; BONNEAU J, 1995, RAPPORT MISSION AFSE; BORTON N, 1995, RWANDA CIVIL STRIFE; BRACKEN PJ, 1995, SOC SCI MED, V40, P1073, DOI 10.1016/0277-9536(94)00181-R; BRAHMADATHAN KN, 1988, J TROP MED HYG, V91, P306; *BUR HUM RESP, 1994, 14 BUR HUM RESP US A; *BUR HUM RESP, 1994, 11 BUR HUM RESP US A; CALLAGHAN MP, 1995, PUBLIC HEALTH REP, V110, P95; CALVIN F, 1985, POST TRAUMATIC STRES, P103; CARNEY A, 1994, BRIT J PSYCHIAT, V165, P556, DOI 10.1192/bjp.165.4.556a; Chapin HD, 1915, J AMER MED ASSOC, V64, P1; *CTR INT HLTH INF, 1995, RWAND COUNTR HLTH ST; DABELSTEIN N, 1996, INT RESPONSE GENOCID, P7; DAWES A, 1990, INT J PSYCHOL, V25, P13, DOI 10.1080/00207599008246811; *DECHARRY A, 1995, SYNTHESE ORPHELINATS; DOWELL SF, 1995, JAMA-J AM MED ASSOC, V273, P1802, DOI 10.1001/jama.273.22.1802; EISENBRUCH M, 1988, INT MIGR REV, V22, P282, DOI 10.2307/2546651; FARINA JJ, 1987, TERRORISMO ESTADO EF, P21; Frank DA, 1996, PEDIATRICS, V97, P569; GARBARINO J, 1992, PSYCHOL WELL BEING R, P1; GOLDFARB W, 1945, AM J PSYCHIAT, V102, P18, DOI 10.1176/ajp.102.1.18; GORDONBATES K, 1995, INT COMMITTEE RED CR, P14; GRUBER A, 1978, CHILDREN FOSTER CARE; GUPTA L, 1996, EXPOSURE WAR RELATED; HALL P, 1984, RWANDA 1994 REPORT G; HANSEN AB, 1971, ACTA PAEDIATR SCAND, V60, P571, DOI 10.1111/j.1651-2227.1971.tb06992.x; JANOFF EN, 1990, AM J TROP MED HYG, V43, P248, DOI 10.4269/ajtmh.1990.43.248; KANJI N, 1990, COMMUNITY DEV J, V25, P102, DOI 10.1093/cdj/25.2.102; KINZIE JD, 1989, J AM ACAD CHILD PSY, V28, P501, DOI 10.1097/00004583-198907000-00006; KLACKENBERG G, 1956, Acta Paediatr, V45, P1, DOI 10.1111/j.1651-2227.1956.tb17668.x; Lifton R.J, 1988, NAZI DOCTORS MED KIL; LIFTON RJ, 1980, SURVIVORS VICTIMS PE, P123; LORCH D, 1995, NY TIMES        0918, pA1; Makhlouf Samia A. M., 1994, Journal of the Egyptian Society of Parasitology, V24, P137; MCKELVEY RS, 1993, J AM ACAD CHILD PSY, V32, P1013, DOI 10.1097/00004583-199309000-00020; MELVILLE MB, 1992, SOC SCI MED, V34, P533, DOI 10.1016/0277-9536(92)90209-9; MILLER LC, 1995, ARCH PEDIAT ADOL MED, V149, P40, DOI 10.1001/archpedi.1995.02170130042009; MILLER N, 1994, AIDS SOC, V4, P1; MOLLICA RF, 1989, REPATRIATION DISABIL, V2; MURRAYLEE M, 1994, RWANDAS LOST SOULS; Nosiglia J., 1985, BOTIN GUERRA; OMAAR R, 1994, RWANDA DEATH DESPAIR; *P C CAR DEP CHILD, 1971, P NAT C CAR CHILDR 1, P6; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; REID E, 1994, AIDS SOC, V4, P6; REIN M, 1974, CHILDREN DECENT PEOP, P24; REISMAN MW, 1994, LAWS WAR COMPREHENSI, P84; SALTZ R, 1973, CHILD DEV, V17, P80; SCHOEPF BG, 1997, IN PRESS MED ANTHR Q; SIMASATHIEN S, 1980, LANCET, V2, P1214; STOVER E, 1995, MED GLOBAL SURVIVAL, V3, P1480; Suarez-Orozco M., 1992, PATHS DOMINATION RES, P219; SUAREZOROZCO MM, 1990, ETHOS, V18, P353, DOI 10.1525/eth.1990.18.3.02a00050; Summerfield D., 1995, TRAUMA CULTURAL SOC, P17, DOI DOI 10.1007/978-1-4757-9421-2_2; TAKALA AK, 1995, JAMA-J AM MED ASSOC, V273, P859, DOI 10.1001/jama.273.11.859; TIZARD B, 1978, J CHILD PSYCHOL PSYC, V19, P99, DOI 10.1111/j.1469-7610.1978.tb00453.x; TIZARD B, 1989, J CHILD PSYCHOL PSYC, V30, P651; TOOLE MJ, 1993, FRAMEWORK FOR SURVIVAL, P144; *UNICEF, 1996, CHILDR FUT RWAND MIN; *UNICEF, 1995, CHILDREN FUT RWAND U; *UNICEF, 1995, CHILDR RWAND UPD CHI; *US AG INT DEV, 1996, US AG INT DEV C REP; van der Veen G., 1995, TRAUMA CULTURAL SOC, P151	67	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 22	1997	277	4					289	294		10.1001/jama.277.4.289	http://dx.doi.org/10.1001/jama.277.4.289			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WC458	9002482				2022-12-28	WOS:A1997WC45800015
J	Raleigh, VS				Raleigh, VS			Diabetes and hypertension in Britain's ethnic minorities: Implications for the future of renal services	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK; CARE	Diabetes and hypertension are much more prevalent among Britain's 2.5 million Asian and African-Caribbean population than among the white population and are major contributors to end stage renal failure. Asians and African-Caribbeans have threefold to fourfold higher acceptance rates on to renal replacement therapy than white people, and in some districts they comprise up to half of all patients receiving such treatment. Their greater need for renal replacement treatment is accompanied by difficulties of tissue matching in cross racial transplants and a shortage of donor organs. The aging of ethnic minority populations will increase local need for renal services significantly. Measures to control diabetes, hypertension, and secondary complications in Asian and African-Caribbean communities will contribute both to safeguarding health and to economies in spending on renal services. Education about diabetes and hypertension, modification of behavioural risk factors, early diagnosis, effective glycaemic and blood pressure control, and early referral for signs of renal impairment are essential preventive measures. Primary and community health care professionals have a critical role to play here.			Raleigh, VS (corresponding author), UNIV SURREY, NATL INST EPIDEMIOL, GUILDFORD GU2 5YD, SURREY, ENGLAND.							BALARAJAN R, 1995, ETHNICITY HLTH ENGLA; BEEVERS G, 1993, ACCESS HLTH CARE PEO; BENETT IJ, 1994, DIABETIC MED, V11, P586, DOI 10.1111/j.1464-5491.1994.tb02041.x; *BRIT DIAB ASS, 1996, COUNT COST REAL IMP; BURDEN AC, 1992, DIABETIC MED, V9, P641, DOI 10.1111/j.1464-5491.1992.tb01860.x; CLOSE CF, 1995, DIABETIC MED, V12, P619, DOI 10.1111/j.1464-5491.1995.tb00552.x; CRUICKSHANK JK, 1989, ETHNIC FACTORS HLTH; *DEP HLTH, 1996, REN PURCH GUID GOOD; FRIEDMAN EA, 1993, TRANSPLANT P, V25, P2431; GOODWIN AM, 1987, DIABETIC MED, V4, P266, DOI 10.1111/j.1464-5491.1987.tb00878.x; GRELL GAC, 1989, ETHNIC FACTORS HLTH; HAWTHORNE K, 1990, BRIT J GEN PRACT, V40, P243; *HLTH CAR STRAT UN, 1994, REV REN SERV; KAPLAN NM, 1994, LANCET, V344, P450, DOI 10.1016/S0140-6736(94)91774-4; Laing W., 1989, DIABETES MODEL HLTH; *LOND HLTH ED AUTH, 1994, BLACK MIN ETHN GROUP; LOPES AAS, 1994, AM J KIDNEY DIS, V24, P554, DOI 10.1016/S0272-6386(12)80211-3; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MCKEIGUE P, 1994, CORONARY HEART DIS S; MEYER LC, 1994, DIABETIC MED, V11, P670; MORGAN M, 1995, INT J EPIDEMIOL, V24, pS79, DOI 10.1093/ije/24.Supplement_1.S79; PERRY IJ, 1995, BRIT MED J, V310, P560, DOI 10.1136/bmj.310.6979.560; RALEIGH VS, IN PRESS HLTH TRENDS; Roderick PJ, 1996, J EPIDEMIOL COMMUN H, V50, P334, DOI 10.1136/jech.50.3.334; RODERICK PJ, 1994, BRIT MED J, V309, P1111, DOI 10.1136/bmj.309.6962.1111; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIMMONS D, 1989, BRIT MED J, V298, P18, DOI 10.1136/bmj.298.6665.18; STORKEY M, 1995, POPULATION PROJECTIO; Tell G S, 1996, Ethn Health, V1, P21; *UK PROSP DIAB STU, 1994, DIABETOLOGIA, V34, P877; *WHO STUD GROUP, 1994, PREV DIAB MELL; [No title captured]; 1993, REP IND REV REN SERV	33	91	91	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	1997	314	7075					209	213		10.1136/bmj.314.7075.209	http://dx.doi.org/10.1136/bmj.314.7075.209			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	9022442	Green Published			2022-12-28	WOS:A1997WD91100039
J	Drickamer, MA; Lee, MA; Ganzini, L				Drickamer, MA; Lee, MA; Ganzini, L			Practical issues in physician-assisted suicide	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LIFE-SUSTAINING THERAPY; ILL HOSPITALIZED ADULTS; TERMINALLY ILL; EUTHANASIA; DEPRESSION; DEATH; PREFERENCES; ATTITUDES; DESIRE	Support for the participation of physicians in the suicides of terminally ill patients is increasing, and the concrete effects on physician practice of a policy change with regard to physician-assisted suicide must be carefully considered. If physician-assisted suicide is legalized, physicians will need to gain expertise in understanding patients' motivations for requesting physician-assisted suicide, assessing mental status, diagnosing and treating depression, maximizing palliative interventions, and evaluating the external pressures on the patient. They will be asked to prognosticate not only about life expectancy but also about the onset of functional and cognitive decline. They will need access to reliable information about effective medications and dosages. The physician's position on physician-assisted suicide must be open to discussion between practitioner and patient. Protection of the patient's right to confidentiality must be balanced against the need of health care professionals and institutions to know about the patient's choice. Insurance coverage and managed care options may be affected. All of these issues need to be further explored through research, education, decision making by individual practitioners, and ongoing societal debate.	PORTLAND VET AFFAIRS MED CTR, PORTLAND, OR 97207 USA; YALE UNIV, SCH MED, NEW HAVEN, CT USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; VA Portland Health Care System; Yale University; Oregon Health & Science University	Drickamer, MA (corresponding author), W HAVEN VET AFFAIRS MED CTR, 111C, 950 CAMPBELL AVE, W HAVEN, CT 06516 USA.							*AM NURS ASS, 1994, POS STAT ASS SUIC; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; *COUNC ETH JUD AFF, 1994, COD MED ETH REP COUN, P274; EMANUEL EJ, 1995, J CLIN ETHIC, V6, P158; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; GANZINI L, 1994, AM J PSYCHIAT, V151, P1631; *HAST CTR, 1987, GUID TERM LIF SUST T; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEE M, 1994, J GERONTOL, V49, pM15, DOI 10.1093/geronj/49.1.M15; LEE MA, 1992, J AM GERIATR SOC, V40, P983, DOI 10.1111/j.1532-5415.1992.tb04473.x; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; Lipowski Z.J, 1990, DELIRIUM ACUTE CONFU; LYNN J, 1995, WESTERN J MED, V163, P250; MCDANIEL JS, 1993, CURRENT EMERGING ISS; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; Owen C., 1992, PSYCHO-ONCOLOGY, V1, P79, DOI [10.1002/pon.2960010205, DOI 10.1002/PON.2960010205]; PHAIR JP, 1994, AIDS RES HUM RETROV, V10, P883, DOI 10.1089/aid.1994.10.883; POPKIN MK, 1985, ARCH GEN PSYCHIAT, V42, P1160; *PUBL HLTH SERV CT, 1993, HLTH US 1993; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; ROHDE K, 1995, J AM GERIATR SOC, V43, P187, DOI 10.1111/j.1532-5415.1995.tb06388.x; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDONGEN CJ, 1991, J FAM PRACTICE, V33, P375; 1995, J AM GERIATR SOC, V43, P579	37	35	35	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					146	151		10.7326/0003-4819-126-2-199701150-00009	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	WD298	9005749				2022-12-28	WOS:A1997WD29800010
J	Harrison, L; Johnston, M; Massicotte, MP; Crowther, M; Moffat, K; Hirsh, J				Harrison, L; Johnston, M; Massicotte, MP; Crowther, M; Moffat, K; Hirsh, J			Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy	ANNALS OF INTERNAL MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; PROTEIN-C; DIFFERENT INTENSITIES; HEART-VALVES	Background: Loading doses of warfarin that are larger than those used for maintenance therapy are widely used in clinical practice, but they have never been prospectively evaluated. Objective: To compare the effect of 5- to 10-mg loading doses of warfarin on laboratory markers of warfarin's anticoagulant effect. Design: Randomized clinical trial. Setting: Tertiary care teaching hospital. Patients: 49 patients seen over a 5-month period with a target international normalized ratio (INR) of 2.0 to 3.0. Intervention: Patients were randomly assigned to receive an initial dose of 5 or 10 mg of warfarin. Subsequent doses of warfarin were administered on the basis of dosing monograms. Measurements: INRs and levels of factor II, VII, IX, and X and protein C were measured daily for 5 days. Results: 11 of 25 patients in the 10-mg group (44% [95% CI, 34% to 54%]) and 2 of 24 patients in the 5-mg group (8% [CI, 3% to 14%]) had INRs greater than 2.0 at 36 hours (P = 0.005), at which time the factor VII levels were 27% (CI, 18% to 36%) in the 10-mg group and 54% (CI, 43% to 65%) in the 5-mg group (P < 0.001). In contrast, factor II levels were 74% (CI, 67% to 81%) in the 10-mg group and 82% (CI, 73% to 93%) in the 5-mg group (P > 0.2). At 60 hours, 9 of 25 patients in the 10-mg group (36% [CI, 17% to 54%]) and no patients in the 5-mg group had INRs greater than 3.0. At 84 hours, 15 of 24 patients in the 10-mg group (63% [CI, 43% to 81%]) and 19 of 24 patients in the 5-mg group (79% [CI, 62% to 95%]) had INRs between 2.0 and 3.0. Four patients in the 10-mg group and 1 patient in the 5-mg group received vitamin K for excessive prolongation of the INR. Conclusions: A 5-mg loading dose of warfarin produces less excess anticoagulation than does a 10-mg loading dose; the smaller dose also avoids the development of a potential hypercoagulable state caused by precipitous decreases in levels of protein C during the first 36 hours of warfarin therapy.	MCMASTER UNIV, RES CTR, HAMILTON CIV HOSP, HAMILTON, ON L8V 1C3, CANADA	McMaster University								ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; BIGGS R, 1972, HUMAN BLOOD COAGULAT, P614; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HELLEMANS J, 1963, BRIT J HAEMATOL, V9, P506, DOI 10.1111/j.1365-2141.1963.tb05475.x; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; Johnston M, 1996, J LAB CLIN MED, V128, P214, DOI 10.1016/S0022-2143(96)90014-1; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; OKAJIMA K, 1990, THROMB HAEMOSTASIS, V63, P48; Quick AJ, 1935, J BIOL CHEM, V110, P107; ROBERTS HR, 1965, THROMB DIATH HAEMOST, V13, P305, DOI 10.1055/s-0038-1656232; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; TURPIE AGG, 1988, LANCET, V1, P1242; VIGANO S, 1984, BRIT J HAEMATOL, V57, P213, DOI 10.1111/j.1365-2141.1984.tb02889.x; WESSLER S, 1984, NEW ENGL J MED, V311, P645; WHO Expert Committee on Biological Standardization 33rd Report, 1983, WHO TECHN REP SER, V687, P81; ZIVELIN A, 1993, J CLIN INVEST, V92, P2131, DOI 10.1172/JCI116814	18	243	258	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1997	126	2					133	136		10.7326/0003-4819-126-2-199701150-00006	http://dx.doi.org/10.7326/0003-4819-126-2-199701150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD298	9005747				2022-12-28	WOS:A1997WD29800008
J	Sharma, SD; Smith, EM; Hazleman, BL; Jenner, JR				Sharma, SD; Smith, EM; Hazleman, BL; Jenner, JR			Thermographic changes in keyboard operators with chronic forearm pain	BRITISH MEDICAL JOURNAL			English	Article									ADDENBROOKES NHS TRUST,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital	Sharma, SD (corresponding author), RHEUMATOL RES UNIT,BOX 194,CAMBRIDGE CB2 2QQ,ENGLAND.							COHEN ML, 1992, MED J AUSTRALIA, V156, P432, DOI 10.5694/j.1326-5377.1992.tb139853.x; COHEN ML, 1990, PAIN S, V5, pS465; HADLER NM, 1992, J OCCUP ENVIRON MED, V34, P113, DOI 10.1097/00043764-199202000-00009; MILLER MH, 1988, J RHEUMATOL, V15, P1705; ROBERTS WJ, 1986, PAIN, V24, P297, DOI 10.1016/0304-3959(86)90116-8	5	32	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 11	1997	314	7074					118	118		10.1136/bmj.314.7074.118	http://dx.doi.org/10.1136/bmj.314.7074.118			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WC479	9006470	Green Published			2022-12-28	WOS:A1997WC47900024
J	Harrison, J				Harrison, J			Is this what we really want?	BRITISH MEDICAL JOURNAL			English	Article											Harrison, J (corresponding author), CHEVELEY PK MED CTR,DURHAM DH1 2UW,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 21	1996	313	7072					1643	1643		10.1136/bmj.313.7072.1643	http://dx.doi.org/10.1136/bmj.313.7072.1643			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VZ811	9011291	Green Published			2022-12-28	WOS:A1996VZ81100052
